"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","Good morning, and welcome to Johnson & Johnson's Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] I would now like t",51,"Good morning, and welcome to Johnson & Johnson's Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] 
I would now like to turn the conference call over to Johnson & Johnson. You may begin."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Good morning, and welcome. I'm Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure this morning to review our business results for the fourth quarter of 2015. Joining me on the call today are Alex Gorsky, C",1983,"Good morning, and welcome. I'm Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure this morning to review our business results for the fourth quarter of 2015. 
Joining me on the call today are Alex Gorsky, Chairman of the Board of Directors and Chief Executive Officer; and Dominic Caruso, Vice President, Finance, and Chief Financial Officer. 
A few logistics before we get into the details. This review is being made available via webcast accessible through the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. 
I'll begin by briefly reviewing results for the corporation and our 3 business segments. Following my remarks, Alex will comment on 2015 results and provide a strategic outlook for the company. Then Dominic will provide some additional commentary on the business, review the income statement and provide guidance for 2016. We will then open the call to your questions. We expect the call to last approximately 90 minutes. 
Included with the press release that was issued earlier this morning is the schedule of sales for key products and/or businesses to facilitate updating your models. These schedules are available on the Johnson & Johnson website as is the press release. 
Please note, we will be using a presentation to complement today's commentary. The presentation is also available on our website. 
Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements. The 10-K for the fiscal year 2014 and the company's subsequent filings identify certain factors that could cause the company's actual results to differ materially from those projected in any forward-looking statements made today. The company does not undertake to update any forward-looking statements as a result of new information or future events or developments. Our SEC filings, including the 10-K, are available to the company and on our website. 
During the review, non-GAAP financial measures are used to provide information pertinent to ongoing business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with GAAP results. Tables reconciling these measures to the most comparable GAAP measures are available in the schedules accompanying the press release and on the Investor Relations section of the Johnson & Johnson website. A number of the products and compounds discussed today are being developed in cooperation with strategic partners or license for other companies. This slide list acknowledgment of those relationships not otherwise referenced in today's presentations. 
Now I would like to review our results for the fourth quarter of 2015. Worldwide sales to customers were $17.8 billion for the fourth quarter of 2015, down 2.4% versus fourth quarter of 2014. On an operational basis, sales were up 4.4% and currency have a negative impact of 6.8%. In the U.S., sales were up 8%. 
In regions outside the U.S., our operational growth was 1.2%, while the effect of currency exchange rates negatively impacted our reported results by 12.9%. 
On an operational basis, the Western Hemisphere, excluding the U.S., grew 2.8%, while the Asia-Pacific, Africa region grew 0.9% and [indiscernible] grew 0.8%. Growth in all regions is negatively impacted by the divestiture of the Cordis business with Europe, Latin America and Canada also negatively impacted by hepatitis C competition. 
Excluding the net impact of acquisitions and divestitures and hepatitis C sales, underlying operational growth was 7.8% worldwide, 13.4% in the U.S. and 2.9% outside the U.S. 
I would like to point out that our 2015 fiscal year included an additional week. Since this week occurred during the holiday period, we did not achieved a full week of sales, however, we did have a few more shipping these. These additional shipment dates added approximately 4 points to the quarterly sales growth rate and 1.2 to the annual growth rate. The additional sales are more heavily skewed to the U.S. 
While these few shipping days added to sales, we also had a full week worth of operating costs, therefore the bottom line impact was negligible. 
Turning now to earnings. Net earnings were $3.2 billion and diluted earnings per share were $1.15 versus $0.89 a year ago. 
As referenced in the tables reconciling non-GAAP measures, 2015 fourth quarter net earnings were adjusted to exclude after-tax amortization expense of $220 million and a net charge of $608 million for after-tax special items. 
2014 fourth quarter net earnings [indiscernible] include after-tax amortization expense of $275 million and a charge of approximately $1.1 billion after-tax special items. Dominic will discuss special items in his remarks. 
Excluding amortization expense and special items for both periods, adjusted net earnings for the current quarter were $4 billion and adjusted earnings per share were $1.44, representing increase at 4% and 5.1%, respectively, as compared to the same period in 2014. 
Currency translation significantly impacted net earnings. On an operational basis, adjusted diluted earnings per share grew 12.4%. 
Now turning to the financial highlights for the full year of 2015. Consolidated sales to customers for the year of 2015 were $17.1 billion, a decrease of 5.7% as compared to the same period a year ago. 
On an annual basis, sales grew 1.8% operationally and currency had a negative impact of 7.5%. Excluding the net impact of acquisitions and divestitures and hepatitis C sales, underlying operational growth was approximately 6.5% worldwide, 10.6% in the U.S. and 3% outside the U.S. 
Turning now to earnings. 2015 annual net earnings were $15.4 billion and diluted earnings per share were $5.48. 
For the year 2015 adjusted net earnings were $17.4 billion and adjusted earnings per share were $6.20, down 4.8% and 3%, respectively, versus the 2014 results. 
On an operational basis, adjusted diluted earnings per share grew 5.8%. Estimated free cash flow for the year was strong at $15.9 billion, up $1.1 billion versus 2014. 
Turning now to quarterly business segment highlights, please note percentage of quote that represent operational sales changes in comparison to the fourth quarter of 2014 unless otherwise stated and therefore exclude the impact of currency translation. 
I'll begin with the consumer segment. Worldwide Consumer segment sales of $3.3 billion increased 1.8% with U.S. sales down 4.9%, while outside the U.S. sales grew 5.5%. Excluding the net impact of acquisitions and divestitures underlying growth of approximately 4.7% worldwide, 1.7% in the U.S. and 6.3% outside the U.S. Growth was driven by worldwide OTC and Oral Care as well as Women's Health outside the U.S. 
OTC sales results in the U.S. were driven by the ZYRTEC and product relaunches for desk of health products. 
Strong growth for analgesics was partially offset by timing of inventory builds as noted in the third quarter and a slower start to the flu season. 
In the U.S., adult analgesic market share was approximately 13.5%, up from approximately 11.5% a year ago, while U.S. pediatric share was approximately 45.5%, up from approximately 42% a year ago. 
Results outside a U.S. were driven by strong sales of upper respiratory products and the relaunch of anti-smoking products. 
Strong sales momentum driven by successful marketing campaigns and geographic expansion for new products drove results for LISTERINE and Oral Care and in Women's Health products outside the U.S. 
Moving now to our pharmaceutical segment. Worldwide sales of $8.1 billion increased 6.5%, with U.S. sales up 12.7% and sales outside the U.S. down 0.9%. 
Competitors in hepatitis C significantly impacted sales results. Excluding sales of our hepatitis C products, OLYSIO and INCIVO as well as the impact of acquisitions and divestitures, underlying growth was approximately 11.1% worldwide and 21% in the U.S. 
Sales outside the U.S. declined approximately 0.2%, with strong growth of new and core products offset primarily by lower sales of REMICADE and SIMPONI to our distribution partner. 
Important contributors to growth were STELARA, INVOKANA/INVOKAMET, IMBRUVICA, and U.S. sales of [indiscernible]. 
STELARA achieved strong growth across all the major regions, driven by robust market growth and increase penetration with the psoriatic arthritis indication. 
Strong momentum in market share drove results for INVOKANA/INVOKAMET. In the U.S., INVOKANA/INVOKAMET achieved 6.5% total prescriptions share or TRx within the defined market of type 2 diabetes, excluding insulin and metformin, up from 4.2% last year. 
TRx with endocrinologist was 12.8% for the quarter and 5.8% in primary care. Strong patient uptake was demonstrated efficacy drove results for IMBRUVICA in the U.S. IMBRUVICA is the leader in both new and total patient regimen share in second line CLL and MCL. 
Outside the U.S., results were driven primarily by Europe with strong patient uptake and shared momentum. IMBRUVICA is now approved in over 60 countries. As an update on our oncology pipeline, we received FDA approval for DARZALEX in November. DARZALEX is off to a robust start with strong underlying demand. 
INVEGA SUSTENNA or XEPLION achieved strong results in all major regions primarily due to increased market share and the launch earlier this year of INVEGA Trinza. 
Continued share growth drove results to sales results with TRx for the quarter in the U.S. anticoagulant market of 16.1%, up nearly 1.5 points from a year ago. XARELTO is broadly reimbursed with approximately 95% of commercial and Medicare Part D patients covered at the lowest branded product co-pay. 
REMICADE in the U.S. benefited from strong market growth, partially offset by lower market share. REMICADE U.S. export sales and international sales were negatively impacted by lower distribution partners sales due to the weakening of the euro and the loss of exclusivity in Europe, partially offset by a higher inventory reduction last year.  Strong results were achieved in the Western Hemisphere, excluding the U.S. 
I'll now review the Medical Devices segment results. As a reminder, we announced last week that we will use a new format for the reporting of sales in the Medical Devices segment, and we provided historical sales results in a new format at that time. The historical sales are available on our website. 
Worldwide Medical Devices segment sales of $6.4 billion increased 3.4%. U.S. sales increased 6.7%, while sales outside the U.S. increased 0.6%. Excluding the net impact of acquisitions and divestitures, underlying growth was approximately 5.8% worldwide, with the U.S. up 8% and growth of 3.9% outside the U.S. Growth was driven by surgery, orthopedics, electrophysiology and Vision Care, partially offset by the divestiture of the Cordis business. 
Growth in our surgery business was driven by strong results for the advanced products with endocutters growth of 15%, biosurgical's growth of 9% and energy growth of 5%. 
In addition, ASP and mental products and in our specialty products made significant contributions to sales in the quarter. 
Market growth, additional selling days and new products drove strong results for the U.S. Orthopaedics business. Pricing pressure continued across the major categories, partially offset by positive mix for trauma and spine products. 
The successful introduction in early 2015 at the TFNA nailing system in trauma, the success of the in knees, our primary stent platform in hips and ORTHOVISC MONOVISC in spine or other made important information contributions to the results. 
Orthopaedics sales outside the U.S. were negatively impacted by result in China due to softer demand and a reduction in inventory. Spine, other and trauma were the categories most impacted. 
Our electrophysiology business grew 19% worldwide due to strong market growth, complemented by the success of Dr. MacColl stretch SmartTouch catheter. 
Vision Care results were driven by very strong growth in the U.S. due to the introduction of new products as well as the trade inventory build. 
That concludes the segment highlights for Johnson & Johnson's fourth quarter of 2015. For your reference, there was some notable developments in the fourth quarter, which we have summarized on this slide to assist as you develop your models. 
Lastly, to assist you in updating your models for the full year 2015 on our website, you will find annual sales highlights by segment. It is now my pleasure to turn the call over to Alex Gorsky. Alex?"
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Louise. Let me start by saying how optimistic and confident I am as we enter 2016. We had a strong finish to 2015 with a healthy balance sheet, we are well positioned to continue to invest for future growth. Our core business is very strong, an",2887,"Thank you, Louise. Let me start by saying how optimistic and confident I am as we enter 2016. We had a strong finish to 2015 with a healthy balance sheet, we are well positioned to continue to invest for future growth. Our core business is very strong, and we expect the number of additional new products and in line extensions in the coming year. 
Now as we enter 2016, we look forward to: First, continued growth of core products across our segments; next, a rich near term pipeline and our pharmaceutical segment; positive momentum in our consumer segment with a the full portfolio of OTC's back on the market; setting a strong foundation for sustainable growth with the bold actions we are taken in our Medical Devices segment; and continued financial strength and strong free cash flows to return capital to shareholders and take disciplined and decisive actions regarding M&A that contributed to sustainable growth and long-term value creation. 
Now I'll share more specifics in my discussion with you today about the health care environment, our 2015 results and why we're so optimistic and confident about the future for the enterprise in each of our business segments. But with that as a backdrop, I'd like to begin where I always do by talking about our credo. 
Our credo is the beginning of everything at Johnson & Johnson. It guides all of our decisions, and I believe it sets us apart. 
This year's Johnson & Johnson's 130th year, think of that for a moment. 130 years of working to balance our mission of helping people everywhere live longer, healthier and happier lives, and I'm proud to see the employees of Johnson & Johnson around the world continuing to uphold the imperatives of our credo everyday, through both our philanthropy initiatives as recent commitment to supporting the immediate ongoing needs of Syrian refugees in partnership with Save the Children as well as to our commitments of the health care community with investments that will accelerate how we address global health crises like a Ebola, AIDS and mental health. 
You even heard me say that I believe health care is one of society's greatest challenges. And this global challenge grows with aging populations, rising cost in developed world and growing middle classes in emerging economies, we have increasing expectations for access to quality care. Now as the world's largest and most broadly based health care company, it's not just an opportunity for us to help manage this transformation, it is our responsibility to help lead the way to a better future. 
Now in this environment, ensuring access to important medicines and medical procedures remains a key objective for us. As government officials, politicians and other stakeholders debate significant issues around the world, we're pleased to see the health care is such a focus on the the dialog, and we believe that our goals, and those of the policymakers are aligned to find the best ways to ensure the delivery of quality health care and the best patient outcomes and a high quality and sustainable manner. Now in this discussion, it's a responsibility of all stakeholders to consider the economic and financial implications of health care. We got to look at the whole picture, drugs, devices and share of hospitals and governments put the patient in the center and reward innovation to drive better outcomes. 
Here in the United States, prescription drugs represent approximately 12% of total health care costs and Medical Devices for percent around 6%. These cures and treatments not only improved quality of life for many patients, extend life for others and contribute to the productivity of our society, but they can also help to reduce caregiver burden, disability and health care spending overall. The promise of innovation and health care is great. It will remain great if we can take a holistic approach to reforming the health care system. 
At Johnson & Johnson, we believe in this holistic approach to health care solutions. It's a vital to developing the best innovations, to meeting the needs of our stakeholders and to sustaining our legacy of strong and consistent business performance. Our consumer medical devices and pharmaceuticals segments were increasingly interconnected businesses, and we believe that being broadly based in health care has been and will continue to be a significant factor in Johnson & Johnson's success as a positions as well to lead and grow our business with the evolving health care landscape. Our broad global footprint enables us to reach more patients and consumers in fast developing and changing markets. In fact, Johnson & Johnson's operating in 60 countries today, and we're continuing to invest in implementing new operating models, forging strong relationships with local governments and health systems and further accelerating growth through strategic acquisitions and partnerships with local companies. 
Because of our broad-based across health care, we are uniquely positioned to be a partner of choice. Now let me just go over a few examples. With large health systems, we are taken more of the business to business model to help them with innovative contracting strategies, integrated services and solutions and with dedicated customer-focused teams. We're working with technology companies like Google, IBM and Apple, we're advancing medical innovation through an infusion of technology that can benefit from the deep health care expertise Johnson & Johnson can uniquely provide. 
We're continuing to support biotech and med tech start-ups who appreciate the value we place on innovation and the reach and breadth of our footprint in the health care market. And with public health organizations, we have a tremendous opportunity to address the gaps that remain in innovation, access and delivery of effective prevention and treatment. We're collaborating more than ever before to meet the world's most pressing public health challenges. 
Our scale, financial flexibility and business and health care expertise make Johnson & Johnson a key partner for a number of our stakeholders. And our relationships with these partners will help Johnson & Johnson continue to be a leader in the future. 
Applying our expertise in design thinking, strategic innovation models and a commitment to collaborating with all stakeholders, we've developed a number of cross segment innovations. 
For example, we've created the China Lung Cancer Center, which is developing a holistic approach to treat lung cancer in China where the disease is particularly prevalent. We're pioneering cell therapy for age-related macular degeneration, combining technologies from pharma and from our Vision business to find a way to address this condition. 
And we're leveraging capabilities from our Medical Devices, pharma and consumer businesses to treat obesity and diabetes in the ways. 
In fact, almost everyone of our programs can benefit from the advantages of our broad base. 
Over the past several years, we've also been leveraging our scale by developing enterprise efficiencies and capabilities across all of our sectors, targeting as much as $1 billion in operational savings by 2018 to support our growth. And we believe innovation is taking place within our supply chain and quality systems is actually creating a competitive advantage for Johnson & Johnson. 
But the bottom line, well, it's the bottom line. In this broad-based structure has helped us deliver strong, consistent and sustainable financial performance. Let's consider some of the numbers. 
First, 53 consecutive years of dividend increases at Johnson & Johnson. That means we have provided steady dividend increases since we first put a man in space. And 32 years of consecutive adjusted operational earnings growth more than 3 decades. 
Over the past 10 years, we have returned approximately 70% of our free cash flow to our shareholders. And today, 70% of our revenues come from brands that are #1 or #2 in their markets. We have 24 brands that represent billion dollar platforms. If you think about that, 1999, the entire corporation had revenues of $24 billion and about 25% of our sales come from brands launched in the last 5 years. That's a result of constant learning, collaboration and innovation. 
Our corporate structure, our broad-based is a strategic choice and one that is grounded our performance, not just our heritage. We know it has been a significant driver in the past and expect it will be more important in the future. 
As we've said, we see global health care growing at 3% to 5% over the next 5 years, and we have a clear objective that Johnson & Johnson should grow sales organically at a faster rate than the market. We also intend to grow our earnings faster than sales. 
In addition, we will continue to create value through strategic acquisitions and partnerships that generate additional growth. All of this, coupled with our strong dividend yield, and you're a looking at the very compelling total shareholder return. 
As part of our performance-driven strategy, we regularly review the structure and portfolio of our businesses to a valid how dare delivering on our responsibilities to stakeholders outlined in our credo, meeting evolving health care needs and achieving performance expectations. Johnson & Johnson has a rigorous and disciplined portfolio review program focused on creating long-term shareholder value, and this applies to all our businesses. We have a track record of evolving our business and taking decisive actions when necessary to meet changing industry and consumer dynamics, and we'll continue to do so in the future. We're actively looking for the right opportunities to create greater value for our shareholders. We are seeking companies with a mutual desire to partner, but we're also patients. We will only act when we see the right value-creating deal at a right price and with the right partners. 
Now historically, about half of our growth has come from M&A and half from internal development, which we fully expect to continue and with our strong balance sheet, we've got the resources to do just that. 
Now let me take a few minutes to review the priorities we laid out for you last year. One, we will continue to be focused on delivering on our financial equality commitments; two, in pharmaceuticals, our objective, as always, is constant innovation. We're building in our launch excellence and continuing to develop a robust pipeline of transformational medicines. 
In our Consumer business, we positioned our entire portfolio to focus on key geographies, need states and mega- brands. We're prioritizing and investing to expand our market leadership and key consumer segments in OTC, Oral Care, Baby and Beauty. 
And as you heard through our announcement last week, our priority in Medical Devices is accelerating growth through strategic investments in innovation and by transforming our go-to-market models. We're confident that these priorities will deliver the results that you expect from us. And just as importantly, the results that we expect from ourselves. 
As we've said, we are pleased with our 2015 performance. In 2015, we generated sales of $70.1 billion, reflecting strong underlying operational growth across our enterprise. Our end market portfolio and pharmaceuticals delivered strong growth. We built positive momentum in our consumer segment and we've just announced bold actions to accelerate growth in our medical device segment. 
Throughout the year, you've heard from each of our business segment leaders about the strategies we put in place to meet our commitments, so I'll touch on just a few of the recent actions we've taken to advance those strategies. 
As Joaquin Duato laid out for you at our pharmaceuticals business review in May, our pharmaceuticals business has a clear strategy focused on 5 therapeutic areas of high unmet medical need, a robust innovation engine, improving commercial capabilities. Joaquin talked to you about how we're investing in our future with 10 new products we plan to file by 2019, each with a potential to exceed $1 billion in annual sales. And in fact, we are already delivering one of those promising medicines to the market, 4 months ahead of schedule with the U.S. approval for DARZALEX, the first human monoclonal antibody to be approved anywhere in the road for patients with multiple myeloma, which is off to a very good start. 
In the near term, I know many of you are keeping an eye on potential biosimilar completion of the United States. As you've heard us say, biosimilars are not generics. With more than 2.4 million people having been treated with REMICADE and about 70% of the current patients receiving sustained and effective treatment, we believe doctors will be reluctant to switch them off with that level of success. 
And we've seen this play out in many markets where biosimilars have already been introduced. And we also have a patent for REMICADE that expires in September 2018 that will obviously continue to vigorously defend. 
We consider our Immunology products part of an important and robust portfolio for patients, physicians and payers. So when you consider our continued expectations for REMICADE as well as the future potential of products like STELARA and SIMPONI and the pending submissions of [indiscernible] and [indiscernible], we are confident in our ability to continue driving strong growth from our Immunology portfolio. 
When you combine these advances with additional line extension approvals expected in 2016 like those for IMBRUVICA, STELARA, INVOKANA and DARZALEX approval in the EU, our new term pipeline is incredibly robust and may not be fully appreciated in the market. With the combined strength of our end market portfolio and a deep late stage pipeline, we expect to deliver above industry compound average growth through 2019. 
Our consumer expertise, insight and access are becoming increasingly valuable to payers and providers as demographic and technology trends in health care are moving the system toward more consumer driven decision-making and in some cases, self-care alternatives. We see this as a key differentiator for our company, and we're investing in technologies that help us exploit this expertise across our broad base. Troy and our other consumer business leaders will share more details of our consumer business review this may. 
For 2015, our U.S. OTC business continue to grow faster than the market, and we're happy to report that nearly all of our OTC products will return to shelves, and we are proud the quality system improvements we have put into place. 
Our consumer medical device businesses, the Johnson & Johnson diabetes Solution Companies and Johnson & Johnson Vision Care made progress in 2015 to improve our competitiveness. Both businesses, which command global leadership positions in their respective categories, focused their 2015 turnarounds on launching new products, solidifying their base businesses and accelerating growth.  And both businesses have regained stub less market share and market leadership and introduced important new product such as Animas Vibe and ACUVUE OASYS 1-Day with hydro lacks in the U.S. 
In our broader Medical Device businesses, last week, we announced a strategic restructuring initiative designed to directly support and accelerate the strategy Gary Pruden laid out for you on our third quarter earnings call. We are allocating resources to priority platforms like endocutters, knees, trauma and EP and recent history showed that when we doubled down in an area, we are able to accelerate meaningful innovation and outcomes as we saw with our endocutters portfolio, which is now the fastest growing platform in our medical devices segment. 
Additionally, we're making progress on transforming our go-to-market models of our cross-selling efforts between Ethicon and DePuy Synthes joined reconstructions of spine which resulted in over 600 leads through 2015. We are now co-selling in over 1,200 accounts and all sales teams will be trained covering all markets and by the end of the first quarter. 
And finally, our recent acquisition of the Herrick's medical in the area of atrial fibrilation and surgical robotics collaboration with Verily, formerly Google Life Sciences, are examples of the type of focus and strategic investments that you will see us make more off in the future. 
Our goal is to reach more patients, outperform the markets in which we compete and consistently identify build and acquire new platforms for growth. 
Moving forward into 2016, we will continue to take bold but appropriate steps to put our Medical Device business in the best position to deliver more value for customers and for our company and for our shareholders. 
In summary, we believe that improved universal access to quality health care, rewarding innovation and a more vital culture of health, wellness and prevention are the keys to the future where people are healthier and businesses and economies are stronger. Our broad based experience and scale uniquely positions Johnson & Johnson as a leader and partner of choice and the movement towards outcomes and episodes of care some-based approaches and ultimately, a healthier society. We are optimistic about the future opportunities in health care and confident in the strength of our business. 
In 2016, we will remain focused on our near-term priorities and continue to advance our longer-term growth drivers, enabling us to continue delivering shareholder value year after year. 
With the guidance of our credo, we'll continue to meet our responsibilities to all stakeholders. That's been true for 129 years of breakthrough, life-saving innovation, and we are confident Johnson & Johnson is well positioned to continue meeting those responsibilities for the next 130 years. 
Thank you. I look forward to further dialogue during the Q&A session. But first, I'll turn it over to Dominic Caruso, who will talk more about our results and expectations for 2016. Dominic?"
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Thanks, Alex, and good morning, everyone. As you've heard from Alex, we're very pleased with our 2015 performance. We believe we managed our business well and I provided you insights during the year in a transparent manner that allowed all of you to und",2445,"Thanks, Alex, and good morning, everyone. 
As you've heard from Alex, we're very pleased with our 2015 performance. We believe we managed our business well and I provided you insights during the year in a transparent manner that allowed all of you to understand our plans and expectations. We finished the year strong, and we're carrying that momentum into 2016. 
We ended the year at the top end of our operational guidance range for both sales and earnings, and exceeded estimates for earnings as published by first call. 
Turning to the next slide. You can see our condensed consolidated statement of earnings for the full year 2015. I'd first like to remind you about some of the key assumptions in our guidance for 2015. At the beginning of the year, we discussed that, while we reinvested some of the profitability from OLYSIO sales, our earnings in 2014 did benefit by approximately $0.20 per share even after those investments, making 2015 comparison to 2014 results more challenging. 
Additionally, currency headwinds increased quite substantially in 2015, negatively impacting both sales and earnings for 2015 by approximately 8%. 
Given those expected headwinds, last January, we guided that we would deliver operational sales growth in the range of 1% to 2%. 
As you can see, well reported sales results showed a decrease of 5.7%, on an operational basis, we ended up at the high end of our guidance where operational sales growth at 1.8%. 
We also provided you with an estimate of our underlying operational sales growth for 2015, which excluded the impact of all acquisitions and divestitures as well as the impact of hepatitis C sales. We expected that underlying operational growth will be approximately 6%, and we exceeded that estimate, delivering 6.5%. 
On earnings, our adjusted operational EPS growth in our original 2015 guidance was expected to range between 2.3% and 4.7%. 
As reported this morning, our EPS of 6.20, reflects operational growth of 5.8% and is at the top of the updated EPS guidance range we gave in October. 
And finally, our adjusted net income margin improved to 24.9%. 
Now let's take a few moments to talk about certain items on the statement of our earnings for the quarter. Turning to the next slide. You can see our condensed consolidated statement of earnings for the fourth quarter of 2015. 
As we expected, direct comparisons to our fourth quarter of 2014 will be challenging to the stronger OLYSIO sales that we benefited from last year as well as divestitures and currency headwinds in 2015. Our results on an operational basis, excluding the impact of acquisitions and divestitures and excluding the impact of hep C sales are up 7.8% for the quarter. 
As Louise noted, sales did benefit from additional shipping days in the fourth quarter of 2015. 
Please now direct your attention to the box section of the schedule where we have provided earnings adjusted to exclude special items and intangible asset amortization expense. 
Adjusted net earnings were $4 billion in the quarter, up 4% compared to the fourth quarter of 2014 and adjusted earnings per share of $1.44 versus $1.37 a year ago are up 5.1%. And the adjusted EPS results exceeded the meaning of the analysts estimate as published by first call. 
Excluding the impact of translational currency, our operational adjusted EPS was $1.54 or up 12.4% for the fourth quarter. 
In the quarter, we incurred intangible amortization expense of $200 million on an after-tax basis as well as after-tax special charges of $600 million, which included an expense of $400 million related to the restructuring of our Medical Device business, which we announced last week and in process research and development charge of $200 million. 
Now let's take a few moments to talk about the other items on the statement of earnings. Cost of goods sold was 30 basis points lower than the same period last year, impacted by changes in our business and product mix. Selling marketing and administrative expenses were 33.1% of sales. This is 120 basis points higher than last year as we continue to invest to drive growth in our key brands. Our investment in research and development as a percent of sales were 16.1% in the quarter and 170 basis points higher than the prior year as we continue to make important investments in our pipeline for future growth. 
In fact, in the fourth quarter, we entered into important new licensing agreements, made milestone payments and increased spending to advance our R&D portfolio, which are all positive developments as we continued to strengthen our pipeline. 
Interest expense, net of interest income, was slightly lower, reflecting higher earnings on our investments. Other income and expense was a net gain of $1.2 billion in the quarter compared to a net charge of approximately $1 billion in the same period last year. Of course, this line item includes several special items in both years. Excluding those special items, other income and expense was a net gain of approximately $1.3 billion compared to a net gain of approximately $130 million in the prior year period. This year's fourth quarter reflects the gain on the previously announced divestitures of Cordis. 
As a reminder, we indicated that any gains from divestitures, which are reflected in the other income and expense line would largely be reinvested in the business as well as used to mitigate the negative impact of currency and the lower level of income in 2015 from reduced OLYSIO sales. And therefore, our pretax operating margin would be expected to be lower in 2015 versus 2014. And 
our 2015 results reflect just that. We funded important investments with a higher level of other income that will benefit us going forward. 
The adjusted fourth quarter effort tax rate for 2015 was 17.7%. This was lower than the rate in the previous 9 months due to the passing of legislation, which renewed the R&D tax credit and look through provisions. The R&D tax credit and look through provisions were always included in our annual guidance. 
The adjusted full year effective tax rate for 2015 was 20.7%, slightly below guidance due to the mix of income from higher to lower tax jurisdictions. 
Turning to the next slide, I will now review adjusted income before tax by segment. Adjusted income before tax for the entire enterprise improved from 30.7% of sales at '14 to 31.4% of sales in 2015. 
Looking at the adjusted pretax income by segment. Medical Devices expanded 360 basis points due primarily to the gain associated with the Cordis divestiture, while pharmaceutical margins contracted 50 basis points due to the lower OLYSIO sales and increased investments in research and development, partially offset by the gain earlier in the year of divestiture of NUCYNTA. 
Consumer margins contracted 110 basis points due to lower divestitures gains in 2015 versus 2014 as well as important investments for future growth as we returned our iconic consumer brands to the market. 
Now I will provide some guidance for you to consider as you refine your models for 2016. Before I discuss sales and earnings, I'll first give you some guidance on items we know may be difficult to forecast. 
I first like to address our cash position and remind you about our capital acquisition approach. At the end of the quarter, we had approximately $18.5 billion of net cash, which consist of approximately $38.5 billion of cash and marketable securities and approximately $20 billion of debt. This is a higher level of cash than we typically hold and as Alex said earlier, we're actively looking for the right opportunities to deploy that capital to create greater value for our shareholders. But we are patient. We are seeking companies with a mutual desire to partner and will only act when we see the right value-creating deal at the right price with the right partners. 
We have a transparent and disciplined capital allocation strategy that starts with evidence to our shareholders, followed by value creating M&A and then we consider other put in place to return value to shareholders such a share repurchase programs. And due to our strong balance sheet, we had a financial strength and flexibility to execute on all 3 of these capital allocation priorities simultaneously. 
During Q4, 2015,, we used approximately $1 billion to repurchase shares of our stock in connection with our $10 billion share repurchase program that we announced in October. 
Although we are continuing to evaluate external value-creating opportunities in line with the strategy, the purposes of your models, assuming no major acquisitions or other major uses of cash, we suggest you consider modeling 2016 net interest expense of between $450 million and $550 million. 
Regarding other income and expense, as a reminder, this is the account where we record royalty income as well as gains and losses, providing such items as litigation, investments by our development corporation as well as divestitures, asset sales and write-offs. 
We would be comfortable with your models for 2016 reflecting other income and expense, excluding special items as a net gain, ranging from approximately $1.1 billion to $1.2 billion. Although we expect to have a significantly lower level of other income in 2016 versus 2015, our pretax operating margin in 2016 is expected to expand by more than 200 basis points. 
As we've discussed several times during the year, we continue to evaluate our portfolio, and we expected at any gains from divestitures would be lower than the level we saw in 2015. However, we also discussed that we would nonetheless, improve on earnings as we see the benefits of good expense management and meaningful investments we made in 2015. 
And now a word on taxes. We're very pleased that the R&D tax credit was made permanent and approved by Congress this last year. We would be comfortable with your models reflecting an effective tax rate for 2016 excluding special items of approximately 19.5% to 20.5%. 
Turning to sales and earnings guidance. Our sales guidance for 2016 assumes no biosimilar entrance for Procreate and REMICADE in the U.S. We also do not anticipate generic competition this year for ZYTIGA, word and INVEGA SUSTENNA. But as expected, there are generic entrance for INVEGA and [indiscernible]. 
As we've done for several years, our guidance first based on a constant currency basis reflecting our results from operation. This is the way we manage our business, and we believe this provides a good understanding of the underlying performance of our business and will also provide an estimate of our sales and earnings and EPS results for 2016 with the impact of exchange rates could have on the translation of those results. 
For the full year 2016, we would be comfortable with your models reflecting an operational sales increase of between 2.5% and 3.5% for the year. This would result in sales for 2016 on a constant currency basis of approximately $71.9 billion to $72.6 billion. 
Additionally, while we have comparison to how we describe our sale results in 2015, our 2015 operating sales growth, excluding the impact of all acquisitions and divestitures and hep C sales was approximately 6.5%. After adjusting for extra shipping days in 2015, that underlying growth rate was approximately 5.5% 2015. 
Our sales guidance for '16 on a same basis is expected to continue at a similar growth rate of around 5.5%. 
While the euro has been fairly stable over the last few months, many of the other currencies have been volatile. Although we're not predicting the impact of currency movements, using the euro at 1.09, our guidance for sales growth would decrease by approximately 1.5%. We are watching the other currencies closely as it is uncertain as to how they will settle after the year. Of course, we will update this assessment as we progress through out the year. 
Plus under this scenario, we would expect reported sales to reflect the change in the range of 1% to 2% for a total expected level of reported sales of approximately $70.8 billion to $71.5 billion. 
Now turning to earnings. By continue to impact our earnings guidance for 2016 is the impact of currency movements on transactions, which, although hedged, is still somewhat negative. We expect transaction currency impact and negatively impact our gross margin by approximately 60 to 80 basis points in 2016 as compared to 2015. We would be comfortable with adjusted EPS guidance in the range of $6.53 to $6.68 per share on a constant currency basis, reflecting operational or constant currency growth rates of 5% to 8%. Again, we're not predicting the impact of currency movements, but to give you an idea of the potential impact on EPS with the euro at 1.09. Our reported adjusted EPS would be negatively impacted by approximately $0.10 per share. Therefore, our reported adjusted EPS would range from $6.43 to $6.58 per share. At this early-stage in the year, we would do comfortable with your models reflecting the midpoint of this range, which at approximately 5%, is higher in current consensus estimate. 
So in summary, as you update your models for the guidance I just provided, I'd like to make a few points. Although operational sales growth is expected to range between 2.5% and 3.5%, we're pleased to note when excluding the impact of acquisitions and divestitures and hep C sales, our operational sales growth is expected to be around 5.5% for the full year 2016. 
With regards to expected EPS growth on an operational basis, our adjusted EPS growth guidance is strong in the range of 5% to 8%. 
Also for 2016, pretax operating margins are expected to expand by more than 200 basis points based on the guidance I just provided. The margin expansion is driven by combination of investments we've made in 2015, coupled with the benefit of disciplined expense management across the enterprise. 
Moving into 2016. We are confident in the strength of our business. As we execute on our growth plans and near-term priorities that Alex laid out for you this morning, we're well-positioned with the strong balance sheet to deliver solid results, while continuing to invest in innovation, which will ensure our future growth and success. Our goal remains to grow our sales organically at a rate faster than the markets, in which we compete, grow our earnings faster than sales and create value through strategic acquisitions and partnerships that generate additional growth. 
All these, coupled with our strong dividend yield, provides a very compelling long-term shareholder return. Finally, before I turn it over to Louise for Q&A, just a reminder to please save the date for our Consumer and Medical Device Business Review on Wednesday, May 18. 
Thank you. Now back to Louise."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Dominic. Manny, could you please give the instructions for the Q&A session?",14,"Thank you, Dominic. Manny, could you please give the instructions for the Q&A session?"
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","[Operator Instructions] And your first question comes from Mike Weinstein of JPMorgan.",12,"[Operator Instructions] And your first question comes from Mike Weinstein of JPMorgan."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","So let me start with the margin expansion piece for guidance and this kind of fits in with the announcement last week on the MD&D business. And there's 2 parts for the question. So if I look at MD&D and where you ended up with pretax margins in 2015, they",145,"So let me start with the margin expansion piece for guidance and this kind of fits in with the announcement last week on the MD&D business. And there's 2 parts for the question. So if I look at MD&D and where you ended up with pretax margins in 2015, they were at 35.6%, and observed would say these are very high margins. And for the overall company, you're guiding to 200 basis points plus of pretax margin improvement, which would make 2016 the biggest year margin expansion in the last 15. So talk about the decision to be as aggressive as you are being in 2016 on operating cost. And for the in MD&D business, in particular, why is the consolidation that you're pursuing called the cost transformation imperative at this point in time? And why are you being as aggressive as you're being?"
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Sure, Mike. Thanks for the question. So a couple of things. One is the 2015 as you saw was a heavy investment year because we benefited from the divestitures and I think we are very transparent that we would make important investments going into 2015, and",195,"Sure, Mike. Thanks for the question. So a couple of things. One is the 2015 as you saw was a heavy investment year because we benefited from the divestitures and I think we are very transparent that we would make important investments going into 2015, and we did just that. So in 2016, we have a lower level of those investments consistent with a lower level of the other income that we just guided to. Also, it's important to point out that those investments we made in 2015 we're seeing the benefits of those already in 2016, so we think they are wise investments. And finally, we've talked a lot about our various programs of reducing our cost structure and Alex today mentioned the program that we're embarking -- that we embarked on several years ago that will reduce costs by $1 billion by 2018. While we're well on our way in implementing that program after several years of investment, in 2016, we'll see a year where the actual benefit associated with that program outlay any incremental investments. And maybe, Alex, comment on the MD&D restructuring and why that's appropriate for us to do today."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes, Mike. We do think that this is the right time to be making the moves. But really, I think it's important to kind of step back and put it in the larger perspective. If you think about what we've been doing a Medical Devices over the last several years",172,"Yes, Mike. We do think that this is the right time to be making the moves. But really, I think it's important to kind of step back and put it in the larger perspective. If you think about what we've been doing a Medical Devices over the last several years, we've had a range of activities ranging from some of divestitures with OCD as well as Cordis underway. At the same time, we've been making changes internally with the way that our organizations are innovating as well as the way that they're going to market. And so we see this as the next logical step in that overall process. Our Medical Device businesses one that we remain very committed to. We believe this has got an exciting future, a lot of new innovation coming, new ways of dealing with our customers. And so we think this is the right time to make sure that we're set up for growth, not only in 2016, but actually for the next 5 and 10 years."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Dominic, can you share in the commentary about how you're thinking about the respective businesses in 2016 versus your 2015 performance? And then maybe just on the MD&D topics, it's hard to tease out what the kind of underlying growth with extra selling d",72,"Dominic, can you share in the commentary about how you're thinking about the respective businesses in 2016 versus your 2015 performance? And then maybe just on the MD&D topics, it's hard to tease out what the kind of underlying growth with extra selling days, but it did growth 5.8% this quarter. That's obviously inflated by that. Do you have any thoughts just in terms of where you are performance in MD&D business?"
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes, sure Mike. Let me comment overall. As you know, our growth in 2015 primarily driven by pharmaceuticals, and we expect healthy growth in 2016 from pharma. We're probably slightly lower rate of growth than what we saw in '15 as those products that we l",131,"Yes, sure Mike. Let me comment overall. As you know, our growth in 2015 primarily driven by pharmaceuticals, and we expect healthy growth in 2016 from pharma. We're probably slightly lower rate of growth than what we saw in '15 as those products that we launched are beginning to mature in their growth trajectory but still a lot of growth ahead of them. So we're not going to give guidance by sector, but overall, a little bit lower growth than 2016 than 2015 for pharma. Better growth in consumer, good momentum in '15 carrying on into '16, and we expect higher growth rates in '16 versus '15 part of Medical Device business as well. And as you saw, we ended the year with good strong momentum in that business as well."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Guillen Navarro of RBC Capital Markets.",11,"The next question is from Guillen Navarro of RBC Capital Markets."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Question for Alex. Alex, given the strong balance sheet, I'm somewhat surprised you were not more aggressive with the balance sheet in 2015, especially on the M&A front. And you made some comments about the balance sheet going forward. But I'm just curiou",102,"Question for Alex. Alex, given the strong balance sheet, I'm somewhat surprised you were not more aggressive with the balance sheet in 2015, especially on the M&A front. And you made some comments about the balance sheet going forward. But I'm just curious, as you evaluate your options particularly on the M&A front, is the fact that we haven't seen deals year-to-date or so far, is because the targets still have very high valuation expectations? Or is it that most of your cash is trapped outside the U.S, limiting your ability to do acquisitions? Or is it a little bit of both?"
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Glenn, thank you very much for your question. Look, we are, and we have been and will continue to be very active in the M&A category. As we mentioned during the earlier comments, if you look at it historically really over about any time frame 20 years, 10",262,"Glenn, thank you very much for your question. Look, we are, and we have been and will continue to be very active in the M&A category. As we mentioned during the earlier comments, if you look at it historically really over about any time frame 20 years, 10 years what you see is about half of our growth being generated from organic innovation platforms and about 50% being generated vis-a-vis M&A. We reflect back on 2015, we realized that the market was premium priced. We remain very active in a number of different areas. And while we didn't necessarily close on a larger deal, I would not assume that we were not engaged and involved. At the same time, we think it's really important for you, our shareholders, as you think about long-term returns that we stay at the appropriate level of discipline and decisiveness as we go through that process. And as we look at the environment today, we see a number of opportunities across the consumer the Medical Device and the pharmaceutical groups. We're going to remain very active. I think that our financial team has done a great job of using our offshore assets in a very compliant but also tax effective way. And we'll continue to look for opportunities that ultimately we believe are going to provide -- are going to help us continue to get into growing markets to improve our share position, to provide complementary products and services to platforms that we already have that ultimately are going to lead to long-term sustainable growth for JNJ."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","So if I hear you correctly, you're saying valuations were elevated for the targets in 2015. But I sense from you that the target value, the valuations of your targets, valuations are coming down, and it sounds like that the cash sitting outside the U.S. w",81,"So if I hear you correctly, you're saying valuations were elevated for the targets in 2015. But I sense from you that the target value, the valuations of your targets, valuations are coming down, and it sounds like that the cash sitting outside the U.S. will not inhibit deal flow. So is that a fair assumption? And then, is there any one business versus the other that you would be more likely inclined to do an acquisition to help accelerate growth?"
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes, Glenn. Look, we're fortunate because of our strong performance, our strong cash flows that our balance sheet is actually quite strong. I also believe that if you look at our track record of how we've utilized that cash to make the right capital inves",169,"Yes, Glenn. Look, we're fortunate because of our strong performance, our strong cash flows that our balance sheet is actually quite strong. I also believe that if you look at our track record of how we've utilized that cash to make the right capital investments in companies that we've been successful with that. And look, we think that there's opportunities across all 3 of our different sectors. And it's not an algorithm per se as we decide, which and where to invest, but rather, it really depends on the opportunity and many of the factors that Dominic described earlier as far as what are the specific platforms that we're looking at, where is the partner in terms of their decision-making, what they want to do with the business and frankly what the competitive environment is like. So we think that there are opportunities. We intend to be quite active as we look at 2016 and beyond in a manner that's been consistent with our track record in that area."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Matt Miksic of UBS.",9,"The next question is from Matt Miksic of UBS."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","So one kind of broader question on the sort of changes in the health economy in the U.S., and then I have one follow-up on sort of the extra day commentary that you made. So looking forward to the MD&D day and the update on sort of the restructuring there",145,"So one kind of broader question on the sort of changes in the health economy in the U.S., and then I have one follow-up on sort of the extra day commentary that you made. So looking forward to the MD&D day and the update on sort of the restructuring there. But stepping back, you've been one of the leaders here in sort of broader contracting strategies and development some of these value-added services like care center and outpatient solutions. I think it would just be helpful to get your thoughts on what you're seeing in the marketplace in terms of uptake, of those kinds of strategies. And maybe talk about whether we're in the early innings here and how you think about some of the benefit you're seeing or hope to see with those approaches to the business. And then I have one follow-up."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Sure, Matt. Thank you very much. Look, overall, we feel that we're still in the very early innings what I would call as the market evolution that we clearly expect to see over the next 3, 5 and even 10 years. Now for all the reasons that we've discussed a",484,"Sure, Matt. Thank you very much. Look, overall, we feel that we're still in the very early innings what I would call as the market evolution that we clearly expect to see over the next 3, 5 and even 10 years. Now for all the reasons that we've discussed around increasing demands based on demographics certainly here in the U.S. and the rising middle class and demographics outside the United States and the pressure that, that's likely going to put on payers and governments and others in between, we realize that there is an opportunity for us to participate, not only in bringing great innovations, going to outpatient, but also doing it in a value-added way. And clearly, the consumer, the patient, is weighing in much heavier in these decisions as they take on higher co-pays, as they can get more information that's available online. And frankly, they just have higher expectations about their ability to participate in that health care decision-making process. So what we see is a range of customers, but we see some customers who are still very innovation focused. And to be clear, we remain very innovation focused. We think at the end of the day, what we do best is bring new products, new solutions to our customers that are going to ultimately have better outcomes for patients. And so that's an area where we are very focused on, and we'll continue to be focused on. We are starting I'd also see hospital systems. And I think one important point here is it's certainly taking place in the United States, but it's also definitely taking place in places like Europe and even some of the developing and emerging markets that frankly don't have the history of the legacy of some of the infrastructure that you see in the more developed markets. And there, what we see is an evolution more towards the business to business relationship where U.S. customers want to see innovation but they also want to see how you're going to interact, how can you assist them in working with our supply chain to make it more efficient, how can we work together as part of a broader partnership that ultimately is focusing not just on our product sell, but actually and an out, on an episodic care for the patient, and it creates a much broader partnership. We are seeing those organizations becoming more and more interested, and that's why we are adapting to make sure that we are part of that. So I think, overall, it's important that we continue to innovate, we continue to operate with a lot of excellence in the current environment. At the same time, it's important that we set the stage for this evolution that's taking place out there to make sure that we cannot only be successful, but we'll actually be a leader as the market evolves as well."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Very, very helpful. And then the clarification on the extra shipping day as you talked about holiday week and maybe or surgery days were not as much of a factor shipping days from what I can tell in your commentary. But your strong in Vision Care always b",120,"Very, very helpful. And then the clarification on the extra shipping day as you talked about holiday week and maybe or surgery days were not as much of a factor shipping days from what I can tell in your commentary. But your strong in Vision Care always been shipping type of business, strong at pharma. Just wondering, Dominic, if you have any comment on some of your consignment businesses where we think about orthopedics, spine and trauma where the inventories in the field that's on your balance sheet, is it -- was there any difference in the way dose business were impacted versus businesses where you're actually shipping and billing for things in the last couple days of the quarter?"
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Sure, Matt. Well, just overarching comment on this. Of course, these extra shipping days were already included in our guidance for the year, and I think the all modeled for them. And as you know, our sales came in pretty much in line with expectations. Ab",117,"Sure, Matt. Well, just overarching comment on this. Of course, these extra shipping days were already included in our guidance for the year, and I think the all modeled for them. And as you know, our sales came in pretty much in line with expectations. About 1% for the year, we think, is the impact overall for the enterprise and about 4% in the quarter. You're right, it does vary slightly by different businesses within the U.S. in particular. This is largely U.S. phenomenon as opposed to a global phenomenon. And with respect to the Orthopaedics business line, which I think you're referring to specifically, I think, Louise, you might have the details on the impact there."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes. So -- additional days in the U.S. in orthopedics was about 2.5 days and outside the U.S., about 1.5-day average.",21,"Yes. So -- additional days in the U.S. in orthopedics was about 2.5 days and outside the U.S., about 1.5-day average."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","So not really that much difference from the overall total because of that 2.5 days get you to this 4% and 1% that I talked about earlier.",28,"So not really that much difference from the overall total because of that 2.5 days get you to this 4% and 1% that I talked about earlier."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","It's interesting also when you look at the underlying growth in the Orthopaedics, third quarter, fourth quarter taking out the additional days, we saw sequential improvement across hips, knees, spine and trauma.",33,"It's interesting also when you look at the underlying growth in the Orthopaedics, third quarter, fourth quarter taking out the additional days, we saw sequential improvement across hips, knees, spine and trauma."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","That's right.",3,"That's right."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes.",1,"Yes."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","On a worldwide basis, okay?",5,"On a worldwide basis, okay?"
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Larry Biegelsen of Wells Fargo.",10,"The next question is from Larry Biegelsen of Wells Fargo."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Let me just start with Med Tech and then I have a follow-up on pharma. So Alex, can you talk about the health of the Med Tech end market in the U.S. and emerging markets? And what drives the acceleration for Europe business specifically in 2016? When I lo",95,"Let me just start with Med Tech and then I have a follow-up on pharma. So Alex, can you talk about the health of the Med Tech end market in the U.S. and emerging markets? And what drives the acceleration for Europe business specifically in 2016? When I look at the general surgery business, it looked like adjusting for the extra days in the U.S., that was a worldwide, that was slightly weaker in Q4. So just the health of the end markets in the U.S. in emerging markets, and I had a follow-up."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Sure. Thanks a lot for the question, Larry. I think what we would say overall is we continue to see, -- let's say, a slightly increasing positive trends. So we saw hospital admissions, I believe, up around 2%, we saw surgical procedures up a little over 1",619,"Sure. Thanks a lot for the question, Larry. I think what we would say overall is we continue to see, -- let's say, a slightly increasing positive trends. So we saw hospital admissions, I believe, up around 2%, we saw surgical procedures up a little over 1% in the U.S., that the most recent data that we have. If you go outside a U.S., we think rates in Europe have been pretty steady. And even in the markets in which we compete most significantly in the developing markets, we haven't seen a major impact from secular shifts perhaps from China some, but not dramatic. And then putting it in the context what that represents overall in our business, we don't see it as a major indicator. As I look towards 2016, look, there's a few things that cost as to be optimistic about our Medical Device business. It really starts with innovation. And we've got about 30 products that we'll be launching by the end of 2016, over half of those have either been launched or well underway as we speak. And what we're seeing is bringing new technologies to market like our new contact lenses, like our new insulin pump, like our new energy instrumentation, like the tune knee, we're seeing very good uptake and in fact, in those categories, we're seeing share gains and certainly in areas like electrophysiology, endocutters, the same thing. And so we believe that the market that still reward significant innovation when we are introducing it. So that's one aspect. The second aspect, frankly, is one just improved execution. And I think if you look across all our device businesses, if you think about Diabetes Care, the major price resets that we have there a couple of years ago and as all of you know, when you take that kind of a reduction, resizing your business, going back in each and every line, in setting up for the new marketplace caused us an tremendous amount of change. If you look at our Vision Care business last year, we went in, and we really increased the cadence out of our innovation pipeline, launching 5 new products. We did a price resets there to make us more competitive with the ECPs, we made a lot of other internally adjustments to improve our selling and marketing. We are definitely seeing the impact of that now, not only on the sales results about 8% but as maybe more importantly, if you look at the leading indicators as far as new shares being generated and new patient starts in the offices, those things are positive. Louise mentioned earlier the improvement that we're seeing across the Orthopaedics business. Look, this is one where we know that when you bring large organizations together, when you standardized quality systems, manufacturing systems, we think that we've made a lot of progress there. And frankly, when you compound that with the innovation roll out that we've seen in Orthopaedics, the knee, the hip, the TFNA nail, we're starting to see that come back as well as some of frankly the approaches that we're taking that Gary will be talking more about in May where at Ethicon and our DePuy Synthes team are actually co-selling, co-contracting a number of their innovative ways. Compounded with the fact that, look, we think some of the performance issues related to China in our Orthopaedics are more of a onetime event. That's getting normalized. So as we burn our way through those and head into 2016 overall, we think that innovation, we think changes in our commercial model, we think improved execution, all those things make us more optimistic about the growth prospects as we head into 2016."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","That's very helpful, Alex. And I just have more follow-up on biosimilars REMICADE. So obviously there's a panel schedule that rescheduled last month so wondering if you can talk about what issues you think we should be listening for, what your expectation",70,"That's very helpful, Alex. And I just have more follow-up on biosimilars REMICADE. So obviously there's a panel schedule that rescheduled last month so wondering if you can talk about what issues you think we should be listening for, what your expectations are and what you're seeing in Europe where biosimilar REMICADE is on the market and why or why not that might be a proxy for the U.S?"
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Certainly. Well, obviously we will also be watching the advisory committee in participating it as well coming up. We think there's a few things to keep in consideration about this. First and foremost, is that as Dominic stated earlier, biosimilars are ver",525,"Certainly. Well, obviously we will also be watching the advisory committee in participating it as well coming up. We think there's a few things to keep in consideration about this. First and foremost, is that as Dominic stated earlier, biosimilars are very different from generics. And particularly in this category, keeping the patient in the center of all these, we've got a tremendous amount of experience in the biologics category going back to, REMICADE one day, we think the differences between molecules can have manifested themselves in significant ways with patients. So making sure I think things that we'll be watching for the AC or what kind of data that the biosimilars actually have, what kind of indications, what will be the guidance around substitutability. All those frankly sitting here today are known so we'll need more clarification. But we think each of those means that the expected uptake even when a biosimilar does launch will lead to a significantly different curve in what you see with generics. We think secondly, it's very important to actually think about it from a patient perspective, and we know, for example, there's about 2.5 million patients with REMICADE. About 70% of those are either continuing therapy and have pretty high satisfaction rates. So if you look at the available population, there's likely to be switched, we think it's in the 30% range. And last but certainly, not least, there's the whole issue of the business model and the way that we actually work with customers in this setting. And this is an area where we've got a lot of experience in contracting, we've got some great relationships with providers in this area right now. We also have a very broad product portfolio. If you think about what REMICADE does, if you look more broadly at the performance recently of a product like STELARA, a multibillion dollar compound, growing at 20-plus percent rate. If you look at SIMPONI, same thing, SIMPONI ARIA, in particular, the great dosing convenience that they provide, that's another multibillion addition that we have been that portfolio and you augment that with the submissions that we have in 2016 plan for [indiscernible] and IL 23 and IL-6, we think that, that positions us very well with our portfolio from a contracting point of view with large providers and payers and certainly in the U.S. was also abroad. Now what we're seeing outside the United States, eh most of the markets we introduced is a relatively minor impact. We're seeing that we're holding onto about 90%-plus or minus, it varies by market. You have to look at each 1 individually. And it's difficult to project exactly what that impact will be going forward. But I think when we think of it broadly across all those different areas, what's the clinical data show, what ultimately the labeling, the regulatory aspects, what about our contracting, the business aspects, and we think all those are very important will result in a different impact from biosimilars and ultimately, we'll continue to defend our intellectual property as well to what we believe is the right path and in September of 2018."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","And just add to that, we have REMICADE in Canada as a Johnson & Johnson product, and we've seen fairly -- it's actually still growing in Canada even with a biosimilar there. Biosimilar has a limited indication there, but it's still growing. And we'll be l",57,"And just add to that, we have REMICADE in Canada as a Johnson & Johnson product, and we've seen fairly -- it's actually still growing in Canada even with a biosimilar there. Biosimilar has a limited indication there, but it's still growing. And we'll be listening to Merck's call as well to see the latest in Europe."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Jami Rubin of Goldman Sachs.",10,"The next question is from Jami Rubin of Goldman Sachs."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Just a question for you, Dominic and I have a question for Alex. Just trying to understand the difference between consensus estimates for 2016 in your guidance, do you have a sense for what the Street was assuming for nonoperating income? When I go back h",184,"Just a question for you, Dominic and I have a question for Alex. Just trying to understand the difference between consensus estimates for 2016 in your guidance, do you have a sense for what the Street was assuming for nonoperating income? When I go back historically, that's been in the $500 million to $600 million range. Clearly it was $2 billion last year but just curious to know what consensus models had assumed for that. Secondly, did your guidance assume that the medical device tax will be suspended as I think within the said other device companies. Just curious know if that savings reinvested a in the business or if that is part of the guidance. And then for you, Alex, just curious to know your thoughts on pricing. I mean, we heard Bernie tell you last night go after pricing again and I think that's also something we're going to hear from the Republican candidate. What are your expectations in terms of pricing in 2016 and 2017? Do you expect that there will be a change in terms of list prices going forward?"
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Okay, Jami, let me try to for take the first 2 and then have Alex maybe comment on the drug pricing. You were referring to our nonoperating, let's call it the other income and expense line for 2016, what was assumed an analyst models versus what we have p",312,"Okay, Jami, let me try to for take the first 2 and then have Alex maybe comment on the drug pricing. You were referring to our nonoperating, let's call it the other income and expense line for 2016, what was assumed an analyst models versus what we have provided in guidance. When we look at the analyst consensus models, overall, it looked like that number average in the high $900 million, so nearly $1 billion. And our guidance, of course, is somewhere at $1.1 billion to $1.2. billion So our guidance are slightly higher than the analyst models. But just as a reminder, we always take the opportunity to our portfolio choices to use any of those gains to offset some other expenses we like to invest in. And then with respect to the medical device tax, we have assumed that it would be a benefit in 2016. But I must say the benefit for us is very, very minor. Remember when the medical device tax is incurred, it's incurred upon the first manufacturer of a product and therefore, it can be, for example, orthopedic companies hung up in inventory for quite some time. So the overall impact of not having a medical device tax in 2016 is not significant for Johnson & Johnson, it may be significant for certain other company that may be of pure orthopedic players, but not overall significant for us. And secondly, I would say that whatever benefit we see there, we've already assume that would be reinvested in innovation as, of course, during the time that the medical device tax was a drag on earnings, obviously, decisions have to be made on where to invest, now we're happy that would that easement of the device tax for a couple of years, we'll be able to actually invest more on medical the motivation on the medical device."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes, Jami, thanks for the question on pricing. Look, we realize and understand the pricing in pharmaceuticals all of health care certainly a very important issue. And we believe that it's important to consider it just in that way. As we think about pharma",259,"Yes, Jami, thanks for the question on pricing. Look, we realize and understand the pricing in pharmaceuticals all of health care certainly a very important issue. And we believe that it's important to consider it just in that way. As we think about pharmaceuticals, for example, they currently make up about 12% of health care spending in the United States, slightly higher in Europe. If you think about medical devices, they represent about 6%. And if you go beyond those areas, of course, there's a lot of other cost built into the system, ranging from hospital, patient care, insurance companies, many other people, particularly in an environment today where frankly we're seeing such transformational outcomes and moving more and more towards cures, disease prevention, interception than we ever have because of some of the great science that's been produced. So we understand and would certainly expect there to be a continued spotlight in this area. Obviously, we're working with a lot of stakeholders to try and make sure that we look at it in a very holistic way. And it's very, I think, difficult at this point in time, to try to project was going to happen in 2016 or 2017. All of us know that the health care system, not only here in the United States but frankly around the, world is complex. There's a lot of other -- a lot of issues that are intertwined, but it's obviously a conversation that we'll be participating in. And ultimately where we want to be a part of the solution."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Vamil Divan of Crdit Suisse.",10,"The next question is from Vamil Divan of Crdit Suisse."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","So just a couple on the pharma aside, I guess, one of the pharma side and one other one for Dominic. You mentioned STELARA and you mentioned strong quarter 20% growth is showing. I just wonder if you can share a little bit you could talk about 2016 and be",150,"So just a couple on the pharma aside, I guess, one of the pharma side and one other one for Dominic. You mentioned STELARA and you mentioned strong quarter 20% growth is showing. I just wonder if you can share a little bit you could talk about 2016 and beyond your expectations that product going forward just given the competition, it's kind of base from the IL 17, both in psoriatic and arthritis. So is this sort of 20% range still sustainable or do you think you'll see more of a decline? And then second for Dominic just on the guidance and apologize if I missed this. But in terms of your EPS guidance, can you comment on what share count you're using to get the guidance of just get some sense of the buybacks, I guess, that you've sort of incorporated and the way you think about the year?"
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Sure. Why don't I take that first part first? So we announced the share buyback in October, and I we said we're already through the fourth quarter spent about $1 billion of that $10 billion and our plans for 2016, we have not assumed that it's totally com",91,"Sure. Why don't I take that first part first? So we announced the share buyback in October, and I we said we're already through the fourth quarter spent about $1 billion of that $10 billion and our plans for 2016, we have not assumed that it's totally complete, but certainly, more than a majority of the share buyback will be completed by the end of 2016, maybe 3 quarters of it sort of around that range, and that's what we've assumed in our models for 2016 the guidance I just gave."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes, thanks for the question. Look we look at STELARA, one, it just starts with a great compound. It's had very nice uptake, very good growth, and we certainly see that psoriatic arthritis, but we're also excited about the planned indications in areas lik",129,"Yes, thanks for the question. Look we look at STELARA, one, it just starts with a great compound. It's had very nice uptake, very good growth, and we certainly see that psoriatic arthritis, but we're also excited about the planned indications in areas like UC and spondylitis. So when you take the profile, the momentum that we're seeing in the marketplace and our share that continues to grow, you combine it with some additional indications as we go forward, particularly as part of our broader immunology portfolio, we think that there's -- and the other important issue, I believe, this category is only about 22% or 23% penetrated. In terms of the patients that are coming in, all of that represents a nice growth opportunity for this important product."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Kristen Stewart of Deutsche Bank.",10,"The next question is from Kristen Stewart of Deutsche Bank."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","I have 2 questions. The first for Dominic. I believe a couple of years ago, you've talked about the opportunities for margin expansion within consumer we really haven't seen that just yet with most of the products have returned in the OTC business, do you",87,"I have 2 questions. The first for Dominic. I believe a couple of years ago, you've talked about the opportunities for margin expansion within consumer we really haven't seen that just yet with most of the products have returned in the OTC business, do you expect to see consumer really starting to reach an inflection point with the goal that we talked about 2 years ago at the last consumer update getting back into that kind of 20% range still achievable for the next couple of years?"
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes, Kristen. We do expect that the consumer business -- now that the products that they've launched and the cost remediations associated with the consent decree are largely behind us, although we still comply with the Consent Decree for another 5 years.",90,"Yes, Kristen. We do expect that the consumer business -- now that the products that they've launched and the cost remediations associated with the consent decree are largely behind us, although we still comply with the Consent Decree for another 5 years. We did want to launch those products with the right support. But it is true that we do expect, and we'll see it in '16, we'll report on it later in the year throughout the quarters, an improvement in the operating margins of the consumer business going forward."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Okay. And I guess, just dialing back, will M&A be a key driver to improving the margins? Or any sort of portfolio management? And then more broadly, I know I've always asked Alex this question every now and again, I guess, you guys have always talked abou",106,"Okay. And I guess, just dialing back, will M&A be a key driver to improving the margins? Or any sort of portfolio management? And then more broadly, I know I've always asked Alex this question every now and again, I guess, you guys have always talked about the sort fourth wag and we've seen from your competitors more solutions-based approach around programs. You have some of those as well Orthopaedics business. Is that something that you think off when you're thinking about M&A moving more towards a holistic health care model and maybe perhaps rolling in some more lifestyle programs or something on the other side?"
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Sure. Look, I just picked up what Dominic has just said about our consumer business is that I'm really proud of the work we've done on the Consent Decree and the great strides that they have taken around quality. In fact, I think in working closely and pa",426,"Sure. Look, I just picked up what Dominic has just said about our consumer business is that I'm really proud of the work we've done on the Consent Decree and the great strides that they have taken around quality. In fact, I think in working closely and partnering with FDA, we likely have a benchmark organization now, and we're really proud having done that. At the same time, I think as they begin to shift from only remediation to remediation and relaunch across a number of these areas, while certainly keeping a very high eye on quality, as we increase our volumes, as we are able to deepen our relationships that allow the major trade partners, that's where we see a great growth opportunity as well, and obviously, that's going to have an impact in our margins as we go forward. I also think of the other thing that team is doing is we're transitioning more and more to online marketing versus just traditional marketing. The way we are partnering with some of the large customers, I think, there's a lot of opportunities not only to drive share and volume, but actually to improve efficiencies on our back end as well. As a step back and look more broadly, we think the 3 areas that we're in, consumer medical devices and pharmaceuticals are all great platform and great businesses. Of course, we would look -- first for areas that what is the next ZYTIGA, what's the next Vision Care platform, what's the next NEUTROGENA? That would certainly be our focus. And other would be, are there chances to grow and perhaps some of the faster growing developing markets with the right kind of opportunity? Those are things that we would be interested in. And then what are ways to consummate our existing business? I think the way that you pointed out as the markets evolve, we are looking, not only at M&A, but also broader partnerships that we've done, for example, with companies like Google and barely where we see a big opportunity to really have transform robotics surgery space in a pretty significantly longer term. And then, I guess, the final option there would be for us to actually acquire something outside the current 3. And again, if it something where we thought there was a lot of unmet patient or consumer need, if we feel that it's consistent with the capabilities that we can bring to bear actually have it be a successful business, if the financials work, then we would take that step."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Bob Hopkins of Bank of America.",11,"The next question is from Bob Hopkins of Bank of America."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","So two things, and I'll just drive them off. First, I just wondering if you guys could comment a little bit on emerging market growth in Q4 relative to trends earlier in the year. And then more importantly, just talk about the current operating environmen",130,"So two things, and I'll just drive them off. First, I just wondering if you guys could comment a little bit on emerging market growth in Q4 relative to trends earlier in the year. And then more importantly, just talk about the current operating environment China and when do you think we could see reacceleration of emerging market growth for J&J, that's question #1. And then question #2 is just back to the original question on the 200 basis points of pretax operating margin improvement in '16. I was wondering if you could give us just a little bit more detail exactly where that comes from. Maybe mention how much extra spend was there in 2015 that will materialize in '16. Just looking for a little bit more color there."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Okay so in the emerging market grow, excluding the impact of Cordis and OCD, it was about 6.5% in the fourth quarter and year-to-date basis, it was about 5.5%. Those are both operational numbers.",34,"Okay so in the emerging market grow, excluding the impact of Cordis and OCD, it was about 6.5% in the fourth quarter and year-to-date basis, it was about 5.5%. Those are both operational numbers."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","And on China, just a couple of comments that China we did see a slowdown in China primarily in the consumer business because both medical device and pharma businesses still had high single digit growth in China, and we're optimistic about China are going",350,"And on China, just a couple of comments that China we did see a slowdown in China primarily in the consumer business because both medical device and pharma businesses still had high single digit growth in China, and we're optimistic about China are going into 2016. Our plans are for improved growth in China in 2016. But I just want to put China in perspective, it's less than 5% of our sales. It's an important market for us longer-term with 1.3 billion people and lots of health care needs, et cetera. But any short-term changes in their economy is unlikely to have any significant impact on our results. And then on the 200 basis point improvement, Bob, it's actually across all 3 lines of the P&L, COGS, selling, marketing as well as R&D. So in the case of COGS where we have a long-term program that we we've executing on to reduce footprint, we're accelerating some of those programs that will benefit us in the COGS line when the selling, marketing and administrative line I talked earlier about, the fact that we have a program in place for a couple of years shooting for $1 billion of cost savings by 2018, we're well on our way. We'll see cost reductions in that line. In R&D, that depends on the individual licensing deals that we have and the timing of when we would spend those milestone payments or enter into new licensing agreement. But as it looks today, the advancement in the portfolio in 2015 from the milestone payments, et cetera, are not expected to be at the same level in '16 that they were in '15. So  it's across all 3 lines in the P&L, and I can't give you an exact number on the amount of investment we made in '15, extra investment made in '15. But just to say that we had $2.8 billion of other income in 2015 well above the year has passed, and we still improved overall income before tax by not quite that amount, right? So most of it was reinvested in the business."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Josh Jennings of Cowen and Company.",11,"The next question is from Josh Jennings of Cowen and Company."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","We just have one for Alex. You have a formal plan in place to accelerate growth in the Medical Device unit, it's reasonable. If I believe your target of return unit to 45% or 46% growth, I just want to ask how patient you'll be before you look externally",69,"We just have one for Alex. You have a formal plan in place to accelerate growth in the Medical Device unit, it's reasonable. If I believe your target of return unit to 45% or 46% growth, I just want to ask how patient you'll be before you look externally in the transformational way? Is it a 12- to 24-month initiative or longer time period that you put in place?"
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes, Josh. Thanks a lot for the question. The way I would say, this is something that has been underway for the last several months. But clearly, we're accelerating it. And whenever you make this kind of the decision, we certainly think about the impact t",203,"Yes, Josh. Thanks a lot for the question. The way I would say, this is something that has been underway for the last several months. But clearly, we're accelerating it. And whenever you make this kind of the decision, we certainly think about the impact that has on employees. But we also see as our responsibility to make sure that this business is positioned for the next 5, the next 10 years. And with that note, we have a high sense of urgency about increasing our rate of innovation, about making the business model changes. And ultimately, about making sure that we're more competitive in delivering in the markets. We try to be clear, our goal is to grow faster than the markets even given our size and given our scale, we think we've got over 10 platforms, there are $1 billion, majority of those are #1 or #2. But we realize there's a lot of opportunities. So while we are pleased with what we've seen, we're far from satisfied. And I know Gary and the rest of his team as well as all of us are completely committed to accelerating the performance of this group to be -- frankly, benchmarking the industry."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","We'll take the last question and Alex will provide some closing remarks.",13,"We'll take the last question and Alex will provide some closing remarks."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","Our final question comes from David Lewis of Morgan Stanley.",10,"Our final question comes from David Lewis of Morgan Stanley."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Just 2 quick ones. I'll start with strategic one for Alex and then a quick follow-up question for Dominic or others. Alex, just taking about M&A for a second, I know it's been a theme for this call. But how the segment performance to deploy capital in tho",101,"Just 2 quick ones. I'll start with strategic one for Alex and then a quick follow-up question for Dominic or others. Alex, just taking about M&A for a second, I know it's been a theme for this call. But how the segment performance to deploy capital in those segments? So are you more inclined to deploy capital in outperforming segments or not? And I guess, related, does it make sense to deploy material capital and devices through M&A and total restructuring has been digested in growth is back to market rates in those franchises? And then a quick question for Dominic."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes, David. Thanks for the question. Look, it depends on a number of different factors. And obviously, as we think about it, for example, in our pharmaceutical group, we think that the model that we pull together, we try to find the next INVOKANA, the nex",298,"Yes, David. Thanks for the question. Look, it depends on a number of different factors. And obviously, as we think about it, for example, in our pharmaceutical group, we think that the model that we pull together, we try to find the next INVOKANA, the next DARZALEX very early compounds, where frankly we've got solid scientific insights, we bring it inside and because of our clinical development, our regulatory capabilities, we can launch and then very strong sales marketing and reimbursement practices around that. Frankly, that's what helped us create the number of billion dollars blockbuster that we've been able to launches his 2009 I think 16 new products and 7 of which are right at $1 billion or certainly will be. And so we think that's a good model. In Medical Devices, we've done tuck-ins as well as large and look, I think in both cases, whether it's pharma or Medical Devices, the smaller tuck-ins our frankly more straightforward to get done. We haven't shied -- we wont shy away from large why we think it's makes for a significant opportunity and something that we'll continue to look at in Consumer. As far as the question that's underperforming, I think it depends on why it's underperforming. If it's a market -- if it's an in exogenous market shift, there's something else, then obviously, that would not necessarily have shy away from that particular area. On the other hand, if it's an internal, more executional issue, absolutely, we'd want to make sure that we've got the meeting where we need it before we add on to that particular opportunity. So that's the way we tend to look at it. But again, it's part of a broader strategic question really on how we're managing the portfolio across the enterprise."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Okay, very helpful. And then Dominic just a quick one for you or the team. On INVOKANA, it hasn't come up on the call. I'm wondering if you could give us a sense of what's happening on the market post as it relates to class expansion or your market share.",69,"Okay, very helpful. And then Dominic just a quick one for you or the team. On INVOKANA, it hasn't come up on the call. I'm wondering if you could give us a sense of what's happening on the market post as it relates to class expansion or your market share. And can you give us an update on the canvas trial and when can we get data in '17?"
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","So I'll give you the market share third quarter here versus fourth quarter, which will give you some nice trend information. So -- this is the U.S. for the total, we went from 6.3% in the third quarter to 6.5% in the fourth quarter. Now primary care, we w",63,"So I'll give you the market share third quarter here versus fourth quarter, which will give you some nice trend information. So -- this is the U.S. for the total, we went from 6.3% in the third quarter to 6.5% in the fourth quarter. Now primary care, we went from 5.6% to 5.8% and and endo, it's flat at about 13% quarter-to-quarter."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","And the reading that we're getting from the field is that most physicians and in fact some guidelines recently published that the cardiovascular benefit that we saw with the other STL 2 is most likely a class effect absolutely physicians treated and the f",64,"And the reading that we're getting from the field is that most physicians and in fact some guidelines recently published that the cardiovascular benefit that we saw with the other STL 2 is most likely a class effect absolutely physicians treated and the fact guidelines we just recently issued a call class effect. Our data won't be until sometime mid 2017, I believe."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","2017.",1,"2017."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Those results actually be able to put those results in our label. But until then, I think the market recognizes it as a beneficial effect on cardiovascular.",27,"Those results actually be able to put those results in our label. But until then, I think the market recognizes it as a beneficial effect on cardiovascular."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Thank you. And for final remarks?",6,"Thank you. And for final remarks?"
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes, so thank you very much, everybody. Look in closing, I'd like to say thank you again for joining today's call. We are pleased with the results we delivered in 2015, and we think our strong underlying operational growth across the enterprise, combined",93,"Yes, so thank you very much, everybody. Look in closing, I'd like to say thank you again for joining today's call. We are pleased with the results we delivered in 2015, and we think our strong underlying operational growth across the enterprise, combined with a very high sense of urgency gives us a lot of confidence as we head into 2016. And we're optimistic about the opportunities in health care and frankly about the underlying strength of our core business. So thank you very much, and I hope everyone has a great day."
139677,320178319,920766,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","Thank you. This concludes today's Johnson & Johnson's Fourth Quarter 2015 Earnings Conference Call. You may now disconnect, and have a wonderful day.",23,"Thank you. This concludes today's Johnson & Johnson's Fourth Quarter 2015 Earnings Conference Call. You may now disconnect, and have a wonderful day."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","Good morning, and welcome to Johnson & Johnson's Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] I would now like to",51,"Good morning, and welcome to Johnson & Johnson's Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] I would now like to turn the conference call over to Johnson & Johnson. You may begin."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Good morning, and welcome. I'm Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure this morning to review our business results for the fourth quarter of 2015. Joining me on the call today are Alex Gorsky, Cha",1992,"Good morning, and welcome. I'm Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure this morning to review our business results for the fourth quarter of 2015. Joining me on the call today are Alex Gorsky, Chairman of the Board of Directors and Chief Executive Officer; and Dominic Caruso, Vice President, Finance, and Chief Financial Officer.
A few logistics before we get into the details. This review is being made available via webcast accessible through the Investor Relations section of the Johnson & Johnson website at investor.jnj.com.
I'll begin by briefly reviewing results for the corporation and for our 3 business segments. Following my remarks, Alex will comment on 2015 results and provide a strategic outlook for the company. Then Dominic will provide some additional commentary on the business, review the income statement and provide guidance for 2016. We will then open the call to your questions. We expect the call to last approximately 90 minutes.
Included with the press release that was issued earlier this morning is the schedule of sales for key products and/or businesses to facilitate updating your models. These schedules are available on the Johnson & Johnson website as is the press release. Please note, we will be using a presentation to complement today's commentary. The presentation is also available on our website.
Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements. The 10-K for the fiscal year 2014 and the company's subsequent filings identify certain factors that could cause the company's actual results to differ materially from those projected in any forward-looking statements made today. The company does not undertake to update any forward-looking statements as a result of new information or future events or developments. Our SEC filings, including the 10-K, are available through the company and on our website.
During the review, non-GAAP financial measures are used to provide information pertinent to ongoing business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with GAAP results. Tables reconciling these measures to the most comparable GAAP measures are available in the schedules accompanying the press release and on the Investor Relations section of the Johnson & Johnson website. A number of the products and compounds discussed today are being developed in collaboration with strategic partners or license from other companies. This slide lists acknowledgment of those relationships not otherwise referenced in today's presentations.
Now I would like to review our results for the fourth quarter of 2015. Worldwide sales to customers were $17.8 billion for the fourth quarter of 2015, down 2.4% versus fourth quarter of 2014. On an operational basis, sales were up 4.4% and currency had a negative impact of 6.8%. In the U.S., sales were up 8%. In regions outside the U.S., our operational growth was 1.2%, while the effect of currency exchange rates negatively impacted our reported results by 12.9%.
On an operational basis, the Western Hemisphere, excluding the U.S., grew 2.8%, while the Asia-Pacific, Africa region grew 0.9% and Europe grew 0.8%. Growth in all regions was negatively impacted by the divestiture of the Cordis business with Europe, Latin America and Canada also negatively impacted by hepatitis C competition. Excluding the net impact of acquisitions and divestitures and hepatitis C sales, underlying operational growth was 7.8% worldwide, 13.4% in the U.S. and 2.9% outside the U.S.
I'd like to point out that our 2015 fiscal year included an additional week. Since this week occurred during a holiday period, we did not achieve a full week of sales. However, we did have a few more shipping days. These additional shipment days added approximately 4 points to the quarterly sales growth rate and 1 point to the annual growth rate. The additional sales are more heavily skewed to the U.S. While these few shipping days added to sales, we also had a full week's worth of operating costs, therefore, the bottom line impact was negligible.
Turning now to earnings. Net earnings were $3.2 billion and diluted earnings per share were $1.15 versus $0.89 a year ago. As referenced in the tables reconciling non-GAAP measures, 2015 fourth quarter net earnings were adjusted to exclude after-tax amortization expense of $220 million and a net charge of $608 million for after-tax special items. 2014 fourth quarter net earnings were adjusted to exclude after-tax amortization expense of $275 million and a charge of approximately $1.1 billion for after-tax special items. Dominic will discuss special items in his remarks.
Excluding amortization expense and special items for both periods, adjusted net earnings for the current quarter were $4 billion and adjusted earnings per share were $1.44, representing increases of 4% and 5.1%, respectively, as compared to the same period in 2014. Currency translation significantly impacted net earnings. On an operational basis, adjusted diluted earnings per share grew 12.4%.
Now turning to the financial highlights for the full year of 2015. Consolidated sales to customers for the year of 2015 were $70.1 billion, a decrease of 5.7% as compared to the same period a year ago. On an annual basis, sales grew 1.8% operationally and currency had a negative impact of 7.5%. Excluding the net impact of acquisitions and divestitures and hepatitis C sales, underlying operational growth was approximately 6.5% worldwide, 10.6% in the U.S. and 3% outside the U.S.
Turning now to earnings. 2015 annual net earnings were $15.4 billion and diluted earnings per share were $5.48. For the year, 2015 adjusted net earnings were $17.4 billion and adjusted earnings per share were $6.20, down 4.8% and 3%, respectively, versus the 2014 results. On an operational basis, adjusted diluted earnings per share grew 5.8%. Estimated free cash flow for the year was strong at $15.9 billion, up $1.1 billion versus 2014.
Turning now to quarterly business segment highlights. Please note, percentage of quote [ph] represent operational sales changes in comparison to the fourth quarter of 2014 unless otherwise stated and therefore, exclude the impact of currency translation.
I'll begin with the consumer segment. Worldwide Consumer segment sales of $3.3 billion increased 1.8%, with U.S. sales down 4.9%, while outside the U.S., sales grew 5.5%. Excluding the net impact of acquisitions and divestitures, underlying growth was approximately 4.7% worldwide, 1.7% in the U.S. and 6.3% outside the U.S. Growth was driven by worldwide OTC and Oral Care as well as Women's Health outside the U.S. OTC sales results in the U.S. were driven by the ZYRTEC and product relaunches for the depth of [ph] health products.
Strong growth for analgesics was partially offset by timing of inventory builds as noted in the third quarter and a slower start to the flu season. In the U.S., adult analgesic market share was approximately 13.5%, up from approximately 11.5% a year ago, while U.S. pediatric share was approximately 45.5%, up from approximately 42% a year ago.
Results outside a U.S. were driven by strong sales of upper respiratory products and the relaunch of anti-smoking products. Strong sales momentum, driven by successful marketing campaigns and geographic expansion for new products, drove results for LISTERINE and Oral Care and in Women's Health products outside the U.S.
Moving now to our pharmaceutical segment. Worldwide sales of $8.1 billion increased 6.5%, with U.S. sales up 12.7% and sales outside the U.S. down 0.9%. Competitors in hepatitis C significantly impacted sales results. Excluding sales of our hepatitis C products, OLYSIO and INCIVO, as well as the impact of acquisitions and divestitures, underlying growth was approximately 11.1% worldwide and 21% in the U.S. Sales outside the U.S. declined approximately 0.2%, with strong growth of new and core products, offset primarily by lower sales of REMICADE and SIMPONI to our distribution partner.
Important contributors to growth were STELARA, INVOKANA/INVOKAMET, IMBRUVICA, INVEGA SUSTENNA and XEPLION, XARELTO and U.S. sales of REMICADE. STELARA achieved strong growth across all the major regions, driven by robust market growth and increased penetration with the psoriatic arthritis indication. Strong momentum in market share drove results for INVOKANA/INVOKAMET. In the U.S., INVOKANA/INVOKAMET achieved 6.5% total prescriptions share or TRx within the defined market of type 2 diabetes, excluding insulin and metformin, up from 4.2% last year. TRx with endocrinologists was 12.8% for the quarter and 5.8% in primary care. Strong patient uptake with demonstrated efficacy drove results for IMBRUVICA in the U.S. IMBRUVICA is the leader in both new and total patient regimen share in second-line CLL and MCL.
Outside the U.S., results were driven primarily by Europe with strong patient uptake and shared momentum. IMBRUVICA is now approved in over 60 countries. As an update on our oncology pipeline, we received FDA approval for DARZALEX in November. DARZALEX is off to a robust start with strong underlying demand. INVEGA SUSTENNA or XEPLION achieved strong results in all major regions primarily due to increased market share and the launch earlier this year of INVEGA TRINZA.
Continued share growth drove XARELTO sales results with TRx for the quarter in the U.S. anticoagulant market of 16.1%, up nearly 1.5 points from a year ago. XARELTO is broadly reimbursed with approximately 95% of commercial and Medicare Part D patients covered at the lowest branded product copay.
REMICADE in the U.S. benefited from strong market growth, partially offset by lower market share. REMICADE U.S. export sales and international sales were negatively impacted by lower distribution partner sales due to the weakening of the euro and the loss of exclusivity in Europe, partially offset by a higher inventory reduction last year. Strong results were achieved in the Western Hemisphere, excluding the U.S.
I'll now review the Medical Devices segment results. As a reminder, we announced last week that we will use a new format for the reporting of sales in the Medical Devices segment, and we provided historical sales results in the new format at that time. The historical sales are available on our website.
Worldwide Medical Devices segment sales of $6.4 billion increased 3.4%. U.S. sales increased 6.7%, while sales outside the U.S. increased 0.6%. Excluding the net impact of acquisitions and divestitures, underlying growth was approximately 5.8% worldwide, with the U.S. up 8% and growth of 3.9% outside the U.S. Growth was driven by surgery, orthopedics, electrophysiology and Vision Care, partially offset by the divestiture of the Cordis business.
Growth in our surgery business was driven by strong results for the advanced products with endocutters growth of 15%, biosurgical's growth of 9% and energy growth of 5%. In addition, ASP and Mentor products and our specialty products made significant contributions to sales in the quarter.
Market growth, additional selling days and new products drove strong results for the U.S. Orthopaedics business. Pricing pressure continued across the major categories, partially offset by positive mix for trauma and spine products. The successful introduction in early 2015 of the TFNA nailing system in trauma, the success of the ATTUNE platform in knees, our primary stent platform in hips and ORTHOVISC, MONOVISC in spine or other made important information contributions to the results.
Orthopaedics sales outside the U.S. were negatively impacted by result in China due to softer demand and a reduction in inventory. Spine, other and trauma were the categories most impacted. Our electrophysiology business grew 19% worldwide due to strong market growth, complemented by the success of the THERMOCOOL SMARTTOUCH Catheter. Vision Care results were driven by very strong growth in the U.S. due to the introduction of new products as well as the trade inventory build.
That concludes the segment highlights for Johnson & Johnson's fourth quarter of 2015. For your reference, there were some notable developments in the fourth quarter, which we have summarized on this slide to assist as you develop your models. Lastly, to assist you in updating your models for the full year 2015, on our website, you will find annual sales highlights by segment 
It is now my pleasure to turn the call over to Alex Gorsky. Alex?"
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Louise. Let me start by saying how optimistic and confident I am as we enter 2016. We had a strong finish to 2015. With our healthy balance sheet, we are well positioned to continue to invest for future growth. Our core business is very strong,",2884,"Thank you, Louise. Let me start by saying how optimistic and confident I am as we enter 2016. We had a strong finish to 2015. With our healthy balance sheet, we are well positioned to continue to invest for future growth. Our core business is very strong, and we expect a number of additional new products and line extensions in the coming year.
Now as we enter 2016, we look forward to: First, continued growth of core products across our segments; next, a rich near-term pipeline in our Pharmaceutical segment; positive momentum in our Consumer segment with a full portfolio of OTCs back on the market; setting a strong foundation for sustainable growth with the bold actions we are taking in our Medical Devices segment; and continued financial strength and strong free cash flows to return capital to shareholders and take disciplined and decisive actions regarding M&A that contribute to sustainable growth and long-term value creation.
Now I'll share more specifics in my discussion with you today about the health care environment, our 2015 results and why we're so optimistic and confident about the future for the enterprise in each of our business segments. But with that as a backdrop, I'd like to begin where I always do by talking about our credo.
Our credo is the beginning of everything at Johnson & Johnson. It guides all of our decisions, and I believe it sets us apart. This year's Johnson & Johnson's 130th year, think of that for a moment. 130 years of working to balance our mission of helping people everywhere live longer, healthier and happier lives. And I'm proud to see the employees of Johnson & Johnson around the world continuing to uphold the imperatives of our credo every day, through both our philanthropy initiatives and recent commitment to supporting the immediate and ongoing needs of Syrian refugees in partnership with Save the Children as well as to our commitments of the health care community with investments that will accelerate how we address global health crises like Ebola, AIDS and mental health.
You undoubtedly heard me say that I believe health care is one of society's greatest challenges. And this global challenge grows with aging populations, rising cost in developed world and growing middle classes in emerging economies. We have increasing expectations for access to quality care. Now as the world's largest and most broadly based health care company, it's not just an opportunity for us to help manage this transformation. It is our responsibility to help lead the way to a better future.
Now in this environment, ensuring access to important medicines and medical procedures remains a key objective for us. As government officials, politicians and other stakeholders debate significant issues around the world, we're pleased to see that health care is such a focus in the dialogue. And we believe that our goals and those of public policymakers are aligned to find the best ways to ensure the delivery of quality health care and the best patient outcomes in a high quality and sustainable manner. Now in this discussion, it's a responsibility of all stakeholders to consider the economic and financial implications of health care. We got to look at the whole picture, drugs, devices and share [ph] of hospitals and governments put the patient in the center and reward innovations that drive better outcomes.
Here in the United States, prescription drugs represent approximately 12% of total health care costs and medical devices represent around 6%. These cures and treatments not only improve quality of life for many patients, extend life for others and contribute to the productivity of our society, but they can also help to reduce caregiver burden, disability and health care spending overall. The promise of innovation and health care is great. It will remain great if we can take a holistic approach to reforming the health care system.
At Johnson & Johnson, we believe in this holistic approach to health care solutions. It's vital to developing the best innovations, to meeting the needs of our stakeholders and to sustaining our legacy of strong and consistent business performance. Our consumer Medical Devices and Pharmaceuticals segments are increasingly interconnected businesses. And we believe that being broadly based in health care has been and will continue to be a significant factor in Johnson & Johnson's success as it positions us well to lead and grow our business with the evolving health care landscape.
Our broad global footprint enables us to reach more patients and consumers in fast-developing and changing markets. In fact, Johnson & Johnson is operating in 60 countries today, and we are continuing to invest in implementing new operating models, forging strong relationships with local governments and health systems and further accelerating growth through strategic acquisitions and partnerships with local companies.
Because of our broad base across health care, we are uniquely positioned to be a partner of choice. Now let me just go over a few examples. With large health systems, we are taking more of a business-to-business model to help them with innovative contracting strategies, integrated services and solutions and with dedicated customer-focused teams. We're working with technology companies like Google, IBM and Apple. We're advancing medical innovation through an infusion of technology that can benefit from the deep health care expertise Johnson & Johnson can uniquely provide.
We're continuing to support biotech and med tech start-ups who appreciate the value we place on innovation and the reach and breadth of our footprint in the health care market. And with public health organizations, we have a tremendous opportunity to address the gaps that remain in innovation, access and delivery of effective prevention and treatment. We're collaborating more than ever before to meet the world's most pressing public health challenges.
Our scale, financial flexibility and business and health care expertise make Johnson & Johnson a key partner for a number of our stakeholders, and our relationships with these partners will help Johnson & Johnson continue to be a leader in the future. Applying our expertise in design thinking, strategic innovation models and a commitment to collaborating with all stakeholders, we've developed a number of cross-segment innovations.
For example, we've created the China Lung Cancer Center, which is developing a holistic approach to treat lung cancer in China where the disease is particularly prevalent. We're pioneering cell therapy for age-related macular degeneration, combining technologies from Pharma and from our Vision business to find a way to address this condition. And we're leveraging capabilities from our Medical Devices, Pharma and Consumer businesses to treat obesity and diabetes in new ways. In fact, almost every one of our programs can benefit from the advantages of our broad base.
Over the past several years, we've also been leveraging our scale by developing enterprise efficiencies and capabilities across all of our sectors, targeting as much as $1 billion in operational savings by 2018 to support our growth. And we believe the innovation that is taking place within our supply chain and quality systems is actually creating a competitive advantage for Johnson & Johnson.
But the bottom line, well, it's the bottom line. And this broad-based structure has helped us deliver strong, consistent and sustainable financial performance. Let's consider some of the numbers.
First, 53 consecutive years of dividend increases at Johnson & Johnson. That means we have provided steady dividend increases since we first put a man in space. And 32 years of consecutive adjusted operational earnings growth, more than 3 decades.
Over the past 10 years, we have returned approximately 70% of our free cash flow to our shareholders. And today, 70% of our revenues come from brands that are #1 or #2 in their markets. We have 24 brands that represent billion-dollar platforms. If you think about that, in 1999, the entire corporation had revenues of $24 billion, and about 25% of our sales come from brands launched in the last 5 years. That's a result of constant learning, collaboration and innovation.
Our corporate structure, our broad base is a strategic choice and one that is grounded our performance, not just our heritage. We know it has been a significant driver in the past and expect it will be more important in the future.
As we've said, we see global health care growing at 3% to 5% over the next 5 years, and we have a clear objective that Johnson & Johnson should grow sales organically at a faster rate than the market. We also intend to grow our earnings faster than sales. In addition, we will continue to create value through strategic acquisitions and partnerships that generate additional growth. All of this, coupled with our strong dividend yield, and you are a looking at a very compelling long-term total shareholder return.
As part of our performance-driven strategy, we regularly review the structure and portfolio of our businesses to evaluate how they're delivering on our responsibilities to the stakeholders outlined in our credo, meeting evolving health care needs and achieving performance expectations. Johnson & Johnson has a rigorous and disciplined portfolio review program focused on creating long-term shareholder value, and this applies to all our businesses.
We have a track record of evolving our business and taking decisive actions when necessary to meet changing industry and consumer dynamics, and we'll continue to do so in the future. We're actively looking for the right opportunities to create greater value for our shareholders. We are seeking companies with the mutual desire to partner, but we're also patient. We will only act when we see the right value-creating deal at the right price and with the right partners.
Now historically, about half of our growth has come from M&A and half from internal development, which we fully expect to continue, and with our strong balance sheet, we've got the resources to do just that.
Now let me take a few minutes to review the priorities we laid out for you last year. One, we will continue to be focused on delivering on our financial and quality commitments. Two, in Pharmaceuticals, our objective, as always, is constant innovation. We're building on our launch excellence and continuing to develop a robust pipeline of transformational medicines.
In our Consumer business, we positioned our entire portfolio to focus on key geographies, need states and mega-brands. We are prioritizing and investing to expand our market leadership in key consumer segments in OTC, Oral Care, Baby and Beauty. And as you heard through our announcement last week, our priority in Medical Devices is accelerating growth through the strategic investments in innovation and by transforming our go-to-market models. We're confident that these priorities will deliver the results that you expect from us and just as importantly, the results that we expect from ourselves.
As we've said, we are pleased with our 2015 performance. In 2015, we generated sales of $70.1 billion, reflecting strong underlying operational growth across our enterprise. Our end market portfolio and Pharmaceuticals delivered strong growth. We built positive momentum in our Consumer segment, and we've just announced bold actions to accelerate growth in our Medical Device segment.
Throughout the year, you've heard from each of our business segment leaders about the strategies we put in place to meet our commitments, so I'll touch on just a few of the recent actions we've taken to advance those strategies.
As Joaquin Duato laid out for you at our pharmaceuticals business review in May, our Pharmaceuticals business has a clear strategy focused on 5 therapeutic areas of high unmet medical need, a robust innovation engine, improving commercial capabilities. Joaquin talked to you about how we're investing in our future with 10 new products we plan to file by 2019, each with a potential to exceed $1 billion in annual sales. And in fact, we are already delivering one of those promising medicines to the market, 4 months ahead of schedule with the U.S. approval for DARZALEX, the first human monoclonal antibody to be approved anywhere in the world for patients with multiple myeloma, which is off to a very good start.
In the near term, I know many of you are keeping an eye on potential biosimilar completion in the United States. As you've heard us say, biosimilars are not generics. With more than 2.4 million people having been treated with REMICADE and about 70% of the current patients receiving sustained and effective treatment, we believe doctors will be reluctant to switch them off with that level of success. And we've seen this play out in many markets where biosimilars have already been introduced. And we also have a patent for REMICADE that expires in September 2018 that we'll obviously continue to vigorously defend.
We consider our Immunology products part of an important and robust portfolio for patients, physicians and payers. So when you consider our continued expectations for REMICADE as well as the future potential of products like STELARA and SIMPONI and the pending submissions of guselkumab and sirukumab, we are confident in our ability to continue driving strong growth from our Immunology portfolio.
When you combine these advances with additional line extension approvals expected in 2016 like those for IMBRUVICA, STELARA and INVOKANA and DARZALEX approval in the EU, our near-term pipeline is incredibly robust and may not be fully appreciated in the market. With the combined strength of our end market portfolio and deep late-stage pipeline, we expect to deliver above-industry compound average growth through 2019.
Our consumer expertise, insight and access are becoming increasingly valuable to payers and providers as demographic and technology trends in health care are moving the system toward more consumer-driven decision-making and in some cases, self-care alternatives. We see this as a key differentiator for our company, and we're investing in technologies that help us exploit this expertise across our broad base. Jorge Mesquita and our other consumer business leaders will share more details at our consumer business review this May.
For 2015, our U.S. OTC business continue to grow faster than the market, and we're happy to report that nearly all of our OTC products have returned to shelves, and we are proud of the quality system improvements we have put into place.
Our consumer Medical Device businesses, the Johnson & Johnson Diabetes Solution companies and Johnson & Johnson Vision Care made progress in 2015 to improve our competitiveness. Both businesses, which command global leadership positions in their respective categories, focused their 2015 turnarounds on launching new products, solidifying their base businesses and accelerating growth.  And both businesses have regained or stabilized market share and market leadership and introduced important new product such as Animas Vibe and ACUVUE OASYS 1-Day with HydraLuxe in the U.S.
In our broader Medical Device businesses, last week, we announced a strategic restructuring initiative designed to directly support and accelerate the strategy Gary Pruden laid out for you on our third quarter earnings call. We are reallocating resources to priority platforms like endocutters, knees, trauma and EP. And recent history showed that when we doubled down in an area, we are able to accelerate meaningful innovation and outcomes as we saw with our endocutters portfolio, which is now the fastest-growing platform in our Medical Devices segment.
Additionally, we're making progress on transforming our go-to-market models like our cross-selling efforts between Ethicon and DePuy Synthes' joint reconstruction and spine, which resulted in over 600 leads through 2015. We are now co-selling in over 1,200 accounts, and all sales teams will be trained, covering all markets by the end of the first quarter.
And finally, our recent acquisition of Coherex Medical in the area of atrial fibrillation and the surgical robotics collaboration with Verily, formerly Google Life Sciences, are examples of the type of focus and strategic investments that you will see us make more of in the future.
Our goal is to reach more patients, outperform the markets in which we compete and consistently identify, build and acquire new platforms for growth. Moving forward into 2016, we will continue to take bold but appropriate steps to put our Medical Device business in the best position to deliver more value for customers and for our company and for our shareholders.
In summary, we believe that improved universal access to quality health care, rewarding innovation and a more vital culture of health, wellness and prevention are the keys to a future where people are healthier and businesses and economies are stronger. Our broad-based experience and scale uniquely positions Johnson & Johnson as a leader and partner of choice in the movement towards outcomes and episodes of care based approaches and ultimately, a healthier society. We are optimistic about the future opportunities in health care and confident in the strength of our business.
In 2016, we will remain focused on our near-term priorities and continue to advance our longer-term growth drivers, enabling us to continue delivering shareholder value year after year. With the guidance of our credo, we'll continue to meet our responsibilities to all stakeholders. That's been true for 129 years of breakthrough, life-saving innovation, and we are confident Johnson & Johnson is well positioned to continue meeting those responsibilities for the next 130 years.
Thank you. I look forward to further dialogue during the Q&A session. But first, I'll turn it over to Dominic Caruso, who will talk more about our results and expectations for 2016. Dominic?"
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Thanks, Alex, and good morning, everyone. As you've heard from Alex, we're very pleased with our 2015 performance. We believe we managed our business well, and I provided you insights during the year in a transparent manner that allowed all of you to unde",2452,"Thanks, Alex, and good morning, everyone. As you've heard from Alex, we're very pleased with our 2015 performance. We believe we managed our business well, and I provided you insights during the year in a transparent manner that allowed all of you to understand our plans and expectations. We finished the year strong and we're carrying that momentum into 2016. We ended the year at the top end of our operational guidance range for both sales and earnings and exceeded estimates for earnings as published by our first call.
Turning to the next slide. You can see our condensed consolidated statement of earnings for the full year 2015. I'd first like to remind you about some of the key assumptions in our guidance for 2015. At the beginning of the year, we discussed that, while we reinvested some of the profitability from OLYSIO sales, our earnings in 2014 did benefit by approximately $0.20 per share even after those investments, making 2015 comparisons to 2014 results more challenging.
Additionally, currency headwinds increased quite substantially in 2015, negatively impacting both sales and earnings for 2015 by approximately 8%. Given those expected headwinds, last January, we guided that we would deliver operational sales growth in the range of 1% to 2%. As you can see, well reported sales results show a decrease of 5.7%, on an operational basis, we ended up at the high end of our guidance with operational sales growth at 1.8%.
We also provided you with an estimate of our underlying operational sales growth for 2015, which excluded the impact of all acquisitions and divestitures as well as the impact of hepatitis C sales. We expected that underlying operational growth would be approximately 6%, and we exceeded that estimate, delivering 6.5%.
On earnings, our adjusted operational EPS growth in our original 2015 guidance was expected to range between 2.3% and 4.7%. As reported this morning, our EPS of $6.20 reflects operational growth of 5.8% and is at the top of the updated EPS guidance range we gave in October. And finally, our adjusted net income margin improved to 24.9%.
Now let's take a few moments to talk about certain items on the statement of earnings for the quarter. Turning to the next slide. You can see our condensed consolidated statement of earnings for the fourth quarter of 2015.
As we expected, direct comparisons to our fourth quarter of 2014 will be challenging to the stronger OLYSIO sales that we benefited from last year as well as divestitures and currency headwinds in 2015. Our results on an operational basis, excluding the impact of acquisitions and divestitures and excluding the impact of hep C sales, were up 7.8% for the quarter. As Louise noted, sales did benefit from additional shipping days in the fourth quarter of 2015.
Please now direct your attention to the boxed section of the schedule where we have provided earnings adjusted to exclude special items and intangible asset amortization expense. Adjusted net earnings were $4 billion in the quarter, up 4% compared to the fourth quarter of 2014, and adjusted earnings per share of $1.44 versus $1.37 a year ago are up 5.1%. And the adjusted EPS results exceeded the mean of the analyst estimates as published by first call. Excluding the impact of translational currency, our operational adjusted EPS was $1.54 or up 12.4% for the fourth quarter.
In the quarter, we incurred intangible amortization expense of $200 million on an after-tax basis as well as after-tax special charges of $600 million, which included an expense of $400 million related to the restructuring of our Medical Device business, which we announced last week and in-process research and development charge of $200 million.
Now let's take a few moments to talk about the other items on the statement of earnings. Cost of goods sold was 30 basis points lower than the same period last year, impacted by changes in our business and product mix. Selling, marketing and administrative expenses were 33.1% of sales. This is 120 basis points higher than last year as we continued to invest to drive growth in our key brands 
Our investment in research and development as a percent of sales were 16.1% in the quarter and 170 basis points higher than the prior year as we continue to make important investments in our pipeline for future growth. In fact, in the fourth quarter, we entered into important new licensing agreements, made milestone payments and increased spending to advance our R&D portfolio, which are all positive developments as we continue to strengthen our pipeline.
Interest expense net of interest income was slightly lower, reflecting higher earnings on our investments. Other income and expense was a net gain of $1.2 billion in the quarter compared to a net charge of approximately $1 billion in the same period last year. Of course, this line item includes several special items of both years. Excluding those special items, other income and expense was a net gain of approximately $1.3 billion compared to a net gain of approximately $130 million in the prior year period. This year's fourth quarter reflects the gain on the previously announced divestiture of Cordis.
As a reminder, we indicated that any gains from divestitures, which are reflected in the other income and expense line, would largely be reinvested in the business as well as used to mitigate the negative impact of currency and the lower level of income in 2015 from reduced OLYSIO sales. And therefore, our pretax operating margin would be expected to be lower in 2015 versus 2014. And our 2015 results reflect just that. We funded important investments with the higher level of other income that will benefit us going forward.
The adjusted fourth quarter effective tax rate for 2015 was 17.7%. This was lower than the rate in the previous 9 months due to the passing of legislation which renewed the R&D tax credit and look-through provisions. The R&D tax credit and look-through provisions were always included in our annual guidance. The adjusted full year effective tax rate for 2015 was 20.7%, slightly below guidance due to the mix of income from higher to lower tax jurisdictions.
Turning to the next slide, I will now review adjusted income before tax by segment. Adjusted income before tax for the entire enterprise improved from 30.7% of sales in '14 to 31.4% of sales in 2015.
Looking at the adjusted pretax income by segment. Medical Devices expanded 360 basis points, due primarily to the gain associated with the Cordis divestiture, while Pharmaceutical margins contracted 50 basis points due to the lower OLYSIO sales and increased investments in research and development, partially offset by the gain earlier in the year of divestiture of NUCYNTA.
Consumer margins contracted 110 basis points due to lower divestitures gains in 2015 versus 2014 as well as important investments for future growth as we returned our iconic consumer brands to the market.
Now I will provide some guidance for you to consider as you refine your models for 2016. Before I discuss sales and earnings, I'll first give you some guidance on items we know may be difficult to forecast.
I would first like to address our cash position and remind you about our capital allocation approach. At the end of the quarter, we had approximately $18.5 billion of net cash, which consists of approximately $38.5 billion of cash and marketable securities and approximately $20 billion of debt. This is a higher level of cash than we typically hold. And as Alex said earlier, we are actively looking for the right opportunities to deploy that capital to create greater value for our shareholders. But we are patient. We are seeking companies with a mutual desire to partner and will only act when we see the right value-creating deal at the right price with the right partners.
We have a transparent and disciplined capital allocation strategy that starts with dividends to our shareholders, followed by value-creating M&A and then we consider other prudent ways to return value to shareholders such as share repurchase programs. And due to our strong balance sheet, we have the financial strength and flexibility to execute on all 3 of these capital allocation priorities simultaneously.
During Q4 2015, we used approximately $1 billion to repurchase shares of our stock in connection with our $10 billion share repurchase program that we announced in October. Although we are continuing to evaluate external value-creating opportunities in line with this strategy, the purposes of your models, assuming no major acquisitions or other major uses of cash, we suggest you consider modeling 2016 net interest expense of between $450 million and $550 million.
Regarding other income and expense, as a reminder, this is the account where we record royalty income as well as gains and losses, providing from such items as litigation, investments by our development corporation as well as divestitures, asset sales and write-offs.
We would be comfortable with your models for 2016 reflecting other income and expense, excluding special items as a net gain, ranging from approximately $1.1 billion to $1.2 billion. Although we expect to have a significantly lower level of other income in 2016 versus 2015, our pretax operating margin in 2016 is expected to expand by more than 200 basis points.
As we've discussed several times during the year, we continue to evaluate our portfolio, and we expected at any gains from divestitures would be lower than the level we saw in 2015. However, we also discussed that we would nonetheless improve on earnings as we see the benefits of good expense management and meaningful investments we made in 2015.
And now a word on taxes. We're very pleased that the R&D tax credit was made permanent and approved by Congress this last year. We would be comfortable with your models reflecting an effective tax rate for 2016 excluding special items of approximately 19.5% to 20.5%.
Turning to sales and earnings guidance. Our sales guidance for 2016 assumes no biosimilar entrance for PROCRIT or REMICADE in the U.S. We also do not anticipate generic competition this year for ZYTIGA, RISPERDAL CONSTA and INVEGA SUSTENNA. But as expected, there are generic entrance for INVEGA and ORTHO TRI-CYCLEN LO.
As we've done for several years, our guidance will be first based on a constant currency basis, reflecting our results from operations. This is the way we manage our business, and we believe this provides a good understanding of the underlying performance of our business and will also provide an estimate of our sales and earnings and EPS results for 2016 with the impact that exchange rates could have on the translation of those results.
For the full year of 2016, we would be comfortable with your models reflecting an operational sales increase of between 2.5% and 3.5% for the year. This would result in sales for 2016 on a constant currency basis of approximately $71.9 billion to $72.6 billion. Additionally, while we have comparison to how we describe our sales and results in 2015, our 2015 operating sales growth, excluding the impact of all acquisitions and divestitures and hep C sales, was approximately 6.5%. After adjusting for extra shipping days in 2015, that underlying growth rate was approximately 5.5% 2015. Our sales guidance for '16 on the same basis is expected to continue at a similar growth rate of around 5.5%.
While the euro has been fairly stable over the last few months, many of the other currencies have been volatile. Although we're not predicting the impact of currency movements, using the euro at $1.09, our guidance for sales growth would decrease by approximately 1.5%. We are watching the other currencies closely as it is uncertain as to how they will settle out for the year. Of course, we will update the assessment as we progress throughout the year.
Plus, under this scenario, we would expect reported sales to reflect the change in the range of 1% to 2% for a total expected level of reported sales of approximately $70.8 billion to $71.5 billion.
Now turning to earnings. A continuing factor impacting earnings guidance for 2016 is the impact of currency movements on transactions, which, although hedged, is still somewhat negative. We expect transaction currency impacts to negatively impact our gross margin by approximately 60 to 80 basis points in 2016 as compared to 2015. We would be comfortable with adjusted EPS guidance in the range of $6.53 to $6.68 per share on a constant currency basis, reflecting operational or constant currency growth rates of 5% to 8%.
Again, we're not predicting the impact of currency movements. But to give you an idea of the potential impact on EPS, with the euro at $1.09, our reported adjusted EPS would be negatively impacted by approximately $0.10 per share. Therefore, our reported adjusted EPS would range from $6.43 to $6.58 per share. At this early stage in the year, we would be comfortable with your models reflecting the midpoint of this range, which, at approximately 5%, is higher than current consensus estimate.
So in summary, as you update your models for the guidance I just provided, I'd like to make a few points. Although operational sales growth is expected to range between 2.5% and 3.5%, we're pleased to note, when excluding the impact of acquisitions and divestitures and hep C sales, our operational sales growth is expected to be around 5.5% for the full year 2016. With regards to expected EPS growth on an operational basis, our adjusted EPS growth guidance is strong in the range of 5% to 8%.
Also for 2016, pretax operating margins are expected to expand by more than 200 basis points based on the guidance I just provided. The margin expansion is driven by a combination of investments we made in 2015, coupled with the benefit of disciplined expense management across the enterprise.
Moving into 2016. We are confident in the strength of our business. As we execute our growth plans and near-term priorities that Alex laid out for you this morning, we're well positioned with the strong balance sheet to deliver solid results while continuing to invest in innovation, which will ensure our future growth and success. Our goal remains to grow our sales organically at a rate faster than the markets in which we compete, grow our earnings faster than sales and create value through strategic acquisitions and partnerships that generate additional growth. All of this, coupled with our strong dividend yield, provides a very compelling long-term shareholder return 
Finally, before I turn it over to Louise for Q&A, just a reminder to please save the date for our Consumer and Medical Device Business Review on Wednesday, May 18.
Thank you. Now back to Louise."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Dominic. Manny, could you please give the instructions for the Q&A session?",14,"Thank you, Dominic. Manny, could you please give the instructions for the Q&A session?"
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","[Operator Instructions] And your first question comes from Mike Weinstein of JPMorgan.",12,"[Operator Instructions] And your first question comes from Mike Weinstein of JPMorgan."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","So let me start with the margin expansion piece for the guidance, and this kind of fits in with the announcement last week on the MD&D business. And there's really -- like there's 2 parts to the question. So if I look at MD&D and where you ended up with p",155,"So let me start with the margin expansion piece for the guidance, and this kind of fits in with the announcement last week on the MD&D business. And there's really -- like there's 2 parts to the question. So if I look at MD&D and where you ended up with pretax margins in 2015, they were at 35.6% and which -- whatever [ph] observer would say those are very high margins. And for the overall company, you're guiding to 200 basis points plus of pretax margin improvement, which would make 2016 the biggest year of margin expansion in the last 15. So talk about the decision to be as aggressive as you're being in 2016 on operating cost. And for the MD&D business in particular, why is the consolidation that you're pursuing in -- that's called the cost transformation imperative at this point in time? And why are you being as aggressive as you're being?"
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Sure, Mike. Thanks for the question. Well, a couple of things. One is the -- 2015, as you saw, was a heavy investment year because we benefited from the divestitures, and I think we are very transparent that we would make important investments going into",198,"Sure, Mike. Thanks for the question. Well, a couple of things. One is the -- 2015, as you saw, was a heavy investment year because we benefited from the divestitures, and I think we are very transparent that we would make important investments going into 2015, and we did just that. So in 2016, we have a lower level of those investments consistent with a lower level of the other income that we just guided to. Also, it's important to point out that those investments we made in 2015, we're seeing the benefits of those already in 2016, so we think they are wise investments. And finally, we have talked a lot about our various programs of reducing our cost structure. And Alex today mentioned the program that we're embarking -- that we embarked on several years ago that will reduce costs by $1 billion by 2018. Well, we're well on our way in implementing that program after several years of investment. In 2016, we'll see a year where the actual benefits associated with that program outlay any incremental investments. And maybe Alex may comment on the MD&D restructuring and why that's appropriate for us to do today."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes, Mike. We do think that this is the right time to be making the moves. But really, I think it's important to kind of step back and put it in the larger perspective. If you think about what we've been doing in Medical Devices over the last several year",174,"Yes, Mike. We do think that this is the right time to be making the moves. But really, I think it's important to kind of step back and put it in the larger perspective. If you think about what we've been doing in Medical Devices over the last several years, we've had a range of activities ranging from some of divestitures with OCD as well as Cordis underway. At the same time, we've been making changes internally with the way that our organizations are innovating as well as in the way that they're going to market. And so we see this as the next logical step in that overall process. Our Medical Device business is one that we remain very committed to. We believe that it's got an exciting future, a lot of new innovation coming, new ways of dealing with our customers. And so we think this is the right time to make sure that we're set up for growth, not only in 2016, but actually for the next 5 and 10 years."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Dominic, can you share in the commentary about how you're thinking about the respective businesses in 2016 versus your 2015 performance? And then maybe just the -- on the MD&D topic, it's hard to ease out what the kind of underlying growth is with the ext",84,"Dominic, can you share in the commentary about how you're thinking about the respective businesses in 2016 versus your 2015 performance? And then maybe just the -- on the MD&D topic, it's hard to ease out what the kind of underlying growth is with the extra selling days, but MD&D did grow 5.8% this quarter. That's obviously inflated by that. Do you have any thoughts in -- just in terms of where you are in the turn [ph] of performance of the MD&D business?"
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes. Well, sure, Mike. Well, let me comment overall. As you know, our growth in 2015, primarily driven by Pharmaceuticals, and we expect healthy growth in 2016 from pharma. We're probably in a slightly lower rate of growth than what we saw in '15 as those",136,"Yes. Well, sure, Mike. Well, let me comment overall. As you know, our growth in 2015, primarily driven by Pharmaceuticals, and we expect healthy growth in 2016 from pharma. We're probably in a slightly lower rate of growth than what we saw in '15 as those products that we launched are beginning to mature in their growth trajectory, but still a lot of growth ahead of them. So we're not going to give guidance by sector, but overall, a little bit lower growth than 2016 versus '15 for Pharma. Better growth in Consumer, good momentum in '15 carrying on into '16, and we expect higher growth rates in '16 versus '15 for the Medical Device business as well. And as you saw, we ended the year with a good strong momentum in that business as well."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Glenn Novarro of RBC Capital Markets.",11,"The next question is from Glenn Novarro of RBC Capital Markets."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","A question for Alex. Alex, given the strong balance sheet, I'm somewhat surprised you were not more aggressive with the balance sheet in 2015, especially on the M&A front. And you made some comments about the balance sheet going forward. But I'm just curi",104,"A question for Alex. Alex, given the strong balance sheet, I'm somewhat surprised you were not more aggressive with the balance sheet in 2015, especially on the M&A front. And you made some comments about the balance sheet going forward. But I'm just curious, as you evaluate your options, particularly on the M&A front, is the fact that we haven't seen deals year-to-date or so far, is it because the targets still have very high valuation expectations? Or is it that most of your cash is trapped outside the U.S., limiting your ability to do acquisitions? Or is it a little bit of both?"
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Thank you very much for your question. Look, we are and we have been and will continue to be very active in the M&A category. As we mentioned during the earlier comments, if you look at it historically really, over about any time frame, 20 years, 10 years",261,"Thank you very much for your question. Look, we are and we have been and will continue to be very active in the M&A category. As we mentioned during the earlier comments, if you look at it historically really, over about any time frame, 20 years, 10 years, what you see is about half of our growth being generated from organic innovation platforms and about 50% being generated vis--vis M&A. As we reflect back on 2015, we realize that the market was premium priced. We remain very active in a number of different areas. And while we didn't necessarily close on a larger deal, I would not assume that we were not engaged and involved. But at the same time, we think it's really important for you, our shareholders, as you think about long-term returns, that we stay at the appropriate level of discipline and decisiveness as we go through that process. As we look at the environment today, we see a number of opportunities across the consumer, the Medical Device and the Pharmaceutical groups. We're going to remain very active. I think that our financial team has done a great job of using our offshore assets in a very compliant but also tax-effective way. And we'll continue to look for opportunities that ultimately, we believe, are going to provide -- are going to help us continue to get into growing markets to improve our share position, to provide complementary products and services to platforms that we already have that ultimately are going to lead to long-term sustainable growth for J&J."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","So if I hear you correctly, you're saying valuations were elevated for the targets in 2015. But I sense from you that the target value, the valuations of your targets, valuations are coming down, and it sounds like that the cash sitting outside the U.S. w",81,"So if I hear you correctly, you're saying valuations were elevated for the targets in 2015. But I sense from you that the target value, the valuations of your targets, valuations are coming down, and it sounds like that the cash sitting outside the U.S. will not inhibit deal flow. So is that a fair assumption? And then, is there any one business versus the other that you would be more likely inclined to do an acquisition to help accelerate growth?"
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes, Glenn. Look, we're fortunate in that because of our strong performance, our strong cash flows that our balance sheet is actually quite strong. I'd also believe that if you look at our track record of how we've utilized that cash to make the right cap",172,"Yes, Glenn. Look, we're fortunate in that because of our strong performance, our strong cash flows that our balance sheet is actually quite strong. I'd also believe that if you look at our track record of how we've utilized that cash to make the right capital investments in companies that we've been successful with that. And look, we think that there's opportunities across all 3 of our different sectors. And it's not an algorithm per se as we decide which and where to invest. But rather, it really depends on the opportunity and many of the factors that Dominic described earlier as far as what are the specific platforms that we're looking at, where is the partner in terms of their decision-making, what they want to do with the business and frankly, what the competitive environment is like. So we think that there are opportunities. And we intend to be quite active as we look at 2016 and beyond in a manner that's been consistent with our track record in that area."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Matt Miksic of UBS.",9,"The next question is from Matt Miksic of UBS."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","So one kind of broader question on the sort of changes in the health economy in the U.S., and then I have one follow-up on top of the [ph] extra day commentary that you made. So looking forward to the MD&D day and the update on sort of the restructuring t",147,"So one kind of broader question on the sort of changes in the health economy in the U.S., and then I have one follow-up on top of the [ph] extra day commentary that you made. So looking forward to the MD&D day and the update on sort of the restructuring there. But stepping back, you've been one of the leaders here in sort of broader contracting strategies and development of some of these value-added services like care center [ph] and outpatient solutions. Alex, it would be just helpful to get your thoughts on what you're seeing in the marketplace in terms of uptake, of those kinds of strategies and maybe talk about whether we're in the early innings here and how you think about some of the benefit you're seeing or hope to see with those approaches to the business. And then I have one follow-up."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Sure, Matt. Thank you very much. Look, overall, we feel that we're still in the very early innings out of what I would call as the market evolution that we clearly expect to see over the next 3, 5 and even 10 years. Now for all the reasons that we've disc",490,"Sure, Matt. Thank you very much. Look, overall, we feel that we're still in the very early innings out of what I would call as the market evolution that we clearly expect to see over the next 3, 5 and even 10 years. Now for all the reasons that we've discussed around increasing demands based on demographics, certainly here in the U.S., and a rising middle class and demographics outside the United States and the pressure that, that's likely going to put on payers and governments and others in between, we realize that there is an opportunity for us to participate, not only in bringing great innovations that's going to help patients, but also doing it in a value-added way. And clearly, the consumer, the patient, is weighing in much heavier in these decisions as they take on higher copays as they can get more information that's available online. And frankly, they just have higher expectations about their ability to participate in that health care decision-making process. So what we see is a range of customers, but we see some customers who are still very innovation focused. And to be clear, we remain very innovation focused. We think, at the end of the day, what we do best is bring new products, new solutions to our customers that are going to ultimately have better outcomes for patients. And so that's an area where we are very focused on and we'll continue to be focused on. We are though starting to [ph] also see hospital systems. And I think one important point here is it's certainly taking place in the United States, but it's also definitely taking place in places like Europe and even some of the developing and emerging markets that frankly don't have the history and the legacy of some of the infrastructure that you see in the more developed markets. In there, it -- what we see is an evolution more towards the business-to-business relationship where yes, customers want to see innovation, but they also want to see how are you going to interact, how can you assist in working with our supply chain to make it more efficient, how can we work together as part of a broader partnership that ultimately is focusing not just on a product sell, but actually on outcome, on an episodic care for the patient and it creates a much broader partnership. We are seeing those organizations becoming more and more interested, and that's why we're adapting to make sure that we're part of that. So I think, overall, it's important that we continue to innovate, we continue to operate with a lot of excellence in the current environment. At the same time, it's important that we set the stage for this evolution that's taking place out there to make sure that we cannot only be successful, that we're -- but we'll actually be a leader as that market evolves as well."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Very, very helpful. And then the clarification on the extra shipping day, as you talked about, it's a holiday week and maybe OR surgery days were not as much of a factor as shipping days, from what I could tell in your commentary. But you're strong in Vis",127,"Very, very helpful. And then the clarification on the extra shipping day, as you talked about, it's a holiday week and maybe OR surgery days were not as much of a factor as shipping days, from what I could tell in your commentary. But you're strong in Vision Care, obviously a shipping type of business, strong in Pharma. Just wondering, Dominic, if -- or if you have any color on some of your consignment businesses where we think about orthopedics, spine and trauma where the inventory is in the field, it's on your balance sheet. Is it -- was there any difference in the way those business were impacted versus businesses where you're actually shipping and billing for things in the last couple days of the quarter?"
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Sure, Matt. Well, just overarching comment on this. Of course, these extra shipping days were already included in our guidance for the year, and I think you've all modeled for them. And as you know, our sales came in pretty much in line with expectations.",119,"Sure, Matt. Well, just overarching comment on this. Of course, these extra shipping days were already included in our guidance for the year, and I think you've all modeled for them. And as you know, our sales came in pretty much in line with expectations. About 1% for the year, we think, is the impact overall for the enterprise and about 4% in the quarter. You're right. It does vary slightly by different businesses within the U.S. in particular. So this is largely a U.S. phenomenon as opposed to a global phenomenon. And with respect to the Orthopaedics business line, which I think you're referring to specifically, I think, Louise, you might have the details on the impact there."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes. So the additional days in the U.S. in Orthopaedics was about 2.5 days. In -- and outside the U.S., about 1.5 days average.",24,"Yes. So the additional days in the U.S. in Orthopaedics was about 2.5 days. In -- and outside the U.S., about 1.5 days average."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","So not really that -- not really much different from the overall total because that 2.5 days get you to this 4% and 1% that I talked about earlier.",29,"So not really that -- not really much different from the overall total because that 2.5 days get you to this 4% and 1% that I talked about earlier."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","And what's interesting also, when you look at the underlying growth in the Orthopaedics, third quarter, fourth quarter, taking out the additional shipping days, we saw sequential improvement across hips, knees, spine and trauma.",35,"And what's interesting also, when you look at the underlying growth in the Orthopaedics, third quarter, fourth quarter, taking out the additional shipping days, we saw sequential improvement across hips, knees, spine and trauma."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","That's right.",3,"That's right."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","On a worldwide basis. Okay?",5,"On a worldwide basis. Okay?"
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Larry Biegelsen of Wells Fargo.",10,"The next question is from Larry Biegelsen of Wells Fargo."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Let me just start with med tech and then I had a follow-up on pharma. So Alex, can you talk about the health of the med tech end markets in the U.S. and emerging markets? And what drives the acceleration for your business specifically in 2016? When I look",96,"Let me just start with med tech and then I had a follow-up on pharma. So Alex, can you talk about the health of the med tech end markets in the U.S. and emerging markets? And what drives the acceleration for your business specifically in 2016? When I look at the general surgery business, it looked like adjusting for the extra days in the U.S., that was -- or worldwide, that was slightly weaker in Q4. So just the health of the end markets in the U.S. and emerging markets, and I had a follow-up."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Sure. Thanks a lot for the question, Larry. I think what we would say overall is we continue to see, let's say, a slightly increasing positive trends. So we saw hospital admissions, I believe, up around 2%, we saw surgical procedures up a little over 1% i",639,"Sure. Thanks a lot for the question, Larry. I think what we would say overall is we continue to see, let's say, a slightly increasing positive trends. So we saw hospital admissions, I believe, up around 2%, we saw surgical procedures up a little over 1% in the U.S., that's the most recent data that we have. If you go outside a U.S., we think rates in Europe have been pretty steady. And even in the markets in which we compete most significantly, in the developing markets, we haven't seen a major impact from secular shifts perhaps in China some, but not dramatic. And then putting that into context, what that represents overall on our business, we don't see it as a major indicator. As I look towards 2016, look, there's a few things that cause us to be optimistic about our Medical Device business. It really starts with innovation. And we've got about 30 products that we'll be launching by the end of 2016. Over half of those have either been launched or well on their way as we speak. And what we're seeing is when we're bringing new technologies to the market like our new contact lenses, like our new insulin pump, like our new energy instrumentation, like the ATTUNE Knee, we're seeing very good uptake. And in fact, in those categories, we're seeing share gains. And certainly, in areas like electrophysiology, endocutters, the same thing. And so we believe that the market does still reward significant innovation when we're introducing it. So that's one aspect. The second aspect, frankly, is one, just improved execution. And I think if you look across all of our device businesses, if you think about diabetes care, the major price reset that we had there a couple of years ago -- and as all of you know, when you're -- when you take that kind of a reduction, resizing your business, going back in each and every line and setting it for the new marketplace caused us an tremendous amount of change. If you look at our Vision Care business last year, we went in and we really increased the cadence out of our innovation pipeline, launching 5 new products. We did a price reset there to make us more competitive with the ECPs. We made a lot of other internal adjustments to improve our selling and marketing. We are definitely seeing the impact of that now, not only on the sales results of about 8%, but as -- maybe even more importantly, if you look at the leading indicators as far as new share that's being generated and new patient starts in the offices, those things are positive. Louise mentioned earlier the improvement that we're seeing across the Orthopaedics business. And look, this is one where we know that when you bring large organizations together, when you standardize quality systems, manufacturing systems, we think that we've made a lot of progress there. And frankly, when you compound that with the innovation rollout that we've seen in Orthopaedics of the ATTUNE Knee, the CORAIL Hip, the TFNA nail, we're starting to see that come back as well as some of the, frankly, the new approaches that we're taking that Gary will be talking more about in May where our Ethicon and our DePuy Synthes teams were actually co-selling, co-contracting in a number of very innovative ways, compounded with the fact that -- look, we think some of the performance issues related to China in our Orthopaedics are more of a onetime event. That's getting normalized. So as we burn our way through those and head into 2016 overall, we think that innovation, we think changes in our commercial model, we think improved execution, all those things are -- make us more optimistic about the growth prospects as we head into 2016."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","That's very helpful, Alex. And I just have one follow-up on biosimilar REMICADE. So obviously, there's a panel schedule that rescheduled last month. So I'm wondering if you can talk about what issues you think we should be listening for, what your expecta",71,"That's very helpful, Alex. And I just have one follow-up on biosimilar REMICADE. So obviously, there's a panel schedule that rescheduled last month. So I'm wondering if you can talk about what issues you think we should be listening for, what your expectations are and what you're seeing in Europe where biosimilar REMICADE is on the market and why or why not that might be a proxy for the U.S."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Certainly. Well, obviously, we'll also be watching the advisory committee and participating in it as well coming up. And we think there's a few things to keep in consideration about this. And first and foremost is that as Dominic stated earlier, biosimila",545,"Certainly. Well, obviously, we'll also be watching the advisory committee and participating in it as well coming up. And we think there's a few things to keep in consideration about this. And first and foremost is that as Dominic stated earlier, biosimilars are very different from generics. And particularly, in this category, I think keeping the patient in the center of all these -- we've got a tremendous amount of experience in the biologics category going back to PROCRIT, REMICADE some of our days. And we think the differences between molecules can have -- manifest themselves in significant ways with patients. So making sure -- and I think things that we'll be watching for the AC or what kind of data that the biosimilars actually have, what kind of indications, what will be the guidance around substitutability. All those, frankly, sitting here today, are unknowns. We'll need more clarification. But we think each of those means that the expected uptake, even when a biosimilar does launch, will lead to a significantly different curve than what you see with generics. We think, secondly, it's very important -- if you actually think about it from a patient perspective. And we know, for example, there's about 2.5 million patients with REMICADE, and about 70% of those are either continuing therapy and have a pretty high satisfaction rate. So if you look at the available population who's likely to be switched, we think it's in the 30% range. And last but certainly not least, there's the whole issue of the business model and the way that we actually work with customers in this setting. And this is an area where we've got a lot of experience in contracting. We've got some great relationships with providers in this area right now. We also have a very broad portfolio. If you think about what REMICADE does, but you look more broadly at the performance recently of a product like STELARA, a multibillion dollar compound, growing at 20-plus percent rate; if you look at SIMPONI, same thing, SIMPONI ARIA, in particular, the great dosing convenience that it provides, that's another multibillion addition that we have to that portfolio, then you augment that with the submissions that we have in 2016 planned for, guselkumab, sirukumab and IL 23 and then IL-6, we think that, that positions us very well with our portfolio and from a contracting point of view with large providers and payers in certainly in the U.S. but also abroad. What we're seeing outside the United States is that most of the markets where they're introduced is a relatively minor impact. We're seeing that we're holding on to about 90% plus or minus. It varies by market. You have to look at each one individually. And it's difficult to project exactly what that impact will be going forward. But I think when we think of it broadly across all those different areas, what's the clinical data show, what ultimately is the labeling, the regulatory aspects, what about our contracting, the business aspects, and we think all those are very important, will result in a different impact from biosimilars. And ultimately, we'll continue to defend our intellectual property as well through what we believe is the right path in September of 2018."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","And just add to that, we have -- REMICADE in Canada is a Johnson & Johnson product, and we've seen fairly -- it's actually still growing in Canada even with the biosimilar there. Now the biosimilar has a limited indication there, but it's still growing. A",62,"And just add to that, we have -- REMICADE in Canada is a Johnson & Johnson product, and we've seen fairly -- it's actually still growing in Canada even with the biosimilar there. Now the biosimilar has a limited indication there, but it's still growing. And we'll be listening to Merck's call as well to see if -- the latest in Europe."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Jami Rubin of Goldman Sachs.",10,"The next question is from Jami Rubin of Goldman Sachs."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Just a question for you, Dominic, and I have a question for Alex. Just trying to understand the difference between consensus estimates for 2016 in your guidance. Do you have a sense for what The Street was assuming for nonoperating income? When I go back",185,"Just a question for you, Dominic, and I have a question for Alex. Just trying to understand the difference between consensus estimates for 2016 in your guidance. Do you have a sense for what The Street was assuming for nonoperating income? When I go back historically, that's been in the $500 million to $600 million range. Clearly, it was $2 billion last year, but just curious to know what consensus models had assumed for that. Secondly, did your guidance assume that the medical device tax will be suspended as I think we've seen with other device companies? Just curious know if that savings is reinvested in the business or if that is part of the guidance. And then for you, Alex, just curious to know your thoughts on pricing. I mean, we heard Bernie and Hillary last night go after drug pricing again. And I think that's also something we're going to hear from the Republican candidates. What are your expectations in terms of pricing in 2016 and 2017? Do you expect that there will be a change in terms of list prices going forward?"
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Okay. Jami, let me try to take the first 2 and then have Alex -- maybe he'll comment on the drug pricing. You were referring to our nonoperating, now let's call it the other income and expense line for 2016, what was assumed in analyst models versus what",315,"Okay. Jami, let me try to take the first 2 and then have Alex -- maybe he'll comment on the drug pricing. You were referring to our nonoperating, now let's call it the other income and expense line for 2016, what was assumed in analyst models versus what we have provided in guidance. When we looked at the analyst consensus models, overall, it looks like that number averaged in the high $900 million, so nearly $1 billion. And our guidance, of course, is somewhere at $1.1 billion to $1.2 billion. So our guidance is slightly higher than the analyst models. But just as a reminder, we always take the opportunity to -- these are portfolio choices to use any of those gains to offset some other expenses we'd like to invest in. And then with respect to the Medical Device Tax, the -- we have assumed that it would be a benefit in 2016. But I must say, the benefit for us is very, very minor. Remember, when the Medical Device Tax is incurred, it's incurred upon the first manufacturer of a product and therefore, it can be, for example, orthopedic companies hung up in inventory for quite some time. So the overall impact of not having a Medical Device Tax in 2016 is not significant for Johnson & Johnson. It may be significant for certain other companies that maybe are pure orthopedic players, but not overall significant for us. And secondly, I would say that whatever benefit we see there, we've already assumed would be reinvested in innovation as, of course, during the time that the Medical Device Tax was a drag on earnings, obviously, decisions had to be made on where to invest. Now we're happy that with that easement of the Device Tax for a couple of years, we'll be able to actually invest more in innovation in the medical device space."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes, Jami, thanks for the question on pricing. Look, we realize and understand the pricing in pharmaceuticals but [ph] all of health care. It's certainly a very important issue. And we believe that it's important to consider it just in that way. As we thi",265,"Yes, Jami, thanks for the question on pricing. Look, we realize and understand the pricing in pharmaceuticals but [ph] all of health care. It's certainly a very important issue. And we believe that it's important to consider it just in that way. As we think about pharmaceuticals, for example, they currently make up about 12% of health care spending in the United States, slightly higher in Europe. If you think about medical devices, they represent about 6%. And if you go beyond those areas, of course, there's a lot of other cost built into that system, ranging from hospital, patient care, insurance companies, many other people and particularly, in an environment today, where frankly, we're seeing such transformational outcomes and moving more and more towards cures, disease prevention, interception than we ever have because of some of the great science that's being produced. So we understand and would certainly expect there to be a continued spotlight in this area. Obviously, we're working with a lot of stakeholders to try and make sure that we look at it in a very holistic way. And it's very, I think, difficult, at this point in time, to try to project what's going to happen in 2016 or 2017. All of us know that the health care system, not only here in the United States, but frankly, around the world, is complex. There's a lot of other -- a lot of issues that are intertwined and -- but it's obviously a conversation that we'll be participating in and ultimately, where we want to be a part of the solution."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Vamil Divan of Crdit Suisse.",10,"The next question is from Vamil Divan of Crdit Suisse."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","So just a couple on the pharma side, I guess, one on the pharma side and one other one for Dominic. You mentioned STELARA and you mentioned the strong quarter and 20% growth is showing. I'm just wondering if you can share a little bit, if you talk about 2",159,"So just a couple on the pharma side, I guess, one on the pharma side and one other one for Dominic. You mentioned STELARA and you mentioned the strong quarter and 20% growth is showing. I'm just wondering if you can share a little bit, if you talk about 2016 and maybe beyond the -- your expectations of that product going forward just given the competition. It's kind of based [ph] from the IL-17, both in psoriasis and psoriatic arthritis. So is this sort of 20% range still sustainable or do you think you'll see more of a decline? And then second, for Dominic, just on the guidance. And I apologize if I missed this. But in terms of your EPS guidance, can you comment on what share count you're using to get to that guidance or just get some sense of the buybacks, I guess, that you've sort of incorporated into the way you think about the year?"
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Sure. Why don't I take that first part first? So Vamil, we -- obviously, we announced the share buyback in October. And I said we, already through the fourth quarter, spent about $1 billion of that $10 billion. In our plans for 2016, we have not assumed t",94,"Sure. Why don't I take that first part first? So Vamil, we -- obviously, we announced the share buyback in October. And I said we, already through the fourth quarter, spent about $1 billion of that $10 billion. In our plans for 2016, we have not assumed that it's totally complete. But certainly, more than a majority of the share buyback will be completed by the end of 2016, maybe 3 quarters of it, sort of around that range. And that's what we've assumed in our models for 2016, the guidance I just gave."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes, Vamil. Thanks for the question. Look, if we look at STELARA, one, it just starts with a great compound. It's had very nice uptake, very good growth and we've certainly seen that in psoriatic arthritis. But we're also excited about the planned indicat",136,"Yes, Vamil. Thanks for the question. Look, if we look at STELARA, one, it just starts with a great compound. It's had very nice uptake, very good growth and we've certainly seen that in psoriatic arthritis. But we're also excited about the planned indications in areas like UC and axial spondylitis. So when you take the profile, the momentum that we're seeing in the current marketplace and the share that continues to grow, you combine it with some additional indications as we go forward, particularly as part of our broader immunology portfolio, we think that there's -- and the other important issue, I believe, this category is only about 22% or 23% penetrated. So in terms of the new patients that are coming in, all of that represents a nice growth opportunity for this important product."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Kristen Stewart of Deutsche Bank.",10,"The next question is from Kristen Stewart of Deutsche Bank."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","I have 2 questions, the first for Dominic. I believe, a couple of years ago, you talked about the opportunities for margin expansion within Consumer, and we really haven't seen that just yet. With most of the products now returned in the OTC business, sho",95,"I have 2 questions, the first for Dominic. I believe, a couple of years ago, you talked about the opportunities for margin expansion within Consumer, and we really haven't seen that just yet. With most of the products now returned in the OTC business, should we expect to see Consumer really starting to reach an inflection point? And with the goal, I believe, [indiscernible] had talked about 2 years ago at the last kind of Consumer update, really getting back into that kind of 20% range, still really achievable for the next couple of years?"
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes, Kristen. We do expect that the Consumer business, out of the products that they've launched and the cost remediations associated with the Consent Decree are largely behind us, although we still comply with the Consent Decree for another 5 years. We d",91,"Yes, Kristen. We do expect that the Consumer business, out of the products that they've launched and the cost remediations associated with the Consent Decree are largely behind us, although we still comply with the Consent Decree for another 5 years. We did want to launch those products with the right support. But it is true that we do expect, and we'll see it in '16, we'll report on it later in the year throughout the quarters, the -- an improvement in the operating margins of the Consumer business going forward."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Okay. And Alex, I guess, just following that, will M&A be a key driver to improving the margins or any sort of portfolio management? And then more broadly, I know I've always asked Dominic this question every now and again. I guess, you guys have always t",117,"Okay. And Alex, I guess, just following that, will M&A be a key driver to improving the margins or any sort of portfolio management? And then more broadly, I know I've always asked Dominic this question every now and again. I guess, you guys have always talked about the fourth leg [ph], and we've seen some of your competitors go to more solutions-based approach in wraparound [ph] programs. You have some of those as well, particularly within the Orthopaedics business. Is that something that you think of when you're thinking about M&A moving more towards a holistic health care model and maybe perhaps rolling in some more lifestyle disease management programs or something on the service side?"
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Sure. Look, I just picked up what Dominic had just said about our Consumer business is that I'm really proud of the work that we've done on the Consent Decree and the great strides that they have taken around quality. In fact, I think in working closely a",434,"Sure. Look, I just picked up what Dominic had just said about our Consumer business is that I'm really proud of the work that we've done on the Consent Decree and the great strides that they have taken around quality. In fact, I think in working closely and partnering with the FDA, we likely have a benchmark organization now, and we're really proud having done that. At the same time, I think as they begin to shift from only remediation to remediation and relaunch, across a number of these areas, while certainly keeping a very high eye on quality, as we increase our volumes, as we are able to deepen our relationships with a lot of the major trade partners, that's where we see a great growth opportunity as well and obviously, that's going to have an impact in our margins as we go forward. I also think that the other thing that, that team is doing is as we're transitioning more and more to online marketing versus just traditional marketing, the way we're partnering with some of the large customers, I think there's a lot of opportunities not only to drive share and volume, but actually to improve efficiencies on our back end as well. As I step back and look more broadly, look, we think the 3 areas that we're in, consumer, medical devices and pharmaceuticals, are all great platform and great businesses. Of course, we would look, first, for areas that -- what is the next ZYTIGA? What's the next Vision Care platform? What's the next NEUTROGENA? That would certainly be our focus. Another would be, are there chances to grow in perhaps some of the faster-growing developing markets with the right kind of opportunity? Those are things that we would be interested in. And then what are ways to complement our existing businesses? I think the way that you point it out, as the markets evolve, we are looking, not only at M&A, but also broader partnerships that we've done, for example, with companies like Google, barely where we see a big opportunity to really help transform the robotics surgery space in a pretty significant way longer term. And then, I guess, so the final option there would be for us to actually acquire something outside the current 3. And again, if it's something where we thought there was a lot of unmet patient or consumer need, if we feel that it's consistent with the capabilities that we can bring to bear to actually have it be a successful business, if the financials work, then we would take that step."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Bob Hopkins of Bank of America.",11,"The next question is from Bob Hopkins of Bank of America."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","So 2 things, and I'll just rattle [ph] them off. First, I was wondering if you guys could comment a little bit on emerging market growth in Q4 relative to trends earlier in the year. And then more importantly, just talk about the current operating environ",133,"So 2 things, and I'll just rattle [ph] them off. First, I was wondering if you guys could comment a little bit on emerging market growth in Q4 relative to trends earlier in the year. And then more importantly, just talk about the current operating environment, China, and when do you think we could see reacceleration of emerging market growth for J&J, that's question number one. And then question number two is just back to the original question on the 200 basis points of pretax operating margin improvement in '16. I was wondering if you could give us just a little more detail on exactly where that comes from, maybe mention how much extra spend was there in 2015 that won't materialize in '16. Just looking for a little bit more color there."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Okay. So on the emerging market's growth, excluding the impact, of course, of Cordis and OCD, it was about 6.5% in the fourth quarter. On a year-to-date basis, it was about 5.5%. Those are both operational numbers.",37,"Okay. So on the emerging market's growth, excluding the impact, of course, of Cordis and OCD, it was about 6.5% in the fourth quarter. On a year-to-date basis, it was about 5.5%. Those are both operational numbers."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","And on China, just a couple of comments that China -- we did see a slowdown in China, primarily in the Consumer business because the -- both Medical Device and Pharma businesses still had high single digit growth in China, and we're optimistic about China",353,"And on China, just a couple of comments that China -- we did see a slowdown in China, primarily in the Consumer business because the -- both Medical Device and Pharma businesses still had high single digit growth in China, and we're optimistic about China going into 2016. Our plans are for improved growth in China in 2016. But I just want to put China in perspective. It's less than 5% of our sales. It's an important market for us longer term with 1.3 billion people and lots of health care needs, et cetera. But any short-term changes in their economy is unlikely to have any significant impact on our results. And then on the 200 basis point improvement, Bob, it's actually across all 3 lines of the P&L, COGS, selling, marketing as well as R&D. So in the case of COGS where we have a long-term program that we've been executing on to reduce footprint, we're accelerating some of those programs that will benefit us in the COGS line, on the selling, marketing and administrative line. I talked earlier about the fact that we had a program in place for a couple of years, shooting for $1 billion of cost savings by 2018, we're well on our way. We'll see cost reductions in that line. In R&D, that depends on the individual licensing deals that we have and the timing of when we would spend those milestone payments or enter into new licensing agreements. But as it looks today, the advancement in the portfolio in 2015 from the milestone payments, et cetera, are not expected to be at the same level in '16 that they were in '15. So it's across all 3 lines in the P&L. And I can't give you an exact number on the amount of investment we made in '15, extra investment made in '15. But just to say that we had $2.8 billion of other income in 2015, well above the year that's passed, and we still improved overall income before tax by not quite that amount, right? So most of it was reinvested in the business."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Josh Jennings of Cowen and Company.",11,"The next question is from Josh Jennings of Cowen and Company."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Just -- we just have one for Alex. And you have a formal plan in place to accelerate growth in the Medical Device unit that's reasonable. And I believe that your target of returning it to 45% or 46% growth -- I just want to ask how patient you'll be befor",76,"Just -- we just have one for Alex. And you have a formal plan in place to accelerate growth in the Medical Device unit that's reasonable. And I believe that your target of returning it to 45% or 46% growth -- I just want to ask how patient you'll be before you look externally in the transformational way. And is this a 12- to 24-month initiative or a longer time period that you'll put in place?"
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes, Josh. Thanks a lot for the question. The way I would say it, this is something that has been underway for the last several months. But clearly, we're accelerating it. And whenever you make this kind of a decision, you're certain -- we certainly think",211,"Yes, Josh. Thanks a lot for the question. The way I would say it, this is something that has been underway for the last several months. But clearly, we're accelerating it. And whenever you make this kind of a decision, you're certain -- we certainly think about the impact that it has on employees. But we also see it as our responsibility to make sure that this business is positioned for the next 5, the next 10 years. And with that note, we have a high sense of urgency about increasing our rate of innovation, about making the business model changes and ultimately, about making sure that we're more competitive in delivering in the markets. We try to be very clear where -- our goal is to grow faster than the markets, even given our size and given our scale. We think we've got over 10 platforms that are $1 billion. Majority of those are #1 or #2. But we realize there's still a lot of opportunity, So while we're pleased with what we've seen, we're far from satisfied. And I know Gary and the rest of his team as well as all of us are completely committed to accelerating the performance of this group to be, frankly, benchmarking the industry."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","We'll take the last question, and Alex will provide some brief closing remarks.",14,"We'll take the last question, and Alex will provide some brief closing remarks."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","Our final question comes from David Lewis of Morgan Stanley.",10,"Our final question comes from David Lewis of Morgan Stanley."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Just 2 quick ones. I'll start with a strategic one for Alex and then a quick follow-up question for Dominic or others. Alex, just thinking about M&A for a second. I know it's been a theme for this call, but how does segment performance influence your will",107,"Just 2 quick ones. I'll start with a strategic one for Alex and then a quick follow-up question for Dominic or others. Alex, just thinking about M&A for a second. I know it's been a theme for this call, but how does segment performance influence your willingness to deploy capital in those segments? So are you more inclined to deploy capital in the outperforming segments or not? And I guess related, does it make sense to deploy material capital in devices through M&A and told our restructuring has been digested and growth is back to market rates in those franchises? And then a quick question for Dominic."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes, David. Thanks for the question. Look, it depends on a number of different factors. And obviously, as we think about it, for example, in our Pharmaceutical group, we think that the model that we pull together, while we try to find the next INVOKANA, t",303,"Yes, David. Thanks for the question. Look, it depends on a number of different factors. And obviously, as we think about it, for example, in our Pharmaceutical group, we think that the model that we pull together, while we try to find the next INVOKANA, the next DARZALEX, very early compounds, where frankly we've got solid scientific insights, we bring it inside. And because of our clinical development, our regulatory capabilities, we can launch, and then very strong sales marketing and reimbursement practices around that. Frankly, that's what helped us create the number of billion-dollar blockbusters that we've been able to launch since 2009, I think 16 new products and 7 of which are like right at $1 billion or shortly will be. And so we think that's a good model. In Medical Devices, we've done tuck-ins as well as large. And look, I think in both cases, whether it's Pharma or Medical Devices, the smaller tuck-ins are frankly more straightforward to get done. We haven't shied -- we won't shy away from large where we think it makes for a significant opportunity, and it's something that we'll continue to look at in Consumer. As far as the question that it's underperforming, now I think it depends on why it's underperforming. If it's a market -- if it's an in exogenous market shift or something else, then obviously, that would not necessarily have a shy away from that particular area. On the other hand, if it's an internal, more executional issue, absolutely, we'd want to make sure that we've got the knitting where we need it before we add on to that particular opportunity. So that's the way we tend to look at it. But again, it's part of a broader strategic question really on how we're managing the portfolio across the enterprise."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Okay, very helpful. And then to Dominic, just a quick one for you or the team. Just on -- INVOKANA hasn't come up yet on the call. I wonder if you can just give us a sense of what's happening in the market post EMPA-REG as it relates to class expansion or",74,"Okay, very helpful. And then to Dominic, just a quick one for you or the team. Just on -- INVOKANA hasn't come up yet on the call. I wonder if you can just give us a sense of what's happening in the market post EMPA-REG as it relates to class expansion or your market share. And can you give us an update on the CANVAS trial and when can you get data in '17?"
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Okay. So what -- I'll give you the market share third quarter versus fourth quarter, which will give you some nice trend information. So -- and this is U.S. For the total, we went from 6.3% in the third quarter to 6.5% in the fourth quarter. Now at primar",64,"Okay. So what -- I'll give you the market share third quarter versus fourth quarter, which will give you some nice trend information. So -- and this is U.S. For the total, we went from 6.3% in the third quarter to 6.5% in the fourth quarter. Now at primary care, we went from 5.6% to 5.8% and endo, it's flat at about 13% quarter-to-quarter."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","And what -- the reading that we're getting from the field is that most physicians -- and in fact, some guidelines were recently published that the cardiovascular benefit that we saw with the other SGLT2 is most likely a class effect as absolutely [ph] phy",70,"And what -- the reading that we're getting from the field is that most physicians -- and in fact, some guidelines were recently published that the cardiovascular benefit that we saw with the other SGLT2 is most likely a class effect as absolutely [ph] physicians treated. And in fact, the guidelines were just recently issued that called it a class effect. Our data won't be until sometime mid-2017, I believe."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","2017.",1,"2017."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","On those results where we'll actually then be able to put those results in our label. But until then, I think the market recognizes it as a beneficial effect on cardiovascular.",32,"On those results where we'll actually then be able to put those results in our label. But until then, I think the market recognizes it as a beneficial effect on cardiovascular."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Thank you. And for final remarks?",6,"Thank you. And for final remarks?"
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","So thank you very much, everybody. Look, and in closing, I'd like to thank you again for joining today's call. We're pleased with the results we delivered in 2015. And we think our strong underlying operational growth across the enterprise, combined with",91,"So thank you very much, everybody. Look, and in closing, I'd like to thank you again for joining today's call. We're pleased with the results we delivered in 2015. And we think our strong underlying operational growth across the enterprise, combined with a very high sense of urgency, gives us a lot of confidence as we head into 2016. And we're optimistic about the opportunities in health care and frankly about the underlying strength of our core business. So thank you very much, and I hope everyone has a great day."
139677,320178319,920995,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","Thank you. This concludes today's Johnson & Johnson's Fourth Quarter 2015 Earnings Conference Call. You may now disconnect, and have a wonderful day.",23,"Thank you. This concludes today's Johnson & Johnson's Fourth Quarter 2015 Earnings Conference Call. You may now disconnect, and have a wonderful day."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","Good morning, and welcome to Johnson & Johnson's Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] I would now like to",51,"Good morning, and welcome to Johnson & Johnson's Fourth Quarter 2015 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] I would now like to turn the conference call over to Johnson & Johnson. You may begin."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Good morning, and welcome. I'm Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure this morning to review our business results for the fourth quarter of 2015. Joining me on the call today are Alex Gorsky, Cha",1988,"Good morning, and welcome. I'm Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure this morning to review our business results for the fourth quarter of 2015. Joining me on the call today are Alex Gorsky, Chairman of the Board of Directors and Chief Executive Officer; and Dominic Caruso, Vice President, Finance, and Chief Financial Officer.
A few logistics before we get into the details. This review is being made available via webcast accessible through the Investor Relations section of the Johnson & Johnson website at investor.jnj.com.
I'll begin by briefly reviewing results for the corporation and for our 3 business segments. Following my remarks, Alex will comment on 2015 results and provide a strategic outlook for the company. Then Dominic will provide some additional commentary on the business, review the income statement and provide guidance for 2016. We will then open the call to your questions. We expect the call to last approximately 90 minutes.
Included with the press release that was issued earlier this morning is the schedule of sales for key products and/or businesses to facilitate updating your models. These schedules are available on the Johnson & Johnson website as is the press release. Please note, we will be using a presentation to complement today's commentary. The presentation is also available on our website.
Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements. The 10-K for the fiscal year 2014 and the company's subsequent filings identify certain factors that could cause the company's actual results to differ materially from those projected in any forward-looking statements made today. The company does not undertake to update any forward-looking statements as a result of new information or future events or developments. Our SEC filings, including the 10-K, are available through the company and on our website.
During the review, non-GAAP financial measures are used to provide information pertinent to ongoing business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with GAAP results. Tables reconciling these measures to the most comparable GAAP measures are available in the schedules accompanying the press release and on the Investor Relations section of the Johnson & Johnson website. A number of the products and compounds discussed today are being developed in collaboration with strategic partners or license from other companies. This slide lists acknowledgment of those relationships not otherwise referenced in today's presentations.
Now I would like to review our results for the fourth quarter of 2015. Worldwide sales to customers were $17.8 billion for the fourth quarter of 2015, down 2.4% versus fourth quarter of 2014. On an operational basis, sales were up 4.4% and currency had a negative impact of 6.8%. In the U.S., sales were up 8%. In regions outside the U.S., our operational growth was 1.2%, while the effect of currency exchange rates negatively impacted our reported results by 12.9%.
On an operational basis, the Western Hemisphere, excluding the U.S., grew 2.8%, while the Asia-Pacific, Africa region grew 0.9% and Europe grew 0.8%. Growth in all regions was negatively impacted by the divestiture of the Cordis business with Europe, Latin America and Canada also negatively impacted by hepatitis C competition. Excluding the net impact of acquisitions and divestitures and hepatitis C sales, underlying operational growth was 7.8% worldwide, 13.4% in the U.S. and 2.9% outside the U.S.
I'd like to point out that our 2015 fiscal year included an additional week. Since this week occurred during a holiday period, we did not achieve a full week of sales. However, we did have a few more shipping days. These additional shipment days added approximately 4 points to the quarterly sales growth rate and 1 point to the annual growth rate. The additional sales are more heavily skewed to the U.S. While these few shipping days added to sales, we also had a full week's worth of operating costs, therefore, the bottom line impact was negligible.
Turning now to earnings. Net earnings were $3.2 billion and diluted earnings per share were $1.15 versus $0.89 a year ago. As referenced in the tables reconciling non-GAAP measures, 2015 fourth quarter net earnings were adjusted to exclude after-tax amortization expense of $220 million and a net charge of $608 million for after-tax special items. 2014 fourth quarter net earnings were adjusted to exclude after-tax amortization expense of $275 million and a charge of approximately $1.1 billion for after-tax special items. Dominic will discuss special items in his remarks.
Excluding amortization expense and special items for both periods, adjusted net earnings for the current quarter were $4 billion and adjusted earnings per share were $1.44, representing increases of 4% and 5.1%, respectively, as compared to the same period in 2014. Currency translation significantly impacted net earnings. On an operational basis, adjusted diluted earnings per share grew 12.4%.
Now turning to the financial highlights for the full year of 2015. Consolidated sales to customers for the year of 2015 were $70.1 billion, a decrease of 5.7% as compared to the same period a year ago. On an annual basis, sales grew 1.8% operationally and currency had a negative impact of 7.5%. Excluding the net impact of acquisitions and divestitures and hepatitis C sales, underlying operational growth was approximately 6.5% worldwide, 10.6% in the U.S. and 3% outside the U.S.
Turning now to earnings. 2015 annual net earnings were $15.4 billion and diluted earnings per share were $5.48. For the year, 2015 adjusted net earnings were $17.4 billion and adjusted earnings per share were $6.20, down 4.8% and 3%, respectively, versus the 2014 results. On an operational basis, adjusted diluted earnings per share grew 5.8%. Estimated free cash flow for the year was strong at $15.9 billion, up $1.1 billion versus 2014.
Turning now to quarterly business segment highlights. Please note, percentage of quota  represent operational sales changes in comparison to the fourth quarter of 2014 unless otherwise stated and therefore, exclude the impact of currency translation.
I'll begin with the consumer segment. Worldwide Consumer segment sales of $3.3 billion increased 1.8%, with U.S. sales down 4.9%, while outside the U.S., sales grew 5.5%. Excluding the net impact of acquisitions and divestitures, underlying growth was approximately 4.7% worldwide, 1.7% in the U.S. and 6.3% outside the U.S. Growth was driven by worldwide OTC and Oral Care as well as Women's Health outside the U.S. OTC sales results in the U.S. were driven by ZYRTEC and product relaunches for digestive health products.
Strong growth for analgesics was partially offset by timing of inventory builds as noted in the third quarter and a slower start to the flu season. In the U.S., adult analgesic market share was approximately 13.5%, up from approximately 11.5% a year ago, while U.S. pediatric share was approximately 45.5%, up from approximately 42% a year ago.
Results outside the U.S. were driven by strong sales of upper respiratory products and the relaunch of anti-smoking products. Strong sales momentum, driven by successful marketing campaigns and geographic expansion for new products, drove results for LISTERINE and Oral Care and in Women's Health products outside the U.S.
Moving now to our pharmaceutical segment. Worldwide sales of $8.1 billion increased 6.5%, with U.S. sales up 12.7% and sales outside the U.S. down 0.9%. Competitors in hepatitis C significantly impacted sales results. Excluding sales of our hepatitis C products, OLYSIO and INCIVO, as well as the impact of acquisitions and divestitures, underlying growth was approximately 11.1% worldwide and 21% in the U.S. Sales outside the U.S. declined approximately 0.2%, with strong growth of new and core products, offset primarily by lower sales of REMICADE and SIMPONI to our distribution partner.
Important contributors to growth were STELARA, INVOKANA/INVOKAMET, IMBRUVICA, INVEGA SUSTENNA and XEPLION, XARELTO and U.S. sales of REMICADE. STELARA achieved strong growth across all the major regions, driven by robust market growth and increased penetration with the psoriatic arthritis indication. Strong momentum in market share drove results for INVOKANA/INVOKAMET. In the U.S., INVOKANA/INVOKAMET achieved 6.5% total prescriptions share or TRx within the defined market of type 2 diabetes, excluding insulin and metformin, up from 4.2% last year. TRx with endocrinologists was 12.8% for the quarter and 5.8% in primary care. Strong patient uptake with demonstrated efficacy drove results for IMBRUVICA in the U.S. IMBRUVICA is the leader in both new and total patient regimen share in second-line CLL and MCL.
Outside the U.S., results were driven primarily by Europe with strong patient uptake and shared momentum. IMBRUVICA is now approved in over 60 countries. As an update on our oncology pipeline, we received FDA approval for DARZALEX in November. DARZALEX is off to a robust start with strong underlying market demand. INVEGA SUSTENNA or XEPLION achieved strong results in all major regions primarily due to increased market share and the launch earlier this year of INVEGA TRINZA.
Continued share growth drove XARELTO sales results with TRx for the quarter in the U.S. anticoagulant market of 16.1%, up nearly 1.5 points from a year ago. XARELTO is broadly reimbursed with approximately 95% of commercial and Medicare Part D patients covered at the lowest branded product copay.
REMICADE in the U.S. benefited from strong market growth, partially offset by lower market share. REMICADE U.S. export sales and international sales were negatively impacted by lower distribution partner sales due to the weakening of the euro and the loss of exclusivity in Europe, partially offset by a higher inventory reduction last year. Strong results were achieved in the Western Hemisphere, excluding the U.S.
I'll now review the Medical Devices segment results. As a reminder, we announced last week that we will use a new format for the reporting of sales in the Medical Devices segment, and we provided historical sales results in the new format at that time. The historical sales are available on our website.
Worldwide Medical Devices segment sales of $6.4 billion increased 3.4%. U.S. sales increased 6.7%, while sales outside the U.S. increased 0.6%. Excluding the net impact of acquisitions and divestitures, underlying growth was approximately 5.8% worldwide, with the U.S. up 8% and growth of 3.9% outside the U.S. Growth was driven by surgery, orthopedics, electrophysiology and Vision Care, partially offset by the divestiture of the Cordis business.
Growth in our surgery business was driven by strong results for the advanced products with endocutters growth of 15%, biosurgical's growth of 9% and energy growth of 5%. In addition, ASP and Mentor products and our specialty products made significant contributions to sales in the quarter.
Market growth, additional selling days and new products drove strong results for the U.S. Orthopaedics business. Pricing pressure continued across the major categories, partially offset by positive mix for trauma and spine products. The successful introduction in early 2015 of the TFNA nailing system in trauma, the success of the ATTUNE platform in knees, our primary stent platform in hips and ORTHOVISC, MONOVISC in spine or other made important information contributions to the results.
Orthopaedics sales outside the U.S. were negatively impacted by result in China due to softer demand and a reduction in inventory. Spine, other and trauma were the categories most impacted. Our electrophysiology business grew 19% worldwide due to strong market growth, complemented by the success of the THERMOCOOL SMARTTOUCH Catheter. Vision Care results were driven by very strong growth in the U.S. due to the introduction of new products as well as the trade inventory build.
That concludes the segment highlights for Johnson & Johnson's fourth quarter of 2015. For your reference, there were some notable developments in the fourth quarter, which we have summarized on this slide to assist as you develop your models. Lastly, to assist you in updating your models for the full year 2015, on our website, you will find annual sales highlights by segment.
It is now my pleasure to turn the call over to Alex Gorsky. Alex?"
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Louise. Let me start by saying how optimistic and confident I am as we enter 2016. We had a strong finish to 2015. With our healthy balance sheet, we are well positioned to continue to invest for future growth. Our core business is very strong,",2882,"Thank you, Louise. Let me start by saying how optimistic and confident I am as we enter 2016. We had a strong finish to 2015. With our healthy balance sheet, we are well positioned to continue to invest for future growth. Our core business is very strong, and we expect a number of additional new products and line extensions in the coming year.
Now as we enter 2016, we look forward to: First, continued growth of core products across our segments; next, a rich near-term pipeline in our Pharmaceutical segment; positive momentum in our Consumer segment with a full portfolio of OTCs back on the market; setting a strong foundation for sustainable growth with the bold actions we are taking in our Medical Devices segment; and continued financial strength and strong free cash flows to return capital to shareholders and take disciplined and decisive actions regarding M&A that contribute to sustainable growth and long-term value creation.
Now I'll share more specifics in my discussion with you today about the health care environment, our 2015 results and why we're so optimistic and confident about the future for the enterprise in each of our business segments. But with that as a backdrop, I'd like to begin where I always do by talking about our credo.
Our credo is the beginning of everything at Johnson & Johnson. It guides all of our decisions, and I believe it sets us apart. This year's Johnson & Johnson's 130th year, think of that for a moment. 130 years of working to balance our mission of helping people everywhere live longer, healthier and happier lives. And I'm proud to see the employees of Johnson & Johnson around the world continuing to uphold the imperatives of our credo every day, through both our philanthropy initiatives and recent commitment to supporting the immediate and ongoing needs of Syrian refugees in partnership with Save the Children as well as to our commitments of the health care community with investments that will accelerate how we address global health crises like Ebola, AIDS and mental health.
You undoubtedly heard me say that I believe health care is one of society's greatest challenges. And this global challenge grows with aging populations, rising cost in developed world and growing middle classes in emerging economies. We have increasing expectations for access to quality care. Now as the world's largest and most broadly based health care company, it's not just an opportunity for us to help manage this transformation. It is our responsibility to help lead the way to a better future.
Now in this environment, ensuring access to important medicines and medical procedures remains a key objective for us. As government officials, politicians and other stakeholders debate significant issues around the world, we're pleased to see that health care is such a focus in the dialogue. And we believe that our goals and those of public policymakers are aligned to find the best ways to ensure the delivery of quality health care and the best patient outcomes in a high quality and sustainable manner. Now in this discussion, it's a responsibility of all stakeholders to consider the economic and financial implications of health care. We got to look at the whole picture, drugs, devices, insurers, hospitals and governments put the patient in the center and reward innovations that drive better outcomes.
Here in the United States, prescription drugs represent approximately 12% of total health care costs and medical devices represent around 6%. These cures and treatments not only improve quality of life for many patients, extend life for others and contribute to the productivity of our society, but they can also help to reduce caregiver burden, disability and health care spending overall. The promise of innovation and health care is great. It will remain great if we can take a holistic approach to reforming the health care system.
At Johnson & Johnson, we believe in this holistic approach to health care solutions. It's vital to developing the best innovations, to meeting the needs of our stakeholders and to sustaining our legacy of strong and consistent business performance. Our consumer Medical Devices and Pharmaceuticals segments are increasingly interconnected businesses. And we believe that being broadly based in health care has been and will continue to be a significant factor in Johnson & Johnson's success as it positions us well to lead and grow our business with the evolving health care landscape.
Our broad global footprint enables us to reach more patients and consumers in fast-developing and changing markets. In fact, Johnson & Johnson is operating in 60 countries today, and we are continuing to invest in implementing new operating models, forging strong relationships with local governments and health systems and further accelerating growth through strategic acquisitions and partnerships with local companies.
Because of our broad base across health care, we are uniquely positioned to be a partner of choice. Now let me just go over a few examples. With large health systems, we are taking more of a business-to-business model to help them with innovative contracting strategies, integrated services and solutions and with dedicated customer-focused teams. We're working with technology companies like Google, IBM and Apple. We're advancing medical innovation through an infusion of technology that can benefit from the deep health care expertise Johnson & Johnson can uniquely provide.
We're continuing to support biotech and med tech start-ups who appreciate the value we place on innovation and the reach and breadth of our footprint in the health care market. And with public health organizations, we have a tremendous opportunity to address the gaps that remain in innovation, access and delivery of effective prevention and treatment. We're collaborating more than ever before to meet the world's most pressing public health challenges.
Our scale, financial flexibility and business and health care expertise make Johnson & Johnson a key partner for a number of our stakeholders, and our relationships with these partners will help Johnson & Johnson continue to be a leader in the future. Applying our expertise in design thinking, strategic innovation models and a commitment to collaborating with all stakeholders, we've developed a number of cross-segment innovations.
For example, we've created the China Lung Cancer Center, which is developing a holistic approach to treat lung cancer in China where the disease is particularly prevalent. We're pioneering cell therapy for age-related macular degeneration, combining technologies from Pharma and from our Vision business to find a way to address this condition. And we're leveraging capabilities from our Medical Devices, Pharma and Consumer businesses to treat obesity and diabetes in new ways. In fact, almost every one of our programs can benefit from the advantages of our broad base.
Over the past several years, we've also been leveraging our scale by developing enterprise efficiencies and capabilities across all of our sectors, targeting as much as $1 billion in operational savings by 2018 to support our growth. And we believe the innovation that is taking place within our supply chain and quality systems is actually creating a competitive advantage for Johnson & Johnson.
But the bottom line, well, it's the bottom line. And this broad-based structure has helped us deliver strong, consistent and sustainable financial performance. Let's consider some of the numbers.
First, 53 consecutive years of dividend increases at Johnson & Johnson. That means we have provided steady dividend increases since we first put a man in space. And 32 years of consecutive adjusted operational earnings growth, more than 3 decades.
Over the past 10 years, we have returned approximately 70% of our free cash flow to our shareholders. And today, 70% of our revenues come from brands that are #1 or #2 in their markets. We have 24 brands that represent billion-dollar platforms. If you think about that, in 1999, the entire corporation had revenues of $24 billion, and about 25% of our sales come from brands launched in the last 5 years. That's a result of constant learning, collaboration and innovation.
Our corporate structure, our broad base is a strategic choice and one that is grounded our performance, not just our heritage. We know it has been a significant driver in the past and expect it will be more important in the future.
As we've said, we see global health care growing at 3% to 5% over the next 5 years, and we have a clear objective that Johnson & Johnson should grow sales organically at a faster rate than the market. We also intend to grow our earnings faster than sales. In addition, we will continue to create value through strategic acquisitions and partnerships that generate additional growth. All of this, coupled with our strong dividend yield, and you are a looking at a very compelling long-term total shareholder return.
As part of our performance-driven strategy, we regularly review the structure and portfolio of our businesses to evaluate how they're delivering on our responsibilities to the stakeholders outlined in our credo, meeting evolving health care needs and achieving performance expectations. Johnson & Johnson has a rigorous and disciplined portfolio review program focused on creating long-term shareholder value, and this applies to all our businesses.
We have a track record of evolving our business and taking decisive actions when necessary to meet changing industry and consumer dynamics, and we'll continue to do so in the future. We're actively looking for the right opportunities to create greater value for our shareholders. We are seeking companies with the mutual desire to partner, but we're also patient. We will only act when we see the right value-creating deal at the right price and with the right partners.
Now historically, about half of our growth has come from M&A and half from internal development, which we fully expect to continue, and with our strong balance sheet, we've got the resources to do just that.
Now let me take a few minutes to review the priorities we laid out for you last year. One, we will continue to be focused on delivering on our financial and quality commitments. Two, in Pharmaceuticals, our objective, as always, is constant innovation. We're building on our launch excellence and continuing to develop a robust pipeline of transformational medicines.
In our Consumer business, we positioned our entire portfolio to focus on key geographies, need states and mega-brands. We are prioritizing and investing to expand our market leadership in key consumer segments in OTC, Oral Care, Baby and Beauty. And as you heard through our announcement last week, our priority in Medical Devices is accelerating growth through the strategic investments in innovation and by transforming our go-to-market models. We're confident that these priorities will deliver the results that you expect from us and just as importantly, the results that we expect from ourselves.
As we've said, we are pleased with our 2015 performance. In 2015, we generated sales of $70.1 billion, reflecting strong underlying operational growth across our enterprise. Our end market portfolio and Pharmaceuticals delivered strong growth. We built positive momentum in our Consumer segment, and we've just announced bold actions to accelerate growth in our Medical Device segment.
Throughout the year, you've heard from each of our business segment leaders about the strategies we put in place to meet our commitments, so I'll touch on just a few of the recent actions we've taken to advance those strategies.
As Joaquin Duato laid out for you at our pharmaceuticals business review in May, our Pharmaceuticals business has a clear strategy focused on 5 therapeutic areas of high unmet medical need, a robust innovation engine, and proven commercial capabilities. Joaquin talked to you about how we're investing in our future with 10 new products we plan to file by 2019, each with a potential to exceed $1 billion in annual sales. And in fact, we are already delivering one of those promising medicines to the market, 4 months ahead of schedule with the U.S. approval for DARZALEX, the first human monoclonal antibody to be approved anywhere in the world for patients with multiple myeloma, which is off to a very good start.
In the near term, I know many of you are keeping an eye on potential biosimilar completion in the United States. As you've heard us say, biosimilars are not generics. With more than 2.4 million people having been treated with REMICADE and about 70% of the current patients receiving sustained and effective treatment, we believe doctors will be reluctant to switch them off with that level of success. And we've seen this play out in many markets where biosimilars have already been introduced. And we also have a patent for REMICADE that expires in September 2018 that we'll obviously continue to vigorously defend.
We consider our Immunology products part of an important and robust portfolio for patients, physicians and payers. So when you consider our continued expectations for REMICADE as well as the future potential of products like STELARA and SIMPONI and the pending submissions of guselkumab and sirukumab, we are confident in our ability to continue driving strong growth from our Immunology portfolio.
When you combine these advances with additional line extension approvals expected in 2016 like those for IMBRUVICA, STELARA and INVOKANA and DARZALEX approval in the EU, our near-term pipeline is incredibly robust and may not be fully appreciated in the market. With the combined strength of our end market portfolio and deep late-stage pipeline, we expect to deliver above-industry compound average growth through 2019.
Our consumer expertise, insight and access are becoming increasingly valuable to payers and providers as demographic and technology trends in health care are moving the system toward more consumer-driven decision-making and in some cases, self-care alternatives. We see this as a key differentiator for our company, and we're investing in technologies that help us exploit this expertise across our broad base. Jorge Mesquita and our other consumer business leaders will share more details at our consumer business review this May.
For 2015, our U.S. OTC business continue to grow faster than the market, and we're happy to report that nearly all of our OTC products have returned to shelves, and we are proud of the quality system improvements we have put into place.
Our consumer Medical Device businesses, the Johnson & Johnson Diabetes Solution companies and Johnson & Johnson Vision Care made progress in 2015 to improve our competitiveness. Both businesses, which command global leadership positions in their respective categories, focused their 2015 turnarounds on launching new products, solidifying their base businesses and accelerating growth.  And both businesses have regained or stabilized market share and market leadership and introduced important new product such as Animas Vibe and ACUVUE OASYS 1-Day with HydraLuxe in the U.S.
In our broader Medical Device businesses, last week, we announced a strategic restructuring initiative designed to directly support and accelerate the strategy Gary Pruden laid out for you on our third quarter earnings call. We are reallocating resources to priority platforms like endocutters, knees, trauma and EP. And recent history showed that when we doubled down in an area, we are able to accelerate meaningful innovation and outcomes as we saw with our endocutters portfolio, which is now the fastest-growing platform in our Medical Devices segment.
Additionally, we're making progress on transforming our go-to-market models like our cross-selling efforts between Ethicon and DePuy Synthes' joint reconstruction and spine, which resulted in over 600 leads through 2015. We are now co-selling in over 1,200 accounts, and all sales teams will be trained, covering all markets by the end of the first quarter.
And finally, our recent acquisition of Coherex Medical in the area of atrial fibrillation and the surgical robotics collaboration with Verily, formerly Google Life Sciences, are examples of the type of focus and strategic investments that you will see us make more of in the future.
Our goal is to reach more patients, outperform the markets in which we compete and consistently identify, build and acquire new platforms for growth. Moving forward into 2016, we will continue to take bold but appropriate steps to put our Medical Device business in the best position to deliver more value for customers and for our company and for our shareholders.
In summary, we believe that improved universal access to quality health care, rewarding innovation and a more vital culture of health, wellness and prevention are the keys to a future where people are healthier and businesses and economies are stronger. Our broad-based experience and scale uniquely positions Johnson & Johnson as a leader and partner of choice in the movement towards outcomes and episodes of care based approaches and ultimately, a healthier society. We are optimistic about the future opportunities in health care and confident in the strength of our business.
In 2016, we will remain focused on our near-term priorities and continue to advance our longer-term growth drivers, enabling us to continue delivering shareholder value year after year. With the guidance of our credo, we'll continue to meet our responsibilities to all stakeholders. That's been true for 129 years of breakthrough, life-saving innovation, and we are confident Johnson & Johnson is well positioned to continue meeting those responsibilities for the next 130 years.
Thank you. I look forward to further dialogue during the Q&A session. But first, I'll turn it over to Dominic Caruso, who will talk more about our results and expectations for 2016. Dominic?"
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Thanks, Alex, and good morning, everyone. As you've heard from Alex, we're very pleased with our 2015 performance. We believe we managed our business well, and have provided you insights during the year in a transparent manner that allowed all of you to u",2452,"Thanks, Alex, and good morning, everyone. As you've heard from Alex, we're very pleased with our 2015 performance. We believe we managed our business well, and have provided you insights during the year in a transparent manner that allowed all of you to understand our plans and expectations. We finished the year strong and we're carrying that momentum into 2016. We ended the year at the top end of our operational guidance range for both sales and earnings and exceeded estimates for earnings as published by our first call.
Turning to the next slide. You can see our condensed consolidated statement of earnings for the full year 2015. I'd first like to remind you about some of the key assumptions in our guidance for 2015. At the beginning of the year, we discussed that, while we reinvested some of the profitability from OLYSIO sales, our earnings in 2014 did benefit by approximately $0.20 per share even after those investments, making 2015 comparisons to 2014 results more challenging.
Additionally, currency headwinds increased quite substantially in 2015, negatively impacting both sales and earnings for 2015 by approximately 8%. Given those expected headwinds, last January, we guided that we would deliver operational sales growth in the range of 1% to 2%. As you can see, while reported sales results show a decrease of 5.7%, on an operational basis  we ended up at the high end of our guidance with operational sales growth at 1.8%.
We also provided you with an estimate of our underlying operational sales growth for 2015, which excluded the impact of all acquisitions and divestitures as well as the impact of hepatitis C sales. We expected that underlying operational growth would be approximately 6%, and we exceeded that estimate, delivering 6.5%.
On earnings, our adjusted operational EPS growth in our original 2015 guidance was expected to range between 2.3% and 4.7%. As reported this morning, our EPS of $6.20 reflects operational growth of 5.8% and is at the top of the updated EPS guidance range we gave in October. And finally, our adjusted net income margin improved to 24.9%.
Now let's take a few moments to talk about certain items on the statement of earnings for the quarter. Turning to the next slide. You can see our condensed consolidated statement of earnings for the fourth quarter of 2015.
As we expected, direct comparisons to our fourth quarter of 2014 will be challenging to the stronger OLYSIO sales that we benefited from last year as well as divestitures and currency headwinds in 2015. Our results on an operational basis, excluding the impact of acquisitions and divestitures and excluding the impact of hep C sales, were up 7.8% for the quarter. As Louise noted, sales did benefit from additional shipping days in the fourth quarter of 2015.
Please now direct your attention to the boxed section of the schedule where we have provided earnings adjusted to exclude special items and intangible asset amortization expense. Adjusted net earnings were $4 billion in the quarter, up 4% compared to the fourth quarter of 2014, and adjusted earnings per share of $1.44 versus $1.37 a year ago are up 5.1%. And the adjusted EPS results exceeded the mean of the analyst estimates as published by first call. Excluding the impact of translational currency, our operational adjusted EPS was $1.54 or up 12.4% for the fourth quarter.
In the quarter, we incurred intangible amortization expense of $200 million on an after-tax basis as well as after-tax special charges of $600 million, which included an expense of $400 million related to the restructuring of our Medical Device business, which we announced last week and in-process research and development charge of $200 million.
Now let's take a few moments to talk about the other items on the statement of earnings. Cost of goods sold was 30 basis points lower than the same period last year, impacted by changes in our business and product mix. Selling, marketing and administrative expenses were 33.1% of sales. This is 120 basis points higher than last year as we continued to invest to drive growth in our key brands.
Our investment in research and development as a percent of sales were 16.1% in the quarter and 170 basis points higher than the prior year as we continue to make important investments in our pipeline for future growth. In fact, in the fourth quarter, we entered into important new licensing agreements, made milestone payments and increased spending to advance our R&D portfolio, which are all positive developments as we continue to strengthen our pipeline.
Interest expense net of interest income was slightly lower, reflecting higher earnings on our investments. Other income and expense was a net gain of $1.2 billion in the quarter compared to a net charge of approximately $1 billion in the same period last year. Of course, this line item includes several special items of both years. Excluding those special items, other income and expense was a net gain of approximately $1.3 billion compared to a net gain of approximately $130 million in the prior year period. This year's fourth quarter reflects the gain on the previously announced divestiture of Cordis.
As a reminder, we indicated that any gains from divestitures, which are reflected in the other income and expense line, would largely be reinvested in the business as well as used to mitigate the negative impact of currency and the lower level of income in 2015 from reduced OLYSIO sales. And therefore, our pretax operating margin would be expected to be lower in 2015 versus 2014. And our 2015 results reflect just that. We funded important investments with the higher level of other income that will benefit us going forward.
The adjusted fourth quarter effective tax rate for 2015 was 17.7%. This was lower than the rate in the previous 9 months due to the passing of legislation which renewed the R&D tax credit and look-through provisions. The R&D tax credit and look-through provisions were always included in our annual guidance. The adjusted full year effective tax rate for 2015 was 20.7%, slightly below guidance due to the mix of income from higher to lower tax jurisdictions.
Turning to the next slide, I will now review adjusted income before tax by segment. Adjusted income before tax for the entire enterprise improved from 30.7% of sales in '14 to 31.4% of sales in 2015.
Looking at the adjusted pretax income by segment. Medical Devices expanded 360 basis points, due primarily to the gain associated with the Cordis divestiture, while Pharmaceutical margins contracted 50 basis points due to the lower OLYSIO sales and increased investments in research and development, partially offset by the gain earlier in the year of divestiture of NUCYNTA.
Consumer margins contracted 110 basis points due to lower divestitures gains in 2015 versus 2014 as well as important investments for future growth as we returned our iconic consumer brands to the market.
Now I will provide some guidance for you to consider as you refine your models for 2016. Before I discuss sales and earnings, I'll first give you some guidance on items we know may be difficult to forecast.
I would first like to address our cash position and remind you about our capital allocation approach. At the end of the quarter, we had approximately $18.5 billion of net cash, which consists of approximately $38.5 billion of cash and marketable securities and approximately $20 billion of debt. This is a higher level of cash than we typically hold. And as Alex said earlier, we are actively looking for the right opportunities to deploy that capital to create greater value for our shareholders. But we are patient. We are seeking companies with a mutual desire to partner and will only act when we see the right value-creating deal at the right price with the right partners.
We have a transparent and disciplined capital allocation strategy that starts with dividends to our shareholders, followed by value-creating M&A and then we consider other prudent ways to return value to shareholders such as share repurchase programs. And due to our strong balance sheet, we have the financial strength and flexibility to execute on all 3 of these capital allocation priorities simultaneously.
During Q4 2015, we used approximately $1 billion to repurchase shares of our stock in connection with our $10 billion share repurchase program that we announced in October. Although we are continuing to evaluate external value-creating opportunities in line with this strategy, for purposes of your models, assuming no major acquisitions or other major uses of cash, we suggest you consider modeling 2016 net interest expense of between $450 million and $550 million.
Regarding other income and expense, as a reminder, this is the account where we record royalty income as well as gains and losses, providing from such items as litigation, investments by our development corporation as well as divestitures, asset sales and write-offs.
We would be comfortable with your models for 2016 reflecting other income and expense, excluding special items as a net gain, ranging from approximately $1.1 billion to $1.2 billion. Although we expect to have a significantly lower level of other income in 2016 versus 2015, our pretax operating margin in 2016 is expected to expand by more than 200 basis points.
As we've discussed several times during the year, we continue to evaluate our portfolio, and we expected that any gains from divestitures would be lower than the level we saw in 2015. However, we also discussed that we would nonetheless improve on earnings as we see the benefits of good expense management and meaningful investments we made in 2015.
And now a word on taxes. We're very pleased that the R&D tax credit was made permanent and approved by Congress this last year. We would be comfortable with your models reflecting an effective tax rate for 2016 excluding special items of approximately 19.5% to 20.5%.
Turning to sales and earnings guidance. Our sales guidance for 2016 assumes no biosimilar entrance for PROCRIT or REMICADE in the U.S. We also do not anticipate generic competition this year for ZYTIGA, RISPERDAL CONSTA and INVEGA SUSTENNA. But as expected, there are generic entrance for INVEGA and ORTHO TRI-CYCLEN LO.
As we've done for several years, our guidance will be based first on a constant currency basis, reflecting our results from operations. This is the way we manage our business, and we believe this provides a good understanding of the underlying performance of our business and will also provide an estimate of our sales and earnings and EPS results for 2016 with the impact that exchange rates could have on the translation of those results.
For the full year of 2016, we would be comfortable with your models reflecting an operational sales increase of between 2.5% and 3.5% for the year. This would result in sales for 2016 on a constant currency basis of approximately $71.9 billion to $72.6 billion. Additionally, while we have comparison to how we described our sales and results in 2015, our 2015 operating sales growth, excluding the impact of all acquisitions and divestitures and hep C sales, was approximately 6.5%. After adjusting for extra shipping days in 2015, that underlying growth rate was approximately 5.5% 2015. Our sales guidance for '16 on the same basis is expected to continue at a similar growth rate of around 5.5%.
While the euro has been fairly stable over the last few months, many of the other currencies have been volatile. Although we're not predicting the impact of currency movements, using the euro at $1.09, our guidance for sales growth would decrease by approximately 1.5%. We are watching the other currencies closely as it is uncertain as to how they will settle out for the year. Of course, we will update the assessment as we progress throughout the year.
Thus, under this scenario, we would expect reported sales to reflect the change in the range of 1% to 2% for a total expected level of reported sales of approximately $70.8 billion to $71.5 billion.
Now turning to earnings. A continuing factor impacting earnings guidance for 2016 is the impact of currency movements on transactions, which, although hedged, is still somewhat negative. We expect transaction currency impacts to negatively impact our gross margin by approximately 60 to 80 basis points in 2016 as compared to 2015. We would be comfortable with adjusted EPS guidance in the range of $6.53 to $6.68 per share on a constant currency basis, reflecting operational or constant currency growth rates of 5% to 8%.
Again, we're not predicting the impact of currency movements. But to give you an idea of the potential impact on EPS, with the euro at $1.09, our reported adjusted EPS would be negatively impacted by approximately $0.10 per share. Therefore, our reported adjusted EPS would range from $6.43 to $6.58 per share. At this early stage in the year, we would be comfortable with your models reflecting the midpoint of this range, which, at approximately 5%, is higher than current consensus estimate.
So in summary, as you update your models for the guidance I just provided, I'd like to make a few points. Although operational sales growth is expected to range between 2.5% and 3.5%, we're pleased to note, when excluding the impact of acquisitions and divestitures and hep C sales, our operational sales growth is expected to be around 5.5% for the full year 2016. With regards to expected EPS growth on an operational basis, our adjusted EPS growth guidance is strong in the range of 5% to 8%.
Also for 2016, pretax operating margins are expected to expand by more than 200 basis points based on the guidance I just provided. The margin expansion is driven by a combination of investments we made in 2015, coupled with the benefit of disciplined expense management across the enterprise.
Moving into 2016. We are confident in the strength of our business. As we execute our growth plans and near-term priorities that Alex laid out for you this morning, we're well positioned with the strong balance sheet to deliver solid results while continuing to invest in innovation, which will ensure our future growth and success. Our goal remains to grow our sales organically at a rate faster than the markets in which we compete, grow our earnings faster than sales and create value through strategic acquisitions and partnerships that generate additional growth. All of this, coupled with our strong dividend yield, provides a very compelling long-term shareholder return.
Finally, before I turn it over to Louise for Q&A, just a reminder to please save the date for our Consumer and Medical Device Business Review on Wednesday, May 18.
Thank you. Now back to Louise."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Dominic. Manny, could you please give the instructions for the Q&A session?",14,"Thank you, Dominic. Manny, could you please give the instructions for the Q&A session?"
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","[Operator Instructions] And your first question comes from Mike Weinstein of JPMorgan.",12,"[Operator Instructions] And your first question comes from Mike Weinstein of JPMorgan."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","So let me start with the margin expansion piece for the guidance, and this kind of fits in with the announcement last week on the MD&D business. And there's really -- like there's 2 parts to the question. So if I look at MD&D and where you ended up with p",153,"So let me start with the margin expansion piece for the guidance, and this kind of fits in with the announcement last week on the MD&D business. And there's really -- like there's 2 parts to the question. So if I look at MD&D and where you ended up with pretax margins in 2015, they were at 35.6% and which -- every observer would say those are very high margins. And for the overall company, you're guiding to 200 basis points plus of pretax margin improvement, which would make 2016 the biggest year of margin expansion in the last 15. So talk about the decision to be as aggressive as you're being in 2016 on operating cost. And for the MD&D business in particular, why is the consolidation that you're pursuing in what's called the cost transformation imperative at this point in time? And why are you being as aggressive as you're being?"
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Sure, Mike. Thanks for the question. Well, a couple of things. One is the -- 2015, as you saw, was a heavy investment year because we benefited from the divestitures, and I think we are very transparent that we would make important investments going into",198,"Sure, Mike. Thanks for the question. Well, a couple of things. One is the -- 2015, as you saw, was a heavy investment year because we benefited from the divestitures, and I think we are very transparent that we would make important investments going into 2015, and we did just that. So in 2016, we have a lower level of those investments consistent with a lower level of the other income that we just guided to. Also, it's important to point out that those investments we made in 2015, we're seeing the benefits of those already in 2016, so we think they are wise investments. And finally, we have talked a lot about our various programs of reducing our cost structure. And Alex today mentioned the program that we're embarking -- that we embarked on several years ago that will reduce costs by $1 billion by 2018. Well, we're well on our way in implementing that program after several years of investment. In 2016, we'll see a year where the actual benefits associated with that program outweigh any incremental investments. And maybe Alex may comment on the MD&D restructuring and why that's appropriate for us to do today."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes, Mike. We do think that this is the right time to be making the moves. But really, I think it's important to kind of step back and put it in the larger perspective. If you think about what we've been doing in Medical Devices over the last several year",175,"Yes, Mike. We do think that this is the right time to be making the moves. But really, I think it's important to kind of step back and put it in the larger perspective. If you think about what we've been doing in Medical Devices over the last several years, we've had a range of activities ranging from some of the divestitures with OCD as well as Cordis underway. At the same time, we've been making changes internally with the way that our organizations are innovating as well as in the way that they're going to market. And so we see this as the next logical step in that overall process. Our Medical Device business is one that we remain very committed to. We believe that it's got an exciting future, a lot of new innovation coming, new ways of dealing with our customers. And so we think this is the right time to make sure that we're set up for growth, not only in 2016, but actually for the next 5 and 10 years."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Dominic, can you share in the commentary about how you're thinking about the respective businesses in 2016 versus your 2015 performance? And then maybe just the -- on the MD&D topic, it's hard to ease out what the kind of underlying growth is with the ext",84,"Dominic, can you share in the commentary about how you're thinking about the respective businesses in 2016 versus your 2015 performance? And then maybe just the -- on the MD&D topic, it's hard to ease out what the kind of underlying growth is with the extra selling days, but MD&D did grow 5.8% this quarter. That's obviously inflated by that. Do you have any thoughts in -- just in terms of where you are in the turn of the performance of the MD&D business?"
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes. Well, sure, Mike. Well, let me comment overall. As you know, our growth in 2015, primarily driven by Pharmaceuticals, and we expect healthy growth in 2016 from pharma. We're probably at a slightly lower rate of growth than what we saw in '15 as those",136,"Yes. Well, sure, Mike. Well, let me comment overall. As you know, our growth in 2015, primarily driven by Pharmaceuticals, and we expect healthy growth in 2016 from pharma. We're probably at a slightly lower rate of growth than what we saw in '15 as those products that we launched are beginning to mature in their growth trajectory, but still a lot of growth ahead of them. So we're not going to give guidance by sector, but overall, a little bit lower growth than 2016 versus '15 for Pharma. Better growth in Consumer, good momentum in '15 carrying on into '16, and we expect higher growth rates in '16 versus '15 for the Medical Device business as well. And as you saw, we ended the year with a good strong momentum in that business as well."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Glenn Novarro of RBC Capital Markets.",11,"The next question is from Glenn Novarro of RBC Capital Markets."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","A question for Alex. Alex, given the strong balance sheet, I'm somewhat surprised you were not more aggressive with the balance sheet in 2015, especially on the M&A front. And you made some comments about the balance sheet going forward. But I'm just curi",104,"A question for Alex. Alex, given the strong balance sheet, I'm somewhat surprised you were not more aggressive with the balance sheet in 2015, especially on the M&A front. And you made some comments about the balance sheet going forward. But I'm just curious, as you evaluate your options, particularly on the M&A front, is the fact that we haven't seen deals year-to-date or so far, is it because the targets still have very high valuation expectations? Or is it that most of your cash is trapped outside the U.S., limiting your ability to do acquisitions? Or is it a little bit of both?"
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Thank you very much for your question. Look, we are and we have been and will continue to be very active in the M&A category. As we mentioned during the earlier comments, if you look at it historically really, over about any time frame, 20 years, 10 years",261,"Thank you very much for your question. Look, we are and we have been and will continue to be very active in the M&A category. As we mentioned during the earlier comments, if you look at it historically really, over about any time frame, 20 years, 10 years, what you see is about half of our growth being generated from organic innovation platforms and about 50% being generated vis--vis M&A. As we reflect back on 2015, we realize that the market was premium priced. We remain very active in a number of different areas. And while we didn't necessarily close on a larger deal, I would not assume that we were not engaged and involved. But at the same time, we think it's really important for you, our shareholders, as you think about long-term returns, that we stay at the appropriate level of discipline and decisiveness as we go through that process. As we look at the environment today, we see a number of opportunities across the consumer, the Medical Device and the Pharmaceutical groups. We're going to remain very active. I think that our financial team has done a great job of using our offshore assets in a very compliant but also tax-effective way. And we'll continue to look for opportunities that ultimately, we believe, are going to provide -- are going to help us continue to get into growing markets to improve our share position, to provide complementary products and services to platforms that we already have that ultimately are going to lead to long-term sustainable growth for J&J."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","So if I hear you correctly, you're saying valuations were elevated for the targets in 2015. But I sense from you that the target value, the valuations of your targets, valuations are coming down, and it sounds like that the cash sitting outside the U.S. w",81,"So if I hear you correctly, you're saying valuations were elevated for the targets in 2015. But I sense from you that the target value, the valuations of your targets, valuations are coming down, and it sounds like that the cash sitting outside the U.S. will not inhibit deal flow. So is that a fair assumption? And then, is there any one business versus the other that you would be more likely inclined to do an acquisition to help accelerate growth?"
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes, Glenn. Look, we're fortunate in that because of our strong performance, our strong cash flows that our balance sheet is actually quite strong. I'd also believe that if you look at our track record of how we've utilized that cash to make the right cap",172,"Yes, Glenn. Look, we're fortunate in that because of our strong performance, our strong cash flows that our balance sheet is actually quite strong. I'd also believe that if you look at our track record of how we've utilized that cash to make the right capital investments in companies that we've been successful with that. And look, we think that there's opportunities across all 3 of our different sectors. And it's not an algorithm per se as we decide which and where to invest. But rather, it really depends on the opportunity and many of the factors that Dominic described earlier as far as what are the specific platforms that we're looking at, where is the partner in terms of their decision-making, what they want to do with the business and frankly, what the competitive environment is like. So we think that there are opportunities. And we intend to be quite active as we look at 2016 and beyond in a manner that's been consistent with our track record in that area."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Matt Miksic of UBS.",9,"The next question is from Matt Miksic of UBS."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","So one kind of broader question on the sort of changes in the health economy in the U.S., and then I have one follow-up on top of the extra day commentary that you made. So looking forward to the MD&D day and the update on sort of the restructuring there.",146,"So one kind of broader question on the sort of changes in the health economy in the U.S., and then I have one follow-up on top of the extra day commentary that you made. So looking forward to the MD&D day and the update on sort of the restructuring there. But stepping back, you've been one of the leaders here in sort of broader contracting strategies and development of some of these value-added services like care center [ph] and outpatient solutions. Alex, it would be just helpful to get your thoughts on what you're seeing in the marketplace in terms of uptake, of those kinds of strategies and maybe talk about whether we're in the early innings here and how you think about some of the benefit you're seeing or hope to see with those approaches to the business. And then I have one follow-up."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Sure, Matt. Thank you very much. Look, overall, we feel that we're still in the very early innings out of what I would call as the market evolution that we clearly expect to see over the next 3, 5 and even 10 years. Now for all the reasons that we've disc",491,"Sure, Matt. Thank you very much. Look, overall, we feel that we're still in the very early innings out of what I would call as the market evolution that we clearly expect to see over the next 3, 5 and even 10 years. Now for all the reasons that we've discussed around increasing demands based on demographics, certainly here in the U.S., and a rising middle class and demographics outside the United States and the pressure that, that's likely going to put on payers and governments and others in between, we realize that there is an opportunity for us to participate, not only in bringing great innovations that's going to help patients, but also doing it in a value-added way. And clearly, the consumer, the patient, is weighing in much heavier in these decisions as they take on higher copays as they can get more information that's available online. And frankly, they just have higher expectations about their ability to participate in that health care decision-making process. So what we see is a range of customers, but we see some customers who are still very innovation focused. And to be clear, we remain very innovation focused. We think, at the end of the day, what we do best is bring new products, new solutions to our customers that are going to ultimately have better outcomes for patients. And so that's an area where we are very focused on and we'll continue to be focused on. We are though starting to also see hospital systems. And I think one important point here is it's certainly taking place in the United States, but it's also definitely taking place in places like Europe and even some of the developing and emerging markets that frankly don't have the history and the legacy of some of the infrastructure that you see in the more developed markets. In there, it -- what we see is an evolution more towards the business-to-business relationship where yes, customers want to see innovation, but they also want to see how are you going to interact, how can you assist in working with our supply chain to make it more efficient, how can we work together as part of a broader partnership that ultimately is focusing not just on a product sell, but actually on an outcome, on an episodic care for the patient and it creates a much broader partnership. We are seeing those organizations becoming more and more interested, and that's why we're adapting to make sure that we're part of that. So I think, overall, it's important that we continue to innovate, we continue to operate with a lot of excellence in the current environment. At the same time, it's important that we set the stage for this evolution that's taking place out there to make sure that we can not only be successful, that we're -- but we'll actually be a leader as that market evolves as well."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Very, very helpful. And then the clarification on the extra shipping day, as you talked about, it's a holiday week and maybe OR surgery days were not as much of a factor as shipping days, from what I could tell in your commentary. But you're strong in Vis",127,"Very, very helpful. And then the clarification on the extra shipping day, as you talked about, it's a holiday week and maybe OR surgery days were not as much of a factor as shipping days, from what I could tell in your commentary. But you're strong in Vision Care, obviously a shipping type of business, strong in Pharma. Just wondering, Dominic, if -- or if you have any color on some of your consignment businesses where we think about orthopedics, spine and trauma where the inventory is in the field, it's on your balance sheet. Is it -- was there any difference in the way those business were impacted versus businesses where you're actually shipping and billing for things in the last couple days of the quarter?"
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Sure, Matt. Well, just overarching comment on this. Of course, these extra shipping days were already included in our guidance for the year, and I think you've all modeled for them. And as you know, our sales came in pretty much in line with expectations.",119,"Sure, Matt. Well, just overarching comment on this. Of course, these extra shipping days were already included in our guidance for the year, and I think you've all modeled for them. And as you know, our sales came in pretty much in line with expectations. About 1% for the year, we think, is the impact overall for the enterprise and about 4% in the quarter. You're right. It does vary slightly by different businesses within the U.S. in particular. So this is largely a U.S. phenomenon as opposed to a global phenomenon. And with respect to the Orthopaedics business line, which I think you're referring to specifically, I think, Louise, you might have the details on the impact there."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes. So the additional days in the U.S. in Orthopaedics was about 2.5 days. In -- and outside the U.S., about 1.5 days average.",24,"Yes. So the additional days in the U.S. in Orthopaedics was about 2.5 days. In -- and outside the U.S., about 1.5 days average."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","So not really that -- not really much different from the overall total because that 2.5 days get you to this 4% and 1% that I talked about earlier.",29,"So not really that -- not really much different from the overall total because that 2.5 days get you to this 4% and 1% that I talked about earlier."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","And what's interesting also, when you look at the underlying growth in the Orthopaedics, third quarter, fourth quarter, taking out the additional shipping days, we saw sequential improvement across hips, knees, spine and trauma.",35,"And what's interesting also, when you look at the underlying growth in the Orthopaedics, third quarter, fourth quarter, taking out the additional shipping days, we saw sequential improvement across hips, knees, spine and trauma."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","That's right.",3,"That's right."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","On a worldwide basis. Okay?",5,"On a worldwide basis. Okay?"
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Larry Biegelsen of Wells Fargo.",10,"The next question is from Larry Biegelsen of Wells Fargo."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Let me just start with med tech and then I had a follow-up on pharma. So Alex, can you talk about the health of the med tech end markets in the U.S. and emerging markets? And what drives the acceleration for your business specifically in 2016? When I look",96,"Let me just start with med tech and then I had a follow-up on pharma. So Alex, can you talk about the health of the med tech end markets in the U.S. and emerging markets? And what drives the acceleration for your business specifically in 2016? When I look at the general surgery business, it looked like adjusting for the extra days in the U.S., that was -- or worldwide, that was slightly weaker in Q4. So just the health of the end markets in the U.S. and emerging markets, and I had a follow-up."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Sure. Thanks a lot for the question, Larry. I think what we would say overall is we continue to see, let's say, a slightly increasing positive trends. So we saw hospital admissions, I believe, up around 2%, we saw surgical procedures up a little over 1% i",641,"Sure. Thanks a lot for the question, Larry. I think what we would say overall is we continue to see, let's say, a slightly increasing positive trends. So we saw hospital admissions, I believe, up around 2%, we saw surgical procedures up a little over 1% in the U.S., that's the most recent data that we have. If we go outside a U.S., we think rates in Europe have been pretty steady. And even in the markets in which we compete most significantly, in the developing markets, we haven't seen a major impact from secular shifts, perhaps in China some, but not dramatic. And then putting that into context, what that represents overall on our business, we don't see it as a major indicator. As I look towards 2016, look, there's a few things that cause us to be optimistic about our Medical Device business. It really starts with innovation. And we've got about 30 products that we'll be launching by the end of 2016. Over half of those have either been launched or are well on their way as we speak. And what we're seeing is when we're bringing new technologies to the market like our new contact lenses, like our new insulin pump, like our new energy instrumentation, like the ATTUNE Knee, we're seeing very good uptake. And in fact, in those categories, we're seeing share gains. And certainly, in areas like electrophysiology, endocutters, the same thing. And so we believe that the market does still reward significant innovation when we're introducing it. So that's one aspect. The second aspect, frankly, is one, just improved execution. And I think if you look across all of our device businesses, if you think about diabetes care, the major price reset that we had there a couple of years ago -- and as all of you know, when you're -- when you take that kind of a reduction, resizing your business, going back in each and every line and setting it for the new marketplace caused us an tremendous amount of change. If you look at our Vision Care business last year, we went in and we really increased the cadence out of our innovation pipeline, launching 5 new products. We did a price reset there to make us more competitive with the ECPs. We made a lot of other internal adjustments to improve our selling and marketing. We are definitely seeing the impact of that now, not only on the sales results of up to 8%, but as -- maybe even more importantly, if you look at the leading indicators as far as new share that's being generated and new patient starts in the offices, those things are positive. Louise mentioned earlier the improvement that we're seeing across the Orthopaedics business. And look, this is one where we know that when you bring large organizations together, when you standardize quality systems, manufacturing systems, we think that we've made a lot of progress there. And frankly, when you compound that with the innovation rollout that we've seen in Orthopaedics of the ATTUNE Knee, the CORAIL Hip, the TFNA nail, we're starting to see that come back as well as some of the, frankly, the new approaches that we're taking that Gary will be talking more about in May where our Ethicon and our DePuy Synthes teams were actually co-selling, co-contracting in a number of very innovative ways, compounded with the fact that -- look, we think some of the performance issues related to China in our Orthopaedics are more of a onetime event. That's getting normalized. So as we burn our way through those and head into 2016 overall, we think that innovation, we think changes in our commercial model, we think improved execution, all those things are -- make us more optimistic about the growth prospects as we head into 2016."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","That's very helpful, Alex. And I just have one follow-up on biosimilar REMICADE. So obviously, there's a panel schedule that rescheduled last month. So I'm wondering if you can talk about what issues you think we should be listening for, what your expecta",71,"That's very helpful, Alex. And I just have one follow-up on biosimilar REMICADE. So obviously, there's a panel schedule that rescheduled last month. So I'm wondering if you can talk about what issues you think we should be listening for, what your expectations are and what you're seeing in Europe where biosimilar REMICADE is on the market and why or why not that might be a proxy for the U.S."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Certainly. Well, obviously, we'll also be watching the advisory committee and participating in it as well coming up. And we think there's a few things to keep in consideration about this. And first and foremost is that as Dominic stated earlier, biosimila",547,"Certainly. Well, obviously, we'll also be watching the advisory committee and participating in it as well coming up. And we think there's a few things to keep in consideration about this. And first and foremost is that as Dominic stated earlier, biosimilars are very different from generics. And particularly, in this category, I think keeping the patient in the center of all these -- we've got a tremendous amount of experience in the biologics category going back to PROCRIT, REMICADE, a number of our days. And we think the differences between molecules can have -- manifest themselves in significant ways with patients. So making sure -- and I think things that we'll be watching for the at AC or what kind of data that the biosimilars actually have, what kind of indications, what will be the guidance around substitutability. All those, frankly, sitting here today, are unknowns. We'll need more clarification. But we think each of those means that the expected uptake, even when a biosimilar does launch, will lead to a significantly different curve than what you see with generics. We think, secondly, it's very important -- if you actually think about it from a patient perspective. And we know, for example, there's about 2.5 million patients with REMICADE, and about 70% of those are either continuing therapy and have a pretty high satisfaction rate. So if you look at the available population who's likely to be switched, we think it's in the 30% range. And last but certainly not least, there's the whole issue of the business model and the way that we actually work with customers in this setting. And this is an area where we've got a lot of experience in contracting. We've got some great relationships with providers in this area right now. We also have a very broad portfolio. If you think about what REMICADE does, but you look more broadly at the performance recently of a product like STELARA, a multibillion dollar compound, growing at 20-plus percent rate; if you look at SIMPONI, same thing, SIMPONI ARIA, in particular, the great dosing convenience that it provides, that's another multibillion addition that we add to that portfolio, then you augment that with the submissions that we have in 2016 planned for, guselkumab, sirukumab and IL-23 and then IL-6, we think that, that positions us very well with our portfolio and from a contracting point of view with large providers and payers in -- certainly in the U.S. but also abroad. What we're seeing outside the United States is that most of the markets where they're introduced is a relatively minor impact. We're seeing that we're holding on to about 90% plus or minus. It varies by market. You have to look at each one individually. And it's difficult to project exactly what that impact will be going forward. But I think when we think of it broadly across all those different areas, what's the clinical data show, what ultimately is the labeling, the regulatory aspects, what about our contracting, the business aspects, and we think all those are very important, will result in a different impact from biosimilars. And ultimately, we'll continue to defend our intellectual property as well through what we believe is the right patent in September of 2018."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","And just add to that, we have -- REMICADE in Canada is a Johnson & Johnson product, and we've seen fairly -- it's actually still growing in Canada even with the biosimilar there. Now the biosimilar has a limited indication there, but it's still growing. A",62,"And just add to that, we have -- REMICADE in Canada is a Johnson & Johnson product, and we've seen fairly -- it's actually still growing in Canada even with the biosimilar there. Now the biosimilar has a limited indication there, but it's still growing. And we'll be listening to Merck's call as well to see if -- the latest in Europe."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Jami Rubin of Goldman Sachs.",10,"The next question is from Jami Rubin of Goldman Sachs."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Just a question for you, Dominic, and I have a question for Alex. Just trying to understand the difference between consensus estimates for 2016 in your guidance. Do you have a sense for what The Street was assuming for nonoperating income? When I go back",186,"Just a question for you, Dominic, and I have a question for Alex. Just trying to understand the difference between consensus estimates for 2016 in your guidance. Do you have a sense for what The Street was assuming for nonoperating income? When I go back historically, that's been in the $500 million to $600 million range. Clearly, it was $2 billion last year, but just curious to know what consensus models had assumed for that. Secondly, did your guidance assume that the medical device tax will be suspended as I think we've seen with other device companies? Just curious to know if that savings is reinvested in the business or if that is part of the guidance. And then for you, Alex, just curious to know your thoughts on pricing. I mean, we heard Bernie and Hillary last night go after drug pricing again. And I think that's also something we're going to hear from the Republican candidates. What are your expectations in terms of pricing in 2016 and 2017? Do you expect that there will be a change in terms of list prices going forward?"
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Okay. Jami, let me try to take the first 2 and then have Alex -- maybe he'll comment on the drug pricing. You were referring to our nonoperating, now let's call it the other income and expense line for 2016, what was assumed in analyst models versus what",315,"Okay. Jami, let me try to take the first 2 and then have Alex -- maybe he'll comment on the drug pricing. You were referring to our nonoperating, now let's call it the other income and expense line for 2016, what was assumed in analyst models versus what we have provided in guidance. When we looked at the analyst consensus models, overall, it looks like that number averaged in the high $900 million, so nearly $1 billion. And our guidance, of course, is somewhere at $1.1 billion to $1.2 billion. So our guidance is slightly higher than the analyst models. But just as a reminder, we always take the opportunity to -- these are portfolio choices to use any of those gains to offset some other expenses we'd like to invest in. And then with respect to the Medical Device Tax, the -- we have assumed that it would be a benefit in 2016. But I must say, the benefit for us is very, very minor. Remember, when the Medical Device Tax is incurred, it's incurred upon the first manufacturer of a product and therefore, it can be, for example, orthopedic companies hung up in inventory for quite some time. So the overall impact of not having a Medical Device Tax in 2016 is not significant for Johnson & Johnson. It may be significant for certain other companies that maybe are pure orthopedic players, but not overall significant for us. And secondly, I would say that whatever benefit we see there, we've already assumed would be reinvested in innovation because, of course, during the time that the Medical Device Tax was a drag on earnings, obviously, decisions had to be made on where to invest. Now we're happy that with that easement of the Device Tax for a couple of years, we'll be able to actually invest more in innovation in the medical device space."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes, Jami, thanks for the question on pricing. Look, we realize and understand the pricing in pharmaceuticals, let alone all of health care, it's certainly a very important issue. And we believe that it's important to consider it just in that way. As we t",265,"Yes, Jami, thanks for the question on pricing. Look, we realize and understand the pricing in pharmaceuticals, let alone all of health care, it's certainly a very important issue. And we believe that it's important to consider it just in that way. As we think about pharmaceuticals, for example, they currently make up about 12% of health care spending in the United States, slightly higher in Europe. If you think about medical devices, they represent about 6%. And if you go beyond those areas, of course, there's a lot of other cost built into that system, ranging from hospital, patient care, insurance companies, many other people and particularly, in an environment today, where frankly, we're seeing such transformational outcomes and moving more and more towards cures, disease prevention, interception than we ever have because of some of the great science that's being produced. So we understand and would certainly expect there to be a continued spotlight in this area. Obviously, we're working with a lot of stakeholders to try and make sure that we look at it in a very holistic way. And it's very, I think, difficult, at this point in time, to try to project what's going to happen in 2016 or 2017. All of us know that the health care system, not only here in the United States, but frankly, around the world, is complex. There's a lot of other -- a lot of issues that are intertwined and -- but it's obviously a conversation that we'll be participating in and ultimately, where we want to be a part of the solution."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Vamil Divan of Crdit Suisse.",10,"The next question is from Vamil Divan of Crdit Suisse."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","So just a couple on the pharma side, I guess, one on the pharma side and one other one for Dominic. You mentioned STELARA and you mentioned the strong quarter and 20% growth is showing. I'm just wondering if you can share a little bit, if you thought abou",159,"So just a couple on the pharma side, I guess, one on the pharma side and one other one for Dominic. You mentioned STELARA and you mentioned the strong quarter and 20% growth is showing. I'm just wondering if you can share a little bit, if you thought about 2016 and maybe beyond the -- your expectations of that product going forward just given the competition. It's kind of based [ph] from the IL-17, both in psoriasis and psoriatic arthritis. So is this sort of 20% range still sustainable or do you think you'll see more of a decline? And then second, for Dominic, just on the guidance. And I apologize if I missed this. But in terms of your EPS guidance, can you comment on what share count you're using to get to that guidance or just get some sense of the buybacks, I guess, that you've sort of incorporated into the way you think about the year?"
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Sure. Why don't I take that first part first? So Vamil, we -- obviously, we announced the share buyback in October. And I said we, already through the fourth quarter, spent about $1 billion of that $10 billion. In our plans for 2016, we have not assumed t",94,"Sure. Why don't I take that first part first? So Vamil, we -- obviously, we announced the share buyback in October. And I said we, already through the fourth quarter, spent about $1 billion of that $10 billion. In our plans for 2016, we have not assumed that it's totally complete. But certainly, more than a majority of the share buyback will be completed by the end of 2016, maybe 3 quarters of it, sort of around that range. And that's what we've assumed in our models for 2016, the guidance I just gave."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes, Vamil. Thanks for the question. Look, if we look at STELARA, one, it just starts with a great compound. It's had very nice uptake, very good growth and we've certainly seen that in psoriatic arthritis. But we're also excited about the planned indicat",135,"Yes, Vamil. Thanks for the question. Look, if we look at STELARA, one, it just starts with a great compound. It's had very nice uptake, very good growth and we've certainly seen that in psoriatic arthritis. But we're also excited about the planned indications in areas like UC and axial spondylitis. So when you take the profile, the momentum that we're seeing in the current marketplace and the share that continues to grow, you combine it with some additional indications as we go forward, particularly as part of our broader immunology portfolio, we think that there's -- and the other important issue, I believe, this category is only about 22% or 23% penetrated. So in terms of new patients that are coming in, all of that represents a nice growth opportunity for this important product."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Kristen Stewart of Deutsche Bank.",10,"The next question is from Kristen Stewart of Deutsche Bank."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","I have 2 questions, the first for Dominic. I believe, a couple of years ago, you talked about the opportunities for margin expansion within Consumer, and we really haven't seen that just yet. With most of the products now returned in the OTC business, sho",95,"I have 2 questions, the first for Dominic. I believe, a couple of years ago, you talked about the opportunities for margin expansion within Consumer, and we really haven't seen that just yet. With most of the products now returned in the OTC business, should we expect to see Consumer really starting to reach an inflection point? And with the goal, I believe, Andy had talked about 2 years ago at the last kind of Consumer update, really getting back into that kind of 20% range, still really achievable for the next couple of years?"
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes, Kristen. We do expect that the Consumer business, out of the products that they've launched and the cost remediations associated with the Consent Decree are largely behind us, although we still comply with the Consent Decree for another 5 years. We d",91,"Yes, Kristen. We do expect that the Consumer business, out of the products that they've launched and the cost remediations associated with the Consent Decree are largely behind us, although we still comply with the Consent Decree for another 5 years. We did want to launch those products with the right support. But it is true that we do expect, and we'll see it in '16, we'll report on it later in the year throughout the quarters, the -- an improvement in the operating margins of the Consumer business going forward."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Okay. And Alex, I guess, just following that, will M&A be a key driver to improving the margins or any sort of portfolio management? And then more broadly, I know I've always asked Dominic this question every now and again. I guess, you guys have always t",116,"Okay. And Alex, I guess, just following that, will M&A be a key driver to improving the margins or any sort of portfolio management? And then more broadly, I know I've always asked Dominic this question every now and again. I guess, you guys have always talked about the fourth leg, and we've seen some of your competitors go to more solutions-based approach in wraparound programs. You have some of those as well, particularly within the Orthopaedics business. Is that something that you think of when you're thinking about M&A moving more towards a holistic health care model and maybe perhaps rolling in some more lifestyle disease management programs or something more on the service side?"
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Sure. Look, I just pick up what Dominic had just said about our Consumer business is that I'm really proud of the work that we've done on the Consent Decree and the great strides that they have taken around quality. In fact, I think in working closely and",435,"Sure. Look, I just pick up what Dominic had just said about our Consumer business is that I'm really proud of the work that we've done on the Consent Decree and the great strides that they have taken around quality. In fact, I think in working closely and partnering with the FDA, we likely have a benchmark organization now, and we're really proud having done that. At the same time, I think as they begin to shift from only remediation to remediation and relaunch, across a number of these areas, while certainly keeping a very high eye on quality, as we increase our volumes, as we are able to deepen our relationships with a lot of the major trade partners, that's where we see a great growth opportunity as well and obviously, that's going to have an impact on our margins as we go forward. I also think that the other thing that, that team is doing is as we're transitioning more and more to online marketing versus just traditional marketing, the way we're partnering with some of the large customers, I think there's a lot of opportunities not only to drive share and volume, but actually to improve efficiencies on our back end as well. As I step back and look more broadly, look, we think the 3 areas that we're in, consumer, medical devices and pharmaceuticals, are all great platform and great businesses. Of course, we would look, first, for areas that -- what is the next ZYTIGA? What's the next Vision Care platform? What's the next NEUTROGENA? That would certainly be our focus. Another would be, are there chances to grow in perhaps some of the faster-growing developing markets with the right kind of opportunity? Those are things that we would be interested in. And then what are ways to complement our existing businesses? I think the way that you point it out, as the markets evolve, we are looking, not only at M&A, but also broader partnerships that we've done, for example, with companies like Google, and verily, where we see a big opportunity to really help transform the robotics surgery space in a pretty significant way longer term. And then, I guess, so the final option there would be for us to actually acquire something outside the current 3. And again, if it's something where we thought there was a lot of unmet patient or consumer need, if we feel that it's consistent with the capabilities that we can bring to bear to actually have it be a successful business, if the financials work, then we would take that step."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Bob Hopkins of Bank of America.",11,"The next question is from Bob Hopkins of Bank of America."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","So 2 things, and I'll just rattle them off. First, I was wondering if you guys could comment a little bit on emerging market growth in Q4 relative to trends earlier in the year. And then more importantly, just talk about the current operating environment,",132,"So 2 things, and I'll just rattle them off. First, I was wondering if you guys could comment a little bit on emerging market growth in Q4 relative to trends earlier in the year. And then more importantly, just talk about the current operating environment, China, and when do you think we could see reacceleration of emerging market growth for J&J, that's question number one. And then question number two is just back to the original question on the 200 basis points of pretax operating margin improvement in '16. I was wondering if you could give us just a little more detail on exactly where that comes from, maybe mention how much extra spend was there in 2015 that won't materialize in '16. Just looking for a little bit more color there."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Okay. So on the emerging market's growth, excluding the impact, of course, of Cordis and OCD, it was about 6.5% in the fourth quarter. On a year-to-date basis, it was about 5.5%. Those are both operational numbers.",37,"Okay. So on the emerging market's growth, excluding the impact, of course, of Cordis and OCD, it was about 6.5% in the fourth quarter. On a year-to-date basis, it was about 5.5%. Those are both operational numbers."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","And on China, just a couple of comments that China -- we did see a slowdown in China, primarily in the Consumer business because the -- both Medical Device and Pharma businesses still had high single digit growth in China, and we're optimistic about China",352,"And on China, just a couple of comments that China -- we did see a slowdown in China, primarily in the Consumer business because the -- both Medical Device and Pharma businesses still had high single digit growth in China, and we're optimistic about China going into 2016. Our plans are for improved growth in China in 2016. But I just want to put China in perspective. It's less than 5% of our sales. It's an important market for us longer term with 1.3 billion people and lots of health care needs, et cetera. But any short-term changes in their economy is unlikely to have any significant impact on our results. And then on the 200 basis point improvement, Bob, it's actually across all 3 lines of the P&L, COGS, selling, marketing as well as R&D. So in the case of COGS where we have a long-term program that we've been executing on to reduce footprint, we're accelerating some of those programs that will benefit us in the COGS line. On the selling, marketing and administrative line, I talked earlier about the fact that we had a program in place for a couple of years, shooting for $1 billion of cost savings by 2018, we're well on our way. We'll see cost reductions in that line. In R&D, that depends on the individual licensing deals that we have and the timing of when we would spend those milestone payments or enter into new licensing agreements. But as it looks today, the advancement in the portfolio in 2015 from the milestone payments, et cetera, are not expected to be at the same level in '16 that they were in '15. So it's across all 3 lines in the P&L. And I can't give you an exact number on the amount of investment we made in '15, extra investment made in '15. But just to say that we had $2.8 billion of other income in 2015, well above the years passed, and we still improved overall income before tax by not quite that amount, right? So most of it was reinvested in the business."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Josh Jennings of Cowen and Company.",11,"The next question is from Josh Jennings of Cowen and Company."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Just -- we just have one for Alex. And you have a formal plan in place to accelerate growth in the Medical Device unit that's reasonable. And I believe that your target of returning it to 4% to 5% or 4% to 6% growth -- I just want to ask how patient you'l",80,"Just -- we just have one for Alex. And you have a formal plan in place to accelerate growth in the Medical Device unit that's reasonable. And I believe that your target of returning it to 4% to 5% or 4% to 6% growth -- I just want to ask how patient you'll be before you look externally in a transformational way. And is this a 12- to 24-month initiative or a longer time period that you'll put in place?"
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes, Josh. Thanks a lot for the question. The way I would say it, this is something that has been underway for the last several months. But clearly, we're accelerating it. And whenever you make this kind of a decision, you certain -- we certainly think ab",211,"Yes, Josh. Thanks a lot for the question. The way I would say it, this is something that has been underway for the last several months. But clearly, we're accelerating it. And whenever you make this kind of a decision, you certain -- we certainly think about the impact that it has on employees. But we also see it as our responsibility to make sure that this business is positioned for the next 5, the next 10 years. And with that note, we have a high sense of urgency about increasing our rate of innovation, about making the business model changes and ultimately, about making sure that we're more competitive in delivering in the markets. We try to be very clear where -- our goal is to grow faster than the markets, even given our size and given our scale. We think we've got over 10 platforms that are $1 billion. Majority of those are #1 or #2. But we realize there's still a lot of opportunity, So while we're pleased with what we've seen, we're far from satisfied. And I know Gary and the rest of his team as well as all of us are completely committed to accelerating the performance of this group to be, frankly, benchmarking the industry."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","We'll take the last question, and Alex will provide some brief closing remarks.",14,"We'll take the last question, and Alex will provide some brief closing remarks."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","Our final question comes from David Lewis of Morgan Stanley.",10,"Our final question comes from David Lewis of Morgan Stanley."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Just 2 quick ones. I'll start with a strategic one for Alex and then a quick follow-up question for Dominic or others. Alex, just thinking about M&A for a second. I know it's been a theme for this call, but how does segment performance influence your will",107,"Just 2 quick ones. I'll start with a strategic one for Alex and then a quick follow-up question for Dominic or others. Alex, just thinking about M&A for a second. I know it's been a theme for this call, but how does segment performance influence your willingness to deploy capital in those segments? So are you more inclined to deploy capital in the outperforming segments or not? And I guess related, does it make sense to deploy material capital and devices through M&A and told our restructuring has been digested and growth is back to market rates in those franchises? And then a quick question for Dominic."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Yes, David. Thanks for the question. Look, it depends on a number of different factors. And obviously, as we think about it, for example, in our Pharmaceutical group, we think that the model that we pull together, while we try to find the next INVOKANA, t",302,"Yes, David. Thanks for the question. Look, it depends on a number of different factors. And obviously, as we think about it, for example, in our Pharmaceutical group, we think that the model that we pull together, while we try to find the next INVOKANA, the next DARZALEX, very early compounds, where frankly we've got solid scientific insights, we bring it inside. And because of our clinical development, our regulatory capabilities, we can launch, and then very strong sales marketing and reimbursement practices around that. Frankly, that's what helped us create the number of billion-dollar blockbusters that we've been able to launch since 2009, I think 16 new products and 7 of which are like right at $1 billion or shortly will be. And so we think that's a good model. In Medical Devices, we've done tuck-ins as well as large. And look, I think in both cases, whether it's Pharma or Medical Devices, the smaller tuck-ins are frankly more straightforward to get done. We haven't shied -- we won't shy away from large where we think it makes for a significant opportunity, and it's something that we'll continue to look at in Consumer. As far as the question that it's underperforming, now I think it depends on why it's underperforming. If it's a market -- if it's an exogenous market shift or something else, then obviously, that would not necessarily have us shy away from that particular area. On the other hand, if it's an internal, more executional issue, absolutely, we'd want to make sure that we've got the knitting where we need it before we add on to that particular opportunity. So that's the way we tend to look at it. But again, it's part of a broader strategic question really on how we're managing the portfolio across the enterprise."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Analysts","Okay, very helpful. And then to Dominic, just a quick one for you or the team. Just on -- INVOKANA hasn't come up yet on the call. I wonder if you can just give us a sense of what's happening in the market post EMPA-REG as it relates to class expansion or",74,"Okay, very helpful. And then to Dominic, just a quick one for you or the team. Just on -- INVOKANA hasn't come up yet on the call. I wonder if you can just give us a sense of what's happening in the market post EMPA-REG as it relates to class expansion or your market share. And can you give us any update on the CANVAS trial and when can you get data in '17?"
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Okay. So what -- I'll give you the market share third quarter versus fourth quarter, which will give you some nice trend information. So -- and this is U.S. For the total, we went from 6.3% in the third quarter to 6.5% in the fourth quarter. Now at primar",64,"Okay. So what -- I'll give you the market share third quarter versus fourth quarter, which will give you some nice trend information. So -- and this is U.S. For the total, we went from 6.3% in the third quarter to 6.5% in the fourth quarter. Now at primary care, we went from 5.6% to 5.8% and endo, it's flat at about 13% quarter-to-quarter."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","And what -- the reading that we're getting from the field is that most physicians -- and in fact, some guidelines were recently published that the cardiovascular benefit that we saw with the other SGLT2 is most likely a class effect as absolutely [ph] phy",70,"And what -- the reading that we're getting from the field is that most physicians -- and in fact, some guidelines were recently published that the cardiovascular benefit that we saw with the other SGLT2 is most likely a class effect as absolutely [ph] physicians treated. And in fact, the guidelines were just recently issued that called it a class effect. Our data won't be until sometime mid-2017, I believe."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","2017.",1,"2017."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","On those results where we'll actually then be able to put those results in our label. But until then, I think the market recognizes it as a beneficial effect on cardiovascular.",32,"On those results where we'll actually then be able to put those results in our label. But until then, I think the market recognizes it as a beneficial effect on cardiovascular."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","Thank you. And for final remarks?",6,"Thank you. And for final remarks?"
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Executives","So thank you very much, everybody. Look, and in closing, I'd like to thank you again for joining today's call. We're pleased with the results we delivered in 2015. And we think our strong underlying operational growth across the enterprise, combined with",91,"So thank you very much, everybody. Look, and in closing, I'd like to thank you again for joining today's call. We're pleased with the results we delivered in 2015. And we think our strong underlying operational growth across the enterprise, combined with a very high sense of urgency, gives us a lot of confidence as we head into 2016. And we're optimistic about the opportunities in health care and frankly about the underlying strength of our core business. So thank you very much, and I hope everyone has a great day."
139677,320178319,921101,"Johnson & Johnson, Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Johnson & Johnson","Operator","Thank you. This concludes today's Johnson & Johnson's Fourth Quarter 2015 Earnings Conference Call. You may now disconnect, and have a wonderful day.",23,"Thank you. This concludes today's Johnson & Johnson's Fourth Quarter 2015 Earnings Conference Call. You may now disconnect, and have a wonderful day."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","Good morning, and welcome to Johnson & Johnson's First Quarter 2016 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] I would now turn th",49,"Good morning, and welcome to Johnson & Johnson's First Quarter 2016 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] 
I would now turn the conference call over to Johnson & Johnson. You may begin."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Good morning, and welcome. I'm Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure this morning to review our business results for the first quarter of 2016. Joining me on the call today is Dominic Caruso,",1724,"Good morning, and welcome. I'm Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure this morning to review our business results for the first quarter of 2016. 
Joining me on the call today is Dominic Caruso, our Chief Financial Officer. 
A few logistics before we get into the details. This review is being made available via a webcast accessible through the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. I'll begin by briefly reviewing the first quarter for the corporation and for our 3 business segments. Then Dominic will provide some additional commentary on the business, review the income statement and guidance for 2016. We will then open the call to your questions. We expect the call to last approximately one hour. 
Included with the press release that was issued earlier this morning is the schedule of sales for key products and/or businesses to facilitate updating your models. These schedules are available on the Johnson & Johnson website as is the press release. 
Please note, we will be using a presentation to complement today's commentary. The presentation is also available on our website. 
Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements. The 10-K for the fiscal year 2015 and the company's subsequent filings identify certain factors that could cause the company's actual results to differ materially from those projected in any forward-looking statements made today. The company does not undertake to update any forward-looking statements as a result of new information or future events or developments. 
Our SEC filings, including the 10-K, are available through the company and on our website. 
During the review, non-GAAP financial measures are used to provide information pertinent to ongoing business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with GAAP results. Tables reconciling these measures to the most comparable GAAP measures are available in the schedules accompanying the press release and on the Investor Relations section of the Johnson & Johnson website. A number of the products and compounds discussed today are being developed in collaboration with strategic partners or license from other companies. This slide acknowledges those relationships. 
Now I would like to review our results for the first quarter of 2016. Worldwide sales to customers were $17.5 billion for the first quarter of 2016, up 0.6% versus first quarter 2015. 
On an operational basis, sales were up 3.9% and currency had a negative impact of 3.3%. In the U.S., sales were up 7.2%. In regions outside the U.S., our operational growth was 0.6%, while the effect of currency exchange rates negatively impacted our reported results by 6.6%. 
On an operational basis, Asia-Pacific and Africa grew 3%. Europe declined 0.8% and the Western Hemisphere, excluding the U.S., declined by 0.6%. 
Results in all regions were negatively impacted by hepatitis C competition and divestitures, the most significant one being Cordis. 
In addition, the devaluation in Venezuela impacted operational growth in the Western Hemisphere, excluding the U.S. Excluding the net impact of acquisitions, divestitures and hepatitis C, underlying operational growth was 6.9% worldwide, 9.8% in the U.S. and 3.8% outside the U.S. 
In addition, the devaluation in Venezuela impacted worldwide and outside the U.S. operational growth by 60 basis points and 120 basis points, respectively. 
Turning now to earnings. Net earnings were $4.3 billion and earnings per share were $1.54 versus $1.53 a year ago. As referenced in the table reconciling non-GAAP measures, 2016 first quarter net earnings were adjusted to exclude after-tax amortization expense of $205 million and the charge of $192 million for after-tax special items. 2015 first quarter net earnings were adjusted to exclude a next charge of $98 million. Dominic will discuss special items in his remarks. 
Excluding amortization expense and special items for both periods, adjusted net earnings for the current quarter were $4.7 billion and diluted earnings per share were $1.68, representing increases of 6.1% and 7.7%, respectively, as compared to the same period in 2015. 
Currency translation significantly impacted net earnings. On an operational basis, adjusted net earnings per share grew 10.3%. 
Turning now to business segment highlights. Please note percentages quoted represents operational sales change in comparison to the first quarter of 2015 unless otherwise stated and therefore, exclude the currency translation impact. I'll begin with the consumer segment. 
Worldwide Consumer segment sales of $3.2 billion decreased 0.2%, with U.S. sales down 0.1%, while outside the U.S., sales were down 0.3%. Excluding the net impact of acquisitions and divestitures underlying operational sales growth was 1.9% worldwide, 4.1% in the U.S. and 0.5% outside the U.S. 
In addition, the devaluation in Venezuela impacted growth worldwide and outside the U.S. by 200 basis points and 320 basis points, respectively, with the the most significant impact to Women's Health, Oral Care and Baby Care. Growth for the segment was driven primarily by OTC worldwide and Oral Care. OTC sales growth was strong despite a weak flu season. U.S. OTC sales growth was driven by analgesics share growth and an inventory build as well as seasonal and new product launch inventory for upper respiratory products. 
In the U.S., adult analgesic market share was approximately 14%, up from approximately 12% a year ago, while U.S. pediatric share was nearly 46%, up from nearly 43% a year ago. Major contributors to the growth outside the U.S. were the strong performance of analgesics and anti-smoking aids, partially offset by lower sales of upper respiratory products due to the fourth quarter and distributor inventory build, as noted last quarter. 
New product launches and successful marketing campaigns drove the results for LISTERINE in Oral Care. 
Moving now to our Pharmaceutical segment. Worldwide sales of $8.2 billion increased 8.5% with U.S. sales up 12.9% and sales outside the U.S. up 2.6%, driven by both strong sales of new products as well as core growth products. Competitors in hepatitis C significantly impacted sales this quarter. Excluding sales of our hepatitis C products, OLYSIO and INCIVO as well as the impact of acquisitions and divestitures, underlying sales growth worldwide U.S. and outside the U.S. was 12.3%, 16.2% and 7.1%, respectively. 
As we discussed last year, U.S. results in the first quarter of 2015 included a positive adjustment for gross to net, including managed Medicaid rebates. In the first quarter this year, U.S. results including an adjustment for a similar amount and therefore overall growth was not impacted. However, on a product basis, STELARA growth in 2016 was positively impacted by approximately 16 points, XERALTA by 4 points and REMICADE by 3 points. 
Significant contributors to growth for Immunology products, REMICADE, STELARA and SIMPONI/SIMPONI ARIA, Oncology products, IMBRUVICA and recently launched, DARZALEX, as well as cardiovascular metabolic products XARELTO and INVOKANA. The results for Immunology were driven by strong double-digit market growth as well as gross to net to the sales that I mentioned. 
Combined REMICADE export sales and international  sales grew approximately 11%. Sales to distribution partners were up approximately 5%. Sales to our international direct markets were up approximately 17% due primarily to strong double-digit growth in the Western Hemisphere, excluding the U.S., primarily driven by timing of shipments and market growth. 
Strong patient timing uptake with new indications, approvals and demonstrated efficacy drove the results for IMBRUVICA both in the U.S. and outside U.S. In the U.S., IMBRUVICA remains the new patient share and total share leader in second line CLL and MCL. IMBRUVICA is now launched in more than 65 countries. 
DARZALEX was approved in the U.S. in November 2015 and has achieved rapid uptake. DARZALEX contributed over 2% to the U.S. pharmaceutical growth rate. 
XARELTO sales were up 29% and total prescription share or TRx for the quarter in the U.S. anticoagulant market grew to over 16.5%, up over 1.5 points from a year ago. TRx in primary care was nearly 14% and in cardiology, nearly 23.5%, up on a sequential basis by 0.5 points and 0.3 points, respectively. XARELTO is broadly reimbursed with 95% of commercial and Medicare Part D patients covered at the lowest co-pay for a branded product. 
INVOKANA/INVOKAMET sales were up nearly 18% on a worldwide basis and nearly 12% in the U.S. In the U.S., INVOKANA/INVOKAMET TRx within the defined market of type 2 diabetes, including insulin and metformin, was 6.1%, up from 5.1% in the first quarter of 2015. TRx with endocrinologist with 11.5% and 5.5% in the primary care. 
On a sequential basis, sales declined due to the extra shipping days in the fourth quarter, incremental rebates and savings program redemptions as well as increased competition in formulary positions. INVOKANA access remains strong at 80% preferred combined commercial and Part D. 
I'll now reviewed the medical devices segment results. Worldwide Medical Devices segment sales of $6.1 billion increased 0.5%. U.S. sales increased 2.2%, while sales outside the U.S. declined 1%. Cordis was divested in the fourth quarter of 2015. 
Excluding the net impact of acquisitions and divestitures, underlying operational sales growth was 3% worldwide with the U.S. up 3.3% and the growth of 2.8% outside the U.S. 
Growth was driven by Orthopaedics, Advanced Surgery  and Electrophysiology. 
Orthopaedics sales growth was driven by worldwide knees and hips, and U.S. trauma and spine. Market growth and the success of product launches drove results for the U.S. Orthopaedics business. Pricing pressure continued across a major category, partially offset by positive mix for trauma and spine products. The success of the TFNA mailing system in trauma, the [indiscernible] platform in knees, our primary platforms in hips and ORTHOVISC/MONOVISC, a new spine product introductions made important contributions to results. 
Orthopaedics sales outside the U.S. were negatively impacted by results in China due to softer demand and a reduction in inventory. Trauma in spine, other were the categories most impacted. 
In addition, timing of tender business negatively impacted trauma growth for the quarter. 
Strong results were achieved for Advanced Surgery products with endocutters growth of 10%, biosurgical's growth of 8% and energy growth of 8%. 
Electrophysiology grew 19% worldwide due to strong market growth, complemented by new product launches and increase penetration for both ultrasound and diagnostic catheters. 
That concludes the segment highlights for Johnson & Johnson's first quarter of 2016. It is now my pleasure to turn the call over to Dominic Caruso. Dominic?"
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Thanks, Louise, and good morning, everyone. We carried last year's momentum into 2016, and we're off to a strong start this year. We're very pleased with the results generated in the first quarter, and we continue to make very good progress on our near-te",2268,"Thanks, Louise, and good morning, everyone. We carried last year's momentum into 2016, and we're off to a strong start this year. We're very pleased with the results generated in the first quarter, and we continue to make very good progress on our near-term priorities as well as our long-term growth drivers, which we discussed during our January call. We remain confident in the strength of our business. 
As we previously discussed in 2015, our underlying operational sales growth, which excludes the impact of acquisitions, divestitures as well as hepatitis C sales and a few extra shipping days in 2015 was 5.5%. 
On this same basis, we gained momentum in the first quarter with strong underlying operational sales growth of approximately 7% and in line with analysts' estimates. 
In our Pharmaceutical business, our strong performance from 2015 continued into the first quarter with underlying operational growth at over 12%. First quarter underlying operational sales growth for consumer increased approximately 4% when also adjusting for the impact of the devaluation in Venezuela that Louise mentioned earlier. And in Medical Devices, we're off to a good start in the first quarter with underlying operational growth of approximately 3%. Growth in our consumer-facing medical businesses was negatively impacted by challenges in the diabetes market. 
For the hospital-focused medical businesses, we're seeing signs of continued improvement with underlying operational growth in those businesses are approximately 4%, driven by strength in our Orthopaedics, Advanced Surgery and electrophysiology businesses. 
We also saw an improvement in our overall adjusted pretax operating margin. For 2016, our guidance from January included a 200 basis point increase on an adjusted basis, and we remain comfortable with that forecast as we accelerate throughout the year with the restructuring activities in our Medical Device business and lower levels of spending in the back half as compared to the prior year. 
As a reminder, pretax operating margin is defined as gross profit, less selling, marketing administrative and R&D expenses. 
Now I'll take a few minutes to highlight some key developments on the first quarter as well as some key points regarding our results, and then I'll provide some updates to our guidance for you to consider in refining your models for 2016. 
During the quarter, we had several key developments across the business. In our Pharmaceutical business, we received an additional approval for IMBRUVICA for first line treatment for chronic lymphocytic leukemia and also entered in a worldwide collaboration and license agreement with TESARO for exclusive rights in the investigational compound by niraparib in prostate cancer. 
Niraparib is an orally administered poly polymerase or PARP inhibitor. 
We also continued our efforts to combat major global health challenges from collaborations with government organizations and others in the industry with the call for innovative ideas to reduce HIV infections in sub-Saharan Africa as well as providing funding for nonprofit organizations supporting underserved communities in the United States. 
In March 2016, we entered into agreement to sell our control substance raw material and API business. In 2015, these businesses totaled approximately $250 million in net trade sales. 
This divestiture remains subject to customary closing conditions and regulatory approvals but is expected to be completed towards the middle of 2016. 
In Medical Devices, Ethicon completed the acquisition of NeuWave Medical, a probably held medical device company that manufactures in markets minimally invasive soft tissue microwave ablation systems. We look forward to providing an in-depth review of the ongoing efforts of our consumer and medical device businesses at our upcoming business review meeting on May 18, which will take place in New Brunswick, New Jersey. 
I will now turn to our consolidated statement of earnings for the first quarter of 2016. As we've mentioned, our operational sales growth this quarter was 3.9% and excluding the impact of acquisitions and divestiture and hep C sales, it was a strong 6.9%. If you'll direct your attention to the boxed section of the schedule, you will see we have provided our earnings adjusted to exclude intangible amortization and special items. 
As referenced in the table of non-GAAP measures, the 2016 first quarter net earnings were adjusted to exclude intangible asset amortization expense and special items of approximately $400 million on an after-tax basis, which consisted primarily of the following: Intangible asset amortization of $200 million and litigation charges and our Medical Devices restructuring charge. 
Our adjusted earnings per share is therefore $1.68 per share, exceeding the mean of the analyst estimates as published by first call. This is an increase in adjusted EPS of 7.7% versus the prior year.  Adjusted EPS on a constant currency basis was $1.72, up 10% over the prior year. 
Now let's take a few moments to talk about the other items in the statement of earnings. Cost of goods sold increased with an basis points mostly due to transactional currency, partially offset by a favorable mix in the business. Selling, marketing, administrative expenses were 26.8% of sales or 110 basis points lower as compared to the first quarter of 2015 due to continued good cost management. 
Our investment in research and development as a percent of sales was 11.5% higher than the prior year due to increased project spending as we advance our promising product pipelines. 
Our pretax operating margin when excluding special items and intangible amortization expense was 32.9%, 30 basis points higher than the first quarter of the prior year. Interest expense net of interest income was lower than last year due to slightly better rates on our investments. Other income and expense was a net gain of $39 million in the quarter compared to a net gain of $348 million in the same period last year. 
Excluding special items that are reflected in this line item, other income and expense was a net gain of $127 million compared to a net gain of $91 million in the prior year period. 
Excluding special items, the effective tax rate was 19.2% compared to 21.5% in the same period last year. This year's effective rate reflects the R&D tax credit, which was passed by Congress late last year and the current mix of our business. 
Turning to the next slide. I will now review adjusted income before tax by segment. 
On our 2015 year-end call, we commented on our segment results for adjusted income before tax versus the prior year. Now that all of our competitors have reported their results for 2015, I would like to take the opportunity to point out that our 2015 adjusted income before tax was 31.4% compared to 26.2% weighted average for our competitive set. This was driven by higher margins in both pharmaceutical and medical devices and somewhat lower margins in our consumer business as compared to our competitive set. 
In the first quarter of 2016, our adjusted income before tax for the enterprise improved 80 basis points versus the first quarter of 2015, driven by improvement in both our pharmaceutical and medical device businesses. Our consumer business had a lower-margin this year as compared to last year due principally to the devaluation in Venezuela. We are confident that our consumer business will show when improved adjusted income before tax margin for full year 2016 as compared to 2015. 
Now I will provide some guidance for you to consider as you refine your models for 2016. At the end of the quarter, we had approximately $17 billion of net cash, which consist of approximately $40 billion of cash and marketable securities and approximately $23 billion of debt. 
As you know, in February, we took the opportunity to finance our share repurchase program and upcoming debt maturities at very attractive interest rates with a debt issuance of $7.5 billion. Through the end of the first quarter, we completed approximately 25% of our $10 billion share repurchase program, and we expect to complete 75% of the program by the end of this year. 
For purposes of your models and assuming no major acquisitions or other major uses of cash, I suggest you consider modeling net interest expense of a between $450 million and $550 million. This is unchanged from our prior guidance. 
Regarding other income and expense as a reminder, as the account where we record royalty income as well as gains and losses arising from such items as litigation, investments prior development corporation, divestiture, asset sales and write-offs. We'll be comfortable with your models for 2016 reflecting net other income and expense, excluding special items as a net gain ranging from approximately $1.1 billion to $1.2 billion, and this is also unchanged versus our January guidance. 
And now a word on taxes. Our guidance for 2016 includes the R&D tax credit that Congress made permanent in 2015. We are, therefore, comfortable with your models reflecting an effective tax rate for 2016, excluding special items of approximately 19% to 20%, lower by 50 basis points in our previous guidance due to updating our outlook for a higher mix of our earnings from lower tax jurisdictions in 2016  than we anticipated in our previous guidance. 
And now turning to sales and earnings. While share and guidance for 2016 takes into account several assumptions and key factors that I would like to highlight. As a reminder, our sales guidance for 2016 assumes no biosimilar entrants for PROCRIT or REMICADE in the U.S. and our assumption with regard to REMICADE biosimilar remains unchanged even with the recent FDA approval of Inflectra due to our intellectual property, which we intend to defend. 
We also do not anticipate generic competition this year from ZYTIGA, Respo and INVEGA SUSTENNA, but as expected there are generic entrants for INVEGA and [indiscernible]. 
As we've done for several years, our guidance will be based first on a constant currency basis reflecting our results from operations. This is the way we manage our business, and we believe this provides a very good understanding of the underlying performance of our business. 
We also provide an estimate of our sales and EPS results for 2016 with the impact that current exchange rates could have on the translation of those results. 
Consistent with our previous guidance, we'll be comfortable with your models reflecting an operational sales increase on a constant currency basis of between 2.5% and 3.5% for the year. This would result in sales for 2016 on a constant currency basis of approximately $71.9 billion to $72.6 billion. 
Additionally, by way of comparison to how we described our sales results in 2015, our operational sales growth for 2016, excluding the impact of all acquisitions and divestiture and hepatitis C sales would be approximately 5.5%, a level of growth comparable last year after adjusting for the extra shipping days in 2015, which we mentioned earlier. 
The devaluation in Venezuela that we previously discussed is anticipated to be a headwind of approximately 30 basis points for the full year, which we anticipate will be offset by the strength of the business. 
Although we're not predicting the impact of currency movements, using the euro as of last week at $1.13, the negative impact of foreign currency translation will be approximately 1%. This is an improvement of 50 basis points since we last provided guidance. We're watching the euro and other currencies closely as it is uncertain how they will eventually settle after the year. 
Plus under this scenario, we would expect reported sales to reflect the change in the range of 1.5% to 2.5% for a total expect level of reported sales of approximately $71.2 billion to $71.9 billion, higher than our previous guidance. 
Now turning to earnings. As a reminder, we expect transaction currency impacts to bit negative to our gross margin by approximately 60 to 80 basis points in 2016 as compared to 2015. We would be comfortable with adjusted EPS guidance in a range between $6.56 to $6.71 per share on a constant currency basis, reflecting an operational or constant currency growth rate of 6% to 8%. This is higher than our previous guidance. 
If currency exchange rates for all of 2016 were to remain where they were as of last week, then our reported adjusted EPS will be negatively impacted by approximately $0.03 per share due to currency movements, a better outlook than the approximate $0.10 negative impact we discussed in our January guidance. Therefore, we will be comfortable with our reported adjusted EPS ranging from $6.53 to $6.68 per share, which is an increase from our previous guidance due to an update to our tax rate and current currency estimates. As it's still early in the year, we will be comfortable with your models reflecting the midpoint of this range. 
In closing, we're very pleased with our strong start for the year, and we are optimistic with what we see ahead for the full year, namely we're expecting operational sales growth of 2.5% to 3.5% and underlying operational sales growth of 5.5% consistent with '15 -- 2015 growth on a comparable basis. 
Our operating margins are on tract to meet the expectations we laid out in our guidance of more than 200 basis point improvement over the prior year. Our operational adjusted EPS growth and guidance remains strong in the range of 6% to 8% and our businesses are continuing to invest, while also delivering on our growth expectations. 
In particular, we're pleased to see our medical device businesses showing continued signs of improvement and our restructuring activities in that business are on track. And we look forward to discussing with you in more detail these activities on our May 18 Investor Day. 
Now I'd like to turn things back to Louise for the Q&A portion of the call. Louise?"
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Dominic. And Manny, could you please give the instructions for the Q&A session?",15,"Thank you, Dominic. And Manny, could you please give the instructions for the Q&A session?"
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","[Operator Instructions] Our first question is from David Lewis of Morgan Stanley.",12,"[Operator Instructions] Our first question is from David Lewis of Morgan Stanley."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","I want to start with the strategic question for Dominic and then one follow up. Dominic, the long-standing view of J&J has been sort of defensiveness of having these 3 major franchises under the J&J family of companies. Does that still remain the prevaili",58,"I want to start with the strategic question for Dominic and then one follow up. Dominic, the long-standing view of J&J has been sort of defensiveness of having these 3 major franchises under the J&J family of companies. Does that still remain the prevailing view of management and the Board? And then I have a quick follow up."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, David. It's our view, both management and the Board that are broadly based business is the right approach to have in health care certainly will serve us well, and we expect it will continue to serve as well as health care industry evolves in the futu",82,"Yes, David. It's our view, both management and the Board that are broadly based business is the right approach to have in health care certainly will serve us well, and we expect it will continue to serve as well as health care industry evolves in the future. We think of ourselves as a health care company and, of course, that allows us to access opportunities and health care no matter where they be either in pharma, Medical Devices or in consumer health."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay, that's very helpful. And then the second question may be for Louise our Dominic. Just REMICADE, gross to net dynamics in the quarter. Any more detail you can sort of provide us on that, any sense of what you expecting sort of net pricing gains to be",55,"Okay, that's very helpful. And then the second question may be for Louise our Dominic. Just REMICADE, gross to net dynamics in the quarter. Any more detail you can sort of provide us on that, any sense of what you expecting sort of net pricing gains to be for REMICADE in the U.S. for 2016?"
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","So as we discussed, we had the prior year growth to net that you saw, contributed -- I think it was 3% to the REMICADE growth. And pricing dynamics continue to be okay in that market.",36,"So as we discussed, we had the prior year growth to net that you saw, contributed -- I think it was 3% to the REMICADE growth. And pricing dynamics continue to be okay in that market."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","So I don't  think it's expected that REMICADE sales will be significantly impacted year-over-year by growth to net adjustments.",20,"So I don't  think it's expected that REMICADE sales will be significantly impacted year-over-year by growth to net adjustments."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Josh Jennings of Cowen and Company.",11,"The next question is from Josh Jennings of Cowen and Company."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","I know you had some public comments, Dominic, recently around the REMICADE franchise. But now we have the panel and the FDA approval in the review. When do you clearly don't expect any biosimilar competition in 2016 due to your events of IP. But any updat",62,"I know you had some public comments, Dominic, recently around the REMICADE franchise. But now we have the panel and the FDA approval in the review. When do you clearly don't expect any biosimilar competition in 2016 due to your events of IP. But any updated thoughts on the potential impact of biosimilar competition to the REMICADE franchise in 2017 and beyond?"
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Well, you're right, Josh. We don't expect biosimilar competition in 2016. And as you know, we have several patents that we intend to defend. And for example, the U.S. patent, the 471 patent extends to 2018 and another patent that we have extends to 2027.",133,"Well, you're right, Josh. We don't expect biosimilar competition in 2016. And as you know, we have several patents that we intend to defend. And for example, the U.S. patent, the 471 patent extends to 2018 and another patent that we have extends to 2027. Having said that, I think, overall, the Immunology franchise of Johnson & Johnson is very strong because it's not just about REMICADE, of course, we have STELARA, SIMPONI, et cetera, and the overall pipeline in the Pharmaceutical business as you know from our review last May is very, very robust with 10 new products being filed, each of which having more than $1 billion potential. So overall, we remain very, very comfortable with the growth outlook for the Pharmaceutical business regardless of the outcome of any REMICADE biosimilar."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","And I just want to follow up on the question in the operating margin guidance. Maintaining a 200 basis points, I was just curious about the Venezuelan crisis impact. It looks like it was primarily hit the consumer units operating margins. But can you talk",121,"And I just want to follow up on the question in the operating margin guidance. Maintaining a 200 basis points, I was just curious about the Venezuelan crisis impact. It looks like it was primarily hit the consumer units operating margins. But can you talk about the expectations of Venezuela's impact on your operating margin guidance at the beginning of the year, how your internal expectations of evolved clearly with maintaining that guidance. The performance of the rest of the business units are going to offset any direct impact from Venezuela? But just wanted to hear about -- any offsets there and the impact operating margin performance of the consumer unit and can consumer still expense operating margin expansion in 2016?"
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, sure, Josh. Well, just to put things in perspective, Venezuela is no less than 1% of our sales, less than 0.5% of our sales, and so it's not a very significant impact. It's more significant in consumer than in the other businesses. But we're very con",99,"Yes, sure, Josh. Well, just to put things in perspective, Venezuela is no less than 1% of our sales, less than 0.5% of our sales, and so it's not a very significant impact. It's more significant in consumer than in the other businesses. But we're very confident in our outlook for 200 basis point improvement in operating margin expansion, pretax operating margin expansion for 2016, and that will be across all the businesses, including consumer who will make a significant contribution to that even despite the impacts of Venezuela. So we're very confident with that outlook for the year."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Mike Weinstein of JPMorgan.",9,"The next question is from Mike Weinstein of JPMorgan."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","The Immunology franchise, REMICADE, STELARA all had much better growth than what the scripts was suggested. Outside of the gross to net, was there and inventory catch-up this quarter that might have impacted these products?",35,"The Immunology franchise, REMICADE, STELARA all had much better growth than what the scripts was suggested. Outside of the gross to net, was there and inventory catch-up this quarter that might have impacted these products?"
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","So in the U.S. not insignificant and inventory. That market grows strong, strong double-digit and that has a good contributor to the Immunology. STELARA continues to grow market share SIMPONI ARIA is contributing to the results but in the U.S., no signifi",45,"So in the U.S. not insignificant and inventory. That market grows strong, strong double-digit and that has a good contributor to the Immunology. STELARA continues to grow market share SIMPONI ARIA is contributing to the results but in the U.S., no significant inventory build."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. Can we talk about DARZALEX those. DARZALEX is very, very strong for the first quarter [indiscernible] out of the box here. Can you just talk about the uptake in multiple myeloma and how you see it playing out on the back of the relapsed refractory d",47,"Okay. Can we talk about DARZALEX those. DARZALEX is very, very strong for the first quarter [indiscernible] out of the box here. Can you just talk about the uptake in multiple myeloma and how you see it playing out on the back of the relapsed refractory data?"
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, Mike, we've obviously very pleased with the early uptake of DARZALEX and as we said it contributed 2 points of growth of our U.S. pharma business so it's off to a great start. The CD38 mechanism of actions need to be something that KOLs really respec",73,"Yes, Mike, we've obviously very pleased with the early uptake of DARZALEX and as we said it contributed 2 points of growth of our U.S. pharma business so it's off to a great start. The CD38 mechanism of actions need to be something that KOLs really respect us as having a significant impact on the disease, and we think the product can do extremely well, and we'll see continued update throughout the year."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","And also, we have the Castor trial, which we actually that IDMC has recommended to stop early so that's a very positive sign as well.",25,"And also, we have the Castor trial, which we actually that IDMC has recommended to stop early so that's a very positive sign as well."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Dominic, one quick finance question for you. The tax rate having down is -- a little bit counter to the performance of the business because your growth in the U.S. has been so strong, particularly in the Pharmaceutical business. SO what we optically is ve",97,"Dominic, one quick finance question for you. The tax rate having down is -- a little bit counter to the performance of the business because your growth in the U.S. has been so strong, particularly in the Pharmaceutical business. SO what we optically is very strong in the U.S. revenue growth, we assume U.S. profit growth. But obviously, the manufacturing of IP and some of those products is outside the U.S. Can you just shed a little bit of like there on how you're managing that because the U.S. business relative to o-U.S. business looks very different."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, Mike. It's an excellent observation. Actually, the strength of the sales in any one particular region was not necessarily correlate with the strength of the earnings in that region. And it's for that very reason that you mentioned, which is where the",104,"Yes, Mike. It's an excellent observation. Actually, the strength of the sales in any one particular region was not necessarily correlate with the strength of the earnings in that region. And it's for that very reason that you mentioned, which is where the IP is located, where the manufacturing takes place, et cetera. So what we did is we just updated our outlook with how the profits will fall amongst the different regions and different jurisdictions. And we thought about 0.5 points improvement and overall tax rate would be achievable this year for the full year and therefore, we adjusted that in our outlook."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Kristen Stewart of Deutsche Bank.",10,"The next question is from Kristen Stewart of Deutsche Bank."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","I was just wondering if you could comment a little bit more about the diabetes business. I think Dominic you had mentioned there's challenges in the market. I was just wondering if you could comment about INVOKANA and the additional competition that's in",54,"I was just wondering if you could comment a little bit more about the diabetes business. I think Dominic you had mentioned there's challenges in the market. I was just wondering if you could comment about INVOKANA and the additional competition that's in the market or just provide a little bit more commentary there."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Sure. Well, just to clarify what I said, was talking about challenges in the market with respect to our medical -- consumer medical device diabetes business, the LifeScan business. What I meant by that was we see continued pricing pressure in that market,",113,"Sure. Well, just to clarify what I said, was talking about challenges in the market with respect to our medical -- consumer medical device diabetes business, the LifeScan business. What I meant by that was we see continued pricing pressure in that market, and we also see some competition with respect to new pumps being launched. We've just launched a new pump obviously so we're also seeing good uptake with our current path. So the dynamics I'm been talking about are in the medical device piece of the business as being challenges. Overall, INVOKANA continues to do well, its uptake is strong quarter-over-quarter and a remains a growth driver for us going forward."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. And then, I guess, just more broadly, what are you seeing -- can you just go back and address kind of China? I know that was something that you have brought out in terms of fulfilling a little bit of softness, I think you had mentioned more within t",64,"Okay. And then, I guess, just more broadly, what are you seeing -- can you just go back and address kind of China? I know that was something that you have brought out in terms of fulfilling a little bit of softness, I think you had mentioned more within the medical device segment. Any changes there? Is it getting worse or getting any better?"
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Sure. Well, China, again, just to put it in perspective, it's about 5% overall business and a slowdown in the economy actually last year is what caused some distributor inventory to be at relatively high levels. That distributor inventory is beginning to",79,"Sure. Well, China, again, just to put it in perspective, it's about 5% overall business and a slowdown in the economy actually last year is what caused some distributor inventory to be at relatively high levels. That distributor inventory is beginning to bleed off. We saw that in the first quarter, and we think that, that bleed off will be completed shortly, so we don't  expect to see a continued impact of that for the rest of the year."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Jami Rubin of Goldman Sachs.",10,"The next question is from Jami Rubin of Goldman Sachs."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","I have a few questions. Just back to Kristen's question on diabetes. Just INVOKANA is an important growth driver for the company, but sales did come in a bit lighted than we had anticipated despite I think the growing excitement about this class of drugs.",181,"I have a few questions. Just back to Kristen's question on diabetes. Just INVOKANA is an important growth driver for the company, but sales did come in a bit lighted than we had anticipated despite I think the growing excitement about this class of drugs. Dominic, can you comment generally on what drug categories you are seeing widening gross to net discounts? And are you seeing more gross to net discounts or widening discounts, specifically in diabetes? And can you comment on where you might be seeing that elsewhere in the pharma business? My second question is on the OTC business. You've clearly highlighted the strong growth that you've seeing in the U.S. and particularly, the analgesics market. How much of that growth is just regaining back lost market share from private label when you were out of the market? And how much of that is market growth? And maybe you can comment just generally on the dynamics of the OTC marketplace, where you see store brand market share now. And I have one more follow up, one more follow up."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Okay, let's take them in order. And Louise, you could add actual, obviously, if I've left anything out. I wouldn't say, Jami, that this one any particular area in the business where we see sort of a widening of gross to net or rebating that's any differen",155,"Okay, let's take them in order. And Louise, you could add actual, obviously, if I've left anything out. I wouldn't say, Jami, that this one any particular area in the business where we see sort of a widening of gross to net or rebating that's any different than what we've seen before in the business. So I won't comment on any one particular area. I would say generally speaking, there's nothing that sticks out as a widening trend. With respect to U.S. OTC, a couple of things to mention. We are gaining back share and the products are doing very, very well. And this particular quarter was a relatively low growth market quarter because of a very, very soft flu season. Very, very soft flu season. So most of the growth that we saw is not on the back of market expansion, but on the back of share expansion as we continue to regain share."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Are you aware where you want to be in terms of regaining back that lost share? And what is the realistic goal? You're out of the market completely? Where are you now?",32,"Are you aware where you want to be in terms of regaining back that lost share? And what is the realistic goal? You're out of the market completely? Where are you now?"
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. So we're not where we want to be. We're pleased. As Alex often says, we're pleased, we're not satisfied. So we're going to continue to gain there. And Louise, do you have the year-over-year comparison of share?",38,"Yes. So we're not where we want to be. We're pleased. As Alex often says, we're pleased, we're not satisfied. So we're going to continue to gain there. And Louise, do you have the year-over-year comparison of share?"
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. So in 2009, before the Jami issues that we had, the adult share is about 25%, and we're back to 14%. Pediatric was about 70%, and we're now back to 46% so you're seeing some nice growth on that. And if you take a look at year-over-year, the adult sha",81,"Yes. So in 2009, before the Jami issues that we had, the adult share is about 25%, and we're back to 14%. Pediatric was about 70%, and we're now back to 46% so you're seeing some nice growth on that. And if you take a look at year-over-year, the adult share a year ago was 43%, so you see it going up about 3 points and then the pediatric share, it's also going up to the 46%. So we're making progress."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","So we're making progress, Jami, but we're not finished. We think these products of a long products and long legacy. They are very, very important and overall health period quite frankly, they are admired by consumers. So we expect to see continued share g",45,"So we're making progress, Jami, but we're not finished. We think these products of a long products and long legacy. They are very, very important and overall health period quite frankly, they are admired by consumers. So we expect to see continued share growth."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. And it's 14% U.S. share now, and it was 12%. And you asked about the private label. We think in the U.S. market, the adult is about 1/3 and in the pediatric is about 40.",36,"Yes. And it's 14% U.S. share now, and it was 12%. And you asked about the private label. We think in the U.S. market, the adult is about 1/3 and in the pediatric is about 40."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","And can I follow up, Dominic? I'm actually shocked with the fixed question that hasn't come up yet. Your net cash position is now $17 billion. That keeps growing. I don't think any company that I cover or anybody else covers has that kind of balance sheet",186,"And can I follow up, Dominic? I'm actually shocked with the fixed question that hasn't come up yet. Your net cash position is now $17 billion. That keeps growing. I don't think any company that I cover or anybody else covers has that kind of balance sheet provost that you have, the lack of debt on your balance sheet. And I think it was, I think what was it back in September at the investor conference you have mentioned that you were -- I'm comfortable with the amount of cash you had growing on the balance sheet and now year we are 6, 7 months later and don't really see any activity with respect to putting that cash to work, with the exception of a buyback that you announced earlier this year. Can you just give us an update on your thoughts on capital allocation? And clearly, we had a lot of disruption in the marketplace with valuations on many names coming back. And I'm just surprised that we haven't really seen much action on the part of capital allocation from J&J. And then I'm done."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Okay, all right. Well, just to clarify, back in September, I didn't really say I was uncomfortable with the level of cash. I just said that it was a higher level of cash that we normally hold. And then of course, after that, we announced a $10 billion sha",186,"Okay, all right. Well, just to clarify, back in September, I didn't really say I was uncomfortable with the level of cash. I just said that it was a higher level of cash that we normally hold. And then of course, after that, we announced a $10 billion share buyback. So we're very conscious of the fact that, while we're evaluating M&A opportunities, we can continue to return capital to shareholders, which in addition to our very, very strong dividend, we can do share buybacks. We're in the middle of doing one right now, and we'll obviously evaluate whether we can continue to increase that particular share buyback as time goes on. With respect to not allocating capital to any particular deals, I could tell you that we're very active. But as you know, we're also very disciplined. We do see opportunities, but we want to do the right deal at the right time with the right part the at the right valuation. And we we're comfortable waiting for that to take place because we think that's what we're ultimately generates the most value for shareholders."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","But is that what you plan to do with your cash M&A Dominic? Is that what the message is today?",21,"But is that what you plan to do with your cash M&A Dominic? Is that what the message is today?"
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Well, the message is very consistent what it has always been. Our first priority is allocating capital dividends. So we'll announce what we're going to do with dividends at our April 28 shareholder meeting. After that, we'd like to grow the business and c",100,"Well, the message is very consistent what it has always been. Our first priority is allocating capital dividends. So we'll announce what we're going to do with dividends at our April 28 shareholder meeting. After that, we'd like to grow the business and create value for shareholders through M&A and in addition to that, we'll continue to return capital to shareholders through share purchases -- repurchase. So that really changed. So our attitude, our capital allocation policy does not change depending on how much capital we have. It's all about creating the most value for shareholders whatever capital we deploy."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Glenn Novarro of RBC Capital Markets.",11,"The next question is from Glenn Novarro of RBC Capital Markets."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Just 2 questions. Let me versus piggyback on what Jami just asked because I think we're all surprised that J&J hasn't done more with the balance sheet so far. And I'm just wondering, Dominic, as you're having these discussions, it appears that some of the",123,"Just 2 questions. Let me versus piggyback on what Jami just asked because I think we're all surprised that J&J hasn't done more with the balance sheet so far. And I'm just wondering, Dominic, as you're having these discussions, it appears that some of the targets you may be having discussions with have unrealistic valuation expectations. So maybe talk about where valuation expectations have come. Are they getting at least in the ballpark of what J&J thinks is appropriate valuation? And then with Allergan and Pfizer no longer getting together, you have 2 more companies that are going to be actively looking at deals. And does that make the competitive landscape more challenging for J&J? And then I had a follow-up on devices."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Glenn. Well, in certain areas of the market, valuations are still high. They're coming down, as you know, in biotech, in particular, but certain other areas, in med device, for example, certain valuations are still inflated, in our opinion. Things w",161,"Sure, Glenn. Well, in certain areas of the market, valuations are still high. They're coming down, as you know, in biotech, in particular, but certain other areas, in med device, for example, certain valuations are still inflated, in our opinion. Things will get better as time goes on, we believe, we're patient, disciplined and then I said earlier, we look for the right opportunity but at the right time, the right valuation. With respect to Allergan and Pfizer, maybe being in the market now and creating more competition. That's probably true. I can't speak for what they're going to do, but we's are accustomed to looking at various acquisition candidates where more than one party may be interested in a particular asset. That does not to sway us from being disciplined and have a clear focus on ultimately what matters, which is the deployment of that capital to create shareholder value. Yes, we'll lead more competition, we'll still remain very disciplined."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. And then just follow up on the device business. When you ex out divestitures and currency, the device business grew 3% in the first quarter That's pretty much in line with most of the device categories that we cover. But I don't think J&J had any ma",98,"Okay. And then just follow up on the device business. When you ex out divestitures and currency, the device business grew 3% in the first quarter That's pretty much in line with most of the device categories that we cover. But I don't think J&J had any major new product launches here recently. So is the improvement in the device business for J&J, is that just better execution and better blocking and tackling? Or did some of the major end markets in cardio and ortho and spine in the first quarter come in slightly better than you expected?"
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. Just to clarify, 3% overall is the Medical Device business ex acquisition, divestiture, but the hospital-based Medical Device business, excluding the consumer-facing medical businesses, that's 4% on a comparable basis. We did have a number of product",150,"Yes. Just to clarify, 3% overall is the Medical Device business ex acquisition, divestiture, but the hospital-based Medical Device business, excluding the consumer-facing medical businesses, that's 4% on a comparable basis. We did have a number of products that we filed last year, and we have about 30 new products that we're launching have of those have already been launched, so we are seeing the impact of those. But I think it's also a matter of focus, focus on our primary growth drivers, for example, use a very good results in energy, in endocutters, in electrophysiologist as major drivers of growth and also, we're very pleased with the results in orthopedics and the ATTUNE knee, for example, in the U.S. in particular, the U.S. growth was over 8% for knees, which is pretty fantastic growth in the ATTUNE knees that's still a new product that's being launched in that marketplace."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","But as you talked to the division head, is everything as the status quo, no change, no stable? Or is there any pickup in some of these end markets?",29,"But as you talked to the division head, is everything as the status quo, no change, no stable? Or is there any pickup in some of these end markets?"
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","I think from what we've seen back in the fourth quarter trends because we don't have all the first quarter trends continued improvement I n procedural growth, but not dramatic, Glenn, just to continued steady improvement in procedural growth. Anything els",43,"I think from what we've seen back in the fourth quarter trends because we don't have all the first quarter trends continued improvement I n procedural growth, but not dramatic, Glenn, just to continued steady improvement in procedural growth. Anything else, Louise?"
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","So our estimate of the first quarter hip market is about 3.5% in the U.S, again, qualified, but we haven't seen all the competitor's report. We think the U.S. knee market grew about 4.5%, and we believe be grew faster than those markets. Now we did have a",78,"So our estimate of the first quarter hip market is about 3.5% in the U.S, again, qualified, but we haven't seen all the competitor's report. We think the U.S. knee market grew about 4.5%, and we believe be grew faster than those markets. Now we did have about 1.5 extra selling days, but even if you take that out of there, we do believe we grew faster than the market in hips and knees in the U.S."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Vamil Divan of Crdit Suisse.",10,"The next question is from Vamil Divan of Crdit Suisse."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","So just a couple following up on some of the topics that's been raised already. So one, recently you're getting a lot of questions around your desire on the consumers site to maybe do business development and I know you talked generally about M&A, but may",161,"So just a couple following up on some of the topics that's been raised already. So one, recently you're getting a lot of questions around your desire on the consumers site to maybe do business development and I know you talked generally about M&A, but maybe if you could just provide a little more color on the consumer side, specifically in areas where you're looking to boost it? Is there a preference you can try? In the past, you talked to an emerging market, but I was wondering if there are any more time you can share today on that. And then the second question relates back to the INVOKANA discussion before it was announced last week that the M&A is looking into an increase in sort of has been seen in the canvas study. I'm curious if you have any comments on that at this point. And also if the FDA is also looking into it at this point?"
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Vamil. So on M&A, just in general, we're looking at M&A as an important additional growth driver in all of our businesses, including consumer. As we've said before, consumer can generally benefit from taking very, very specific plans with certain re",227,"Sure, Vamil. So on M&A, just in general, we're looking at M&A as an important additional growth driver in all of our businesses, including consumer. As we've said before, consumer can generally benefit from taking very, very specific plans with certain regional categories. We're certainly in our sweet spot of Skin Care, Baby, Oral Care, et cetera, where we think we could do better with the combination of the technology that we have and the overall market and distribution presence that we have. So we'll continue to look there. And again, like every other M&A evaluation, we'll make sure that it's the right valuation at the right time. With respect to INVOKANA, a couple of things that are mentioned there. There's been previous to this canvas study, there's been 12 previous studies with INVOKANA where we saw no such indications of increased in lower amputations, particularly the toe, so this seems to be focused only on the patients in the canvas study. It's important to note that, yes, the European regulatory body is taking a look at it, but already the independent monitoring committee that reviews the clinical trial after reviewing all the data concluded that the trial should continue. So that's what I can tell you about that. And obviously, we'll look to advise physicians appropriately of the results once we have more understanding of them."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Geoff Meacham of Barclays.",9,"The next question is from Geoff Meacham of Barclays."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Just a couple on the pharma segment. You guys have a new product cycle obviously coming up with guselkumab, sirukumab, I guess, when you think about this on the context of the pricing environment, especially with Inflectra down the road, how do you guys t",66,"Just a couple on the pharma segment. You guys have a new product cycle obviously coming up with guselkumab, sirukumab, I guess, when you think about this on the context of the pricing environment, especially with Inflectra down the road, how do you guys think about durability of pricing and innovation -- or sorry -- in the Immunology segment? I have one follow up for pharma."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, sure. Both guselkumab and sirukumab are different mechanisms of actions in the current products that we have in Immunology. And typically, innovative products that have a significant impact on unmet medical need. In this case, it would be those patie",178,"Yes, sure. Both guselkumab and sirukumab are different mechanisms of actions in the current products that we have in Immunology. And typically, innovative products that have a significant impact on unmet medical need. In this case, it would be those patients that are not otherwise responding to, for example, TNF therapy. Our view is that pricing will still continue to be -- either the products will still continue to be valued and therefore, not have a lot of pressure on pricing because there is some still significant unmet medical needs, and that's a new mechanism of action that should have an impact on patients. I think that, that's irrespective of whether or not there's a biosimilar in the market with respect to REMICADE because overall, pricing for Immunology products particularly in the TNF category are already have pretty significant, close to net discounts in the marketplace that we have talked before about that ours are already in the 25% range. So I don't think there's that much room for them to be significantly lower pricing in that market."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Got you. And then just as a follow up on the other questions on M&A. The TESARO agreement with the PARP clearly has lot of excitement with this class. I guess, the question is the focus on prostate strategic, or is it data-driven? I just want to get your",71,"Got you. And then just as a follow up on the other questions on M&A. The TESARO agreement with the PARP clearly has lot of excitement with this class. I guess, the question is the focus on prostate strategic, or is it data-driven? I just want to get your sense, Dominic, for maybe other indications that you could have some enthusiasm for, 4 PARP such as ovarian, breast cancer, et cetera?"
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Right. While our agreement with respect to this PARP inhibitor was the result of our oncology therapeutic area taking a look at where PARP can have an added benefit. Our first approach to this is going to be with prostate cancer in conjunction with our de",64,"Right. While our agreement with respect to this PARP inhibitor was the result of our oncology therapeutic area taking a look at where PARP can have an added benefit. Our first approach to this is going to be with prostate cancer in conjunction with our development of ARN 509 in prostate cancer. So that particular focus at the moment is on prostate cancer, Geoff."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Damien Conover of Morningstar.",9,"The next question is from Damien Conover of Morningstar."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Just a question on the nerve growth factor, just continuation. Looks like there's prioritization within the pipeline to discontinue that. Just had a question what projects you might be accelerating? Also given that those Phase III studies are coming up sh",96,"Just a question on the nerve growth factor, just continuation. Looks like there's prioritization within the pipeline to discontinue that. Just had a question what projects you might be accelerating? Also given that those Phase III studies are coming up shortly. Just kind of what to understand that a little bit more. Also with the hepatitis C products there. You got some coat product. Wanted to see what the next steps were for bringing those to the market, the timeline. And then lastly, just on REMICADE. Has J&J received 180-day notice of a launch from Pfizer?"
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","All right. Let me take them in the order you gave them and Louise can help here as well. So with respect to that launch -- take the hepatitis C question.",31,"All right. Let me take them in the order you gave them and Louise can help here as well. So with respect to that launch -- take the hepatitis C question."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Okay. So we expected to see Phase II date of our AL-335 and the 3 direct acting inhibitors in 2016.",20,"Okay. So we expected to see Phase II date of our AL-335 and the 3 direct acting inhibitors in 2016."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Right. And also, with respect to your question on the 180-day notice period, yes, we have received that from [indiscernible]. And with respect to the growth factor discontinuance, what you said was exactly right. This is a portfolio question. As we mentio",95,"Right. And also, with respect to your question on the 180-day notice period, yes, we have received that from [indiscernible]. And with respect to the growth factor discontinuance, what you said was exactly right. This is a portfolio question. As we mentioned, we have 19 -- sorry, we have 10 new products that we're planning to file between now and 2019. Obviously, we're going to focus on this. They all have more than $1 billion potential, so we make portfolio decisions all the time and this is just another one of those types of decisions."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Matt Miksic of UBS.",9,"The next question is from Matt Miksic of UBS."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","This is Vik in for Matt. I have 2 questions. Now that the bundle system is in effect for hips and knees. Can you talk a little bit about your approach to customers and what you can expect to help there? And the second question I have is an update on the p",68,"This is Vik in for Matt. I have 2 questions. Now that the bundle system is in effect for hips and knees. Can you talk a little bit about your approach to customers and what you can expect to help there? And the second question I have is an update on the payer environment in spine. Any meaningful changes that you guys have seen in support amongst payers?"
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Well generally speaking, on the bundling approach, which is now certain markets, but not across all markets in the U.S, we do think they were positioned very well there. Because obviously we have a very broad portfolio of products so the bundling approach",123,"Well generally speaking, on the bundling approach, which is now certain markets, but not across all markets in the U.S, we do think they were positioned very well there. Because obviously we have a very broad portfolio of products so the bundling approach where the hospital for the degree of the care network would include multiple Johnson & Johnson products, which we think we're in a great position to partner with in that regard. The payer economics in spine, we haven't seen much of a dramatic change there. One thing I'd like to point out this we did see a growth in our spine business this quarter, of about 2% so we're very pleased with that business coming back and showing some improvement."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Larry Biegelsen of Wells Fargo.",10,"The next question is from Larry Biegelsen of Wells Fargo."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","So Dominic, on the call today, you guided organic sales growth in 2016 about the same as in 2015, which was 5.5%, excluding the benefit from extra selling days. However, if we compare 2016 and 2015 organic growth on the same 52-week basis, we estimate tha",88,"So Dominic, on the call today, you guided organic sales growth in 2016 about the same as in 2015, which was 5.5%, excluding the benefit from extra selling days. However, if we compare 2016 and 2015 organic growth on the same 52-week basis, we estimate that your 2016 organic growth should be closer to 6% to 6.5%. In other words, the 5.5% in 2016 doesn't adjust for the extra selling days in 2015. Is that -- is our math directionally right, Dominic? And I had one follow up."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, I think you're directionally right. I think you're right that without the -- if you just neutralize, I guess, is what you did, extra selling days, you would see growth better than 5.5%, right.",35,"Yes, I think you're directionally right. I think you're right that without the -- if you just neutralize, I guess, is what you did, extra selling days, you would see growth better than 5.5%, right."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay, just wanted to confirm that. And then lastly, last week you just announced that you discontinued time you in your basic on business. Can you talk about the rationale there and what this signals regarding any change in your strategy and how you're  r",94,"Okay, just wanted to confirm that. And then lastly, last week you just announced that you discontinued time you in your basic on business. Can you talk about the rationale there and what this signals regarding any change in your strategy and how you're  running your contact lens business. If I recall 2 years ago when you implemented you PPF it was disruptive to your U.S. business. So why should we not assume or be concerned that you might have similar types of distractions discontinuing UPP and moving to a different pricing model now?"
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Larry. Thanks for the question. Just on the Vision Care business and our ACUVUE brand. As you know, the ACUVUE business has a long heritage of strong category growth as well as good innovation, which creates a fantastic products for contact lens wea",294,"Sure, Larry. Thanks for the question. Just on the Vision Care business and our ACUVUE brand. As you know, the ACUVUE business has a long heritage of strong category growth as well as good innovation, which creates a fantastic products for contact lens wearers. And as you know, we are the world in contact lenses with the ACUVUE brand. And we just launched 4 new products in 2015, which have been received very well by the eye care professional and a contact lens wearer. Back in 2014, we did not have that kind of innovation coming to market first of all. And secondly, we saw some unevenness in the pricing in the market with their very different pricing and different channels. So we decided to implement the unilateral pricing policy in order to even out the pricing and of the end of the day, what happened there was we did see a lower overall price for our products, which are made the products more affordable. So today, the majority of the patients who get ACUVUE contact lens are paying less than they did for that brand 2 years ago. Now with innovation, with the market stabilizing, we adopted a new program that encourages patients to see their eye care professional and provides rebates and incentives for the purchase of contact lenses in conjunction with their eye exam as prescribed by a very eye care professional. And we think this just the next evolution as a market leader to focus on eye health and not just price of the contact lens. So just continued evolution of how we approach the market and slight disruption in the market we think that overall the long term benefit to the overall category into our business is worth it."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Thank you. And that concludes the Q&A. And we'll have some closing comments from Dominic.",15,"Thank you. And that concludes the Q&A. And we'll have some closing comments from Dominic."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Louise. As mentioned earlier continued momentum as we enter 2015. I just want to take this time to recognize and thank all our associates around the world for their extraordinary achievements and dedication to the success of Johnson & Johnson.",65,"Thank you, Louise. As mentioned earlier continued momentum as we enter 2015. I just want to take this time to recognize and thank all our associates around the world for their extraordinary achievements and dedication to the success of Johnson & Johnson. 
Thank you for your time this morning. I look forward to updating on our progress throughout the year, and have a great day."
139677,329029101,959314,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","Thank you. This concludes today's Johnson & Johnson's First Quarter 2016 Earnings Conference Call. You may now disconnect your lines, and thank you for your participation.",26,"Thank you. This concludes today's Johnson & Johnson's First Quarter 2016 Earnings Conference Call. You may now disconnect your lines, and thank you for your participation."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","Good morning, and welcome to Johnson & Johnson's First Quarter 2016 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] I would now turn th",49,"Good morning, and welcome to Johnson & Johnson's First Quarter 2016 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] 
I would now turn the conference call over to Johnson & Johnson. You may begin."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Good morning, and welcome. I'm Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure this morning to review our business results for the first quarter of 2016. Joining me on the call today is Dominic Caruso,",1727,"Good morning, and welcome. I'm Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure this morning to review our business results for the first quarter of 2016. 
Joining me on the call today is Dominic Caruso, our Chief Financial Officer. 
A few logistics before we get into the details. This review is being made available via a webcast accessible through the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. I'll begin by briefly reviewing the first quarter for the corporation and for our 3 business segments, then Dominic will provide some additional commentary on the business, review the income statement and guidance for 2016. We will then open the call to your questions. We expect the call to last approximately 1 hour. 
Included with the press release that was issued earlier this morning is the schedule of sales for key products and/or businesses to facilitate updating your models. These schedules are available on the Johnson & Johnson website, as is the press release. 
Please note, we will be using a presentation to complement today's commentary. The presentation is also available on our website. 
Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements. The 10-K for the fiscal year 2015 and the company's subsequent filings identify certain factors that could cause the company's actual results to differ materially from those projected in any forward-looking statements made today. The company does not undertake to update any forward-looking statements as a result of new information or future events or developments. Our SEC filings, including the 10-K, are available through the company and on our website. 
During the review, non-GAAP financial measures are used to provide information pertinent to ongoing business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with GAAP results. Tables reconciling these measures to the most comparable GAAP measures are available in the schedules accompanying the press release and on the Investor Relations section of the Johnson & Johnson website. A number of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships. 
Now I would like to review our results for the first quarter of 2016. Worldwide sales to customers were $17.5 billion for the first quarter of 2016, up 0.6% versus first quarter 2015. On an operational basis, sales were up 3.9%, and currency had a negative impact of 3.3%. In the U.S., sales were up 7.2%. In regions outside the U.S., our operational growth was 0.6%, while the effect of currency exchange rates negatively impacted our reported results by 6.6%. 
On an operational basis, Asia Pacific and Africa grew 3%. Europe declined 0.8% and the Western Hemisphere, excluding the U.S., declined by 0.6%. Results in all regions were negatively impacted by hepatitis C competition and divestitures, the most significant one being Cordis. 
In addition, the devaluation in Venezuela impacted operational growth in the Western Hemisphere, excluding the U.S. Excluding the net impact of acquisitions, divestitures and hepatitis C, underlying operational growth was 6.9% worldwide, 9.8% in the U.S. and 3.8% outside the U.S. In addition, the devaluation in Venezuela impacted worldwide and outside the U.S. operational growth by 60 basis points and 120 basis points, respectively. 
Turning now to earnings. Net earnings were $4.3 billion, and earnings per share were $1.54 versus $1.53 a year ago. As referenced in the table reconciling non-GAAP measures, 2016 first quarter net earnings were adjusted to exclude after-tax amortization expense of $205 million and the charge of $192 million for after-tax special items. 2015 first quarter net earnings were adjusted to exclude a next charge of $98 million. Dominic will discuss special items in his remarks. 
Excluding amortization expense and special items for both periods, adjusted net earnings for the current quarter were $4.7 billion and diluted earnings per share were $1.68, representing increases of 6.1% and 7.7%, respectively, as compared to the same period in 2015. 
Currency translation significantly impacted net earnings. On an operational basis, adjusted net earnings per share grew 10.3%. 
Turning now to business segment highlights. Please note percentages quoted represent operational sales change in comparison to the first quarter of 2015 unless otherwise stated and therefore, exclude the currency translation impact. I'll begin with the Consumer segment. 
Worldwide Consumer segment sales of $3.2 billion decreased 0.2%, with U.S. sales down 0.1%, while outside the U.S. sales were down 0.3%. Excluding the net impact of acquisitions and divestitures, underlying operational sales growth was 1.9% worldwide, 4.1% in the U.S. and 0.5% outside the U.S. 
In addition, the devaluation in Venezuela impacted growth worldwide and outside the U.S. by 200 basis points and 320 basis points, respectively, with the most significant impact to Women's Health, Oral Care and Baby Care. Growth for the segment was driven primarily by OTC worldwide and Oral Care. OTC sales growth was strong despite a weak flu season. U.S. OTC sales growth was driven by analgesic share growth and an inventory build as well as seasonal and new product launch inventory for upper respiratory products. 
In the U.S., adult analgesic market share was approximately 14%, up from approximately 12% a year ago; while U.S. pediatric share was nearly 46%, up from nearly 43% a year ago. Major contributors to the growth outside the U.S. were the strong performance of analgesics and anti-smoking aids, partially offset by lower sales of upper respiratory products due to the fourth quarter distributor inventory build, as noted last quarter. 
New product launches and successful marketing campaigns drove the results for LISTERINE in Oral Care. 
Moving now to our Pharmaceutical segment. Worldwide sales of $8.2 billion increased 8.5%, with U.S. sales up 12.9% and sales outside the U.S. up 2.6%, driven by both strong sales of new products as well as core growth products. Competitors in hepatitis C significantly impacted sales this quarter. Excluding sales of our hepatitis C products, OLYSIO and INCIVO, as well as the impact of acquisitions and divestitures, underlying sales growth worldwide U.S. and outside the U.S. was 12.3%, 16.2% and 7.1%, respectively. 
As we discussed last year, U.S. results in the first quarter of 2015 included a positive adjustment for gross to net, including managed Medicaid rebates. In the first quarter this year, U.S. results included an adjustment for a similar amount and therefore, overall growth was not impacted. However, on a product basis, STELARA growth in 2016 was positively impacted by approximately 16 points, XARELTO by 4 points and REMICADE by 3 points. 
Significant contributors to growth were immunology products, REMICADE, STELARA and SIMPONI/SIMPONI ARIA; oncology products, IMBRUVICA and recently launched DARZALEX; as well as cardiovascular metabolic products, XARELTO and INVOKANA. The results for immunology were driven by strong double-digit market growth as well as a gross to net adjustment to sales that I mentioned. 
Combined REMICADE export sales and international sales grew approximately 11%. Sales to distribution partners were up approximately 5%. Sales to our international direct markets were up approximately 17%, due primarily to strong double-digit growth in the Western Hemisphere, excluding the U.S., primarily driven by timing of shipments and market growth. 
Strong patient uptake with new indications, approvals and demonstrated efficacy drove the results for IMBRUVICA, both in the U.S. and outside the U.S. In the U.S., IMBRUVICA remains the new patient share and total share leader in second line CLL and MCL. IMBRUVICA is now launched in more than 65 countries. 
DARZALEX was approved in the U.S. in November 2015 and has achieved rapid uptake. DARZALEX contributed over 2% to the U.S. pharmaceutical growth rate. 
XARELTO sales were up 29%, and total prescription share or TRx for the quarter in the U.S. anticoagulant market grew to over 16.5%, up over 1.5 points from a year ago. TRx in primary care was nearly 14% and in cardiology, nearly 23.5%, up on a sequential basis by 0.5 points and 0.3 points, respectively. XARELTO is broadly reimbursed, with 95% of commercial and Medicare Part D patients covered at the lowest co-pay for a branded product. 
INVOKANA/INVOKAMET sales were up nearly 18% on a worldwide basis and nearly 12% in the U.S. In the U.S., INVOKANA/INVOKAMET TRx within the defined market of type 2 diabetes, excluding insulin and metformin, was 6.1%, up from 5.1% in the first quarter of 2015. TRx with endocrinologists was 11.5% and 5.5% in the primary care. 
On a sequential basis, sales declined due to the extra shipping days in the fourth quarter, incremental rebates and savings program redemptions as well as increased competition in formulary positions. INVOKANA access remains strong at 80% preferred for combined commercial and Part D. 
I'll now review the Medical Devices segment results. Worldwide Medical Devices segment sales of $6.1 billion increased 0.5%. U.S. sales increased 2.2%, while sales outside the U.S. declined 1%. Cordis was divested in the fourth quarter of 2015. Excluding the net impact of acquisitions and divestitures, underlying operational sales growth was 3% worldwide, with the U.S. up 3.3% and the growth of 2.8% outside the U.S. Growth was driven by Orthopaedics, advanced surgery and electrophysiology. 
Orthopaedics sales growth was driven by worldwide knees and hips, and U.S. trauma and spine. Market growth and the success of product launches drove results for the U.S. Orthopaedics business. Pricing pressure continued across the major categories, partially offset by positive mix for trauma and spine products. The success of the TFNA mailing system in trauma, the Attune platform in knees, our primary stem platform in hips and ORTHOVISC/MONOVISC and new spine product introductions made important contributions to results. 
Orthopaedics sales outside the U.S. were negatively impacted by results in China due to a softer demand and a reduction in inventory. Trauma and spine, other were the categories most impacted. In addition, timing of tender business negatively impacted trauma growth for the quarter. 
Strong results were achieved for advanced surgery products with endocutters growth of 10%, biosurgicals growth of 8% and energy growth of 8%. 
Electrophysiology grew 19% worldwide due to strong market growth, complemented by new product launches and increased penetration for both ultrasound and diagnostic catheters. 
That concludes the segment highlights for Johnson & Johnson's first quarter of 2016. It is now my pleasure to turn the call over to Dominic Caruso. Dominic?"
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Thanks, Louise, and good morning, everyone. We carried last year's momentum into 2016, and we're off to a strong start this year. We are very pleased with the results generated in the first quarter, and we continue to make very good progress on our near-t",2284,"Thanks, Louise, and good morning, everyone. We carried last year's momentum into 2016, and we're off to a strong start this year. We are very pleased with the results generated in the first quarter, and we continue to make very good progress on our near-term priorities as well as our long-term growth drivers, which we discussed during our January call. We remain confident in the strength of our business. 
As we've previously discussed in 2015, our underlying operational sales growth, which excludes the impact of acquisitions, divestitures as well as hepatitis C sales and a few extra shipping days in 2015, was 5.5%. On this same basis, we gained momentum in the first quarter, with strong underlying operational sales growth of approximately 7% and in line with analysts' estimates. 
In our Pharmaceutical business, our strong performance from 2015 continued into the first quarter, with underlying operational growth at over 12%. 
First quarter underlying operational sales growth for Consumer increased approximately 4% when also adjusting for the impact of the devaluation in Venezuela that Louise mentioned earlier. 
And in Medical Devices, we're off to a good start in the first quarter, with underlying operational growth of approximately 3%. Growth in our consumer-facing medical businesses was negatively impacted by challenges in the diabetes market. 
For the hospital-focused medical device businesses, we're seeing signs of continued improvement, with underlying operational growth in those businesses of approximately 4%, driven by strength in our Orthopaedics, advanced surgery and electrophysiology businesses. 
We also saw an improvement in our overall adjusted pretax operating margin. For 2016, our guidance from January included a 200 basis point increase on an adjusted basis, and we remain comfortable with that forecast as we will accelerate throughout the year with the restructuring activities in our Medical Device business and lower levels of spending in the back half as compared to the prior year. As a reminder, pretax operating margin is defined as gross profit less selling, marketing, administrative and R&D expenses. 
Now I'll take a few minutes to highlight some key developments on the first quarter as well as some key points regarding our results, and then I'll provide some updates to our guidance for you to consider in refining your models for 2016. 
During the quarter, we had several key developments across the business. In our Pharmaceutical business, we received an additional approval for IMBRUVICA for first line treatment of chronic lymphocytic leukemia and also entered into a worldwide collaboration and license agreement with TESARO for exclusive rights to the investigational compound niraparib in prostate cancer. Niraparib is an orally administered poly polymerase, or PARP, inhibitor. 
We also continued our efforts to combat major global health challenges through collaborations with government organizations and others in the industry with a call for innovative ideas to reduce HIV infections in sub-Saharan Africa as well as providing funding for nonprofit organizations supporting underserved communities in the United States. 
In March 2016, we entered into an agreement to sell our controlled substance raw material and API business. In 2015, these businesses totaled approximately $250 million in net trade sales. This divestiture remains subject to customary closing conditions and regulatory approvals but is expected to be completed towards the middle of 2016. 
In Medical Devices, Ethicon completed the acquisition of NeuWave Medical, a privately held medical device company that manufactures and markets minimally invasive soft tissue microwave ablation systems. We look forward to providing an in-depth review of the ongoing efforts of our Consumer and Medical Device businesses at our upcoming business review meeting on May 18, which will take place in New Brunswick, New Jersey. 
I will now turn to our consolidated statement of earnings for the first quarter of 2016. As we've mentioned, our operational sales growth this quarter was 3.9%. And excluding the impact of acquisitions and divestitures and hep C sales, it was a strong 6.9%. If you'll direct your attention to the boxed section of the schedule, you will see we have provided our earnings adjusted to exclude intangible amortization and special items. 
As referenced in the table of non-GAAP measures, the 2016 first quarter net earnings were adjusted to exclude intangible asset amortization expense and special items of approximately $400 million on an after-tax basis, which consisted primarily of the following: intangible asset amortization of $200 million and litigation charges and our Medical Devices restructuring charge. 
Our adjusted earnings per share is therefore $1.68 per share, exceeding the mean of the analyst estimates, as published by first call. This is an increase in adjusted EPS of 7.7% versus the prior year. Adjusted EPS on a constant currency basis was $1.72, up 10% over the prior year. 
Now let's take a few moments to talk about the other items in the statement of earnings. Cost of goods sold increased by 10 basis points, mostly due to transactional currency, partially offset by a favorable mix in the business. Selling, marketing and administrative expenses were 26.8% of sales or 110 basis points lower as compared to the first quarter of 2015 due to continued good cost management. 
Our investment in research and development as a percent of sales was 11.5% higher than the prior year due to increased project spending as we advance our promising product pipelines. 
Our pretax operating margin, when excluding special items and intangible amortization expense, was 32.9%, 30 basis points higher than the first quarter of the prior year. Interest expense net of interest income was lower than last year due to slightly better rates on our investments. Other income and expense was a net gain of $39 million in the quarter compared to a net gain of $348 million in the same period last year. 
Excluding special items that are reflected in this line item, other income and expense was a net gain of $127 million compared to a net gain of $91 million in the prior year period. 
Excluding special items, the effective tax rate was 19.2% compared to 21.5% in the same period last year. This year's effective rate reflects the R&D tax credit, which was passed by Congress late last year and the current mix of our business. 
Turning to the next slide. I will now review adjusted income before tax by segment. On our 2015 year-end call, we commented on our segment results for adjusted income before tax versus the prior year. Now that all of our competitors have reported their results for 2015, I would like to take the opportunity to point out that our 2015 adjusted income before tax was 31.4% compared to 26.2% weighted average for our competitive set. This was driven by higher margins in both Pharmaceutical and Medical Devices and somewhat lower margins in our Consumer business as compared to our competitive set. 
In the first quarter of 2016, our adjusted income before tax for the enterprise improved 80 basis points versus the first quarter of 2015, driven by improvement in both our Pharmaceutical and Medical Device businesses. Our Consumer business had a lower margin this year as compared to last year, due principally to the devaluation in Venezuela. We are confident that our Consumer business will show an improved adjusted income before tax margin for full year 2016 as compared to 2015. 
Now I will provide some guidance for you to consider as you refine your models for 2016. At the end of the quarter, we had approximately $17 billion of net cash, which consist of approximately $40 billion of cash and marketable securities and approximately $23 billion of debt. As you know, in February, we took the opportunity to finance our share repurchase program and upcoming debt maturities at very attractive interest rates with a debt issuance of $7.5 billion. Through the end of the first quarter, we completed approximately 25% of our $10 billion share repurchase program, and we expect to complete 75% of the program by the end of this year. 
For purposes of your models and assuming no major acquisitions or other major uses of cash, I suggest you consider modeling net interest expense of between $450 million and $550 million. This is unchanged from our prior guidance. 
Regarding other income and expense, as a reminder, this is the account where we record royalty income as well as gains and losses arising from such items as litigation, investments by our development corporation, divestitures, asset sales and write-offs. We'll be comfortable with your models for 2016 reflecting net other income and expense, excluding special items, as a net gain ranging from approximately $1.1 billion to $1.2 billion. And this is also unchanged versus our January guidance. 
And now a word on taxes. Our guidance for 2016 includes the R&D tax credit that Congress made permanent in 2015. We are, therefore, comfortable with your models reflecting an effective tax rate for 2016, excluding special items, of approximately 19% to 20%, lower by 50 basis points in our previous guidance due to updating our outlook for a higher mix of our earnings from lower tax jurisdictions in 2016 than we anticipated in our previous guidance. 
And now turning to sales and earnings. Our sales and earnings guidance for 2016 takes into account several assumptions and key factors that I would like to highlight. As a reminder, our sales guidance for 2016 assumes no biosimilar entrant for PROCRIT or REMICADE in the U.S. And our assumption with regard to REMICADE biosimilar remains unchanged, even with the recent FDA approval of Inflectra due to our intellectual property, which we intend to defend. 
We also do not anticipate generic competition this year from ZYTIGA, RISPERDAL CONSTA and INVEGA SUSTENNA. But as expected, there are generic entrants for INVEGA and ORTHO TRI-CYCLEN LO. 
As we've done for several years, our guidance will be based first on a constant currency basis reflecting our results from operations. This is the way we manage our business, and we believe this provides a very good understanding of the underlying performance of our business. 
We will also provide an estimate of our sales and EPS results for 2016 with the impact that current exchange rates could have on the translation of those results. 
Consistent with our previous guidance, we'd be comfortable with your models reflecting an operational sales increase on a constant currency basis of between 2.5% and 3.5% for the year. This would result in sales for 2016 on a constant currency basis of approximately $71.9 billion to $72.6 billion. 
Additionally, by way of comparison to how we described our sales results in 2015, our operational sales growth for 2016, excluding the impact of all acquisitions and divestiture and hepatitis C sales, would be approximately 5.5%, a level of growth comparable to last year after adjusting for the extra shipping days in 2015, which we mentioned earlier. 
The devaluation in Venezuela that we previously discussed is anticipated to be a headwind of approximately 30 basis points for the full year, which we anticipate will be offset by the strength of the business. 
Although we're not predicting the impact of currency movements, using the euro as of last week at $1.13, the negative impact of foreign currency translation will be approximately 1%. This is an improvement of 50 basis points since we last provided guidance. We're watching the euro and other currencies closely as it is uncertain how they will eventually settle out for the year. 
Thus, under this scenario, we would expect reported sales to reflect the change in the range of 1.5% to 2.5% for a total expected level of reported sales of approximately $71.2 billion to $71.9 billion, higher than our previous guidance. 
Now turning to earnings. As a reminder, we expect transaction currency impacts to be negative to our gross margin by approximately 60 to 80 basis points in 2016 as compared to 2015. We would be comfortable with adjusted EPS guidance in a range between $6.56 to $6.71 per share on a constant currency basis, reflecting an operational or constant currency growth rate of 6% to 8%. This is higher than our previous guidance. 
If currency exchange rates for all of 2016 were to remain where they were as of last week, then our reported adjusted EPS would be negatively impacted by approximately $0.03 per share due to currency movements, a better outlook than the approximately $0.10 negative impact we discussed in our January guidance. Therefore, we would be comfortable with our reported adjusted EPS ranging from $6.53 to $6.68 per share, which is an increase from our previous guidance due to an update to our tax rate and current currency estimates. As it's still early in the year, we would be comfortable with your models reflecting the midpoint of this range. 
In closing, we're very pleased with our strong start for the year, and we are optimistic with what we see ahead for the full year, namely we're expecting operational sales growth of 2.5% to 3.5% and underlying operational sales growth of 5.5%, consistent with '15 -- 2015 growth on a comparable basis. 
Our operating margins improvements are on track to meet the expectations we laid out in our guidance of more than a 200 basis point improvement over the prior year. Our operational adjusted EPS growth in our guidance remains strong in the range of 6% to 8%, and our businesses are continuing to invest while also delivering on our growth expectations. 
In particular, we're pleased to see our Medical Device businesses showing continued signs of improvement, and our restructuring activities in that business are on track. And we look forward to discussing with you in more detail these activities on our May 18 Investor Day. 
Now I'd like to turn things back to Louise for the Q&A portion of the call. Louise?"
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Dominic. And Manny, could you please give the instructions for the Q&A session?",15,"Thank you, Dominic. And Manny, could you please give the instructions for the Q&A session?"
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","[Operator Instructions] Our first question is from David Lewis of Morgan Stanley.",12,"[Operator Instructions] Our first question is from David Lewis of Morgan Stanley."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","I'm going to start with a strategic question for Dominic, and then one follow up. Dominic, the long-standing view of J&J has been this sort of asserted defensiveness of having these 3 major franchises under the J&J family of companies. Does that still rem",60,"I'm going to start with a strategic question for Dominic, and then one follow up. Dominic, the long-standing view of J&J has been this sort of asserted defensiveness of having these 3 major franchises under the J&J family of companies. Does that still remain the prevailing view of management and the board? And then I had a quick follow-up."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, David. It's our view, both management and the board, that our broadly based business is the right approach to have in health care. It certainly has served us well, and we expect it'll continue to serve us well as health care industry evolves in the f",82,"Yes, David. It's our view, both management and the board, that our broadly based business is the right approach to have in health care. It certainly has served us well, and we expect it'll continue to serve us well as health care industry evolves in the future. We think of ourselves as a health care company. And of course, that allows us to access opportunities in health care no matter where they be, either in pharma, medical devices or in consumer health."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay, that's very helpful. And then the second question maybe for Louise or Dominic. Just REMICADE, gross to net dynamics in the quarter. Any more detail you can sort of provide us on that? Or any sense of what you're expecting sort of net pricing gains t",55,"Okay, that's very helpful. And then the second question maybe for Louise or Dominic. Just REMICADE, gross to net dynamics in the quarter. Any more detail you can sort of provide us on that? Or any sense of what you're expecting sort of net pricing gains to be for REMICADE in the U.S. for 2016?"
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Okay. So as we discussed, we had the prior year growth to net that you saw that contributed -- I think it was 3% to the REMICADE growth. And pricing dynamics continue to be okay in that market.",38,"Okay. So as we discussed, we had the prior year growth to net that you saw that contributed -- I think it was 3% to the REMICADE growth. And pricing dynamics continue to be okay in that market."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","So I don't think it's expected that REMICADE sales will be -- significantly impact the year-over-year by growth to net adjustments.",22,"So I don't think it's expected that REMICADE sales will be -- significantly impact the year-over-year by growth to net adjustments."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Josh Jennings of Cowen and Company.",11,"The next question is from Josh Jennings of Cowen and Company."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","I know you've had some public comments, Dominic, recently around the REMICADE franchise. But now that we have the AdCom panel and the FDA approval in the review, when do you -- clearly, you don't expect any biosimilar competition in 2016 due to your event",67,"I know you've had some public comments, Dominic, recently around the REMICADE franchise. But now that we have the AdCom panel and the FDA approval in the review, when do you -- clearly, you don't expect any biosimilar competition in 2016 due to your events of IP. But any updated thoughts on the potential impact of biosimilar competition to the REMICADE franchise in 2017 and beyond?"
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Well, you're right, Josh. We don't expect a biosimilar competition in 2016. And as you know, we have several patents that we intend to defend. And -- for example, the U.S. patent, the '471 patent, extends to 2018. And another patent that we have extends t",136,"Well, you're right, Josh. We don't expect a biosimilar competition in 2016. And as you know, we have several patents that we intend to defend. And -- for example, the U.S. patent, the '471 patent, extends to 2018. And another patent that we have extends to 2027. Having said that, I think, overall, the immunology franchise of Johnson & Johnson is very strong because it's not just about REMICADE. Of course, we have STELARA, SIMPONI, et cetera. And the overall pipeline in the Pharmaceutical business, as you know, from our review last May is very, very robust with 10 new products being filed, each of which having more than a $1 billion potential. So overall, we remain very, very comfortable with the growth outlook for the Pharmaceutical business regardless of the outcome of any REMICADE biosimilar."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","And I just wanted to follow up with a question on your operating margin guidance. Maintaining the 200 basis points. I was just curious about the Venezuelan crisis impact. It looks like it has primarily hit the consumer units operating margins. But can you",123,"And I just wanted to follow up with a question on your operating margin guidance. Maintaining the 200 basis points. I was just curious about the Venezuelan crisis impact. It looks like it has primarily hit the consumer units operating margins. But can you talk about the expectations of Venezuela's impact on your operating margin guidance at the beginning of the year, how your internal expectations have evolved, clearly, with maintaining that guidance? The performance of the rest of the business units are going to offset any direct impact from Venezuela, but just wanted to hear about -- any offsets there and net impact to the operating margin performance of the consumer unit. And can Consumer still experience operating margin expansion in 2016?"
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. Sure, Josh. Well, just to put things in perspective, Venezuela is less than 1% of our sales, less than 0.5% of our sales, so it's not a very significant impact. It is more significant in Consumer than in the other businesses. But we're very confident",100,"Yes. Sure, Josh. Well, just to put things in perspective, Venezuela is less than 1% of our sales, less than 0.5% of our sales, so it's not a very significant impact. It is more significant in Consumer than in the other businesses. But we're very confident in our outlook for a 200 basis point improvement in operating margin expansion -- pretax operating margin expansion for 2016, and that will be across all the businesses, including Consumer, who will make a significant contribution to that, even despite the impacts of Venezuela. So we're very confident with that outlook for the year."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Mike Weinstein of JPMorgan.",9,"The next question is from Mike Weinstein of JPMorgan."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","The Immunology franchise, REMICADE, SIMPONI, STELARA, all had much better growth than what the scripts suggested. So outside of the gross to net, was there an inventory catch-up this quarter that might have impacted these products?",36,"The Immunology franchise, REMICADE, SIMPONI, STELARA, all had much better growth than what the scripts suggested. So outside of the gross to net, was there an inventory catch-up this quarter that might have impacted these products?"
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","So in the U.S., nothing insignificant in the inventory. That market grows strong, strong double digits, and that is a good contributor to the Immunology. STELARA continues to grow market share. SIMPONI ARIA is contributing to the results. But in the U.S.,",47,"So in the U.S., nothing insignificant in the inventory. That market grows strong, strong double digits, and that is a good contributor to the Immunology. STELARA continues to grow market share. SIMPONI ARIA is contributing to the results. But in the U.S., no significant inventory build."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. Can we talk about DARZALEX? DARZALEX [indiscernible] very, very strong first quarter out of the box here. Can you just talk about the uptake in multiple myeloma and how you see it playing out on the back of the relapsed/refractory data?",42,"Okay. Can we talk about DARZALEX? DARZALEX [indiscernible] very, very strong first quarter out of the box here. Can you just talk about the uptake in multiple myeloma and how you see it playing out on the back of the relapsed/refractory data?"
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. Mike, we're obviously very pleased with the early uptake of DARZALEX. And as we said, it contributed 2 points of growth to our U.S. pharma business, so off to a great start. It's -- the CD38 mechanism of action seems to be something that the KOLs rea",76,"Yes. Mike, we're obviously very pleased with the early uptake of DARZALEX. And as we said, it contributed 2 points of growth to our U.S. pharma business, so off to a great start. It's -- the CD38 mechanism of action seems to be something that the KOLs really respect us as having a significant impact on the disease. And we think the product's going to do extremely well, and we'll see continued uptake throughout the year."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. And also, we have the CASTOR trial, which actually the IDMC has recommended to stop early. So that's a very positive sign as well in that end.",28,"Yes. And also, we have the CASTOR trial, which actually the IDMC has recommended to stop early. So that's a very positive sign as well in that end."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Great. Dominic, one quick finance question for you. The tax rate coming down is -- runs a little bit counter to the performance of the business because your growth in the U.S. has been so strong, particularly in the Pharmaceutical business. So what we opt",99,"Great. Dominic, one quick finance question for you. The tax rate coming down is -- runs a little bit counter to the performance of the business because your growth in the U.S. has been so strong, particularly in the Pharmaceutical business. So what we optically is very strong U.S. revenue growth, and we assume U.S. profit growth. But obviously, the manufacturing and IP of some of those products is outside the U.S. Can you just shed a little bit of light there on how you're managing that because the U.S. business relative to o U.S. business looks very different?"
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, Mike. Well, it's an excellent observation. Actually, the strength of the sales in any one particular region does not necessarily correlate with the strength of the earnings in that region, and it's for the very reason that you mentioned, which is whe",107,"Yes, Mike. Well, it's an excellent observation. Actually, the strength of the sales in any one particular region does not necessarily correlate with the strength of the earnings in that region, and it's for the very reason that you mentioned, which is where the IP is located, where the manufacturing takes place, et cetera. So what we did is we just updated our outlook with how the profits will fall amongst the different regions and different jurisdictions. And we thought about a 0.5 points improvement in the overall tax rate would be achievable this year for the full year. And therefore, we adjusted that in our outlook."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Kristen Stewart of Deutsche Bank.",10,"The next question is from Kristen Stewart of Deutsche Bank."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","I was just wondering if you could comment a little bit more about the diabetes business. I think, Dominic, you had mentioned there's challenges in the market. I was just wondering if you could comment about INVOKANA and the additional competition that's i",54,"I was just wondering if you could comment a little bit more about the diabetes business. I think, Dominic, you had mentioned there's challenges in the market. I was just wondering if you could comment about INVOKANA and the additional competition that's in the market or just provide a little bit more commentary there."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Sure. Well, just to clarify what I said, I was talking about challenges in the market with respect to our medical -- consumer medical device diabetes business, the LifeScan business. And what I meant by that was we see continued pricing pressure in that m",113,"Sure. Well, just to clarify what I said, I was talking about challenges in the market with respect to our medical -- consumer medical device diabetes business, the LifeScan business. And what I meant by that was we see continued pricing pressure in that market, and we also see some competition with respect to new pumps being launched. We've just launched a new pump, obviously, so we're also seeing good uptake with our current pump. So the dynamics I'm talking about are in the medical device piece of the business as being challenging. Overall, INVOKANA continues to do well. Its uptake is strong quarter-over-quarter and remains a growth driver for us going forward."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. And then, I guess, just more broadly, what are you seeing -- can you just go back and address kind of China? I know that was something that you had brought up just in terms of still seeing a little bit of softness. I think you had mentioned more wit",66,"Okay. And then, I guess, just more broadly, what are you seeing -- can you just go back and address kind of China? I know that was something that you had brought up just in terms of still seeing a little bit of softness. I think you had mentioned more within the Medical Device segment. Any changes there? Is it getting worse or getting any better?"
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Sure. Well, China, again, just to put it in perspective, it's about 5% of our overall business. And a slowdown in the economy actually last year is what caused some distributor inventory to be at relatively high levels. That distributor inventory is begin",80,"Sure. Well, China, again, just to put it in perspective, it's about 5% of our overall business. And a slowdown in the economy actually last year is what caused some distributor inventory to be at relatively high levels. That distributor inventory is beginning to bleed off. We saw that in the first quarter, and we think that, that bleed-off will be completed shortly, so we don't expect to see a continued impact of that for the rest of the year."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Jami Rubin of Goldman Sachs.",10,"The next question is from Jami Rubin of Goldman Sachs."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","I have a few questions. Just back to Kristen's question on diabetes. Just -- INVOKANA is an important growth driver for the company, but sales did come in a bit lighter than we had anticipated despite, I think, the growing excitement about this class of d",182,"I have a few questions. Just back to Kristen's question on diabetes. Just -- INVOKANA is an important growth driver for the company, but sales did come in a bit lighter than we had anticipated despite, I think, the growing excitement about this class of drugs. Dominic, can you comment just generally on what drug categories you are seeing widening gross to net discounts? And are you seeing more gross to net discounts or widening discounts specifically in diabetes? And can you comment on where you might be seeing that elsewhere in the pharma business? My second question is on the OTC business. You've clearly highlighted the strong growth that you're seeing in the U.S. and particularly, the analgesics market. How much of that growth is just regaining back lost market share from private label when you were out of the market? And how much of that is market growth? And maybe you can comment just generally on the dynamics of the OTC marketplace and where you see store brand market share now. And I have one more follow-up, one more follow-up."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Okay, let's take them in order. So -- and Louise, you could add, obviously, if I've left anything out. I wouldn't say, Jami, that there's any one particular area in the business where we see sort of a widening of gross to net or rebating that's any differ",157,"Okay, let's take them in order. So -- and Louise, you could add, obviously, if I've left anything out. I wouldn't say, Jami, that there's any one particular area in the business where we see sort of a widening of gross to net or rebating that's any different than what we've seen before in the business. So I won't comment on any one particular area. I would say generally speaking, there's nothing that sticks out to us as a widening trend. With respect to U.S. OTC, a couple of things to mention. We are gaining back share, and the products are doing very, very well. And this particular quarter was a relatively low-growth market quarter because of a very, very soft flu season. Very, very soft flu season. So most of the growth that we saw is not on the back of market expansion, but on the back of share expansion as we continue to regain share."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Are you where you want to be in terms of regaining back that lost share? And where -- what is a realistic goal? I mean, you're out of market completely. Where are you now?",34,"Are you where you want to be in terms of regaining back that lost share? And where -- what is a realistic goal? I mean, you're out of market completely. Where are you now?"
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. So we're not where we want to be. We're pleased. As Alex often says, we're pleased, but not satisfied. So we're going to continue to gain share there. And Louise, do you have the year-over-year comparison of share?",39,"Yes. So we're not where we want to be. We're pleased. As Alex often says, we're pleased, but not satisfied. So we're going to continue to gain share there. And Louise, do you have the year-over-year comparison of share?"
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. So in 2009, before the McNeil issues that we had, the adult share is about 25%, and we're back to 14%. Pediatric was about 70%, and we're now back to 46%. So you're seeing some nice growth on that. And if you take a look at year-over-year, the adult",94,"Yes. So in 2009, before the McNeil issues that we had, the adult share is about 25%, and we're back to 14%. Pediatric was about 70%, and we're now back to 46%. So you're seeing some nice growth on that. And if you take a look at year-over-year, the adult share a year ago was 43%, so you see it going up about 3 points. And then the pediatric share is at the -- it's also going up to the 46%. So we're making progress. Sorry, that was pediatric share from 43% to 46%."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Making progress, Jami, but we're not finished. I think these products have a long heritage and legacy. They're very, very important in overall health care. And quite frankly, they are admired by consumers. So we expect to see continued share growth.",41,"Making progress, Jami, but we're not finished. I think these products have a long heritage and legacy. They're very, very important in overall health care. And quite frankly, they are admired by consumers. So we expect to see continued share growth."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. And it's 14% U.S. share now, and it was 12%. And you asked about the private label. We think in the U.S. market, the adult is about 1/3, and the -- in the pediatric, it's about 40%.",38,"Yes. And it's 14% U.S. share now, and it was 12%. And you asked about the private label. We think in the U.S. market, the adult is about 1/3, and the -- in the pediatric, it's about 40%."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. And then just -- can I follow up, Dominic? I'm actually shocked that I'm with the sixth question this hasn't come up yet. Your net cash position is now $17 billion. That keeps growing. I don't think any company that I cover or anybody else covers ha",202,"Okay. And then just -- can I follow up, Dominic? I'm actually shocked that I'm with the sixth question this hasn't come up yet. Your net cash position is now $17 billion. That keeps growing. I don't think any company that I cover or anybody else covers has the kind of balance sheet prowess that you have, the lack of debt on your balance sheet. And I think it was -- I think what was it back in September at a Investor Conference, you had mentioned that you were -- I'm comfortable with the amount of cash that you had growing on the balance sheet. And now here we are 6 to 7 months later and don't really see any activity with respect to putting that cash to work, with the exception of a buyback that you announced earlier this year. Can you just give us an update on your thoughts of -- thoughts on capital allocation? And clearly, we've had a lot of disruption in the marketplace with valuations on many names coming back. And I'm just surprised that we haven't really seen much action on the part of capital allocation from J&J. And then I'm done. And then I'm done."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Jami. Yes, okay, great. Okay, good. All right. Well, just to clarify, back in September, I didn't really say I was uncomfortable with the level of cash. I just said that it was a higher level of cash that we normally hold. And then of course, after",188,"Sure, Jami. Yes, okay, great. Okay, good. All right. Well, just to clarify, back in September, I didn't really say I was uncomfortable with the level of cash. I just said that it was a higher level of cash that we normally hold. And then of course, after that, we announced a $10 billion share buyback. So we're very conscious of the fact that while we're evaluating M&A opportunities, we can continue to return capital to shareholders, which, in addition to our very, very strong dividend, we can do share buybacks. We're in the middle of doing one right now, and we'll obviously evaluate whether we continue to increase that particular share buyback as time goes on. With respect to not allocating capital to any particular deals, I could tell you that we're very active. But as you know, we're also very disciplined. We do see opportunities, but we want to do the right deal at the right time with the right party at the right valuation. And we're comfortable waiting for that to take place because we think that's what ultimately generates the most value for shareholders."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. But is that what you plan to do with your cash? M&A, Dominic? Is that what you're -- is that what the message is today?",26,"Okay. But is that what you plan to do with your cash? M&A, Dominic? Is that what you're -- is that what the message is today?"
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Well, the message is very consistent, what it's always been. Our first priority is allocating capital to dividends. So we'll announce what we're going to do with dividends at our April 28 Shareholder Meeting. After that, we'd like to grow the business and",103,"Well, the message is very consistent, what it's always been. Our first priority is allocating capital to dividends. So we'll announce what we're going to do with dividends at our April 28 Shareholder Meeting. After that, we'd like to grow the business and create value for shareholders through M&A. And in addition to that, we'll continue to return share -- capital to shareholders through share purchases -- repurchase. So that really changed. So our attitude, our capital allocation policy does not change depending on how much capital we have. It's all about creating the most value for shareholders with whatever capital we deploy."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Glenn Novarro of RBC Capital Markets.",11,"The next question is from Glenn Novarro of RBC Capital Markets."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Just 2 questions. Let me first just piggyback on what Jami just asked because I think we're all surprised that J&J hasn't done more with the balance sheet so far. And I'm just wondering, Dominic, as you're having these discussions, it appears that some of",124,"Just 2 questions. Let me first just piggyback on what Jami just asked because I think we're all surprised that J&J hasn't done more with the balance sheet so far. And I'm just wondering, Dominic, as you're having these discussions, it appears that some of the targets you may be having discussions with have unrealistic valuation expectations. So maybe talk about where valuation expectations have come. Are they getting at least in the ballpark of what J&J thinks is appropriate valuation? And then with Allergan and Pfizer no longer getting together, you have 2 more companies that are going to be actively looking at deals. And does that make the competitive landscape more challenging for J&J? And then I had a follow-up on devices."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Glenn. Well, in certain areas of the market, valuations are still high. They're coming down, as you know, in biotech, in particular. But certain other areas, in med device, for example, certain valuations are still inflated, in our opinion. Things w",162,"Sure, Glenn. Well, in certain areas of the market, valuations are still high. They're coming down, as you know, in biotech, in particular. But certain other areas, in med device, for example, certain valuations are still inflated, in our opinion. Things will get better as time goes on, we believe. We're patient, disciplined. And as I said earlier, we'll look for the right opportunity, but at the right time at the right valuation. With respect to Allergan and Pfizer maybe being in the market now and creating more competition, that's probably true. I can't speak for what they're going to do. But we're accustomed to looking at various acquisition candidates where more than one party may be interested in a particular asset. That does not to sway us from being disciplined and have a clear focus on ultimately what matters, which is the deployment of that capital to create shareholder value. So yes, there'll be more competition. We'll still remain very disciplined."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. And then just a follow-up on the device business. When you ex out divestitures and currency, the device business grew 3% in the first quarter, and that's pretty much in line with most of the device categories that we cover. But I don't think J&J had",100,"Okay. And then just a follow-up on the device business. When you ex out divestitures and currency, the device business grew 3% in the first quarter, and that's pretty much in line with most of the device categories that we cover. But I don't think J&J had any major new product launches here recently. So is -- the improvement in the device business for J&J, is that just better execution and better blocking and tackling? Or did some of the major end markets in cardio and ortho and spine in the first quarter come in slightly better than you expected?"
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. Well, just to clarify, 3% overall is the Medical Device business ex acquisition, divestitures. But the hospital-based Medical Device business, excluding the consumer-facing medical device businesses, that grew 4% on a comparable basis. We did have a",156,"Yes. Well, just to clarify, 3% overall is the Medical Device business ex acquisition, divestitures. But the hospital-based Medical Device business, excluding the consumer-facing medical device businesses, that grew 4% on a comparable basis. We did have a number of products that we filed last year, and we have about 30 new products that we're launching. Half of those have already been launched, so we are seeing the impact of those. And I think it's also a matter of focus, focus on the primary growth drivers. For example, you saw very good results in energy, in endocutters, in electrophysiology as major drivers of growth. And also, we're very pleased with the results in Orthopedics and the Attune Knee. For example, in the U.S. in particular, the U.S. growth was over 8% for knees, which is pretty fantastic growth. And the Attune Knee is at one -- still a new product that's being launched in that marketplace."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","But as you talk to division heads, is everything -- or the end market status quo, no change, no stable? Or is there any pickup in some of these end markets?",31,"But as you talk to division heads, is everything -- or the end market status quo, no change, no stable? Or is there any pickup in some of these end markets?"
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","I think from what we've seen back in the fourth quarter trends, because we don't have all the first quarter trends, continue the improvement in procedural growth, but not dramatic, Glenn. Just a continued steady improvement in procedural growth. Anything",44,"I think from what we've seen back in the fourth quarter trends, because we don't have all the first quarter trends, continue the improvement in procedural growth, but not dramatic, Glenn. Just a continued steady improvement in procedural growth. Anything else, Louise, there?"
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. So our estimate of the first quarter hip market is about 3.5% in the U.S. Again, qualified, but we haven't seen all the competitors' report. We think the U.S. knee market grew about 4.5%, and we believe we grew faster than those markets. Now we did h",79,"Yes. So our estimate of the first quarter hip market is about 3.5% in the U.S. Again, qualified, but we haven't seen all the competitors' report. We think the U.S. knee market grew about 4.5%, and we believe we grew faster than those markets. Now we did have about a 1.5 extra selling days. But even if you take that out of there, we do believe we grew faster than the market in hips and knees in the U.S."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Vamil Divan of Crdit Suisse.",10,"The next question is from Vamil Divan of Crdit Suisse."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","So just a couple following up on some of the topics that have been raised already. So one, recently, you're getting a lot of questions around your desire on the consumer side to maybe do business development. And I know you talked generally about M&A. But",173,"So just a couple following up on some of the topics that have been raised already. So one, recently, you're getting a lot of questions around your desire on the consumer side to maybe do business development. And I know you talked generally about M&A. But maybe if you could just provide a little more color on the consumer side, specifically in the medicine area, where you're looking to boost it? Is there a preference you can share? I think in the past, you've talked about emerging markets, but just wondering if there's any more timing you can share today on that side of things. And then the second question relates back to the INVOKANA discussion that was going on before. It was announced last week that the EMA is looking into the -- an increase in amputations that have been seen in the CANVAS study. I'm curious if you have any comments on that at this point. And also if there's something that the FDA is also looking into at this point."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Vamil. So on M&A, just in general, we're looking at M&A as an important additional growth driver in all of our businesses, including Consumer. As we've said before, Consumer can generally benefit from taking very, very specific brands with certain r",231,"Sure, Vamil. So on M&A, just in general, we're looking at M&A as an important additional growth driver in all of our businesses, including Consumer. As we've said before, Consumer can generally benefit from taking very, very specific brands with certain regional categories. We're certainly in our sweet spot of Skin Care, Baby, Oral Care, et cetera, where we think we could do better with the combination of the technology that we have and the overall market and distribution presence that we have. So we'll continue to look there. And again, like every other M&A evaluation, we'll make sure that it's at the right valuation at the right time. With respect to INVOKANA, a couple of things to mention there. There has been -- previous to this CANVAS study, there has been 12 previous studies with INVOKANA, where we saw no such indication of increased in lower limb amputations, particularly the toe, so this seems to be focused only on the patients in the CANVAS study. It's important to note that, yes, the European regulatory body is taking a look at it. But already, the independent monitoring committee that reviews the clinical trial after reviewing all the data concluded that the trial should continue. So that's what I can tell you about that. And obviously, we'll look to advise physicians appropriately of the results once we have more understanding of them."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Geoff Meacham of Barclays.",9,"The next question is from Geoff Meacham of Barclays."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Just a couple on the pharma segment. You guys have a new product cycle obviously coming up with guselkumab and sirukumab. I guess when you think about this in the context of the pricing environment, especially with Inflectra down the road, how do you guys",67,"Just a couple on the pharma segment. You guys have a new product cycle obviously coming up with guselkumab and sirukumab. I guess when you think about this in the context of the pricing environment, especially with Inflectra down the road, how do you guys think about durability of pricing and the innovation -- or sorry, in the Immunology segment? I have one more follow-up on pharma."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, sure, Geoff. Well, both guselkumab and sirukumab are different mechanisms of action in the current products that we have in Immunology. And typically, innovative products that have a significant impact on unmet medical need. In this case, it would be",179,"Yes, sure, Geoff. Well, both guselkumab and sirukumab are different mechanisms of action in the current products that we have in Immunology. And typically, innovative products that have a significant impact on unmet medical need. In this case, it would be those patients that are not otherwise responding to, for example, TNF therapy. Our view is that pricing will still continue to be -- either the products will still continue to be valued and therefore, not have a lot of pressure on pricing because there is some still significant unmet medical need, and that's a new mechanism of action that should have an impact on patients. I think that that's irrespective of whether or not there's a biosimilar in the market with respect to REMICADE because, overall, pricing for immunology products, particularly in the TNF category, already have pretty significant gross to net discounts in the marketplace. I think we've talked before about that ours are already in the 25% range. So I don't think there's that much room for there to be significantly lower pricing in that market."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Got you. And then just as a follow-up to the -- to other questions on M&A. The TESARO agreement with the PARP clearly has a lot of excitement with this class. I guess the question is, was the focus on prostate strategic? Or is it data-driven? I just want",79,"Got you. And then just as a follow-up to the -- to other questions on M&A. The TESARO agreement with the PARP clearly has a lot of excitement with this class. I guess the question is, was the focus on prostate strategic? Or is it data-driven? I just want to get your sense, Dominic, for maybe other indications that you could have some enthusiasm for 4 PARP (sic) [ PARP4 ] such as ovarian or breast cancer, et cetera?"
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Right. Well, our agreement with respect to this PARP inhibitor was the result of our oncology therapeutic area taking a look at where PARPs can have an added benefit. Our first approach to this is going to be with prostate cancer in conjunction with our d",63,"Right. Well, our agreement with respect to this PARP inhibitor was the result of our oncology therapeutic area taking a look at where PARPs can have an added benefit. Our first approach to this is going to be with prostate cancer in conjunction with our development of ARN-509 in prostate cancer. So the particular focus at the moment is in prostate cancer, Geoff."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Damien Conover of Morningstar.",9,"The next question is from Damien Conover of Morningstar."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Just a question on the nerve growth factor discontinuation. Looked like there was a prioritization within the pipeline to discontinue that. Just had a question, what projects you might be accelerating? Also, given that those Phase III studies are coming u",101,"Just a question on the nerve growth factor discontinuation. Looked like there was a prioritization within the pipeline to discontinue that. Just had a question, what projects you might be accelerating? Also, given that those Phase III studies are coming up shortly, just kind of want to understand that a little bit more. Also with the hepatitis C products there, you got some very potent products. Wanted to see what the next steps were for bringing those to the market, the time line. And then lastly, just on REMICADE, has J&J received a 180-day notice of a biosimilar launch from Pfizer?"
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","All right. Let me take them in the order you gave them, and Louise can help here as well. So with respect to -- why don't you take the hepatitis C question?",32,"All right. Let me take them in the order you gave them, and Louise can help here as well. So with respect to -- why don't you take the hepatitis C question?"
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Okay. So we're expecting to see some Phase II date of our -- of the AL-335 and the 3 direct acting inhibitors in 2016.",24,"Okay. So we're expecting to see some Phase II date of our -- of the AL-335 and the 3 direct acting inhibitors in 2016."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Right. And also, with respect to your question on the 180-day notice period, yes, we have received that from Celltrion. And with respect to the growth -- nerve factor discontinuance, what you said was exactly right. This is a portfolio question. As we men",100,"Right. And also, with respect to your question on the 180-day notice period, yes, we have received that from Celltrion. And with respect to the growth -- nerve factor discontinuance, what you said was exactly right. This is a portfolio question. As we mentioned, we have 19 -- sorry, we have 10 new products that we're planning to file between now and 2019. Obviously, we're going to focus on those. They all have more than a $1 billion potential. So we make portfolio decisions all the time, and this is just one -- another one of those types of decisions."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Matt Miksic of UBS.",9,"The next question is from Matt Miksic of UBS."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","This is Vik in for Matt. I have 2 questions. Now that the CJR bundle payment system is in effect for hips and knees, can you talk a little bit about your approach to customers and what you can expect to help there? And the second question I have is an upd",70,"This is Vik in for Matt. I have 2 questions. Now that the CJR bundle payment system is in effect for hips and knees, can you talk a little bit about your approach to customers and what you can expect to help there? And the second question I have is an update on the payer environment in spine. Any meaningful changes that you guys have seen in support amongst payers?"
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Well, generally speaking, on the bundling approach, which is now present in certain markets, but not across all markets in the U.S., we do think they were positioned very well there. Because obviously, we have a very broad portfolio of products, so the bu",122,"Well, generally speaking, on the bundling approach, which is now present in certain markets, but not across all markets in the U.S., we do think they were positioned very well there. Because obviously, we have a very broad portfolio of products, so the bundling approach with a hospital or an integrated care network would include multiple Johnson & Johnson products, which we think we're in a great position to partner with in that regard. The payer economics in spine, we haven't seen much of a dramatic change there. One thing I'd like to point out is we did see growth in our spine business this quarter of about 2%. So we're very pleased with that business coming back and showing some improvement."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Larry Biegelsen of Wells Fargo.",10,"The next question is from Larry Biegelsen of Wells Fargo."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","So Dominic, on the call today, you guided organic sales growth in 2016 about the same as in 2015, which was 5.5%, excluding the benefit from extra selling days. However, if we compare 2016 and 2015 organic growth on the same 52-week basis, we estimate tha",87,"So Dominic, on the call today, you guided organic sales growth in 2016 about the same as in 2015, which was 5.5%, excluding the benefit from extra selling days. However, if we compare 2016 and 2015 organic growth on the same 52-week basis, we estimate that your 2016 organic growth should be closer to 6% to 6.5%. In other words, the 5.5% in 2016 doesn't adjust for the extra selling days in 2015. Is that -- is our math directionally right, Dominic? And I had one follow-up."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, I think you're directionally right. I think you're right that without the -- if you just neutralize, I guess, is what you did, the extra selling days, you would see growth better than 5.5%, right.",36,"Yes, I think you're directionally right. I think you're right that without the -- if you just neutralize, I guess, is what you did, the extra selling days, you would see growth better than 5.5%, right."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay, I just wanted to confirm that. And then lastly, Dominic, last week, you just announced that you discontinued UPP or Unilateral Pricing Policy in your VISTAKON business. Can you talk about the rationale there and what this signals regarding any chang",99,"Okay, I just wanted to confirm that. And then lastly, Dominic, last week, you just announced that you discontinued UPP or Unilateral Pricing Policy in your VISTAKON business. Can you talk about the rationale there and what this signals regarding any change in your strategy and how you're running your contact lens business? If I recall, 2 years ago when you implemented UPP, it was disruptive to your U.S. VISTAKON business. So why should we not assume or be concerned that you might have similar types of disruptions from discontinuing UPP and moving to a different pricing model now?"
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Larry. Thanks for the question. Well, just a couple things on the Vision Care business and our ACUVUE brand. As you know, the ACUVUE business is -- has a long heritage of strong category growth as well as good innovation, which creates fantastic pro",306,"Sure, Larry. Thanks for the question. Well, just a couple things on the Vision Care business and our ACUVUE brand. As you know, the ACUVUE business is -- has a long heritage of strong category growth as well as good innovation, which creates fantastic products for contact lens wearers. And as you know, we are the world leader in contact lenses with the ACUVUE brand. And we just launched 4 new products in 2015, which are being received very well by the eye care professional and the contact lens wearer. Back in 2014, we did not have that kind of innovation coming to market first of all. And secondly, we saw some unevenness in the pricing in the market with very, very different pricing in different channels. So we decided to implement the Unilateral Pricing Policy in order to even out the pricing. And at the end of the day, what happened there was we did see a lower overall price for our products, which made the products more affordable. So today, the majority of the patients who get ACUVUE contact lenses are paying less than they did for that brand 2 years ago. Now with innovation, with the market stabilizing, we've adopted a new program that encourages patients to see their eye care professional and provides rebates and incentives for the purchase of contact lenses in conjunction with their eye exam, as prescribed by the eye care professional. And we think that's just the next evolution as a market leader to focus on eye health and not just price of the contact lens. So just a continued evolution of how we approach the market. And there may be -- when there is slight disruption in the market, we think that, overall, the long term benefit to the overall category into our business is worth it."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Thank you. And that concludes the Q&A. And we'll have some closing remarks from Dominic.",15,"Thank you. And that concludes the Q&A. And we'll have some closing remarks from Dominic."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Okay. Thanks, Louise. As I'd noted earlier, we're very pleased with our continued momentum as we entered into 2016. I would just like to take this time to recognize and thank all of our associates around the world for their extraordinary achievements and",74,"Okay. Thanks, Louise. As I'd noted earlier, we're very pleased with our continued momentum as we entered into 2016. I would just like to take this time to recognize and thank all of our associates around the world for their extraordinary achievements and dedication to the success of Johnson & Johnson. 
Thank you for your time this morning. I look forward to updating on our progress throughout the year, and have a great day."
139677,329029101,959429,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","Thank you. This concludes today's Johnson & Johnson First Quarter 2016 Earnings Conference Call. You may now disconnect your lines, and thank you for your participation.",26,"Thank you. This concludes today's Johnson & Johnson First Quarter 2016 Earnings Conference Call. You may now disconnect your lines, and thank you for your participation."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","Good morning, and welcome to Johnson & Johnson's First Quarter 2016 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] I would now turn th",49,"Good morning, and welcome to Johnson & Johnson's First Quarter 2016 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] 
I would now turn the conference call over to Johnson & Johnson. You may begin."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Good morning, and welcome. I'm Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure this morning to review our business results for the first quarter of 2016. Joining me on the call today is Dominic Caruso,",1723,"Good morning, and welcome. I'm Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure this morning to review our business results for the first quarter of 2016. 
Joining me on the call today is Dominic Caruso, our Chief Financial Officer. 
A few logistics before we get into the details. This review is being made available via a webcast accessible through the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. I'll begin by briefly reviewing the first quarter for the corporation and for our 3 business segments, then Dominic will provide some additional commentary on the business, review the income statement and guidance for 2016. We will then open the call to your questions. We expect the call to last approximately 1 hour. 
Included with the press release that was issued earlier this morning is the schedule of sales for key products and/or businesses to facilitate updating your models. These schedules are available on the Johnson & Johnson website, as is the press release. 
Please note, we will be using a presentation to complement today's commentary. The presentation is also available on our website. 
Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements. The 10-K for the fiscal year 2015 and the company's subsequent filings identify certain factors that could cause the company's actual results to differ materially from those projected in any forward-looking statements made today. The company does not undertake to update any forward-looking statements as a result of new information or future events or developments. Our SEC filings, including the 10-K, are available through the company and on our website. 
During the review, non-GAAP financial measures are used to provide information pertinent to ongoing business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with GAAP results. Tables reconciling these measures to the most comparable GAAP measures are available in the schedules accompanying the press release and on the Investor Relations section of the Johnson & Johnson website. A number of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships. 
Now I would like to review our results for the first quarter of 2016. Worldwide sales to customers were $17.5 billion for the first quarter of 2016, up 0.6% versus first quarter 2015. On an operational basis, sales were up 3.9%, and currency had a negative impact of 3.3%. In the U.S., sales were up 7.2%. In regions outside the U.S., our operational growth was 0.6%, while the effect of currency exchange rates negatively impacted our reported results by 6.6%. 
On an operational basis, Asia Pacific and Africa grew 3%. Europe declined 0.8% and the Western Hemisphere, excluding the U.S., declined by 0.6%. Results in all regions were negatively impacted by hepatitis C competition and divestitures, the most significant one being Cordis. 
In addition, the devaluation in Venezuela impacted operational growth in the Western Hemisphere, excluding the U.S. Excluding the net impact of acquisitions, divestitures and hepatitis C, underlying operational growth was 6.9% worldwide, 9.8% in the U.S. and 3.8% outside the U.S. In addition, the devaluation in Venezuela impacted worldwide and outside the U.S. operational growth by 60 basis points and 120 basis points, respectively. 
Turning now to earnings. Net earnings were $4.3 billion, and earnings per share were $1.54 versus $1.53 a year ago. As referenced in the table reconciling non-GAAP measures, 2016 first quarter net earnings were adjusted to exclude after-tax amortization expense of $205 million and the charge of $192 million for after-tax special items. 2015 first quarter net earnings were adjusted to exclude a net charge of $98 million. Dominic will discuss special items in his remarks. 
Excluding amortization expense and special items for both periods, adjusted net earnings for the current quarter were $4.7 billion and diluted earnings per share were $1.68, representing increases of 6.1% and 7.7%, respectively, as compared to the same period in 2015. 
Currency translation significantly impacted net earnings. On an operational basis, adjusted net earnings per share grew 10.3%. 
Turning now to business segment highlights. Please note percentages quoted represent operational sales change in comparison to the first quarter of 2015 unless otherwise stated and therefore, exclude the currency translation impact. I'll begin with the Consumer segment. 
Worldwide Consumer segment sales of $3.2 billion decreased 0.2%, with U.S. sales down 0.1%, while outside the U.S. sales were down 0.3%. Excluding the net impact of acquisitions and divestitures, underlying operational sales growth was 1.9% worldwide, 4.1% in the U.S. and 0.5% outside the U.S. 
In addition, the devaluation in Venezuela impacted growth worldwide and outside the U.S. by 200 basis points and 320 basis points, respectively, with the most significant impact to Women's Health, Oral Care and Baby Care. Growth for the segment was driven primarily by OTC worldwide and Oral Care. OTC sales growth was strong despite a weak flu season. U.S. OTC sales growth was driven by analgesic share growth and an inventory build as well as seasonal and new product launch inventory for upper respiratory products. 
In the U.S., adult analgesic market share was approximately 14%, up from approximately 12% a year ago; while U.S. pediatric share was nearly 46%, up from nearly 43% a year ago. Major contributors to the growth outside the U.S. were the strong performance of analgesics and anti-smoking aids, partially offset by lower sales of upper respiratory products due to the fourth quarter distributor inventory build, as noted last quarter. 
New product launches and successful marketing campaigns drove the results for LISTERINE in Oral Care. 
Moving now to our Pharmaceutical segment. Worldwide sales of $8.2 billion increased 8.5%, with U.S. sales up 12.9% and sales outside the U.S. up 2.6%, driven by both strong sales of new products as well as core growth products. Competitors in hepatitis C significantly impacted sales this quarter. Excluding sales of our hepatitis C products, OLYSIO and INCIVO, as well as the impact of acquisitions and divestitures, underlying sales growth worldwide U.S. and outside the U.S. was 12.3%, 16.2% and 7.1%, respectively. 
As we discussed last year, U.S. results in the first quarter of 2015 included a positive adjustment for gross-to-net, including managed Medicaid rebates. In the first quarter this year, U.S. results included an adjustment for a similar amount and therefore, overall growth was not impacted. However, on a product basis, STELARA growth in 2016 was positively impacted by approximately 16 points, XARELTO by 4 points and REMICADE by 3 points. 
Significant contributors to growth were immunology products, REMICADE, STELARA and SIMPONI/SIMPONI ARIA; oncology products, IMBRUVICA and recently launched DARZALEX; as well as cardiovascular metabolic products, XARELTO and INVOKANA. The results for immunology were driven by strong double-digit market growth as well as a gross-to-net adjustment to sales that I mentioned. 
Combined REMICADE export sales and international sales grew approximately 11%. Sales to distribution partners were up approximately 5%. Sales to our international direct markets were up approximately 17%, due primarily to strong double-digit growth in the Western Hemisphere, excluding the U.S., primarily driven by timing of shipments and market growth. 
Strong patient uptake with new indications, approvals and demonstrated efficacy drove the results for IMBRUVICA, both in the U.S. and outside the U.S. In the U.S., IMBRUVICA remains the new patient share and total share leader in second line CLL and MCL. IMBRUVICA is now launched in more than 65 countries. 
DARZALEX was approved in the U.S. in November 2015 and has achieved rapid uptake. DARZALEX contributed over 2% to the U.S. pharmaceutical growth rate. 
XARELTO sales were up 29%, and total prescription share or TRx for the quarter in the U.S. anticoagulant market grew to over 16.5%, up over 1.5 points from a year ago. TRx in primary care was nearly 14% and in cardiology, nearly 23.5%, up on a sequential basis by 0.5 point and 0.3 points, respectively. XARELTO is broadly reimbursed, with 95% of commercial and Medicare Part D patients covered at the lowest co-pay for a branded product. 
INVOKANA/INVOKAMET sales were up nearly 18% on a worldwide basis and nearly 12% in the U.S. In the U.S., INVOKANA/INVOKAMET TRx within the defined market of type 2 diabetes, excluding insulin and metformin, was 6.1%, up from 5.1% in the first quarter of 2015. TRx with endocrinologists was 11.5% and 5.5% in the primary care. 
On a sequential basis, sales declined due to the extra shipping days in the fourth quarter, incremental rebates and savings program redemptions as well as increased competition in formulary positions. INVOKANA access remains strong at 80% preferred for combined commercial and Part D. 
I'll now review the Medical Devices segment results. Worldwide Medical Devices segment sales of $6.1 billion increased 0.5%. U.S. sales increased 2.2%, while sales outside the U.S. declined 1%. Cordis was divested in the fourth quarter of 2015. Excluding the net impact of acquisitions and divestitures, underlying operational sales growth was 3% worldwide, with the U.S. up 3.3% and the growth of 2.8% outside the U.S. Growth was driven by Orthopaedics, advanced surgery and electrophysiology. 
Orthopaedics sales growth was driven by worldwide knees and hips, and U.S. trauma and spine. Market growth and the success of product launches drove results for the U.S. Orthopaedics business. Pricing pressure continued across the major categories, partially offset by positive mix for trauma and spine products. The success of the TFNA nailing system in trauma, the Attune platform in knees, our primary stem platform in hips and ORTHOVISC/MONOVISC and new spine product introductions made important contributions to results. 
Orthopaedics sales outside the U.S. were negatively impacted by results in China due to a softer demand and a reduction in inventory. Trauma and spine, other were the categories most impacted. In addition, timing of tender business negatively impacted trauma growth for the quarter. 
Strong results were achieved for advanced surgery products with endocutters growth of 10%, biosurgicals growth of 8% and energy growth of 8%. 
Electrophysiology grew 19% worldwide due to strong market growth, complemented by new product launches and increased penetration for both ultrasound and diagnostic catheters. 
That concludes the segment highlights for Johnson & Johnson's first quarter of 2016. It is now my pleasure to turn the call over to Dominic Caruso. Dominic?"
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Thanks, Louise, and good morning, everyone. We carried last year's momentum into 2016, and we're off to a strong start this year. We are very pleased with the results generated in the first quarter, and we continue to make very good progress on our near-t",2283,"Thanks, Louise, and good morning, everyone. We carried last year's momentum into 2016, and we're off to a strong start this year. We are very pleased with the results generated in the first quarter, and we continue to make very good progress on our near-term priorities as well as our long-term growth drivers, which we discussed during our January call. We remain confident in the strength of our business. 
As we've previously discussed in 2015, our underlying operational sales growth, which excludes the impact of acquisitions, divestitures as well as hepatitis C sales and a few extra shipping days in 2015, was 5.5%. On this same basis, we gained momentum in the first quarter, with strong underlying operational sales growth of approximately 7% and in line with analysts' estimates. 
In our Pharmaceutical business, our strong performance from 2015 continued into the first quarter, with underlying operational growth at over 12%. 
First quarter underlying operational sales growth for Consumer increased approximately 4% when also adjusting for the impact of the devaluation in Venezuela that Louise mentioned earlier. 
And in Medical Devices, we're off to a good start in the first quarter, with underlying operational growth of approximately 3%. Growth in our consumer-facing medical device businesses was negatively impacted by challenges in the diabetes market. 
For the hospital-focused medical device businesses, we're seeing signs of continued improvement, with underlying operational growth in those businesses of approximately 4%, driven by strength in our Orthopaedics, advanced surgery and electrophysiology businesses. 
We also saw an improvement in our overall adjusted pretax operating margin. For 2016, our guidance from January included a 200 basis point increase on an adjusted basis, and we remain comfortable with that forecast as we will accelerate throughout the year with the restructuring activities in our Medical Device business and lower levels of spending in the back half as compared to the prior year. As a reminder, pretax operating margin is defined as gross profit less selling, marketing, administrative and R&D expenses. 
Now I'll take a few minutes to highlight some key developments on the first quarter as well as some key points regarding our results, and then I'll provide some updates to our guidance for you to consider in refining your models for 2016. 
During the quarter, we had several key developments across the business. In our Pharmaceutical business, we received an additional approval for IMBRUVICA for first line treatment of chronic lymphocytic leukemia and also entered into a worldwide collaboration and license agreement with TESARO for exclusive rights to the investigational compound niraparib in prostate cancer. Niraparib is an orally administered poly polymerase, or PARP, inhibitor. 
We also continued our efforts to combat major global health challenges through collaborations with government organizations and others in the industry with a call for innovative ideas to reduce HIV infections in sub-Saharan Africa as well as providing funding for nonprofit organizations supporting underserved communities in the United States. 
In March 2016, we entered into an agreement to sell our controlled substance raw material and API business. In 2015, these businesses totaled approximately $250 million in net trade sales. This divestiture remains subject to customary closing conditions and regulatory approvals but is expected to be completed towards the middle of 2016. 
In Medical Devices, Ethicon completed the acquisition of NeuWave Medical, a privately held medical device company that manufactures and markets minimally invasive soft tissue microwave ablation systems. We look forward to providing an in-depth review of the ongoing efforts of our Consumer and Medical Device businesses at our upcoming business review meeting on May 18, which will take place in New Brunswick, New Jersey. 
I will now turn to our consolidated statement of earnings for the first quarter of 2016. As we've mentioned, our operational sales growth this quarter was 3.9%. And excluding the impact of acquisitions and divestitures and hep C sales, it was a strong 6.9%. If you'll direct your attention to the boxed section of the schedule, you will see we have provided our earnings adjusted to exclude intangible amortization and special items. 
As referenced in the table of non-GAAP measures, the 2016 first quarter net earnings were adjusted to exclude intangible asset amortization expense and special items of approximately $400 million on an after-tax basis, which consisted primarily of the following: intangible asset amortization of $200 million and litigation charges and our Medical Devices restructuring charge. 
Our adjusted earnings per share is therefore $1.68 per share, exceeding the mean of the analyst estimates, as published by First Call. This is an increase in adjusted EPS of 7.7% versus the prior year. Adjusted EPS on a constant currency basis was $1.72, up 10% over the prior year. 
Now let's take a few moments to talk about the other items in the statement of earnings. Cost of goods sold increased by 10 basis points, mostly due to transactional currency, partially offset by a favorable mix in the business. Selling, marketing and administrative expenses were 26.8% of sales or 110 basis points lower as compared to the first quarter of 2015 due to continued good cost management. 
Our investment in research and development as a percent of sales was 11.5% higher than the prior year due to increased project spending as we advance our promising product pipelines. 
Our pretax operating margin, when excluding special items and intangible amortization expense, was 32.9%, 30 basis points higher than the first quarter of the prior year. Interest expense net of interest income was lower than last year due to slightly better rates on our investments. Other income and expense was a net gain of $39 million in the quarter compared to a net gain of $348 million in the same period last year. 
Excluding special items that are reflected in this line item, other income and expense was a net gain of $127 million compared to a net gain of $91 million in the prior year period. 
Excluding special items, the effective tax rate was 19.2% compared to 21.5% in the same period last year. This year's effective rate reflects the R&D tax credit, which was passed by Congress late last year and the current mix of our business. 
Turning to the next slide. I will now review adjusted income before tax by segment. On our 2015 year-end call, we commented on our segment results for adjusted income before tax versus the prior year. Now that all of our competitors have reported their results for 2015, I would like to take the opportunity to point out that our 2015 adjusted income before tax was 31.4% compared to 26.2% weighted average for our competitive set. This was driven by higher margins in both Pharmaceutical and Medical Devices and somewhat lower margins in our Consumer business as compared to our competitive set. 
In the first quarter of 2016, our adjusted income before tax for the enterprise improved 80 basis points versus the first quarter of 2015, driven by improvement in both our Pharmaceutical and Medical Device businesses. Our Consumer business had a lower margin this year as compared to last year, due principally to devaluation in Venezuela. We are confident that our Consumer business will show an improved adjusted income before tax margin for full year 2016 as compared to 2015. 
Now I will provide some guidance for you to consider as you refine your models for 2016. At the end of the quarter, we had approximately $17 billion of net cash, which consist of approximately $40 billion of cash and marketable securities and approximately $23 billion of debt. As you know, in February, we took the opportunity to finance our share repurchase program and upcoming debt maturities at very attractive interest rates with a debt issuance of $7.5 billion. Through the end of the first quarter, we completed approximately 25% of our $10 billion share repurchase program, and we expect to complete 75% of the program by the end of this year. 
For purposes of your models and assuming no major acquisitions or other major uses of cash, I suggest you consider modeling net interest expense of between $450 million and $550 million. This is unchanged from our prior guidance. 
Regarding other income and expense, as a reminder, this is the account where we record royalty income as well as gains and losses arising from such items as litigation, investments by our development corporation, divestitures, asset sales and write-offs. We'll be comfortable with your models for 2016 reflecting net other income and expense, excluding special items, as a net gain ranging from approximately $1.1 billion to $1.2 billion. And this is also unchanged versus our January guidance. 
And now a word on taxes. Our guidance for 2016 includes the R&D tax credit that Congress made permanent in 2015. We are, therefore, comfortable with your models reflecting an effective tax rate for 2016, excluding special items, of approximately 19% to 20%, lower by 50 basis points than our previous guidance due to updating our outlook for a higher mix of our earnings from lower tax jurisdictions in 2016 than we anticipated in our previous guidance. 
And now turning to sales and earnings. Our sales and earnings guidance for 2016 takes into account several assumptions and key factors that I would like to highlight. As a reminder, our sales guidance for 2016 assumes no biosimilar entrant for PROCRIT or REMICADE in the U.S. And our assumption with regard to REMICADE biosimilar remains unchanged, even with the recent FDA approval of Inflectra due to our intellectual property, which we intend to defend. 
We also do not anticipate generic competition this year from ZYTIGA, RISPERDAL CONSTA and INVEGA SUSTENNA. But as expected, there are generic entrants for INVEGA and ORTHO TRI-CYCLEN LO. 
As we've done for several years, our guidance will be based first on a constant currency basis reflecting our results from operations. This is the way we manage our business, and we believe this provides a very good understanding of the underlying performance of our business. 
We will also provide an estimate of our sales and EPS results for 2016 with the impact that current exchange rates could have on the translation of those results. 
Consistent with our previous guidance, we'd be comfortable with your models reflecting an operational sales increase on a constant currency basis of between 2.5% and 3.5% for the year. This would result in sales for 2016 on a constant currency basis of approximately $71.9 billion to $72.6 billion. 
Additionally, by way of comparison to how we described our sales results in 2015, our operational sales growth for 2016, excluding the impact of all acquisitions and divestitures and hepatitis C sales, would be approximately 5.5%, a level of growth comparable to last year after adjusting for the extra shipping days in 2015, which we mentioned earlier. 
The devaluation in Venezuela that we previously discussed is anticipated to be a headwind of approximately 30 basis points for the full year, which we anticipate will be offset by the strength of the business. 
Although we're not predicting the impact of currency movements, using the euro as of last week at $1.13, the negative impact of foreign currency translation would be approximately 1%. This is an improvement of 50 basis points since we last provided guidance. We're watching the euro and other currencies closely as it is uncertain how they will eventually settle out for the year. 
Thus, under this scenario, we would expect reported sales to reflect the change in the range of 1.5% to 2.5% for a total expected level of reported sales of approximately $71.2 billion to $71.9 billion, higher than our previous guidance. 
Now turning to earnings. As a reminder, we expect transaction currency impacts to be negative to our gross margin by approximately 60 to 80 basis points in 2016 as compared to 2015. We would be comfortable with adjusted EPS guidance in a range between $6.56 to $6.71 per share on a constant currency basis, reflecting an operational or constant currency growth rate of 6% to 8%. This is higher than our previous guidance. 
If currency exchange rates for all of 2016 were to remain where they were as of last week, then our reported adjusted EPS would be negatively impacted by approximately $0.03 per share due to currency movements, a better outlook than the approximate $0.10 negative impact we discussed in our January guidance. Therefore, we would be comfortable with our reported adjusted EPS ranging from $6.53 to $6.68 per share, which is an increase from our previous guidance due to an update to our tax rate and current currency estimates. As it's still early in the year, we would be comfortable with your models reflecting the midpoint of this range. 
In closing, we're very pleased with our strong start for the year, and we are optimistic with what we see ahead for the full year, namely we're expecting operational sales growth of 2.5% to 3.5% and underlying operational sales growth of 5.5%, consistent with '15 -- 2015 growth on a comparable basis. 
Our operating margin improvements are on track to meet the expectations we laid out in our guidance of more than 200 basis point improvement over the prior year. Our operational adjusted EPS growth in our guidance remains strong in the range of 6% to 8%, and our businesses are continuing to invest while also delivering on our growth expectations. 
In particular, we're pleased to see our Medical Device businesses showing continued signs of improvement, and our restructuring activities in that business are on track. And we look forward to discussing with you in more detail these activities on our May 18 Investor Day. 
Now I'd like to turn things back to Louise for the Q&A portion of the call. Louise?"
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Dominic. And Manny, could you please give the instructions for the Q&A session?",15,"Thank you, Dominic. And Manny, could you please give the instructions for the Q&A session?"
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","[Operator Instructions] Our first question is from David Lewis of Morgan Stanley.",12,"[Operator Instructions] Our first question is from David Lewis of Morgan Stanley."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","I'm going to start with a strategic question for Dominic, and then one follow up. Dominic, the long-standing view of J&J has been to sort of assert the defensiveness of having these 3 major franchises under the J&J family of companies. Does that still rem",61,"I'm going to start with a strategic question for Dominic, and then one follow up. Dominic, the long-standing view of J&J has been to sort of assert the defensiveness of having these 3 major franchises under the J&J family of companies. Does that still remain the prevailing view of management and the board? And then I had a quick follow-up."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, David. It's our view, both management and the board, that our broadly based business is the right approach to have in health care. It certainly has served us well, and we expect it'll continue to serve us well as health care industry evolves in the f",82,"Yes, David. It's our view, both management and the board, that our broadly based business is the right approach to have in health care. It certainly has served us well, and we expect it'll continue to serve us well as health care industry evolves in the future. We think of ourselves as a health care company. And of course, that allows us to access opportunities in health care no matter where they be, either in pharma, medical devices or in consumer health."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay, that's very helpful. And then the second question maybe for Louise or Dominic. Just REMICADE, gross-to-net dynamics in the quarter. Any more detail you can sort of provide us on that? Or any sense of what you're expecting sort of net pricing gains t",53,"Okay, that's very helpful. And then the second question maybe for Louise or Dominic. Just REMICADE, gross-to-net dynamics in the quarter. Any more detail you can sort of provide us on that? Or any sense of what you're expecting sort of net pricing gains to be for REMICADE in the U.S. for 2016?"
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Okay. So as we discussed, we had the prior year gross-to-net that you saw that contributed -- I think it was 3% to the REMICADE growth. And pricing dynamics continue to be okay in that market.",36,"Okay. So as we discussed, we had the prior year gross-to-net that you saw that contributed -- I think it was 3% to the REMICADE growth. And pricing dynamics continue to be okay in that market."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","So I don't think it's expected that REMICADE sales will be -- significantly impacted year-over-year by gross-to-net adjustments.",19,"So I don't think it's expected that REMICADE sales will be -- significantly impacted year-over-year by gross-to-net adjustments."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Josh Jennings of Cowen and Company.",11,"The next question is from Josh Jennings of Cowen and Company."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","I know you've had some public comments, Dominic, recently around the REMICADE franchise. But now that we have the AdCom panel and the FDA approval in the review window, clearly, you don't expect any biosimilar competition in 2016 due to your defense of IP",64,"I know you've had some public comments, Dominic, recently around the REMICADE franchise. But now that we have the AdCom panel and the FDA approval in the review window, clearly, you don't expect any biosimilar competition in 2016 due to your defense of IP. But any updated thoughts on the potential impact of biosimilar competition to the REMICADE franchise in 2017 and beyond?"
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Well, you're right, Josh. We don't expect a biosimilar competition in 2016. And as you know, we have several patents that we intend to defend. And -- for example, the U.S. patent, the '471 patent, extends to 2018. And another patent that we have extends t",136,"Well, you're right, Josh. We don't expect a biosimilar competition in 2016. And as you know, we have several patents that we intend to defend. And -- for example, the U.S. patent, the '471 patent, extends to 2018. And another patent that we have extends to 2027. Having said that, I think, overall, the immunology franchise of Johnson & Johnson is very strong because it's not just about REMICADE. Of course, we have STELARA, SIMPONI, et cetera. And the overall pipeline in the Pharmaceutical business, as you know, from our review last May is very, very robust with 10 new products being filed, each of which having more than a $1 billion potential. So overall, we remain very, very comfortable with the growth outlook for the Pharmaceutical business regardless of the outcome of any REMICADE biosimilar."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","And I just wanted to follow up with a question on your operating margin guidance. Maintaining the 200 basis points. I was just curious about the Venezuelan crisis impact. It looks like it was primarily -- hit the consumer units operating margins. But can",125,"And I just wanted to follow up with a question on your operating margin guidance. Maintaining the 200 basis points. I was just curious about the Venezuelan crisis impact. It looks like it was primarily -- hit the consumer units operating margins. But can you talk about the expectations of Venezuela's impact on your operating margin guidance at the beginning of the year, how your internal expectations have evolved, clearly, with maintaining that guidance? The performance of the rest of the business units are going to offset any direct impact from Venezuela, but just wanted to hear about -- any offsets there and that impact to the operating margin -- performance of the Consumer unit. And can Consumer still experience operating margin expansion in 2016?"
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. Sure, Josh. Well, just to put things in perspective, Venezuela is less than 1% of our sales, less than 0.5% of our sales, so it's not a very significant impact. It is more significant in Consumer than in the other businesses. But we're very confident",100,"Yes. Sure, Josh. Well, just to put things in perspective, Venezuela is less than 1% of our sales, less than 0.5% of our sales, so it's not a very significant impact. It is more significant in Consumer than in the other businesses. But we're very confident in our outlook for a 200 basis point improvement in operating margin expansion -- pretax operating margin expansion for 2016, and that will be across all the businesses, including Consumer, who will make a significant contribution to that, even despite the impacts of Venezuela. So we're very confident with that outlook for the year."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Mike Weinstein of JPMorgan.",9,"The next question is from Mike Weinstein of JPMorgan."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","The Immunology franchise, REMICADE, SIMPONI, STELARA, all had much better growth than what the scripts would have suggested. So outside of the gross-to-net, was there an inventory catch-up this quarter that might have impacted those products?",36,"The Immunology franchise, REMICADE, SIMPONI, STELARA, all had much better growth than what the scripts would have suggested. So outside of the gross-to-net, was there an inventory catch-up this quarter that might have impacted those products?"
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","So in the U.S., nothing significant in the inventory. That market grows strong, strong double digits, and that is a good contributor to the Immunology. STELARA continues to grow market share. SIMPONI ARIA is contributing to the results. But in the U.S., n",47,"So in the U.S., nothing significant in the inventory. That market grows strong, strong double digits, and that is a good contributor to the Immunology. STELARA continues to grow market share. SIMPONI ARIA is contributing to the results. But in the U.S., no significant inventory build."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. Can we talk about DARZALEX? DARZALEX [indiscernible] very, very strong first full quarter out of the box here. Can you just talk about the uptake in multiple myeloma and how you see it playing out on the back of the relapsed/refractory data?",43,"Okay. Can we talk about DARZALEX? DARZALEX [indiscernible] very, very strong first full quarter out of the box here. Can you just talk about the uptake in multiple myeloma and how you see it playing out on the back of the relapsed/refractory data?"
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. Mike, we're obviously very pleased with the early uptake of DARZALEX. And as we said, it contributed 2 points of growth to our U.S. pharma business, so off to a great start. It's -- the CD38 mechanism of action seems to be something that the KOLs rea",75,"Yes. Mike, we're obviously very pleased with the early uptake of DARZALEX. And as we said, it contributed 2 points of growth to our U.S. pharma business, so off to a great start. It's -- the CD38 mechanism of action seems to be something that the KOLs really respect as having a significant impact on the disease. And we think the product's going to do extremely well, and we'll see continued uptake throughout the year."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. And also, we have the CASTOR trial, which actually the IDMC has recommended to stop early. So that's a very positive sign as well in that end.",28,"Yes. And also, we have the CASTOR trial, which actually the IDMC has recommended to stop early. So that's a very positive sign as well in that end."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Great. Dominic, one quick finance question for you. The tax rate coming down is -- runs a little bit counter to the performance of the business because your growth in the U.S. has been so strong, particularly in the Pharmaceutical business. So what we opt",99,"Great. Dominic, one quick finance question for you. The tax rate coming down is -- runs a little bit counter to the performance of the business because your growth in the U.S. has been so strong, particularly in the Pharmaceutical business. So what we optically is very strong U.S. revenue growth, and we assume U.S. profit growth. But obviously, the manufacturing and IP of some of those products is outside the U.S. Can you just shed a little bit of light there on how you're managing that because the U.S. business relative to o U.S. business looks very different?"
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, Mike. Well, it's an interesting observation. Actually, the strength of the sales in any one particular region does not necessarily correlate with the strength of the earnings in that region, and it's for the very reason that you mentioned, which is w",107,"Yes, Mike. Well, it's an interesting observation. Actually, the strength of the sales in any one particular region does not necessarily correlate with the strength of the earnings in that region, and it's for the very reason that you mentioned, which is where the IP is located, where the manufacturing takes place, et cetera. So what we did is we just updated our outlook with how the profits will fall amongst the different regions and different jurisdictions. And we thought about a 0.5 points improvement in the overall tax rate would be achievable this year for the full year. And therefore, we adjusted that in our outlook."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Kristen Stewart of Deutsche Bank.",10,"The next question is from Kristen Stewart of Deutsche Bank."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","I was just wondering if you could comment a little bit more about the diabetes business. I think, Dominic, you had mentioned there's challenges in the market. I was just wondering if you could comment about INVOKANA and the additional competition that's i",54,"I was just wondering if you could comment a little bit more about the diabetes business. I think, Dominic, you had mentioned there's challenges in the market. I was just wondering if you could comment about INVOKANA and the additional competition that's in the market or just provide a little bit more commentary there."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Sure. Well, just to clarify what I said, I was talking about challenges in the market with respect to our medical -- consumer medical device diabetes business, the LifeScan business. And what I meant by that was we see continued pricing pressure in that m",113,"Sure. Well, just to clarify what I said, I was talking about challenges in the market with respect to our medical -- consumer medical device diabetes business, the LifeScan business. And what I meant by that was we see continued pricing pressure in that market, and we also see some competition with respect to new pumps being launched. We've just launched a new pump, obviously, so we're also seeing good uptake with our current pump. So the dynamics I'm talking about are in the medical device piece of the business as being challenging. Overall, INVOKANA continues to do well. Its uptake is strong quarter-over-quarter and remains a growth driver for us going forward."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. And then, I guess, just more broadly, what are you seeing -- can you just go back and address kind of China? I know that was something that you had brought up just in terms of still seeing a little bit of softness. I think you had mentioned more wit",66,"Okay. And then, I guess, just more broadly, what are you seeing -- can you just go back and address kind of China? I know that was something that you had brought up just in terms of still seeing a little bit of softness. I think you had mentioned more within the Medical Device segment. Any changes there? Is it getting worse or getting any better?"
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Sure. Well, China, again, just to put it in perspective, it's about 5% of our overall business. And a slowdown in the economy actually last year is what caused some distributor inventory to be at relatively high levels. That distributor inventory is begin",80,"Sure. Well, China, again, just to put it in perspective, it's about 5% of our overall business. And a slowdown in the economy actually last year is what caused some distributor inventory to be at relatively high levels. That distributor inventory is beginning to bleed off. We saw that in the first quarter, and we think that, that bleed-off will be completed shortly, so we don't expect to see a continued impact of that for the rest of the year."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Jami Rubin of Goldman Sachs.",10,"The next question is from Jami Rubin of Goldman Sachs."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","I have a few questions. Just back to Kristen's question on diabetes. Just -- INVOKANA is an important growth driver for the company, but sales did come in a bit lighter than we had anticipated despite, I think, the growing excitement about this class of d",179,"I have a few questions. Just back to Kristen's question on diabetes. Just -- INVOKANA is an important growth driver for the company, but sales did come in a bit lighter than we had anticipated despite, I think, the growing excitement about this class of drugs. Dominic, can you comment just generally on what drug categories you are seeing widening gross-to-net discounts? And are you seeing more gross-to-net discounts or widening discounts specifically in diabetes? And can you comment on where you might be seeing that elsewhere in the pharma business? My second question is on the OTC business. You've clearly highlighted the strong growth that you're seeing in the U.S. and particularly, the analgesics market. How much of that growth is just regaining back lost market share from private label when you were out of the market? And how much of that is market growth? And maybe you can comment just generally on the dynamics of the OTC marketplace and where you see store brand market share now. And then I have one more follow-up, one more follow-up."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Okay, let's take them in order. So -- and Louise, you could add, obviously, if I've left anything out. I wouldn't say, Jami, that there's any one particular area in the business where we see sort of the widening of gross-to-net or rebating that's any diff",155,"Okay, let's take them in order. So -- and Louise, you could add, obviously, if I've left anything out. I wouldn't say, Jami, that there's any one particular area in the business where we see sort of the widening of gross-to-net or rebating that's any different than what we've seen before in the business. So rather than comment on any one particular area, I would say generally speaking, there's nothing that sticks out to us as a widening trend. With respect to U.S. OTC, a couple of things to mention. We are gaining back share, and the products are doing very, very well. And this particular quarter was a relatively low-growth market quarter because of a very, very soft flu season. Very, very soft flu season. So most of the growth that we saw is not on the back of market expansion, but on the back of share expansion as we continue to regain share."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Are you where you want to be in terms of regaining back that lost share? And where -- what is a realistic goal? I mean, you were out of the market completely. Where are you now?",36,"Are you where you want to be in terms of regaining back that lost share? And where -- what is a realistic goal? I mean, you were out of the market completely. Where are you now?"
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. So we're not where we want to be. We're pleased. As Alex often says, we're pleased, but not satisfied. So we're going to continue to gain share there. And Louise, do you have the year-over-year comparison of share?",39,"Yes. So we're not where we want to be. We're pleased. As Alex often says, we're pleased, but not satisfied. So we're going to continue to gain share there. And Louise, do you have the year-over-year comparison of share?"
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. So in 2009, before the McNeil issues that we had, the adult share was about 25%, and we're back to 14%. Pediatric was about 70%, and we're now back to 46%. So you're seeing some nice growth on that. And if you take a look at year-over-year, the adult",94,"Yes. So in 2009, before the McNeil issues that we had, the adult share was about 25%, and we're back to 14%. Pediatric was about 70%, and we're now back to 46%. So you're seeing some nice growth on that. And if you take a look at year-over-year, the adult share a year ago was 43%, so you see it going up about 3 points. And then the pediatric share is at the -- it's also going up to the 46%. So we're making progress. Sorry, that was pediatric share from 43% to 46%."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","We're making progress, Jami, but we're not finished. I think these products have a long heritage and legacy. They're very, very important in overall health care. And quite frankly, they are admired by consumers. So we expect to see continued share growth.",43,"We're making progress, Jami, but we're not finished. I think these products have a long heritage and legacy. They're very, very important in overall health care. And quite frankly, they are admired by consumers. So we expect to see continued share growth."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. And it's 14% U.S. share now, and it was 12%. And you asked about the private label. We think in the U.S. market, the adult is about 1/3, and the -- in the pediatric, it's about 40%.",38,"Yes. And it's 14% U.S. share now, and it was 12%. And you asked about the private label. We think in the U.S. market, the adult is about 1/3, and the -- in the pediatric, it's about 40%."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. And then just -- can I follow up, Dominic? I'm actually shocked that I'm, what, the sixth question -- this hasn't come up yet. Your net cash position is now $17 billion. That keeps growing. I don't think any company that I cover or anybody else cove",201,"Okay. And then just -- can I follow up, Dominic? I'm actually shocked that I'm, what, the sixth question -- this hasn't come up yet. Your net cash position is now $17 billion. That keeps growing. I don't think any company that I cover or anybody else covers has the kind of balance sheet prowess that you have, the lack of debt on your balance sheet. And I think it was -- I think, what was it, back in September at a Investor Conference, you had mentioned that you were uncomfortable with the amount of cash that you had growing on the balance sheet. And now here we are 6 to 7 months later and don't really see any activity with respect to putting that cash to work, with the exception of a buyback that you announced earlier this year. Can you just give us an update on your thoughts of -- thoughts on capital allocation? And clearly, we've had a lot of disruption in the marketplace with valuations on many names coming back. And I'm just surprised that we haven't really seen much action on the part of capital allocation from J&J. And then I'm done. And then I'm done."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Jami. Yes, okay, great. Okay, good. All right. Well, just to clarify, back in September, I didn't really say I was uncomfortable with the level of cash. I just said that it was a higher level of cash than we normally hold. And then of course, after",188,"Sure, Jami. Yes, okay, great. Okay, good. All right. Well, just to clarify, back in September, I didn't really say I was uncomfortable with the level of cash. I just said that it was a higher level of cash than we normally hold. And then of course, after that, we announced a $10 billion share buyback. So we're very conscious of the fact that while we're evaluating M&A opportunities, we can continue to return capital to shareholders, which, in addition to our very, very strong dividend, we can do share buybacks. We're in the middle of doing one right now, and we'll obviously evaluate whether we continue to increase that particular share buyback as time goes on. With respect to not allocating capital to any particular deals, I could tell you that we're very active. But as you know, we're also very disciplined. We do see opportunities, but we want to do the right deal at the right time with the right party at the right valuation. And we're comfortable waiting for that to take place because we think that's what ultimately generates the most value for shareholders."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. But is that what you plan to do with your cash? M&A, Dominic? Is that what you're -- is that what the message is today?",26,"Okay. But is that what you plan to do with your cash? M&A, Dominic? Is that what you're -- is that what the message is today?"
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Well, the message is very consistent, what it's always been. Our first priority is allocating capital to dividends. So we'll announce what we're going to do with dividends at our April 28 Shareholder Meeting. After that, we'd like to grow the business and",105,"Well, the message is very consistent, what it's always been. Our first priority is allocating capital to dividends. So we'll announce what we're going to do with dividends at our April 28 Shareholder Meeting. After that, we'd like to grow the business and create value for shareholders through M&A. And in addition to that, we'll continue to return share -- capital to shareholders through share purchases -- repurchase. So it's not really a change. So our attitude, our capital allocation policy does not change depending on how much capital we have. It's all about creating the most value for shareholders with whatever capital we deploy."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Glenn Novarro of RBC Capital Markets.",11,"The next question is from Glenn Novarro of RBC Capital Markets."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Just 2 questions. Let me first just piggyback on what Jami just asked because I think we're all surprised that J&J hasn't done more with the balance sheet so far. And I'm just wondering, Dominic, as you're having these discussions, it appears that some of",124,"Just 2 questions. Let me first just piggyback on what Jami just asked because I think we're all surprised that J&J hasn't done more with the balance sheet so far. And I'm just wondering, Dominic, as you're having these discussions, it appears that some of the targets you may be having discussions with have unrealistic valuation expectations. So maybe talk about where valuation expectations have come. Are they getting at least in the ballpark of what J&J thinks is appropriate valuation? And then with Allergan and Pfizer no longer getting together, you have 2 more companies that are going to be actively looking at deals. And does that make the competitive landscape more challenging for J&J? And then I had a follow-up on devices."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Glenn. Well, in certain areas of the market, valuations are still high. They're coming down, as you know, in biotech, in particular. But certain other areas, in med device, for example, certain valuations are still inflated, in our opinion. Things w",161,"Sure, Glenn. Well, in certain areas of the market, valuations are still high. They're coming down, as you know, in biotech, in particular. But certain other areas, in med device, for example, certain valuations are still inflated, in our opinion. Things will get better as time goes on, we believe. We're patient, disciplined. And as I said earlier, we'll look for the right opportunity, but at the right time at the right valuation. With respect to Allergan and Pfizer maybe being in the market now and creating more competition, that's probably true. I can't speak for what they're going to do. But we're accustomed to looking at various acquisition candidates where more than one party may be interested in a particular asset. That does not dissuade us from being disciplined and have a clear focus on ultimately what matters, which is the deployment of that capital to create shareholder value. So yes, there'll be more competition. We'll still remain very disciplined."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. And then just a follow-up on the device business. When you ex out divestitures and currency, the device business grew 3% in the first quarter, and that's pretty much in line with most of the device categories that we cover. But I don't think J&J had",100,"Okay. And then just a follow-up on the device business. When you ex out divestitures and currency, the device business grew 3% in the first quarter, and that's pretty much in line with most of the device categories that we cover. But I don't think J&J had any major new product launches here recently. So is -- the improvement in the device business for J&J, is that just better execution and better blocking and tackling? Or did some of the major end markets in cardio and ortho and spine in the first quarter come in slightly better than you expected?"
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. Well, just to clarify, 3% overall is the Medical Device business ex acquisition, divestitures. But the hospital-based Medical Device business, excluding the consumer-facing medical device businesses, that grew 4% on a comparable basis. We did have a",156,"Yes. Well, just to clarify, 3% overall is the Medical Device business ex acquisition, divestitures. But the hospital-based Medical Device business, excluding the consumer-facing medical device businesses, that grew 4% on a comparable basis. We did have a number of products that we filed last year, and we have about 30 new products that we're launching. Half of those have already been launched, so we are seeing the impact of those. And I think it's also a matter of focus, focus on the primary growth drivers. For example, you saw very good results in energy, in endocutters, in electrophysiology as major drivers of growth. And also, we're very pleased with the results in Orthopaedics and the Attune Knee. For example, in the U.S. in particular, the U.S. growth was over 8% for knees, which is pretty fantastic growth. And the Attune Knee is at one -- still a new product that's being launched in that marketplace."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","But as you talk to division heads, is everything -- are the end market status quo, no change, still stable? Or is there any pickup in some of these end markets?",31,"But as you talk to division heads, is everything -- are the end market status quo, no change, still stable? Or is there any pickup in some of these end markets?"
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","I think from what we've seen back in the fourth quarter trends, because we don't have all the first quarter trends, continued improvement in procedural growth, but not dramatic, Glenn. Just a continued steady improvement in procedural growth. Anything els",43,"I think from what we've seen back in the fourth quarter trends, because we don't have all the first quarter trends, continued improvement in procedural growth, but not dramatic, Glenn. Just a continued steady improvement in procedural growth. Anything else, Louise, there?"
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. So our estimate of the first quarter hip market is about 3.5% in the U.S. Again, qualified, but we haven't seen all the competitors' report. We think the U.S. knee market grew about 4.5%, and we believe we grew faster than those markets. Now we did h",79,"Yes. So our estimate of the first quarter hip market is about 3.5% in the U.S. Again, qualified, but we haven't seen all the competitors' report. We think the U.S. knee market grew about 4.5%, and we believe we grew faster than those markets. Now we did have about a 1.5 extra selling days. But even if you take that out of there, we do believe we grew faster than the market in hips and knees in the U.S."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Vamil Divan of Crdit Suisse.",10,"The next question is from Vamil Divan of Crdit Suisse."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","So just a couple following up on some of the topics that have been raised already. So one, recently [ph], you're getting a lot of questions around your desire on the consumer side to maybe do business development. And I know you talked generally about M&A",178,"So just a couple following up on some of the topics that have been raised already. So one, recently [ph], you're getting a lot of questions around your desire on the consumer side to maybe do business development. And I know you talked generally about M&A. But maybe if you could just provide a little more color on the consumer side, specifically in the medicine [ph] area, where you're looking to boost it? Is there a preference you can share? I think in the past, you've talked about emerging markets, but just wondering if there's anything more -- time that you can share today on that side of things. And then the second question relates back to the INVOKANA discussion that was going on before. There was an announcement last week that the EMA is looking into the -- an increase in amputations that have been seen in the CANVAS study. I'm curious if you have any comments on that at this point. And also if there's something that the FDA is also looking into at this point."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Vamil. So on M&A, just in general, we're looking at M&A as an important additional growth driver in all of our businesses, including Consumer. As we've said before, Consumer can generally benefit from taking very, very specific brands that are in ce",233,"Sure, Vamil. So on M&A, just in general, we're looking at M&A as an important additional growth driver in all of our businesses, including Consumer. As we've said before, Consumer can generally benefit from taking very, very specific brands that are in certain regional categories. We're certainly in our sweet spot of Skin Care, Baby, Oral Care, et cetera, where we think we could do better with the combination of the technology that we have and the overall market and distribution presence that we have. So we'll continue to look there. And again, like every other M&A evaluation, we'll make sure that it's at the right valuation at the right time. With respect to INVOKANA, a couple of things to mention there. There has been -- previous to this CANVAS study, there has been 12 previous studies with INVOKANA, where we saw no such indication of increased in lower limb amputations, particularly the toe, so this seems to be focused only on the patients in the CANVAS study. It's important to note that, yes, the European regulatory body is taking a look at it. But already, the independent monitoring committee that reviews the clinical trial after reviewing all the data concluded that the trial should continue. So that's what I can tell you about that. And obviously, we'll look to advise physicians appropriately of the results once we have more understanding of them."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Geoff Meacham of Barclays.",9,"The next question is from Geoff Meacham of Barclays."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Just a couple on the pharma segment. You guys have a new product cycle obviously coming up with guselkumab and sirukumab. I guess when you think about this in the context of the pricing environment, especially with Inflectra down the road, how do you guys",67,"Just a couple on the pharma segment. You guys have a new product cycle obviously coming up with guselkumab and sirukumab. I guess when you think about this in the context of the pricing environment, especially with Inflectra down the road, how do you guys think about durability of pricing and the innovation -- or sorry, in the Immunology segment? I have one more follow-up on pharma."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, sure, Geoff. Well, both guselkumab and sirukumab are different mechanisms of action than the current products that we have in Immunology. And typically, innovative products that have a significant impact on unmet medical need. In this case, it would",176,"Yes, sure, Geoff. Well, both guselkumab and sirukumab are different mechanisms of action than the current products that we have in Immunology. And typically, innovative products that have a significant impact on unmet medical need. In this case, it would be those patients that are not otherwise responding to, for example, TNF therapy. Our view is that pricing will still continue to be -- the products will still continue to be valued and, therefore, not have a lot of pressure on pricing because there is some still significant unmet medical need, and that's a new mechanism of action that should have an impact on patients. I think that that's irrespective of whether or not there's a biosimilar in the market with respect to REMICADE because, overall, pricing for immunology products, particularly in the TNF category, already have pretty significant gross-to-net discounts in the marketplace. I think we've talked before about that ours are already in the 25% range. So I don't think there's that much room for there to be significantly lower pricing in that market."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Got you. And then just as a follow-up to the -- to other questions on M&A. The TESARO agreement with the PARP clearly has a lot of excitement with this class. I guess the question is, was the focus on prostate strategic? Or is it data-driven? I just want",79,"Got you. And then just as a follow-up to the -- to other questions on M&A. The TESARO agreement with the PARP clearly has a lot of excitement with this class. I guess the question is, was the focus on prostate strategic? Or is it data-driven? I just want to get your sense, Dominic, for maybe other indications that you could have some enthusiasm for 4 PARP (sic) [ PARP4 ] such as ovarian or breast cancer, et cetera?"
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Right. Well, our agreement with respect to this PARP inhibitor was the result of our oncology therapeutic area taking a look at where PARPs can have an added benefit. Our first approach to this is going to be with prostate cancer in conjunction with our d",63,"Right. Well, our agreement with respect to this PARP inhibitor was the result of our oncology therapeutic area taking a look at where PARPs can have an added benefit. Our first approach to this is going to be with prostate cancer in conjunction with our development of ARN-509 in prostate cancer. So the particular focus at the moment is in prostate cancer, Geoff."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Damien Conover of Morningstar.",9,"The next question is from Damien Conover of Morningstar."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Just a question on the nerve growth factor discontinuation. Looked like there was a prioritization within the pipeline to discontinue that. Just had a question, what projects you might be accelerating? Also, given that those Phase III studies are coming u",101,"Just a question on the nerve growth factor discontinuation. Looked like there was a prioritization within the pipeline to discontinue that. Just had a question, what projects you might be accelerating? Also, given that those Phase III studies are coming up shortly, just kind of want to understand that a little bit more. Also with the hepatitis C products there, you got some very potent products. Wanted to see what the next steps were for bringing those to the market, the time line. And then lastly, just on REMICADE, has J&J received a 180-day notice of a biosimilar launch from Pfizer?"
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","All right. Let me take them in the order you gave them, and Louise can help here as well. So with respect to -- why don't you take the hepatitis C question?",32,"All right. Let me take them in the order you gave them, and Louise can help here as well. So with respect to -- why don't you take the hepatitis C question?"
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Okay. So we're expecting to see some Phase II data of our -- of the AL-335 and the 3 direct acting inhibitors in 2016.",24,"Okay. So we're expecting to see some Phase II data of our -- of the AL-335 and the 3 direct acting inhibitors in 2016."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Right. And also, with respect to your question on the 180-day notice period, yes, we have received that from Celltrion. And with respect to the growth -- nerve factor discontinuance, what you said was exactly right. This is a portfolio question. As we men",100,"Right. And also, with respect to your question on the 180-day notice period, yes, we have received that from Celltrion. And with respect to the growth -- nerve factor discontinuance, what you said was exactly right. This is a portfolio question. As we mentioned, we have 19 -- sorry, we have 10 new products that we're planning to file between now and 2019. Obviously, we're going to focus on those. They all have more than a $1 billion potential. So we make portfolio decisions all the time, and this is just one -- another one of those types of decisions."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Matt Miksic of UBS.",9,"The next question is from Matt Miksic of UBS."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","This is Vik in for Matt. I have 2 questions. Now that the CJR bundle payment system is in effect for hips and knees, can you talk a little bit about your approach to customers and what you can expect to help there? And the second question I have is an upd",70,"This is Vik in for Matt. I have 2 questions. Now that the CJR bundle payment system is in effect for hips and knees, can you talk a little bit about your approach to customers and what you can expect to help there? And the second question I have is an update on the payer environment in spine. Any meaningful changes that you guys have seen in support amongst payers?"
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Well, generally speaking, on the bundling approach, which is now present in certain markets, but not across all markets in the U.S., we do think that we're positioned very well there. Because obviously, we have a very broad portfolio of products, so the b",122,"Well, generally speaking, on the bundling approach, which is now present in certain markets, but not across all markets in the U.S., we do think that we're positioned very well there. Because obviously, we have a very broad portfolio of products, so the bundling approach with a hospital or an integrated care network would include multiple Johnson & Johnson products, which we think we're in a great position to partner with in that regard. The payer economics in spine, we haven't seen much of a dramatic change there. One thing I'd like to point out is we did see growth in our spine business this quarter of about 2%. So we're very pleased with that business coming back and showing some improvement."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","The next question is from Larry Biegelsen of Wells Fargo.",10,"The next question is from Larry Biegelsen of Wells Fargo."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","So Dominic, on the call today, you guided organic sales growth in 2016 about the same as in 2015, which was 5.5%, excluding the benefit from extra selling days. However, if we compare 2016 and 2015 organic growth on the same 52-week basis, we estimate tha",87,"So Dominic, on the call today, you guided organic sales growth in 2016 about the same as in 2015, which was 5.5%, excluding the benefit from extra selling days. However, if we compare 2016 and 2015 organic growth on the same 52-week basis, we estimate that your 2016 organic growth should be closer to 6% to 6.5%. In other words, the 5.5% in 2016 doesn't adjust for the extra selling days in 2015. Is that -- is our math directionally right, Dominic? And I had one follow-up."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, I think you're directionally right. I think you're right that without the -- if you just neutralized, I guess, is what you did, 3 [ph] extra selling days, you would see growth better than 5.5%, right.",37,"Yes, I think you're directionally right. I think you're right that without the -- if you just neutralized, I guess, is what you did, 3 [ph] extra selling days, you would see growth better than 5.5%, right."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay, I just wanted to confirm that. And then lastly, Dominic, last week, you announced that you discontinued UPP or Unilateral Pricing Policy in your VISTAKON business. Can you talk about the rationale there and what this signals regarding any change in",98,"Okay, I just wanted to confirm that. And then lastly, Dominic, last week, you announced that you discontinued UPP or Unilateral Pricing Policy in your VISTAKON business. Can you talk about the rationale there and what this signals regarding any change in your strategy and how you're running your contact lens business? If I recall, 2 years ago when you implemented UPP, it was disruptive to your U.S. VISTAKON business. So why should we not assume or be concerned that you might have similar types of disruptions from discontinuing UPP and moving to a different pricing model now?"
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Larry. Thanks for the question. Well, just a couple things on the Vision Care business and our ACUVUE brand. As you know, the ACUVUE business is -- has a long heritage of strong category growth as well as good innovation, which creates fantastic pro",307,"Sure, Larry. Thanks for the question. Well, just a couple things on the Vision Care business and our ACUVUE brand. As you know, the ACUVUE business is -- has a long heritage of strong category growth as well as good innovation, which creates fantastic products for contact lens wearers. And as you know, we are the world leader in contact lenses with the ACUVUE brand. And we just launched 4 new products in 2015, which are being received very well by the eye care professional and the contact lens wearer. Back in 2014, we did not have that kind of innovation coming to market first of all. And secondly, we saw some unevenness in the pricing in the market with very, very different pricing in different channels. So we decided to implement the Unilateral Pricing Policy in order to even out the pricing. And at the end of the day, what happened there was we did see a lower overall price for our products, which made the products more affordable. So today, the majority of the patients who get ACUVUE contact lenses are paying less than they did for that brand 2 years ago. Now with innovation, with the market stabilizing, we've adopted a new program that encourages patients to see their eye care professional and provides rebates and incentives for the purchase of contact lenses in conjunction with their eye exam, as prescribed by the eye care professional. And we think that's just the next evolution as a market leader to focus on eye health and not just price of the contact lens. So just a continued evolution of how we approach the market. And there may be -- when there is some slight disruption in the market, we think that, overall, the long term benefit to the overall category into our business is worth it."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Thank you. And that concludes the Q&A. And we'll have some closing remarks from Dominic.",15,"Thank you. And that concludes the Q&A. And we'll have some closing remarks from Dominic."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Executives","Okay. Thanks, Louise. As I'd noted earlier, we're very pleased with our continued momentum as we entered into 2016. I would just like to take this time to recognize and thank all of our associates around the world for their extraordinary achievements and",74,"Okay. Thanks, Louise. As I'd noted earlier, we're very pleased with our continued momentum as we entered into 2016. I would just like to take this time to recognize and thank all of our associates around the world for their extraordinary achievements and dedication to the success of Johnson & Johnson. 
Thank you for your time this morning. I look forward to updating on our progress throughout the year, and have a great day."
139677,329029101,959630,"Johnson & Johnson, Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Johnson & Johnson","Operator","Thank you. This concludes today's Johnson & Johnson First Quarter 2016 Earnings Conference Call. You may now disconnect your lines, and thank you for your participation.",26,"Thank you. This concludes today's Johnson & Johnson First Quarter 2016 Earnings Conference Call. You may now disconnect your lines, and thank you for your participation."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Good morning, and welcome to Johnson & Johnson's Second Quarter 2016 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] I would now like t",51,"Good morning, and welcome to Johnson & Johnson's Second Quarter 2016 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] 
I would now like to turn the conference call over to Johnson & Johnson. You may begin."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Good morning, and welcome. I'm Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure this morning to review our business results for the second quarter of 2016. Joining the on the call today is Alex Gorsky, C",2027,"Good morning, and welcome. I'm Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure this morning to review our business results for the second quarter of 2016. 
Joining the on the call today is Alex Gorsky, Chairman of the Board of Directors and Chief Executive Officer; and Dominic Caruso, our Chief Financial Officer. 
A few logistics before we get into the details. This review is being made available via webcast accessible through the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. I'll begin by briefly reviewing the second quarter for the corporation and for our 3 business segments. Following my remarks, Alex will comment on the 2016 results to date and provide a strategic outlook for the company. Next, Dominic will provide some additional commentary on the business, review the income statement and update guidance for 2016. We will then open the call to your questions. We expect the call to last approximately 90 minutes. 
Included with the press release that was issued earlier this morning is the schedule of sales for key products and/or businesses to facilitate updating your models. These schedules are available on the Johnson & Johnson website, as is the press release. 
Please note, we will be using a presentation to complement today's commentary. The presentation is also available on our website. 
Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements. The 10-K for the fiscal year 2015 and the company's subsequent filings identify certain factors that could cause the company's actual results to differ materially from those projected in any forward-looking statements made today. The company does not undertake to update any forward-looking statements as a result of new information or future events or developments. Our SEC filings, including the 10-K, are available through the company and on our website. 
During the review, non-GAAP financial measures are used to provide information pertinent to evaluating business performance period-over-period. These non-GAAP financial measures should not be considered replacements for and should be read together with GAAP results. Tables reconciling these measures to the most comparable GAAP measures are available in the schedules accompanying the press release and on the Investor Relations section of the Johnson & Johnson website. A number of products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships. 
Also to assist you with your models, this slide provide you with a summary of important developments for the current calendar quarter. 
Now I would like to review our results for the second quarter of 2016. Worldwide sales to customers were $18.5 billion, up 3.9% versus second quarter 2015. 
On an operational basis, sales were up 5.3% and currency have a negative impact of 1.4%. In the U.S., sales were up 7.4%. In regions outside the U.S., our operational growth was 3.1%, while the effect of currency exchange rates negatively impacted our reported results by 2.7%. 
On an operational basis, the Western Hemisphere, excluding the U.S., grew by 15.4% with approximately 1/3 of the growth due to an inventory build that will reverse in the third quarter. Asia Pacific, Africa grew 2.1%, while Europe declined 0.6%. Results in all regions were negatively impacted by hepatitis C competition and divestitures. The most significant one being Cordis. Excluding the next impact of acquisitions, divestitures and hepatitis C, underlying operational growth was 7.9% worldwide, 8.8% in the U.S. and 6.9% outside the U.S. 
In addition, operations in Venezuela negatively impacted worldwide and outside the U.S. operational growth by 30 basis points and 70 basis points, respectively. 
Turning now to earnings. Net earnings were $4 billion and earnings per share were $1.43 versus $1.61 a year ago. As a reference in the table reconciling non-GAAP measures, 2016 second quarter net earnings were adjusted to exclude after-tax amortization expense of $238 million and charges for after-tax special items of $631 million. 
2015 second quarter net earnings were adjusted to exclude after-tax amortization expense of $230 million and charges for after-tax special items of $66 million. Dominic will discuss special items in his remarks. 
Excluding amortization expense and special items for both periods, adjusted net earnings for the current quarter were $4.9 billion and diluted earnings per share were $1.74, representing increases of 1.1% and 1.8%, respectively, as compared to the same period in 2015. On an operational basis, adjusted net earnings per share also grew 1.8%. 
Now turning to the highlights for the first 6 months of 2016. Consolidated sales to customers were $36 billion, an increase of 2.3% as compared to the same period a year ago. On a year-to-date basis, sales grew 4.6% operationally and currency had a negative impact of 2.3%. 
Excluding the net impact of acquisitions and divestitures and hepatitis C sales, underlying operational growth was approximately 7.4% worldwide, 9.3% in the U.S. and 5.4% outside the U.S. 
In addition, operations in Venezuela negatively impacted worldwide and outside the U.S., operational growth by 50 basis points and 90 basis points, respectively. 
Turning now to earnings for the first 6 months of 2016. Net earnings were $8.5 billion and diluted earnings per share were $3.02. Adjusted net earnings were $9.7 billion and adjusted earnings per share were $3.47, up 5.3% and 6.1%, respectively, versus the same period last year. 
On an operational basis, adjusted net earnings per share grew 7.3%. 
Turning now to business segment highlights for the second quarter of 2016. Please note, percentages quoted represent operational sales change in comparison to the second quarter of 2015 unless otherwise stated and therefore, exclude the currency translation impact. 
I'll begin with the Consumer segment. Worldwide Consumer segment sales of $3.4 billion increased 1.5%, with U.S. sales up 2.1%, while outside the U.S. sales were up 1%. 
Excluding the net impact of acquisitions and divestitures, underlying operational sales growth was 3.9% worldwide, 6.8% in the U.S. and 2% outside the U.S. 
In addition, operations in Venezuela negatively impacted growth worldwide and outside the U.S. by 120 basis points and 200 basis points, respectively, with the most significant impact to Women's Health, Baby Care and Oral Care. 
Growth for the segment was driven primarily by Skin Care, OTC and Oral Care. 
In Skin Care, market share increases in a growing market as well as timing of inventory drove double-digit growth for both NEUTROGENA and AVEENO. 
OTC sales growth was strong despite a weak allergy season. U.S. OTC sales growth was driven by analgesic and adjusted held share growth. In the U.S., adult analgesic market share was approximately 14%, up from approximately 11% a year ago, while U.S. pediatric share was nearly 47%, up from nearly 44% a year ago. Major contributors to the growth outside the U.S. were the strong performance of anti-smoking aids, children's analgesics and adjusted health products. New product launches and successful marketing campaigns drove the results for LISTERINE in Oral Care. 
Moving now to our Pharmaceutical segment. Worldwide sales of $8.7 billion increased 9.7% with U.S. sales up 13.2% and sales outside the U.S. up 4.9%, driven by both strong sales of new products as well as core growth products. 
Competitors in hepatitis C significantly impacted sales this quarter. Excluding sales of our hepatitis C products, OLYSIO and INCIVO as well as the impact of acquisitions and divestitures, underlying sales growth worldwide U.S. and outside the U.S. was 12.8%, 13.9% and 11.2%, respectively. 
As you know, there were discounts and rebates in the pharmaceutical industry that are reflected in net sales. These amounts are estimated until the related claims data is received and then they are actualized. We have adjusted our estimates to reflect the most current claims trends. 
U.S. pharmaceutical results this quarter included a positive adjustment to sales reserves across many channels, which was approximately $140 million higher than the adjustment in the second quarter of 2015 and positively impacted second quarter 2016 worldwide growth by approximately 1.5 points and U.S. growth by approximately 2.5 points. 
On a product basis, REMICADE U.S. growth in the second quarter of 2016 was positively impacted by approximately 8 points, STELARA by 11 points, SIMPONI by 13 points, ZYTIGA by 8 points and PROCRIT by 31 points. 
Significant contributors to growth were immunology products: REMICADE, STELARA and SIMPONI/SIMPONI ARIA; oncology products, IMBRUVICA and recently launched DARZALEX; as well as cardiovascular metabolic products, XARELTO and INVOKANA. 
Within Neuroscience, strong growth for INVEGA SUSTENNA TRINZA was partially offset by lower sales of INVEGA due to the impact of generic competition. The results for immunology were driven by strong double-digit market growth, share growth for STELARA and SIMPONI ARIA as well as the growth to net adjustment to U.S. sales that I mentioned. 
The decline in REMICADE export sales to our distribution partners is due to the impact of biosimilars. 
Strong patient uptake with new indications approvals and demonstrated efficacy drove results for IMBRUVICA both in the U.S. and outside the U.S. 
In the U.S., IMBRUVICA remains the new patient share and total share leader in second-line CLL and MCL. IMBRUVICA is now launched in more than 70 countries. 
DARZALEX was approved in the U.S. in November 2015 and has achieved rapid uptake with strong underlying demand. DARZALEX contributed approximately 2 points to the U.S. pharmaceutical growth rate. DARZALEX received European Commission conditional approval this quarter and was launched in certain European countries. 
XARELTO sales were up 25.8% and total prescription share or TRx for the quarter in the U.S. anticoagulant market grew to nearly 17%, up 1.5 points from a year ago. TRx in primary care was over 14% and in cardiology, over 23%. XARELTO is broadly reimbursed with approximately 95% of commercial and Medicare Part D patients covered at the lowest co-pay for a branded product. 
INVOKANA/INVOKAMET sales were up 21% on a worldwide basis and 15.2% in the U.S. 
In the U.S., INVOKANA/INVOKAMET TRx within the defined market of type 2 diabetes, excluding insulin and metformin, was 6.3%, up from 6% in the second quarter of 2015. 
TRx with endocrinologist was approximately 11.5% and over 5.5% in primary care. 
INVOKANA access remains strong at nearly 70% preferred for commercial and over 90% for Medicare Part D. 
I'll now review the Medical Devices segment results. Worldwide Medical Devices segment sales of $6.4 billion increased 1.8%. U.S. sales increased 1%, while sales outside the U.S. increased 2.6%. As a reminder, Cordis was divested in the fourth quarter of 2015. Excluding the net impact of acquisitions and divestitures, underlying operational sales growth was 3.9% worldwide with U.S., up 1.9% and growth of 5.8% outside the U.S. 
In addition, operations in Venezuela negatively impacted growth worldwide and outside the U.S. by 30 basis points and 50 basis points, respectively. 
Growth was driven by advanced surgery, electrophysiology, orthopedics and Vision Care. Strong results were achieved for advanced surgery products with endocutters growth of 13%, energy growth of 9% and biosurgical's growth of 8%. 
The acquisition of NeuWave Medical also contributed to growth this quarter. 
Electrophysiology grew 18% worldwide due to strong market growth, complemented by new product launches and increased penetration for both ultrasound and diagnostic catheters. 
Orthopaedics sales growth was driven by U.S. trauma and worldwide hips and knees. Market growth in the success of product launches drove results for the U.S. Orthopaedics business. Pricing pressure continued across the major categories, partially offset by positive mix for trauma and spine products. 
The success of the TFNA mailing system in trauma, the ATTUNE platform in knees, our primary stem platform in hips and ORTHOVISC/MONOVISC and new spine product introductions made important contributions to the results. 
Orthopaedics sales outside the U.S. were negatively impacted results in China due to continued reduction in inventory, trauma and spine other were the categories most impacted. 
In addition, timing of tender business negatively impacted trauma growth for the quarter. 
Vision Care sales were driven by strong growth across the major regions, partially offset in the U.S. by a customer reward program. 
That concludes the segment highlights for Johnson & Johnson's second quarter of 2016. 
It is now my pleasure to turn the call over to Alex Gorsky. Alex?"
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Louise, and good morning, everyone, and thank all of you for joining us on the conference call or webcast today. As you just heard from Louise, our second quarter results have continued the momentum that began with our great start to 2016, an",2197,"Thank you, Louise, and good morning, everyone, and thank all of you for joining us on the conference call or webcast today. 
As you just heard from Louise, our second quarter results have continued the momentum that began with our great start to 2016, and we're pleased with our shareholders are seeing above-average returns on their investment in Johnson & Johnson. 
Delivering a fair return to shareholders is the final line of our credo, which clearly defines our first responsibilities, the doctors, nurses and patients, the mothers and fathers and all others who use our products. 
When we meet those responsibilities and when we continuously work to improve outcomes for patients around the world, we succeed all of our stakeholders. 
Now over the last 130 years, the people at Johnson & Johnson have been helping people everywhere live longer, healthier and happier lives. With that remarkable heritage, I'm excited and optimistic about the opportunities for the future of Johnson & Johnson and committed to continuing our long-term success. With our broad base of strong businesses, focused strategies and comprehensive approach to innovation, we're well prepared to address the challenges of today's health care market and well positioned to lead in the movement towards healthier societies. 
As I've discussed before, we believe our broad base in human health care is vital to achieving that vision. Our broad-based is a strategic choice based on performance, and it has helped us to deliver strong, consistent and sustainable financial performance through various economic cycles, meeting our financial commitments in the midst of global events like the U.K.'s vote to exit from the EU or the economic issues in Venezuela this year. 
Our broad base enables us to create and access growth opportunities wherever they may arise at the right time and in the right markets. 
Our deep health care expertise also makes Johnson & Johnson companies strategic partner of choice for many companies whether that means with innovative start-ups, information technology giants or large hospital systems looking to improve patient outcomes and reduce the cost of care. 
We also work with local governments and public health organizations where we're collaborating more than ever to address the world's most pressing health challenges. Our broad base allows us to create product platforms and systems across categories and establish new sources of innovation to converge in combination products. 
And finally, our broad base is helping us to realize advantages of scale to achieve enterprise efficiencies and capabilities across all of our segments. 
All of these advantages of our broad base in human health care contribute to the long-term value we are able to create for our shareholders. 
And we continue to have a clear set of objectives for creating that long-term value. We expect global health care to grow at 3% to 5% over the next 5 years, and we have an objective to grow our sales organically at a faster rate than the market. 
We also intend to grow our earnings faster than sales. When we combine these objectives with our plans that continue creating value through strategic acquisitions and partnerships as well as our strong dividend yields, we believe the result to be a basis for compelling, long-term total shareholder returns. 
And that is our focus. We invest for the long-term success of our business. In fact, we've increased our spending on R&D every year for the last 5 years. We invest above industry average levels to build our robust pipelines and continue to nurture the investments we've already made. 
We also invest in innovative sales and marketing initiatives and consistently benchmark to ensure the return on our investments is as competitive and as efficient as possible. 
I'm proud that we are able to make these important investments in our business, while also generating enterprise adjusted net income margins that have increased in our above-industry benchmarks. 
After we've made the appropriate investments in our business, we look to capitalize on the right opportunities to create greater long-term value for our shareholders. Our capital allocation framework starts with paying dividends to our shareholders, which is why we have increased our dividend every year for the last 54 years. 
Next, we seek value-creating strategic acquisitions and partnership opportunities. And finally, we consider other prudent ways to return value to shareholders such as repurchase programs. 
In fact, over the last 3, 10 and 20-year periods, Johnson & Johnson total shareholder return has exceeded our competitive composite and as you can see in this chart, we're up to a very strong start in 2016 with total shareholder return of approximately 20% through the first half of the year. 
And while we manage our business for the long term, we also have a number of near-term priorities, which I've shared with you before. As an enterprise, we're focused on delivering on our financial and quality commitments. Through the first 6 months, we generated sales of $36 billion, resulting in an operational growth of 4.6% when you exclude the impact of acquisitions, divestitures, hepatitis C sales and operations in Venezuela, underlying growth was 7.9%. 
To the first half of this year, we have delivered adjusted net earnings of $9.7 billion and adjusted EPS of $3.47.  On an operational basis, adjusted EPS was $3.51, representing growth of 7.3%. 
In our Pharmaceutical business, we continue to deliver very strong results. On the same underlying basis, growth was 12.7% through the first half of 2016, and we are continuing to build momentum in our Consumer and Medical Device businesses, with first half underlying growth of 4.5% and 3.7%, respectively. 
We also continue making progress with our quality system, including resolving a warning letter in our ASP business in completion of the Cindy's corporate integrity agreement. 
In pharmaceuticals, we're continuing to build on our launch excellence and robust pipeline. In the last several months, we have made significant advancements in our pipeline, including: Conditional EU approval for DARZALEX for monotherapy of adults with relapse and refractory multiple myeloma and presented positive Phase III data on castor and polyps studies, which are evaluating combination therapies for DARZALEX. 
We also received the EU approval for frontline IMBRUVICA treatment in CLL as well as FDA expansion of the IMBRUVICA label to include new Phase III data on survival and in combination therapies. 
Phase III data on STELARA demonstrated maintain clinical remission after 1 year treatment in patients with moderate to severe Crohn's disease. 
Clinical trial in real world data was presented on INVOKANA, including Phase II data on type 1 diabetes and chronic weight management. 
We received EU approval for TREVICTA, a once every 3 months injection for maintenance treatment of schizophrenia as well as line extension approval both INVOKAMET and SIMPONI. 
Positive Phase III data was presented on sirukumab for patients with moderately to severe active rheumatoid arthritis. 
And just recently, FDA granted a fourth Breakthrough Therapy designation for IMBRUVICA in graft-versus-host GDHD, which makes 6 total breakthrough designations for our Pharmaceutical business so far. 
In addition to these pipeline milestones as Louise pointed out, we also delivered strong growth with our in market products, including IMBRUVICA, DARZALEX, XARELTO, STELARA and SIMPONI. 
In consumer, our priority is expanding market leadership in key segments within OTC, Oral Care, baby and beauty. 
As part of our focus on the beauty space, we had just completed the strategic acquisition of Vogue International. The award-winning beauty products in this portfolio, including the OGX brand, enhance our existing position in the market in a highly complementary to our heritage of breakthrough innovations in this space. 
Vogue International has grown double digits over the last 5 years with a compound annual growth rate of about 25% and the acquisition will take us from #8 to #4 in the U.S. haircare market. 
And as we discussed in May at our Analyst Day, we're continuing to see operating margin improvement in our consumer business and plan to continue that trend for the next several years. 
And in Medical Devices, we're focused on accelerating growth through innovation and transforming our go-to-market models. In this segment, we're gaining momentum in accelerating growth through our unique and broad-based approach to innovation. Our performance this quarter was roughly in line with market growth. And we're pleased with the progress here, but far from satisfied. Our goal to be clear is to grow above market overall. 
And while we're making strategic decisions in our portfolio to achieve that growth like the recent acquisition of BioMedical Enterprises, which still the key portfolio gap in ankle, foot surgery, we're also realigning our commercial models in line with our near-term priority. Our innovation model in Hospital Medical Devices includes innovating our product offerings, but it also looks at innovation in terms of our commercial offerings and contracting. 
As we outlined during our business review day, today, about 25% of our U.S. orthopedic and surgery business is in multi-product line agreements. These agreements perform almost 2x better than single product contract agreements. We see this percentage growing to 40% in the near future, which we believe will help us accelerate our business going forward. 
And finally, we're also serving customers in a more end-to-end manner with risk sharing contracts and outcome-based patients solutions. 
We're also on track to deliver approximately $800 million to $1 billion in annual savings from our medical device restructuring, the majority of which we expect will be realized by the end of 2018. 
And also, we continue to make progress in launching new competitive entries in our Consumer Medical Device businesses like the ACUVUE VITA, a 30-day daily wear contact lens that provides superior comfort over leading monthly brands. 
With all these progress through our Medical Devices segment, we are confident that we are poised to deliver above-market growth. 
Altogether, these near-term priorities will help drive success for each of our business segments, while also enabling us to achieve the growth we expect for our company in the long term. With the progress we made on our near-term priorities, our businesses are strong, positioning us for above-market growth. With the combined strength of our in market portfolio, deep late-stage pipeline and robust early-stage pipeline, we feel confident our Pharmaceutical business can successfully navigate through the launches of new competitive biosimilar or generic entrance and evolving market dynamics. And our objective is to continue delivering above-industry growth. 
Our consumer business is positioned to grow above market, while also achieving benchmark profitability and investing for the future. 
In Hospital Medical Devices, we are poised to grow above the market, driven by our innovative pipelines, expanding global presence and novel commercial models. 
Our consumer Medical Devices businesses are holding leading positions and seeking opportunities to expand a large growing markets with significant unmet needs. 
With the strength of each of our business segments, we feel optimistic about the future opportunities in health care, and we are confident our long-term strategies have positioned us for continued growth. Our holistic approach to innovation, going beyond products and solutions, will allow us to address the evolving health care landscape, driving better outcomes and delivering long-term value. We have the right internal capabilities and are developing strategic partnerships in health tech to reshape the way health care is delivered, managed and experienced. 
And finally, our broad-based across human health care uniquely positions Johnson & Johnson as a leader in partner of choice in the health care market. 
But perhaps most importantly of all, our continued strong performance means we are able to create better products, more valuable services and improved outcomes for patients, consumers and their families. 
I'd like to thank you. I look forward to further dialogue during the Q&A session. But first, I'd like to take a moment to recognize Louise Mehrotra, who was most of you from our announcement last month, has decided to retire after more than 35 years with Johnson & Johnson and more than 10 years as Vice President of Investor Relations. 
I know many of you on the call today have gotten to know Louise pretty well over the last several years, a real testament to the strong relationship she's built in the investment community on behalf of Johnson & Johnson. And you may know that she's an incredibly committed credo-based leader and had a remarkable career and impact in our company. I think I can speak for all of us at Johnson & Johnson in saying that we will miss her trusted, experience, respected advice and her ever presence determination to do the best interest of our credo stakeholders. 
Louise, we're so proud of the best-in-class Investor Relations function you've developed for us over the last decade. And we sincerely thank you for your many years of service and dedication to Johnson & Johnson. 
Now we know we'll be in good hands with Joe Wolk, previously Vice President group finance for our pharmaceutical groups, will become Vice President Investor Relations effective August 1 and will transition with Louise over the next 5 months. 
We are confident that Joe will continue Louise's legacy of transparent and credible communication with you, our investors. 
So now, I'll turn it over to Dominic Caruso, who will talk more about our results and expectations for the second half of 2016. Dominic?"
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Thanks, Alex, and good morning, everyone. Before I get into our results, I'd like to echo Alex's sentiments and personally thank Louise for her significant contributions to Johnson & Johnson and for our valued support and friendship during my time as Ch",2646,"Thanks, Alex, and good morning, everyone. 
Before I get into our results, I'd like to echo Alex's sentiments and personally thank Louise for her significant contributions to Johnson & Johnson and for our valued support and friendship during my time as Chief Financial Officer. 
Over the last 10 years, Louise and the entire IR team has transformed our Investor Relations function, significantly developing our reputation with the investment community, which has been recognized with several awards and recognitions, including those from institutional investor and IR Magazine. And through surveys of money managers conducted by Barron's Magazine, Johnson & Johnson has been ranked at/or near the top of the most respected companies list for 10 of the last 12 years. In fact, I'm also pleased to report the Johnson & Johnson was recognized this year by Barron's Magazine as the #1 most respected company for 2016. 
As Alex noted, Louise's outstanding leadership and dedication to advancing our reputation will continue with her successor, Joe Wolk, who we're happy to have joining us on our call next quarter. We all wish Louise well, and we are certainly going to miss her. 
With that, I will now turn our discussion back to the quarter. We're very pleased with our second quarter results as we continue to see improved performance across the enterprise. And as Alex said, we remain confident in the strength of our business. 
As we've previously discussed in 2015, our underlying operational sales growth, which excludes the impact of acquisitions, divestitures as well as hepatitis C sales and the few shipping days in 2015, was about 5.5% On this same basis, we continue to deliver strong underlying operational sales growth of approximately 7.9% for the second quarter and our sales results are above analyst estimates. 
Our second quarter earnings were also above analyst estimates, driven by strong sales performance and operating margin improvement. 
As you may remember for 2016, our guidance from January included a 200 basis point increase in pretax operating margin on an adjusted basis. We were pleased to see progress towards this improvement during the second quarter, which I will discuss later. And we remain comfortable with that forecast as we continue to accelerate throughout the year with the restructuring activities in our Medical Device business and lower levels of spending in the back half as compared to the prior year. 
Now I'll take a few minutes to highlight some key points regarding our results and then I'll provide some updates to our guidance for you to consider in refining your models for 2016. 
I will now turn to our consolidated statement of earnings for the second quarter of 2016. As we've mentioned, our operational sales growth this quarter was 5.3% and excluding the impact of acquisitions and divestitures, hepatitis C sales and also the impact of the devaluation that occurred in Venezuela last year, it was strong at more than 8%. 
If you will direct your attention to the box section of the schedule, you will see we have provided our earnings adjusted to exclude intangible amortization, expense and special items. 
As referenced in the table of non-GAAP measures, the 2016 second quarter net earnings were adjusted to exclude intangible asset amortization expense and special items approximately $900 million on an after-tax basis, which consisted primarily of the following: Intangible asset amortization expense of about $200 million; litigation charges from ongoing legal matters of about $500 million; and additional charges as we continue to execute on the Medical Devices restructuring. 
Our adjusted earnings per share is therefore, $1.74, exceeding the mean of the analyst estimates as published by our first call. This is an increase in adjusted EPS of 1.8% versus the prior year and adjusted EPS on a constant currency basis was the same as the impact of currency was flat year-over-year. 
Now let's take a few moments to talk about the other items in the statement of earnings. Cost of goods sold decreased by 120 basis points, mostly due to favorable mix and manufacturing efficiencies, partially offset by transactional currency. 
Selling marketing and administrative expenses were 28% of sales or 230 basis points lower as compared to the second quarter 2015 due to good cost management. 
Our investment in research and development as a percent of sales was 12.2% and higher than the prior year due to increased project spending as we advanced our promising product pipelines. 
Our pretax operating margin when excluding special items and intangible amortization expense was 32.5% or 320 basis points higher than the second quarter of the prior year. 
As a reminder, pretax operating margin is defined as gross profit less selling marketing administrative and R&D expenses. 
As we anticipated, we are seeing improvement as we progressed throughout the year and through 6 months, we have achieved 180 basis point improvement in this measure of profitability. 
Interest expense net of interest income was slightly lower than last year due to slightly better rates on our investments. Other income and expense was a net expense of approximately $600 million in the quarter compared to a net gain of approximately $900 million in the same period last year. 
Excluding the special items that are reflected in this line, other income and expense was a net gain of approximately $100 million compared to a net gain of approximately $1 billion in the prior year period.  The significant decrease is due to the divestiture of NUCYNTA in the prior year period. 
Excluding special items, the effective tax rate was 19.2% compared to 23% in the same period last year. This year's effective tax rate reflect the R&D credit, which was passed by Congress late last year, the current mix of our business and the impact of new accounting standards related to the tax benefit on share-based compensation, which I will discuss further in a moment. 
Turning to the next slide. I will now review adjusted income before tax by segment. 
In the second quarter of 2016 , our adjusted income before tax margin for the enterprise declined by 250 basis points versus the second quarter of 2015. 
During the second quarter 2015, as I mentioned earlier, we recorded a gain from the divestiture of NUCYNTA, and this gain, which as you know from our discussions last year, was invested in various parts of the business but those investments occurred later in the year. 
If the NUCYNTA divestiture gain is excluded, year-on-year adjusted income before tax margin which show an improvement of approximately 300 basis points. We're very pleased to see a significant improvement in our consumer business adjusted income tax margin this quarter. As you may recall, from our business review day in May, we said that we are focused on improving our margins in the consumer business to benchmark levels. We are confident that our consumer business will show an improved adjusted income before tax margin of full year 2016 as compared to 2015. 
Overall, we expect income before tax margins for the enterprise to show an improvement over the prior year for all of 2016 as our increase in the pretax operating profit margin, which I noted earlier, more than offsets the lower level of divestiture gains in 2016 as compared to 2015. 
Now I will provide some guidance for you to consider as you refine your models for 2016. At the end of the quarter, we had approximately $16 billion of net cash, which consist of approximately $42 billion of cash and marketable securities and approximately $26 billion of debt. As you know, in May, we took the opportunity to finance our share repurchase program and upcoming debt maturities at very attractive interest rates, with the European debt issuance equivalent to $4.5 billion. 
Through the end of the second quarter, we have completed nearly 50% of our $10 billion share repurchase program, and we continue to expect to complete approximately 75% of the program by the end of this year. 
For purposes of your models and assuming no major acquisitions or other major uses of cash, I suggest you consider modeling net interest expense between $400 million and $500 million. This is a slight decrease from our prior guidance. 
Regarding other income and expense. As a reminder, this is the account where we recorded royalty income as well as gains and losses arising from such items as litigation investments prior development corporation divestitures, asset sales and write offs. We will be comfortable with your models for 2016 reflecting net other income and expense, excluding special items as of net gain, ranging from approximately $900 million to $1 billion, a lower range than our previous guidance related to the timing of underlying activity. This impact will be offset by the strength of our business, primarily due to our outlook for higher level of sales as noted in the increased sales guidance in our press release today. 
And now just a word on taxes. During the second quarter, the company elected for early adoption of a new accounting standard related to share-based compensation. With this update, increased tax benefits are recognized in earnings on the employee exercises options or received shares. Previously, these tax benefits were recorded in equity. 
The first quarter -- first quarter impact was approximately $165 million or $0.05 per share and is reflected in the year-to-date results and not in the second quarter when we adopted the standard. 
The second quarter impact is offset by additional tax cost reflected in this quarter. For adoption guidance, the first quarter does not need to be reissued. However, all future comparisons for the first quarter should reflect the recasted numbers. We have included a supplementary schedule on our website that includes the updated first quarter impact for the P&L. 
You will note that the first quarter recast number reflects a tax rate of 15.8%. The company issued shares related to employee stock compensation such as restricted stock, awards or performance share units in the first quarter. Therefore historically, a significant portion of the annual tax benefit is recognized in the first quarter. The tax benefit for stock options is recognized throughout the year as employees exercise their options, but timing is less predictable for stock options. 
We are comfortable with your models reflecting an effective tax rate for 2016 excluding special items will approximately 18.5% to 19%, lower than our previous guidance, primarily due to the accounting for share-based compensation tax benefit that I just described. 
Now turning to sales and earnings. Our sales and earnings guidance for 2016 takes into account several assumptions and key factors that I would like to highlight. 
As a reminder,  our sales guidance for 2016 assumes no biosimilar entrance for PROCRIT or REMICADE in the U.S. and our assumption remains unchanged with the recent FDA approval of Inflectra. 
We also do not anticipate generic competition this year for ZYTIGA, RISPERDAL CONSTA or INVEGA SUSTENNA. But as expected, there are generic and transport INVEGA and TRI-CYCLEN LO. 
As Alex mentioned, we have now closed the acquisition of Vogue International so our guidance now reflects 6 months of additional sales. This is a fast-growing business and will contribute to the profitability of our consumer business beginning the first full year as well as be accretive to our adjusted EPS beginning in the first full year. 
Also during the second quarter, we closed on our divestiture for the controlled substance raw material and API business and therefore, those sales were no longer be recorded. 
As we've done for several years, our guidance will be based first on a constant currency basis reflected our results for operation. This is the way we manage our business, and we believe this does provide a good understanding of the underlying performance of our business. 
We will also provide an estimate of our sales and adjusted EPS results for 2016 with the impact at current exchange rates could have on the translation of those results. 
As noted on our press release, we are increasing our operational sales guidance for 2016 primarily reflecting the strong results from the first half as well as 6 additional months of sales from the Vogue acquisition, partially offset by the divestiture of our controlled substance raw material and API business. We would, therefore, be comfortable with your models reflecting an operational sales increase on a constant currency basis of between 3% and 4% for the year. This would result in sales for 2016 on a constant currency basis of approximately $72.2 billion to $72.9 billion and higher than our previous guidance. 
Additionally, by way of comparison to how do we describe our sales results in 2015, our operational sales growth for 2016, excluding the impact of acquisitions, divestitures and hepatitis C sales would be approximately 6%, a higher level of growth than we saw last year after adjusting for the extra shipping days in 2015, which we've mentioned earlier. 
Although we're not predicting the impact of currency movements using the euro as of last week at $1.11, the negative impact of foreign currency translation will be approximately 1% on sales. This is consistent with our previous guidance as other major currencies strengthened since our last update. We are watching the euro and other currencies closely as it is uncertain how they will eventually settle after the year. Of course,  we're closely following the situation with the UK's vote to exit from the EU. We expect this will take them to fully determine what the impact will be, if any. 
To put it into perspective though, the U.K. represents about 3% of our total sales. So after impacts of currency, we would expect reported sales to reflect the change in the range of 2% to 3% for a total expected level of reported sales of approximately $71.5 billion to $72.2 billion and higher than our previous guidance. 
And now turning to earnings. As a reminder, we expect transaction currency impacts to be negative to our gross margin by about 60 to 80 basis points in 2016 as compared to 2015. We would be comfortable with adjusted operational EPS guidance in the range of between $6.66 to $6.76 per share on a constant currency basis, reflecting an operational constant currency growth rate of 7.4% to 9%. This is a narrower range as well as higher than our previous guidance, and includes the first quarter impact from the tax accounting change we discussed earlier. 
If currency exchange rates for all of 2016 were to remain where they were as of last week, then our reported adjusted EPS would be negatively impacted by approximately $0.03 per share due to currency movements, and this is consistent with our guidance in April. Therefore, we would be comfortable with our reported adjusted EPS ranging from $6.63, $6.73 per share, which is an increase from our previous guidance due both to the continued strength of the business and a lower tax rate. 
And at this point in the year, we will be comfortable with your models reflecting the midpoint of this range. 
In closing, we are very pleased with our strong start for the first 6 months of this year, and we are optimistic with what we see ahead for the full year, namely, we're expecting operational sales growth of 3% to 4% and underlying operational sales growth of 6% or higher than we saw in 2015 on a comparable basis. 
Our adjusted pretax operating margin improvements are on track to meet the expectations we laid out in our guidance of more than a 200 basis point improvement over the prior year. 
Our adjusted operational EPS growth in our guidance improved and remains strong in the range of $6.66 to $6.76 a share, that's a growth rate of between 7% and 9%. 
Our businesses are continuing to invest while also delivering on our growth expectations. 
And now, I'd like to turn things back to Louise for the Q&A portion of the call. Louise?"
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Dominic. Michelle, could you please give the instructions for the Q&A session?",14,"Thank you, Dominic. Michelle, could you please give the instructions for the Q&A session?"
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","[Operator Instructions] Our first question comes from the line of Mike Weinstein with JPMorgan.",14,"[Operator Instructions] Our first question comes from the line of Mike Weinstein with JPMorgan."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Dominic, just a couple items that we could help get you to clarify. So number one is, what's the impact for the full year EPS of ASU 2016 109 adoption? The tax rate coming down as it did suggest a range of anywhere from $0.04 to $0.12, so maybe you can he",79,"Dominic, just a couple items that we could help get you to clarify. So number one is, what's the impact for the full year EPS of ASU 2016 109 adoption? The tax rate coming down as it did suggest a range of anywhere from $0.04 to $0.12, so maybe you can help with that. And then second, can you just walk through the net impact of the Vogue acquisition and then the API business divestiture on sales and earnings?"
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Mike. Well with respect to the early adoption, I mentioned earlier that the first quarter impact was $0.05, and that's the most significant impact we expect for the year because that's where the majority of stock-based compensation is issued to empl",154,"Sure, Mike. Well with respect to the early adoption, I mentioned earlier that the first quarter impact was $0.05, and that's the most significant impact we expect for the year because that's where the majority of stock-based compensation is issued to employees. The second quarter impact was lower than that, but was almost entirely offset by other tax items, and the rest of the year will depend on when employees exercise stock options, so very difficult to predict. So for now, we've included in our effective tax rate for the year only the first quarter impact, which after we adopted in the second quarter, we're letting the first quarter impact flow through for the remainder of the year. Second quarter have already been offset by other items and remaining quarterly impacts we think will either likely be offset by other items or very difficult to predict because it's timing of when employees exercise options."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Yes, so your updated guidance, Dominic, doesn't assume any benefit in the second half of the year?",17,"Yes, so your updated guidance, Dominic, doesn't assume any benefit in the second half of the year?"
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","That's right. Only the first quarter flow through that we've experienced. And as I said, that's the largest single quarter of any stock-based compensation tax benefit. Sales with respect to Vogue and the API business. Vogue, for the full year, is in the $",119,"That's right. Only the first quarter flow through that we've experienced. And as I said, that's the largest single quarter of any stock-based compensation tax benefit. Sales with respect to Vogue and the API business. Vogue, for the full year, is in the $350 million range. We have about half a year of sales added to our guidance, and the API business was an annual business of about $250 million, and we'll have half a year of those sales no longer included in our guidance. So that's part of the increase in our overall growth in sales of about 0.5 points. The rest of it is due to the underlying strength we saw in the first 6 months."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. And then on the pharma business, can I get you just a comment in a couple of items. So one, this is obviously very important quarter for DARZALEX with the data we saw at ASCO with EHA. And we would love to get some high-level commentary on where you",88,"Okay. And then on the pharma business, can I get you just a comment in a couple of items. So one, this is obviously very important quarter for DARZALEX with the data we saw at ASCO with EHA. And we would love to get some high-level commentary on where you think that's position going forward in multiple myeloma. And then second, could you talk about the competitiveness of sirukumab given the Phase III data we just saw at EULAR and your expectation there on filing, timing and approval?"
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Now let me say a few words on both, and Alex, why don't you add a few and and Louise, also, on the timing question. So DARZALEX, we're very pleased with initial uptake of DARZALEX. The product is well received by the medical community and the data, as you",156,"Now let me say a few words on both, and Alex, why don't you add a few and and Louise, also, on the timing question. So DARZALEX, we're very pleased with initial uptake of DARZALEX. The product is well received by the medical community and the data, as you you pointed out, continues to be very impressive, and we believe DARZALEX can be essentially a backbone therapy for the treatment of multiple myeloma. So we expect that will get additional indications for DARZALEX, but it's already been quite well received by investment community having great results for patients and as I said, likely to be backbone therapy going forward. So sirukumab also very positive data there. It's an important product in our autoimmune franchise and Alex, maybe can comment a little bit more on that. And Louise, on the timing of filing for sirukumab, I just don't have it handy, if you can just give that."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","2016.",1,"2016."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","2016, so we'll file this year for sirukumab.",8,"2016, so we'll file this year for sirukumab."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Okay, look, we're excited about sirukumab on a number of fronts. First, as an IL-6, you know in this category, there's a lot of patient variability and having the option for patients, based upon the early days that we've seen in RA, some of the presentati",122,"Okay, look, we're excited about sirukumab on a number of fronts. First, as an IL-6, you know in this category, there's a lot of patient variability and having the option for patients, based upon the early days that we've seen in RA, some of the presentations recently at the EULAR conference, we're very encouraged by. We're going to be looking at it obviously in other areas. And I think what we're most enthusiastic about is if you combine sirukumab along with the work that we're doing with [indiscernible] as well, the IL-23 being looked at in psoriasis, it's really going to help us build out an even stronger portfolio and platform in immunology as we go forward over the next several years."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Larry Biegelsen with Wells Fargo.",13,"Our next question comes from the line of Larry Biegelsen with Wells Fargo."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Louise, congratulations on your retirement. I know you'll be missed. So one for Dominic, start financial start-up within net interest, that one market-related question. So Dominic, just on the guidance, 2 clarification questions. So the $0.10 raise at the",137,"Louise, congratulations on your retirement. I know you'll be missed. So one for Dominic, start financial start-up within net interest, that one market-related question. So Dominic, just on the guidance, 2 clarification questions. So the $0.10 raise at the lower end of the operational EPS and the $0.05 on the high end, is $0.05 due to the accounting change and the rest due to the underlying strength in the business? And then it appears there's a lot of moving parts on the sales guidance as well. That 5.5% in 2015 that you raised to 6% for 2016. By my math, that implies that you're expecting similar growth in the second half of 2016 compared to the first half of 2016. If one adjust for the extra week in the year ago period. So is that directionally accurate?"
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Larry. Well, with respect to EPS guidance, you mentioned 2 of the items, which, obviously, was tax as well as the stronger sales performance. But I just want to remind you that we also lowered our other income and expense guidance for the year. So o",150,"Sure, Larry. Well, with respect to EPS guidance, you mentioned 2 of the items, which, obviously, was tax as well as the stronger sales performance. But I just want to remind you that we also lowered our other income and expense guidance for the year. So one way to think about it is that other income and expense guidance is slower, the tax rate is also lower. Those 2 generally offset and the midpoint of the guidance is up about $0.07 and when I do the midpoint versus the 2 ends and the $0.07 is primarily due to the overall increases in sales guidance that we provided today. Your observations with respect to the back half of the year, you're right that if we exclude the extra shipping days in 2015 from the analysis, the back half of 2016 would be similar to what we saw for the first half."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And then just maybe the market for the U.S. maybe, Alex, if you could comment a little bit or Dominic on what you're seeing procedure volume in the U.S. in ortho and more broadly, in Med Tech, that would be great.",42,"And then just maybe the market for the U.S. maybe, Alex, if you could comment a little bit or Dominic on what you're seeing procedure volume in the U.S. in ortho and more broadly, in Med Tech, that would be great."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, thanks, Larry. Larry, we are seeing a pickup in terms of hospital admissions and surgical procedures. I think hospital admissions were up around 3%. We think the procedures are probably up around 3.5%. We continue to see some decrease overall in offi",99,"Yes, thanks, Larry. Larry, we are seeing a pickup in terms of hospital admissions and surgical procedures. I think hospital admissions were up around 3%. We think the procedures are probably up around 3.5%. We continue to see some decrease overall in office physician visits, down a couple of percent. We think that that's due to a more moderated utilization, the front-end due to increased co-pays and a number of other dynamics. But overall, as we look at the core growth rate in the medical hospital device area, we're encouraged by some of the recent trends that we seeing."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Kristen Stewart with Deutsche Bank.",13,"Our next question comes from the line of Kristen Stewart with Deutsche Bank."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","I'll echo, Louise, we'll be definitely missing you. But congratulations. I was just wondering if you could just comment a little bit about just on the capital allocations, obviously, Vogue. Is that what we should be thinking going forward in terms of the",62,"I'll echo, Louise, we'll be definitely missing you. But congratulations. I was just wondering if you could just comment a little bit about just on the capital allocations, obviously, Vogue. Is that what we should be thinking going forward in terms of the type of acquisition to look forward, the smaller more [indiscernible], I think for you guys in that range?"
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","All right , Kristen, thanks a lot for the question and couldn't agree with you more regarding Louise. But look, we are really happy that we're able to add Vogue to J&J consumer portfolio. And as we've been talking about over the last several years, we fel",372,"All right , Kristen, thanks a lot for the question and couldn't agree with you more regarding Louise. But look, we are really happy that we're able to add Vogue to J&J consumer portfolio. And as we've been talking about over the last several years, we felt that what's most important the consumer group was to actually ensure that we were able to get through the early stages of the remediation in a really high-quality and effective way. And I think the team has done a great job more broadly across an entire consumer group. I think we see that in the core trends and of course, was we establish that, we continue to see consumer us a great growth opportunity for the organization going forward. And as Jorge and as you saw when we did the medical device and consumer Investor Relations review now about a little over a month ago, I think they've got a really ambitious but also realistic plan for that, built on our existing brands, and we're really pleased to see performance, for example, LISTERINE up 7%; OTC is up 6%; analgesics within OTC were up over 13% and in beauty, we saw about 9% lift with really strong performance for NEUTROGENA and AVEENO. And when you take that and augment it, I think with thoughtful additions such as we saw over this last quarter whether it was NeoStrata, whether it was HIPOGLS or with Vogue, we think that those are great additions our existing portfolio and we'll  likely be part of a continuous stream of additions to that part of that portfolio. As we said for sometime whenever we're looking at inorganic growth opportunities, we look at tuck-ins, we look at midsize deals, we look at large deals, of course, the tuck in in strategy, particularly in pharma -- actually in all of our segments medical device and consumer are those that where we feel that we can create the most value, but we do think of there's other opportunities to create value as well. And again, in mid-larger deals, but we're going to be very disciplined, we're going to be very decisive about how we do it and ultimately, try to better serve patients and consumers."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And just, I guess, on that part, I guess, now that consumer has turned the corner has done well with the remediation, is that now a platform as you said is more ready for acquisitions? I know Medical Devices is in the midst of the restructuring. Is that h",61,"And just, I guess, on that part, I guess, now that consumer has turned the corner has done well with the remediation, is that now a platform as you said is more ready for acquisitions? I know Medical Devices is in the midst of the restructuring. Is that how we should think about it? And I have a follow-up for Dominic."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Sure. Look, we believe that mission one was really focusing on the core business as we see. I do feel that consumer like all of our businesses we are pleased we never completely satisfied and they've made a lot of progress on the core. And so we would exp",193,"Sure. Look, we believe that mission one was really focusing on the core business as we see. I do feel that consumer like all of our businesses we are pleased we never completely satisfied and they've made a lot of progress on the core. And so we would expect, again, in a very thoughtful disciplined way to continue to do additions when we think they're right. But we would look for the same thing in our other segments as well. And by the way, we're pleased with the progress that we've seen in our medical device group over the last quarter as well. I mean, if we look at the restructuring, I think overall the team is on track, they're doing actions to strengthen their go-to-market model, to accelerate their pace of innovation, they're prioritizing some additional platforms and geographies and all the while streamlining some operations but really keeping their high-quality standards. We think they're on track with the plan that they articulated earlier in the year, and we're confident that as they move through this, they will be -- not only stronger, but a more innovative and a more efficient business."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Great. And then Dominic, for the rebate in pharma, should we think about that as flowing through this quarter, or was that mainly reinvested as I know there was a higher rate of R&D this quarter?",36,"Great. And then Dominic, for the rebate in pharma, should we think about that as flowing through this quarter, or was that mainly reinvested as I know there was a higher rate of R&D this quarter?"
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Well, the way to think about it may be, Kristen, is that's a year-over-year change in about $140 million sales level, so obviously, some of that drops to the bottom line. And you're right, we do also take the opportunity to invest. Investments in R&D, rea",111,"Well, the way to think about it may be, Kristen, is that's a year-over-year change in about $140 million sales level, so obviously, some of that drops to the bottom line. And you're right, we do also take the opportunity to invest. Investments in R&D, really, are related to progress in the pipeline regardless of whether these gross to net adjustments would be available. But another way to think about it that we're now at the point where these actualizations of prior estimates, our current reserves are a significant portion of them our current because data has been coming in recently. So I wouldn't expect similar type of adjustments going forward."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Matt Miksic with UBS.",12,"Our next question comes from the line of Matt Miksic with UBS."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Alex, what I got you here just one strategic question and I don't know if this is consistent with what you're seeing or where you think things are going. But in devices, what we've seen is a lot of these new innovations and structural part, in particular,",131,"Alex, what I got you here just one strategic question and I don't know if this is consistent with what you're seeing or where you think things are going. But in devices, what we've seen is a lot of these new innovations and structural part, in particular, some of the vital payment initiatives seem to be driving more volumes to sort of higher volume centers, larger networks potentially augmented by outpatient centers. It's early in some of these initiatives, but that seems to be directionally where things are headed. First, would love to get your sense as to whether you think that's where things are going as well. And if so, how it changes position the devices side to support this kind of trend. And then I have one follow up."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Matt. Thank you very much for the question. Over the past 3 or 4 years I think we've been pretty consistent in our thinking, in our projections about likely increasing consolidation among providers and hospitals, particular here in the United States",249,"Sure, Matt. Thank you very much for the question. Over the past 3 or 4 years I think we've been pretty consistent in our thinking, in our projections about likely increasing consolidation among providers and hospitals, particular here in the United States and just broader health care systems. And as systems feel continuing from our pricing pressure, we think that will manifest itself by then having consolidation I think we've seen those trends. And I think they're clearly starting an effort to try and be as effective in as efficient as possible. So we do believe that, that will be a longer secular trend that's going to continue. That's why we believe having a diverse and enough critical mass in our medical device portfolio. It's so important going forward. We see it in the way that expectation are changing among decision-makers, including not only surgeons, but also people in procurement and other C suite executives, administrators and hospital systems. And we think as a result of that we'll be very well positioned, particularly when you think about our surgical franchise, our orthopaedics franchise. We've also been consistent in saying that we're extremely pleased with cardiovascular unit, particularly our EP group [indiscernible] Webster. We, once again, this quarter, they've delivered over 18.5% growth with great innovation and great execution, but we also realize that, that's an area where we will continue to look for the right kind of additions organically and inorganically to ensure that we're properly positioned going forward."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","That's great. And then on another topic that we spent a lot of time on, I guess, over the past year, and we're now a quarter away from what looked like a competitive launch in the U.S. biosimilar side on and REMICADE. I'd love to -- without asking you to",168,"That's great. And then on another topic that we spent a lot of time on, I guess, over the past year, and we're now a quarter away from what looked like a competitive launch in the U.S. biosimilar side on and REMICADE. I'd love to -- without asking you to tip your hand, of course, I'd like to get a sense as to can you -- is there other steps you can take given your portfolio on your relationship with these payers and networks? Are there steps you can take to sort of stop -- I don't know what the right word is potentially offset some of the potential impact or get ahead some of potential impact through some of the contracts that you're talking with these folks about. And I think you know the question I'm asking, and I'm sure you're not going to get through a ton of data, but any color would be helpful to the extent your ability to contract around that event."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","As we look at the landscape going forward we fully predict the generics and biosimilars are going to be part of the competitive landscape. And look, we think that, that is essential for the health care system. We think in the long run, it's actually a ben",400,"As we look at the landscape going forward we fully predict the generics and biosimilars are going to be part of the competitive landscape. And look, we think that, that is essential for the health care system. We think in the long run, it's actually a benefit for very innovative focused company because that's the only the pressure over the long term. Of course, that's predicated upon the market and companies respecting intellectual property. It's very important to produce the right scientific information so that we're guaranteeing patient safety. In understanding the important clinical differences between some of these compounds as they may or may not manifest themselves. And so we projected them. As we look at our strategic plan, we think they will be there. But we also feel that's what so important to keep innovating with new product launches going forward. And it's also critical to establish a strong critical mass in terms of products, but also expertise in clinical data and information in certain platforms. And so for us, in the immunology platform, we're very proud the extensive of track record that the REMICADE the team of a compound had and what it continues to do. we're continue to defend our intellectual property around it. But at the same time, if you look at compounds like STELARA and SIMPONI, not only have they both generated an excess of 30% growth this quarter, but we've also produced additional data that we think is going to be very important to patients and physicians in how they adopt these products and these are all already multibillion dollar platform for Johnson & Johnson. And then when you compound that with sirukumab and [indiscernible] again an IL-6 and IL-23 approach where we know there's a lot of patient variability, we think that's important. Also as we look at REMICADE itself, we know that there's about 2.4 million patients who've been treated with the compound. We know that about 70% of them in fact are getting good relief and good FX. We know that they're unlikely to be switched when they're getting a positive reference from the therapy, and we also know that when we contract across the Johnson & Johnson portfolio that it provides is a very important position with larger health care networks. So that's the way we think about it, and that's the way we plan for it going forward."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Josh Jennings with Cowen and Company.",14,"Our next question comes from the line of Josh Jennings with Cowen and Company."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","I wanted to ask a question, Dominic, first, just the operating margin performance again kind of meet our expectations. You reiterated your guidance for the year on the operating margin, expansion side of things. But I just wanted -- there are multiple dri",136,"I wanted to ask a question, Dominic, first, just the operating margin performance again kind of meet our expectations. You reiterated your guidance for the year on the operating margin, expansion side of things. But I just wanted -- there are multiple drivers operating margin expansion and there is -- you had a program in place I think you announced a couple of years ago and just started to ramp last year about $1 billion in cost savings by '18 that was exclusive of the medical device restructuring plan. I just wanted to get a sense of the contribution to operating margin expansion this year and if we're still in the early innings and whether we should see stronger benefit from that cost-savings plan as well as the medical device restructuring initiative in '17 and '18."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. Well, Josh you are right there are many factors that contribute. I mean, GP is one, so we continue to see good manufacturing efficiencies and cost improvements across the supply chain, that's a major initiative we've had ongoing for quite some time,",266,"Yes. Well, Josh you are right there are many factors that contribute. I mean, GP is one, so we continue to see good manufacturing efficiencies and cost improvements across the supply chain, that's a major initiative we've had ongoing for quite some time, so we saw some of that benefit this quarter. We expect that we'll see it going forward as well. In the selling market administrative line, that's where you see the benefit of the program you're referring to, where we anticipate about $1 billion of savings for 2018. That program is on track, we're seeing the savings. We also making some investments as the investments tail off, the savings will be more significant and more impactful in that line item going forward. So we're beginning to see the savings now. They're somewhat partially offset by some investments we need to make to continue the program. But in the future, those investments tail off and the savings ramp up, and they have more of an impact. And then also, as you mentioned, the medical device restructuring is a whole another area that's unrelated to the 2 that I just mentioned earlier, and we expect to see continued improvements there, although that's a business where we want also to accelerate the pace of innovation with those savings. So some of those will be reinvested in the business. So it's across those 3 areas, and we're committed to the operating margin improvement that I've mentioned earlier of greater than 200 basis points and halfway through the year, we feel very good about our ability to achieve that."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Excellent. And I just wanted to have a follow-up maybe for Alex and Louise. Just you commented on utilization levels in the U.S. and procedure volumes and I know you experienced just a modest apples-to-apples in selling days from sequentially modest decel",69,"Excellent. And I just wanted to have a follow-up maybe for Alex and Louise. Just you commented on utilization levels in the U.S. and procedure volumes and I know you experienced just a modest apples-to-apples in selling days from sequentially modest deceleration in knees and hips and spine on the ortho segment. Is there anything specific to Q2 that you're seeing in the marketplace that you can comment on?"
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Now, look, overall -- and thank you for the question. Overall, I think we saw solid growth in both knees and hips. I think we have about 4.5% in knees, about 5%, 5.5% in hips, and we think that, that's continued pick up from the ATTUNE launch and the CORA",80,"Now, look, overall -- and thank you for the question. Overall, I think we saw solid growth in both knees and hips. I think we have about 4.5% in knees, about 5%, 5.5% in hips, and we think that, that's continued pick up from the ATTUNE launch and the CORAIL hip. So I would say that consistent with what we're seeing in the broader market, consistent with what we're seeing in our business, we're seeing positive growth in that area."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","And for the OUS, it was about additional 1.5 days of selling days in the second quarter. And in the first quarter, we had additional selling days in the U.S. business as a reminder on that one.",37,"And for the OUS, it was about additional 1.5 days of selling days in the second quarter. And in the first quarter, we had additional selling days in the U.S. business as a reminder on that one."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Joanne Wuensch with BMO Capital Markets.",14,"Our next question comes from the line of Joanne Wuensch with BMO Capital Markets."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","I appreciate the commentary on the volumes, but I was curious if you can give us a commentary on pricing. And also with the April 1 implementation of the bundled payment program in the United States, if you're seeing any impact from that?",43,"I appreciate the commentary on the volumes, but I was curious if you can give us a commentary on pricing. And also with the April 1 implementation of the bundled payment program in the United States, if you're seeing any impact from that?"
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","So we talked about pricing on a Johnson & Johnson basis. And overall, pricing is modest in the quarter.",18,"So we talked about pricing on a Johnson & Johnson basis. And overall, pricing is modest in the quarter."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","I'd say, Joanne, that we haven't seen the impact yet in particular new mechanism that you just described. As Louise pointed out, pricing overall for the quarter year-over-year growth of the pricing is very, very modest in our results.",40,"I'd say, Joanne, that we haven't seen the impact yet in particular new mechanism that you just described. As Louise pointed out, pricing overall for the quarter year-over-year growth of the pricing is very, very modest in our results."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","I can provide some further color on hips and knees in the U.S., price mix if you'd like?",19,"I can provide some further color on hips and knees in the U.S., price mix if you'd like?"
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","That would be wonderful. Thank you so much.",8,"That would be wonderful. Thank you so much."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","So the second quarter for the hips was about 2.2% negative, price mix together and this is U.S. only. And for knees, it was about 2.6% negative, and that's similar trends to what we've seen consistently over time.",39,"So the second quarter for the hips was about 2.2% negative, price mix together and this is U.S. only. And for knees, it was about 2.6% negative, and that's similar trends to what we've seen consistently over time."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And then as to my second question had to do more with Vision Care. We saw a real difference between what is happening in the U.S. and what's OUS sale, and you commented on rebates. Is that the replacement program UPP that we're seeing in that U.S. impact?",48,"And then as to my second question had to do more with Vision Care. We saw a real difference between what is happening in the U.S. and what's OUS sale, and you commented on rebates. Is that the replacement program UPP that we're seeing in that U.S. impact?"
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","So it's a customer reward program that we have implemented. And what we have booked in the second quarter is the year-to-date because it was implemented in the second quarter, but it applies to the full year sales. So in the U.S., if you normalize it for",66,"So it's a customer reward program that we have implemented. And what we have booked in the second quarter is the year-to-date because it was implemented in the second quarter, but it applies to the full year sales. So in the U.S., if you normalize it for the half that applied to the first half, the U.S. is up about 6% on a like basis."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","And we continue to be pleased with what we're seeing and the turnaround in our Vision Care business as well. If we look at the early demand signals that we're seeing, it continues to give us confidence that we're gaining share. We continue to launch into",89,"And we continue to be pleased with what we're seeing and the turnaround in our Vision Care business as well. If we look at the early demand signals that we're seeing, it continues to give us confidence that we're gaining share. We continue to launch into beauty, astigmatism, reusables, along with a number of other new launches and line extensions. And frankly, the team was really executing well, so we encouraged by the opportunity that we see in Vision Care as we move to the rest of 2016."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Glenn Novarro with RBC Capital Markets.",14,"Our next question comes from the line of Glenn Novarro with RBC Capital Markets."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Louise, I echo the sentiments, so best of luck in the future. My question is for Alex and for Dominic. And I asked a similar question on the last quarterly call because I continue to be surprised that J&J is not doing more with its cash, particularly on t",136,"Louise, I echo the sentiments, so best of luck in the future. My question is for Alex and for Dominic. And I asked a similar question on the last quarterly call because I continue to be surprised that J&J is not doing more with its cash, particularly on the M&A front. You've done Vogue, but we haven't seen much in the way of at least meaningful acquisition from devices and on pharma. And so my question is, the targets that you're having discussions with today, do they still have very unrealistic valuation expectation? And is that the reason why we haven't seen deals in devices in pharma? And then as a follow-up, you still have a bulk of your cash sitting outside the United States. Is that another reason why we haven't seen any meaningful acquisitions?"
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Well, sure, Glenn. Well, consistent with what we said last time when you asked a very similar question. We, as you know, we're very disciplined in our approach to acquisitions and although we're  actively involved in considering them, valuations come into",287,"Well, sure, Glenn. Well, consistent with what we said last time when you asked a very similar question. We, as you know, we're very disciplined in our approach to acquisitions and although we're  actively involved in considering them, valuations come into play and the willingness of the other party to do an acquisition have certain valuations come into play. So that's regardless of how much money we have available to spend, right? So we don't really look at that as the main driver of how we're going to the acquisitions. We look at what value we're going to create for shareholders by doing the acquisition of the right value, so we can improve returns for our shareholders. There are some expectations that are still not, in our opinion, normalized for appropriate valuations in the market, so that's a factor, and that will take time, and we're patient with that and we'll take -- we'll see how the market evolves overtime or as we learn more about the acquisition candidates and their progress in various areas. And then finally, whether or not the cash is trapped overseas or not is not at all an impediment to our ability to do any acquisitions. We'll either obviously try to find a way to do it in the tax efficient basis as we've done with other acquisitions and utilize that cash as much is possible only if it's tax efficient but then obviously, we can continue to borrow and we have ability to borrow to do the acquisitions that we think are value creative for our shareholders. So we won't let that hold us back should the acquisition beat value creating, we exercise our ability to borrow and do that acquisition."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And just as a follow-up -- Alex, did you want to add something?",14,"And just as a follow-up -- Alex, did you want to add something?"
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, Glenn, right. I guess, what I would also say is look, I think the M&A approach that we've talked about in the past is a balanced one. I mean, if you look over the last 20 years, I think we've done about 124 deals, I think there's been about 13-or-so",183,"Yes, Glenn, right. I guess, what I would also say is look, I think the M&A approach that we've talked about in the past is a balanced one. I mean, if you look over the last 20 years, I think we've done about 124 deals, I think there's been about 13-or-so that have been over $1 billion. The majority of these have been smaller and frankly, if you look at our pharmaceutical performance, and whether it's the partnerships that we have on a compound like IMBRUVICA, DARZALEX, others, I think the strategy ha worked really well and something that we continue to pursue. I think we have a lot of examples of that Medical Devices and also consumer. And there's nothing that we would like more to take several $100 million platform like Vogue and create the next multibillion platform as we see in things like NEUTROGENA and others. So all that being said, if when we see larger opportunities present an opportunity to really create longer-term shareholder value, those are things we'd be simply interested, but we'll be particularly thoughtful about these."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And just one quickly on REMICADE, I know Matt has asked a question about REMICADE but remain very confident that biosimilar won't be launched in 2016. Has anything changed that you can reveal to us on the litigation front that gives you more confidence?",44,"And just one quickly on REMICADE, I know Matt has asked a question about REMICADE but remain very confident that biosimilar won't be launched in 2016. Has anything changed that you can reveal to us on the litigation front that gives you more confidence?"
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Glenn, what we've said is that our guidance does not assume any biosimilar launch in 2016. There's ongoing developments in the litigation. There's a hearing scheduled for August related to the 471 patents, so love to see how that -- what the results of th",167,"Glenn, what we've said is that our guidance does not assume any biosimilar launch in 2016. There's ongoing developments in the litigation. There's a hearing scheduled for August related to the 471 patents, so love to see how that -- what the results of that hearing, we don't know that yet. There was also a ruling issued in relation to another biosimilar, not our biosimilar, which made it very clear when the 180-day waiting period would apply. And for us, that 180-day waiting period extend to October 6, obviously, there could that be any launch before that date. And then as we've mentioned, we're continuously and vigorously defending our patent, and we'll continue to do that. So whether or not our biosimilar launch happens is uncertain, but we have not included it in our guidance estimates. But as you know, our guidance, of course, is a range, and between certain ranges of 3% to 4% and overall growth, so we feel confident about that in any event."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of David Lewis with Morgan Stanley.",13,"Our next question comes from the line of David Lewis with Morgan Stanley."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Congrats, Louise. Once again, in echo other sentiments. So just 2 quick questions, I know we're  at the end So Dominic, I'm trying to reconcile revenue guidance just on the margins. So if I take the upside in the quarter, plus the net impact of M&A sort o",100,"Congrats, Louise. Once again, in echo other sentiments. So just 2 quick questions, I know we're  at the end So Dominic, I'm trying to reconcile revenue guidance just on the margins. So if I take the upside in the quarter, plus the net impact of M&A sort of Vogue minus the API business, I kind of get guidance should come up, sort of $700 million, it's coming up around $300 million. Is that difference in the back half of the year largely an expectation for lower or minimal gross to net adjustments in the back half versus the first half?"
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Well, certainly, as I mentioned earlier, the gross to net adjustments that we saw in the first half have now resulted in our overall estimates for these amounts as being largely current, no greater than 90% current. Therefore, we wouldn't expect to have t",56,"Well, certainly, as I mentioned earlier, the gross to net adjustments that we saw in the first half have now resulted in our overall estimates for these amounts as being largely current, no greater than 90% current. Therefore, we wouldn't expect to have the same level of those kinds of adjustments going forward, David, that's right."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay, helpful. Maybe 2 questions on consumer, one for Alex and one for Dominic. Dominic, just start with you with margins. Have the Analyst Day feeling that consumer outlook is probably conservative but if I look at the reported results in the quarter, yo",103,"Okay, helpful. Maybe 2 questions on consumer, one for Alex and one for Dominic. Dominic, just start with you with margins. Have the Analyst Day feeling that consumer outlook is probably conservative but if I look at the reported results in the quarter, you're well ahead of expectations in pursuing that sort of pure-based 20% consumer margin. So how do we think about that? Is to simply onetime in nature of war is it much more likely now you reasonably exceed your targets either in time or magnitude here in consumer? And then I have a quick follow up for Alex in consumer."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Well, as you know, we were committed to this and as Jorge Mesquita said in the business review day, he was personally committed to making it happen, and we're very pleased to see that they're off to a great start. Whether they exceed the overall benchmark",116,"Well, as you know, we were committed to this and as Jorge Mesquita said in the business review day, he was personally committed to making it happen, and we're very pleased to see that they're off to a great start. Whether they exceed the overall benchmark level in a shorter amount of time, we'll  wait to see because obviously, we want to see them investment our brands and keep the momentum up in the business as well. But it's obviously off to a great start. We are confident that they be able to do it and they've done a great job, and we're confident that they will continue to do a great job in improving margins."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. And Alex, I think many investors have felt that consumers sort of kept in the cloud in the last several years and clearly, the last 6 months company is working hard sort of show the consumer franchise the great extent both margins and growth. My que",112,"Okay. And Alex, I think many investors have felt that consumers sort of kept in the cloud in the last several years and clearly, the last 6 months company is working hard sort of show the consumer franchise the great extent both margins and growth. My question is more on growth. If I x out Venezuela in the quarter, consumer did about 5% growth. I felt like the messaging from Jorge and others was this business can be sort of an upper single-digit grower with obviously expanding margins. What is your stand in that 5% number ex-Venezuela. Would you feel confident here that consumer is stable and can improve from these levels?"
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, David, thank you very much. Again, let me reiterate, we're really please with the performance that we continue to see in the consumer group and literally, from quarter-to-quarter, it continues to improve. Not only its core performance but market shar",160,"Yes, David, thank you very much. Again, let me reiterate, we're really please with the performance that we continue to see in the consumer group and literally, from quarter-to-quarter, it continues to improve. Not only its core performance but market share the number of other areas. We feel like the majority of the platforms right now we actually gaining share. The same time we realize we've got some areas such as baby such as China, where we need to do a better job in the team is focusing on that in addition, to the margin improvement that Dominic was talking about earlier. But overall, our goal is to grow faster than the market. We think we currently are. It's something that we want to do and accelerate as we go forward. And I'm very confident that Jorge and his team, we've got the strategies and are now executing in a manner that's going to allow them to do just that."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Danielle Antalffy with Leerink Partners.",13,"Our next question comes from the line of Danielle Antalffy with Leerink Partners."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Question for you, Alex, just higher level. sorry to do this, but following up the M&A commentary. Some of your competitors have been acquiring scale, most recently Abbot and St. Jude. And I know J&J is already in it competitively advantageous position giv",129,"Question for you, Alex, just higher level. sorry to do this, but following up the M&A commentary. Some of your competitors have been acquiring scale, most recently Abbot and St. Jude. And I know J&J is already in it competitively advantageous position given your current product lines, but cardiovascular is an area where you specifically under scale relative to some of those other competitors. Now I'm just wondering if you could comment on whether you think it's important to build scale within cardiology to be -- to continue to be a major competitor in Med Tech or if you think there's other areas where J&J is already positioned and will continue to focus on? I'm just trying think about the difference subsectors within med Tech where you're focused most?"
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, thanks, Danielle. Look, consistent with what we said previously, we do think that there's an opportunity for expansion on cardiovascular. And for us, really, it started several years ago when we made the decision to exit the stent business, we did th",239,"Yes, thanks, Danielle. Look, consistent with what we said previously, we do think that there's an opportunity for expansion on cardiovascular. And for us, really, it started several years ago when we made the decision to exit the stent business, we did the divestment of Cordis, which I think the team executed really well. And we think now the greater focus that we have, what you're seeing as a result of that frankly is better growth. Now we're in the cardiovascular business, the [indiscernible] Webster but across the greater medical hospital business that we have. But we know that going forward, other areas in cardiovascular ranging from valves to structural to heart to others could definitely be opportunities, but we're going to continue to see how the technology  evolves, how the markets evolve and that fortunately, I think we're positioned in a way that gives us a lot of different opportunities. At the same time, I would say that there other areas in Medical Devices that we remain interested in. We talked about the Vision Care area. It's one way of a very strong contact lens platform. We think there's opportunity spit back of the eye, surgery and other spaces that, that business could be augmented. And we'll continue to look for other thoughtful place in orthopedics as well as in general surgery that offer growth opportunities and help us better address areas of unmet medical need as well."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Jami Rubin with Goldman Sachs.",13,"Our next question comes from the line of Jami Rubin with Goldman Sachs."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Dominic, I'm sorry to where the growth to net adjustment, I'm unclear as to how it occurred and how it means and I think most importantly, these are all categories REMICADE, STELARA, ZYTIGA which are crowded categories. can you comment on what's happening",180,"Dominic, I'm sorry to where the growth to net adjustment, I'm unclear as to how it occurred and how it means and I think most importantly, these are all categories REMICADE, STELARA, ZYTIGA which are crowded categories. can you comment on what's happening respect to growth to net, the gap between gross to net and how it's changed over the last year or 2, if it is changed at all? Are you able to take this same sort of list price that you have before without having to pay a higher rebate. If you could just kind of comment on that generally. And then also my follow up question relates to INVOKANA sales, again, continue to be strong, you're showing nice improvements in market care. What are your expectations for the whole CTL 2 class -- I'm sure you paid attention to the FDA panel meeting on Guardians and whether or not Guardians will get a superior label with respect to CV mortality reduction and if it does get the stable update, what that might mean to INVOKANA going forward?"
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Jami. Let me take the first question on gross to net and then Alex will cover the CLT 2 commentary. So U.S. how does it occur and what's going on with list price versus net price, and those sort of things. So just to put it in perspective, this is n",252,"Sure, Jami. Let me take the first question on gross to net and then Alex will cover the CLT 2 commentary. So U.S. how does it occur and what's going on with list price versus net price, and those sort of things. So just to put it in perspective, this is not unusual in our industry, as you know,, everyone in the pharmaceutical industry is estimating what the rebates might be and then, of course, we'll actualize them was actual data is submitted. Recently, that actual data has been more timely and in that more timely data from the payers, we're able to see trends -- so we're able to not only actualize prior period amounts but also able to estimate better what the ultimate gross to net variation will be going forward. With respect to list price net of rebates, as you probably know, we said this before, I think we price our products responsibly and our overall list price increases have been relatively below, substantially below the average industry. But in the end, the net price that's achieved is far from the gross price increase that happened. So rebates continue to be an increasing part of the business and the overall realization of gross price to net price that is expanding I would say overtime. And therefore, as I said, now, we're much more current with our ability to predict these estimates, and that's what's going on. And as I mentioned, we don't expect to see significant adjustments in [indiscernible]."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","So you're saying the gap is going to continue to grow, but you overestimated the growth of that gap and that therefore, is the adjustment? But big picture, you expect the gap to grow?",35,"So you're saying the gap is going to continue to grow, but you overestimated the growth of that gap and that therefore, is the adjustment? But big picture, you expect the gap to grow?"
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","That's right.",3,"That's right."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","And Jami, regarding INVOKANA in the class, look, first of all, we are pleased with the performance, to continue performance of INVOKANA in the market. I mean, it remains the #1 SGLT2 in the U.S. both at new and total scripts. I think we've got between 9 m",218,"And Jami, regarding INVOKANA in the class, look, first of all, we are pleased with the performance, to continue performance of INVOKANA in the market. I mean, it remains the #1 SGLT2 in the U.S. both at new and total scripts. I think we've got between 9 million and 10 million prescriptions that have gone out since launch. That being said, we still takes that there's a good opportunity for growth in INVOKANA. We've got a very strong clinical profile that's well documented, strong access across managed care. And look, we're confident that given the experience that HCP has had with it, combined with its profile, that's going to continue to grow. Regarding the broader issues around cost, look, we think that it's really good news. Frankly, for type 2 patients given some of the news that's coming out about CV benefits. And really regardless of the eventual decision by the FDA regarding potential claims for agents, we're looking forward to seeing the results of our campus program that will be coming out in about a year, and we'll have to see that this ongoing CV outcome trials validate some of the current perceptions of KOLs regarding the cardiovascular effect of SGLT2 inhibitors across the joint class, we'll see. But overall, we think it's good news for patients."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from Vamil Divan with Crdit Suisse.",10,"Our next question comes from Vamil Divan with Crdit Suisse."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Just following up on Jami's question on the gross to net commentary. I don't think you touched on this, but specifically, on immunology, it seems a lot of those products, in particular, saw that benefit. Is there anything that you're seeing in that specif",148,"Just following up on Jami's question on the gross to net commentary. I don't think you touched on this, but specifically, on immunology, it seems a lot of those products, in particular, saw that benefit. Is there anything that you're seeing in that specific market that may be causing the difference there -- the greater than what you see with your -- the other therapeutic areas? And then one other unrelated just on IMBRUVICA, it came in a little bit lighter than what we were expecting, a lot of good data and a lot of growth ahead. But maybe you could just comment on the trend you're seeing there and also I guess about a year now since you partnered on that product with pharmaceutical [indiscernible] by Abbott, just the dynamics on that partnership and how you see that relative to what you're seeing previously with Pharmacyclics."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, let me take, there's nothing substantially different between biologics and I know other than the biologics products that have a longer delay in terms of receiving information. So therefore there may be more adjustments related to those products and i",67,"Yes, let me take, there's nothing substantially different between biologics and I know other than the biologics products that have a longer delay in terms of receiving information. So therefore there may be more adjustments related to those products and in a particular period. But other than that, there's no other significant trend that we're  seeing that and the different what we see overall in the market."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","And regarding IMBRUVICA, look, we're very pleased with the continued launch uptick that we see with that. It continues to be strong, good increase versus last year. And look, IMBRUVICA is also maintaining really good total patient market leadership in CLL",87,"And regarding IMBRUVICA, look, we're very pleased with the continued launch uptick that we see with that. It continues to be strong, good increase versus last year. And look, IMBRUVICA is also maintaining really good total patient market leadership in CLL line 2 plus lymphoma as well as WM in the U.S. We have additional approvals and line indications done in other markets as well, so we continue to be pleased with the performance and look forward to getting out additional information additional indications on the calendar."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, and just on the quarter, there's additional -- a patient assistance program as a little bit of bump in that said, that might have touched probably the trend different that you see.",33,"Yes, and just on the quarter, there's additional -- a patient assistance program as a little bit of bump in that said, that might have touched probably the trend different that you see."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our final question comes from the line of Jayson Bedford with Raymond James.",13,"Our final question comes from the line of Jayson Bedford with Raymond James."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Just to clarify and kind of follow up on an earlier question. U.S. med device growth in the quarter decelerated from first quarter levels. International growth accelerated. It was quite big difference in growth in these 2 geographies. It sounds like this",62,"Just to clarify and kind of follow up on an earlier question. U.S. med device growth in the quarter decelerated from first quarter levels. International growth accelerated. It was quite big difference in growth in these 2 geographies. It sounds like this is more a function of selling days with no real change in the operating environment. Is that a fair characterization?"
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","So in the OUS, we have an additional 1.5 selling days an average. That contributes to the OUS growth about 220 basis points. But on top of that, we seeing strong market growth in China, we have some strong markets in Russia, Australia in the hips, we're s",92,"So in the OUS, we have an additional 1.5 selling days an average. That contributes to the OUS growth about 220 basis points. But on top of that, we seeing strong market growth in China, we have some strong markets in Russia, Australia in the hips, we're seeing as growth on the word also seeing some as growth in a tin. So it's a combination of both the selling days that 220 basis points for selling days OUS you're still seeing really nice growth in both these hips and knees in yes."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Jayson, one thing to add to that. When you're talking about obviously do some dynamics in diabetes and some dynamics that we talked about earlier with Vision Care with the customer loyalty program. So if you look at the hospital base Medical Device busine",84,"Jayson, one thing to add to that. When you're talking about obviously do some dynamics in diabetes and some dynamics that we talked about earlier with Vision Care with the customer loyalty program. So if you look at the hospital base Medical Device business then you exclude the impact of acquisitions and divestitures, that growth did accelerate. So the second quarter growth of about 4.7% and first quarter growth of about 4.2%. So on the base hospital medical business, overall, we're  seeing accelerated growth."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","We'll have some final remarks from Alex.",8,"We'll have some final remarks from Alex."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Okay, thank you very much, everyone, for joining us this morning. And as I noted earlier, look, we're really pleased with the continued momentum as evidenced by our increased guidance for both sales and earnings for the full year 2016. Look, I really beli",143,"Okay, thank you very much, everyone, for joining us this morning. And as I noted earlier, look, we're really pleased with the continued momentum as evidenced by our increased guidance for both sales and earnings for the full year 2016. Look, I really believe that some of the clear strategic choices that we've been making, the really strong focus and execution, combined with an incredibly talented group of leaders that I'm honored and humbled to be able to work with everyday at Johnson & Johnson are enabling us to really deliver extraordinary achievements and results that we've just been able to share with you and really building the success of Johnson & Johnson going forward. So thank you for your time this morning. I look forward to updating of the progress throughout the year, and hope everybody has a great day. Thank you."
139677,367223456,1007800,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Thank you. This concludes today's Johnson & Johnson Second Quarter 2016 Earnings Conference Call. You may now disconnect.",18,"Thank you. This concludes today's Johnson & Johnson Second Quarter 2016 Earnings Conference Call. You may now disconnect."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Good morning, and welcome to Johnson & Johnson's Second Quarter 2016 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] I would now like t",51,"Good morning, and welcome to Johnson & Johnson's Second Quarter 2016 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] 
I would now like to turn the conference call over to Johnson & Johnson. You may begin."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Good morning, and welcome. I'm Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure this morning to review our business results for the second quarter of 2016. Joining the on the call today is Alex Gorsky, C",2030,"Good morning, and welcome. I'm Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure this morning to review our business results for the second quarter of 2016. 
Joining the on the call today is Alex Gorsky, Chairman of the Board of Directors and Chief Executive Officer; and Dominic Caruso, our Chief Financial Officer. 
A few logistics before we get into the details. This review is being made available via webcast accessible through the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. I'll begin by briefly reviewing the second quarter for the corporation and for our 3 business segments. Following my remarks, Alex will comment on the 2016 results to date and provide a strategic outlook for the company. Next, Dominic will provide some additional commentary on the business, review the income statement and update guidance for 2016. We will then open the call to your questions. We expect the call to last approximately 90 minutes. 
Included with the press release that was issued earlier this morning is the schedule of sales for key products and/or businesses to facilitate updating your models. These schedules are available on the Johnson & Johnson website, as is the press release. 
Please note, we will be using a presentation to complement today's commentary. The presentation is also available on our website. 
Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements. The 10-K for the fiscal year 2015 and the company's subsequent filings identify certain factors that could cause the company's actual results to differ materially from those projected in any forward-looking statements made today. The company does not undertake to update any forward-looking statements as a result of new information or future events or developments. Our SEC filings, including the 10-K, are available through the company and on our website. 
During the review, non-GAAP financial measures are used to provide information pertinent to evaluating business performance period-over-period. These non-GAAP financial measures should not be considered replacements for and should be read together with GAAP results. Tables reconciling these measures to the most comparable GAAP measures are available in the schedules accompanying the press release and on the Investor Relations section of the Johnson & Johnson website. A number of products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships. 
Also, to assist you with your models, this slide provide you with a summary of important developments for the current during the quarter. 
Now I would like to review our results for the second quarter of 2016. Worldwide sales to customers were $18.5 billion, up 3.9% versus second quarter 2015. 
On an operational basis, sales were up 5.3% and currency have a negative impact of 1.4%. In the U.S., sales were up 7.4%. In regions outside the U.S., our operational growth was 3.1% while the effect of currency exchange rates negatively impacted our reported results by 2.7%. 
On an operational basis, the Western Hemisphere, excluding the U.S., grew by 15.4% with approximately 1/3 of the growth due to an inventory build that will reverse in the third quarter. Asia Pacific, Africa grew 2.1%, while Europe declined 0.6%. Results in all regions were negatively impacted by hepatitis C competition and divestitures. The most significant one being Cordis. Excluding the net impact of acquisitions, divestitures and hepatitis C, underlying operational growth was 7.9% worldwide, 8.8% in the U.S. and 6.9% outside the U.S. In addition, operations in Venezuela negatively impacted worldwide and outside the U.S. operational growth by 30 basis points and 70 basis points, respectively. 
Turning now to earnings. Net earnings were $4 billion and earnings per share were $1.43 versus $1.61 a year ago. As a reference in the table reconciling non-GAAP measures, 2016 second quarter net earnings were adjusted to exclude after-tax amortization expense of $238 million and charges for after-tax special items of $631 million. 
2015 second quarter net earnings were adjusted to exclude after-tax amortization expense of $230 million and charges for after-tax special items of $66 million. Dominic will discuss special items in his remarks. 
Excluding amortization expense and special items for both periods, adjusted net earnings for the current quarter were $4.9 billion and diluted earnings per share were $1.74, representing increases of 1.1% and 1.8%, respectively, as compared to the same period in 2015. On an operational basis, adjusted net earnings per share also grew 1.8%. 
Now turning to the highlights for the first 6 months of 2016. Consolidated sales to customers were $36 billion, an increase of 2.3% as compared to the same period a year ago. On a year-to-date basis, sales grew 4.6% operationally and currency had a negative impact of 2.3%. 
Excluding the net impact of acquisitions and divestitures and hepatitis C sales, underlying operational growth was approximately 7.4% worldwide, 9.3% in the U.S. and 5.4% outside the U.S. 
In addition, operations in Venezuela negatively impacted worldwide and outside the U.S., operational growth by 50 basis points and 90 basis points, respectively. 
Turning now to earnings for the first 6 months of 2016. Net earnings were $8.5 billion and diluted earnings per share were $3.02. Adjusted net earnings were $9.7 billion and adjusted earnings per share were $3.47, up 5.3% and 6.1%, respectively, versus the same period last year. On an operational basis, adjusted net earnings per share grew 7.3%. 
Turning now to business segment highlights for the second quarter of 2016. Please note, percentages quoted represent operational sales change in comparison to the second quarter of 2015 unless otherwise stated and therefore, exclude the currency translation impact. 
I'll begin with the Consumer segment. Worldwide Consumer segment sales of $3.4 billion increased 1.5%, with U.S. sales up 2.1% while outside the U.S. sales were up 1%. Excluding the net impact of acquisitions and divestitures, underlying operational sales growth was 3.9% worldwide, 6.8% in the U.S. and 2% outside the U.S. 
In addition, operations in Venezuela negatively impacted growth worldwide and outside the U.S. by 120 basis points and 200 basis points, respectively, with the most significant impact to Women's Health, Baby Care and Oral Care. Growth for the segment was driven primarily by Skin Care, OTC and Oral Care. 
In Skin Care, market share increases in a growing market as well as timing of inventory builds to have double-digit growth for both NEUTROGENA and AVEENO. 
OTC sales growth was strong despite a weak allergy season. U.S. OTC sales growth was driven by analgesic and adjusted held share growth. In the U.S., adult analgesic market share was approximately 14%, up from approximately 11% a year ago, while U.S. pediatric share was nearly 47%, up from nearly 44% a year ago. Major contributors to the growth outside the U.S. were the strong performance of anti-smoking aids, children's analgesics and adjusted health products. New product launches and successful marketing campaigns drove the results for LISTERINE in Oral Care. 
Moving now to our Pharmaceutical segment. Worldwide sales of $8.7 billion increased 9.7% with U.S. sales up 13.2% and sales outside the U.S. up 4.9%, driven by both strong sales of new products as well as core growth products. 
Competitors in hepatitis C significantly impacted sales this quarter. Excluding sales of our hepatitis C products, OLYSIO and INCIVO as well as the impact of acquisitions and divestitures, underlying sales growth worldwide, U.S. and outside the U.S. was 12.8%, 13.9% and 11.2%, respectively. 
As you know, there were discounts and rebates in the pharmaceutical industry that are reflected in net sales. These amounts are estimated until the related claims data is received and then they are actualized. We have adjusted our estimates to reflect the most current claims trends. 
U.S. pharmaceutical results this quarter included a positive adjustment to sales reserves across many channels, which was approximately $140 million higher than the adjustment in the second quarter of 2015 and positively impacted second quarter 2016 worldwide growth by approximately 1.5 points and U.S. growth by approximately 2.5 points. 
On a product basis, REMICADE U.S. growth in the second quarter of 2016 was positively impacted by approximately 8 points, STELARA by 11 points, SIMPONI by 13 points, ZYTIGA by 8 points and PROCRIT by 31 points. 
Significant contributors to growth were immunology products, REMICADE, STELARA and SIMPONI/SIMPONI ARIA; oncology products, IMBRUVICA and recently launched DARZALEX; as well as cardiovascular metabolic products, XARELTO and INVOKANA. 
Within Neuroscience, strong growth for INVEGA SUSTENNA TRINZA was partially offset by lower sales of INVEGA due to the impact of generic competition. The results for immunology were driven by strong double-digit market growth, share growth for STELARA and SIMPONI ARIA as well as the growth to net adjustments to U.S. sales that I mentioned. 
The decline in REMICADE export sales to our distribution partners was due to the impact of biosimilars. 
Strong patient uptake with new indications, approvals and demonstrated efficacy drove results for IMBRUVICA, both in the U.S. and outside the U.S. In the U.S., IMBRUVICA remains the new patient share and total share leader in second-line CLL and MCL. IMBRUVICA is now launched in more than 70 countries. 
DARZALEX was approved in the U.S. in November 2015 and has achieved rapid uptake with strong underlying demand. DARZALEX contributed approximately 2 points to the U.S. pharmaceutical growth rate. DARZALEX received European Commission conditional approval this quarter and was launched in certain European countries. 
XARELTO sales were up 25.8% and total prescription share or TRx for the quarter in the U.S. anticoagulant market grew to nearly 17%, up 1.5 points from a year ago. TRx in primary care was over 14% and in cardiology, over 23%. XARELTO is broadly reimbursed with approximately 95% of commercial and Medicare Part D patients covered at the lowest co-pay for a branded product. 
INVOKANA/INVOKAMET sales were up 21% on a worldwide basis and 15.2% in the U.S. In the U.S., INVOKANA/INVOKAMET TRx within the defined market of type 2 diabetes, excluding insulin and metformin, was 6.3%, up from 6% in the second quarter of 2015. TRx with endocrinologist was approximately 11.5% and over 5.5% in primary care. INVOKANA access remains strong at nearly 70% preferred for commercial and over 90% for Medicare Part D. 
I'll now review the Medical Devices segment results. Worldwide Medical Devices segment sales of $6.4 billion increased 1.8%. U.S. sales increased 1%, while sales outside the U.S. increased 2.6%. As a reminder, Cordis was divested in the fourth quarter of 2015. Excluding the net impact of acquisitions and divestitures, underlying operational sales growth was 3.9% worldwide with U.S. up 1.9% and growth of 5.8% outside the U.S. In addition, operations in Venezuela negatively impacted growth worldwide and outside the U.S. by 30 basis points and 50 basis points, respectively. Growth was driven by advanced surgery, electrophysiology, orthopedics and Vision Care. 
Strong results were achieved for advanced surgery products with endocutters growth of 13%, energy growth of 9% and biosurgicals growth of 8%. The acquisition of NeuWave Medical also contributed to growth this quarter. 
Electrophysiology grew 18% worldwide due to strong market growth, complemented by new product launches and increased penetration for both ultrasound and diagnostic catheters. 
Orthopaedics sales growth was driven by U.S. trauma and worldwide hips and knees. Market growth in the success of product launches drove results for the U.S. Orthopaedics business. Pricing pressure continued across the major categories, partially offset by positive mix for trauma and spine products. 
The success of the TFNA mailing system in trauma, the ATTUNE platform in knees, our primary stem platforms in hips and ORTHOVISC/MONOVISC and new spine product introductions made important contributions to the results.
Orthopaedics sales outside the U.S. were negatively impacted results in China due to continued reduction in inventory. Trauma and spine, other were the categories most impacted. 
In addition, timing of tender business negatively impacted trauma growth for the quarter. 
Vision Care sales were driven by strong growth across the major regions, partially offset in the U.S. by a customer reward program. 
That concludes the segment highlights for Johnson & Johnson's second quarter of 2016. 
It is now my pleasure to turn the call over to Alex Gorsky. Alex?"
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Louise, and good morning, everyone, and thank all of you for joining us on the conference call or webcast today. As you just heard from Louise, our second quarter results have continued the momentum that began with our great start to 2016, an",2212,"Thank you, Louise, and good morning, everyone, and thank all of you for joining us on the conference call or webcast today. 
As you just heard from Louise, our second quarter results have continued the momentum that began with our great start to 2016, and we're pleased that our shareholders are seeing above-average returns on their investment in Johnson & Johnson. 
Delivering a fair return to shareholders is the final line of our credo, which clearly defines our first responsibilities, the doctors, nurses and patients, the mothers and fathers and all others who use our products. When we meet those responsibilities and when we continuously work to improve outcomes for patients around the world, we succeed with all of our stakeholders. 
Now over the last 130 years, the people of Johnson & Johnson have been helping people everywhere live longer, healthier and happier lives. With that remarkable heritage, I'm excited and optimistic about the opportunities for the future of Johnson & Johnson and committed to continuing our long-term success. With our broad base of strong businesses, focused strategies and comprehensive approach to innovation, we're well prepared to address the challenges of today's health care market and well positioned to lead in the movement towards healthier societies. 
As I've discussed before, we believe our broad base in human health care is vital to achieving that vision. Our broad base is a strategic choice based on performance, and it has helped us to deliver strong, consistent and sustainable financial performance through various economic cycles, meeting our financial commitments in the midst of global events like the U.K.'s vote to exit from the EU or the economic issues in Venezuela this year. Our broad base enables us to create and access growth opportunities wherever they may arise at the right time and in the right markets. 
Our deep health care expertise also makes Johnson & Johnson companies strategic partner of choice for many companies whether that means with innovative start-ups, information technology giants or large hospital systems looking to improve patient outcomes and reduce the cost of care. 
We also work with local governments and public health organizations where we're collaborating more than ever to address the world's most pressing health challenges. Our broad base allows us to create product platforms and systems across categories and establish new sources of innovation to converge in combination products. And finally, our broad base is helping us to realize advantages of scale to achieve enterprise efficiencies and capabilities across all of our segments. 
All of these advantages of our broad base in human health care contribute to the long-term value we are able to create for our shareholders, and we continue to have a clear set of objectives for creating that long-term value. We expect global health care to grow at 3% to 5% over the next 5 years, and we have an objective to grow our sales organically at a faster rate than the market. 
We also intend to grow our earnings faster than sales. When we combine these objectives with our plans that continue creating value through strategic acquisitions and partnerships as well as our strong dividend yield, we believe the result to be a basis for compelling, long-term total shareholder returns. And that is our focus. We invest for the long-term success of our business. In fact, we have increased our spending on R&D every year for the last 5 years. We invest above-industry average levels to build our robust pipelines and continue to nurture the investments we've already made. 
We also invest in innovative sales and marketing initiatives and consistently benchmark to ensure the return on our investments is as competitive and as efficient as possible. 
I'm proud that we are able to make these important investments in our business, while also generating enterprise adjusted net income margins that have increased in our above-industry benchmarks. 
After we've made the appropriate investments in our business, we look to capitalize on the right opportunities to create greater long-term value for our shareholders. Our capital allocation framework starts with paying dividends to our shareholders, which is why we have increased our dividend every year for the last 54 years. Next, we seek value-creating strategic acquisitions and partnership opportunities. And finally, we consider other prudent ways to return value to shareholders such as repurchase programs. 
In fact, over the last 3, 10 and 20-year periods, Johnson & Johnson total shareholder return has exceeded our competitive composite. And as you can see in this chart, we're up to a very strong start in 2016 with total shareholder return of approximately 20% through the first half of the year. 
And while we manage our business for the long term, we also have a number of near-term priorities, which I've shared with you before. As an enterprise, we're focused on delivering on our financial and quality commitments. Through the first 6 months, we generated sales of $36 billion, resulting in an operational growth of 4.6% when you exclude the impact of acquisitions, divestitures, hepatitis C sales. And operations in Venezuela, underlying growth was 7.9%. 
To the first half of this year, we have delivered adjusted net earnings of $9.7 billion and adjusted EPS of $3.47. On an operational basis, adjusted EPS was $3.51, representing growth of 7.3%. 
In our Pharmaceutical business, we continue to deliver very strong results. On the same underlying basis, growth was 12.7% through the first half of 2016, and we are continuing to build momentum in our Consumer and Medical Device businesses with first half underlying growth of 4.5% and 3.7%, respectively. 
We also continue making progress with our quality system, including resolving a warning letter in our ASP business in completion of the Cintas' corporate integrity agreement. 
In pharmaceuticals, we're continuing to build on our launch excellence and robust pipeline. In the last several months, we have made significant advancements in our pipeline, including conditional EU approval for DARZALEX for monotherapy of adults with relapse and refractory multiple myeloma and presented positive Phase III data on the CASTOR and POLLUX studies, which are evaluating combination therapies for DARZALEX. 
We also received the EU approval for frontline IMBRUVICA treatment in CLL as well as FDA expansion of the IMBRUVICA label to include new Phase III data on survival and in combination therapies. 
Phase III data on STELARA demonstrated maintain clinical remission after 1 year of treatment in patients with moderate to severe Crohn's disease. 
Clinical trial in real-world data was presented on INVOKANA, including Phase II data on type 1 diabetes and chronic weight management. 
We received EU approval for TREVICTA, a once every 3 months injection for maintenance treatment of schizophrenia as well as line extension approval for both INVOKAMET and SIMPONI. 
Positive Phase III data was presented on sirukumab for patients with moderately to severe active rheumatoid arthritis. 
And just recently, FDA granted the fourth Breakthrough Therapy designation for IMBRUVICA in graft versus host disease, GDHD, which makes 6 total breakthrough designations for our Pharmaceutical business so far. 
In addition to these pipeline milestones, as Louise pointed out, we also delivered strong growth with our in-market products, including IMBRUVICA, DARZALEX, XARELTO, STELARA and SIMPONI. 
In consumer, our priority is expanding market leadership in key segments within OTC, Oral Care, Baby and beauty. 
As part of our focus on the beauty space, we had just completed the strategic acquisition of Vogue International. The award-winning beauty products in this portfolio, including the OGX brand, enhance our existing position in the market in a highly complementary to our heritage of breakthrough innovations in this space. 
Vogue International has grown double digits over the last 5 years with a compound annual growth rate of about 25%, and the acquisition will take us from #8 to #4 in the U.S. hair care market. 
And as we discussed in May at our Analyst Day, we're continuing to see operating margin improvement in our consumer business and plan to continue that trend for the next several years. 
And in Medical Devices, we're focused on accelerating growth through innovation and transforming our go-to-market models. In this segment, we're gaining momentum in accelerating growth through our unique and broad-based approach to innovation. Our performance this quarter was roughly in line with market growth. And we're pleased with the progress here, but far from satisfied. Our goal to be clear is to grow above market overall. 
And while we're making strategic decisions in our portfolio to achieve that growth like the recent acquisition of BioMedical Enterprises, Inc., which filled the key portfolio gap in elective foot and ankle surgery, we're also realigning our commercial models in line with our near-term priority. Our innovation model in Hospital Medical Devices includes innovating our product offerings, but it also looks at innovation in terms of our commercial offerings and contracting. 
As we outlined during our business review day, today, about 25% of our U.S. orthopedic and surgery business is in multiproduct line agreements. These agreements perform almost 2x better than single-product contract agreements. We see this percentage growing to 40% in the near future, which we believe will help us accelerate our business going forward. 
And finally, we're also serving customers in a more end-to-end manner with risk-sharing contracts and outcome-based patient solutions. 
We're also on track to deliver approximately $800 million to $1 billion in annual savings from our medical device restructuring, the majority of which we expect will be realized by the end of 2018. 
And also, we continue to make progress in launching new competitive entries in our Consumer Medical Device businesses like the ACUVUE VITA, a 30-day daily wear contact lens that provides superior comfort over leading monthly brands. 
With all these progress through our Medical Devices segment, we are confident that we are poised to deliver above-market growth. Altogether, these near-term priorities will help drive success for each of our business segments, while also enabling us to achieve the growth we expect for our company in the long term. With the progress we made on our near-term priorities, our businesses are strong, positioning us for above-market growth. With the combined strength of our in-market portfolio, deep late-stage pipeline and robust early-stage pipeline, we feel confident our Pharmaceutical business can successfully navigate through the launches of new competitive biosimilar or generic entrance and evolving market dynamics. And our objective is to continue delivering above-industry growth. Our consumer business is positioned to grow above market, while also achieving benchmark profitability and investing for the future. 
And in Hospital Medical Devices, we are poised to grow above the market, driven by our innovative pipelines, expanding global presence and novel commercial models. 
Our Consumer Medical Device businesses are holding leading positions and seeking opportunities to expand in large growing markets with significant unmet needs. With the strength of each of our business segments, we feel optimistic about the future opportunities in health care, and we are confident our long-term strategies have positioned us for continued growth. Our holistic approach to innovation, going beyond products and solutions, will allow us to address the evolving health care landscape, driving better outcomes and delivering long-term value. We have the right internal capabilities and are developing strategic partnerships in health tech to reshape the way health care is delivered, managed and experienced. 
And finally, our broad base across human health care uniquely positions Johnson & Johnson as a leader in partner of choice in the health care market. 
But perhaps most importantly of all, our continued strong performance means we are able to create better products, more valuable services and improved outcomes for patients, consumers and their families. 
So I'd like to thank you. I look forward to further dialogue during the Q&A session. But first, I'd like to take a moment to recognize Louise Mehrotra, who, as most of you know from our announcement last month, has decided to retire after more than 35 years with Johnson & Johnson and more than 10 years as Vice President of Investor Relations. 
I know many of you on the call today have gotten to know Louise pretty well over the last several years, a real testament to the strong relationship she's built in the investment community on behalf of Johnson & Johnson. And you may know that she's an incredibly committed credo-based leader and had a remarkable career and impact on our company. I think I can speak for all of us at Johnson & Johnson in saying that we will miss her trusted, experienced, respected advice and her ever-present determination to do as in the best interest of all of our credo stakeholders. 
Louise, we're so proud of the best-in-class Investor Relations function you've developed for us over the last decade, and we sincerely thank you for your many years of service and dedication to Johnson & Johnson. 
Now we know we'll all be in good hands with Joe Wolk, previously Vice President in Group Finance for our Pharmaceuticals Group, will become Vice President Investor Relations effective August 1 and transition with Louise over the next 5 months. We are confident that Joe will continue Louise's legacy of transparent and credible communication with you, our investors. 
So now, I'll turn it over to Dominic Caruso, who will talk more about our results and expectations for the second half of 2016. Dominic?"
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Thanks, Alex, and good morning, everyone. Before I get into our results, I'd like to echo Alex's sentiments and personally thank Louise for her significant contributions to Johnson & Johnson and for her valued support and friendship during my time as Chie",2644,"Thanks, Alex, and good morning, everyone. Before I get into our results, I'd like to echo Alex's sentiments and personally thank Louise for her significant contributions to Johnson & Johnson and for her valued support and friendship during my time as Chief Financial Officer. 
Over the last 10 years, Louise and the entire IR team has transformed our Investor Relations function, significantly developing our reputation with the investment community, which has been recognized with several awards and recognitions, including those from institutional investor and IR Magazine. And through surveys of money managers conducted by Barron's Magazine, Johnson & Johnson has been ranked at/or near the top of the most respected companies list for 10 of the last 12 years. In fact, I'm also pleased to report that Johnson & Johnson was recognized this year by Barron's Magazine as the #1 most respected company for 2016.
As Alex noted, Louise's outstanding leadership and dedication to advancing our reputation will continue with her successor, Joe Wolk, who we're happy to have joining us on our call next quarter. We all wish Louise well, and we are certainly going to miss her. 
With that, I will now turn our discussion back to the quarter. We're very pleased with our second quarter results as we continue to see improved performance across the enterprise. And as Alex said, we remain confident in the strength of our business. 
As we've previously discussed in 2015, our underlying operational sales growth, which excludes the impact of acquisitions, divestitures as well as hepatitis C sales and the few extra shipping days in 2015, was about 5.5% On this same basis, we continue to deliver strong underlying operational sales growth of approximately 7.9% for the second quarter, and our sales results are above analyst estimates. Our second quarter earnings were also above analyst estimates, driven by strong sales performance and operating margin improvement. 
As you may remember for 2016, our guidance from January included a 200 basis point increase in pretax operating margin on an adjusted basis. We were pleased to see progress towards this improvement during the second quarter, which I will discuss later. And we remain comfortable with that forecast as we continue to accelerate throughout the year with the restructuring activities in our Medical Device business and lower levels of spending in the back half as compared to the prior year. 
Now I'll take a few minutes to highlight some key points regarding our results, and then I'll provide some updates to our guidance for you to consider in refining your models for 2016. 
I will now turn to our consolidated statement of earnings for the second quarter of 2016. As we've mentioned, our operational sales growth this quarter was 5.3%. And excluding the impact of acquisitions and divestitures, hepatitis C sales and also the impact of the devaluation that occurred in Venezuela last year, it was strong at more than 8%. 
If you will direct your attention to the box section of the schedule, you will see we have provided our earnings adjusted to exclude intangible amortization, expense and special items. 
As referenced in the table of non-GAAP measures, the 2016 second quarter net earnings were adjusted to exclude intangible asset amortization expense and special items on approximately $900 million on an after-tax basis, which consisted primarily of the following: Intangible asset amortization expense of about $200 million, litigation charges from ongoing legal matters of about $500 million and additional charges as we continue to execute on the Medical Devices restructuring. 
Our adjusted earnings per share is therefore, $1.74, exceeding the mean of the analyst estimates as published by our first call. This is an increase in adjusted EPS of 1.8% versus the prior year, and adjusted EPS on a constant currency basis was the same as the impact of currency was flat year-over-year. 
Now let's take a few moments to talk about the other items on the statement of earnings. Cost of goods sold decreased by 120 basis points, mostly due to favorable mix and manufacturing efficiencies, partially offset by transactional currency. 
Selling, marketing and administrative expenses were 28% of sales or 230 basis points lower as compared to the second quarter 2015 due to good cost management. 
Our investment in research and development as a percent of sales was 12.2% and higher than the prior year due to increased project spending as we advanced our promising product pipelines. 
Our pretax operating margin when excluding special items and intangible amortization expense was 32.5% or 320 basis points higher than the second quarter of the prior year. As a reminder, pretax operating margin is defined as gross profit less selling, marketing, administrative and R&D expenses. 
As we anticipated, we are seeing improvement as we progressed throughout the year. And through 6 months, we have achieved 180 basis point improvement in this measure of profitability. 
Interest expense, net of interest income was slightly lower than last year due to slightly better rates on our investments. Other income and expense was a net expense of approximately $600 million in the quarter compared to a net gain of approximately $900 million in the same period last year. 
Excluding the special items that are reflected in this line, other income and expense was a net gain of approximately $100 million compared to a net gain of approximately $1 billion in the prior year period. The significant decrease is due to the divestiture of NUCYNTA in the prior year period. 
Excluding special items, the effective tax rate was 19.2% compared to 23% in the same period last year. This year's effective tax rate reflect the R&D credit, which was passed by Congress late last year, the current mix of our business and the impact of new accounting standards related to the tax benefit on share-based compensation, which I will discuss further in a moment. 
Turning to the next slide. I will now review adjusted income before tax by segment. In the second quarter of 2016, our adjusted income before tax margin for the enterprise declined by 250 basis points versus the second quarter of 2015. 
During the second quarter of 2015, as I mentioned earlier, we recorded a gain from the divestiture of NUCYNTA. And this gain, which, as you know from our discussions last year, was invested in various parts of the business, but those investments occurred later in the year. 
If the NUCYNTA divestiture gain is excluded, year-on-year adjusted income before tax margin which show an improvement of approximately 300 basis points. We're very pleased to see a significant improvement in our Consumer business adjusted income tax margin this quarter. As you may recall from our business review day in May, we said that we are focused on improving our margins in the Consumer business to benchmark levels. We are confident that our Consumer business will show an improved adjusted income before tax margin of full year 2016 as compared to 2015. 
Overall, we expect income before tax margins for the enterprise to show an improvement over the prior year for all of 2016 as our increase in the pretax operating profit margin, which I noted earlier, more than offsets the lower level of divestiture gains in 2016 as compared to 2015. 
Now I will provide some guidance for you to consider as you refine your models for 2016. At the end of the quarter, we had approximately $16 billion of net cash, which consist of approximately $42 billion of cash and marketable securities and approximately $26 billion of debt. As you know, in May, we took the opportunity to finance our share repurchase program and upcoming debt maturities at very attractive interest rates, with the European debt issuance equivalent to $4.5 billion. 
Through the end of the second quarter, we have completed nearly 50% of our $10 billion share repurchase program, and we continue to expect to complete approximately 75% of the program by the end of this year. 
For purposes of your models and assuming no major acquisitions or other major uses of cash, I suggest you consider modeling net interest expense between $400 million and $500 million. There's a slight decrease from our prior guidance. 
Regarding other income and expense. As a reminder, this is the account where we record royalty income as well as gains and losses arising from such items as litigation investments, prior development corporation divestitures, asset sales and write-offs. We will be comfortable with your models for 2016, reflecting net other income and expense, excluding special items as of net gain, ranging from approximately $900 million to $1 billion, a lower range than our previous guidance related to the timing of underlying activity. This impact will be offset by the strength of our business, primarily due to our outlook for higher level of sales as noted in the increased sales guidance in our press release today. 
And now just a word on taxes. During the second quarter, the company elected for early adoption of a new accounting standard related to share-based compensation. With this update, increased tax benefits are recognized in earnings on the employee exercises options or received shares. Previously, these tax benefits were recorded in equity. 
The first quarter impact was approximately $165 million or $0.05 per share and is reflected in the year-to-date results and not in the second quarter when we adopted the standard. The second quarter impact is offset by additional tax costs reflected in this quarter. 
For adoption guidance, the first quarter does not need to be reissued. However, all future comparisons for the first quarter should reflect the recasted numbers. We have included a supplementary schedule on our website that includes the updated first quarter impact for the P&L. 
You will note that the first quarter recast number reflects a tax rate of 15.8%. The company issued shares related to employee stock compensation such as restricted stock, awards or performance share units in the first quarter. Therefore, historically, a significant portion of the annual tax benefit is recognized in the first quarter. The tax benefit for stock options is recognized throughout the year as employees exercise their options, but timing is less predictable for stock options. 
We are comfortable with your models reflecting an effective tax rate for 2016, excluding special items, were approximately 18.5% to 19%, lower than our previous guidance, primarily due to the accounting for share-based compensation tax benefits that I just described. 
Now turning to sales and earnings. Our sales and earnings guidance for 2016 takes into account several assumptions and key factors that I would like to highlight. As a reminder, our sales guidance for 2016 assumes no biosimilar entrance for PROCRIT or REMICADE in the U.S., and our assumption remains unchanged with the recent FDA approval of Inflectra. 
We also do not anticipate generic competition this year for ZYTIGA, RISPERDAL CONSTA or INVEGA SUSTENNA. But as expected, there are generic entrance for INVEGA and ORTHO TRI-CYCLEN LO. 
As Alex mentioned, we have now closed the acquisition of Vogue International. So our guidance now reflects 6 months of additional sales. This is a fast-growing business and will contribute to the profitability of our Consumer business beginning the first full year as well as be accretive to our adjusted EPS beginning in the first full year. 
Also, during the second quarter, we closed on our divestiture for the controlled substance raw material and API business and therefore, those sales were no longer be recorded. 
As we've done for several years, our guidance will be based first on a constant currency basis reflecting our results from operations. This is the way we manage our business, and we believe this does provide a good understanding of the underlying performance of our business. 
We will also provide an estimate of our sales and adjusted EPS results for 2016 with the impact that current exchange rates could have on the translation of those results. 
As noted on our press release, we are increasing our operational sales guidance for 2016, primarily reflecting the strong results from the first half as well as 6 additional months of sales from the Vogue acquisition, partially offset by the divestiture of our controlled substance raw material and API business. We would, therefore, be comfortable with your models reflecting an operational sales increase on a constant currency basis of between 3% and 4% for the year. This would result in sales for 2016 on a constant currency basis of approximately $72.2 billion to $72.9 billion and higher than our previous guidance. 
Additionally, by way of comparison to how we describe our sales results in 2015, our operational sales growth for 2016, excluding the impact of acquisitions, divestitures and hepatitis C sales, would be approximately 6%, a higher level of growth than we saw last year after adjusting for the extra shipping days in 2015, which we've mentioned earlier. 
Although we're not predicting the impact of currency movements using the euro as of last week at $1.11, the negative impact of foreign currency translation will be approximately 1% on sales. This is consistent with our previous guidance as other major currencies strengthened since our last update. We are watching the euro and other currencies closely as it is uncertain how they will eventually settle after the year. Of course, we're closely following the situation with the U.K.'s vote to exit from the EU. We expect this will take them to fully determine what the impact will be, if any. 
To put it into perspective though, the U.K. represents about 3% of our total sales. So after impacts of currency, we would expect reported sales to reflect the change in the range of 2% to 3% for a total expected level of reported sales of approximately $71.5 billion to $72.2 billion and higher than our previous guidance. 
And now turning to earnings. As a reminder, we expect transaction currency impacts to be negative to our gross margin by about 60 to 80 basis points in 2016 as compared to 2015. We would be comfortable with adjusted operational EPS guidance in the range of between $6.66 to $6.76 per share on a constant currency basis, reflecting an operational constant currency growth rate of 7.4% to 9%. This is a narrower range as well as higher than our previous guidance and includes the first quarter impact from the tax accounting change we discussed earlier. 
If currency exchange rates for all of 2016 were to remain where they were as of last week, then our reported adjusted EPS would be negatively impacted by approximately $0.03 per share due to currency movements, and this is consistent with our guidance in April. Therefore, we would be comfortable with our reported adjusted EPS ranging from $6.63 to $6.73 per share, which is an increase from our previous guidance due both to the continued strength of the business and a lower tax rate. And at this point in the year, we will be comfortable with your models reflecting the midpoint of this range. 
In closing, we are very pleased with our strong start for the first 6 months of this year, and we are optimistic with what we see ahead for the full year, namely, we're expecting operational sales growth of 3% to 4% and underlying operational sales growth of 6% or higher than we saw in 2015 on a comparable basis. 
Our adjusted pretax operating margin improvements are on track to meet the expectations we laid out in our guidance of more than a 200 basis point improvement over the prior year. 
Our adjusted operational EPS growth in our guidance improved and remains strong in the range of $6.66 to $6.76 a share, that's a growth rate of between 7% and 9%. Our businesses are continuing to invest while also delivering on our growth expectations. 
And now I'd like to turn things back to Louise for the Q&A portion of the call. Louise?"
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Dominic. Michelle, could you please give the instructions for the Q&A session?",14,"Thank you, Dominic. Michelle, could you please give the instructions for the Q&A session?"
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","[Operator Instructions] Our first question comes from the line of Mike Weinstein with JPMorgan.",14,"[Operator Instructions] Our first question comes from the line of Mike Weinstein with JPMorgan."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Dominic, just a couple items that we could hopefully get you to clarify. So number one is, what's the impact for the full year EPS of ASU 2016-109 [ph] adoption? The tax rate coming down as it did suggest a range of anywhere from $0.04 to $0.12, so maybe",79,"Dominic, just a couple items that we could hopefully get you to clarify. So number one is, what's the impact for the full year EPS of ASU 2016-109 [ph] adoption? The tax rate coming down as it did suggest a range of anywhere from $0.04 to $0.12, so maybe you can help with that. And then second, can you just walk through the net impact of the Vogue acquisition and then the API business divestiture on sales and earnings?"
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Mike. Well, with respect to the early adoption, I mentioned earlier that the first quarter impact was $0.05, and that's the most significant impact we expect for the year because that's where the majority of stock-based compensation is issued to emp",154,"Sure, Mike. Well, with respect to the early adoption, I mentioned earlier that the first quarter impact was $0.05, and that's the most significant impact we expect for the year because that's where the majority of stock-based compensation is issued to employees. The second quarter impact was lower than that, but was almost entirely offset by other tax items. And the rest of the year will depend on when employees exercise stock options, so very difficult to predict. So for now, we've included in our effective tax rate for the year only the first quarter impact, which after we adopted in the second quarter, we're letting the first quarter impact flow through for the remainder of the year. Second quarter impacts already been offset by other items, and remaining quarterly impacts, we think, will either likely be offset by other items or very difficult to predict because it's timing of when employees exercise options."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Yes. So your updated guidance, Dominic, doesn't assume any benefit in the second half of the year?",17,"Yes. So your updated guidance, Dominic, doesn't assume any benefit in the second half of the year?"
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","That's right. Only the first quarter flow through that we experienced. And as I said, that's the largest single quarter of any stock-based compensation tax benefit. Sales with respect to Vogue and the API business. Vogue, for the full year, is in the $350",119,"That's right. Only the first quarter flow through that we experienced. And as I said, that's the largest single quarter of any stock-based compensation tax benefit. Sales with respect to Vogue and the API business. Vogue, for the full year, is in the $350 million range. We have about half a year of sales added to our guidance. And the API business was an annual business of about $250 million, and we'll have half a year of those sales no longer included in our guidance. So that's part of the increase in our overall growth in sales of about 0.5 points. The rest of it is due to the underlying strength we saw in the first 6 months."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. And then on the pharma business, can I get you just to comment on a couple of items. So one, this is obviously a very important quarter for DARZALEX with the data we saw at ASCO with the EHA. And would just -- would love to get some high-level comme",93,"Okay. And then on the pharma business, can I get you just to comment on a couple of items. So one, this is obviously a very important quarter for DARZALEX with the data we saw at ASCO with the EHA. And would just -- would love to get some high-level commentary on where you think that gets positioned going forward in multiple myeloma. And then second, could you talk about the competitiveness of sirukumab, given the Phase III data we just saw at EULAR and your expectations there on filing, timing and approval?"
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Now let me say a few words on both. And then, Alex, why don't you add a few, and Louise also on the timing question? So DARZALEX, we're very pleased with the initial uptake of DARZALEX. The product is well-received by the medical community. And the data,",153,"Now let me say a few words on both. And then, Alex, why don't you add a few, and Louise also on the timing question? So DARZALEX, we're very pleased with the initial uptake of DARZALEX. The product is well-received by the medical community. And the data, as you pointed out, continues to be very impressive. And we believe DARZALEX can be essentially backbone therapy for the treatment of multiple myeloma. So we expect that we'll get additional indications for DARZALEX, but it's already been quite well-received by the investment community, having great results for patients, and as I said, likely to be backbone therapy going forward. Sirukumab, also very positive data there. It's an important product in our autoimmune franchise. And Alex, maybe you can comment a little bit more on that. And Louise, on the timing of filing for sirukumab, I just don't have it handy, if you could give that."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","2016.",1,"2016."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","2016. So we'll file this year for sirukumab.",8,"2016. So we'll file this year for sirukumab."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. I'll let some other -- yes?",7,"Okay. I'll let some other -- yes?"
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, we -- look, we're excited about sirukumab on a number of fronts. First, as an IL-6. Given what we know in this category, there's a lot of inter-patient variability and having the another option for patients. And based upon the early data that we've s",128,"Yes, we -- look, we're excited about sirukumab on a number of fronts. First, as an IL-6. Given what we know in this category, there's a lot of inter-patient variability and having the another option for patients. And based upon the early data that we've seen in RA, some of the percentages recently at the EULAR conference, we're very encouraged by. We're going to be looking at it, obviously, in other areas. And I think what we're most enthusiastic about is if you combine sirukumab along with the work that we're doing with guselkumab as well, the IL-23 being looked at in psoriasis, it's really going to help us build out an even stronger portfolio and platform in immunology as we go forward over the next several years."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Larry Biegelsen with Wells Fargo.",13,"Our next question comes from the line of Larry Biegelsen with Wells Fargo."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Louise, congratulations on your retirement. I know you'll be missed. So one for Dominic, start -- financial, to start off with, and then just one market-related question. So Dominic, just on the guidance, 2 clarification questions. So the $0.10 raise at t",139,"Louise, congratulations on your retirement. I know you'll be missed. So one for Dominic, start -- financial, to start off with, and then just one market-related question. So Dominic, just on the guidance, 2 clarification questions. So the $0.10 raise at the lower end on operational EPS and the $0.05 on the high end, is $0.05 due to the accounting change and the rest due to the underlying strength in the business? And then it appears there's a lot of moving parts on the sales guidance as well. That 5.5% in 2015 that you raised to 6% for 2016, by my math, it implies that you're expecting similar growth in the second half of 2016 compared to the first half of 2016. If one adjust for the extra week in the year ago period, so is that directionally accurate?"
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Larry. Well, with respect to EPS guidance, you mentioned 2 of the items, which obviously was tax as well as the stronger sales performance. But I just wanted to remind you that we also lowered our other income and expense guidance for the year. So o",149,"Sure, Larry. Well, with respect to EPS guidance, you mentioned 2 of the items, which obviously was tax as well as the stronger sales performance. But I just wanted to remind you that we also lowered our other income and expense guidance for the year. So one way to think about it is that other income and expense guidance is slower. The tax rate is also lower. Those 2 generally offset. And the midpoint of the guidance is up about $0.07, when I do the midpoint versus the 2 ends. And the $0.07 is primarily due to the overall increase in sales guidance that we provided today. Your observations with respect to the back half of the year, you're right. That if we exclude the extra shipping days in 2015 from the analysis, the back half of 2016 would be similar to what we saw for the first half."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And then just on the market in the U.S. Maybe, Alex, if you could comment a little bit, or Dominic, on what you're seeing on procedure volume in the U.S. in ortho, and more broadly, in Med Tech? That would be great.",43,"And then just on the market in the U.S. Maybe, Alex, if you could comment a little bit, or Dominic, on what you're seeing on procedure volume in the U.S. in ortho, and more broadly, in Med Tech? That would be great."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. Thanks, Larry. Larry, we are seeing a pickup in terms of hospital admissions and surgical procedures. I think hospital admissions are up around 3%. We think the procedures are probably up around 3.5%. We continue to see some decrease, overall, in off",99,"Yes. Thanks, Larry. Larry, we are seeing a pickup in terms of hospital admissions and surgical procedures. I think hospital admissions are up around 3%. We think the procedures are probably up around 3.5%. We continue to see some decrease, overall, in office physician visits, down a couple of percent. We think that, that's due to a more moderated utilization. The front-end due to increased co-pays and a number of other dynamics. But overall, if we look at the core growth rate in the medical hospital device area, we're encouraged by some of the recent trends that we're seeing."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Kristen Stewart with Deutsche Bank.",13,"Our next question comes from the line of Kristen Stewart with Deutsche Bank."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And I'll echo, Louise, we'll definitely be missing you, but congratulations. I was wondering, Alex, if you could just comment a little bit about just on the capital allocations side. Obviously, we saw Vogue. Is that what we should be thinking going forwar",66,"And I'll echo, Louise, we'll definitely be missing you, but congratulations. I was wondering, Alex, if you could just comment a little bit about just on the capital allocations side. Obviously, we saw Vogue. Is that what we should be thinking going forward in terms of the type of acquisitions to look forward, the smaller more, I guess, tuck-in for you guys in that range?"
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","All right, Kristen. Thanks a lot for the question. And I couldn't agree with you more regarding Louise. But look, we were really happy that we were able to add Vogue to J&J Consumer portfolio. As we've been talking about over the last several years, we fe",389,"All right, Kristen. Thanks a lot for the question. And I couldn't agree with you more regarding Louise. But look, we were really happy that we were able to add Vogue to J&J Consumer portfolio. As we've been talking about over the last several years, we felt that what was most important to the Consumer group was to actually ensure that we were able to get through the early stages of the remediation in a really high-quality and effective way. And I think the team has done a great job at making it a little bit more broadly across an entire Consumer group. I think we see that in the core trends. And of course, once we establish that, we continue to see Consumer as a great growth opportunity for the organization going forward. And as Jorge and -- as you saw when we did the Medical Device and Consumer Investor Relations review now about a little over a month ago, I think they've got a really ambitious but also realistic plan for that, built on our existing brands. And we were really pleased to see performance. For example, LISTERINE, up 7%; OTC's up 6%; analgesics within OTCs were up over 13%. And then in beauty, you saw about a 9% lift with really strong performance from NEUTROGENA and AVEENO. And when you take that and augment it, I think with thoughtful additions such as we saw over this last quarter, whether it was NeoStrata, whether it was HIPOGLS or with Vogue, we think that those are great additions to our existing portfolio. And we'll likely be part of a continuous stream of additions to that part of the portfolio. And as we said for some time, whenever we're looking at inorganic growth opportunities, we look at tuck-ins, we look at midsized deals, we'll look at large deals. Of course, the tuck-in strategy, particularly in pharma -- or actually, in all of our segments, Medical Device and Consumer, are those that -- where we feel that we can create the most value. But we do think that there's other opportunities to create value as well, and again, in mid- and larger deals. But we're going to be very disciplined. We're going to be very decisive about how we do it. And ultimately, try to better serve patients and consumers."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And just -- I guess, on that broader note, I guess now that Consumer has turned the quarter and has done well with the remediations, is that now a platform that, as you said, is more ready for acquisitions? I know Medical Devices is in the midst of the re",65,"And just -- I guess, on that broader note, I guess now that Consumer has turned the quarter and has done well with the remediations, is that now a platform that, as you said, is more ready for acquisitions? I know Medical Devices is in the midst of the restructuring. Is that how we should think about it? And I have a follow-up for Dominic."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Sure. Look, we believe that mission one was really focusing on the core business, as we said. And I do feel that Consumer, like all of our businesses were pleased -- were never completely satisfied. And they've made a lot of progress on the core. And so w",192,"Sure. Look, we believe that mission one was really focusing on the core business, as we said. And I do feel that Consumer, like all of our businesses were pleased -- were never completely satisfied. And they've made a lot of progress on the core. And so we would expect, again, in a very thoughtful, disciplined way, to continue to do additions when we think they're right. But we would look for the same thing in our other segments as well. And by the way, we're pleased with the progress that we've seen in our Medical Device group over the last quarter as well. I mean, if we look at the restructuring, I think, overall, that team's on track. They're doing actions that strengthen their go-to-market model, to accelerate their pace of innovation. They're prioritizing some additional platforms and geographies, and all while streamlining some operations but really keeping very high-quality standards. We think they're on track with the plan that they articulated earlier in the year. And we're confident that as they move through this, they will be not only a stronger, but a more innovative and a more efficient business."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Great. And Dominic, for the rebate in pharma, should we think about that as flowing through this quarter? Or was that mainly reinvested because I know there was a higher rate of R&D this quarter?",35,"Great. And Dominic, for the rebate in pharma, should we think about that as flowing through this quarter? Or was that mainly reinvested because I know there was a higher rate of R&D this quarter?"
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Well, the -- the way to think about it, maybe, Kristen, is that it's a year-over-year change in about a $140 million sales level. So obviously, some of that drops through the bottom line. And you're right, we do also take the opportunity to invest. Invest",116,"Well, the -- the way to think about it, maybe, Kristen, is that it's a year-over-year change in about a $140 million sales level. So obviously, some of that drops through the bottom line. And you're right, we do also take the opportunity to invest. Investments in R&D, really, are related to progress in the pipeline, regardless of whether these gross to net adjustments would be available. But another way to think about it is that we're now at a point where these actualizations of prior estimates, our current reserves are -- a significant portion of them are current because data has been coming in recently. So I wouldn't expect similar type of adjustments going forward."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Matt Miksic with UBS.",12,"Our next question comes from the line of Matt Miksic with UBS."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Alex, while I've got you here, just one strategic question. And I don't know if this is consistent with what you're seeing or where you think things are going. But on devices, like what we've seen is a lot of these new innovations in structural heart, in",135,"Alex, while I've got you here, just one strategic question. And I don't know if this is consistent with what you're seeing or where you think things are going. But on devices, like what we've seen is a lot of these new innovations in structural heart, in particular, some of the bundled payment initiatives seem to be driving more volumes to sort of higher volume centers, larger networks potentially augmented by outpatient centers. It's early in some of these initiatives, but that seems to be directionally where things are headed. And first, we'd love to get your sense as to whether you think that's where things are going as well. And if so, how change is positioned on the device side to benefit or support these kinds of trends. And then I had one follow-up."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Matt. Thank you very much for the question. Over the past 3 or 4 years, I think we've been pretty consistent in our thinking and in our projections about likely increasing consolidation among providers and hospitals, particular here in the United St",252,"Sure, Matt. Thank you very much for the question. Over the past 3 or 4 years, I think we've been pretty consistent in our thinking and in our projections about likely increasing consolidation among providers and hospitals, particular here in the United States and just broader health care systems. And as systems feel continuing pricing pressure, we think that will manifest itself by them having consolidation. I think we've seen those trends. And I think they're clearly starting an effort to try and be as effective and as efficient as possible. So we do believe that, that will be a longer secular trend that's going to continue. That's why we believe having a diverse and enough critical mass in our medical device portfolio is so important going forward. We see it in the way that expectations are changing among decision-makers, including not only surgeons, but also people in procurement and other C suite executives, administrators and hospital systems. And we think as a result of that, we'll be very well positioned, particularly when you think about our surgical franchise, our Orthopaedics franchise. We've also been consistent in saying that we're extremely pleased with the performance of our cardiovascular unit, particularly our EP group, Biosense Webster. I mean, once again, this quarter, they've delivered over 18.5% growth with great innovation and great execution. But we also realized that, that's an area where we'll continue to look for the right kind of additions, organically and inorganically, to ensure that we're properly positioned going forward."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","That's great. And then on another topic that we spend a lot of time on, I guess, over the past year, and, we're now a quarter away from what looked like a competitive launch in the U.S. biosimilar side on REMICADE. I'd love to -- without asking you to tip",174,"That's great. And then on another topic that we spend a lot of time on, I guess, over the past year, and, we're now a quarter away from what looked like a competitive launch in the U.S. biosimilar side on REMICADE. I'd love to -- without asking you to tip your hand, of course, or -- I'd love to get a sense as to can you -- is there -- are there steps you can take given your portfolio and your relationship with these payers and networks? Are there steps you can take to sort of stop -- I don't know what the right word is. That can offset some of the potential impact or get ahead some of potential impact through some of the contracts that you're talking with these folks about. And I think you know the question I'm asking, and I'm sure you're not going to get into a ton of detail. But any color would be helpful as to the extent of your ability to contract around that event."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, Matt. Look, as we look at the landscape going forward, we fully predict that generics and biosimilars are going to be part of the competitive landscape. And look, we think that, that is essential for the health care system. We think, in the long run,",410,"Yes, Matt. Look, as we look at the landscape going forward, we fully predict that generics and biosimilars are going to be part of the competitive landscape. And look, we think that, that is essential for the health care system. We think, in the long run, it's actually a benefit for very innovative-focused companies because that's the only way you can relieve pressure over the long term. Of course, that's predicated upon the market and companies respecting intellectual property. It's very important to produce the right scientific information so that we're guaranteeing patient safety and understanding the important clinical differences between some of these compounds as they may or may not manifest themselves. And so we projected them. As we look at our strategic plan, we think they will be there. But we also feel that, that's why it's so important to keep innovating with new product launches going forward. And it's also critical to establish a strong critical mass in terms of products, but also expertise in clinical data and information in certain platforms. And so for us, in the Immunology platform, we're very proud of the extensive track record that REMICADE, the TNF-alpha compound has had and what it continues to do. We'll continue to defend our intellectual property around it. But at the same time, if you look at compounds like STELARA and SIMPONI, not only have they both generated an excess of 30% growth this quarter, but we've also produced additional data that we think is going to be very important to patients and physicians in how they adopt these products. And these are already multibillion dollar platforms for Janssen and Johnson & Johnson. And then when you compound that with sirukumab and guselkumab, again an IL-6 and IL-23 approach where we know there's a lot of patient variability, we think that's important. Also, as we look at REMICADE itself, we know that there's about 2.4 million patients who've been treated with the compound. We know that about 70% of them in fact are getting good relief and good effects. We know that they're unlikely to be switched when they're getting a positive response from their therapy. And we also know that when we contract across the Janssen and Johnson & Johnson portfolio, that it provides us a very important position with larger health care systems and networks. So that's the way we think about it, and that's the way we plan for it going forward."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Josh Jennings with Cowen and Company.",14,"Our next question comes from the line of Josh Jennings with Cowen and Company."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","I wanted to ask a question. Dominic, first, just the operating margin performance again kind of beat our expectations. You reiterated your guidance for the year on the operating margin expansion side of things. But I just wanted -- there are multiple driv",138,"I wanted to ask a question. Dominic, first, just the operating margin performance again kind of beat our expectations. You reiterated your guidance for the year on the operating margin expansion side of things. But I just wanted -- there are multiple drivers of operating margin expansion, and there is -- you've had a program in place I think you announced a couple of years ago and just started to ramp last year about $1 billion in cost savings by '18. That was exclusive of the medical device restructuring plan. I just wanted to get a sense of the contribution to operating margin expansion this year, and if we're still in the very early innings and whether we should see stronger benefit from that cost-savings plan as well as the Medical Device restructuring initiative in '17 and '18."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. Well, Josh, you're right. There are many factors that contribute. I mean, GP is one. So we continue to see good manufacturing efficiencies and cost improvements across the supply chain. That's a major initiative we've had ongoing for quite some time.",268,"Yes. Well, Josh, you're right. There are many factors that contribute. I mean, GP is one. So we continue to see good manufacturing efficiencies and cost improvements across the supply chain. That's a major initiative we've had ongoing for quite some time. So we saw some of that benefit this quarter. We expect that we'll see it going forward as well. In the selling, market and administrative line, that's where you see the benefits of the program you were referring to, where we anticipate about $1 billion of savings for 2018. That program's on track. We're seeing the savings. We're also making some investments. As the investments tail off, the savings will be more significant and more impactful in that line item going forward. So we're beginning to see the savings now. They're somewhat partially offset by some investments we need to make to continue the program. But in the future, those investments tail off and the savings ramp up, and there -- have more of an impact. And then also, as you mentioned, the Medical Device restructuring is a whole another area that's unrelated to the 2 that I just mentioned earlier and that we expect to see continued improvements there, although that's a business where we want also to accelerate the pace of innovation with those savings. So some of those will be reinvested in the business. So it's across those 3 areas, and we're committed to the operating margin improvement that I've mentioned earlier of greater than 200 basis points. And halfway through the year, we feel very good about our ability to achieve that."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Excellent. And I just wanted to have a follow-up maybe for Alex and Louise. Just that you commented on utilization levels in the U.S. and procedure volumes, and I -- you experienced just a modest apples-to-apples in selling days from sequentially modest d",71,"Excellent. And I just wanted to have a follow-up maybe for Alex and Louise. Just that you commented on utilization levels in the U.S. and procedure volumes, and I -- you experienced just a modest apples-to-apples in selling days from sequentially modest deceleration in knees and hips and spine or in the ortho segment. Is there anything specific to Q2 that you're seeing in the marketplace that you can comment on?"
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Now look, overall -- and thank you for the question. Overall, I think we saw solid growth in both knees and hips. I think we earned about 4.5% in knees, about 5%, 5.5% in hips. And we think that, that's continued pick-up from the ATTUNE launch and the COR",79,"Now look, overall -- and thank you for the question. Overall, I think we saw solid growth in both knees and hips. I think we earned about 4.5% in knees, about 5%, 5.5% in hips. And we think that, that's continued pick-up from the ATTUNE launch and the CORAIL hip. So I would say that, consistent with what we're seeing in the broader market, consistent with what we're seeing in our business, we're seeing positive growth in that area."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","And for the OUS business, it was about an additional 1.5 days of selling days in the second quarter. And in the first quarter, we had additional selling days in the U.S. business, so that's a reminder on that one.",40,"And for the OUS business, it was about an additional 1.5 days of selling days in the second quarter. And in the first quarter, we had additional selling days in the U.S. business, so that's a reminder on that one."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Joanne Wuensch with BMO Capital Markets.",14,"Our next question comes from the line of Joanne Wuensch with BMO Capital Markets."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","I appreciate the commentary on the volumes. But I was curious if you can give us a commentary on pricing. And also with the April 1 implementation of the bundled payment program in the United States, if you're seeing any impact from that?",43,"I appreciate the commentary on the volumes. But I was curious if you can give us a commentary on pricing. And also with the April 1 implementation of the bundled payment program in the United States, if you're seeing any impact from that?"
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","So we talk about pricing on a Johnson & Johnson basis. And overall, pricing is modest in the quarter.",18,"So we talk about pricing on a Johnson & Johnson basis. And overall, pricing is modest in the quarter."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","I would say, Joanne, that we haven't seen the impact yet in that particular new mechanism that you've just described. As Louise pointed out, pricing overall for the quarter, a year-over-year growth to the pricing is very, very modest in our results.",42,"I would say, Joanne, that we haven't seen the impact yet in that particular new mechanism that you've just described. As Louise pointed out, pricing overall for the quarter, a year-over-year growth to the pricing is very, very modest in our results."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","I can provide some further color on hips and knees in the U.S. Price mix, if you'd like?",19,"I can provide some further color on hips and knees in the U.S. Price mix, if you'd like?"
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","That would be wonderful.",4,"That would be wonderful."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","So the second quarter for the hips was about 2.2% negative, price mix together and this is U.S. only. And for knees, it was about 2.6% negative. And that's similar trends to what we've seen consistently over time.",39,"So the second quarter for the hips was about 2.2% negative, price mix together and this is U.S. only. And for knees, it was about 2.6% negative. And that's similar trends to what we've seen consistently over time."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And then as to my second question had to do more with Vision Care, we saw a real difference between what was happening in the U.S. and what's OUS sale. And you commented on rebates. Is that the replacement program for UPP that we're seeing in that U.S. im",49,"And then as to my second question had to do more with Vision Care, we saw a real difference between what was happening in the U.S. and what's OUS sale. And you commented on rebates. Is that the replacement program for UPP that we're seeing in that U.S. impact?"
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","So it's a customer reward program that we have implemented. And what we have booked in the second quarter is the year-to-date because it was implemented in the second quarter, but it replies to the full year sales. So in the U.S., if you normalized it for",66,"So it's a customer reward program that we have implemented. And what we have booked in the second quarter is the year-to-date because it was implemented in the second quarter, but it replies to the full year sales. So in the U.S., if you normalized it for the half that applied to the first half, the U.S. is up about 6% on a like basis."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","And look, we continue to be very pleased with what we're seeing in the turnaround in our Vision Care business as well. If we look at the early demand signals that we're seeing, it continues to give us confidence that we're gaining share. We continue to la",90,"And look, we continue to be very pleased with what we're seeing in the turnaround in our Vision Care business as well. If we look at the early demand signals that we're seeing, it continues to give us confidence that we're gaining share. We continue to launch into beauty, astigmatism, reusables, along with a number of other new launches and line extensions. And frankly, the team is really executing well. So we're encouraged by the opportunity that we see in Vision Care as we move to the rest of 2016."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Glenn Novarro with RBC Capital Markets.",14,"Our next question comes from the line of Glenn Novarro with RBC Capital Markets."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Louise, I echo the sentiments, so best of luck in the future. My question is for Alex and for Dominic. And I asked a similar question on the last quarterly call because I continue to be surprised that J&J is not doing more with its cash, particularly on t",136,"Louise, I echo the sentiments, so best of luck in the future. My question is for Alex and for Dominic. And I asked a similar question on the last quarterly call because I continue to be surprised that J&J is not doing more with its cash, particularly on the M&A front. You've done Vogue, but we haven't seen much in the way of at least meaningful acquisition from devices and on pharma. And so my question is, the targets that you're having discussions with today, do they still have very unrealistic valuation expectations? And is that the reason why we haven't seen deals in devices in pharma? And then as a follow-up, you still have a bulk of your cash sitting outside the United States. Is that another reason why we haven't seen any meaningful acquisitions?"
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Well, sure, Glenn. Well, consistent with what we said last time when you asked a very similar question. We -- as you know, we're very disciplined in our approach to acquisitions. And although we're actively involved in considering them, valuations come in",291,"Well, sure, Glenn. Well, consistent with what we said last time when you asked a very similar question. We -- as you know, we're very disciplined in our approach to acquisitions. And although we're actively involved in considering them, valuations come into play. And willingness of the other party to do an acquisition have certain valuations come into play. So that's regardless of how much money we have available to spend, right? So we don't really look at that as the main driver of how we're going to do acquisitions. We look at what value we're going to create for shareholders by doing the acquisition at the right value so we can improve returns for our shareholders. There are some expectations that are still not, in our opinion, normalized for appropriate valuations in the market, so that's a factor. And that will take time, and we're patient with that. And then we'll take -- we'll see how the market evolves over time or as we learn more about the acquisition candidates and their progress in various areas. And then finally, whether or not the cash is trapped overseas or not, is not at all an impediment to our ability to do any acquisitions. We'll either obviously try to find a way to do it in the tax efficient basis as we've done with other acquisitions and utilize that cash as much is possible, only if it's tax efficient. But then, obviously, we can continue to borrow, and we have ability to borrow to do the acquisitions that we think are value-creating for our shareholders. So we wouldn't let that hold us back, should the acquisition beat value-creating. We'd exercise what -- we'd exercise our ability to borrow to do that acquisition."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And just as a follow-up -- go ahead, Alex. Did you want to add something?",16,"And just as a follow-up -- go ahead, Alex. Did you want to add something?"
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, Glenn. Right. I guess, what I would also say is, look, I think that our -- the M&A approach that we talked about in the past is a balanced one. I mean, if you look over the last 20 years, I think we've done about 124 deals. I think there's been about",192,"Yes, Glenn. Right. I guess, what I would also say is, look, I think that our -- the M&A approach that we talked about in the past is a balanced one. I mean, if you look over the last 20 years, I think we've done about 124 deals. I think there's been about 13-or-so that have been over $1 billion. But majority of these have been smaller. And frankly, if you look at our pharmaceutical performance and whether it's the partnerships that we have on a compound like IMBRUVICA, DARZALEX, others, I think the strategy has worked really well and it's that we'll continue to pursue. I think we have a lot of examples of that in Medical Devices and also Consumer. And there's nothing that we would like more than to take a several hundred million dollar platform like Vogue and create the next multibillion platform as we see in things like NEUTROGENA and others. So all that being said, if and when we see larger opportunities present an opportunity to really create longer-term shareholder value, those are things we'd certainly be interested in, but we'll be particularly thoughtful about those."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And just one quickly on REMICADE. I know Matt had asked a question on REMICADE, but you remain very confident that a biosimilar won't be launched in 2016. Has anything changed that you can reveal to us on the litigation front that gives you more confidenc",46,"And just one quickly on REMICADE. I know Matt had asked a question on REMICADE, but you remain very confident that a biosimilar won't be launched in 2016. Has anything changed that you can reveal to us on the litigation front that gives you more confidence?"
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Glenn, well, what we said is that our guidance does not assume any biosimilar launch in 2016. There's ongoing developments in the litigation. There's a hearing scheduled for August related to the 471 patents. We'll have to see how that -- what the results",169,"Glenn, well, what we said is that our guidance does not assume any biosimilar launch in 2016. There's ongoing developments in the litigation. There's a hearing scheduled for August related to the 471 patents. We'll have to see how that -- what the results of that hearing are. So we don't know that yet. There was also a ruling issued in relation to another biosimilar, not our biosimilar, which made it very clear when the 180-day waiting period applies. And for us, that 180-day waiting period extends to October 6. Well, obviously, there cannot be any launch before that date. And then as we've mentioned, we're continuously and vigorously defending our patent, and we'll continue to do that. So whether or not a biosimilar launch happens is uncertain. But we have not included it in our guidance estimates. But as you know, our guidance, of course, is a range, and between certain ranges of 3% to 4% and overall growth. So we feel confident about that in any event."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of David Lewis with Morgan Stanley.",13,"Our next question comes from the line of David Lewis with Morgan Stanley."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Congrats, Louise. Once again, echo other sentiments. So just 2 quick questions, now that we're near the end. So Dominic, I'm trying to reconcile revenue guidance just on the margins. So if I take the upside in the quarter plus the net impact of M&A, sort",100,"Congrats, Louise. Once again, echo other sentiments. So just 2 quick questions, now that we're near the end. So Dominic, I'm trying to reconcile revenue guidance just on the margins. So if I take the upside in the quarter plus the net impact of M&A, sort of Vogue minus the API business, I kind of get -- guidance should come up sort of $700 million. It's coming up around $300 million. Is that difference in the back half of the year largely an expectation for lower or minimal gross to net adjustments in the back half versus the first half?"
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Well, certainly, as I mentioned earlier, the gross to net adjustments that we saw in the first half have now resulted in our overall estimates for these amounts as being largely current. No greater than 90% current. But therefore, we wouldn't expect to ha",57,"Well, certainly, as I mentioned earlier, the gross to net adjustments that we saw in the first half have now resulted in our overall estimates for these amounts as being largely current. No greater than 90% current. But therefore, we wouldn't expect to have the same level of those kinds of adjustments going forward, David. That's right."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay, helpful. And then maybe 2 questions on Consumer, one for Alex and one for Dominic. I mean, Dominic, just to start with you on margins. I think we'd left the Analyst Day feeling that Consumer margin outlook was probably conservative. But if I look at",110,"Okay, helpful. And then maybe 2 questions on Consumer, one for Alex and one for Dominic. I mean, Dominic, just to start with you on margins. I think we'd left the Analyst Day feeling that Consumer margin outlook was probably conservative. But if I look at the reported results in the quarter, I mean, you're well ahead of expectations and pursuing that sort of pure-based 20% Consumer margin. So how do we think about that? Is that simply onetime in nature? Or is it much more likely now? You reasonably exceed your targets either in time or magnitude here in Consumer. And then a quick follow-up for Alex in Consumer."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Well, as you know, we were committed to this. And as Jorge Mesquita said in the business review day, he was personally committed to making it happen. And we're very pleased to see that they're off to a great start. Whether they exceed the overall benchmar",118,"Well, as you know, we were committed to this. And as Jorge Mesquita said in the business review day, he was personally committed to making it happen. And we're very pleased to see that they're off to a great start. Whether they exceed the overall benchmark level in a shorter amount of time, that will -- we'll wait to see. Because obviously, we want to see them investment behind brands and keep the momentum up in the business as well. But we're obviously off to a great start. We were confident that they would be able to do it. And they've done a great job, and we're confident they'll continue to do a great job in improving margins."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. And then, Alex, I think many investors had felt that Consumer was sort of kept in the closet here the last several years, and clearly, the last 6 months. The company's working hard to sort of show the Consumer franchise, and to a greater extent, bot",120,"Okay. And then, Alex, I think many investors had felt that Consumer was sort of kept in the closet here the last several years, and clearly, the last 6 months. The company's working hard to sort of show the Consumer franchise, and to a greater extent, both margins and growth. Yes, my question's more on growth. If I ex out Venezuela in the quarter, Consumer did about 5% growth. I felt like the messaging from Jorge and others was, yes, this business can be sort of an upper single-digit grower with obviously expanding margins. What is your sense in that 5% number ex-Venezuela? I mean, do you feel confident here that Consumer is stable and can improve from these levels?"
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, David. Thank you very much. And again, let me reiterate. We're really pleased with the performance that we continue to see in the Consumer group. And literally, from quarter-to-quarter, it continues to improve in not only its core performance but mar",164,"Yes, David. Thank you very much. And again, let me reiterate. We're really pleased with the performance that we continue to see in the Consumer group. And literally, from quarter-to-quarter, it continues to improve in not only its core performance but market share and a number of other areas. We feel like the majority of the platforms right now, we're actually gaining share. At the same time, we realized we've got some areas such as Baby, such as China, where we need to do a better job, and the team is focusing on that, in addition to the margin improvement that Dominic was talking about earlier. But overall, our goal is to grow faster than the market. We think we currently are. It's something that we want to do and accelerate as we go forward. And I'm very confident that Jorge and his team, we've got the strategies and are now executing in a manner that's going to allow them to do just that."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Danielle Antalffy with Leerink Partners.",13,"Our next question comes from the line of Danielle Antalffy with Leerink Partners."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Louise, we're really going to miss you. Question for you, Alex, just higher level. Sorry to do this. But following-up on the M&A commentary, some of your competitors have been acquiring scale, most recently Abbot and St. Jude. And I know J&J is already in",136,"Louise, we're really going to miss you. Question for you, Alex, just higher level. Sorry to do this. But following-up on the M&A commentary, some of your competitors have been acquiring scale, most recently Abbot and St. Jude. And I know J&J is already in a competitively advantageous position, given your current product lines. But Cardiovascular is an area where you're specifically under-scaled relative to some of those other competitors. Now I was just wondering if you could comment on whether you think it's important to build scale within cardiology to be -- to continue to be a major competitor in Med Tech or if you think there's other areas where J&J is already positioned and will continue to focus on? I'm just trying think about the different subsectors within Med Tech where you'll focus most."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. Thanks, Danielle. Look, consistent with what we said previously, we do think that there's an opportunity for expansion in cardiovascular. And for us, really, it started several years ago when we made the decision to exit the stent business. We did th",246,"Yes. Thanks, Danielle. Look, consistent with what we said previously, we do think that there's an opportunity for expansion in cardiovascular. And for us, really, it started several years ago when we made the decision to exit the stent business. We did the divestment of Cordis, which I think the team executed really well. And look, we think now the greater focus that we have, what you're seeing as a result of that, frankly, is better growth, not only in our cardiovascular business, the Biosense Webster, but across the greater hospital Medical Device business that we have. But we know that going forward, other areas in cardiovascular, ranging from valves to structural heart to others, could definitely be opportunities. But we're going to continue to see how the technology evolves, how the markets evolve. And that -- and fortunately, I think we're positioned in a way that gives us a lot of different opportunities. And at the same time, I would say that there other areas in Medical Devices that we remain interested in. We've talked about the Vision Care area. It's one where you have a very strong contact lens platform. But we think there's opportunities, be it back of the eye, surgery and other spaces that, that business could be augmented. And we'll continue to look for other thoughtful plays in orthopedics as well as in general surgery that offer growth opportunities and help us better address areas of unmet medical need as well."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Jami Rubin with Goldman Sachs.",13,"Our next question comes from the line of Jami Rubin with Goldman Sachs."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And Louise, I'm really going to miss talking to you. You've been extremely helpful over the years. Dominic, I'm sorry to belabor gross to net adjustment. But I'm unclear as to how it occurred and what it means. And I think more importantly, these are all",201,"And Louise, I'm really going to miss talking to you. You've been extremely helpful over the years. Dominic, I'm sorry to belabor gross to net adjustment. But I'm unclear as to how it occurred and what it means. And I think more importantly, these are all categories, REMICADE, STELARA, SIMPONI, ZYTIGA, which are crowded categories. And can you comment on what's happening with respect to gross to net -- the gap between gross to net and how it's changed over the last year or 2? If it has changed at all, are you able to take the same sort of list price that you had before, without having to pay a higher rebate? If you can just kind of comment on that, generally? And then also my follow-up question relates to INVOKANA. Sales, again, were -- continue to be very strong. You're showing nice improvements in market care. What are your expectations for the whole SGLT2 class? I'm sure you've paid attention to the FDA panel meeting on Jardiance and whether or not Jardiance will get a superior label with respect to CV mortality reduction? And if it does get that label update, what that might mean to INVOKANA going forward?"
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Jami. Let me take the first question on gross to net, and then Alex will cover the SGLT2 commentary. So U.S., how does it occur and what's going on with list price versus net price and those sorts of things. So just to put it in perspective, this is",256,"Sure, Jami. Let me take the first question on gross to net, and then Alex will cover the SGLT2 commentary. So U.S., how does it occur and what's going on with list price versus net price and those sorts of things. So just to put it in perspective, this is not unusual in our industry, as you know. Everyone in the pharmaceutical industry is estimating what the rebates might be. And then, of course, we'll actualize them was actual data is submitted. Recently, that actual data has been more timely. And in that more timely data from the payers, we're able to see trends -- so we're able to not only actualize prior period amounts, but we're also able to estimate better what the ultimate gross to net variation will be going forward. With respect to list price net of rebates, as you probably know, we said this before, we think we price our products responsibly and our overall list price increases have been relatively below -- substantially below the average industry. But in the end, the net price that's achieved is far from the gross price increase that happened. So rebates continue to be an increasing part of the business, and the overall realization of gross price to net price -- that delta is expanding, I would, say over time. And therefore, as I said, now, we're much more current with our ability to predict these estimates, and that's what's going on. And as I mentioned, we don't expect to see significant adjustments in [indiscernible]."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","So you're saying the gap is going to continue to grow. But you overestimated the growth of that gap, and that, therefore, is the adjustment? But big picture, you expect the gap to grow?",35,"So you're saying the gap is going to continue to grow. But you overestimated the growth of that gap, and that, therefore, is the adjustment? But big picture, you expect the gap to grow?"
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","That's right.",3,"That's right."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","And Jami, regarding INVOKANA in the class, look, first of all, we are pleased with the performance -- the continued performance of INVOKANA in the market. I mean, it remains the #1 SGLT2 in the U.S., both in new and total scripts. I think we've got betwee",223,"And Jami, regarding INVOKANA in the class, look, first of all, we are pleased with the performance -- the continued performance of INVOKANA in the market. I mean, it remains the #1 SGLT2 in the U.S., both in new and total scripts. I think we've got between 9 million and 10 million prescriptions that have already gone out since launch. That being said, we still think that there is a good opportunity for growth in INVOKANA. We've got a very strong clinical profile that's well documented, strong access across managed care. And look, we're confident that given the experience that ACP have had with it, combined with its profile, that's going to continue to grow. Regarding the broader issues around class, look, we think that it's really good news, frankly, for type 2 patients, given some of the news that's coming out about CV benefits. And really, regardless of the eventual decision by the FDA regarding potential claims for other agents, we're looking forward to seeing the results of our campus [ph] program that will be coming out in about a year. And we'll have to see if these ongoing CV outcome trials validate some of the current perceptions of KOLs regarding the cardiovascular effects of SGLT2 inhibitors across the joint class. We'll see. But overall, we think it's good news for patients."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Vamil Divan with Crdit Suisse.",13,"Our next question comes from the line of Vamil Divan with Crdit Suisse."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Congrats again to Louise. Just following-up on Jami's question on the gross to net commentary. Just -- I don't think you touched on this. But specifically, on Immunology, it seems a lot of those products, in particular, saw that benefit. Is there anything",163,"Congrats again to Louise. Just following-up on Jami's question on the gross to net commentary. Just -- I don't think you touched on this. But specifically, on Immunology, it seems a lot of those products, in particular, saw that benefit. Is there anything that you're seeing in that specific market that may be causing the difference there to be greater than what you see with your -- in the other therapeutic areas? And then one other unrelated, just on IMBRUVICA, it came in a little bit lighter than what we were expecting. Obviously, a lot of good data and a lot of growth ahead. But maybe if you could just comment on the trend you're seeing there. And also it's -- I guess, it's been about a year now since you now have a partner on that product with Pharmacyclics being acquired by AbbVie. Just the dynamics in that partnership and how you see that related to what you're seeing previously with Pharmacyclics."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","So let me take the -- there's nothing substantially different between biologics and others, other than the biologics products tend to have a longer delay in terms of receiving the information. So therefore, there may be more adjustments related to those p",69,"So let me take the -- there's nothing substantially different between biologics and others, other than the biologics products tend to have a longer delay in terms of receiving the information. So therefore, there may be more adjustments related to those products in any particular period. But other than that, there's no other significant trend that we're seeing that's any different than what we've see overall in the market."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","And look, regarding IMBRUVICA, no, we're very pleased with the continued launch uptake that we see with it. It continues to be strong, good increase versus last year. And look, IMBRUVICA's also maintaining really good total patient market leadership in CL",89,"And look, regarding IMBRUVICA, no, we're very pleased with the continued launch uptake that we see with it. It continues to be strong, good increase versus last year. And look, IMBRUVICA's also maintaining really good total patient market leadership in CLL line 2-plus mantle cell lymphoma as well as WM in the U.S. We have additional approvals and line indications done in other markets as well. So we continue to be pleased with the performance and look forward to getting out additional information and additional indications on the countdown."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. And just on the quarter, there's additional -- we have a patient assistance program, and there's a little bit of bump in that. So that may have -- that's probably the trend difference that you see.",37,"Yes. And just on the quarter, there's additional -- we have a patient assistance program, and there's a little bit of bump in that. So that may have -- that's probably the trend difference that you see."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our final question comes from the line of Jayson Bedford with Raymond James.",13,"Our final question comes from the line of Jayson Bedford with Raymond James."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Just to clarify and kind of follow-up on an earlier question. U.S. Med Device growth in the quarter decelerated from first quarter levels. International growth accelerated. There was quite a big difference in growth in these 2 geographies. It sounds like",63,"Just to clarify and kind of follow-up on an earlier question. U.S. Med Device growth in the quarter decelerated from first quarter levels. International growth accelerated. There was quite a big difference in growth in these 2 geographies. It sounds like this is more a function of selling days with no real change in the operating environment. Is that a fair characterization?"
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","So in the OUS, we have an additional 1.5 selling days on average. That contributes to the OUS growth about 220 basis points. But on top of that, we're seeing strong market growth in China. We have some strong markets in Russia. Australia in the hips. And",97,"So in the OUS, we have an additional 1.5 selling days on average. That contributes to the OUS growth about 220 basis points. But on top of that, we're seeing strong market growth in China. We have some strong markets in Russia. Australia in the hips. And then we're seeing nice growth in the [indiscernible]. Also seeing some as growth in the [indiscernible]. So it's a combination of both the selling days, but if you strip out the 220 basis points for selling days OUS, you're still seeing really nice growth in both hips and knees OUS."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","And Jayson, one thing I would add to that is when we're talking about the Medical Device business, obviously, there's some dynamics in diabetes and some dynamics that we talked about earlier with Vision Care with the customer loyalty program. So if you lo",91,"And Jayson, one thing I would add to that is when we're talking about the Medical Device business, obviously, there's some dynamics in diabetes and some dynamics that we talked about earlier with Vision Care with the customer loyalty program. So if you look at the hospital based Medical Device business then you exclude the impact of acquisitions and divestitures, that growth did accelerate. So the second quarter growth at about 4.7%, and first quarter growth at about 4.2%. So on the base hospital medical business, overall, we're seeing accelerated growth."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","We'll have some final remarks from Alex.",8,"We'll have some final remarks from Alex."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Okay. Well, thank you very much, everyone, for joining us this morning. And as I noted earlier, look, we're really pleased with the continued momentum as evidenced by our increased guidance for both sales and earnings for the full year 2016. Look, I rea",148,"Okay. Well, thank you very much, everyone, for joining us this morning. 
And as I noted earlier, look, we're really pleased with the continued momentum as evidenced by our increased guidance for both sales and earnings for the full year 2016. Look, I really believe that some of the clear strategic choices that we've been making, the really strong focus and execution, combined with an incredibly talented group of leaders that I'm honored and humbled to be able to work with everyday at Johnson & Johnson, are enabling us to really deliver extraordinary achievements and results that we've just been able to share with you and to really build on the success of Johnson & Johnson going forward. 
So thank you for your time this morning. I look forward to updating you on the progress throughout the year, and I hope everybody has a great day. Thank you."
139677,367223456,1007971,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Thank you. This concludes today's Johnson & Johnson Second Quarter 2016 Earnings Conference Call. You may now disconnect.",18,"Thank you. This concludes today's Johnson & Johnson Second Quarter 2016 Earnings Conference Call. You may now disconnect."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Good morning, and welcome to Johnson & Johnson's Second Quarter 2016 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] I would now like t",51,"Good morning, and welcome to Johnson & Johnson's Second Quarter 2016 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] 
I would now like to turn the conference call over to Johnson & Johnson. You may begin."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Good morning, and welcome. I'm Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure this morning to review our business results for the second quarter of 2016. Joining me the on the call today is Alex Gorsky",2027,"Good morning, and welcome. I'm Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure this morning to review our business results for the second quarter of 2016. 
Joining me the on the call today is Alex Gorsky, Chairman of the Board of Directors and Chief Executive Officer; and Dominic Caruso, our Chief Financial Officer. 
A few logistics before we get into the details. This review is being made available via webcast accessible through the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. I'll begin by briefly reviewing the second quarter for the corporation and for our 3 business segments. Following my remarks, Alex will comment on the 2016 results to date and provide a strategic outlook for the company. Next, Dominic will provide some additional commentary on the business, review the income statement and update guidance for 2016. We will then open the call to your questions. We expect the call to last approximately 90 minutes. 
Included with the press release that was issued earlier this morning is the schedule of sales for key products and/or businesses to facilitate updating your models. These schedules are available on the Johnson & Johnson website, as is the press release. 
Please note, we will be using a presentation to complement today's commentary. The presentation is also available on our website. 
Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements. The 10-K for the fiscal year 2015 and the company's subsequent filings identify certain factors that could cause the company's actual results to differ materially from those projected in any forward-looking statements made today. The company does not undertake to update any forward-looking statements as a result of new information or future events or developments. Our SEC filings, including the 10-K, are available through the company and on our website. 
During the review, non-GAAP financial measures are used to provide information pertinent to evaluating business performance period-over-period. These non-GAAP financial measures should not be considered replacements for and should be read together with GAAP results. Tables reconciling these measures to the most comparable GAAP measures are available in the schedules accompanying the press release and on the Investor Relations section of the Johnson & Johnson website. A number of products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships. 
Also, to assist you with your models, this slide provide you with a summary of important developments that occurred during the quarter. 
Now I would like to review our results for the second quarter of 2016. Worldwide sales to customers were $18.5 billion, up 3.9% versus second quarter 2015. 
On an operational basis, sales were up 5.3% and currency had a negative impact of 1.4%. In the U.S., sales were up 7.4%. In regions outside the U.S., our operational growth was 3.1% while the effect of currency exchange rates negatively impacted our reported results by 2.7%. 
On an operational basis, the Western Hemisphere, excluding the U.S., grew by 15.4% with approximately 1/3 of the growth due to an inventory build that will reverse in the third quarter. Asia Pacific, Africa grew 2.1%, while Europe declined 0.6%. Results in all regions were negatively impacted by hepatitis C competition and divestitures, the most significant one being Cordis. Excluding the net impact of acquisitions, divestitures and hepatitis C, underlying operational growth was 7.9% worldwide, 8.8% in the U.S. and 6.9% outside the U.S. In addition, operations in Venezuela negatively impacted worldwide and outside the U.S. operational growth by 30 basis points and 70 basis points, respectively. 
Turning now to earnings. Net earnings were $4 billion and earnings per share were $1.43 versus $1.61 a year ago. As a reference in the table reconciling non-GAAP measures, 2016 second quarter net earnings were adjusted to exclude after-tax amortization expense of $238 million and charges for after-tax special items of $631 million. 
2015 second quarter net earnings were adjusted to exclude after-tax amortization expense of $230 million and charges for after-tax special items of $66 million. Dominic will discuss special items in his remarks. 
Excluding amortization expense and special items for both periods, adjusted net earnings for the current quarter were $4.9 billion and diluted earnings per share were $1.74, representing increases of 1.1% and 1.8%, respectively, as compared to the same period in 2015. On an operational basis, adjusted net earnings per share also grew 1.8%. 
Now turning to the highlights for the first 6 months of 2016. Consolidated sales to customers were $36 billion, an increase of 2.3% as compared to the same period a year ago. On a year-to-date basis, sales grew 4.6% operationally and currency had a negative impact of 2.3%. 
Excluding the net impact of acquisitions and divestitures and hepatitis C sales, underlying operational growth was approximately 7.4% worldwide, 9.3% in the U.S. and 5.4% outside the U.S. 
In addition, operations in Venezuela negatively impacted worldwide and outside the U.S., operational growth by 50 basis points and 90 basis points, respectively. 
Turning now to earnings for the first 6 months of 2016. Net earnings were $8.5 billion and diluted earnings per share were $3.02. Adjusted net earnings were $9.7 billion and adjusted earnings per share were $3.47, up 5.3% and 6.1%, respectively, versus the same period last year. On an operational basis, adjusted net earnings per share grew 7.3%. 
Turning now to business segment highlights for the second quarter of 2016. Please note, percentages quoted represent operational sales change in comparison to the second quarter of 2015 unless otherwise stated and therefore, exclude the currency translation impact. 
I'll begin with the Consumer segment. Worldwide Consumer segment sales of $3.4 billion increased 1.5%, with U.S. sales up 2.1% while outside the U.S. sales were up 1%. Excluding the net impact of acquisitions and divestitures, underlying operational sales growth was 3.9% worldwide, 6.8% in the U.S. and 2% outside the U.S. 
In addition, operations in Venezuela negatively impacted growth worldwide and outside the U.S. by 120 basis points and 200 basis points, respectively, with the most significant impact to Women's Health, Baby Care and Oral Care. Growth for the segment was driven primarily by Skin Care, OTC and Oral Care. 
In Skin Care, market share increases in a growing market as well as timing of inventory builds drove double-digit growth for both NEUTROGENA and AVEENO. 
OTC sales growth was strong despite a weak allergy season. U.S. OTC sales growth was driven by analgesic and digestive health share growth. In the U.S., adult analgesic market share was approximately 14%, up from approximately 11% a year ago, while U.S. pediatric share was nearly 47%, up from nearly 44% a year ago. Major contributors to the growth outside the U.S. were the strong performance of anti-smoking aids, children's analgesics and digestive health products. New product launches and successful marketing campaigns drove the results for LISTERINE in Oral Care. 
Moving now to our Pharmaceutical segment. Worldwide sales of $8.7 billion increased 9.7%, with U.S. sales up 13.2% and sales outside the U.S. up 4.9%, driven by both strong sales of new products as well as core growth products. 
Competitors in hepatitis C significantly impacted sales this quarter. Excluding sales of our hepatitis C products, OLYSIO and INCIVO as well as the impact of acquisitions and divestitures, underlying sales growth worldwide, U.S. and outside the U.S. was 12.8%, 13.9% and 11.2%, respectively. 
As you know, there were discounts and rebates in the pharmaceutical industry that are reflected in net sales. These amounts are estimated until the related claims data is received and then they are actualized. We have adjusted our estimates to reflect the most current claims trends. 
U.S. Pharmaceutical results this quarter included a positive adjustment to sales reserves across many channels, which was approximately $140 million higher than the adjustment in the second quarter of 2015 and positively impacted second quarter 2016 worldwide growth by approximately 1.5 points and U.S. growth by approximately 2.5 points. 
On a product basis, REMICADE U.S. growth in the second quarter of 2016 was positively impacted by approximately 8 points, STELARA by 11 points, SIMPONI by 13 points, ZYTIGA by 8 points and PROCRIT by 31 points. 
Significant contributors to growth were immunology products, REMICADE, STELARA and SIMPONI/SIMPONI ARIA; oncology products, IMBRUVICA and recently launched DARZALEX; as well as cardiovascular and metabolic products, XARELTO and INVOKANA. 
Within Neuroscience, strong growth for INVEGA SUSTENNA/TRINZA was partially offset by lower sales of INVEGA due to the impact of generic competition. The results for immunology were driven by strong double-digit market growth, share growth for STELARA and SIMPONI ARIA as well as the gross-to-net adjustments to U.S. sales that I mentioned. 
The decline in REMICADE export sales to our distribution partners was due to the impact of biosimilars. 
Strong patient uptake with new indications, approvals and demonstrated efficacy drove results for IMBRUVICA, both in the U.S. and outside the U.S. In the U.S., IMBRUVICA remains the new patient share and total share leader in second-line CLL and MCL. IMBRUVICA is now launched in more than 70 countries. 
DARZALEX was approved in the U.S. in November 2015 and has achieved rapid uptake with strong underlying demand. DARZALEX contributed approximately 2 points to the U.S. pharmaceutical growth rate. DARZALEX received European Commission conditional approval this quarter and was launched in certain European countries. 
XARELTO sales were up 25.8% and total prescription share or TRx for the quarter in the U.S. anticoagulant market grew to nearly 17%, up 1.5 points from a year ago. TRx in primary care was over 14% and in cardiology, over 23%. XARELTO is broadly reimbursed with approximately 95% of commercial and Medicare Part D patients covered at the lowest co-pay for a branded product. 
INVOKANA/INVOKAMET sales were up 21% on a worldwide basis and 15.2% in the U.S. In the U.S., INVOKANA/INVOKAMET TRx within the defined market of type 2 diabetes, excluding insulin and metformin, was 6.3%, up from 6% in the second quarter of 2015. TRx with endocrinologists was approximately 11.5% and over 5.5% in primary care. INVOKANA access remains strong at nearly 70% preferred for commercial and over 90% for Medicare Part D. 
I'll now review the Medical Devices segment results. Worldwide Medical Devices segment sales of $6.4 billion increased 1.8%. U.S. sales increased 1% while sales outside the U.S. increased 2.6%. As a reminder, Cordis was divested in the fourth quarter of 2015. Excluding the net impact of acquisitions and divestitures, underlying operational sales growth was 3.9% worldwide, with U.S. up 1.9% and growth of 5.8% outside the U.S. In addition, operations in Venezuela negatively impacted growth worldwide and outside the U.S. by 30 basis points and 50 basis points, respectively. Growth was driven by advanced surgery, electrophysiology, orthopedics and Vision Care. 
Strong results were achieved for advanced surgery products with endocutters growth of 13%, energy growth of 9% and biosurgicals growth of 8%. The acquisition of NeuWave Medical also contributed to growth this quarter. 
Electrophysiology grew 18% worldwide due to strong market growth, complemented by new product launches and increased penetration for both ultrasound and diagnostic catheters. 
Orthopaedics sales growth was driven by U.S. trauma and worldwide hips and knees. Market growth and the success of product launches drove results for the U.S. Orthopaedics business. Pricing pressure continued across the major categories, partially offset by positive mix for trauma and spine products. 
The success of the TFNA nailing system in trauma, the ATTUNE platform in knees, our primary stem platforms in hips and ORTHOVISC/MONOVISC and new spine product introductions made important contributions to the results.
Orthopaedics sales outside the U.S. were -- negatively impacted results in China due to continued reduction in inventory. Trauma and spine/other were the categories most impacted. 
In addition, timing of tender business negatively impacted trauma growth for the quarter. 
Vision Care sales were driven by strong growth across the major regions, partially offset in the U.S. by a customer reward program. 
That concludes the segment highlights for Johnson & Johnson's second quarter of 2016. 
It is now my pleasure to turn the call over to Alex Gorsky. Alex?"
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Louise, and good morning, everyone, and thank all of you for joining us on the conference call or webcast today. As you just heard from Louise, our second quarter results have continued the momentum that began with our great start to 2016, an",2214,"Thank you, Louise, and good morning, everyone, and thank all of you for joining us on the conference call or webcast today. 
As you just heard from Louise, our second quarter results have continued the momentum that began with our great start to 2016, and we're pleased that our shareholders are seeing above-average returns on their investment in Johnson & Johnson. 
Delivering a fair return to shareholders is the final line of our credo, which clearly defines our first responsibilities, the doctors, nurses and patients, the mothers and fathers and all others who use our products. When we meet those responsibilities and when we continuously work to improve outcomes for patients around the world, we succeed with all of our stakeholders. 
Now over the last 130 years, the people of Johnson & Johnson have been helping people everywhere live longer, healthier and happier lives. With that remarkable heritage, I'm excited and optimistic about the opportunities for the future of Johnson & Johnson and committed to continuing our long-term success. With our broad base of strong businesses, focused strategies and comprehensive approach to innovation, we're well prepared to address the challenges of today's health care market and well positioned to lead in the movement towards healthier societies. 
As I've discussed before, we believe our broad base in human health care is vital to achieving that vision. Our broad base is a strategic choice based on performance, and it has helped us to deliver strong, consistent and sustainable financial performance through various economic cycles, meeting our financial commitments in the midst of global events like the U.K.'s vote to exit from the EU or the economic issues in Venezuela this year. Our broad base enables us to create and access growth opportunities wherever they may arise at the right time and in the right markets. 
Our deep health care expertise also makes Johnson & Johnson companies strategic partners of choice for many companies, whether that means with innovative start-ups, information technology giants or large hospital systems looking to improve patient outcomes and reduce the cost of care. 
We also work with local governments and public health organizations where we're collaborating more than ever to address the world's most pressing health challenges. Our broad base allows us to create product platforms and systems that cross categories and establish new sources of innovation to converge in combination products. And finally, our broad base is helping us to realize advantages of scale to achieve enterprise efficiencies and capabilities across all of our segments. 
All of these advantages of our broad base in human health care contribute to the long-term value we are able to create for our shareholders, and we continue to have a clear set of objectives for creating that long-term value. We expect global health care to grow at 3% to 5% over the next 5 years, and we have an objective to grow our sales organically at a faster rate than the market. 
We also intend to grow our earnings faster than sales. When we combine these objectives with our plans that continue creating value through strategic acquisitions and partnerships as well as our strong dividend yield, we believe the result to be a basis for compelling, long-term total shareholder returns. And that is our focus. We invest for the long-term success of our business. In fact, we have increased our spending on R&D every year for the last 5 years. We invest above industry average levels to build our robust pipelines and continue to nurture the investments we've already made. 
We also invest in innovative sales and marketing initiatives and consistently benchmark to ensure the return on our investments is as competitive and as efficient as possible. 
I'm proud that we are able to make these important investments in our business, while also generating enterprise adjusted net income margins that have increased in our above-industry benchmarks. 
After we've made the appropriate investments in our business, we look to capitalize on the right opportunities to create greater long-term value for our shareholders. Our capital allocation framework starts with paying dividends to our shareholders, which is why we have increased our dividend every year for the last 54 years. Next, we seek value-creating strategic acquisitions and partnership opportunities. And finally, we consider other prudent ways to return value to shareholders such as repurchase programs. 
In fact, over the last 3-, 10- and 20-year periods, Johnson & Johnson total shareholder return has exceeded our competitive composite. And as you can see in this chart, we're off to a very strong start in 2016 with total shareholder return of approximately 20% through the first half of the year. 
And while we manage our business for the long term, we also have a number of near-term priorities, which I've shared with you before. As an enterprise, we're focused on delivering on our financial and quality commitments. Through the first 6 months, we generated sales of $36 billion, resulting in an operational growth of 4.6%. When you exclude the impact of acquisitions, divestitures, hepatitis C sales and operations in Venezuela, underlying growth was 7.9%. 
Through the first half of this year, we have delivered adjusted net earnings of $9.7 billion and adjusted EPS of $3.47. On an operational basis, adjusted EPS was $3.51, representing growth of 7.3%. 
In our Pharmaceutical business, we continue to deliver very strong results. On the same underlying basis, growth was 12.7% through the first half of 2016, and we are continuing to build momentum in our Consumer and Medical Device businesses with first half underlying growth of 4.5% and 3.7%, respectively. 
We also continue making progress with our quality system, including resolving a warning letter in our ASP business and completion of the Synthes corporate integrity agreement. 
In Pharmaceuticals, we're continuing to build on our launch excellence and robust pipeline. In the last several months, we have made significant advancements in our pipeline, including conditional EU approval for DARZALEX for monotherapy of adults with relapse and refractory multiple myeloma and presented positive Phase III data on the CASTOR and POLLUX studies, which are evaluating combination therapies for DARZALEX. 
We also received the EU approval for frontline IMBRUVICA treatment in CLL as well as FDA expansion of the IMBRUVICA label to include new Phase III data on survival and in combination therapies. 
Phase III data on STELARA demonstrated maintained clinical remission after 1 year of treatment in patients with moderate to severe Crohn's disease. 
Clinical trial and real-world data was presented on INVOKANA, including Phase II data on type 1 diabetes and chronic weight management. 
We received EU approval for TREVICTA, a once every 3 months injection for maintenance treatment of schizophrenia, as well as line extension approval for both INVOKAMET and SIMPONI. 
Positive Phase III data was presented on sirukumab for patients with moderately to severe active rheumatoid arthritis. 
And just recently, FDA granted the fourth Breakthrough Therapy designation for IMBRUVICA in graft versus host disease, GDHD, which makes 6 total breakthrough designations for our Pharmaceutical business so far. 
In addition to these pipeline milestones, as Louise pointed out, we also delivered strong growth with our in-market products, including IMBRUVICA, DARZALEX, XARELTO, STELARA and SIMPONI. 
In Consumer, our priority is expanding market leadership in key segments within OTC, Oral Care, Baby and beauty. 
As part of our focus on the beauty space, we had just completed the strategic acquisition of Vogue International. The award-winning beauty products in this portfolio, including the OGX brand, enhance our existing position in the market and are highly complementary to our heritage of breakthrough innovations in this space. 
Vogue International has grown at double digits over the last 5 years with a compound annual growth rate of about 25%, and the acquisition will take us from #8 to #4 in the U.S. hair care market. 
And as we discussed in May at our Analyst Day, we're continuing to see operating margin improvement in our consumer business and plan to continue that trend for the next several years. 
And in Medical Devices, we're focused on accelerating growth through innovation and transforming our go-to-market models. In this segment, we're gaining momentum and accelerating growth through our unique and broad-based approach to innovation. Our performance this quarter was roughly in line with market growth. And we're pleased with the progress here, but far from satisfied. Our goal, to be clear, is to grow above market overall. 
And while we're making strategic decisions in our portfolio to achieve that growth like the recent acquisition of BioMedical Enterprises, Inc., which filled a key portfolio gap in elective foot and ankle surgery, we're also realigning our commercial models in line with our near-term priority. Our innovation model in Hospital Medical Devices includes innovating our product offerings, but it also looks at innovation in terms of our commercial offerings and contracting. 
As we outlined during our business review day, today, about 25% of our U.S. orthopedic and surgery business is in multiproduct line agreements. These agreements perform almost 2x better than single-product contract agreements. We see this percentage growing to 40% in the near future, which we believe will help us accelerate our business going forward. 
And finally, we're also serving customers in a more end-to-end manner with risk-sharing contracts and outcome-based patient solutions. 
We're also on track to deliver approximately $800 million to $1 billion in annual savings from our Medical Device restructuring, the majority of which we expect will be realized by the end of 2018. 
And also, we continue to make progress in launching new competitive entries in our Consumer Medical Device businesses like the ACUVUE VITA, a 30-day daily-wear contact lens that provides superior comfort over leading monthly brands. 
With all this progress in our Medical Devices segment, we are confident that we are poised to deliver above-market growth. Altogether, these near-term priorities will help drive success for each of our business segments, while also enabling us to achieve the growth we expect for our company in the long term. With the progress we made on our near-term priorities, our businesses are strong, positioning us for above-market growth. With the combined strength of our in-market portfolio, deep late-stage pipeline and robust early-stage pipeline, we feel confident our Pharmaceutical business can successfully navigate through the launches of new competitive, biosimilar or generic entrants and evolving market dynamics. And our objective is to continue delivering above-industry growth. Our Consumer business is positioned to grow above market, while also achieving benchmark profitability and investing for the future. 
And in Hospital Medical Devices, we are poised to grow above the market, driven by our innovative pipelines, expanding global presence and novel commercial models. 
Our Consumer Medical Device businesses are holding leading positions and seeking opportunities to expand in large growing markets with significant unmet needs. With the strength of each of our business segments, we feel optimistic about the future opportunities in health care, and we are confident our long-term strategies have positioned us for continued growth. Our holistic approach to innovation, going beyond products and solutions, will allow us to address the evolving health care landscape, driving better outcomes and delivering long-term value. We have the right internal capabilities and are developing strategic partnerships in health tech to reshape the way health care is delivered, managed and experienced. 
And finally, our broad base across human health care uniquely positions Johnson & Johnson as a leader and partner of choice in the health care market. 
But perhaps most importantly of all, our continued strong performance means we are able to create better products, more valuable services and improved outcomes for patients, consumers and their families. 
So I'd like to thank you. I look forward to further dialogue during the Q&A session. But first, I'd like to take a moment to recognize Louise Mehrotra, who, as most of you know from our announcement last month, has decided to retire after more than 35 years with Johnson & Johnson and more than 10 years as Vice President of Investor Relations. 
I know many of you on the call today have gotten to know Louise pretty well over the last several years, a real testament to the strong relationships she's built in the investment community on behalf of Johnson & Johnson. And you may know that she's an incredibly committed credo-based leader and had a remarkable career and impact on our company. I think I can speak for all of us at Johnson & Johnson in saying that we will miss her trusted, experienced, respected advice and her ever-present determination to do what's in the best interest of all of our credo stakeholders. 
Louise, we're so proud of the best-in-class Investor Relations function you've developed for us over the last decade, and we sincerely thank you for your many years of service and dedication to Johnson & Johnson. 
Now we know we'll all be in good hands with Joe Wolk, previously Vice President of Group Finance for our Pharmaceuticals Group, will become Vice President Investor Relations effective August 1 and transition with Louise over the next 5 months. We are confident that Joe will continue Louise's legacy of transparent and credible communication with you, our investors. 
So now, I'll turn it over to Dominic Caruso, who will talk more about our results and expectations for the second half of 2016. Dominic?"
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Thanks, Alex, and good morning, everyone. Before I get into our results, I'd like to echo Alex's sentiments and personally thank Louise for her significant contributions to Johnson & Johnson and for her valued support and friendship during my time as Chie",2639,"Thanks, Alex, and good morning, everyone. Before I get into our results, I'd like to echo Alex's sentiments and personally thank Louise for her significant contributions to Johnson & Johnson and for her valued support and friendship during my time as Chief Financial Officer. 
Over the last 10 years, Louise and the entire IR team has transformed our Investor Relations function, significantly developing our reputation with the investment community, which has been recognized with several awards and recognitions, including those from Institutional Investor and IR Magazine. And through surveys of money managers conducted by Barron's Magazine, Johnson & Johnson has been ranked at/or near the top of the most respected companies list for 10 of the last 12 years. In fact, I'm also pleased to report that Johnson & Johnson was recognized this year by Barron's Magazine as the #1 most respected company for 2016.
As Alex noted, Louise's outstanding leadership and dedication to advancing our reputation will continue with her successor, Joe Wolk, who we're happy to have joining us on our call next quarter. We all wish Louise well, and we are certainly going to miss her. 
With that, I will now turn our discussion back to the quarter. We're very pleased with our second quarter results as we continue to see improved performance across the enterprise. And as Alex said, we remain confident in the strength of our business. 
As we've previously discussed in 2015, our underlying operational sales growth, which excludes the impact of acquisitions, divestitures as well as hepatitis C sales and the few extra shipping days in 2015, was about 5.5%. On this same basis, we continue to deliver strong underlying operational sales growth of approximately 7.9% for the second quarter, and our sales results are above analyst estimates. Our second quarter earnings were also above analyst estimates, driven by strong sales performance and operating margin improvement. 
As you may remember, for 2016, our guidance from January included a 200 basis point increase in pretax operating margin on an adjusted basis. We were pleased to see progress towards this improvement during the second quarter, which I will discuss later. And we remain comfortable with that forecast as we continue to accelerate throughout the year with the restructuring activities in our Medical Device business and lower levels of spending in the back half as compared to the prior year. 
Now I'll take a few minutes to highlight some key points regarding our results, and then I'll provide some updates to our guidance for you to consider in refining your models for 2016. 
I will now turn to our consolidated statement of earnings for the second quarter of 2016. As we've mentioned, our operational sales growth this quarter was 5.3%. And excluding the impact of acquisitions and divestitures, hepatitis C sales and also the impact of the devaluation that occurred in Venezuela last year, it was strong at more than 8%. 
If you will direct your attention to the box section of the schedule, you will see we have provided our earnings adjusted to exclude intangible amortization, expense and special items. 
As referenced in the table of non-GAAP measures, the 2016 second quarter net earnings were adjusted to exclude intangible asset amortization expense and special items on approximately $900 million on an after-tax basis, which consisted primarily of the following: intangible asset amortization expense of about $200 million, litigation charges from ongoing legal matters of about $500 million and additional charges as we continue to execute on the Medical Devices restructuring. 
Our adjusted earnings per share is therefore, $1.74, exceeding the mean of the analyst estimates as published by First Call. This is an increase in adjusted EPS of 1.8% versus the prior year, and adjusted EPS on a constant currency basis was the same, as the impact of currency was flat year-over-year. 
Now let's take a few moments to talk about the other items on the statement of earnings. Cost of goods sold decreased by 120 basis points, mostly due to favorable mix and manufacturing efficiencies, partially offset by transactional currency. 
Selling, marketing and administrative expenses were 28% of sales or 230 basis points lower as compared to the second quarter 2015 due to good cost management. 
Our investment in research and development as a percent of sales was 12.2% and higher than the prior year due to increased project spending as we advance our promising product pipelines. 
Our pretax operating margin, when excluding special items and intangible amortization expense, was 32.5% or 320 basis points higher than the second quarter of the prior year. As a reminder, pretax operating margin is defined as gross profit less selling, marketing, administrative and R&D expenses. 
As we anticipated, we are seeing improvement as we progress throughout the year. And through 6 months, we have achieved a 180 basis point improvement in this measure of profitability. 
Interest expense, net of interest income, was slightly lower than last year due to slightly better rates on our investments. Other income and expense was a net expense of approximately $600 million in the quarter compared to a net gain of approximately $900 million in the same period last year. 
Excluding the special items that are reflected in this line, other income and expense was a net gain of approximately $100 million compared to a net gain of approximately $1 billion in the prior year period. The significant decrease is due to the divestiture of NUCYNTA in the prior year period. 
Excluding special items, the effective tax rate was 19.2% compared to 23% in the same period last year. This year's effective tax rate reflects the R&D credit, which was passed by Congress late last year, the current mix of our business and the impact of new accounting standards related to the tax benefit on share-based compensation, which I will discuss further in a moment. 
Turning to the next slide. I will now review adjusted income before tax by segment. In the second quarter of 2016, our adjusted income-before-tax margin for the enterprise declined by 250 basis points versus the second quarter of 2015. 
During the second quarter of 2015, as I mentioned earlier, we recorded a gain from the divestiture of NUCYNTA. And this gain, which, as you know from our discussions last year, was invested in various parts of the business, but those investments occurred later in the year. 
If the NUCYNTA divestiture gain is excluded, year-on-year adjusted income-before-tax margin would show an improvement of approximately 300 basis points. We're very pleased to see a significant improvement in our Consumer business adjusted income tax margin this quarter. As you may recall from our business review day in May, we said that we are focused on improving our margins in the Consumer business to benchmark levels. We are confident that our Consumer business will show an improved adjusted income-before-tax margin for full year 2016 as compared to 2015. 
Overall, we expect income-before-tax margins for the enterprise to show an improvement over the prior year for all of 2016 as our increase in the pretax operating profit margin, which I noted earlier, more than offsets the lower level of divestiture gains in 2016 as compared to 2015. 
Now I will provide some guidance for you to consider as you refine your models for 2016. At the end of the quarter, we had approximately $16 billion of net cash, which consists of approximately $42 billion of cash and marketable securities and approximately $26 billion of debt. As you know, in May, we took the opportunity to finance our share repurchase program and upcoming debt maturities at very attractive interest rates, with the European debt issuance equivalent to $4.5 billion. 
Through the end of the second quarter, we have completed nearly 50% of our $10 billion share repurchase program, and we continue to expect to complete approximately 75% of the program by the end of this year. 
For purposes of your models and assuming no major acquisitions or other major uses of cash, I suggest you consider modeling net interest expense between $400 million and $500 million. This is a slight decrease from our prior guidance. 
Regarding other income and expense. As a reminder, this is the account where we record royalty income as well as gains and losses arising from such items as litigation investments, prior development corporation divestitures, asset sales and write-offs. We will be comfortable with your models for 2016 reflecting net other income and expense, excluding special items, as a net gain ranging from approximately $900 million to $1 billion, a lower range than our previous guidance related to the timing of underlying activity. This impact will be offset by the strength of our business, primarily due to our outlook for a higher level of sales as noted in the increased sales guidance in our press release today. 
And now just a word on taxes. During the second quarter, the company elected for early adoption of a new accounting standard related to share-based compensation. With this update, increased tax benefits are recognized in earnings on the employee exercises options or received shares. Previously, these tax benefits were recorded in equity. 
The first quarter impact was approximately $165 million or $0.05 per share and is reflected in the year-to-date results and not in the second quarter, when we adopted the standard. The second quarter impact is offset by additional tax costs reflected in this quarter. 
Per adoption guidance, the first quarter does not need to be reissued. However, all future comparisons for the first quarter should reflect the recasted numbers. We have included a supplementary schedule on our website that includes the updated first quarter impact for the P&L. 
You will note that the first quarter recast number reflects a tax rate of 15.8%. The company issued shares related to employee stock compensation such as restricted stock awards or performance share units in the first quarter. Therefore, historically, a significant portion of the annual tax benefit is recognized in the first quarter. The tax benefit for stock options is recognized throughout the year as employees exercise their options, but timing is less predictable for stock options. 
We are comfortable with your models reflecting an effective tax rate for 2016, excluding special items, of approximately 18.5% to 19%, lower than our previous guidance, primarily due to the accounting for share-based compensation tax benefits that I just described. 
Now turning to sales and earnings. Our sales and earnings guidance for 2016 takes into account several assumptions and key factors that I would like to highlight. As a reminder, our sales guidance for 2016 assumes no biosimilar entrants for PROCRIT or REMICADE in the U.S., and our assumption remains unchanged with the recent FDA approval of Inflectra. 
We also do not anticipate generic competition this year for ZYTIGA, RISPERDAL CONSTA or INVEGA SUSTENNA. But as expected, there are generic entrants for INVEGA and ORTHO TRI-CYCLEN LO. 
As Alex mentioned, we have now closed the acquisition of Vogue International. So our guidance now reflects 6 months of additional sales. This is a fast-growing business and will contribute to the profitability of our Consumer business beginning the first full year, as well as be accretive to our adjusted EPS beginning in the first full year. 
Also, during the second quarter, we closed on our divestiture for the controlled substance raw material and API business and therefore, those sales were no longer be recorded. 
As we've done for several years, our guidance will be based first on a constant currency basis reflecting our results from operations. This is the way we manage our business, and we believe this does provide a good understanding of the underlying performance of our business. 
We will also provide an estimate of our sales and adjusted EPS results for 2016 with the impact that current exchange rates could have on the translation of those results. 
As noted in our press release, we are increasing our operational sales guidance for 2016, primarily reflecting the strong results from the first half as well as 6 additional months of sales from the Vogue acquisition, partially offset by the divestiture of our controlled substance raw material and API business. We would, therefore, be comfortable with your models reflecting an operational sales increase on a constant currency basis of between 3% and 4% for the year. This would result in sales for 2016 on a constant currency basis of approximately $72.2 billion to $72.9 billion and higher than our previous guidance. 
Additionally, by way of comparison to how we describe our sales results in 2015, our operational sales growth for 2016, excluding the impact of acquisitions, divestitures and hepatitis C sales, would be approximately 6%, a higher level of growth than we saw last year after adjusting for the extra shipping days in 2015, which we've mentioned earlier. 
Although we're not predicting the impact of currency movements, using the euro as of last week at $1.11, the negative impact of foreign currency translation will be approximately 1% on sales. This is consistent with our previous guidance as other major currencies strengthened since our last update. We are watching the euro and other currencies closely as it is uncertain how they will eventually settle out for the year. Of course, we're closely following the situation with the U.K.'s vote to exit from the EU. We expect this will take time to fully determine what the impact will be, if any. 
To put it into perspective though, the U.K. represents about 3% of our total sales. So after impacts of currency, we would expect reported sales to reflect the change in the range of 2% to 3% for a total expected level of reported sales of approximately $71.5 billion to $72.2 billion and higher than our previous guidance. 
And now turning to earnings. As a reminder, we expect transaction currency impacts to be negative to our gross margin by about 60 to 80 basis points in 2016 as compared to 2015. We would be comfortable with adjusted operational EPS guidance in the range of between $6.66 to $6.76 per share on a constant currency basis, reflecting an operational constant currency growth rate of 7.4% to 9%. This is a narrower range as well as higher than our previous guidance and includes the first quarter impact from the tax accounting change we discussed earlier. 
If currency exchange rates for all of 2016 were to remain where they were as of last week, then our reported adjusted EPS would be negatively impacted by approximately $0.03 per share due to currency movements, and this is consistent with our guidance in April. Therefore, we would be comfortable with our reported adjusted EPS ranging from $6.63 to $6.73 per share, which is an increase from our previous guidance due both to the continued strength of the business and a lower tax rate. And at this point in the year, we will be comfortable with your models reflecting the midpoint of this range. 
In closing, we are very pleased with our strong start for the first 6 months of this year, and we are optimistic with what we see ahead for the full year, namely, we're expecting operational sales growth of 3% to 4% and underlying operational sales growth of 6% or higher than we saw in 2015 on a comparable basis. 
Our adjusted pretax operating margin improvements are on track to meet the expectations we laid out in our guidance of more than a 200 basis point improvement over the prior year. 
Our adjusted operational EPS growth in our guidance improved and remains strong in the range of $6.66 to $6.76 a share, that's a growth rate of between 7% and 9%. Our businesses are continuing to invest while also delivering on our growth expectations. 
And now I'd like to turn things back to Louise for the Q&A portion of the call. Louise?"
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Dominic. Michelle, could you please give the instructions for the Q&A session?",14,"Thank you, Dominic. Michelle, could you please give the instructions for the Q&A session?"
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","[Operator Instructions] Our first question comes from the line of Mike Weinstein with JPMorgan.",14,"[Operator Instructions] Our first question comes from the line of Mike Weinstein with JPMorgan."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Dominic, just a couple items that we could hopefully get you to clarify. So number one is, what's the impact for the full year EPS of ASU 2016-109 [ph] adoption? The tax rate coming down as it did suggests a range of anywhere from $0.04 to $0.12, so maybe",79,"Dominic, just a couple items that we could hopefully get you to clarify. So number one is, what's the impact for the full year EPS of ASU 2016-109 [ph] adoption? The tax rate coming down as it did suggests a range of anywhere from $0.04 to $0.12, so maybe you can help with that. And then second, can you just walk through the net impact of the Vogue acquisition and then the API business divestiture on sales and earnings?"
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Mike. Well, with respect to the early adoption, I mentioned earlier that the first quarter impact was $0.05, and that's the most significant impact we expect for the year because that's where the majority of stock-based compensation is issued to emp",155,"Sure, Mike. Well, with respect to the early adoption, I mentioned earlier that the first quarter impact was $0.05, and that's the most significant impact we expect for the year because that's where the majority of stock-based compensation is issued to employees. The second quarter impact was lower than that, but was almost entirely offset by other tax items. And the rest of the year will depend on when employees exercise stock options, so very difficult to predict. So for now, we've included in our effective tax rate for the year only the first quarter impact, which after we adopt it in the second quarter, we're letting the first quarter impact flow through for the remainder of the year.
Second quarter impacts already been offset by other items, and remaining quarterly impacts, we think, will either likely be offset by other items or very difficult to predict because it's timing of when employees exercise options."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Yes. So your updated guidance, Dominic, doesn't assume any benefit in the second half of the year?",17,"Yes. So your updated guidance, Dominic, doesn't assume any benefit in the second half of the year?"
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","That's right. Only the first quarter flow through that we experienced. And as I said, that's the largest single quarter of any stock-based compensation tax benefit. Sales with respect to Vogue and the API business. Vogue, for the full year, is in the $350",119,"That's right. Only the first quarter flow through that we experienced. And as I said, that's the largest single quarter of any stock-based compensation tax benefit. Sales with respect to Vogue and the API business. Vogue, for the full year, is in the $350 million range. We have about half a year of sales added to our guidance. And the API business was an annual business of about $250 million, and we'll have half a year of those sales no longer included in our guidance. So that's part of the increase in our overall growth in sales of about 0.5 points. The rest of it is due to the underlying strength we saw in the first 6 months."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. And then on the pharma business, can I get you just to comment on a couple of items. So one, this is obviously a very important quarter for DARZALEX with the data we saw at ASCO and EHA. And would just -- would love to get some high-level commentary",92,"Okay. And then on the pharma business, can I get you just to comment on a couple of items. So one, this is obviously a very important quarter for DARZALEX with the data we saw at ASCO and EHA. And would just -- would love to get some high-level commentary on where you think that gets positioned going forward in multiple myeloma. And then second, could you talk about the competitiveness of sirukumab, given the Phase III data we just saw at EULAR and your expectations there on filing, timing and approval?"
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Now let me say a few words on both. And then, Alex, why don't you add a few, and Louise also on the timing question? So DARZALEX, we're very pleased with the initial uptake of DARZALEX. The product is well received by the medical community. And the data,",155,"Now let me say a few words on both. And then, Alex, why don't you add a few, and Louise also on the timing question? So DARZALEX, we're very pleased with the initial uptake of DARZALEX. The product is well received by the medical community. And the data, as you pointed out, continues to be very impressive. And we believe DARZALEX can be essentially backbone therapy for the treatment of multiple myeloma. So we expect that we'll get additional indications for DARZALEX, but it's already been quite well received by the investment community, having great results for patients, and as I said, likely to be backbone therapy going forward. Sirukumab, also very positive data there. It's an important product in our autoimmune franchise. And Alex, maybe you can comment a little bit more on that. And Louise, on the timing of filing for sirukumab, I just don't have it handy, if you could give that."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","2016.",1,"2016."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","2016. So we'll file this year for sirukumab.",8,"2016. So we'll file this year for sirukumab."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. I'll let some other -- yes?",7,"Okay. I'll let some other -- yes?"
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, we -- look, we're excited about sirukumab on a number of fronts. First, as an IL-6, given what we know in this category, there's a lot of inter-patient variability and having another option for patients. And based upon the early data that we've seen",128,"Yes, we -- look, we're excited about sirukumab on a number of fronts. First, as an IL-6, given what we know in this category, there's a lot of inter-patient variability and having another option for patients. And based upon the early data that we've seen in RA, some of them presented just recently at the EULAR conference, we're very encouraged by. We're going to be looking at it, obviously, in other areas. And I think what we're most enthusiastic about is if you combine sirukumab along with the work that we're doing with guselkumab as well, the IL-23 being looked at in psoriasis, it's really going to help us build out an even stronger portfolio and platform in immunology as we go forward over the next several years."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Larry Biegelsen with Wells Fargo.",13,"Our next question comes from the line of Larry Biegelsen with Wells Fargo."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Louise, congratulations on your retirement. I know you'll be missed. So one for Dominic, start -- financial, to start off with, and then just one market-related question. So Dominic, just on the guidance, 2 clarification questions. So the $0.10 raise at t",138,"Louise, congratulations on your retirement. I know you'll be missed. So one for Dominic, start -- financial, to start off with, and then just one market-related question. So Dominic, just on the guidance, 2 clarification questions. So the $0.10 raise at the lower end on operational EPS and the $0.05 on the high end, is $0.05 due to the accounting change and the rest due to the underlying strength in the business? And then it appears there's a lot of moving parts on the sales guidance as well. That 5.5% in 2015 that you raised to 6% for 2016, by my math, it implies that you're expecting similar growth in the second half of 2016 compared to the first half of 2016, if one adjusts for the extra week in the year-ago period. So is that directionally accurate?"
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Larry. Well, with respect to EPS guidance, you mentioned 2 of the items, which obviously was tax as well as the stronger sales performance. But I just wanted to remind you that we also lowered our other income and expense guidance for the year. So o",149,"Sure, Larry. Well, with respect to EPS guidance, you mentioned 2 of the items, which obviously was tax as well as the stronger sales performance. But I just wanted to remind you that we also lowered our other income and expense guidance for the year. So one way to think about it is that other income and expense guidance is lower. The tax rate is also lower. Those 2 generally offset. And the midpoint of the guidance is up about $0.07, when I do the midpoint versus the 2 ends. And the $0.07 is primarily due to the overall increase in sales guidance that we provided today. Your observations with respect to the back half of the year, you're right that if we exclude the extra shipping days in 2015 from the analysis, the back half of 2016 would be similar to what we saw for the first half."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And then just on the market in the U.S. Maybe, Alex, if you could comment a little bit, or Dominic, on what you're seeing on procedure volume in the U.S. in ortho, and more broadly, in med tech, that would be great.",43,"And then just on the market in the U.S. Maybe, Alex, if you could comment a little bit, or Dominic, on what you're seeing on procedure volume in the U.S. in ortho, and more broadly, in med tech, that would be great."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. Thanks, Larry. Larry, we are seeing a pickup in terms of hospital admissions and surgical procedures. I think hospital admissions are up around 3%. We think the procedures are probably up around 3.5%. We continue to see some decrease, overall, in off",100,"Yes. Thanks, Larry. Larry, we are seeing a pickup in terms of hospital admissions and surgical procedures. I think hospital admissions are up around 3%. We think the procedures are probably up around 3.5%. We continue to see some decrease, overall, in office physician visits, down a couple of percent. We think that that's due to a more moderated utilization at the front-end due to increased co-pays and a number of other dynamics. But overall, if we look at the core growth rate in the medical hospital device area, we're encouraged by some of the recent trends that we're seeing."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Kristen Stewart with Deutsche Bank.",13,"Our next question comes from the line of Kristen Stewart with Deutsche Bank."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And I'll echo, Louise, we'll definitely be missing you, but congratulations. I was wondering, Alex, if you could just comment a little bit about just on the capital allocation side. Obviously, we saw Vogue. Is that what we should be thinking going forward",66,"And I'll echo, Louise, we'll definitely be missing you, but congratulations. I was wondering, Alex, if you could just comment a little bit about just on the capital allocation side. Obviously, we saw Vogue. Is that what we should be thinking going forward in terms of the type of acquisitions to look forward, the smaller, more, I guess, tuck-in for you guys, in that range?"
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Hi, Kristen. Thanks a lot for the question. And I couldn't agree with you more regarding Louise. But look, we were really happy that we were able to add Vogue to the J&J Consumer portfolio. As we've been talking about over the last several years, we felt",389,"Hi, Kristen. Thanks a lot for the question. And I couldn't agree with you more regarding Louise. But look, we were really happy that we were able to add Vogue to the J&J Consumer portfolio. As we've been talking about over the last several years, we felt that what was most important to the Consumer group was to actually ensure that we were able to get through the early stages of the remediation in a really high-quality and effective way. And I think the team has done a great job at making it [ph] a little bit more broadly across that entire Consumer group. I think we see that in the core trends. And of course, once we establish that, we continue to see Consumer as a great growth opportunity for the organization going forward. And as Jorge and as you saw when we did the Medical Device and Consumer Investor Relations review, now about a little over a month ago, I think they've got a really ambitious but also realistic plan for that, built on our existing brands. And we were really pleased to see performance. For example, LISTERINE, up 7%; OTC's up 6%; analgesics within OTCs were up over 13%. And then in beauty, you saw about a 9% lift with really strong performance from NEUTROGENA and AVEENO. And when you take that and augment it, I think, with thoughtful additions such as we saw over this last quarter, whether it was NeoStrata, whether it was HIPOGLS or with Vogue, we think that those are great additions to our existing portfolio, and will likely be part of a continuous stream of additions to that part of the portfolio. And as we said for some time, whenever we're looking at inorganic growth opportunities, we look at tuck-ins, we look at midsized deals, we'll look at large deals. Of course, the tuck-in strategy, particularly in pharma -- or actually, in all of our segments, Medical Device and Consumer, are those that -- where we feel that we can create the most value. But we do think that there's other opportunities to create value as well, and again, in mid- and larger deals. But we're going to be very disciplined. We're going to be very decisive about how we do it. And ultimately, try to better serve patients and consumers."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And just, I guess, on that broader note, I guess now that Consumer has turned the corner and has done well with the remediations, is that now a platform that, as you said, is more ready for acquisitions? I know Medical Devices is in the midst of the restr",64,"And just, I guess, on that broader note, I guess now that Consumer has turned the corner and has done well with the remediations, is that now a platform that, as you said, is more ready for acquisitions? I know Medical Devices is in the midst of the restructuring. Is that how we should think about it? And I have a follow-up for Dominic."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Sure. Look, we believe that mission one was really focusing on the core business, as we said. And I do feel that Consumer, like all of our businesses, we're pleased; we're never completely satisfied. And they've made a lot of progress on the core. And so",191,"Sure. Look, we believe that mission one was really focusing on the core business, as we said. And I do feel that Consumer, like all of our businesses, we're pleased; we're never completely satisfied. And they've made a lot of progress on the core. And so we would expect, again, in a very thoughtful, disciplined way, to continue to do additions when we think they're right. But we would look for the same thing in our other segments as well. And by the way, we're pleased with the progress that we've seen in our Medical Device group over the last quarter as well. I mean, if we look at the restructuring, I think, overall, that team's on track. They're doing actions that strengthen their go-to-market model, to accelerate their pace of innovation. They're prioritizing some additional platforms and geographies, and all while streamlining some operations but really keeping very high-quality standards. We think they're on track with the plan that they articulated earlier in the year. And we're confident that as they move through this, they will be not only a stronger, but a more innovative and a more efficient business."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Great. And Dominic, for the rebate in pharma, should we think about that as flowing through this quarter? Or was that mainly reinvested, because I know there was a higher rate of R&D this quarter?",35,"Great. And Dominic, for the rebate in pharma, should we think about that as flowing through this quarter? Or was that mainly reinvested, because I know there was a higher rate of R&D this quarter?"
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Well, the -- the way to think about it, maybe, Kristen, is that it's a year-over-year change in about a $140 million sales level. So obviously, some of that drops through to the bottom line. And you're right, we do also take the opportunity to invest. Inv",115,"Well, the -- the way to think about it, maybe, Kristen, is that it's a year-over-year change in about a $140 million sales level. So obviously, some of that drops through to the bottom line. And you're right, we do also take the opportunity to invest. Investments in R&D, really, are related to progress in the pipeline, regardless of whether these gross-to-net adjustments would be available. But another way to think about it is that we're now at a point where these actualizations of prior estimates, our current reserves are -- a significant portion of them are current because data has been coming in recently. So I wouldn't expect similar type of adjustments going forward."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Matt Miksic with UBS.",12,"Our next question comes from the line of Matt Miksic with UBS."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Alex, while I've got you here, just one strategic question. And I don't know if this is consistent with what you're seeing or where you think things are going. But on devices, like what we've seen is a lot of these new innovations in structural heart, in",134,"Alex, while I've got you here, just one strategic question. And I don't know if this is consistent with what you're seeing or where you think things are going. But on devices, like what we've seen is a lot of these new innovations in structural heart, in particular, some of the bundled payment initiatives seem to be driving more volumes to sort of higher-volume centers, larger networks, potentially augmented by outpatient centers. It's early in some of these initiatives, but that seems to be directionally where things are headed. And first, we'd love to get your sense as to whether you think that's where things are going as well. And if so, how J&J is positioned on the device side to benefit or support these kinds of trends. And then I had one follow-up."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Matt. Thank you very much for the question. Over the past 3 or 4 years, I think we've been pretty consistent in our thinking and in our projections about likely increasing consolidation among providers and hospitals, particularly here in the United",252,"Sure, Matt. Thank you very much for the question. Over the past 3 or 4 years, I think we've been pretty consistent in our thinking and in our projections about likely increasing consolidation among providers and hospitals, particularly here in the United States and just broader health care systems. And as systems feel continuing pricing pressure, we think that will manifest itself by them having consolidation. I think we've seen those trends. And I think they're clearly starting an effort to try and be as effective and as efficient as possible. So we do believe that, that will be a longer secular trend that's going to continue. That's why we believe having a diverse and enough critical mass in our Medical Device portfolio is so important going forward. We see it in the way that expectations are changing among decision-makers, including not only surgeons, but also people in procurement and other C suite executives, administrators and hospital systems. And we think as a result of that, we'll be very well positioned, particularly when you think about our surgical franchise, our Orthopaedics franchise. We've also been consistent in saying that we're extremely pleased with the performance of our cardiovascular unit, particularly our EP group, Biosense Webster. I mean, once again, this quarter, they've delivered over 18.5% growth with great innovation and great execution. But we also realize that that's an area where we'll continue to look for the right kind of additions, organically and inorganically, to ensure that we're properly positioned going forward."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","That's great. And then on another topic that we spend a lot of time on, I guess, over the past year, and we're now a quarter away from what looked like a competitive launch in the U.S. biosimilar side on REMICADE. I'd love to -- without asking you to tip",176,"That's great. And then on another topic that we spend a lot of time on, I guess, over the past year, and we're now a quarter away from what looked like a competitive launch in the U.S. biosimilar side on REMICADE. I'd love to -- without asking you to tip your hand, of course, or -- I'd love to get a sense as to can you -- is there -- are there steps you can take -- given your portfolio and your relationship with these payers and networks, are there steps you can take to sort of stop -- I don't know what the right word is -- potentially offset some of the potential impact or get ahead some of the potential impact through some of the contracts that you're talking with these folks about? And I think you know the question I'm asking, and I'm sure you're not going to get into a ton of detail. But any color would be helpful as to the extent of your ability to contract around that event."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, Matt. Look, as we look at the landscape going forward, we fully predict that generics and biosimilars are going to be part of the competitive landscape. And look, we think that, that is essential for the health care system. We think, in the long run,",409,"Yes, Matt. Look, as we look at the landscape going forward, we fully predict that generics and biosimilars are going to be part of the competitive landscape. And look, we think that, that is essential for the health care system. We think, in the long run, it's actually a benefit for very innovative-focused companies because that's the only way you can relieve pressure over the long term. Of course, that's predicated upon the market and companies respecting intellectual property. It's very important to produce the right scientific information so that we're guaranteeing patient safety and understanding the important clinical differences between some of these compounds as they may or may not manifest themselves. And so we projected them. As we look at our strategic plan, we think they will be there. But we also feel that that's why it's so important to keep innovating with new product launches going forward. And it's also critical to establish a strong critical mass in terms of products, but also expertise in clinical data and information in certain platforms. And so for us, in the Immunology platform, we're very proud of the extensive track record that REMICADE, the TNF-alpha compound has had and what it continues to do. We'll continue to defend our intellectual property around it. But at the same time, if you look at compounds like STELARA and SIMPONI, not only have they both generated in excess of 30% growth this quarter, but we've also produced additional data that we think is going to be very important to patients and physicians in how they adopt these products. And these are already multibillion-dollar platforms for Janssen and Johnson & Johnson. And then when you compound that with sirukumab and guselkumab, again an IL-6 and IL-23 approach where we know there's a lot of patient variability, we think that's important. Also, as we look at REMICADE itself, we know that there's about 2.4 million patients who've been treated with the compound. We know that about 70% of them in fact are getting good relief and good effects. We know that they're unlikely to be switched when they're getting a positive response from their therapy. And we also know that when we contract across the Janssen and Johnson & Johnson portfolio, that it provides us a very important position with larger health care systems and networks. So that's the way we think about it, and that's the way we plan for it going forward."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Josh Jennings with Cowen and Company.",14,"Our next question comes from the line of Josh Jennings with Cowen and Company."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Louise, congratulations. I wanted to ask a question. Dominic, first, just the operating margin performance again kind of beat our expectations. You reiterated your guidance for the year on the operating margin expansion side of things. But I just wanted -",140,"Louise, congratulations. I wanted to ask a question. Dominic, first, just the operating margin performance again kind of beat our expectations. You reiterated your guidance for the year on the operating margin expansion side of things. But I just wanted -- there are multiple drivers of operating margin expansion, and there is -- you've had a program in place, I think you announced a couple of years ago and just started to ramp last year, about $1 billion in cost savings by '18. That was exclusive of the Medical Device restructuring plan. I just wanted to get a sense of the contribution to operating margin expansion this year, and if we're still in the very early innings and whether we should see stronger benefit from that cost-savings plan as well as the Medical Device restructuring initiative in '17 and '18."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. Well, Josh, you're right. There are many factors that contribute. I mean, GP is one. So we continue to see good manufacturing efficiencies and cost improvements across the supply chain. That's a major initiative we've had ongoing for quite some time.",268,"Yes. Well, Josh, you're right. There are many factors that contribute. I mean, GP is one. So we continue to see good manufacturing efficiencies and cost improvements across the supply chain. That's a major initiative we've had ongoing for quite some time. So we saw some of that benefit this quarter. We expect that we'll see it going forward as well. In the selling, market and administrative line, that's where you see the benefits of the program you were referring to, where we anticipate about $1 billion of savings for 2018. That program's on track. We're seeing the savings. We're also making some investments. As the investments tail off, the savings will be more significant and more impactful in that line item going forward. So we're beginning to see the savings now. They're somewhat partially offset by some investments we need to make to continue the program. But in the future, those investments tail off and the savings ramp up, and there -- have more of an impact. And then also, as you mentioned, the Medical Device restructuring is a whole another area that's unrelated to the 2 that I just mentioned earlier and that we expect to see continued improvements there, although that's a business where we want to also accelerate the pace of innovation with those savings. So some of those will be reinvested in the business. So it's across those 3 areas, and we're committed to the operating margin improvement that I've mentioned earlier of greater than 200 basis points. And halfway through the year, we feel very good about our ability to achieve that."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Excellent. And I just wanted to have a follow-up maybe for Alex and Louise. Just that you commented on utilization levels in the U.S. and procedure volumes, and I -- you experienced just a modest apples-to-apples in selling days from sequentially modest d",71,"Excellent. And I just wanted to have a follow-up maybe for Alex and Louise. Just that you commented on utilization levels in the U.S. and procedure volumes, and I -- you experienced just a modest apples-to-apples in selling days from sequentially modest deceleration in knees and hips and spine or in the ortho segment. Is there anything specific to Q2 that you're seeing in the marketplace that you can comment on?"
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Now look, overall -- and thank you for the question. Overall, I think we saw solid growth in both knees and hips. I think we're at about 4.5% in knees, about 5%, 5.5% in hips. And we think that that's continued pick-up from the ATTUNE launch and the CORAI",79,"Now look, overall -- and thank you for the question. Overall, I think we saw solid growth in both knees and hips. I think we're at about 4.5% in knees, about 5%, 5.5% in hips. And we think that that's continued pick-up from the ATTUNE launch and the CORAIL hip. So I would say that, consistent with what we're seeing in the broader market, consistent with what we're seeing in our business, we're seeing positive growth in that area."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","And for the OUS business, it was about an additional 1.5 days of selling days in the second quarter. And in the first quarter, we had additional selling days in the U.S. business, so that's a reminder on that one.",40,"And for the OUS business, it was about an additional 1.5 days of selling days in the second quarter. And in the first quarter, we had additional selling days in the U.S. business, so that's a reminder on that one."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Joanne Wuensch with BMO Capital Markets.",14,"Our next question comes from the line of Joanne Wuensch with BMO Capital Markets."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","I appreciate the commentary on the volumes. But I was curious if you can give us a commentary on pricing, and also with the April 1 implementation of the bundled payment program in the United States, if you're seeing any impact from that.",43,"I appreciate the commentary on the volumes. But I was curious if you can give us a commentary on pricing, and also with the April 1 implementation of the bundled payment program in the United States, if you're seeing any impact from that."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","So we talk about pricing on a Johnson & Johnson basis. And overall, pricing is modest in the quarter.",18,"So we talk about pricing on a Johnson & Johnson basis. And overall, pricing is modest in the quarter."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","I would say, Joanne, that we haven't seen the impact yet in that particular new mechanism that you've just described. As Louise pointed out, pricing overall for the quarter, our year-over-year growth due to pricing is very, very modest in our results.",42,"I would say, Joanne, that we haven't seen the impact yet in that particular new mechanism that you've just described. As Louise pointed out, pricing overall for the quarter, our year-over-year growth due to pricing is very, very modest in our results."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","I can provide some further color on hips and knees in the U.S. Price/mix, if you'd like?",18,"I can provide some further color on hips and knees in the U.S. Price/mix, if you'd like?"
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","That would be wonderful.",4,"That would be wonderful."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","So the second quarter for the hips was about 2.2% negative, price/mix together, and this is U.S. only. And for knees, it was about 2.6% negative. And that's similar trends to what we've seen consistently over time.",38,"So the second quarter for the hips was about 2.2% negative, price/mix together, and this is U.S. only. And for knees, it was about 2.6% negative. And that's similar trends to what we've seen consistently over time."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And then as to my second question had to do more with Vision Care, we saw a real difference between what was happening in the U.S. and what's OUS sales. And you commented on rebates. Is that the replacement program for UPP that we're seeing in that U.S. i",49,"And then as to my second question had to do more with Vision Care, we saw a real difference between what was happening in the U.S. and what's OUS sales. And you commented on rebates. Is that the replacement program for UPP that we're seeing in that U.S. impact?"
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","So it's a customer reward program that we have implemented. And what we have booked in the second quarter is the year-to-date because it was implemented in the second quarter, but it replies [ph] to the full year sales. So in the U.S., if you normalized i",67,"So it's a customer reward program that we have implemented. And what we have booked in the second quarter is the year-to-date because it was implemented in the second quarter, but it replies [ph] to the full year sales. So in the U.S., if you normalized it for the half that applied to the first half, the U.S. is up about 6% on a like basis."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","And look, we continue to be very pleased with what we're seeing in the turnaround in our Vision Care business as well. If we look at the early demand signals that we're seeing, it continues to give us confidence that we're gaining share. We continue to la",91,"And look, we continue to be very pleased with what we're seeing in the turnaround in our Vision Care business as well. If we look at the early demand signals that we're seeing, it continues to give us confidence that we're gaining share. We continue to launch into beauty, astigmatism, reusables, along with a number of other new launches and line extensions. And frankly, the team is also really executing well. So we're encouraged by the opportunity that we see in Vision Care as we move through the rest of 2016."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Glenn Novarro with RBC Capital Markets.",14,"Our next question comes from the line of Glenn Novarro with RBC Capital Markets."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Louise, I echo the sentiments, so best of luck in the future. My question is for Alex and for Dominic. And I asked a similar question on the last quarterly call because I continue to be surprised that J&J is not doing more with its cash, particularly on t",137,"Louise, I echo the sentiments, so best of luck in the future. My question is for Alex and for Dominic. And I asked a similar question on the last quarterly call because I continue to be surprised that J&J is not doing more with its cash, particularly on the M&A front. You've done Vogue, but we haven't seen much in the way of at least meaningful acquisition on devices and on pharma. And so my question is, the targets that you're having discussions with today, do they still have very unrealistic valuation expectations? And is that the reason why we haven't seen deals in devices and in pharma? And then as a follow-up, you still have a bulk of your cash sitting outside the United States. Is that another reason why we haven't seen any meaningful acquisitions?"
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Well, sure, Glenn. Well, consistent with what we said last time when you asked a very similar question, we -- as you know, we're very disciplined in our approach to acquisitions. And although we're actively involved in considering them, valuations come in",291,"Well, sure, Glenn. Well, consistent with what we said last time when you asked a very similar question, we -- as you know, we're very disciplined in our approach to acquisitions. And although we're actively involved in considering them, valuations come into play. And willingness of the other party to do an acquisition at certain valuations come into play. So that's regardless of how much money we have available to spend, right? So we don't really look at that as the main driver of how we're going to do acquisitions. We look at what value we're going to create for shareholders by doing the acquisition at the right value so we can improve returns for our shareholders. There are some expectations that are still not, in our opinion, normalized for appropriate valuations in the market, so that's a factor. And that will take time, and we're patient with that. And then we'll take -- we'll see how the market evolves over time or as we learn more about the acquisition candidates and their progress in various areas. And then finally, whether or not the cash is trapped overseas or not is not at all an impediment to our ability to do any acquisitions. We'll either obviously try to find a way to do it in a tax-efficient basis as we've done with other acquisitions and utilize that cash as much as possible, only if it's tax efficient. But then, obviously, we can continue to borrow, and we have the ability to borrow to do the acquisitions that we think are value-creating for our shareholders. So we wouldn't let that hold us back. Should the acquisition be value-creating, we'd exercise what -- we'd exercise our ability to borrow to do that acquisition."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And just as a follow-up -- go ahead, Alex. Did you want to add something?",16,"And just as a follow-up -- go ahead, Alex. Did you want to add something?"
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, Glenn. I guess what I would also say is, look, I think that our -- the M&A approach that we talked about in the past is a balanced one. I mean, if you look over the last 20 years, I think we've done about 124 deals. I think there's been about 13 or s",193,"Yes, Glenn. I guess what I would also say is, look, I think that our -- the M&A approach that we talked about in the past is a balanced one. I mean, if you look over the last 20 years, I think we've done about 124 deals. I think there's been about 13 or so that have been over $1 billion. But majority of these have been smaller. And frankly, if you look at our pharmaceutical performance and whether it's the partnerships that we have on a compound like IMBRUVICA, DARZALEX, others, I think the strategy has worked really well and it's something that we'll continue to pursue. I think we have a lot of examples of that in Medical Devices and also Consumer. And there's nothing that we would like more than to take a several hundred million-dollar platform like Vogue and create the next multibillion-dollar platform as we see in things like NEUTROGENA and others. So all that being said, if and when we see larger opportunities present an opportunity to really create longer-term shareholder value, those are things we'd certainly be interested in, but we'll be particularly thoughtful about those."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And just one quickly on REMICADE. I know Matt had asked a question on REMICADE, but you remain very confident that a biosimilar won't be launched in 2016. Has anything changed that you can reveal to us on the litigation front that gives you more confidenc",46,"And just one quickly on REMICADE. I know Matt had asked a question on REMICADE, but you remain very confident that a biosimilar won't be launched in 2016. Has anything changed that you can reveal to us on the litigation front that gives you more confidence?"
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Glenn, well, what we said is that our guidance does not assume any biosimilar launch in 2016. There's ongoing developments in the litigation. There's a hearing scheduled for August related to the '471 patents. We'll have to see how that -- what the result",169,"Glenn, well, what we said is that our guidance does not assume any biosimilar launch in 2016. There's ongoing developments in the litigation. There's a hearing scheduled for August related to the '471 patents. We'll have to see how that -- what the results of that hearing are. So we don't know that yet. There was also a ruling issued in relation to another biosimilar, not our biosimilar, which made it very clear when the 180-day waiting period applies. And for us, that 180-day waiting period extends to October 6. Well, obviously, there cannot be any launch before that date. And then as we've mentioned, we're continuously and vigorously defending our patent, and we'll continue to do that. So whether or not a biosimilar launch happens is uncertain. But we have not included it in our guidance estimates. But as you know, our guidance, of course, is a range, and between certain ranges of 3% to 4% and overall growth. So we feel confident about that in any event."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of David Lewis with Morgan Stanley.",13,"Our next question comes from the line of David Lewis with Morgan Stanley."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Congrats, Louise. Once again, echo other sentiments. So just 2 quick questions, now that we're near the end. So Dominic, I'm trying to reconcile revenue guidance just on the margins. So if I take the upside in the quarter plus the net impact of M&A, sort",98,"Congrats, Louise. Once again, echo other sentiments. So just 2 quick questions, now that we're near the end. So Dominic, I'm trying to reconcile revenue guidance just on the margins. So if I take the upside in the quarter plus the net impact of M&A, sort of Vogue minus the API business, I kind of get -- guidance should come up sort of $700 million. It's coming up around $300 million. Is that difference in the back half of the year largely an expectation for lower or minimal gross-to-net adjustments in the back half versus the first half?"
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Well, certainly, as I mentioned earlier, the gross-to-net adjustments that we saw in the first half have now resulted in our overall estimates for these amounts as being largely current, greater than 90% current. But therefore, we wouldn't expect to have",54,"Well, certainly, as I mentioned earlier, the gross-to-net adjustments that we saw in the first half have now resulted in our overall estimates for these amounts as being largely current, greater than 90% current. But therefore, we wouldn't expect to have the same level of those kinds of adjustments going forward, David. That's right."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay, helpful. And then maybe 2 questions on Consumer, one for Alex and one for Dominic. I mean, Dominic, just to start with you on margins. I think we'd left the Analyst Day feeling that Consumer margin outlook was probably conservative. But if I look at",110,"Okay, helpful. And then maybe 2 questions on Consumer, one for Alex and one for Dominic. I mean, Dominic, just to start with you on margins. I think we'd left the Analyst Day feeling that Consumer margin outlook was probably conservative. But if I look at the reported results in the quarter, I mean, you're well ahead of expectations and pursuing that sort of peer-based 20% Consumer margin. So how do we think about that? Is that simply onetime in nature? Or is it much more likely now you reasonably exceed your targets either in time or magnitude here in Consumer? And then a quick follow-up for Alex in Consumer."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Well, as you know, we were committed to this. And as Jorge Mesquita said in the business review day, he was personally committed to making it happen. And we're very pleased to see that they're off to a great start. Whether they exceed the overall benchmar",118,"Well, as you know, we were committed to this. And as Jorge Mesquita said in the business review day, he was personally committed to making it happen. And we're very pleased to see that they're off to a great start. Whether they exceed the overall benchmark level in a shorter amount of time, that will -- we'll wait to see. Because obviously, we want to see them investment behind brands and keep the momentum up in the business as well. But we're obviously off to a great start. We were confident that they would be able to do it. And they've done a great job, and we're confident they'll continue to do a great job in improving margins."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. And then, Alex, I think many investors had felt that Consumer was sort of kept in the closet here the last several years, and clearly, the last 6 months, the company's working hard to sort of show the Consumer franchise, and to a greater extent, bot",120,"Okay. And then, Alex, I think many investors had felt that Consumer was sort of kept in the closet here the last several years, and clearly, the last 6 months, the company's working hard to sort of show the Consumer franchise, and to a greater extent, both margins and growth. Yes, my question's more on growth. If I ex out Venezuela in the quarter, Consumer did about 5% growth. I felt like the messaging from Jorge and others was, yes, this business can be sort of an upper single-digit grower with obviously expanding margins. What is your sense in that 5% number ex-Venezuela? I mean, do you feel confident here that Consumer is stable and can improve from these levels?"
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, David. Thank you very much. And again, let me reiterate. We're really pleased with the performance that we continue to see in the Consumer group. And literally, from quarter-to-quarter, it continues to improve in not only its core performance but mar",164,"Yes, David. Thank you very much. And again, let me reiterate. We're really pleased with the performance that we continue to see in the Consumer group. And literally, from quarter-to-quarter, it continues to improve in not only its core performance but market share and a number of other areas. We feel like the majority of the platforms right now, we're actually gaining share. At the same time, we realize we've got some areas such as Baby, such as China, where we need to do a better job, and the team is focusing on that, in addition to the margin improvement that Dominic was talking about earlier. But overall, our goal is to grow faster than the market. We think we currently are. It's something that we want to do and accelerate as we go forward. And I'm very confident that Jorge and his team have got the strategies and are now executing in a manner that's going to allow them to do just that."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Danielle Antalffy with Leerink Partners.",13,"Our next question comes from the line of Danielle Antalffy with Leerink Partners."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Louise, we're really going to miss you. Question for you, Alex, just higher level. Sorry to do this. But following-up on the M&A commentary, some of your competitors have been acquiring scale, most recently Abbot and St. Jude. And I know J&J is already in",136,"Louise, we're really going to miss you. Question for you, Alex, just higher level. Sorry to do this. But following-up on the M&A commentary, some of your competitors have been acquiring scale, most recently Abbot and St. Jude. And I know J&J is already in a competitively advantageous position, given your current product lines. But cardiovascular is an area where you're specifically under-scaled relative to some of those other competitors. Now I was just wondering if you could comment on whether you think it's important to build scale within cardiology to be -- to continue to be a major competitor in med tech or if you think there's other areas where J&J is already positioned and will continue to focus on. I'm just trying think about the different subsectors within med tech where you'll focus most."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. Thanks, Danielle. Look, consistent with what we said previously, we do think that there's an opportunity for expansion in cardiovascular. And for us, really, it started several years ago when we made the decision to exit the stent business. We did th",246,"Yes. Thanks, Danielle. Look, consistent with what we said previously, we do think that there's an opportunity for expansion in cardiovascular. And for us, really, it started several years ago when we made the decision to exit the stent business. We did the divestment of Cordis, which I think the team executed really well. And look, we think now the greater focus that we have, what you're seeing as a result of that, frankly, is better growth, not only in our cardiovascular business, the Biosense Webster, but across the greater Hospital Medical Device business that we have. But we know that going forward, other areas in cardiovascular, ranging from valves to structural heart to others, could definitely be opportunities. But we're going to continue to see how the technology evolves, how the markets evolve. And that -- and fortunately, I think we're positioned in a way that gives us a lot of different opportunities. And at the same time, I would say that there other areas in Medical Devices that we remain interested in. We've talked about the Vision Care area. It's one where you have a very strong contact lens platform. But we think there's opportunities, be it back of the eye, surgery and other spaces that, that business could be augmented. And we'll continue to look for other thoughtful plays in orthopedics as well as in general surgery that offer growth opportunities and help us better address areas of unmet medical need as well."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Jami Rubin with Goldman Sachs.",13,"Our next question comes from the line of Jami Rubin with Goldman Sachs."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And Louise, I'm really going to miss talking to you. You've been extremely helpful over the years. Dominic, I'm sorry to belabor the gross-to-net adjustment. But I'm unclear as to how it occurred and what it means. And I think more importantly, these are",201,"And Louise, I'm really going to miss talking to you. You've been extremely helpful over the years. Dominic, I'm sorry to belabor the gross-to-net adjustment. But I'm unclear as to how it occurred and what it means. And I think more importantly, these are all categories, REMICADE, STELARA, SIMPONI, ZYTIGA, which are crowded categories. And can you comment on what's happening with respect to gross to net -- the gap between gross to net and how it's changed over the last year or 2? If it has changed at all, are you able to take the same sort of list price that you had before, without having to pay a higher rebate? If you can just kind of comment on that, generally. And then also my follow-up question relates to INVOKANA. Sales, again, were -- continue to be very strong. You're showing nice improvements in market care [ph]. What are your expectations for the whole SGLT2 class? I'm sure you've paid attention to the FDA panel meeting on Jardiance and whether or not Jardiance will get a superior label with respect to CV mortality reduction? And if it does get that label update, what that might mean to INVOKANA going forward?"
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Jami. Let me take the first question on gross to net, and then Alex will cover the SGLT2 commentary. So U.S., how does it occur and what's going on with list price versus net price and those sorts of things. So just to put it in perspective, this is",251,"Sure, Jami. Let me take the first question on gross to net, and then Alex will cover the SGLT2 commentary. So U.S., how does it occur and what's going on with list price versus net price and those sorts of things. So just to put it in perspective, this is not unusual in our industry, as you know. Everyone in the pharmaceutical industry is estimating what the rebates might be. And then, of course, we'll actualize them once actual data is submitted. Recently, that actual data has been more timely. And in that more timely data from the payers, we're able to see trends, so we're able to not only actualize prior-period amounts, but we're also able to estimate better what the ultimate gross-to-net variation will be going forward. With respect to list price net of rebates, as you probably know, we said this before, we think we price our products responsibly and our overall list price increases have been relatively below -- substantially below the average industry. But in the end, the net price that's achieved is far from the gross price increase that happened. So rebates continue to be an increasing part of the business, and the overall realization of gross price to net price, that delta is expanding, I would, say over time. And therefore, as I said, now, we're much more current with our ability to predict these estimates, and that's what's going on. And as I mentioned, we don't expect to see significant adjustments in [indiscernible]."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","So you're saying the gap is going to continue to grow. But you overestimated the growth of that gap, and that, therefore, is the adjustment. But big picture, you expect the gap to grow.",35,"So you're saying the gap is going to continue to grow. But you overestimated the growth of that gap, and that, therefore, is the adjustment. But big picture, you expect the gap to grow."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","That's right.",3,"That's right."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","And Jami, regarding INVOKANA and the class, look, first of all, we are pleased with the performance -- the continued performance of INVOKANA in the market. I mean, it remains the #1 SGLT2 in the U.S., both in new and total scripts. I think we've got betwe",223,"And Jami, regarding INVOKANA and the class, look, first of all, we are pleased with the performance -- the continued performance of INVOKANA in the market. I mean, it remains the #1 SGLT2 in the U.S., both in new and total scripts. I think we've got between 9 million and 10 million prescriptions that have already gone out since launch. That being said, we still think that there is a good opportunity for growth in INVOKANA. We've got a very strong clinical profile that's well documented, strong access across managed care. And look, we're confident that given the experience that ACPs have had with it, combined with its profile, that's going to continue to grow. Regarding the broader issues around the class, look, we think that it's really good news, frankly, for type 2 patients, given some of the news that's coming out about CV benefits. And really, regardless of the eventual decision by the FDA regarding potential claims for other agents, we're looking forward to seeing the results of our CANVAS program that will be coming out in about a year. And we'll have to see if these ongoing CV outcome trials validate some of the current perceptions of KOLs regarding the cardiovascular effects of SGLT2 inhibitors across the drug class. We'll see. But overall, we think it's good news for patients."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Vamil Divan with Crdit Suisse.",13,"Our next question comes from the line of Vamil Divan with Crdit Suisse."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Congrats again to Louise. Just following up on Jami's question on the gross-to-net commentary. Just -- I don't think you touched on this. But specifically, on Immunology, it seems a lot of those products, in particular, saw that benefit. Is there anything",163,"Congrats again to Louise. Just following up on Jami's question on the gross-to-net commentary. Just -- I don't think you touched on this. But specifically, on Immunology, it seems a lot of those products, in particular, saw that benefit. Is there anything that you're seeing in that specific market that may be causing the difference there to be greater than what you see with your -- in the other therapeutic areas? And then one other unrelated, just on IMBRUVICA, it came in a little bit lighter than what we were expecting. Obviously, a lot of good data and a lot of growth ahead. But maybe if you could just comment on the trend you're seeing there. And also it's -- I guess, it's been about a year now since you now have a new partner on that product with Pharmacyclics being acquired by AbbVie. Just the dynamics in that partnership and how you see that relative to what you're seeing previously with Pharmacyclics."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","So let me take the -- Vamil, there's nothing substantially different between biologics and others, other than the biologics products tend to have a longer delay in terms of receiving the information. So therefore, there may be more adjustments related to",70,"So let me take the -- Vamil, there's nothing substantially different between biologics and others, other than the biologics products tend to have a longer delay in terms of receiving the information. So therefore, there may be more adjustments related to those products in any particular period. But other than that, there's no other significant trend that we're seeing that's any different than what we see overall in the market."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","And look, regarding IMBRUVICA, no, we're very pleased with the continued launch uptake that we see with it. It continues to be strong, good increase versus last year. And look, IMBRUVICA's also maintaining really good total patient market leadership in CL",91,"And look, regarding IMBRUVICA, no, we're very pleased with the continued launch uptake that we see with it. It continues to be strong, good increase versus last year. And look, IMBRUVICA's also maintaining really good total patient market leadership in CLL line 2, plus mantle cell lymphoma as well as WM in the U.S. We have additional approvals and line indications done in other markets as well. So we continue to be pleased with the performance and look forward to getting out additional information and additional indications on the countdown [ph]."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. And just on the quarter, there's additional -- we have a patient assistance program, and there's a little bit of bump in that. So that may have -- that's probably the trend difference that you see.",37,"Yes. And just on the quarter, there's additional -- we have a patient assistance program, and there's a little bit of bump in that. So that may have -- that's probably the trend difference that you see."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our final question comes from the line of Jayson Bedford with Raymond James.",13,"Our final question comes from the line of Jayson Bedford with Raymond James."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Just to clarify and kind of follow-up on an earlier question. U.S. Med Device growth in the quarter decelerated from first quarter levels. International growth accelerated. There was quite a big difference in growth in these 2 geographies. It sounds like",63,"Just to clarify and kind of follow-up on an earlier question. U.S. Med Device growth in the quarter decelerated from first quarter levels. International growth accelerated. There was quite a big difference in growth in these 2 geographies. It sounds like this is more a function of selling days with no real change in the operating environment. Is that a fair characterization?"
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","So in the OUS, we have an additional 1.5 selling days on average. That contributes to the OUS growth about 220 basis points. But on top of that, we're seeing strong market growth in China. We have some strong markets in Russia. Australia in the hips. And",98,"So in the OUS, we have an additional 1.5 selling days on average. That contributes to the OUS growth about 220 basis points. But on top of that, we're seeing strong market growth in China. We have some strong markets in Russia. Australia in the hips. And then we're seeing nice growth in the CORAIL. Also seeing some nice growth in the ATTUNE. So it's a combination of both the selling days, but if you strip out the 220 basis points for selling days OUS, you're still seeing really nice strong growth in both hips and knees OUS."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","And Jayson, one thing I would add to that is when we're talking about the Medical Device business, obviously, there's some dynamics in diabetes and some dynamics that we talked about earlier with Vision Care with the customer loyalty program. So if you lo",91,"And Jayson, one thing I would add to that is when we're talking about the Medical Device business, obviously, there's some dynamics in diabetes and some dynamics that we talked about earlier with Vision Care with the customer loyalty program. So if you look at the hospital-based Medical Device business and you exclude the impact of acquisitions and divestitures, that growth did accelerate. So the second quarter growth at about 4.7%, and first quarter growth at about 4.2%. So on the base Hospital Medical Device business, overall, we're seeing accelerated growth."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","We'll have some final remarks from Alex.",8,"We'll have some final remarks from Alex."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Okay. Well, thank you very much, everyone, for joining us this morning. And as I noted earlier, look, we're really pleased with the continued momentum as evidenced by our increased guidance for both sales and earnings for the full year 2016. Look, I rea",149,"Okay. Well, thank you very much, everyone, for joining us this morning. 
And as I noted earlier, look, we're really pleased with the continued momentum as evidenced by our increased guidance for both sales and earnings for the full year 2016. Look, I really believe that some of the clear strategic choices that we've been making, the really strong focus on execution, combined with an incredibly talented group of leaders that I'm honored and humbled to be able to work with every day at Johnson & Johnson, are enabling us to really deliver extraordinary achievements and results that we've just been able to share with you and to really build on the success of Johnson & Johnson going forward. 
So thank you for your time this morning. I look forward to updating you on the progress throughout the year, and I hope everybody has a great day. Thank you."
139677,367223456,1008028,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Thank you. This concludes today's Johnson & Johnson Second Quarter 2016 Earnings Conference Call. You may now disconnect.",18,"Thank you. This concludes today's Johnson & Johnson Second Quarter 2016 Earnings Conference Call. You may now disconnect."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Good morning, and welcome to Johnson & Johnson's Second Quarter 2016 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] I would now like t",51,"Good morning, and welcome to Johnson & Johnson's Second Quarter 2016 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] 
I would now like to turn the conference call over to Johnson & Johnson. You may begin."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Good morning, and welcome. I'm Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure this morning to review our business results for the second quarter of 2016. Joining me the on the call today is Alex Gorsky",2027,"Good morning, and welcome. I'm Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure this morning to review our business results for the second quarter of 2016. 
Joining me the on the call today is Alex Gorsky, Chairman of the Board of Directors and Chief Executive Officer; and Dominic Caruso, our Chief Financial Officer. 
A few logistics before we get into the details. This review is being made available via webcast accessible through the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. I'll begin by briefly reviewing the second quarter for the corporation and for our 3 business segments. Following my remarks, Alex will comment on the 2016 results to date and provide a strategic outlook for the company. Next, Dominic will provide some additional commentary on the business, review the income statement and update guidance for 2016. We will then open the call to your questions. We expect the call to last approximately 90 minutes. 
Included with the press release that was issued earlier this morning is the schedule of sales for key products and/or businesses to facilitate updating your models. These schedules are available on the Johnson & Johnson website, as is the press release. 
Please note, we will be using a presentation to complement today's commentary. The presentation is also available on our website. 
Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements. The 10-K for the fiscal year 2015 and the company's subsequent filings identify certain factors that could cause the company's actual results to differ materially from those projected in any forward-looking statements made today. The company does not undertake to update any forward-looking statements as a result of new information or future events or developments. Our SEC filings, including the 10-K, are available through the company and on our website. 
During the review, non-GAAP financial measures are used to provide information pertinent to evaluating business performance period-over-period. These non-GAAP financial measures should not be considered replacements for and should be read together with GAAP results. Tables reconciling these measures to the most comparable GAAP measures are available in the schedules accompanying the press release and on the Investor Relations section of the Johnson & Johnson website. A number of products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships. 
Also, to assist you with your models, this slide provide you with a summary of important developments that occurred during the quarter. 
Now I would like to review our results for the second quarter of 2016. Worldwide sales to customers were $18.5 billion, up 3.9% versus second quarter 2015. 
On an operational basis, sales were up 5.3% and currency had a negative impact of 1.4%. In the U.S., sales were up 7.4%. In regions outside the U.S., our operational growth was 3.1% while the effect of currency exchange rates negatively impacted our reported results by 2.7%. 
On an operational basis, the Western Hemisphere, excluding the U.S., grew by 15.4% with approximately 1/3 of the growth due to an inventory build that will reverse in the third quarter. Asia Pacific, Africa grew 2.1%, while Europe declined 0.6%. Results in all regions were negatively impacted by hepatitis C competition and divestitures, the most significant one being Cordis. Excluding the net impact of acquisitions, divestitures and hepatitis C, underlying operational growth was 7.9% worldwide, 8.8% in the U.S. and 6.9% outside the U.S. In addition, operations in Venezuela negatively impacted worldwide and outside the U.S. operational growth by 30 basis points and 70 basis points, respectively. 
Turning now to earnings. Net earnings were $4 billion and earnings per share were $1.43 versus $1.61 a year ago. As a reference in the table reconciling non-GAAP measures, 2016 second quarter net earnings were adjusted to exclude after-tax amortization expense of $238 million and charges for after-tax special items of $631 million. 
2015 second quarter net earnings were adjusted to exclude after-tax amortization expense of $230 million and charges for after-tax special items of $66 million. Dominic will discuss special items in his remarks. 
Excluding amortization expense and special items for both periods, adjusted net earnings for the current quarter were $4.9 billion and diluted earnings per share were $1.74, representing increases of 1.1% and 1.8%, respectively, as compared to the same period in 2015. On an operational basis, adjusted net earnings per share also grew 1.8%. 
Now turning to the highlights for the first 6 months of 2016. Consolidated sales to customers were $36 billion, an increase of 2.3% as compared to the same period a year ago. On a year-to-date basis, sales grew 4.6% operationally and currency had a negative impact of 2.3%. 
Excluding the net impact of acquisitions and divestitures and hepatitis C sales, underlying operational growth was approximately 7.4% worldwide, 9.3% in the U.S. and 5.4% outside the U.S. 
In addition, operations in Venezuela negatively impacted worldwide and outside the U.S., operational growth by 50 basis points and 90 basis points, respectively. 
Turning now to earnings for the first 6 months of 2016. Net earnings were $8.5 billion and diluted earnings per share were $3.02. Adjusted net earnings were $9.7 billion and adjusted earnings per share were $3.47, up 5.3% and 6.1%, respectively, versus the same period last year. On an operational basis, adjusted net earnings per share grew 7.3%. 
Turning now to business segment highlights for the second quarter of 2016. Please note, percentages quoted represent operational sales change in comparison to the second quarter of 2015 unless otherwise stated and therefore, exclude the currency translation impact. 
I'll begin with the Consumer segment. Worldwide Consumer segment sales of $3.4 billion increased 1.5%, with U.S. sales up 2.1% while outside the U.S. sales were up 1%. Excluding the net impact of acquisitions and divestitures, underlying operational sales growth was 3.9% worldwide, 6.8% in the U.S. and 2% outside the U.S. 
In addition, operations in Venezuela negatively impacted growth worldwide and outside the U.S. by 120 basis points and 200 basis points, respectively, with the most significant impact to Women's Health, Baby Care and Oral Care. Growth for the segment was driven primarily by Skin Care, OTC and Oral Care. 
In Skin Care, market share increases in a growing market as well as timing of inventory builds drove double-digit growth for both NEUTROGENA and AVEENO. 
OTC sales growth was strong despite a weak allergy season. U.S. OTC sales growth was driven by analgesic and digestive health share growth. In the U.S., adult analgesic market share was approximately 14%, up from approximately 11% a year ago, while U.S. pediatric share was nearly 47%, up from nearly 44% a year ago. Major contributors to the growth outside the U.S. were the strong performance of anti-smoking aids, children's analgesics and digestive health products. New product launches and successful marketing campaigns drove the results for LISTERINE in Oral Care. 
Moving now to our Pharmaceutical segment. Worldwide sales of $8.7 billion increased 9.7%, with U.S. sales up 13.2% and sales outside the U.S. up 4.9%, driven by both strong sales of new products as well as core growth products. 
Competitors in hepatitis C significantly impacted sales this quarter. Excluding sales of our hepatitis C products, OLYSIO and INCIVO as well as the impact of acquisitions and divestitures, underlying sales growth worldwide, U.S. and outside the U.S. was 12.8%, 13.9% and 11.2%, respectively. 
As you know, there were discounts and rebates in the pharmaceutical industry that are reflected in net sales. These amounts are estimated until the related claims data is received and then they are actualized. We have adjusted our estimates to reflect the most current claims trends. 
U.S. Pharmaceutical results this quarter included a positive adjustment to sales reserves across many channels, which was approximately $140 million higher than the adjustment in the second quarter of 2015 and positively impacted second quarter 2016 worldwide growth by approximately 1.5 points and U.S. growth by approximately 2.5 points. 
On a product basis, REMICADE U.S. growth in the second quarter of 2016 was positively impacted by approximately 8 points, STELARA by 11 points, SIMPONI by 13 points, ZYTIGA by 8 points and PROCRIT by 31 points. 
Significant contributors to growth were immunology products, REMICADE, STELARA and SIMPONI/SIMPONI ARIA; oncology products, IMBRUVICA and recently launched DARZALEX; as well as cardiovascular and metabolic products, XARELTO and INVOKANA. 
Within Neuroscience, strong growth for INVEGA SUSTENNA/TRINZA was partially offset by lower sales of INVEGA due to the impact of generic competition. The results for immunology were driven by strong double-digit market growth, share growth for STELARA and SIMPONI ARIA as well as the gross-to-net adjustments to U.S. sales that I mentioned. 
The decline in REMICADE export sales to our distribution partners was due to the impact of biosimilars. 
Strong patient uptake with new indications, approvals and demonstrated efficacy drove results for IMBRUVICA, both in the U.S. and outside the U.S. In the U.S., IMBRUVICA remains the new patient share and total share leader in second-line CLL and MCL. IMBRUVICA is now launched in more than 70 countries. 
DARZALEX was approved in the U.S. in November 2015 and has achieved rapid uptake with strong underlying demand. DARZALEX contributed approximately 2 points to the U.S. pharmaceutical growth rate. DARZALEX received European Commission conditional approval this quarter and was launched in certain European countries. 
XARELTO sales were up 25.8% and total prescription share or TRx for the quarter in the U.S. anticoagulant market grew to nearly 17%, up 1.5 points from a year ago. TRx in primary care was over 14% and in cardiology, over 23%. XARELTO is broadly reimbursed with approximately 95% of commercial and Medicare Part D patients covered at the lowest co-pay for a branded product. 
INVOKANA/INVOKAMET sales were up 21% on a worldwide basis and 15.2% in the U.S. In the U.S., INVOKANA/INVOKAMET TRx within the defined market of type 2 diabetes, excluding insulin and metformin, was 6.3%, up from 6% in the second quarter of 2015. TRx with endocrinologists was approximately 11.5% and over 5.5% in primary care. INVOKANA access remains strong at nearly 70% preferred for commercial and over 90% for Medicare Part D. 
I'll now review the Medical Devices segment results. Worldwide Medical Devices segment sales of $6.4 billion increased 1.8%. U.S. sales increased 1% while sales outside the U.S. increased 2.6%. As a reminder, Cordis was divested in the fourth quarter of 2015. Excluding the net impact of acquisitions and divestitures, underlying operational sales growth was 3.9% worldwide, with U.S. up 1.9% and growth of 5.8% outside the U.S. In addition, operations in Venezuela negatively impacted growth worldwide and outside the U.S. by 30 basis points and 50 basis points, respectively. Growth was driven by advanced surgery, electrophysiology, orthopedics and Vision Care. 
Strong results were achieved for advanced surgery products with endocutters growth of 13%, energy growth of 9% and biosurgicals growth of 8%. The acquisition of NeuWave Medical also contributed to growth this quarter. 
Electrophysiology grew 18% worldwide due to strong market growth, complemented by new product launches and increased penetration for both ultrasound and diagnostic catheters. 
Orthopaedics sales growth was driven by U.S. trauma and worldwide hips and knees. Market growth and the success of product launches drove results for the U.S. Orthopaedics business. Pricing pressure continued across the major categories, partially offset by positive mix for trauma and spine products. 
The success of the TFNA nailing system in trauma, the ATTUNE platform in knees, our primary stem platforms in hips and ORTHOVISC/MONOVISC and new spine product introductions made important contributions to the results.
Orthopaedics sales outside the U.S. were -- negatively impacted results in China due to continued reduction in inventory. Trauma and spine/other were the categories most impacted. 
In addition, timing of tender business negatively impacted trauma growth for the quarter. 
Vision Care sales were driven by strong growth across the major regions, partially offset in the U.S. by a customer reward program. 
That concludes the segment highlights for Johnson & Johnson's second quarter of 2016. 
It is now my pleasure to turn the call over to Alex Gorsky. Alex?"
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Louise, and good morning, everyone, and thank all of you for joining us on the conference call or webcast today. As you just heard from Louise, our second quarter results have continued the momentum that began with our great start to 2016, an",2214,"Thank you, Louise, and good morning, everyone, and thank all of you for joining us on the conference call or webcast today. 
As you just heard from Louise, our second quarter results have continued the momentum that began with our great start to 2016, and we're pleased that our shareholders are seeing above-average returns on their investment in Johnson & Johnson. 
Delivering a fair return to shareholders is the final line of our credo, which clearly defines our first responsibilities, the doctors, nurses and patients, the mothers and fathers and all others who use our products. When we meet those responsibilities and when we continuously work to improve outcomes for patients around the world, we succeed with all of our stakeholders. 
Now over the last 130 years, the people of Johnson & Johnson have been helping people everywhere live longer, healthier and happier lives. With that remarkable heritage, I'm excited and optimistic about the opportunities for the future of Johnson & Johnson and committed to continuing our long-term success. With our broad base of strong businesses, focused strategies and comprehensive approach to innovation, we're well prepared to address the challenges of today's health care market and well positioned to lead in the movement towards healthier societies. 
As I've discussed before, we believe our broad base in human health care is vital to achieving that vision. Our broad base is a strategic choice based on performance, and it has helped us to deliver strong, consistent and sustainable financial performance through various economic cycles, meeting our financial commitments in the midst of global events like the U.K.'s vote to exit from the EU or the economic issues in Venezuela this year. Our broad base enables us to create and access growth opportunities wherever they may arise at the right time and in the right markets. 
Our deep health care expertise also makes Johnson & Johnson companies strategic partners of choice for many companies, whether that means with innovative start-ups, information technology giants or large hospital systems looking to improve patient outcomes and reduce the cost of care. 
We also work with local governments and public health organizations where we're collaborating more than ever to address the world's most pressing health challenges. Our broad base allows us to create product platforms and systems that cross categories and establish new sources of innovation to converge in combination products. And finally, our broad base is helping us to realize advantages of scale to achieve enterprise efficiencies and capabilities across all of our segments. 
All of these advantages of our broad base in human health care contribute to the long-term value we are able to create for our shareholders, and we continue to have a clear set of objectives for creating that long-term value. We expect global health care to grow at 3% to 5% over the next 5 years, and we have an objective to grow our sales organically at a faster rate than the market. 
We also intend to grow our earnings faster than sales. When we combine these objectives with our plans that continue creating value through strategic acquisitions and partnerships as well as our strong dividend yield, we believe the result to be a basis for compelling, long-term total shareholder returns. And that is our focus. We invest for the long-term success of our business. In fact, we have increased our spending on R&D every year for the last 5 years. We invest above industry average levels to build our robust pipelines and continue to nurture the investments we've already made. 
We also invest in innovative sales and marketing initiatives and consistently benchmark to ensure the return on our investments is as competitive and as efficient as possible. 
I'm proud that we are able to make these important investments in our business, while also generating enterprise adjusted net income margins that have increased in our above-industry benchmarks. 
After we've made the appropriate investments in our business, we look to capitalize on the right opportunities to create greater long-term value for our shareholders. Our capital allocation framework starts with paying dividends to our shareholders, which is why we have increased our dividend every year for the last 54 years. Next, we seek value-creating strategic acquisitions and partnership opportunities. And finally, we consider other prudent ways to return value to shareholders such as repurchase programs. 
In fact, over the last 3-, 10- and 20-year periods, Johnson & Johnson total shareholder return has exceeded our competitive composite. And as you can see in this chart, we're off to a very strong start in 2016 with total shareholder return of approximately 20% through the first half of the year. 
And while we manage our business for the long term, we also have a number of near-term priorities, which I've shared with you before. As an enterprise, we're focused on delivering on our financial and quality commitments. Through the first 6 months, we generated sales of $36 billion, resulting in an operational growth of 4.6%. When you exclude the impact of acquisitions, divestitures, hepatitis C sales and operations in Venezuela, underlying growth was 7.9%. 
Through the first half of this year, we have delivered adjusted net earnings of $9.7 billion and adjusted EPS of $3.47. On an operational basis, adjusted EPS was $3.51, representing growth of 7.3%. 
In our Pharmaceutical business, we continue to deliver very strong results. On the same underlying basis, growth was 12.7% through the first half of 2016, and we are continuing to build momentum in our Consumer and Medical Device businesses with first half underlying growth of 4.5% and 3.7%, respectively. 
We also continue making progress with our quality system, including resolving a warning letter in our ASP business and completion of the Synthes corporate integrity agreement. 
In Pharmaceuticals, we're continuing to build on our launch excellence and robust pipeline. In the last several months, we have made significant advancements in our pipeline, including conditional EU approval for DARZALEX for monotherapy of adults with relapse and refractory multiple myeloma and presented positive Phase III data on the CASTOR and POLLUX studies, which are evaluating combination therapies for DARZALEX. 
We also received the EU approval for frontline IMBRUVICA treatment in CLL as well as FDA expansion of the IMBRUVICA label to include new Phase III data on survival and in combination therapies. 
Phase III data on STELARA demonstrated maintained clinical remission after 1 year of treatment in patients with moderate to severe Crohn's disease. 
Clinical trial and real-world data was presented on INVOKANA, including Phase II data on type 1 diabetes and chronic weight management. 
We received EU approval for TREVICTA, a once every 3 months injection for maintenance treatment of schizophrenia, as well as line extension approval for both INVOKAMET and SIMPONI. 
Positive Phase III data was presented on sirukumab for patients with moderately to severe active rheumatoid arthritis. 
And just recently, FDA granted the fourth Breakthrough Therapy designation for IMBRUVICA in graft versus host disease, GDHD, which makes 6 total breakthrough designations for our Pharmaceutical business so far. 
In addition to these pipeline milestones, as Louise pointed out, we also delivered strong growth with our in-market products, including IMBRUVICA, DARZALEX, XARELTO, STELARA and SIMPONI. 
In Consumer, our priority is expanding market leadership in key segments within OTC, Oral Care, Baby and beauty. 
As part of our focus on the beauty space, we had just completed the strategic acquisition of Vogue International. The award-winning beauty products in this portfolio, including the OGX brand, enhance our existing position in the market and are highly complementary to our heritage of breakthrough innovations in this space. 
Vogue International has grown at double digits over the last 5 years with a compound annual growth rate of about 25%, and the acquisition will take us from #8 to #4 in the U.S. hair care market. 
And as we discussed in May at our Analyst Day, we're continuing to see operating margin improvement in our consumer business and plan to continue that trend for the next several years. 
And in Medical Devices, we're focused on accelerating growth through innovation and transforming our go-to-market models. In this segment, we're gaining momentum and accelerating growth through our unique and broad-based approach to innovation. Our performance this quarter was roughly in line with market growth. And we're pleased with the progress here, but far from satisfied. Our goal, to be clear, is to grow above market overall. 
And while we're making strategic decisions in our portfolio to achieve that growth like the recent acquisition of BioMedical Enterprises, Inc., which filled a key portfolio gap in elective foot and ankle surgery, we're also realigning our commercial models in line with our near-term priority. Our innovation model in Hospital Medical Devices includes innovating our product offerings, but it also looks at innovation in terms of our commercial offerings and contracting. 
As we outlined during our business review day, today, about 25% of our U.S. orthopedic and surgery business is in multiproduct line agreements. These agreements perform almost 2x better than single-product contract agreements. We see this percentage growing to 40% in the near future, which we believe will help us accelerate our business going forward. 
And finally, we're also serving customers in a more end-to-end manner with risk-sharing contracts and outcome-based patient solutions. 
We're also on track to deliver approximately $800 million to $1 billion in annual savings from our Medical Device restructuring, the majority of which we expect will be realized by the end of 2018. 
And also, we continue to make progress in launching new competitive entries in our Consumer Medical Device businesses like the ACUVUE VITA, a 30-day daily-wear contact lens that provides superior comfort over leading monthly brands. 
With all this progress in our Medical Devices segment, we are confident that we are poised to deliver above-market growth. Altogether, these near-term priorities will help drive success for each of our business segments, while also enabling us to achieve the growth we expect for our company in the long term. With the progress we made on our near-term priorities, our businesses are strong, positioning us for above-market growth. With the combined strength of our in-market portfolio, deep late-stage pipeline and robust early-stage pipeline, we feel confident our Pharmaceutical business can successfully navigate through the launches of new competitive, biosimilar or generic entrants and evolving market dynamics. And our objective is to continue delivering above-industry growth. Our Consumer business is positioned to grow above market, while also achieving benchmark profitability and investing for the future. 
And in Hospital Medical Devices, we are poised to grow above the market, driven by our innovative pipelines, expanding global presence and novel commercial models. 
Our Consumer Medical Device businesses are holding leading positions and seeking opportunities to expand in large growing markets with significant unmet needs. With the strength of each of our business segments, we feel optimistic about the future opportunities in health care, and we are confident our long-term strategies have positioned us for continued growth. Our holistic approach to innovation, going beyond products and solutions, will allow us to address the evolving health care landscape, driving better outcomes and delivering long-term value. We have the right internal capabilities and are developing strategic partnerships in health tech to reshape the way health care is delivered, managed and experienced. 
And finally, our broad base across human health care uniquely positions Johnson & Johnson as a leader and partner of choice in the health care market. 
But perhaps most importantly of all, our continued strong performance means we are able to create better products, more valuable services and improved outcomes for patients, consumers and their families. 
So I'd like to thank you. I look forward to further dialogue during the Q&A session. But first, I'd like to take a moment to recognize Louise Mehrotra, who, as most of you know from our announcement last month, has decided to retire after more than 35 years with Johnson & Johnson and more than 10 years as Vice President of Investor Relations. 
I know many of you on the call today have gotten to know Louise pretty well over the last several years, a real testament to the strong relationships she's built in the investment community on behalf of Johnson & Johnson. And you may know that she's an incredibly committed credo-based leader and had a remarkable career and impact on our company. I think I can speak for all of us at Johnson & Johnson in saying that we will miss her trusted, experienced, respected advice and her ever-present determination to do what's in the best interest of all of our credo stakeholders. 
Louise, we're so proud of the best-in-class Investor Relations function you've developed for us over the last decade, and we sincerely thank you for your many years of service and dedication to Johnson & Johnson. 
Now we know we'll all be in good hands with Joe Wolk, previously Vice President of Group Finance for our Pharmaceuticals Group, will become Vice President Investor Relations effective August 1 and transition with Louise over the next 5 months. We are confident that Joe will continue Louise's legacy of transparent and credible communication with you, our investors. 
So now, I'll turn it over to Dominic Caruso, who will talk more about our results and expectations for the second half of 2016. Dominic?"
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Thanks, Alex, and good morning, everyone. Before I get into our results, I'd like to echo Alex's sentiments and personally thank Louise for her significant contributions to Johnson & Johnson and for her valued support and friendship during my time as Chie",2639,"Thanks, Alex, and good morning, everyone. Before I get into our results, I'd like to echo Alex's sentiments and personally thank Louise for her significant contributions to Johnson & Johnson and for her valued support and friendship during my time as Chief Financial Officer. 
Over the last 10 years, Louise and the entire IR team has transformed our Investor Relations function, significantly developing our reputation with the investment community, which has been recognized with several awards and recognitions, including those from Institutional Investor and IR Magazine. And through surveys of money managers conducted by Barron's Magazine, Johnson & Johnson has been ranked at/or near the top of the most respected companies list for 10 of the last 12 years. In fact, I'm also pleased to report that Johnson & Johnson was recognized this year by Barron's Magazine as the #1 most respected company for 2016.
As Alex noted, Louise's outstanding leadership and dedication to advancing our reputation will continue with her successor, Joe Wolk, who we're happy to have joining us on our call next quarter. We all wish Louise well, and we are certainly going to miss her. 
With that, I will now turn our discussion back to the quarter. We're very pleased with our second quarter results as we continue to see improved performance across the enterprise. And as Alex said, we remain confident in the strength of our business. 
As we've previously discussed in 2015, our underlying operational sales growth, which excludes the impact of acquisitions, divestitures as well as hepatitis C sales and the few extra shipping days in 2015, was about 5.5%. On this same basis, we continue to deliver strong underlying operational sales growth of approximately 7.9% for the second quarter, and our sales results are above analyst estimates. Our second quarter earnings were also above analyst estimates, driven by strong sales performance and operating margin improvement. 
As you may remember, for 2016, our guidance from January included a 200 basis point increase in pretax operating margin on an adjusted basis. We were pleased to see progress towards this improvement during the second quarter, which I will discuss later. And we remain comfortable with that forecast as we continue to accelerate throughout the year with the restructuring activities in our Medical Device business and lower levels of spending in the back half as compared to the prior year. 
Now I'll take a few minutes to highlight some key points regarding our results, and then I'll provide some updates to our guidance for you to consider in refining your models for 2016. 
I will now turn to our consolidated statement of earnings for the second quarter of 2016. As we've mentioned, our operational sales growth this quarter was 5.3%. And excluding the impact of acquisitions and divestitures, hepatitis C sales and also the impact of the devaluation that occurred in Venezuela last year, it was strong at more than 8%. 
If you will direct your attention to the box section of the schedule, you will see we have provided our earnings adjusted to exclude intangible amortization, expense and special items. 
As referenced in the table of non-GAAP measures, the 2016 second quarter net earnings were adjusted to exclude intangible asset amortization expense and special items on approximately $900 million on an after-tax basis, which consisted primarily of the following: intangible asset amortization expense of about $200 million, litigation charges from ongoing legal matters of about $500 million and additional charges as we continue to execute on the Medical Devices restructuring. 
Our adjusted earnings per share is therefore, $1.74, exceeding the mean of the analyst estimates as published by First Call. This is an increase in adjusted EPS of 1.8% versus the prior year, and adjusted EPS on a constant currency basis was the same, as the impact of currency was flat year-over-year. 
Now let's take a few moments to talk about the other items on the statement of earnings. Cost of goods sold decreased by 120 basis points, mostly due to favorable mix and manufacturing efficiencies, partially offset by transactional currency. 
Selling, marketing and administrative expenses were 28% of sales or 230 basis points lower as compared to the second quarter 2015 due to good cost management. 
Our investment in research and development as a percent of sales was 12.2% and higher than the prior year due to increased project spending as we advance our promising product pipelines. 
Our pretax operating margin, when excluding special items and intangible amortization expense, was 32.5% or 320 basis points higher than the second quarter of the prior year. As a reminder, pretax operating margin is defined as gross profit less selling, marketing, administrative and R&D expenses. 
As we anticipated, we are seeing improvement as we progress throughout the year. And through 6 months, we have achieved a 180 basis point improvement in this measure of profitability. 
Interest expense, net of interest income, was slightly lower than last year due to slightly better rates on our investments. Other income and expense was a net expense of approximately $600 million in the quarter compared to a net gain of approximately $900 million in the same period last year. 
Excluding the special items that are reflected in this line, other income and expense was a net gain of approximately $100 million compared to a net gain of approximately $1 billion in the prior year period. The significant decrease is due to the divestiture of NUCYNTA in the prior year period. 
Excluding special items, the effective tax rate was 19.2% compared to 23% in the same period last year. This year's effective tax rate reflects the R&D credit, which was passed by Congress late last year, the current mix of our business and the impact of new accounting standards related to the tax benefit on share-based compensation, which I will discuss further in a moment. 
Turning to the next slide. I will now review adjusted income before tax by segment. In the second quarter of 2016, our adjusted income-before-tax margin for the enterprise declined by 250 basis points versus the second quarter of 2015. 
During the second quarter of 2015, as I mentioned earlier, we recorded a gain from the divestiture of NUCYNTA. And this gain, which, as you know from our discussions last year, was invested in various parts of the business, but those investments occurred later in the year. 
If the NUCYNTA divestiture gain is excluded, year-on-year adjusted income-before-tax margin would show an improvement of approximately 300 basis points. We're very pleased to see a significant improvement in our Consumer business adjusted income tax margin this quarter. As you may recall from our business review day in May, we said that we are focused on improving our margins in the Consumer business to benchmark levels. We are confident that our Consumer business will show an improved adjusted income-before-tax margin for full year 2016 as compared to 2015. 
Overall, we expect income-before-tax margins for the enterprise to show an improvement over the prior year for all of 2016 as our increase in the pretax operating profit margin, which I noted earlier, more than offsets the lower level of divestiture gains in 2016 as compared to 2015. 
Now I will provide some guidance for you to consider as you refine your models for 2016. At the end of the quarter, we had approximately $16 billion of net cash, which consists of approximately $42 billion of cash and marketable securities and approximately $26 billion of debt. As you know, in May, we took the opportunity to finance our share repurchase program and upcoming debt maturities at very attractive interest rates, with the European debt issuance equivalent to $4.5 billion. 
Through the end of the second quarter, we have completed nearly 50% of our $10 billion share repurchase program, and we continue to expect to complete approximately 75% of the program by the end of this year. 
For purposes of your models and assuming no major acquisitions or other major uses of cash, I suggest you consider modeling net interest expense between $400 million and $500 million. This is a slight decrease from our prior guidance. 
Regarding other income and expense. As a reminder, this is the account where we record royalty income as well as gains and losses arising from such items as litigation investments, prior development corporation divestitures, asset sales and write-offs. We will be comfortable with your models for 2016 reflecting net other income and expense, excluding special items, as a net gain ranging from approximately $900 million to $1 billion, a lower range than our previous guidance related to the timing of underlying activity. This impact will be offset by the strength of our business, primarily due to our outlook for a higher level of sales as noted in the increased sales guidance in our press release today. 
And now just a word on taxes. During the second quarter, the company elected for early adoption of a new accounting standard related to share-based compensation. With this update, increased tax benefits are recognized in earnings on the employee exercises options or received shares. Previously, these tax benefits were recorded in equity. 
The first quarter impact was approximately $165 million or $0.05 per share and is reflected in the year-to-date results and not in the second quarter, when we adopted the standard. The second quarter impact is offset by additional tax costs reflected in this quarter. 
Per adoption guidance, the first quarter does not need to be reissued. However, all future comparisons for the first quarter should reflect the recasted numbers. We have included a supplementary schedule on our website that includes the updated first quarter impact for the P&L. 
You will note that the first quarter recast number reflects a tax rate of 15.8%. The company issued shares related to employee stock compensation such as restricted stock awards or performance share units in the first quarter. Therefore, historically, a significant portion of the annual tax benefit is recognized in the first quarter. The tax benefit for stock options is recognized throughout the year as employees exercise their options, but timing is less predictable for stock options. 
We are comfortable with your models reflecting an effective tax rate for 2016, excluding special items, of approximately 18.5% to 19%, lower than our previous guidance, primarily due to the accounting for share-based compensation tax benefits that I just described. 
Now turning to sales and earnings. Our sales and earnings guidance for 2016 takes into account several assumptions and key factors that I would like to highlight. As a reminder, our sales guidance for 2016 assumes no biosimilar entrants for PROCRIT or REMICADE in the U.S., and our assumption remains unchanged with the recent FDA approval of Inflectra. 
We also do not anticipate generic competition this year for ZYTIGA, RISPERDAL CONSTA or INVEGA SUSTENNA. But as expected, there are generic entrants for INVEGA and ORTHO TRI-CYCLEN LO. 
As Alex mentioned, we have now closed the acquisition of Vogue International. So our guidance now reflects 6 months of additional sales. This is a fast-growing business and will contribute to the profitability of our Consumer business beginning the first full year, as well as be accretive to our adjusted EPS beginning in the first full year. 
Also, during the second quarter, we closed on our divestiture for the controlled substance raw material and API business and therefore, those sales were no longer be recorded. 
As we've done for several years, our guidance will be based first on a constant currency basis reflecting our results from operations. This is the way we manage our business, and we believe this does provide a good understanding of the underlying performance of our business. 
We will also provide an estimate of our sales and adjusted EPS results for 2016 with the impact that current exchange rates could have on the translation of those results. 
As noted in our press release, we are increasing our operational sales guidance for 2016, primarily reflecting the strong results from the first half as well as 6 additional months of sales from the Vogue acquisition, partially offset by the divestiture of our controlled substance raw material and API business. We would, therefore, be comfortable with your models reflecting an operational sales increase on a constant currency basis of between 3% and 4% for the year. This would result in sales for 2016 on a constant currency basis of approximately $72.2 billion to $72.9 billion and higher than our previous guidance. 
Additionally, by way of comparison to how we describe our sales results in 2015, our operational sales growth for 2016, excluding the impact of acquisitions, divestitures and hepatitis C sales, would be approximately 6%, a higher level of growth than we saw last year after adjusting for the extra shipping days in 2015, which we've mentioned earlier. 
Although we're not predicting the impact of currency movements, using the euro as of last week at $1.11, the negative impact of foreign currency translation will be approximately 1% on sales. This is consistent with our previous guidance as other major currencies strengthened since our last update. We are watching the euro and other currencies closely as it is uncertain how they will eventually settle out for the year. Of course, we're closely following the situation with the U.K.'s vote to exit from the EU. We expect this will take time to fully determine what the impact will be, if any. 
To put it into perspective though, the U.K. represents about 3% of our total sales. So after impacts of currency, we would expect reported sales to reflect the change in the range of 2% to 3% for a total expected level of reported sales of approximately $71.5 billion to $72.2 billion and higher than our previous guidance. 
And now turning to earnings. As a reminder, we expect transaction currency impacts to be negative to our gross margin by about 60 to 80 basis points in 2016 as compared to 2015. We would be comfortable with adjusted operational EPS guidance in the range of between $6.66 to $6.76 per share on a constant currency basis, reflecting an operational constant currency growth rate of 7.4% to 9%. This is a narrower range as well as higher than our previous guidance and includes the first quarter impact from the tax accounting change we discussed earlier. 
If currency exchange rates for all of 2016 were to remain where they were as of last week, then our reported adjusted EPS would be negatively impacted by approximately $0.03 per share due to currency movements, and this is consistent with our guidance in April. Therefore, we would be comfortable with our reported adjusted EPS ranging from $6.63 to $6.73 per share, which is an increase from our previous guidance due both to the continued strength of the business and a lower tax rate. And at this point in the year, we will be comfortable with your models reflecting the midpoint of this range. 
In closing, we are very pleased with our strong start for the first 6 months of this year, and we are optimistic with what we see ahead for the full year, namely, we're expecting operational sales growth of 3% to 4% and underlying operational sales growth of 6% or higher than we saw in 2015 on a comparable basis. 
Our adjusted pretax operating margin improvements are on track to meet the expectations we laid out in our guidance of more than a 200 basis point improvement over the prior year. 
Our adjusted operational EPS growth in our guidance improved and remains strong in the range of $6.66 to $6.76 a share, that's a growth rate of between 7% and 9%. Our businesses are continuing to invest while also delivering on our growth expectations. 
And now I'd like to turn things back to Louise for the Q&A portion of the call. Louise?"
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Dominic. Michelle, could you please give the instructions for the Q&A session?",14,"Thank you, Dominic. Michelle, could you please give the instructions for the Q&A session?"
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","[Operator Instructions] Our first question comes from the line of Mike Weinstein with JPMorgan.",14,"[Operator Instructions] Our first question comes from the line of Mike Weinstein with JPMorgan."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Dominic, just a couple items that we could hopefully get you to clarify. So number one is, what's the impact for the full year EPS of ASU 2016-109 [ph] adoption? The tax rate coming down as it did suggests a range of anywhere from $0.04 to $0.12, so maybe",79,"Dominic, just a couple items that we could hopefully get you to clarify. So number one is, what's the impact for the full year EPS of ASU 2016-109 [ph] adoption? The tax rate coming down as it did suggests a range of anywhere from $0.04 to $0.12, so maybe you can help with that. And then second, can you just walk through the net impact of the Vogue acquisition and then the API business divestiture on sales and earnings?"
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Mike. Well, with respect to the early adoption, I mentioned earlier that the first quarter impact was $0.05, and that's the most significant impact we expect for the year because that's where the majority of stock-based compensation is issued to emp",155,"Sure, Mike. Well, with respect to the early adoption, I mentioned earlier that the first quarter impact was $0.05, and that's the most significant impact we expect for the year because that's where the majority of stock-based compensation is issued to employees. The second quarter impact was lower than that, but was almost entirely offset by other tax items. And the rest of the year will depend on when employees exercise stock options, so very difficult to predict. So for now, we've included in our effective tax rate for the year only the first quarter impact, which after we adopt it in the second quarter, we're letting the first quarter impact flow through for the remainder of the year.
Second quarter impacts already been offset by other items, and remaining quarterly impacts, we think, will either likely be offset by other items or very difficult to predict because it's timing of when employees exercise options."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Yes. So your updated guidance, Dominic, doesn't assume any benefit in the second half of the year?",17,"Yes. So your updated guidance, Dominic, doesn't assume any benefit in the second half of the year?"
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","That's right. Only the first quarter flow through that we experienced. And as I said, that's the largest single quarter of any stock-based compensation tax benefit. Sales with respect to Vogue and the API business. Vogue, for the full year, is in the $350",119,"That's right. Only the first quarter flow through that we experienced. And as I said, that's the largest single quarter of any stock-based compensation tax benefit. Sales with respect to Vogue and the API business. Vogue, for the full year, is in the $350 million range. We have about half a year of sales added to our guidance. And the API business was an annual business of about $250 million, and we'll have half a year of those sales no longer included in our guidance. So that's part of the increase in our overall growth in sales of about 0.5 points. The rest of it is due to the underlying strength we saw in the first 6 months."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. And then on the pharma business, can I get you just to comment on a couple of items. So one, this is obviously a very important quarter for DARZALEX with the data we saw at ASCO and EHA. And would just -- would love to get some high-level commentary",92,"Okay. And then on the pharma business, can I get you just to comment on a couple of items. So one, this is obviously a very important quarter for DARZALEX with the data we saw at ASCO and EHA. And would just -- would love to get some high-level commentary on where you think that gets positioned going forward in multiple myeloma. And then second, could you talk about the competitiveness of sirukumab, given the Phase III data we just saw at EULAR and your expectations there on filing, timing and approval?"
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Now let me say a few words on both. And then, Alex, why don't you add a few, and Louise also on the timing question? So DARZALEX, we're very pleased with the initial uptake of DARZALEX. The product is well received by the medical community. And the data,",155,"Now let me say a few words on both. And then, Alex, why don't you add a few, and Louise also on the timing question? So DARZALEX, we're very pleased with the initial uptake of DARZALEX. The product is well received by the medical community. And the data, as you pointed out, continues to be very impressive. And we believe DARZALEX can be essentially backbone therapy for the treatment of multiple myeloma. So we expect that we'll get additional indications for DARZALEX, but it's already been quite well received by the investment community, having great results for patients, and as I said, likely to be backbone therapy going forward. Sirukumab, also very positive data there. It's an important product in our autoimmune franchise. And Alex, maybe you can comment a little bit more on that. And Louise, on the timing of filing for sirukumab, I just don't have it handy, if you could give that."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","2016.",1,"2016."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","2016. So we'll file this year for sirukumab.",8,"2016. So we'll file this year for sirukumab."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. I'll let some other -- yes?",7,"Okay. I'll let some other -- yes?"
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, we -- look, we're excited about sirukumab on a number of fronts. First, as an IL-6, given what we know in this category, there's a lot of inter-patient variability and having another option for patients. And based upon the early data that we've seen",128,"Yes, we -- look, we're excited about sirukumab on a number of fronts. First, as an IL-6, given what we know in this category, there's a lot of inter-patient variability and having another option for patients. And based upon the early data that we've seen in RA, some of them presented just recently at the EULAR conference, we're very encouraged by. We're going to be looking at it, obviously, in other areas. And I think what we're most enthusiastic about is if you combine sirukumab along with the work that we're doing with guselkumab as well, the IL-23 being looked at in psoriasis, it's really going to help us build out an even stronger portfolio and platform in immunology as we go forward over the next several years."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Larry Biegelsen with Wells Fargo.",13,"Our next question comes from the line of Larry Biegelsen with Wells Fargo."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Louise, congratulations on your retirement. I know you'll be missed. So one for Dominic, start -- financial, to start off with, and then just one market-related question. So Dominic, just on the guidance, 2 clarification questions. So the $0.10 raise at t",138,"Louise, congratulations on your retirement. I know you'll be missed. So one for Dominic, start -- financial, to start off with, and then just one market-related question. So Dominic, just on the guidance, 2 clarification questions. So the $0.10 raise at the lower end on operational EPS and the $0.05 on the high end, is $0.05 due to the accounting change and the rest due to the underlying strength in the business? And then it appears there's a lot of moving parts on the sales guidance as well. That 5.5% in 2015 that you raised to 6% for 2016, by my math, it implies that you're expecting similar growth in the second half of 2016 compared to the first half of 2016, if one adjusts for the extra week in the year-ago period. So is that directionally accurate?"
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Larry. Well, with respect to EPS guidance, you mentioned 2 of the items, which obviously was tax as well as the stronger sales performance. But I just wanted to remind you that we also lowered our other income and expense guidance for the year. So o",149,"Sure, Larry. Well, with respect to EPS guidance, you mentioned 2 of the items, which obviously was tax as well as the stronger sales performance. But I just wanted to remind you that we also lowered our other income and expense guidance for the year. So one way to think about it is that other income and expense guidance is lower. The tax rate is also lower. Those 2 generally offset. And the midpoint of the guidance is up about $0.07, when I do the midpoint versus the 2 ends. And the $0.07 is primarily due to the overall increase in sales guidance that we provided today. Your observations with respect to the back half of the year, you're right that if we exclude the extra shipping days in 2015 from the analysis, the back half of 2016 would be similar to what we saw for the first half."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And then just on the market in the U.S. Maybe, Alex, if you could comment a little bit, or Dominic, on what you're seeing on procedure volume in the U.S. in ortho, and more broadly, in med tech, that would be great.",43,"And then just on the market in the U.S. Maybe, Alex, if you could comment a little bit, or Dominic, on what you're seeing on procedure volume in the U.S. in ortho, and more broadly, in med tech, that would be great."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. Thanks, Larry. Larry, we are seeing a pickup in terms of hospital admissions and surgical procedures. I think hospital admissions are up around 3%. We think the procedures are probably up around 3.5%. We continue to see some decrease, overall, in off",100,"Yes. Thanks, Larry. Larry, we are seeing a pickup in terms of hospital admissions and surgical procedures. I think hospital admissions are up around 3%. We think the procedures are probably up around 3.5%. We continue to see some decrease, overall, in office physician visits, down a couple of percent. We think that that's due to a more moderated utilization at the front-end due to increased co-pays and a number of other dynamics. But overall, if we look at the core growth rate in the medical hospital device area, we're encouraged by some of the recent trends that we're seeing."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Kristen Stewart with Deutsche Bank.",13,"Our next question comes from the line of Kristen Stewart with Deutsche Bank."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And I'll echo, Louise, we'll definitely be missing you, but congratulations. I was wondering, Alex, if you could just comment a little bit about just on the capital allocation side. Obviously, we saw Vogue. Is that what we should be thinking going forward",66,"And I'll echo, Louise, we'll definitely be missing you, but congratulations. I was wondering, Alex, if you could just comment a little bit about just on the capital allocation side. Obviously, we saw Vogue. Is that what we should be thinking going forward in terms of the type of acquisitions to look forward, the smaller, more, I guess, tuck-in for you guys, in that range?"
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Hi, Kristen. Thanks a lot for the question. And I couldn't agree with you more regarding Louise. But look, we were really happy that we were able to add Vogue to the J&J Consumer portfolio. As we've been talking about over the last several years, we felt",389,"Hi, Kristen. Thanks a lot for the question. And I couldn't agree with you more regarding Louise. But look, we were really happy that we were able to add Vogue to the J&J Consumer portfolio. As we've been talking about over the last several years, we felt that what was most important to the Consumer group was to actually ensure that we were able to get through the early stages of the remediation in a really high-quality and effective way. And I think the team has done a great job at making it [ph] a little bit more broadly across that entire Consumer group. I think we see that in the core trends. And of course, once we establish that, we continue to see Consumer as a great growth opportunity for the organization going forward. And as Jorge and as you saw when we did the Medical Device and Consumer Investor Relations review, now about a little over a month ago, I think they've got a really ambitious but also realistic plan for that, built on our existing brands. And we were really pleased to see performance. For example, LISTERINE, up 7%; OTC's up 6%; analgesics within OTCs were up over 13%. And then in beauty, you saw about a 9% lift with really strong performance from NEUTROGENA and AVEENO. And when you take that and augment it, I think, with thoughtful additions such as we saw over this last quarter, whether it was NeoStrata, whether it was HIPOGLS or with Vogue, we think that those are great additions to our existing portfolio, and will likely be part of a continuous stream of additions to that part of the portfolio. And as we said for some time, whenever we're looking at inorganic growth opportunities, we look at tuck-ins, we look at midsized deals, we'll look at large deals. Of course, the tuck-in strategy, particularly in pharma -- or actually, in all of our segments, Medical Device and Consumer, are those that -- where we feel that we can create the most value. But we do think that there's other opportunities to create value as well, and again, in mid- and larger deals. But we're going to be very disciplined. We're going to be very decisive about how we do it. And ultimately, try to better serve patients and consumers."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And just, I guess, on that broader note, I guess now that Consumer has turned the corner and has done well with the remediations, is that now a platform that, as you said, is more ready for acquisitions? I know Medical Devices is in the midst of the restr",64,"And just, I guess, on that broader note, I guess now that Consumer has turned the corner and has done well with the remediations, is that now a platform that, as you said, is more ready for acquisitions? I know Medical Devices is in the midst of the restructuring. Is that how we should think about it? And I have a follow-up for Dominic."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Sure. Look, we believe that mission one was really focusing on the core business, as we said. And I do feel that Consumer, like all of our businesses, we're pleased; we're never completely satisfied. And they've made a lot of progress on the core. And so",191,"Sure. Look, we believe that mission one was really focusing on the core business, as we said. And I do feel that Consumer, like all of our businesses, we're pleased; we're never completely satisfied. And they've made a lot of progress on the core. And so we would expect, again, in a very thoughtful, disciplined way, to continue to do additions when we think they're right. But we would look for the same thing in our other segments as well. And by the way, we're pleased with the progress that we've seen in our Medical Device group over the last quarter as well. I mean, if we look at the restructuring, I think, overall, that team's on track. They're doing actions that strengthen their go-to-market model, to accelerate their pace of innovation. They're prioritizing some additional platforms and geographies, and all while streamlining some operations but really keeping very high-quality standards. We think they're on track with the plan that they articulated earlier in the year. And we're confident that as they move through this, they will be not only a stronger, but a more innovative and a more efficient business."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Great. And Dominic, for the rebate in pharma, should we think about that as flowing through this quarter? Or was that mainly reinvested, because I know there was a higher rate of R&D this quarter?",35,"Great. And Dominic, for the rebate in pharma, should we think about that as flowing through this quarter? Or was that mainly reinvested, because I know there was a higher rate of R&D this quarter?"
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Well, the -- the way to think about it, maybe, Kristen, is that it's a year-over-year change in about a $140 million sales level. So obviously, some of that drops through to the bottom line. And you're right, we do also take the opportunity to invest. Inv",115,"Well, the -- the way to think about it, maybe, Kristen, is that it's a year-over-year change in about a $140 million sales level. So obviously, some of that drops through to the bottom line. And you're right, we do also take the opportunity to invest. Investments in R&D, really, are related to progress in the pipeline, regardless of whether these gross-to-net adjustments would be available. But another way to think about it is that we're now at a point where these actualizations of prior estimates, our current reserves are -- a significant portion of them are current because data has been coming in recently. So I wouldn't expect similar type of adjustments going forward."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Matt Miksic with UBS.",12,"Our next question comes from the line of Matt Miksic with UBS."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Alex, while I've got you here, just one strategic question. And I don't know if this is consistent with what you're seeing or where you think things are going. But on devices, like what we've seen is a lot of these new innovations in structural heart, in",134,"Alex, while I've got you here, just one strategic question. And I don't know if this is consistent with what you're seeing or where you think things are going. But on devices, like what we've seen is a lot of these new innovations in structural heart, in particular, some of the bundled payment initiatives seem to be driving more volumes to sort of higher-volume centers, larger networks, potentially augmented by outpatient centers. It's early in some of these initiatives, but that seems to be directionally where things are headed. And first, we'd love to get your sense as to whether you think that's where things are going as well. And if so, how J&J is positioned on the device side to benefit or support these kinds of trends. And then I had one follow-up."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Matt. Thank you very much for the question. Over the past 3 or 4 years, I think we've been pretty consistent in our thinking and in our projections about likely increasing consolidation among providers and hospitals, particularly here in the United",252,"Sure, Matt. Thank you very much for the question. Over the past 3 or 4 years, I think we've been pretty consistent in our thinking and in our projections about likely increasing consolidation among providers and hospitals, particularly here in the United States and just broader health care systems. And as systems feel continuing pricing pressure, we think that will manifest itself by them having consolidation. I think we've seen those trends. And I think they're clearly starting an effort to try and be as effective and as efficient as possible. So we do believe that, that will be a longer secular trend that's going to continue. That's why we believe having a diverse and enough critical mass in our Medical Device portfolio is so important going forward. We see it in the way that expectations are changing among decision-makers, including not only surgeons, but also people in procurement and other C suite executives, administrators and hospital systems. And we think as a result of that, we'll be very well positioned, particularly when you think about our surgical franchise, our Orthopaedics franchise. We've also been consistent in saying that we're extremely pleased with the performance of our cardiovascular unit, particularly our EP group, Biosense Webster. I mean, once again, this quarter, they've delivered over 18.5% growth with great innovation and great execution. But we also realize that that's an area where we'll continue to look for the right kind of additions, organically and inorganically, to ensure that we're properly positioned going forward."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","That's great. And then on another topic that we spend a lot of time on, I guess, over the past year, and we're now a quarter away from what looked like a competitive launch in the U.S. biosimilar side on REMICADE. I'd love to -- without asking you to tip",176,"That's great. And then on another topic that we spend a lot of time on, I guess, over the past year, and we're now a quarter away from what looked like a competitive launch in the U.S. biosimilar side on REMICADE. I'd love to -- without asking you to tip your hand, of course, or -- I'd love to get a sense as to can you -- is there -- are there steps you can take -- given your portfolio and your relationship with these payers and networks, are there steps you can take to sort of stop -- I don't know what the right word is -- potentially offset some of the potential impact or get ahead some of the potential impact through some of the contracts that you're talking with these folks about? And I think you know the question I'm asking, and I'm sure you're not going to get into a ton of detail. But any color would be helpful as to the extent of your ability to contract around that event."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, Matt. Look, as we look at the landscape going forward, we fully predict that generics and biosimilars are going to be part of the competitive landscape. And look, we think that, that is essential for the health care system. We think, in the long run,",409,"Yes, Matt. Look, as we look at the landscape going forward, we fully predict that generics and biosimilars are going to be part of the competitive landscape. And look, we think that, that is essential for the health care system. We think, in the long run, it's actually a benefit for very innovative-focused companies because that's the only way you can relieve pressure over the long term. Of course, that's predicated upon the market and companies respecting intellectual property. It's very important to produce the right scientific information so that we're guaranteeing patient safety and understanding the important clinical differences between some of these compounds as they may or may not manifest themselves. And so we projected them. As we look at our strategic plan, we think they will be there. But we also feel that that's why it's so important to keep innovating with new product launches going forward. And it's also critical to establish a strong critical mass in terms of products, but also expertise in clinical data and information in certain platforms. And so for us, in the Immunology platform, we're very proud of the extensive track record that REMICADE, the TNF-alpha compound has had and what it continues to do. We'll continue to defend our intellectual property around it. But at the same time, if you look at compounds like STELARA and SIMPONI, not only have they both generated in excess of 30% growth this quarter, but we've also produced additional data that we think is going to be very important to patients and physicians in how they adopt these products. And these are already multibillion-dollar platforms for Janssen and Johnson & Johnson. And then when you compound that with sirukumab and guselkumab, again an IL-6 and IL-23 approach where we know there's a lot of patient variability, we think that's important. Also, as we look at REMICADE itself, we know that there's about 2.4 million patients who've been treated with the compound. We know that about 70% of them in fact are getting good relief and good effects. We know that they're unlikely to be switched when they're getting a positive response from their therapy. And we also know that when we contract across the Janssen and Johnson & Johnson portfolio, that it provides us a very important position with larger health care systems and networks. So that's the way we think about it, and that's the way we plan for it going forward."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Josh Jennings with Cowen and Company.",14,"Our next question comes from the line of Josh Jennings with Cowen and Company."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Louise, congratulations. I wanted to ask a question. Dominic, first, just the operating margin performance again kind of beat our expectations. You reiterated your guidance for the year on the operating margin expansion side of things. But I just wanted -",140,"Louise, congratulations. I wanted to ask a question. Dominic, first, just the operating margin performance again kind of beat our expectations. You reiterated your guidance for the year on the operating margin expansion side of things. But I just wanted -- there are multiple drivers of operating margin expansion, and there is -- you've had a program in place, I think you announced a couple of years ago and just started to ramp last year, about $1 billion in cost savings by '18. That was exclusive of the Medical Device restructuring plan. I just wanted to get a sense of the contribution to operating margin expansion this year, and if we're still in the very early innings and whether we should see stronger benefit from that cost-savings plan as well as the Medical Device restructuring initiative in '17 and '18."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. Well, Josh, you're right. There are many factors that contribute. I mean, GP is one. So we continue to see good manufacturing efficiencies and cost improvements across the supply chain. That's a major initiative we've had ongoing for quite some time.",268,"Yes. Well, Josh, you're right. There are many factors that contribute. I mean, GP is one. So we continue to see good manufacturing efficiencies and cost improvements across the supply chain. That's a major initiative we've had ongoing for quite some time. So we saw some of that benefit this quarter. We expect that we'll see it going forward as well. In the selling, market and administrative line, that's where you see the benefits of the program you were referring to, where we anticipate about $1 billion of savings for 2018. That program's on track. We're seeing the savings. We're also making some investments. As the investments tail off, the savings will be more significant and more impactful in that line item going forward. So we're beginning to see the savings now. They're somewhat partially offset by some investments we need to make to continue the program. But in the future, those investments tail off and the savings ramp up, and there -- have more of an impact. And then also, as you mentioned, the Medical Device restructuring is a whole another area that's unrelated to the 2 that I just mentioned earlier and that we expect to see continued improvements there, although that's a business where we want to also accelerate the pace of innovation with those savings. So some of those will be reinvested in the business. So it's across those 3 areas, and we're committed to the operating margin improvement that I've mentioned earlier of greater than 200 basis points. And halfway through the year, we feel very good about our ability to achieve that."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Excellent. And I just wanted to have a follow-up maybe for Alex and Louise. Just that you commented on utilization levels in the U.S. and procedure volumes, and I -- you experienced just a modest apples-to-apples in selling days from sequentially modest d",71,"Excellent. And I just wanted to have a follow-up maybe for Alex and Louise. Just that you commented on utilization levels in the U.S. and procedure volumes, and I -- you experienced just a modest apples-to-apples in selling days from sequentially modest deceleration in knees and hips and spine or in the ortho segment. Is there anything specific to Q2 that you're seeing in the marketplace that you can comment on?"
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Now look, overall -- and thank you for the question. Overall, I think we saw solid growth in both knees and hips. I think we're at about 4.5% in knees, about 5%, 5.5% in hips. And we think that that's continued pick-up from the ATTUNE launch and the CORAI",79,"Now look, overall -- and thank you for the question. Overall, I think we saw solid growth in both knees and hips. I think we're at about 4.5% in knees, about 5%, 5.5% in hips. And we think that that's continued pick-up from the ATTUNE launch and the CORAIL hip. So I would say that, consistent with what we're seeing in the broader market, consistent with what we're seeing in our business, we're seeing positive growth in that area."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","And for the OUS business, it was about an additional 1.5 days of selling days in the second quarter. And in the first quarter, we had additional selling days in the U.S. business, so that's a reminder on that one.",40,"And for the OUS business, it was about an additional 1.5 days of selling days in the second quarter. And in the first quarter, we had additional selling days in the U.S. business, so that's a reminder on that one."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Joanne Wuensch with BMO Capital Markets.",14,"Our next question comes from the line of Joanne Wuensch with BMO Capital Markets."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","I appreciate the commentary on the volumes. But I was curious if you can give us a commentary on pricing, and also with the April 1 implementation of the bundled payment program in the United States, if you're seeing any impact from that.",43,"I appreciate the commentary on the volumes. But I was curious if you can give us a commentary on pricing, and also with the April 1 implementation of the bundled payment program in the United States, if you're seeing any impact from that."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","So we talk about pricing on a Johnson & Johnson basis. And overall, pricing is modest in the quarter.",18,"So we talk about pricing on a Johnson & Johnson basis. And overall, pricing is modest in the quarter."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","I would say, Joanne, that we haven't seen the impact yet in that particular new mechanism that you've just described. As Louise pointed out, pricing overall for the quarter, our year-over-year growth due to pricing is very, very modest in our results.",42,"I would say, Joanne, that we haven't seen the impact yet in that particular new mechanism that you've just described. As Louise pointed out, pricing overall for the quarter, our year-over-year growth due to pricing is very, very modest in our results."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","I can provide some further color on hips and knees in the U.S. Price/mix, if you'd like?",18,"I can provide some further color on hips and knees in the U.S. Price/mix, if you'd like?"
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","That would be wonderful.",4,"That would be wonderful."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","So the second quarter for the hips was about 2.2% negative, price/mix together, and this is U.S. only. And for knees, it was about 2.6% negative. And that's similar trends to what we've seen consistently over time.",38,"So the second quarter for the hips was about 2.2% negative, price/mix together, and this is U.S. only. And for knees, it was about 2.6% negative. And that's similar trends to what we've seen consistently over time."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And then as to my second question had to do more with Vision Care, we saw a real difference between what was happening in the U.S. and what's OUS sales. And you commented on rebates. Is that the replacement program for UPP that we're seeing in that U.S. i",49,"And then as to my second question had to do more with Vision Care, we saw a real difference between what was happening in the U.S. and what's OUS sales. And you commented on rebates. Is that the replacement program for UPP that we're seeing in that U.S. impact?"
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","So it's a customer reward program that we have implemented. And what we have booked in the second quarter is the year-to-date because it was implemented in the second quarter, but it replies [ph] to the full year sales. So in the U.S., if you normalized i",67,"So it's a customer reward program that we have implemented. And what we have booked in the second quarter is the year-to-date because it was implemented in the second quarter, but it replies [ph] to the full year sales. So in the U.S., if you normalized it for the half that applied to the first half, the U.S. is up about 6% on a like basis."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","And look, we continue to be very pleased with what we're seeing in the turnaround in our Vision Care business as well. If we look at the early demand signals that we're seeing, it continues to give us confidence that we're gaining share. We continue to la",91,"And look, we continue to be very pleased with what we're seeing in the turnaround in our Vision Care business as well. If we look at the early demand signals that we're seeing, it continues to give us confidence that we're gaining share. We continue to launch into beauty, astigmatism, reusables, along with a number of other new launches and line extensions. And frankly, the team is also really executing well. So we're encouraged by the opportunity that we see in Vision Care as we move through the rest of 2016."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Glenn Novarro with RBC Capital Markets.",14,"Our next question comes from the line of Glenn Novarro with RBC Capital Markets."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Louise, I echo the sentiments, so best of luck in the future. My question is for Alex and for Dominic. And I asked a similar question on the last quarterly call because I continue to be surprised that J&J is not doing more with its cash, particularly on t",137,"Louise, I echo the sentiments, so best of luck in the future. My question is for Alex and for Dominic. And I asked a similar question on the last quarterly call because I continue to be surprised that J&J is not doing more with its cash, particularly on the M&A front. You've done Vogue, but we haven't seen much in the way of at least meaningful acquisition on devices and on pharma. And so my question is, the targets that you're having discussions with today, do they still have very unrealistic valuation expectations? And is that the reason why we haven't seen deals in devices and in pharma? And then as a follow-up, you still have a bulk of your cash sitting outside the United States. Is that another reason why we haven't seen any meaningful acquisitions?"
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Well, sure, Glenn. Well, consistent with what we said last time when you asked a very similar question, we -- as you know, we're very disciplined in our approach to acquisitions. And although we're actively involved in considering them, valuations come in",291,"Well, sure, Glenn. Well, consistent with what we said last time when you asked a very similar question, we -- as you know, we're very disciplined in our approach to acquisitions. And although we're actively involved in considering them, valuations come into play. And willingness of the other party to do an acquisition at certain valuations come into play. So that's regardless of how much money we have available to spend, right? So we don't really look at that as the main driver of how we're going to do acquisitions. We look at what value we're going to create for shareholders by doing the acquisition at the right value so we can improve returns for our shareholders. There are some expectations that are still not, in our opinion, normalized for appropriate valuations in the market, so that's a factor. And that will take time, and we're patient with that. And then we'll take -- we'll see how the market evolves over time or as we learn more about the acquisition candidates and their progress in various areas. And then finally, whether or not the cash is trapped overseas or not is not at all an impediment to our ability to do any acquisitions. We'll either obviously try to find a way to do it in a tax-efficient basis as we've done with other acquisitions and utilize that cash as much as possible, only if it's tax efficient. But then, obviously, we can continue to borrow, and we have the ability to borrow to do the acquisitions that we think are value-creating for our shareholders. So we wouldn't let that hold us back. Should the acquisition be value-creating, we'd exercise what -- we'd exercise our ability to borrow to do that acquisition."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And just as a follow-up -- go ahead, Alex. Did you want to add something?",16,"And just as a follow-up -- go ahead, Alex. Did you want to add something?"
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, Glenn. I guess what I would also say is, look, I think that our -- the M&A approach that we talked about in the past is a balanced one. I mean, if you look over the last 20 years, I think we've done about 124 deals. I think there's been about 13 or s",193,"Yes, Glenn. I guess what I would also say is, look, I think that our -- the M&A approach that we talked about in the past is a balanced one. I mean, if you look over the last 20 years, I think we've done about 124 deals. I think there's been about 13 or so that have been over $1 billion. But majority of these have been smaller. And frankly, if you look at our pharmaceutical performance and whether it's the partnerships that we have on a compound like IMBRUVICA, DARZALEX, others, I think the strategy has worked really well and it's something that we'll continue to pursue. I think we have a lot of examples of that in Medical Devices and also Consumer. And there's nothing that we would like more than to take a several hundred million-dollar platform like Vogue and create the next multibillion-dollar platform as we see in things like NEUTROGENA and others. So all that being said, if and when we see larger opportunities present an opportunity to really create longer-term shareholder value, those are things we'd certainly be interested in, but we'll be particularly thoughtful about those."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And just one quickly on REMICADE. I know Matt had asked a question on REMICADE, but you remain very confident that a biosimilar won't be launched in 2016. Has anything changed that you can reveal to us on the litigation front that gives you more confidenc",46,"And just one quickly on REMICADE. I know Matt had asked a question on REMICADE, but you remain very confident that a biosimilar won't be launched in 2016. Has anything changed that you can reveal to us on the litigation front that gives you more confidence?"
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Glenn, well, what we said is that our guidance does not assume any biosimilar launch in 2016. There's ongoing developments in the litigation. There's a hearing scheduled for August related to the '471 patents. We'll have to see how that -- what the result",169,"Glenn, well, what we said is that our guidance does not assume any biosimilar launch in 2016. There's ongoing developments in the litigation. There's a hearing scheduled for August related to the '471 patents. We'll have to see how that -- what the results of that hearing are. So we don't know that yet. There was also a ruling issued in relation to another biosimilar, not our biosimilar, which made it very clear when the 180-day waiting period applies. And for us, that 180-day waiting period extends to October 6. Well, obviously, there cannot be any launch before that date. And then as we've mentioned, we're continuously and vigorously defending our patent, and we'll continue to do that. So whether or not a biosimilar launch happens is uncertain. But we have not included it in our guidance estimates. But as you know, our guidance, of course, is a range, and between certain ranges of 3% to 4% and overall growth. So we feel confident about that in any event."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of David Lewis with Morgan Stanley.",13,"Our next question comes from the line of David Lewis with Morgan Stanley."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Congrats, Louise. Once again, echo other sentiments. So just 2 quick questions, now that we're near the end. So Dominic, I'm trying to reconcile revenue guidance just on the margins. So if I take the upside in the quarter plus the net impact of M&A, sort",98,"Congrats, Louise. Once again, echo other sentiments. So just 2 quick questions, now that we're near the end. So Dominic, I'm trying to reconcile revenue guidance just on the margins. So if I take the upside in the quarter plus the net impact of M&A, sort of Vogue minus the API business, I kind of get -- guidance should come up sort of $700 million. It's coming up around $300 million. Is that difference in the back half of the year largely an expectation for lower or minimal gross-to-net adjustments in the back half versus the first half?"
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Well, certainly, as I mentioned earlier, the gross-to-net adjustments that we saw in the first half have now resulted in our overall estimates for these amounts as being largely current, greater than 90% current. But therefore, we wouldn't expect to have",54,"Well, certainly, as I mentioned earlier, the gross-to-net adjustments that we saw in the first half have now resulted in our overall estimates for these amounts as being largely current, greater than 90% current. But therefore, we wouldn't expect to have the same level of those kinds of adjustments going forward, David. That's right."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay, helpful. And then maybe 2 questions on Consumer, one for Alex and one for Dominic. I mean, Dominic, just to start with you on margins. I think we'd left the Analyst Day feeling that Consumer margin outlook was probably conservative. But if I look at",110,"Okay, helpful. And then maybe 2 questions on Consumer, one for Alex and one for Dominic. I mean, Dominic, just to start with you on margins. I think we'd left the Analyst Day feeling that Consumer margin outlook was probably conservative. But if I look at the reported results in the quarter, I mean, you're well ahead of expectations and pursuing that sort of peer-based 20% Consumer margin. So how do we think about that? Is that simply onetime in nature? Or is it much more likely now you reasonably exceed your targets either in time or magnitude here in Consumer? And then a quick follow-up for Alex in Consumer."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Well, as you know, we were committed to this. And as Jorge Mesquita said in the business review day, he was personally committed to making it happen. And we're very pleased to see that they're off to a great start. Whether they exceed the overall benchmar",118,"Well, as you know, we were committed to this. And as Jorge Mesquita said in the business review day, he was personally committed to making it happen. And we're very pleased to see that they're off to a great start. Whether they exceed the overall benchmark level in a shorter amount of time, that will -- we'll wait to see. Because obviously, we want to see them investment behind brands and keep the momentum up in the business as well. But we're obviously off to a great start. We were confident that they would be able to do it. And they've done a great job, and we're confident they'll continue to do a great job in improving margins."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Okay. And then, Alex, I think many investors had felt that Consumer was sort of kept in the closet here the last several years, and clearly, the last 6 months, the company's working hard to sort of show the Consumer franchise, and to a greater extent, bot",120,"Okay. And then, Alex, I think many investors had felt that Consumer was sort of kept in the closet here the last several years, and clearly, the last 6 months, the company's working hard to sort of show the Consumer franchise, and to a greater extent, both margins and growth. Yes, my question's more on growth. If I ex out Venezuela in the quarter, Consumer did about 5% growth. I felt like the messaging from Jorge and others was, yes, this business can be sort of an upper single-digit grower with obviously expanding margins. What is your sense in that 5% number ex-Venezuela? I mean, do you feel confident here that Consumer is stable and can improve from these levels?"
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes, David. Thank you very much. And again, let me reiterate. We're really pleased with the performance that we continue to see in the Consumer group. And literally, from quarter-to-quarter, it continues to improve in not only its core performance but mar",164,"Yes, David. Thank you very much. And again, let me reiterate. We're really pleased with the performance that we continue to see in the Consumer group. And literally, from quarter-to-quarter, it continues to improve in not only its core performance but market share and a number of other areas. We feel like the majority of the platforms right now, we're actually gaining share. At the same time, we realize we've got some areas such as Baby, such as China, where we need to do a better job, and the team is focusing on that, in addition to the margin improvement that Dominic was talking about earlier. But overall, our goal is to grow faster than the market. We think we currently are. It's something that we want to do and accelerate as we go forward. And I'm very confident that Jorge and his team have got the strategies and are now executing in a manner that's going to allow them to do just that."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Danielle Antalffy with Leerink Partners.",13,"Our next question comes from the line of Danielle Antalffy with Leerink Partners."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Louise, we're really going to miss you. Question for you, Alex, just higher level. Sorry to do this. But following-up on the M&A commentary, some of your competitors have been acquiring scale, most recently Abbot and St. Jude. And I know J&J is already in",136,"Louise, we're really going to miss you. Question for you, Alex, just higher level. Sorry to do this. But following-up on the M&A commentary, some of your competitors have been acquiring scale, most recently Abbot and St. Jude. And I know J&J is already in a competitively advantageous position, given your current product lines. But cardiovascular is an area where you're specifically under-scaled relative to some of those other competitors. Now I was just wondering if you could comment on whether you think it's important to build scale within cardiology to be -- to continue to be a major competitor in med tech or if you think there's other areas where J&J is already positioned and will continue to focus on. I'm just trying think about the different subsectors within med tech where you'll focus most."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. Thanks, Danielle. Look, consistent with what we said previously, we do think that there's an opportunity for expansion in cardiovascular. And for us, really, it started several years ago when we made the decision to exit the stent business. We did th",246,"Yes. Thanks, Danielle. Look, consistent with what we said previously, we do think that there's an opportunity for expansion in cardiovascular. And for us, really, it started several years ago when we made the decision to exit the stent business. We did the divestment of Cordis, which I think the team executed really well. And look, we think now the greater focus that we have, what you're seeing as a result of that, frankly, is better growth, not only in our cardiovascular business, the Biosense Webster, but across the greater Hospital Medical Device business that we have. But we know that going forward, other areas in cardiovascular, ranging from valves to structural heart to others, could definitely be opportunities. But we're going to continue to see how the technology evolves, how the markets evolve. And that -- and fortunately, I think we're positioned in a way that gives us a lot of different opportunities. And at the same time, I would say that there other areas in Medical Devices that we remain interested in. We've talked about the Vision Care area. It's one where you have a very strong contact lens platform. But we think there's opportunities, be it back of the eye, surgery and other spaces that, that business could be augmented. And we'll continue to look for other thoughtful plays in orthopedics as well as in general surgery that offer growth opportunities and help us better address areas of unmet medical need as well."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Jami Rubin with Goldman Sachs.",13,"Our next question comes from the line of Jami Rubin with Goldman Sachs."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","And Louise, I'm really going to miss talking to you. You've been extremely helpful over the years. Dominic, I'm sorry to belabor the gross-to-net adjustment. But I'm unclear as to how it occurred and what it means. And I think more importantly, these are",201,"And Louise, I'm really going to miss talking to you. You've been extremely helpful over the years. Dominic, I'm sorry to belabor the gross-to-net adjustment. But I'm unclear as to how it occurred and what it means. And I think more importantly, these are all categories, REMICADE, STELARA, SIMPONI, ZYTIGA, which are crowded categories. And can you comment on what's happening with respect to gross to net -- the gap between gross to net and how it's changed over the last year or 2? If it has changed at all, are you able to take the same sort of list price that you had before, without having to pay a higher rebate? If you can just kind of comment on that, generally. And then also my follow-up question relates to INVOKANA. Sales, again, were -- continue to be very strong. You're showing nice improvements in market care [ph]. What are your expectations for the whole SGLT2 class? I'm sure you've paid attention to the FDA panel meeting on Jardiance and whether or not Jardiance will get a superior label with respect to CV mortality reduction? And if it does get that label update, what that might mean to INVOKANA going forward?"
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Sure, Jami. Let me take the first question on gross to net, and then Alex will cover the SGLT2 commentary. So U.S., how does it occur and what's going on with list price versus net price and those sorts of things. So just to put it in perspective, this is",251,"Sure, Jami. Let me take the first question on gross to net, and then Alex will cover the SGLT2 commentary. So U.S., how does it occur and what's going on with list price versus net price and those sorts of things. So just to put it in perspective, this is not unusual in our industry, as you know. Everyone in the pharmaceutical industry is estimating what the rebates might be. And then, of course, we'll actualize them once actual data is submitted. Recently, that actual data has been more timely. And in that more timely data from the payers, we're able to see trends, so we're able to not only actualize prior-period amounts, but we're also able to estimate better what the ultimate gross-to-net variation will be going forward. With respect to list price net of rebates, as you probably know, we said this before, we think we price our products responsibly and our overall list price increases have been relatively below -- substantially below the average industry. But in the end, the net price that's achieved is far from the gross price increase that happened. So rebates continue to be an increasing part of the business, and the overall realization of gross price to net price, that delta is expanding, I would, say over time. And therefore, as I said, now, we're much more current with our ability to predict these estimates, and that's what's going on. And as I mentioned, we don't expect to see significant adjustments in [indiscernible]."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","So you're saying the gap is going to continue to grow. But you overestimated the growth of that gap, and that, therefore, is the adjustment. But big picture, you expect the gap to grow.",35,"So you're saying the gap is going to continue to grow. But you overestimated the growth of that gap, and that, therefore, is the adjustment. But big picture, you expect the gap to grow."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","That's right.",3,"That's right."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","And Jami, regarding INVOKANA and the class, look, first of all, we are pleased with the performance -- the continued performance of INVOKANA in the market. I mean, it remains the #1 SGLT2 in the U.S., both in new and total scripts. I think we've got betwe",223,"And Jami, regarding INVOKANA and the class, look, first of all, we are pleased with the performance -- the continued performance of INVOKANA in the market. I mean, it remains the #1 SGLT2 in the U.S., both in new and total scripts. I think we've got between 9 million and 10 million prescriptions that have already gone out since launch. That being said, we still think that there is a good opportunity for growth in INVOKANA. We've got a very strong clinical profile that's well documented, strong access across managed care. And look, we're confident that given the experience that ACPs have had with it, combined with its profile, that's going to continue to grow. Regarding the broader issues around the class, look, we think that it's really good news, frankly, for type 2 patients, given some of the news that's coming out about CV benefits. And really, regardless of the eventual decision by the FDA regarding potential claims for other agents, we're looking forward to seeing the results of our CANVAS program that will be coming out in about a year. And we'll have to see if these ongoing CV outcome trials validate some of the current perceptions of KOLs regarding the cardiovascular effects of SGLT2 inhibitors across the drug class. We'll see. But overall, we think it's good news for patients."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our next question comes from the line of Vamil Divan with Crdit Suisse.",13,"Our next question comes from the line of Vamil Divan with Crdit Suisse."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Congrats again to Louise. Just following up on Jami's question on the gross-to-net commentary. Just -- I don't think you touched on this. But specifically, on Immunology, it seems a lot of those products, in particular, saw that benefit. Is there anything",163,"Congrats again to Louise. Just following up on Jami's question on the gross-to-net commentary. Just -- I don't think you touched on this. But specifically, on Immunology, it seems a lot of those products, in particular, saw that benefit. Is there anything that you're seeing in that specific market that may be causing the difference there to be greater than what you see with your -- in the other therapeutic areas? And then one other unrelated, just on IMBRUVICA, it came in a little bit lighter than what we were expecting. Obviously, a lot of good data and a lot of growth ahead. But maybe if you could just comment on the trend you're seeing there. And also it's -- I guess, it's been about a year now since you now have a new partner on that product with Pharmacyclics being acquired by AbbVie. Just the dynamics in that partnership and how you see that relative to what you're seeing previously with Pharmacyclics."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","So let me take the -- Vamil, there's nothing substantially different between biologics and others, other than the biologics products tend to have a longer delay in terms of receiving the information. So therefore, there may be more adjustments related to",70,"So let me take the -- Vamil, there's nothing substantially different between biologics and others, other than the biologics products tend to have a longer delay in terms of receiving the information. So therefore, there may be more adjustments related to those products in any particular period. But other than that, there's no other significant trend that we're seeing that's any different than what we see overall in the market."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","And look, regarding IMBRUVICA, no, we're very pleased with the continued launch uptake that we see with it. It continues to be strong, good increase versus last year. And look, IMBRUVICA's also maintaining really good total patient market leadership in CL",91,"And look, regarding IMBRUVICA, no, we're very pleased with the continued launch uptake that we see with it. It continues to be strong, good increase versus last year. And look, IMBRUVICA's also maintaining really good total patient market leadership in CLL line 2, plus mantle cell lymphoma as well as WM in the U.S. We have additional approvals and line indications done in other markets as well. So we continue to be pleased with the performance and look forward to getting out additional information and additional indications on the countdown [ph]."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Yes. And just on the quarter, there's additional -- we have a patient assistance program, and there's a little bit of bump in that. So that may have -- that's probably the trend difference that you see.",37,"Yes. And just on the quarter, there's additional -- we have a patient assistance program, and there's a little bit of bump in that. So that may have -- that's probably the trend difference that you see."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Our final question comes from the line of Jayson Bedford with Raymond James.",13,"Our final question comes from the line of Jayson Bedford with Raymond James."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Analysts","Just to clarify and kind of follow-up on an earlier question. U.S. Med Device growth in the quarter decelerated from first quarter levels. International growth accelerated. There was quite a big difference in growth in these 2 geographies. It sounds like",63,"Just to clarify and kind of follow-up on an earlier question. U.S. Med Device growth in the quarter decelerated from first quarter levels. International growth accelerated. There was quite a big difference in growth in these 2 geographies. It sounds like this is more a function of selling days with no real change in the operating environment. Is that a fair characterization?"
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","So in the OUS, we have an additional 1.5 selling days on average. That contributes to the OUS growth about 220 basis points. But on top of that, we're seeing strong market growth in China. We have some strong markets in Russia. Australia in the hips. And",98,"So in the OUS, we have an additional 1.5 selling days on average. That contributes to the OUS growth about 220 basis points. But on top of that, we're seeing strong market growth in China. We have some strong markets in Russia. Australia in the hips. And then we're seeing nice growth in the CORAIL. Also seeing some nice growth in the ATTUNE. So it's a combination of both the selling days, but if you strip out the 220 basis points for selling days OUS, you're still seeing really nice strong growth in both hips and knees OUS."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","And Jayson, one thing I would add to that is when we're talking about the Medical Device business, obviously, there's some dynamics in diabetes and some dynamics that we talked about earlier with Vision Care with the customer loyalty program. So if you lo",91,"And Jayson, one thing I would add to that is when we're talking about the Medical Device business, obviously, there's some dynamics in diabetes and some dynamics that we talked about earlier with Vision Care with the customer loyalty program. So if you look at the hospital-based Medical Device business and you exclude the impact of acquisitions and divestitures, that growth did accelerate. So the second quarter growth at about 4.7%, and first quarter growth at about 4.2%. So on the base Hospital Medical Device business, overall, we're seeing accelerated growth."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","We'll have some final remarks from Alex.",8,"We'll have some final remarks from Alex."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Executives","Okay. Well, thank you very much, everyone, for joining us this morning. And as I noted earlier, look, we're really pleased with the continued momentum as evidenced by our increased guidance for both sales and earnings for the full year 2016. Look, I rea",149,"Okay. Well, thank you very much, everyone, for joining us this morning. 
And as I noted earlier, look, we're really pleased with the continued momentum as evidenced by our increased guidance for both sales and earnings for the full year 2016. Look, I really believe that some of the clear strategic choices that we've been making, the really strong focus on execution, combined with an incredibly talented group of leaders that I'm honored and humbled to be able to work with every day at Johnson & Johnson, are enabling us to really deliver extraordinary achievements and results that we've just been able to share with you and to really build on the success of Johnson & Johnson going forward. 
So thank you for your time this morning. I look forward to updating you on the progress throughout the year, and I hope everybody has a great day. Thank you."
139677,367223456,1008198,"Johnson & Johnson, Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Johnson & Johnson","Operator","Thank you. This concludes today's Johnson & Johnson Second Quarter 2016 Earnings Conference Call. You may now disconnect.",18,"Thank you. This concludes today's Johnson & Johnson Second Quarter 2016 Earnings Conference Call. You may now disconnect."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Good morning, and welcome to the Johnson & Johnson Third Quarter 2016 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] I would now like",52,"Good morning, and welcome to the Johnson & Johnson Third Quarter 2016 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] 
I would now like to turn the conference call over to Johnson & Johnson. You may begin."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Good morning. I'm Joe Wolk, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure to welcome you to the review of our business results for the third quarter of 2016.  Joining me on the call today are Dominic Caruso, Chief Finan",1968,"Good morning. I'm Joe Wolk, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure to welcome you to the review of our business results for the third quarter of 2016.  Joining me on the call today are Dominic Caruso, Chief Financial Officer; Joaquin Duato, Worldwide Chairman, Pharmaceuticals; and Dr. Bill Hait, Global Head of Pharmaceutical Research and Development. 
A few logistics before we discuss the results. This review is being made available via webcast, accessible through the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. 
I will begin today's presentation by briefly reviewing the third quarter sales and earnings results for the corporation and sales results for each of our 3 business segments. Next, Joaquin and Bill will provide an update on our Pharmaceutical business, specifically highlighting how our focus on innovation to address unmet medical needs translates to current and future strong performance. Dominic will then provide some additional commentary on the results, review the income statement and discuss guidance for 2016. Lastly, we will open the call to your questions. We expect today's call to last approximately 90 minutes. 
Included with the press release issued earlier this morning is the schedule of sales for key products and businesses to facilitate updating your models. These schedules are available on the Johnson & Johnson website, as is the press release. Please note, we will be using a presentation to complement today's commentary. The presentation is also available on our website. 
I'd like to remind you that some of the statements made during this review are or may be considered forward-looking statements. The 10-K for fiscal year 2015 and the company's subsequent filings identify certain factors that could cause the company's actual results to differ materially from those projected in any forward-looking statements made here today. The company does not undertake to update any forward-looking statements as a result of new information or future events or developments. 
During the review, non-GAAP financial measures are used to provide information pertinent to ongoing business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with GAAP results. Tables reconciling these measures to the most comparable GAAP measures are available in the schedules accompanying the press release and on the Investor Relations section of the Johnson & Johnson website. 
During the course of today's presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. This slide is an acknowledgment of those relationships. 
I would now like to review our results. Worldwide sales to customers were $17.8 billion for the third quarter of 2016, up 4.2% versus the third quarter of 2015. On an operational basis, sales were up 4.3% and currency had a negative impact of 0.1%. 
In the U.S., sales were up 6.7% while regions outside the U.S. were up 1.5%, comprised of 1.7% operational growth, partially offset by negative impact of currency exchange rates of 0.2%. On an operational basis, the Western Hemisphere, excluding the U.S., declined 1.3%. You may recall that we highlighted growth in the second quarter of 2016 being favorably impacted by an inventory build, which did reverse in the third quarter. Europe grew by 3.2% while the Asia-Pacific, Africa region grew 1.4%. 
Excluding the net impact of acquisitions and divestitures and hepatitis C, underlying operational sales growth was 5.9% worldwide, 7.3% in the U.S. and 4.2% outside the U.S. Additionally, operations in Venezuela reduced reported sales growth. Worldwide, this impact was a reduction of 30 basis points; and outside the U.S., 70 basis points. 
Turning now to earnings. Net earnings were $4.3 billion, and earnings per share were $1.53 versus $1.20 a year ago. As referenced in the table reconciling non-GAAP measures, 2016 third quarter net earnings were adjusted to exclude after-tax amortization expense of $236 million and a charge of $175 million for after-tax special items. Dominic will discuss special items in his remarks. 
Excluding amortization expense and special items for both periods, adjusted net earnings for the current quarter were $4.7 billion, and adjusted diluted earnings per share were $1.68, representing increases of 12.2% and 12.8%, respectively, as compared to the same period in 2015. On an operational basis, adjusted diluted earnings per share also grew 12.8%. 
Beginning with Consumer, let's now turn to segment highlights for the quarter. Please note that the percentages quoted for all segments represent operational sales change in comparison to the third quarter of 2015 unless otherwise stated and, therefore, exclude the impact of currency translation. 
Worldwide Consumer segment sales totaled $3.3 billion, increasing 0.1% from the third quarter of 2015. U.S. sales were up 1.1% while sales outside the U.S. declined 0.6%. Excluding the net impact of acquisitions and divestitures, underlying sales fell 0.4% worldwide, with a decline of 1.5% in the U.S. and growth of 0.3% outside the U.S.  
In addition, operations in Venezuela negatively impacted growth worldwide and outside the U.S. by 110 basis points and 180 basis points, respectively, with the most pronounced impact occurring in Women's Health. Growth was driven by worldwide Skin Care and OTC sales outside the U.S. Baby Care experienced declines over the third quarter of 2015. 
Performance in the Consumer segment was negatively impacted by slower market growth and reductions of customer inventory levels. Overall, the impact of inventory reduction was approximately 3 points on Worldwide Consumer sales growth for the quarter, with the most pronounced effect on OTC and Skin Care results. Dominic will discuss these factors in further detail later in the call. 
OTC sales grew 1.8% worldwide. Results were driven by strong consumption in smoking cessation products across Europe and new product launches in Europe and Asia. U.S. sales growth due to share gains was partially offset by trade inventory levels impacting growth in the U.S. by approximately 10 points, where, as highlighted, for the third quarter of 2015, the business experienced launch build in pain, allergy and digestive health. Also, a weak allergy season in the U.S. during 2016 negatively impacted inventory levels in the third quarter of 2016. In the U.S., adult analgesic market share was approximately 14%, up from 13% a year ago, while U.S. pediatric share was approximately 49%, up from 44% a year ago. 
Skin Care grew 12.2% worldwide and 18.9% in the U.S. These results include the sales from the recent Vogue, NeoStrata acquisitions, which are captured in the U.S. O-U.S. results were driven by stocking of  Dabao products in China and share gains in Latin America. Inventory levels negatively impacted worldwide sales growth by 3 points. Successful marketing campaigns and new products continue to drive the results for LISTERINE in Oral Care. Divestitures impacted sales growth in Wound Care/Other and Women's Health categories. 
Moving now to our Pharmaceutical segment. Worldwide sales of $8.4 billion increased 9.0%, with U.S. sales up 11.8% and sales outside the U.S. up 5.0%, driven by strong performance of new products as well as growth from our core products. Excluding sales of hepatitis C products, OLYSIO and INCIVO, as well as the impact of acquisitions and divestitures, underlying worldwide sales growth was 10.7% as sales in the U.S. were up 13.0%; and outside the U.S., up 7.0%. Contributors to growth included Immunology products, REMICADE, SIMPONI and STELARA; Oncology products, IMBRUVICA and DARZALEX; as well as INVEGA SUSTENNA/XEPLION/TRINZA and XARELTO. 
In Immunology, REMICADE, STELARA and SIMPONI/SIMPONI ARIA achieved strong growth in the U.S. due to market growth and increasing share for STELARA. The results reported for REMICADE export sales was driven entirely by a change in inventory levels accounting for approximately 90 points of growth. Specifically, there was an inventory build of approximately $55 million in the current period and $110 million impact from lower level inventories that we noted in the third quarter of 2015 results. 
Biosimilar competition continues to negatively impact performance of export sales. 
In Neuroscience, INVEGA SUSTENNA/XEPLION/ TRINZA achieved strong results, with worldwide sales growth of 21% due primarily to increased market share. As expected, during the quarter, we saw the impact from generic entries for INVEGA tablets in the U.S. 
In Oncology, strong patient uptake with new indications, approvals and demonstrated efficacy drove results for IMBRUVICA in the U.S. Sales increased 92% worldwide, and IMBRUVICA remains the leader in both new and total patient regimen share in second-line CLL and MCL. 
Outside the U.S., IMBRUVICA continues to experience strong adoption in Canada, in the G5 and has recently launched in Japan, Hong Kong and Korea. 
ZYTIGA sales grew 5.3% worldwide. In the U.S., market growth was essentially flat while market share was up almost 2 points sequentially. Sales outside the U.S. were tied to share gains in Japan and adoption in China since the launch in January of this year. 
DARZALEX continues to gain strong acceptance as a treatment for multiple myeloma and contributed approximately 2 points of Worldwide Pharmaceutical sales growth. 
Turning to Cardiovascular and metabolics. XARELTO continued strong share performance, with TRx market share up 1.7 points versus Q3 of 2015 to 17.5%. Warfarin represents approximately 55% of the total market, down from 62% in the third quarter of 2015. XARELTO continues to be broadly reimbursed, with over 95% of commercial and Medicare Part D patients covered at the lowest branded product copay. 
INVOKANA/INVOKAMET sales declined 3%, with the U.S. down 8.7% due to an increase in price discounts. Some of the increase in discounts is attributable to higher copay program cost in the quarter. While the defined market of type 2 diabetes, excluding insulin and metformin, was up approximately 5%, TRx share was essentially flat to the third quarter of 2015. TRx share with endocrinologists was approximately 11% and approximately 6% with primary care. 
I'll now review the results of the Medical Device segment. Worldwide Medical Device segment sales of $6.2 billion increased 0.7% with U.S. sales increasing 1.4% and sales outside the U.S. decreasing 0.2%. 
As a reminder, Cordis was divested in the fourth quarter of 2015. Excluding the net impact of acquisitions and divestitures, underlying growth was 3.1% worldwide, with the U.S. up 2.3% and growth of 3.9% outside the U.S. Additionally, the devaluation of Venezuela impacted growth worldwide by 10 basis points and outside the U.S. by 30 basis points. 
Growth was driven by electrophysiology, Advanced Surgery, Vision Care and Orthopaedics, slightly offset by general surgery and Diabetes Care. Electrophysiology within Cardiovascular grew 16% worldwide, driven by continued share gains in the U.S. and Europe as the atrial fibrillation procedure market increases. Orthopaedics sales growth was driven by joint reconstruction and U.S. trauma. Pricing pressure continued across all major categories but was partially offset by positive mix in trauma and spine, continued success of the TFNA nailing system in trauma, the ATTUNE platform in knees and the  CORAIL primary stem in hips contributed to the sales results. 
Within Advanced Surgery, endocutters grew 14%, energy was up 10% and biosurgicals up 7%. The acquisition of NeuWave Medical, closed in the second quarter of this year, also contributed modestly to growth. 
Vision Care sales were higher by 5.5% worldwide as new products launched late last year continued on an upward trajectory across all regions. Worldwide general surgery declined by approximately 2% due to discontinuing certain products in Women's Health and hernia, partially offset by both market growth and share gains in sutures. Competitive pressures and price erosion continue to impact Diabetes Care. 
That concludes the segment highlights for Johnson & Johnson's third quarter of 2016. To assist with your models, this slide provides you with a summary of important developments that occurred during the quarter. 
It is now my pleasure to turn the discussion over to Joaquin Duato, Worldwide Chairman, Pharmaceuticals, to inform you about the state of the Pharmaceutical business and the progress made since our May 2015 Business Review Day. Joaquin?"
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thanks, Joe, and good morning, everyone. I'm very pleased to share an update on our Pharmaceutical sector. Since May 2015, when we last met, our Pharmaceuticals business has continued to flourish and remains the primary growth engine of Johnson & Johnson.",1845,"Thanks, Joe, and good morning, everyone. I'm very pleased to share an update on our Pharmaceutical sector. Since May 2015, when we last met, our Pharmaceuticals business has continued to flourish and remains the primary growth engine of Johnson & Johnson. Our market-leading innovative medicines are the foundation of our strong performance, with the vast majority of their growth coming from volume gains. We continue to pursue significant growth opportunities in terms of both penetration within existing indications and planned line extensions. 
Additionally, we have launched DARZALEX, the first of our 10 potential billion-dollars-plus NMEs. As a result, we remain confident that we'll continue to deliver strong growth through 2019 despite biosimilar competition and market dynamics. Our success is a result of our strong track record of execution. Our industry-leading pipeline has delivered 12 NMEs since 2011 and 8 Breakthrough Therapy designations since 2013. And for the fourth year, we are proud to have been named the #1 company in R&D and commercial productive innovation. 
Our focused execution has delivered 11 in-market, billion-dollars-plus brands. 10 of these brands are growing, and 6 of them are growing double digit. Cumulatively, sales from our medicines launched since 2011 are the second highest of any pharmaceutical company. Our R&D and commercial capabilities are a proven strong foundation for future growth. 
First, we will continue to focus on driving volume growth across our current market-leading brands through clinical differentiation. Second, we will accelerate the growth of these in-market brands through approximately 40 potential line extensions. Critically, 10 of these line extensions have more than $0.5 billion potential. Third, as we shared last year, we have a [indiscernible] pipeline investing in 10 potential billion-dollar-plus NMEs planned to be filed through 2019. Of these, we anticipate 5 to deliver significant growth opportunities in the near term. 
Since 2015, our expectations around these near-term opportunities have crystallized. Our latest information provides higher certainty that these products will succeed delivering higher value than originally anticipated. DARZALEX, launched last year, is significantly outperforming expectations. According to your own models, it is well on its way to becoming a multibillion-dollar brand. Sirukumab has just been filed in the U.S. and Europe. Guselkumab has just had very positive data versus Humira presented at the EADV, and we anticipate filing for psoriasis before year-end. 
Apalutamide has a broad clinical development program in both pre-metastatic and metastatic prostate cancer. We also are investigating it in combination with ZYTIGA and with our newly licensed PARP inhibitor, niraparib. Finally, esketamine is already in Phase III and recently received a second Breakthrough Therapy designation. Bill will provide additional clinical details on these near-term opportunities shortly. 
Finally, it is important to note that these 3 strategies will prepare us to deliver robust growth beyond 2019, paving the way for more than 25 potential next-generation NMEs in the 2020 to 2024 time frame. 
The strength of our in-market portfolio, complemented by our near-term line extensions and NME launches, will be more than offset upcoming headwinds, including those anticipated for REMICADE. 
We are fully prepared to execute a focused biosimilar readiness plan. Yesterday, the launch of a U.S. biosimilar to REMICADE was announced for later this year. However, the appeals process is still ongoing, and we believe any commercial launch of a biosimilar remains at risk. 
Biosimilars are very different from generics. For example, in Canada, Australia and Brazil, where there is already biosimilar competition to REMICADE, we have maintained more than 90% volume share. Our U.S. commercial team is ready for a potential biosimilar launch. 
I'm confident in our strategy for 3 reasons. First, with no biosimilar approved for interchangeability, REMICADE's significant long-term safety data, a strong advocacy from patients and clear physician preference means that the 70% of patients who are stable on REMICADE are highly unlikely to switch. Second, our patient assistance programs provide a leading market differentiator. Third, we are confident that we can continue to provide a cost-effective option in all channels. The current market is extremely competitive, and REMICADE ASP is already significantly lower than the list price 
Additionally, in developing innovative contracts, we can utilize the full breadth of our portfolio. 
Our Immunology franchise remains poised to grow through 2019. We have a strong market position and a deep near-term pipeline. Let me give you some examples. Already in rheumatoid arthritis, SIMPONI ARIA is the fastest-growing IV product in the U.S. and has higher new-to-brand share than REMICADE. Outside of the U.S., we continue to gain share with SIMPONI, too. Additionally, we plan to file 2 line extensions for SIMPONI ARIA in psoriatic arthritis and ankylosing spondylitis. Together with the recent submissions of sirukumab for the approval in the U.S. and Europe, we will further strengthen our leading position in Rheumatology. 
Turning to psoriasis. STELARA continues to be the #1 biologic in new-to-brand share in the U.S. and maintains clear share leadership in key markets internationally. One of our 10 potential billion-dollars-plus brands, Guselkumab, is expected to provide a significant boost to our leadership in psoriasis, and Bill will share more on this important upcoming filing. 
Finally, moving to Gastroenterology. The most exciting news is the recent launch of STELARA for Crohn's disease in the U.S. and its anticipated launch in Europe. There is tremendous unmet need in this debilitating disease. For example, 70% to 80% of Crohn's patients on anti-TNFs are not in remission at 1 year, and the patient population is expected to grow 50% over the next decade. This is the first in a series of line extensions, including UC, which will drive more than 35% of STELARA performance by 2019. 
Moving now to Cardiovascular and metabolics. INVOKANA continues to be a standout performer. Globally, it is the leading  SGLT2 inhibitor and the third largest known insulin diabetes medicine. Put into perspective, in the U.S., there have been more prescriptions filled for INVOKANA and INVOKAMET than all other  SGLT2 inhibitors combined. A total of more than 1.3 million patients are treated in the U.S. alone. 
As Joe mentioned earlier, INVOKANA's performance dipped this quarter due to temporary increased costs to administer copay patient access programs. However, I want to emphasize that this was a transitory event. Our return to growth will be driven by INVOKANA's strong access position across U.S. commercial plans and Medicare Part D and the recent approval of INVOKAMET XR. We are expecting our cardiovascular outcomes data to read out in mid-2017. 
XARELTO is another market leader in our Cardiovascular and metabolics portfolio, delivering double-digit growth every year since its launch in 2011. To date, XARELTO has already treated more than 3.8 million patients in the U.S. and is supported by an extremely robust published real-world dataset, including evidence from more than 91,000 patients demonstrating consistency with our clinical trials. As a result, it is broadly reimbursed, with more than 95% Medicare and commercial patients on formulary at the lowest branded copay. 
These considerable achievements are just a start. Approximately, 54% of potential patients are still utilizing Warfarin, presenting significant growth opportunities in current indications.  Additionally, there are 8 new indications seeking clinical studies underway as part of EXPLORER, the largest clinical development program within the anticoagulant space. If successful, the potential patient pull could increase more than fivefold. 
Turning to Neuroscience. INVEGA TRINZA is a growth catalyst for the entire long-acting therapy franchise. Notably, INVEGA TRINZA is the fastest-growing LAT in the U.S. It has also contributed to growing INVEGA SUSTENNA scripts 26% in the 13 months since launch. 
Significant opportunities for growth remain as only 11% of patients are treated with LATs in the U.S. 
Celebrating 10 years of innovation this year, our HIV portfolio has achieved approximately 20% growth annually and cumulative sales of more than $15 billion. Today, 25% of patients in developed markets are treated with a J&J HIV medicine. Our class-leading portfolio has benefited more than 1 million patients, and this legacy will continue with upcoming line extensions. When Prezista first launched, it was part of a 6-tablet regimen. The first upcoming line extension, darunavir single-tablet regimen, will reduce this number to 1, improving adherence and safety. Also, we expect 2 rilpivirine fixed-dose combinations, one with Gilead's TAF and another one with ViiV's dolutegravir, that will drive additional growth for 2019. 
Finally, let's move to our fastest-growing therapeutic area, Oncology. IMBRUVICA has led the recent growth of our oncology franchise, accelerating from a record-breaking global launch to clear market share leadership in total patients in the first-line chronic lymphocytic leukemia. Today, IMBRUVICA is reimbursed in 41 countries with world-class market access. Since launch, an additional 6 indications have been approved, and we anticipate an additional 7 new registrations ahead, 4 of which have $500 million-plus potential.  Together with a number of promising combination therapies in development, these new indications will usher in a very exciting future for IMBRUVICA. 
IMBRUVICA's leadership in Oncology is mirrored by our recently launched asset, DARZALEX. Only 3 months after its launch, DARZALEX became the #1 prescribed therapy in fourth-line and later multiple myeloma. From a launch-aligned sales perspective, DARZALEX has continued to far outpace its competitors. This first-in-class medicine has since been improved in the EU and Canada and is driving positive share trends in earlier therapy lines in the U.S. We are confident DARZALEX can become the standard of care in multiple myeloma and help even more than the 10,000 patients who have benefited already worldwide. 
Growth will continue to accelerate with the anticipated approval in second-line patient populations and the impressive data from the recently published CASTOR and POLLUX studies. An additional 5 Phase III trials are currently underway as well as development of a subcutaneous formulation. As Bill will detail, we have also seen some positive data that DARZALEX may be effective outside of multiple myeloma. What should be clear today is that all of our current market-leading medicines have significant potential for continued volume growth. 
Additionally, we have a multitude of promising potential line extensions across every therapeutic area, approximately 40 in total, by 2019. Of these, 10 have more than $0.5 billion potential. The remaining 30 potential line extensions are not insignificant.  Cumulatively, the line extensions for XARELTO and INVOKANA have the potential to drive $3 billion to $5 billion in incremental sales for the Cardiovascular franchise. We believe these new indications will be a key driver of our growth through 2019 even in the context of biosimilars and market dynamics. 
In my 6 years leading our Pharmaceutical sector, I have never been more excited and more positive about our future as I am today. We have significant growth potential throughout our portfolio with market-leading brands; 40 anticipated line extensions, 10 of which have more than $0.5 billion potential; and 10 NMEs with more than $1 billion potential to be filed by 2019. Combined, these factors will ensure that we continue to outpace the industry growth through 2019. 
It is now my privilege to turn the call over to Dr. William Hait, who heads up our R&D organization. Bill will provide additional detail about our pipeline that is set to deliver this groundbreaking treatments. Bill?"
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Joaquin. Good morning, everyone. My name is Bill Hait, and I'm the Global Head of Research and Development for the Janssen Pharmaceutical Companies of Johnson & Johnson. As Joaquin indicated, at Janssen, we believe that by continuing to execu",2101,"Thank you, Joaquin. Good morning, everyone. My name is Bill Hait, and I'm the Global Head of Research and Development for the Janssen Pharmaceutical Companies of Johnson & Johnson. 
As Joaquin indicated, at Janssen, we believe that by continuing to execute our current strategy, we will consistently deliver valuable products to patients with serious unmet medical needs and that this will sustain our leadership in the pharmaceutical industry. Our strength is built on a blend of deep internal scientific expertise with industry-leading collaborations through the work of Johnson & Johnson innovation. We continue to find efficiencies that produce savings that we invest in our pipeline, and our strategic focus creates an enviable track record. We are delivering against our anticipated 2015 to 2019 NME and LE results that will produce a cadence of significant clinical data, regulatory filings and approvals. For these reasons and the results I will describe today, Janssen has become one of the most productive and most respected pharmaceutical companies. 
Before I share with you the details of our pipeline progress, let me explain how and why we have been able to sustain industry-leading results. Our 5 end-to-end therapeutic areas span basic drug discovery through launch and life cycle management. This structure produces a focused, seamless R&D organization, promotes efficient phase transitions and ensures dedication to major unmet medical needs where there is compelling, translatable science. These 5 therapeutic areas concentrate on 11 high-priority disease areas through our disease area strongholds, nimble and efficient biotech-like teams embedded in the broader context of the therapeutic areas. Each disease area stronghold undergoes rigorous triennial review by our external scientific advisory board, receives a priority score and proportional funding of discovery and early development. 
Our therapeutic areas are supported by substantial research capabilities through our centers of excellence, including biotechnology; medicinal chemistry; diagnostics; clinical operations; and, most recently, oligonucleotide and nucleic acid chemistry, expertise garnered through the acquisition of Alios. Assets that transition into late development are prioritized into 3 categories to ensure that our investment of resources align with our most promising targets. Currently, our top 2 categories, which represent 40% of our assets and 80% of our overall late-development value, receives 60% of our investment. It is through this approach that we remain at the top of the industry in successful phase transitions and speed to market. 
Janssen has achieved considerable success, and we are poised to continuously deliver near- and long-term growth. Our balanced investment across all aspects of our pipeline allows us to enjoy a constant flow of important new data. We launched 12 new products since 2011. We received the most FDA approvals from 2011 to 2016 as well as 8 Breakthrough Therapy designations. 
For 4 consecutive years, we have been named the innovation leader by IDEA Pharma and became the partner of choice through the work of J&J innovation. And for the third consecutive year, Fortune Magazine ranked Janssen Pharmaceutical Companies of Johnson & Johnson #1 in the pharmaceutical category on its annual World's Most Admired Companies list. Our unwavering commitment to global public health is demonstrated by SIRTURO, the first new drug for the treatment of tuberculosis in over 40 years; as well as our work on new, convenient HIV combinations; the first prime-boost Ebola vaccine using Crucell's adenoviral vector and Bavarian Nordic's MVA vector; as well as new chewable forms of mebendazole for children with worm infestations. 
As Joaquin mentioned and as we highlighted at our 2015 Pharmaceutical Business Review Day, between 2015 and 2019, we plan on filing approximately 10 new drugs, each with a potential for greater than $1 billion in peak year sales and 40 line extensions. This slide highlights 10 of these, anticipated to be filed in the 2015 to 2019 time period, with peak year sales potential greater than $0.5 billion 
In addition, our early pipeline is rich in important assets that have the potential to file between 2020 and 2024. We are on track to deliver our anticipated NME and LE results through a cadence of significant clinical data, regulatory filings and approvals. Since May 2015, we garnered 3 new product approvals and filings, with the fourth, Guselkumab, anticipated this year, and we achieved 16 significant line extensions. 
Now let me use our time together to describe in greater detail some of the progress we have made since our May 2015 Pharmaceutical Business Review. Oncology is the newest of our 5 therapeutic areas and achieved industry-leading growth based on our development of several first-in-class drugs, including ZYTIGA, IMBRUVICA and DARZALEX. Our hem malignancies disease area is anchored by IMBRUVICA and DARZALEX. 
IMBRUVICA, the first BTK inhibitor for the treatment of certain B-cell malignancies, received 4 FDA Breakthrough Therapy designations. IMBRUVICA was recently approved for frontline use, based on the unprecedented results in previously untreated CLL patients reported in the RESONATE-2 study published in the December 15 issue of the New England Journal. As shown on this slide, treatment with ibrutinib decreased progression or death from CLL by 84% compared to chlorambucil and demonstrated a similar improvement in overall survival. 
DARZALEX, the first monoclonal antibody for the treatment of multiple myeloma, received 2 FDA Breakthrough Therapy designations and was approved almost 4 months ahead of its PDUFA date in double-refractory myeloma. As shown on this slide, combination therapy with DARZALEX delivered impressive results in treatment of relapsed or refractory multiple myeloma patients. The CASTOR and POLLUX studies demonstrated that the addition of DARZALEX to Zalcaid and [indiscernible] or revlimine in [indiscernible], respectively, produced a greater than 60% decrease in risk of progression or death as compared to [indiscernible] or [indiscernible] alone, both of these studies were published in the New England Journal. 
This month, the FDA granted priority review for daratumumab in combination with [indiscernible] and [indiscernible] or [indiscernible] and [indiscernible] for relapsed multiple myeloma with the PDUFA date in February 2017. 
Our prostate cancer disease area is anchored by Zytiga, the first set 17 inhibitor for the treatment of men with metastatic castrate-resistant prostate cancer, was approved for both pre- and post chemotherapy indications. 
Furthermore, we are developing ARN 509 now known as Apalutamide, a more potent next-generation androgen receptor antagonist that shows a high degree of safety and efficacy in castrate-resistant prostate cancer. 
As seen in these figures, Apalutamide decreased PSA by a median of 85% in patients with non-metastatic castrate-resistant prostate cancer after 12 weeks of treatment. The maximum PSA response shown on the right-hand figure was achieved in 94% of patients. 
Earlier this year, we licensed niraparib from Tesoro to obtain a highly potent and selected part inhibitor for the treatment of prostate cancer patients with DNA repair defects for use in combination with Zytiga or apalutamide. Niraparib is in Phase II trials and is currently to be filed by 2019. This portfolio of assets gives us confidence that we will continue to bring great results of patients with prostate cancer for many years to come. 
While we did not explicitly address immuno-oncology during our 2015 Pharmaceutical Business Review, we continue to make significant progress in this area. Over the last 5 years, we invested in 4 critical areas, including vaccines, T-cell checkpoint inhibitors, T-cell redirection and myeloid mechanisms of actions. We currently have 15 immuno-oncology assets in development, including 8 that are in the clinic. 
Recently, we uncovered an important additional mechanism of action of DARZALEX to be immune mediated through the depletion of immunosuppressive myeloid in lymphoid populations, including a previously unrecognized super suppressor CD38 positive T rate calculation as well as activation of CD8 and CD4 positive effector T-cells. These results provide the impetus for exploring DARZALEX in indications beyond heme malignancies in solid tumors. 
Our immunology therapeutic area continues to deliver extraordinary products for patients with psoriasis, inflammatory bowel disease and rheumatoid arthritis. STELARA was the first IL-12 IL-23 monoclonal antibody introduced for moderate to severe plaque psoriasis and active psoriatic arthritis. It was recently approved and moderately to severely active Crohn's disease in the U.S, received the positive opinion from the committee for additional products for human use of the European Medicines Agency and offers new options for adult patients with IBD. 
[indiscernible] is a first in class selective anti-IL-23 monoclonal antibody that demonstrated significant efficacy versus placebo in superiority compared with the anti-[indiscernible] necrosis factor, Adalimumab in moderate to severe plaque psoriasis. 
The VOYAGE study, whose results are shown in this slide, randomly assigned 750 patients to receive Guselkumab, Adalimumab or placebo, followed by Guselkumab in the 2 to 2 to 1 ratio. Patients treated with Guselkumab achieved a significantly greater chance of obtaining approximately 90 score compared to that of patients treated with Adalimumab or placebo at Week 16 and the advantage over Adalimumab were sustained through Week 48. 
The high degree of efficacy of Guselkumab, the less intensive dosing regimen and the potential for a STELARA-like safety profile makes Guselkumab highly competitive with newly launched anti-IL 17 antibodies. We plan to file for psoriasis this year and advance Guselkumab into Phase III for patients with psoriatic arthritis. 
Neuroscience is a historically strong area patient area for JANSSEN since Dr. Paul Janssen and colleague developed [indiscernible], the first medication for schizophrenia. We have built on Dr. Paul's legacy with the development of next generation antipsychotics and pioneered the development of long-acting injectables that help improve compliance for this difficult-to-treat patient population. 
Most recently with the approval of INVEGA TRINZA in every 3 months injectable formulation. Today, we focus our neuroscience investments in drugs that treat serious mood disorders, including depression, suicide and Alzheimer's disease. Esketamine, an intranasally delivered ketamine, produced groundbreaking results in major depressive disorder with onset of action measured in hours to days rather than weeks to months. 
There's an alarming increase in suicides both in the U.S. and globally, more than 41,000 each year in the U.S. alone. It's a tragic issue that's emerging as a major health priority. 
As shown in this light, esketamine ameliorated suicidal ideation within 4 hours and sustain this effect for over 3 weeks leading to a second FDA Breakthrough Therapy Designation. 
Infectious Diseases is one of our most exciting and important areas and investment for future growth where we focus on respiratory infections and hepatitis. We are pursuing an aggressive strategy for the cure of hepatitis C. We recently reported a 100% FBR 12 in patients with genotype 1 with both an 8 and 6 weeks duration of treatment using a 3DAA combination of OLYSIO AL 335 and [indiscernible]. 
Based on this exceptional data, we are moving to 3DAA regimen into late development studies. 
Our Cardiovascular and Metabolism therapeutic area developed both INVOKANA and XARELTO in partnership with Mitsubishi Tanabe. New line extensions are designed to continue to bring value with these 2 first in class drugs. With XARELTO, we are pursuing studies in congestive heart failure, embolic stroke of undetermined source, DTE prevention in medically ill patients, infect [indiscernible] peripheral artery disease, ZTE prevention in cancer patients and an acute coronary syndrome. 
We anticipate [indiscernible] from 2 INVOKANA cardiovascular outcome studies by mid 2017, which we believe will further strengthen the importance of the STL 2 inhibitor class for the treatment of patients with diabetes. 
We are also studying the role of INVOKANA in diabetic kidney disease and plan to address obesity and prediabetes. 
In summary, at the JANSSEN pharmaceutical companies of Johnson & Johnson, we are executing a clearly defined innovation strategy that drive value to patients around the world. We are on track to meeting our anticipated results described in 2015. We are producing the cadence of transformational innovations that are leading to exceptional results. We are a leader in productivity, approval and FDA Breakthrough Therapy Designations, and we are one of the fastest-growing top 10 pharmaceutical companies. 
We have had the most U.S. FDA approvals in the last 5 years, 2011 to 2016, and 8 Breakthrough Therapy Designation. We anticipate filing approximately 10 NMEs between 2015 and 2019, each with greater than $1 billion peak year sales potential. 
We have approximately 40 planned line extension filings anticipated between 2015 and 2019, several with greater than $500 million in peak year sales potential, supported by a steady flow of clinical data that drive better patient results. 
Finally, we take pride in delivering years of live saved and better quality of life for our first credo responsibility to the doctors, nurses and patients who use our products. 
Now before I turn it over to Dominic, for your reference, let me leave you with a current overview of our pipeline across our 5 therapeutic areas. Dominic will now continue with an update of the company's financial results."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Bill and Joaquin,  and good morning, everyone. As you just heard, our Pharmaceutical business is well positioned for continued above-industry growth as we make the progress against the pipeline expectations we communicated at our 2015 Pharmaceu",2490,"Thank you, Bill and Joaquin,  and good morning, everyone. As you just heard, our Pharmaceutical business is well positioned for continued above-industry growth as we make the progress against the pipeline expectations we communicated at our 2015 Pharmaceutical Business Review. 
With great leaders like Joaquin and Bill, our strong end market performance driven by excellent commercial capabilities and our robust R&D pipeline, you can see what we remain confident that our Pharmaceuticals business will continue to be a major driver of growth moving forward. 
I will now turn our discussion back to the quarter. We are pleased with our overall results. As you know, we have a strong start to the year and as a result, last quarter, we increased our sales and earnings guidance. I'm happy to say, we're tracking with those higher expectations while continuing to invest in our business. 
As you've heard, our Pharmaceutical business delivered strong results this quarter, with underlying operational growth of 10.7%. 
Let me now provide some comments on our other businesses. In our consumer business, we continue to gain share this quarter. However, as reported by Nielsen, the industry saw slowdown in many markets, with category growth rates in 2016, about half of the category growth rate we saw in Q3 of 2015. 
As Joe noted, our sales growth for the quarter was also impacted by lower trade inventory levels. These lower levels are the result of inventory builds in Q3 2015 as we discussed at that time due to relaunches of certain products as well as inventory reduction programs being implemented at some of our larger retailers this past quarter. 
When excluding the impact of acquisitions and divestitures and the impact of the devaluation that occurred in Venezuela last year and this overall impact for trade inventory reductions, overall consumer growth was nearly 4%. Based on increasing share trends of our brands, we expect trade levels to align with consumption going forward. 
In Medical Devices, consistent with the recent analyst reports about the market, we believe the industry experienced lower hospital admission and procedure rates during the mid-summer months. 
Late in the quarter, several reports showed higher levels of activity and in fact, the data that we recently saw published for September looked encouraging. 
Additionally, we're very pleased to see our priority platforms continue to deliver robust growth of nearly 9%, with some at double digits as Joe mentioned earlier. 
Overall, Hospital Medical Devices operational growth, excluding acquisition and divestitures, was approximately 4% this quarter. 
In the Consumer Medical Device businesses, we saw continued price erosion in our Diabetes business. However, in our Vision Care business, we saw good operational growth of 5.5%. 
So in summary, as we previously discussed, in 2015, our underlying operational growth, which excludes the impact of acquisitions divestiture us as well as hepatitis C sales and the extra shipping days that we saw in 2015 was about 5.5%. 
On this same basis, we continue to accelerate our growth, and we delivered strong underlying operational sales growth of approximately 5.9% for the third quarter 2016. 
Our sales were above analyst estimates as were earnings due to significantly higher pretax operating margins. As you may remember, our guidance from January included a more than 200 basis points increase in our 2016 pretax operating margin on an adjusted basis. We have attained that level year-to-date while continuing to invest in our business, and we remain comfortable with a forecast for the full year as continue to execute on the restructuring activities in our medical device businesses while also investing in growth. 
As you know, in September, we announced a definitive agreement to acquire Abbott Medical Optics. We expect this transaction to close in Q1 of 2017. So for 2016, the transaction is expected to have no impact to our adjusted earnings, it's not expected to our guidance. For 2017, again assuming a Q1 close, the transaction is expected to be positive to sales growth and immediately accretive to adjusted EPS. 
We're excited about Abbott Medical Optics' strong and differentiated surgical ophthalmic portfolio, particularly in cataract surgery. That, coupled with our world leading ACUVUE contact lens business will help us become a broad-based leader in Vision Care. 
Now I take the next few minutes to highlight some key points regarding our results for the quarter and then I'll provide some updates to our guidance for you to consider in refining your models for the remainder of 2016. 
I will now turn to our consolidated statement of earnings for the third quarter 2016. Our operational sales growth this quarter was 4.3% and when we exclude the impact of acquisition and divestiture, the impact of hep C sales and the overall impact of Venezuela had, it was strong at more than 6%. 
If you direct your attention to the box section of the schedule, you will see we have provided our earnings adjusted to exclude intangible amortization expense and special items. 
As referenced in the table of non-GAAP measures, the 2016 third quarter net earnings were adjusted to exclude intangible amortization expenses special items of approximately $400 million on an after-tax basis, which consisted primarily of the intangible amortization expense of about $250 million and the anticipated special charges as we continue to execute on the Medical Devices restructuring plan. 
Our adjusted earnings per share is therefore $1.68, which exceeded the mean of the analysts' estimates as published by first call. This is an increase in adjusted EPS of 12.8% versus the prior year. 
Adjusted EPS on a constant currency basis was the same as the impact of currency was flat year-over-year. 
Now let's take a few moments and talk about other items of the statement of earnings. Cost of goods sold increased by 30 basis points, mostly due to unfavorable transaction currency impacts partly offset by favorable mix and a manufacturing efficiencies. 
Selling, marketing and administrative expenses were 26.8% of sales or 290 basis points lower as compared to the third quarter of 2015 due to overall good cost management. 
Our investment in research and development as a percent of sales was 12.2%, lower by 40 basis points due primarily to lower milestone payments, partly offset by increased project spending as we advance our promising product pipeline. 
Our pretax operating margin when excluding special items and intangible amortization expense, was 32% or 310 basis points higher than the third quarter of the prior year. 
As a reminder, pretax operating margin is defined as gross profit less selling, marketing, administrative expenses and less R&D expense. 
As we anticipated, we are seeing improvement as we progressed throughout the year and through 9 months, we have achieved a 220 basis point improvement in this measure of profitability consistent with the expectations we communicated to you throughout the year. 
Interest expense net of interest income was similar to last year. Other income and expense was a net gain of approximately $50 million in the quarter compared to a net expense of approximately $400 million in the same period last year. Excluding special items that are reflected in this line, other income and expense was a net gain of approximately $200 million compared to a net gain of approximately $400 million in the prior year period, which included a higher level of gains from divestitures. 
Excluding special items, the effective tax rate in the quarter was 19.7% compared to 20% in the same period last year. This year's effective rate reflects the R&D tax credit, which was passed by Congress late last year. And it affects the mix of our businesses in the impact from a new accounting standards relating to the tax benefit on share-based compensation, which we discussed in our call in July. 
Turning to the next slide. I will now review adjusted income before tax by segment. In the third quarter of 2016, our adjusted income before tax margin for the enterprise improved by 220 basis points versus the third quarter of 2015. You will notice significant improvements in margins for the Medical Devices and pharmaceutical businesses. 
Last year, our consumer business benefited from gain in the sale of SPLENDA, and you're seeing that are affected in the lower margin this quarter, although still have very healthy rates. 
As you can see at the next slide on a year-to-date basis, we are pleased to see solid improvement in our consumer margin, and we remain confident it will show an improved adjusted income before tax margin for full year 2016 as compared to 2015. 
Overall, we expect adjusted income before tax margins for the enterprise to show an improvement over the prior year for all of 2016 as our increase in pretax operating profit margin, which I noted earlier, more than offsets the lower level of divestiture gains in 2016 as compared to 2015. 
Now I'd like to provide some guidance for you to consider as you refine your models for 2016. I'd like to start with some of the items that we know you'll find difficult to forecast. 
Let's start with cash and interest income and expense. At the end of the quarter, we had approximately $13 billion of net cash, which consist of approximately $40 billion of cash and marketable securities and approximately $27 billion of debt. 
Through the end of the third quarter, we completed nearly 60% of our $10 billion share repurchase program, and we expect to complete approximately 75% of the program by the end of this year. 
For purposes of your models and assuming no major acquisitions or other major uses of cash, I suggest you consider modeling net interest expense of between $400 million and $450 million. There's a slight tightening of the range. 
Regarding other income and expense. As a reminder, this is the account where we record royalty income as well as gains and losses arising from such items as litigation, investments by our development corp, divestitures, asset sales and rails. We will be comfortable with your models for 2016 reflecting net other income and expense, excluding special items as a gain, ranging from approximately $750 million to $850 million, a lower range than our previous guidance related to the underlying activity. This impact will be offset by a lower tax rate. 
And now for taxes, we're very comfortable with your models reflecting an effective tax rate for 2016, excluding special items of approximately 18% to 18.5%, which is lower than our previous guidance, primarily due to higher level of income and lower tax jurisdictions. 
Now turning to sales and earnings. Our sales and earnings guidance for 2016 takes into account several assumptions and key factors that I would like to highlight. Our sales range for 2016 continues to remain the same whether or not a biosimilar REMICADE launches this year in the U.S.. 
Additionally, we do not anticipate biosimilar or generic competition this year for PROCRIT, ZYTIGA, [indiscernible] and INVEGA SUSTENNA but as expected, there are generic entrance for INVEGA and orthro cycle. 
As been done for several years, our guidance will be first based on a constant currency basis reflecting our results from operations. This is the way we manage our business, and we believe this provides a good understanding of the underlying performance of our business. 
We also provide an estimate of our sales and adjusted EPS results for 2016 with the impact that current exchange rates could have on the translation of those results. 
We continue to be comfortable with the sales guidance we provided last quarter, reflecting on operational sales increase on a constant currency basis of between 3% and 4% for the year. This was a result in sales for 2016 on a constant currency basis of between approximately $72.2 billion to $72.9 billion. 
Additionally, by way of comparison to how we describe our sales results in 2015, our operational sales growth for 2016, excluding the impact of all acquisition and divestitures and hepatitis C will be approximately 6%, a higher level of growth than we saw last year even after adjusting for the shipping days in 2015, which we mentioned earlier. 
Although we're not predicting the impact of currency movements, using the euro as of last week at $1.11, the negative impact of foreign currency translation will be approximately 1% on sales growth. This is consistent with our previous guidance as major currencies have not significantly fluctuated since our last update. 
So after impacts of currency, we would expect reported sales to reflect the change in the the range of positive 2% to 3% for a total expected level of reported sales are approximately $71.5 billion to $72.2 billion consistent with our previous guidance. 
And now, turning to earnings. As a reminder, we expect transaction currency impacts to be negative to our gross margin by approximately 60 to 80 basis points in 2016 as compared to 2015. We would be comfortable with adjusted operational EPS guidance in the range between $6.71 and $6.76 per share on a constant currency basis, reflecting on operational or constant currency growth rate of 8% to 9%. And this is a narrowing of the range. 
If currency exchange rates for all of 2016 or to remain where they were as of last week, the negative impact to EPS would be approximately $0.03, consistent with our previous guidance. Therefore, we would be comfortable with our reported adjusted EPS range ranging from $6.68 to $6.73 per share, which again is a narrowing of our previous guidance with a midpoint that is $0.03 higher than our previous guidance range. 
Finally, just remind of some dynamics you will see in our fourth quarter results this year in comparison to the fourth quarter of 2015. 
In 2015, we had additional shipping days based on when our year-end closed, and that contributed approximately 4 points of sales growth in the fourth quarter last year. 
Additionally, in the fourth quarter last year, we closed on the Cordis divestiture. And based on our latest guidance for 2016, we will have significantly lower level of other income from divestitures as compared to the prior year. 
In closing, we are very pleased for our performance so far this year, and we remain confident and optimistic about our future full year growth for 2016. 
Specifically, we're expecting operational sales growth of 3% to 4% and underlying operational sales growth of 6%, a higher level that we experienced last year on a comparable basis. 
Our adjusted pretax operating margin improvements are on track to meet the expectations we laid out in our guidance of more than a 200 basis point improvement over the prior year. We narrowed our guidance and increased the midpoint for adjusted operational EPS growth, which remains strong in the range of $6.71 to $6.76 per share with the growth rate of 8% to 9%, and we are very well positioned to seize the opportunities in our strong pipelines to continue fueling our future growth. 
Now I'd like to turn things back to Joe for the Q&A portion of the call. Joe?"
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Dominic. Michelle, can you please provide instructions for those in the line wishing to participate in the Q&A?",20,"Thank you, Dominic. Michelle, can you please provide instructions for those in the line wishing to participate in the Q&A?"
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","[Operator Instructions] Your first question comes from Larry Biegelsen with Wells Fargo.",12,"[Operator Instructions] Your first question comes from Larry Biegelsen with Wells Fargo."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Welcome, Joe. So Dominic, I wanted to focus on the 2017, the puts and takes. Dominic, at our health care conference in September, you said the only real delta from 2016 to 2017 is a rate at which a biosimilar REMICADE can penetrate the market, assuming Pf",153,"Welcome, Joe. So Dominic, I wanted to focus on the 2017, the puts and takes. Dominic, at our health care conference in September, you said the only real delta from 2016 to 2017 is a rate at which a biosimilar REMICADE can penetrate the market, assuming Pfizer launches at risk, and you don't think the penetration will be dramatic. I took that to mean that you feel that you can grow sales in 2017, is it similar rate to 2016 minus the impact from biosimilar REMICADE. So my questions are that is that the right interpretation? What gives you the confidence that this level of growth will continue? And second, the biosimilar for [indiscernible] captured about 7% in the market in year 1. Would you expect inflector penetration to be less than that? Any color that you can give on the expected penetration been helpful. And I do have one follow-up on pharma."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Sure, Larry. Thanks for the question. I think the way you characterized it is accurate, that excluding the impact of any biosimilar launch, we would expect the business to grow at a rate similar to what we saw this year in the pharma business overall as w",172,"Sure, Larry. Thanks for the question. I think the way you characterized it is accurate, that excluding the impact of any biosimilar launch, we would expect the business to grow at a rate similar to what we saw this year in the pharma business overall as well as I think we will see improved performance in the Medical Device business, and we're see continued share gains in the consumer business. So I think that is a good way to characterize it. We'll provide more color on that when we talk about the 2017 guidance in our discussion in January. We do think that the rate of penetration for biosimilar will be modest and there are several reasons for that. As we talked about before 70% patients are treated well with REMICADE. There is no interchangeability available, that's another factor, and we're already highly competitive environment with respect to biologics, anti-TNF therapy, as you know. Before any comment on [indiscernible], Joaquin, anything else you would like to add on overall penetration of biosimilars?"
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","We're confident that we have a readiness plan for our biosimilar launch in the U.S. What we have seen internationally markets like Australia, Brazil, where we market REMICADE is our volume share has been in excess of 90%, so that is consistent with what y",175,"We're confident that we have a readiness plan for our biosimilar launch in the U.S. What we have seen internationally markets like Australia, Brazil, where we market REMICADE is our volume share has been in excess of 90%, so that is consistent with what you described. We are confident that we have a strong plan based on what Dominic described before, there's been 2.6 million patients treated with REMICADE worldwide. There's no interchangeability and there's a clear patient and physician preference, so it's highly unlikely that you're going to be seeing patients that are stable in REMICADE switch. So that is 70% of the patients. At the same time, we have a strong patient assistance program, which will prove to be a market differentiator, and we are ready to compete in every channel trying to bring patients the most affordable option in every situation. So we feel well prepared to face the biosimilar. And as Dominic said, we are convinced that we will continue to grow our business in the face of biosimilar competition."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Well, I'm not sure whether [indiscernible] is a good analog or not. Obviously, we have Europe, we have a biosimilar in Europe that Merck is responsible for marketing and I think there over about a 2-year period, Merck has retained about 75% share. So that",54,"Well, I'm not sure whether [indiscernible] is a good analog or not. Obviously, we have Europe, we have a biosimilar in Europe that Merck is responsible for marketing and I think there over about a 2-year period, Merck has retained about 75% share. So that's one analog. You had a follow-up question on pharma?"
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Yes, maybe for Joaquin. So on INVOKANA, I saw in the presentation that you expect to present the CANVAS and CANVAS-R data in mid-2017. So my questions are, are you going to present CANVAS and CANVAS-R before mid-2017? And do you have any plan to issue pre",81,"Yes, maybe for Joaquin. So on INVOKANA, I saw in the presentation that you expect to present the CANVAS and CANVAS-R data in mid-2017. So my questions are, are you going to present CANVAS and CANVAS-R before mid-2017? And do you have any plan to issue press release for top line results before the presentation? And lastly, what's your confidence that we'll see similar cardiovascular benefit as we did with [indiscernible] outcome as well as the lack of significant amputation risk?"
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Larry. INVOKANA remains the leading [indiscernible] to us. I have described in the conference call and we took our CANVAS and CANVAS-R and the cardiovascular benefit and I'm going to pass the question to Bill.",37,"Thank you, Larry. INVOKANA remains the leading [indiscernible] to us. I have described in the conference call and we took our CANVAS and CANVAS-R and the cardiovascular benefit and I'm going to pass the question to Bill."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Hi, Larry, this is Bill. So we plan to evaluate CANVAS and CANVAS-R together as 1 analysis. We're in discussions right now on the degrees of statistical confidence with the FDA. We have very strong reason to suspect based on CANVAS that the combination wi",55,"Hi, Larry, this is Bill. So we plan to evaluate CANVAS and CANVAS-R together as 1 analysis. We're in discussions right now on the degrees of statistical confidence with the FDA. We have very strong reason to suspect based on CANVAS that the combination will give data very similar to what was reported with [indiscernible]."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Your next question comes from Kristen Stewart with Deutsche Bank.",10,"Your next question comes from Kristen Stewart with Deutsche Bank."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Just going back to, I guess, REMICADE and just again through of the pipeline, I guess, what are some of the things that you feel confident on to the extent that the biosimilar could take, I guess, I guess, greater share than what you expecting that could",60,"Just going back to, I guess, REMICADE and just again through of the pipeline, I guess, what are some of the things that you feel confident on to the extent that the biosimilar could take, I guess, I guess, greater share than what you expecting that could start to fill in, I guess, some of the gaps from that perspective?"
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Kristen, for the question. I described part of the reasons for optimistic during my conversation before. We not only feel that we're going to be able to grow in the phase of biosimilar, the pharmaceutical business overall, but we also are confi",343,"Thank you, Kristen, for the question. I described part of the reasons for optimistic during my conversation before. We not only feel that we're going to be able to grow in the phase of biosimilar, the pharmaceutical business overall, but we also are confident that we're going to be able to growth our immunology franchise in the phase of biosimilars. Let me give you some examples of why going into the 3 segments: Rheumatology, psoriasis and gastroenterology. In Rheumatology, SIMPONI/SIMPONI ARIA are doing very well. As a matter of fact, SIMPONI ARIA, it's already leading in new brand -- new to brand share in rheumatology in the U.S. and SIMPONI, it's gaining share in all international markets. We plan to file 2 line extensions of SIMPONI ARIA in ankylosing spondylitis and in psoriatic arthritis by 2017. And also we just filed sirukumab with EMEA, and we plan to file it here in the U.S. before the end of the year. So that gives us a strong confidence that where we want to be continue to grow in rheumatology. Then moving into psoriasis, STELARA continues to be the leading in new to brand share in the U.S. and it's leading in most markets internationally. Together with that, we plan to file Guselkumab, that we have presented very impressive data at the last EADV, we plan to file Guselkumab before the end of the year, so that's another reason why we feel real confident that we'll continue to grow in psoriasis. In Gastroenterology, which by the way, is for us is the largest and fastest-growing segment, we just had the approval of STELARA in current disease and we are now -- we're launched it in the U.S. and we anticipate of relaunching it in Europe pretty soon. So that is another reason why, which we believe that we're going to be able to continue to grow in immunology. So overall, we have line extensions, we have continuous penetration and also we have the filing of sirukumab and Guselkumab in the second half of the year."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Your next question comes from Mike Weinstein with JPMorgan.",9,"Your next question comes from Mike Weinstein with JPMorgan."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","So Dominic, I wanted just to follow up on all the discussions in the pharmaceutical business. You made some comments at the investor conference in September that caught my attention. You talked about the 5 major therapeutic categories the company is in to",90,"So Dominic, I wanted just to follow up on all the discussions in the pharmaceutical business. You made some comments at the investor conference in September that caught my attention. You talked about the 5 major therapeutic categories the company is in today. And you opened up I think for the first time the potential of the company would consider adding a new therapeutic category. Just want to get a sense of your interest in doing that and maybe the rest of the team wants to chime in as well."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Yes, sure, Mike. Well, I remember that discussion pretty well. I just want to put into context for everyone. So this was a discussion about the success of our Pharmaceutical business, which has largely been driven by collaboration, licensing, core develop",207,"Yes, sure, Mike. Well, I remember that discussion pretty well. I just want to put into context for everyone. So this was a discussion about the success of our Pharmaceutical business, which has largely been driven by collaboration, licensing, core development, et cetera and not at all by any major acquisition, right? And the question that I got close to me was well that's been very successful why would you ever change that as there is no reason to consider a change in that strategy. And my comment was, well to the extent we have 5 major therapeutic areas today, if we decided that another major therapeutic area was of importance to us and wanted to get into that therapeutic area, and we thought we could add a lot to, but based on our overall scientific knowledge more broadly that I would see that perhaps being done not by necessary licensing strategy, but more of an acquisition type strategy. So it would enhance the overall portfolio of Johnson & Johnson's Pharmaceutical business beyond the current therapeutic areas that we currently are in. And by doing that, that might require a more significant acquisition than we've been doing in the pharma business. So that's the context for that."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","What's important to remember is that our focus is seeing medical innovation. And therefore, our areas in which we'll operate will depend on where science is going and our own internal capabilities on the development and the commercial side. So from that p",75,"What's important to remember is that our focus is seeing medical innovation. And therefore, our areas in which we'll operate will depend on where science is going and our own internal capabilities on the development and the commercial side. So from that perspective, we're constantly evaluating in which therapeutic areas we are in and in our situation. The focus is in transformational medical innovation and is the actual therapeutic areas can change over time."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","And so that -- I mean, Dominic, that comment is that just an indicator that there's an openness or an interest in new therapeutic areas more so today than may be in the last 5 years?",36,"And so that -- I mean, Dominic, that comment is that just an indicator that there's an openness or an interest in new therapeutic areas more so today than may be in the last 5 years?"
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Well, I think there's always an interest in new therapeutic areas where there is medical innovation where we think we can make a difference to patients in the health care system. So I'm not sure that, that's changed dramatically, although over the last se",74,"Well, I think there's always an interest in new therapeutic areas where there is medical innovation where we think we can make a difference to patients in the health care system. So I'm not sure that, that's changed dramatically, although over the last several years, we've built these very prominent disease stronghold within the therapeutic area that we have today and obviously they take some time to build. Bill, any other comments on that?"
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","In fact to get to where we are today, we have to focus down from approximately 33 different diseases we were investing broadly but thinly to 11 diseases where we developed extremely deep expertise internally from basic discovery right through launching co",135,"In fact to get to where we are today, we have to focus down from approximately 33 different diseases we were investing broadly but thinly to 11 diseases where we developed extremely deep expertise internally from basic discovery right through launching commercialization to market understanding to where we are always considering first are there -- is there room for further massive innovation because of the development of transformational science or new knowledge that we can go after. And number two is we've been very familiar with adjacencies to the areas we're in. And if they look attractive, they're often the ones we gave the hardest to look at. So we're always looking to see if there's massive innovation left to go in our disease areas, in therapeutic areas and we're always looking closely at adjacencies."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Your next question comes from David Lewis with Morgan Stanley.",10,"Your next question comes from David Lewis with Morgan Stanley."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Two questions. First for Joaquin and then Dominic, some commentary on medical device utilization. So Joaquin, I found your commentary on the strategy to defend REMICADE a pretty compelling. So should we take, from your comments, that your existing strateg",56,"Two questions. First for Joaquin and then Dominic, some commentary on medical device utilization. So Joaquin, I found your commentary on the strategy to defend REMICADE a pretty compelling. So should we take, from your comments, that your existing strategy is sufficient or should we expect more proactive pricing strategies to emerge in '17 and beyond?"
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Our strategy is three-pronged as I described. The first one is the fact that we believe based on the track record of REMICADE and the lack of interchangeability, it is likely that patients are going to switch if they are stable. So that's a very important",205,"Our strategy is three-pronged as I described. The first one is the fact that we believe based on the track record of REMICADE and the lack of interchangeability, it is likely that patients are going to switch if they are stable. So that's a very important component for us. The second element is that we plan to compete in all channels. And in planning to compete with in all channels, we're going to be utilizing innovative contracting and utilizing the full breadth of our portfolio. And then finally, we plan to utilize market differentiators such as patient assistance programs that are going to enable affordability. So with these 3 components, we feel confident that we are going to be able to have a very strong plan to face the biosimilar. The second element of that overall is what I just described before, what are the elements that lead us to believe that we'll continue to grow immunology, too, and I described the different line extensions and NMEs that we have in the 3 areas: Rheumatology, gastroenterology and psoriasis. So combined, we feel strongly that will be able to grow in immunology and overall, the Pharmaceutical business will grow in the face of the biosimilar."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Okay. So if you had to use price next year more aggressively, Joaquin, that would be an incremental surprise to you?",21,"Okay. So if you had to use price next year more aggressively, Joaquin, that would be an incremental surprise to you?"
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","This is already a very competitive market as it is today. As you can imagine, after there's already significant competition in the market today, both in the sub-q area and in the IV area. So we believe that the level of discount that is today makes it alr",55,"This is already a very competitive market as it is today. As you can imagine, after there's already significant competition in the market today, both in the sub-q area and in the IV area. So we believe that the level of discount that is today makes it already a high bar for any new entrants."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Okay, that's very clear. And then Dominic, you made a series a comments on utilization, I just want to clarify, both the near term and kind of of longer-term environment. So if I heard you correctly, it seems like there was some softening potentially in t",143,"Okay, that's very clear. And then Dominic, you made a series a comments on utilization, I just want to clarify, both the near term and kind of of longer-term environment. So if I heard you correctly, it seems like there was some softening potentially in the Medical Device business in the summer, but that got better in September. I wonder if you could just help us out in terms of how you would characterize the environment here in September entering into October. Is it stable with what you saw in the first half of the year or different? And then the second part of the question is you also said in '17, you actually expect some improvement in the Medical Device business. And maybe you could share with us your confidence level in the areas that you would expect to improve in '17."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Sure. So what we saw, David, this is through published sources, many of which are from the firms such as yours and many of the sales side that published. We saw actually utilization rates as depicted in hospital admissions and hospital surgical procedures",305,"Sure. So what we saw, David, this is through published sources, many of which are from the firms such as yours and many of the sales side that published. We saw actually utilization rates as depicted in hospital admissions and hospital surgical procedures with the first quarter of this year being the highest, by far, and then a slowdown in the second quarter, a slowdown even below the level at which most estimates we're depicting, we're forecasting. And then in the third quarter was even slower then the second quarter overall, but is a very marked difference in September. So once September hit, the data showed quite a rebound from the summer months and the rate of growth in September was actually faster than we saw in the first quarter, which is the highest growth quarter year-over-year in terms of penetration. Now whether that remains at that level or whether it's a rebound effect in the summer, we'll have to see. But I think this is all well chronicled in the multiple reports that many of you I'm sure have seen. So overall, I'd say we're now in a stable environment in hospital procedures. Going into '17, I express confidence in our Medical Device business growing faster and quite frankly, we have a plan for that business to return to growth at above market for the medical device sector and it's continuing to improve. What gives me confidence there is that the areas that we focus the most on, the growth platforms and priority platforms just this quarter, they grew at 9% and within those, 3 of those in particular, electrophysiology, energy and endocutters, each grew at double-digit growth. So we obviously have a very robust growth coming in the priority platforms, which we expect to continue and drive us to above-market growth in 2017."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Your next question comes from Glenn Novarro with RBC capital markets.",11,"Your next question comes from Glenn Novarro with RBC capital markets."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Just a follow-up on REMICADE because Dominic, you said REMICADE -- or the biosimilars, sorry, would be at launch risk. So can your mind is what's next in the legal process? And then you also did a good job of discussing the impact you thought for the top",78,"Just a follow-up on REMICADE because Dominic, you said REMICADE -- or the biosimilars, sorry, would be at launch risk. So can your mind is what's next in the legal process? And then you also did a good job of discussing the impact you thought for the top line. Can you talk about the profitability of REMICADE today? Is this a drug that is still heavily marketed? I can't imagine there's a lot of R&D behind REMICADE."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Right. Well a couple of things, where we stand on the legal front, as you know, we have an upcoming trial on the media related to the production of the biosimilar, and that trial is scheduled for mid-February of 2017, and we're also appealing the ruling r",104,"Right. Well a couple of things, where we stand on the legal front, as you know, we have an upcoming trial on the media related to the production of the biosimilar, and that trial is scheduled for mid-February of 2017, and we're also appealing the ruling recently in the Massachusetts court regarding the patent being invalid, and that will proceed. But we're also separately, and we had been involved in this process for quite some time, we're continuing the appeals process within the U.S. patent office and that process has several more steps to go. Joe, anything else you want to add to that?"
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Yes, just with some specific dates, Glenn. The oral arguments in front of the PTO was heard in September 28. We expect that the decisions to be rendered anywhere from 1 to 3 months. In the courts on the 471 patent. The final judgment just came from the be",70,"Yes, just with some specific dates, Glenn. The oral arguments in front of the PTO was heard in September 28. We expect that the decisions to be rendered anywhere from 1 to 3 months. In the courts on the 471 patent. The final judgment just came from the bench on September 27 so that triggers a timing in which we have to appeal and we're going through the process now."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Okay. And with regards to profitability, obviously, the product like REMICADE is an important product that has obviously delivers significant profitability to the company. But of course, we have a number of new launches, we have some that are already laun",154,"Okay. And with regards to profitability, obviously, the product like REMICADE is an important product that has obviously delivers significant profitability to the company. But of course, we have a number of new launches, we have some that are already launched and are progressing and rapidly growing and their relative cost does not grow at the rate of their sales growth and overall, we have to manage through this period of time when eventually when biosimilar launches and a patent expires, we have to prepare sales for that in any event. So we're very well prepared to adjust accordingly. And as you know, our major focus always is to grow our sales at a rate faster than the rate in which we can -- our markets grow, so gain share and then grow our earnings at a rate faster than sales, so that's the level at which we plan for each and every year."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","So is there some restructuring that may come out over the next announcements that may come out that could service an offset to REMICADE and any potential loss profitability?",29,"So is there some restructuring that may come out over the next announcements that may come out that could service an offset to REMICADE and any potential loss profitability?"
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","We don't see any major restructuring related to the REMICADE situation on the horizon, Glenn, not at all.",19,"We don't see any major restructuring related to the REMICADE situation on the horizon, Glenn, not at all."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Your next question comes from Jami Rubn with Goldman Sachs.",10,"Your next question comes from Jami Rubn with Goldman Sachs."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Dominic, just a couple of questions for you. With the upcoming election, obviously, it's been a major area focus fro health care investors. I'm just curious your thoughts on Proposition 61. And as you know, that polls are showing that, that actually might",183,"Dominic, just a couple of questions for you. With the upcoming election, obviously, it's been a major area focus fro health care investors. I'm just curious your thoughts on Proposition 61. And as you know, that polls are showing that, that actually might pass in the State of California. Just curious to know what you think the industry's response will be to that. And then secondly, I'm interested in your thoughts on the potential for an international tax reform as part of an infrastructure build. Obviously, you would be huge beneficiaries of such a bill because of repatriation. Can you give us your thoughts on the likelihood of that happening? We've had multiple discussions over the years about tax reform, which never happens. Maybe it will happen this time. Just curious to know what your Washington folks are saying. And are we correct in assuming that if we were to do a large mega- transaction adding that 6 tool to your pharmaceutical division, are you more likely to wait until we get visibility on that or is your decision irrespective of potential legislation?"
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Well, Jami, let me take them in reverse orders. So whether or not we do a major transaction will not be dependent on waiting for international tax reform. Obviously, we have plenty of borrowing capacity and obviously, any transaction that's done outside t",283,"Well, Jami, let me take them in reverse orders. So whether or not we do a major transaction will not be dependent on waiting for international tax reform. Obviously, we have plenty of borrowing capacity and obviously, any transaction that's done outside the U.S. will be an effective use of that OUS cash. And as you know, we've had the benefit of being able to structure transactions and effectively use of OUS cash in a tax efficient manner. And we did that with the [indiscernible]  Transaction, we've done recently with the 2 transaction that we recently announced. With respect to international tax reform and what we're hearing, I can tell you that I visit in Washington often and speak with members of the House Ways and Means Committee and the Senate Finance Committee and the tax staffs are busily working and working very collaboratively with U.S. multinationals on an appropriate tax reform package. We think there's more bipartisan support now than there has been in the past. We think that often, we hear, as you mentioned, the benefit of investing in U.S. infrastructure as a result of those repatriated earnings coming back into the U.S., so that would be a positive. And we think that overall, the climate for international tax reform post the election quite frankly, is more positive than it's been in the last year or so. And then with respect to Proposition 61, there are several opponents to that proposition, and we will prefer to have pricing that is more related to outcomes, evidence-based medicine is something that we are advocates of and therefore, outcome-based pricing is a logical consequence of that. But Joaquin, any other thoughts on Proposition 61?"
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you. I mean, as you were seeing, Dominic, despite the pharmaceutical pricing, right, so it's good to take some perspective on that. Pharmaceutical represent 14% of total expenditures, and we understand that we need to work with different stakeholder",176,"Thank you. I mean, as you were seeing, Dominic, despite the pharmaceutical pricing, right, so it's good to take some perspective on that. Pharmaceutical represent 14% of total expenditures, and we understand that we need to work with different stakeholders in order to try to manage to health care cost, and we have advance different ideas in that area us you were describing, Dominic, such as value-based contracting, and we need to work there in order to try to eliminate the regulatory barriers that do not help in that area. As far as Proposition 61 as an example of that rhetoric, as Dominic said, different groups that opposed that measure that includes even better in groups and seniors and unions. The reason being it's unclear what the effects of Proposition 61 would be. It is clear that it will be difficult to operationalize and also would create some access barriers to patients. So overall, we don't see Proposition 61 as the right way to try to work on pharmaceutical pricing. We think it's a misguided action."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Our final question comes from Matt Miksic with UBS.",9,"Our final question comes from Matt Miksic with UBS."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","I have 1 just quick clarification here on I apologize for REMICADE and then I have 1 on sort of capital allocation. So Dominic and Joaquin, if I could just make sure I'm understanding your comments on pricing and expected biosimilar competition as you gon",130,"I have 1 just quick clarification here on I apologize for REMICADE and then I have 1 on sort of capital allocation. So Dominic and Joaquin, if I could just make sure I'm understanding your comments on pricing and expected biosimilar competition as you gone through a number of times here on the call. The perception is that REMICADE pricing will face some kind of new downward pressure, abrupt pressure here as a result of this launch. It sounds like what you're saying is the net price for the drug is already quite competitive. There will be obviously penetration, but it doesn't sound like you're expecting to see any kind of significant abrupt changes in pricing because of the competitive launch, is that a fair characterization of what you're saying?"
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Yes, I think you're right. All drugs -- all medicine space price pressure. This is particularly competitive market as it is today and within the price level, it's already quite competitive, so I think you characterized the situation quite right. I think t",66,"Yes, I think you're right. All drugs -- all medicine space price pressure. This is particularly competitive market as it is today and within the price level, it's already quite competitive, so I think you characterized the situation quite right. I think the competition is going to move into order discussions such as other market differentiators, but the market is already quite competitive as it is."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Got it. And then on capital allocation, just broadly speaking, Dominic, because we get this question quite often. You've made a number of comments throughout September, but the kinds of things that you would be interested and strategically previously be i",98,"Got it. And then on capital allocation, just broadly speaking, Dominic, because we get this question quite often. You've made a number of comments throughout September, but the kinds of things that you would be interested and strategically previously be interested in ophthalmology and you're now pursuing that. If you wouldn't mind just for the record kind of taking through your major divisions and just I think you've touched on pharma already, your preference there but maybe consumer and device just remind us on the kinds of things that you're still interested in there, size and maybe area?"
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Well, Matt, we're as a broad based company in human health care, we have an equal amount of interest across each of the businesses and the way we compensate for that is basically looking at an appropriate risk-adjusted return for the particular assets tha",318,"Well, Matt, we're as a broad based company in human health care, we have an equal amount of interest across each of the businesses and the way we compensate for that is basically looking at an appropriate risk-adjusted return for the particular assets that we're interested in. And that is the same even regardless of size. I mean, obviously, size matters for a couple of reasons. One is that the asset may be well understood, the business may be well penetrated, the premium required for the asset may be excessive and therefore, to generate value for our shareholders will be a challenge. But it doesn't mean we wouldn't try to do that or we wouldn't look for areas where that may in fact be available for us. So that would be across any of the businesses. Within Consumer and Medical Devices, in particular, Consumer just like we have in pharma, we have specific areas of focus. We have 11 need states. The primary focus for us is growing internationally in emerging markets, so strong brands and emerging markets, a focus on over-the-counter medications and beauty space, particularly in Asia are of interest to us. We just did a recent transaction with Dr. Silabo in Japan where we have an interest in that Asian marketplace and utilizing that brand throughout broader, throughout Asia, beyond Japan where it's currently marketed just as an example of one. And the Medical Devices, as you know, we have a very strong presence in orthopedics and in general surgery. We keep looking for additional bolt-on acquisitions there, and we have a very strong electrophysiology business and cardiovascular, but there are other areas within cardiovascular that seem attractive, in structural heart in other areas, but the valuation will be something we'll always consider. So we've also be very disciplined about doing a transaction where the valuation seem pretty high, which is what they are today."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Matt. That concludes the Q&A. I will now turn the discussion back over to Dominic for some closing remarks.",21,"Thank you, Matt. That concludes the Q&A. I will now turn the discussion back over to Dominic for some closing remarks."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Okay. Thanks, Joe. As I noted earlier, we're very pleased with our overall performance this quarter, and we're tracking well through the second half of the year. I would like to thank Joaquin and Bill for their outstanding leadership and for the great pre",109,"Okay. Thanks, Joe. As I noted earlier, we're very pleased with our overall performance this quarter, and we're tracking well through the second half of the year. I would like to thank Joaquin and Bill for their outstanding leadership and for the great presentation they gave this morning about the continued progress we are making in our pharmaceutical business. I would also like to thank all of our colleagues around the world for the extraordinary achievements and dedication to the success of Johnson & Johnson. 
Thank you for your time today, and I look forward to updating you on our full year results in January. Have a great day."
139677,381738381,1056201,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Thank you. This concludes today's Johnson & Johnson Third Quarter 2016 Earnings Conference Call. You may now disconnect.",18,"Thank you. This concludes today's Johnson & Johnson Third Quarter 2016 Earnings Conference Call. You may now disconnect."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Good morning, and welcome to the Johnson & Johnson Third Quarter 2016 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] I would now like",52,"Good morning, and welcome to the Johnson & Johnson Third Quarter 2016 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] 
I would now like to turn the conference call over to Johnson & Johnson. You may begin."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Good morning. I'm Joe Wolk, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure to welcome you to the review of our business results for the third quarter of 2016.  Joining me on the call today are Dominic Caruso, Chief Finan",1968,"Good morning. I'm Joe Wolk, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure to welcome you to the review of our business results for the third quarter of 2016.  Joining me on the call today are Dominic Caruso, Chief Financial Officer; Joaquin Duato, Worldwide Chairman, Pharmaceuticals; and Dr. Bill Hait, Global Head of Pharmaceutical Research and Development. 
A few logistics before we discuss the results. This review is being made available via webcast, accessible through the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. 
I will begin today's presentation by briefly reviewing the third quarter sales and earnings results for the corporation and sales results for each of our 3 business segments. Next, Joaquin and Bill will provide an update on our Pharmaceutical business, specifically highlighting how our focus on innovation to address unmet medical needs translates to current and future strong performance. Dominic will then provide some additional commentary on the results, review the income statement and discuss guidance for 2016. Lastly, we will open the call to your questions. We expect today's call to last approximately 90 minutes. 
Included with the press release issued earlier this morning is the schedule of sales for key products and businesses to facilitate updating your models. These schedules are available on the Johnson & Johnson website, as is the press release. Please note, we will be using a presentation to complement today's commentary. The presentation is also available on our website. 
I'd like to remind you that some of the statements made during this review are or may be considered forward-looking statements. The 10-K for fiscal year 2015 and the company's subsequent filings identify certain factors that could cause the company's actual results to differ materially from those projected in any forward-looking statements made here today. The company does not undertake to update any forward-looking statements as a result of new information or future events or developments. 
During the review, non-GAAP financial measures are used to provide information pertinent to ongoing business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with GAAP results. Tables reconciling these measures to the most comparable GAAP measures are available in the schedules accompanying the press release and on the Investor Relations section of the Johnson & Johnson website. 
During the course of today's presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. This slide is an acknowledgment of those relationships. 
I would now like to review our results. Worldwide sales to customers were $17.8 billion for the third quarter of 2016, up 4.2% versus the third quarter of 2015. On an operational basis, sales were up 4.3% and currency had a negative impact of 0.1%. 
In the U.S., sales were up 6.7% while regions outside the U.S. were up 1.5%, comprised of 1.7% operational growth, partially offset by negative impact of currency exchange rates of 0.2%. On an operational basis, the Western Hemisphere, excluding the U.S., declined 1.3%. You may recall that we highlighted growth in the second quarter of 2016 being favorably impacted by an inventory build, which did reverse in the third quarter. Europe grew by 3.2% while the Asia-Pacific, Africa region grew 1.4%. 
Excluding the net impact of acquisitions and divestitures and hepatitis C, underlying operational sales growth was 5.9% worldwide, 7.3% in the U.S. and 4.2% outside the U.S. Additionally, operations in Venezuela reduced reported sales growth. Worldwide, this impact was a reduction of 30 basis points; and outside the U.S., 70 basis points. 
Turning now to earnings. Net earnings were $4.3 billion, and earnings per share were $1.53 versus $1.20 a year ago. As referenced in the table reconciling non-GAAP measures, 2016 third quarter net earnings were adjusted to exclude after-tax amortization expense of $236 million and a charge of $175 million for after-tax special items. Dominic will discuss special items in his remarks. 
Excluding amortization expense and special items for both periods, adjusted net earnings for the current quarter were $4.7 billion, and adjusted diluted earnings per share were $1.68, representing increases of 12.2% and 12.8%, respectively, as compared to the same period in 2015. On an operational basis, adjusted diluted earnings per share also grew 12.8%. 
Beginning with Consumer, let's now turn to segment highlights for the quarter. Please note that the percentages quoted for all segments represent operational sales change in comparison to the third quarter of 2015 unless otherwise stated and, therefore, exclude the impact of currency translation. 
Worldwide Consumer segment sales totaled $3.3 billion, increasing 0.1% from the third quarter of 2015. U.S. sales were up 1.1% while sales outside the U.S. declined 0.6%. Excluding the net impact of acquisitions and divestitures, underlying sales fell 0.4% worldwide, with a decline of 1.5% in the U.S. and growth of 0.3% outside the U.S.  
In addition, operations in Venezuela negatively impacted growth worldwide and outside the U.S. by 110 basis points and 180 basis points, respectively, with the most pronounced impact occurring in Women's Health. Growth was driven by worldwide Skin Care and OTC sales outside the U.S. Baby Care experienced declines over the third quarter of 2015. 
Performance in the Consumer segment was negatively impacted by slower market growth and reductions of customer inventory levels. Overall, the impact of inventory reduction was approximately 3 points on Worldwide Consumer sales growth for the quarter, with the most pronounced effect on OTC and Skin Care results. Dominic will discuss these factors in further detail later in the call. 
OTC sales grew 1.8% worldwide. Results were driven by strong consumption in smoking cessation products across Europe and new product launches in Europe and Asia. U.S. sales growth due to share gains was partially offset by trade inventory levels impacting growth in the U.S. by approximately 10 points, where, as highlighted, for the third quarter of 2015, the business experienced launch build in pain, allergy and digestive health. Also, a weak allergy season in the U.S. during 2016 negatively impacted inventory levels in the third quarter of 2016. In the U.S., adult analgesic market share was approximately 14%, up from 13% a year ago, while U.S. pediatric share was approximately 49%, up from 44% a year ago. 
Skin Care grew 12.2% worldwide and 18.9% in the U.S. These results include the sales from the recent Vogue, NeoStrata acquisitions, which are captured in the U.S. O-U.S. results were driven by stocking of  Dabao products in China and share gains in Latin America. Inventory levels negatively impacted worldwide sales growth by 3 points. Successful marketing campaigns and new products continue to drive the results for LISTERINE in Oral Care. Divestitures impacted sales growth in Wound Care/Other and Women's Health categories. 
Moving now to our Pharmaceutical segment. Worldwide sales of $8.4 billion increased 9.0%, with U.S. sales up 11.8% and sales outside the U.S. up 5.0%, driven by strong performance of new products as well as growth from our core products. Excluding sales of hepatitis C products, OLYSIO and INCIVO, as well as the impact of acquisitions and divestitures, underlying worldwide sales growth was 10.7% as sales in the U.S. were up 13.0%; and outside the U.S., up 7.0%. Contributors to growth included Immunology products, REMICADE, SIMPONI and STELARA; Oncology products, IMBRUVICA and DARZALEX; as well as INVEGA SUSTENNA/XEPLION/TRINZA and XARELTO. 
In Immunology, REMICADE, STELARA and SIMPONI/SIMPONI ARIA achieved strong growth in the U.S. due to market growth and increasing share for STELARA. The results reported for REMICADE export sales was driven entirely by a change in inventory levels accounting for approximately 90 points of growth. Specifically, there was an inventory build of approximately $55 million in the current period and $110 million impact from lower level inventories that we noted in the third quarter of 2015 results. 
Biosimilar competition continues to negatively impact performance of export sales. 
In Neuroscience, INVEGA SUSTENNA/XEPLION/ TRINZA achieved strong results, with worldwide sales growth of 21% due primarily to increased market share. As expected, during the quarter, we saw the impact from generic entries for INVEGA tablets in the U.S. 
In Oncology, strong patient uptake with new indications, approvals and demonstrated efficacy drove results for IMBRUVICA in the U.S. Sales increased 92% worldwide, and IMBRUVICA remains the leader in both new and total patient regimen share in second-line CLL and MCL. 
Outside the U.S., IMBRUVICA continues to experience strong adoption in Canada, in the G5 and has recently launched in Japan, Hong Kong and Korea. 
ZYTIGA sales grew 5.3% worldwide. In the U.S., market growth was essentially flat while market share was up almost 2 points sequentially. Sales outside the U.S. were tied to share gains in Japan and adoption in China since the launch in January of this year. 
DARZALEX continues to gain strong acceptance as a treatment for multiple myeloma and contributed approximately 2 points of Worldwide Pharmaceutical sales growth. 
Turning to Cardiovascular and metabolics. XARELTO continued strong share performance, with TRx market share up 1.7 points versus Q3 of 2015 to 17.5%. Warfarin represents approximately 55% of the total market, down from 62% in the third quarter of 2015. XARELTO continues to be broadly reimbursed, with over 95% of commercial and Medicare Part D patients covered at the lowest branded product copay. 
INVOKANA/INVOKAMET sales declined 3%, with the U.S. down 8.7% due to an increase in price discounts. Some of the increase in discounts is attributable to higher copay program cost in the quarter. While the defined market of type 2 diabetes, excluding insulin and metformin, was up approximately 5%, TRx share was essentially flat to the third quarter of 2015. TRx share with endocrinologists was approximately 11% and approximately 6% with primary care. 
I'll now review the results of the Medical Device segment. Worldwide Medical Device segment sales of $6.2 billion increased 0.7% with U.S. sales increasing 1.4% and sales outside the U.S. decreasing 0.2%. 
As a reminder, Cordis was divested in the fourth quarter of 2015. Excluding the net impact of acquisitions and divestitures, underlying growth was 3.1% worldwide, with the U.S. up 2.3% and growth of 3.9% outside the U.S. Additionally, the devaluation of Venezuela impacted growth worldwide by 10 basis points and outside the U.S. by 30 basis points. 
Growth was driven by electrophysiology, Advanced Surgery, Vision Care and Orthopaedics, slightly offset by general surgery and Diabetes Care. Electrophysiology within Cardiovascular grew 16% worldwide, driven by continued share gains in the U.S. and Europe as the atrial fibrillation procedure market increases. Orthopaedics sales growth was driven by joint reconstruction and U.S. trauma. Pricing pressure continued across all major categories but was partially offset by positive mix in trauma and spine, continued success of the TFNA nailing system in trauma, the ATTUNE platform in knees and the  CORAIL primary stem in hips contributed to the sales results. 
Within Advanced Surgery, endocutters grew 14%, energy was up 10% and biosurgicals up 7%. The acquisition of NeuWave Medical, closed in the second quarter of this year, also contributed modestly to growth. 
Vision Care sales were higher by 5.5% worldwide as new products launched late last year continued on an upward trajectory across all regions. Worldwide general surgery declined by approximately 2% due to discontinuing certain products in Women's Health and hernia, partially offset by both market growth and share gains in sutures. Competitive pressures and price erosion continue to impact Diabetes Care. 
That concludes the segment highlights for Johnson & Johnson's third quarter of 2016. To assist with your models, this slide provides you with a summary of important developments that occurred during the quarter. 
It is now my pleasure to turn the discussion over to Joaquin Duato, Worldwide Chairman, Pharmaceuticals, to inform you about the state of the Pharmaceutical business and the progress made since our May 2015 Business Review Day. Joaquin?"
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thanks, Joe, and good morning, everyone. I'm very pleased to share an update on our Pharmaceutical sector. Since May 2015, when we last met, our Pharmaceuticals business has continued to flourish and remains the primary growth engine of Johnson & Johnson.",1845,"Thanks, Joe, and good morning, everyone. I'm very pleased to share an update on our Pharmaceutical sector. Since May 2015, when we last met, our Pharmaceuticals business has continued to flourish and remains the primary growth engine of Johnson & Johnson. Our market-leading innovative medicines are the foundation of our strong performance, with the vast majority of their growth coming from volume gains. We continue to pursue significant growth opportunities in terms of both penetration within existing indications and planned line extensions. 
Additionally, we have launched DARZALEX, the first of our 10 potential billion-dollars-plus NMEs. As a result, we remain confident that we'll continue to deliver strong growth through 2019 despite biosimilar competition and market dynamics. Our success is a result of our strong track record of execution. Our industry-leading pipeline has delivered 12 NMEs since 2011 and 8 Breakthrough Therapy designations since 2013. And for the fourth year, we are proud to have been named the #1 company in R&D and commercial productive innovation. 
Our focused execution has delivered 11 in-market, billion-dollars-plus brands. 10 of these brands are growing, and 6 of them are growing double digit. Cumulatively, sales from our medicines launched since 2011 are the second highest of any pharmaceutical company. Our R&D and commercial capabilities are a proven strong foundation for future growth. 
First, we will continue to focus on driving volume growth across our current market-leading brands through clinical differentiation. Second, we will accelerate the growth of these in-market brands through approximately 40 potential line extensions. Critically, 10 of these line extensions have more than $0.5 billion potential. Third, as we shared last year, we have a [indiscernible] pipeline investing in 10 potential billion-dollar-plus NMEs planned to be filed through 2019. Of these, we anticipate 5 to deliver significant growth opportunities in the near term. 
Since 2015, our expectations around these near-term opportunities have crystallized. Our latest information provides higher certainty that these products will succeed delivering higher value than originally anticipated. DARZALEX, launched last year, is significantly outperforming expectations. According to your own models, it is well on its way to becoming a multibillion-dollar brand. Sirukumab has just been filed in the U.S. and Europe. Guselkumab has just had very positive data versus Humira presented at the EADV, and we anticipate filing for psoriasis before year-end. 
Apalutamide has a broad clinical development program in both pre-metastatic and metastatic prostate cancer. We also are investigating it in combination with ZYTIGA and with our newly licensed PARP inhibitor, niraparib. Finally, esketamine is already in Phase III and recently received a second Breakthrough Therapy designation. Bill will provide additional clinical details on these near-term opportunities shortly. 
Finally, it is important to note that these 3 strategies will prepare us to deliver robust growth beyond 2019, paving the way for more than 25 potential next-generation NMEs in the 2020 to 2024 time frame. 
The strength of our in-market portfolio, complemented by our near-term line extensions and NME launches, will be more than offset upcoming headwinds, including those anticipated for REMICADE. 
We are fully prepared to execute a focused biosimilar readiness plan. Yesterday, the launch of a U.S. biosimilar to REMICADE was announced for later this year. However, the appeals process is still ongoing, and we believe any commercial launch of a biosimilar remains at risk. 
Biosimilars are very different from generics. For example, in Canada, Australia and Brazil, where there is already biosimilar competition to REMICADE, we have maintained more than 90% volume share. Our U.S. commercial team is ready for a potential biosimilar launch. 
I'm confident in our strategy for 3 reasons. First, with no biosimilar approved for interchangeability, REMICADE's significant long-term safety data, a strong advocacy from patients and clear physician preference means that the 70% of patients who are stable on REMICADE are highly unlikely to switch. Second, our patient assistance programs provide a leading market differentiator. Third, we are confident that we can continue to provide a cost-effective option in all channels. The current market is extremely competitive, and REMICADE ASP is already significantly lower than the list price 
Additionally, in developing innovative contracts, we can utilize the full breadth of our portfolio. 
Our Immunology franchise remains poised to grow through 2019. We have a strong market position and a deep near-term pipeline. Let me give you some examples. Already in rheumatoid arthritis, SIMPONI ARIA is the fastest-growing IV product in the U.S. and has higher new-to-brand share than REMICADE. Outside of the U.S., we continue to gain share with SIMPONI, too. Additionally, we plan to file 2 line extensions for SIMPONI ARIA in psoriatic arthritis and ankylosing spondylitis. Together with the recent submissions of sirukumab for the approval in the U.S. and Europe, we will further strengthen our leading position in Rheumatology. 
Turning to psoriasis. STELARA continues to be the #1 biologic in new-to-brand share in the U.S. and maintains clear share leadership in key markets internationally. One of our 10 potential billion-dollars-plus brands, Guselkumab, is expected to provide a significant boost to our leadership in psoriasis, and Bill will share more on this important upcoming filing. 
Finally, moving to Gastroenterology. The most exciting news is the recent launch of STELARA for Crohn's disease in the U.S. and its anticipated launch in Europe. There is tremendous unmet need in this debilitating disease. For example, 70% to 80% of Crohn's patients on anti-TNFs are not in remission at 1 year, and the patient population is expected to grow 50% over the next decade. This is the first in a series of line extensions, including UC, which will drive more than 35% of STELARA performance by 2019. 
Moving now to Cardiovascular and metabolics. INVOKANA continues to be a standout performer. Globally, it is the leading  SGLT2 inhibitor and the third largest known insulin diabetes medicine. Put into perspective, in the U.S., there have been more prescriptions filled for INVOKANA and INVOKAMET than all other  SGLT2 inhibitors combined. A total of more than 1.3 million patients are treated in the U.S. alone. 
As Joe mentioned earlier, INVOKANA's performance dipped this quarter due to temporary increased costs to administer copay patient access programs. However, I want to emphasize that this was a transitory event. Our return to growth will be driven by INVOKANA's strong access position across U.S. commercial plans and Medicare Part D and the recent approval of INVOKAMET XR. We are expecting our cardiovascular outcomes data to read out in mid-2017. 
XARELTO is another market leader in our Cardiovascular and metabolics portfolio, delivering double-digit growth every year since its launch in 2011. To date, XARELTO has already treated more than 3.8 million patients in the U.S. and is supported by an extremely robust published real-world dataset, including evidence from more than 91,000 patients demonstrating consistency with our clinical trials. As a result, it is broadly reimbursed, with more than 95% Medicare and commercial patients on formulary at the lowest branded copay. 
These considerable achievements are just a start. Approximately, 54% of potential patients are still utilizing Warfarin, presenting significant growth opportunities in current indications.  Additionally, there are 8 new indications seeking clinical studies underway as part of EXPLORER, the largest clinical development program within the anticoagulant space. If successful, the potential patient pull could increase more than fivefold. 
Turning to Neuroscience. INVEGA TRINZA is a growth catalyst for the entire long-acting therapy franchise. Notably, INVEGA TRINZA is the fastest-growing LAT in the U.S. It has also contributed to growing INVEGA SUSTENNA scripts 26% in the 13 months since launch. 
Significant opportunities for growth remain as only 11% of patients are treated with LATs in the U.S. 
Celebrating 10 years of innovation this year, our HIV portfolio has achieved approximately 20% growth annually and cumulative sales of more than $15 billion. Today, 25% of patients in developed markets are treated with a J&J HIV medicine. Our class-leading portfolio has benefited more than 1 million patients, and this legacy will continue with upcoming line extensions. When Prezista first launched, it was part of a 6-tablet regimen. The first upcoming line extension, darunavir single-tablet regimen, will reduce this number to 1, improving adherence and safety. Also, we expect 2 rilpivirine fixed-dose combinations, one with Gilead's TAF and another one with ViiV's dolutegravir, that will drive additional growth for 2019. 
Finally, let's move to our fastest-growing therapeutic area, Oncology. IMBRUVICA has led the recent growth of our oncology franchise, accelerating from a record-breaking global launch to clear market share leadership in total patients in the first-line chronic lymphocytic leukemia. Today, IMBRUVICA is reimbursed in 41 countries with world-class market access. Since launch, an additional 6 indications have been approved, and we anticipate an additional 7 new registrations ahead, 4 of which have $500 million-plus potential.  Together with a number of promising combination therapies in development, these new indications will usher in a very exciting future for IMBRUVICA. 
IMBRUVICA's leadership in Oncology is mirrored by our recently launched asset, DARZALEX. Only 3 months after its launch, DARZALEX became the #1 prescribed therapy in fourth-line and later multiple myeloma. From a launch-aligned sales perspective, DARZALEX has continued to far outpace its competitors. This first-in-class medicine has since been improved in the EU and Canada and is driving positive share trends in earlier therapy lines in the U.S. We are confident DARZALEX can become the standard of care in multiple myeloma and help even more than the 10,000 patients who have benefited already worldwide. 
Growth will continue to accelerate with the anticipated approval in second-line patient populations and the impressive data from the recently published CASTOR and POLLUX studies. An additional 5 Phase III trials are currently underway as well as development of a subcutaneous formulation. As Bill will detail, we have also seen some positive data that DARZALEX may be effective outside of multiple myeloma. What should be clear today is that all of our current market-leading medicines have significant potential for continued volume growth. 
Additionally, we have a multitude of promising potential line extensions across every therapeutic area, approximately 40 in total, by 2019. Of these, 10 have more than $0.5 billion potential. The remaining 30 potential line extensions are not insignificant.  Cumulatively, the line extensions for XARELTO and INVOKANA have the potential to drive $3 billion to $5 billion in incremental sales for the Cardiovascular franchise. We believe these new indications will be a key driver of our growth through 2019 even in the context of biosimilars and market dynamics. 
In my 6 years leading our Pharmaceutical sector, I have never been more excited and more positive about our future as I am today. We have significant growth potential throughout our portfolio with market-leading brands; 40 anticipated line extensions, 10 of which have more than $0.5 billion potential; and 10 NMEs with more than $1 billion potential to be filed by 2019. Combined, these factors will ensure that we continue to outpace the industry growth through 2019. 
It is now my privilege to turn the call over to Dr. William Hait, who heads up our R&D organization. Bill will provide additional detail about our pipeline that is set to deliver this groundbreaking treatments. Bill?"
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Joaquin. Good morning, everyone. My name is Bill Hait, and I'm the Global Head of Research and Development for the Janssen Pharmaceutical Companies of Johnson & Johnson. As Joaquin indicated, at Janssen, we believe that by continuing to execu",2081,"Thank you, Joaquin. Good morning, everyone. My name is Bill Hait, and I'm the Global Head of Research and Development for the Janssen Pharmaceutical Companies of Johnson & Johnson. 
As Joaquin indicated, at Janssen, we believe that by continuing to execute our current strategy, we will consistently deliver valuable products to patients with serious unmet medical needs and that this will sustain our leadership in the pharmaceutical industry. Our strength is built on a blend of deep internal scientific expertise with industry-leading collaborations through the work of Johnson & Johnson innovation. We continue to find efficiencies that produce savings that we invest in our pipeline, and our strategic focus creates an enviable track record. We are delivering against our anticipated 2015 to 2019 NME and LE results that will produce a cadence of significant clinical data, regulatory filings and approvals. For these reasons and the results I will describe today, Janssen has become one of the most productive and most respected pharmaceutical companies. 
Before I share with you the details of our pipeline progress, let me explain how and why we have been able to sustain industry-leading results. Our 5 end-to-end therapeutic areas span basic drug discovery through launch and life cycle management. This structure produces a focused, seamless R&D organization, promotes efficient phase transitions and ensures dedication to major unmet medical needs where there is compelling, translatable science. These 5 therapeutic areas concentrate on 11 high-priority disease areas through our disease area strongholds, nimble and efficient biotech-like teams embedded in the broader context of the therapeutic areas. Each disease area stronghold undergoes rigorous triennial review by our external scientific advisory board, receives a priority score and proportional funding of discovery and early development. 
Our therapeutic areas are supported by substantial research capabilities through our centers of excellence, including biotechnology; medicinal chemistry; diagnostics; clinical operations; and, most recently, oligonucleotide and nucleic acid chemistry, expertise garnered through the acquisition of Alios. Assets that transition into late development are prioritized into 3 categories to ensure that our investment of resources align with our most promising targets. Currently, our top 2 categories, which represent 40% of our assets and 80% of our overall late-development value, receives 60% of our investment. It is through this approach that we remain at the top of the industry in successful phase transitions and speed to market. 
Janssen has achieved considerable success, and we are poised to continuously deliver near- and long-term growth. Our balanced investment across all aspects of our pipeline allows us to enjoy a constant flow of important new data. We launched 12 new products since 2011. We received the most FDA approvals from 2011 to 2016 as well as 8 Breakthrough Therapy designations. 
For 4 consecutive years, we have been named the innovation leader by IDEA Pharma and became the partner of choice through the work of J&J innovation. And for the third consecutive year, Fortune Magazine ranked Janssen Pharmaceutical Companies of Johnson & Johnson #1 in the pharmaceutical category on its annual World's Most Admired Companies list. Our unwavering commitment to global public health is demonstrated by SIRTURO, the first new drug for the treatment of tuberculosis in over 40 years; as well as our work on new, convenient HIV combinations; the first prime-boost Ebola vaccine using Crucell's adenoviral vector and Bavarian Nordic's MVA vector; as well as new chewable forms of mebendazole for children with worm infestations. 
As Joaquin mentioned and as we highlighted at our 2015 Pharmaceutical Business Review Day, between 2015 and 2019, we plan on filing approximately 10 new drugs, each with a potential for greater than $1 billion in peak year sales and 40 line extensions. This slide highlights 10 of these, anticipated to be filed in the 2015 to 2019 time period, with peak year sales potential greater than $0.5 billion 
In addition, our early pipeline is rich in important assets that have the potential to file between 2020 and 2024. We are on track to deliver our anticipated NME and LE results through a cadence of significant clinical data, regulatory filings and approvals. Since May 2015, we garnered 3 new product approvals and filings, with the fourth, Guselkumab, anticipated this year, and we achieved 16 significant line extensions. 
Now let me use our time together to describe in greater detail some of the progress we have made since our May 2015 Pharmaceutical Business Review. Oncology is the newest of our 5 therapeutic areas and achieved industry-leading growth based on our development of several first-in-class drugs, including ZYTIGA, IMBRUVICA and DARZALEX. Our hem malignancies disease area is anchored by IMBRUVICA and DARZALEX. 
IMBRUVICA, the first BTK inhibitor for the treatment of certain B-cell malignancies, received 4 FDA Breakthrough Therapy designations. IMBRUVICA was recently approved for frontline use, based on the unprecedented results in previously untreated CLL patients reported in the RESONATE-2 study published in the December 15 issue of the New England Journal. As shown on this slide, treatment with ibrutinib decreased progression or death from CLL by 84% compared to chlorambucil and demonstrated a similar improvement in overall survival. 
DARZALEX, the first monoclonal antibody for the treatment of multiple myeloma, received 2 FDA Breakthrough Therapy designations and was approved almost 4 months ahead of its PDUFA date in double-refractory myeloma. As shown on this slide, combination therapy with DARZALEX delivered impressive results in treatment of relapsed or refractory multiple myeloma patients. The CASTOR and POLLUX studies demonstrated that the addition of DARZALEX to Velcade  and dexamethasone or REVLIMID and dexamethasone, respectively, produced a greater than 60% decrease in risk of progression or death as compared to that of Vel/dex or REV/dex alone, both of these studies were published in the New England Journal. This month, the FDA granted priority review for daratumumab in combination with lenalidomide and dexamethasone or bortezomib and  dexamethasone for relapsed multiple myeloma with a PDUFA date in February 2017. 
Our prostate cancer disease area is anchored by ZYTIGA, the first CYP17 inhibitor for the treatment of men with metastatic castrate-resistant prostate cancer and is approved for both pre- and post-chemotherapy indications. Furthermore, we are developing ARN-509, now known as apalutamide, a more potent next-generation androgen receptor antagonist that shows a high degree of safety and efficacy in castrate-resistant prostate cancer. As seen in these figures, apalutamide decreased PSA by a median of 85% in patients with non-metastatic castrate-resistant prostate cancer after 12 weeks of treatment. The maximum PSA response, shown on the right-hand figure, was achieved in 94% of patients. 
Earlier this year, we licensed niraparib from TESARO to obtain a highly potent and selective PARP inhibitor for the treatment of prostate cancer patients with DNA repair defects for use in combination with ZYTIGA or apalutamide. Niraparib is in Phase II clinical trials and currently planned to be filed by 2019. This portfolio of assets gives us confidence that we will continue to bring great results to patients with prostate cancer for many years to come. 
While we did not explicitly address immuno-oncology during our 2015 Pharmaceutical Business Review, we continue to make significant progress in this area. Over the last 5 years, we invested in 4 critical areas, including vaccines, T-cell checkpoint inhibitors, T-cell redirection and myeloid mechanisms of actions. We currently have 15 immuno-oncology assets in development, including 8 that are in the clinic. 
Recently, we uncovered an important additional mechanism of action of DARZALEX to be immune-mediated through the depletion of immunosuppressive myeloid in lymphoid populations, including a previously unrecognized super-suppressor, CD38+ T-reg population; as well as activation of CD8 and CD4+ effector T-cells. These results provide the impetus for exploring DARZALEX in indications beyond hem malignancies in solid tumors. 
Our Immunology therapeutic area continues to deliver extraordinary products for patients with psoriasis, inflammatory bowel disease and rheumatoid arthritis. STELARA was the first IL-12, IL-23 monoclonal antibody introduced for moderate to severe plaque psoriasis and active psoriatic arthritis. It was recently approved in moderately to severely active Crohn's disease in the U.S, received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency and offers new options for adult patients with IBD. 
Guselkumab is a first-in-class selective anti-IL-23 monoclonal antibody that demonstrated significant efficacy versus placebo in superiority compared with the antitumor necrosis factor, adalimumab, in moderate to severe plaque psoriasis. The VOYAGE study, whose results are shown in this slide, randomly assigned 750 patients to receive guselkumab, adalimumab or placebo followed by guselkumab in the 2:2:1 ratio. Patients treated with guselkumab achieved a significantly greater chance of obtaining a PASI 90 score compared to that of patients treated with adalimumab or placebo at week 16, and the advantage over adalimumab was sustained through week 48. The high degree of efficacy of guselkumab, the less intensive dosing regimen and the potential for a STELARA-like safety profile makes guselkumab highly competitive with newly launched anti-IL-17 antibodies. We plan to file for psoriasis this year and advance guselkumab into Phase III for patients with psoriatic arthritis. 
Neuroscience is a historically strong area for Janssen since Dr. Paul Janssen and colleagues developed haloperidol, the first medication for schizophrenia. We have built on Dr. Paul's legacy with the development of next-generation antipsychotics and pioneered the development of long-acting injectables that help improve compliance for this difficult-to-treat patient population, most recently with the approval of INVEGA TRINZA, an every-3-month injectable formulation. 
Today, we focus our neuroscience investment in drugs that treat serious mood disorders, including depression, suicidality and Alzheimer's disease. Esketamine, an intranasally-delivered enantiomer of ketamine, produced groundbreaking results in major depressive disorder, with onset of action measured in hours to days rather than weeks to months. There's an alarming increase in suicides, both in the U.S. and globally, more than 41,000 each year in the U.S. alone. It's a tragic issue that's emerging as a major health priority. As shown in this slide, esketamine ameliorated suicidal ideation within 4 hours and sustained this effect for over 3 weeks, leading to its second FDA Breakthrough Therapy designation. 
Infectious Diseases is one of our most exciting and important areas in investment for future growth, where we focus on respiratory infections and hepatitis. We are pursuing an aggressive strategy for the cure of hepatitis C. We recently reported a 100% SVR12 in patients with genotype 1, with both an 8- and 6-week duration of treatment using a 3DAA combination of OLYSIO, AL-335 and  odalasvir.
Based on this exceptional data, we are moving the 3DAA regimen into late-development studies. 
Our Cardiovascular and Metabolism therapeutic area developed both INVOKANA and XARELTO in partnership with Mitsubishi Tanabe and Bayer, respectively. New line extensions are designed to continue to bring value to these 2 first-in-class drugs. With XARELTO, we are pursuing studies in congestive heart failure, embolic stroke of undetermined source, VTE prevention in medically ill patients, infrainguinal peripheral artery disease, VTE prevention in cancer patients and an acute coronary syndrome. We anticipate readouts from 2 INVOKANA cardiovascular outcomes studies by mid-2017, which we believe will further strengthen the importance of the SGLT2 inhibitor class in the treatment of patients with diabetes. We are also studying the role of INVOKANA in diabetic kidney disease and plan to address obesity and prediabetes. 
In summary, at the Janssen Pharmaceutical Companies of Johnson & Johnson, we are executing a clearly defined innovation strategy that drives value to patients around the world. We are on track to meeting our anticipated results described in 2015. We are producing the cadence of transformational innovations that are leading to exceptional results. We are a leader in productivity, approvals and FDA Breakthrough Therapy designations, and we are one of the fastest-growing top 10 pharmaceutical companies. 
We have had the most U.S. FDA approvals in the last 5 years, 2011 to 2016, and 8 Breakthrough Therapy designations. We anticipate filing approximately 10 NMEs between 2015 and 2019, each with greater than $1 billion peak year sales potential.  We have approximately 40 planned line extension filings anticipated between 2015 and 2019, several with greater than $500 million in peak year sales potential, supported by a steady flow of clinical data that drive better patient results. Finally, we take pride in delivering years of lives saved and better quality of life for our first credo responsibility to the doctors, nurses and patients who use our products. 
Now before I turn it over to Dominic, for your reference, let me leave you with a current overview of our pipeline across our 5 therapeutic areas. Dominic will now continue with an update of the company's financial results."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Bill and Joaquin,  and good morning, everyone. As you just heard, our Pharmaceutical business is well positioned for continued above-industry growth as we make good progress against the pipeline expectations we communicated at our 2015 Pharmace",2502,"Thank you, Bill and Joaquin,  and good morning, everyone. As you just heard, our Pharmaceutical business is well positioned for continued above-industry growth as we make good progress against the pipeline expectations we communicated at our 2015 Pharmaceutical Business Review. With great leaders like Joaquin and Bill, our strong in-market performance driven by excellent commercial capabilities and our robust R&D pipeline, you can see why we remain confident that our Pharmaceuticals business will continue to be a major driver of growth moving forward. 
I will now turn our discussion back to the quarter. We're pleased with our overall results. As you know, we had a strong start to the year, and as a result, last quarter, we increased our sales and earnings guidance. I'm happy to say we're tracking with those higher expectations while continuing to invest in our business. As you've heard, our Pharmaceutical business delivered strong results this quarter, with underlying operational growth of 10.7%. 
Let me now provide some comments on our other businesses. In our Consumer business, we continued to gain share this quarter. However, as reported by Nielsen, the industry saw a slowdown in many markets, with category growth rates in 2016 about half of the category growth rate we saw in Q3 of 2015. As Joe noted, our sales growth for the quarter was also impacted by lower trade inventory levels. These lower levels are the result of inventory builds in Q3 2015, as we discussed at that time, due to relaunches of certain products as well as inventory reduction programs being implemented at some of the larger retailers this past quarter. When excluding the impact of acquisitions and divestitures and the impact of the devaluation that occurred in Venezuela last year and this overall impact from trade inventory reductions, overall consumer growth was nearly 4%. Based on increasing share trend of our brands, we expect trade levels to align with consumption going forward. 
In Medical Devices, consistent with some recent analyst reports about the market, we believe the industry experienced lower hospital admissions and procedure rates during the mid-summer months. 
Late in the quarter, several reports showed higher levels of activity, and in fact, the data that we recently saw published for September looked encouraging. Additionally, we are very pleased to see our priority platforms continue to deliver robust growth of nearly 9%, with some at double digits, as Joe mentioned earlier. 
Overall, Hospital Medical Devices' operational growth, excluding acquisition and divestitures, was approximately 4% this quarter. 
In the Consumer Medical Device businesses, we saw continued price erosion in our Diabetes business. However, in our Vision Care business, we saw good operational growth of 5.5%. 
So in summary, as we previously discussed, in 2015, our underlying operational growth, which excludes the impact of acquisitions, divestiture as well as hepatitis C sales and the few extra shipping days that we saw in 2015, was about 5.5%. On this same basis, we continued to accelerate our growth, and we delivered strong underlying operational sales growth of approximately 5.9% for the third quarter of 2016. 
Our sales were above analyst estimates, as were earnings, due to significantly higher pretax operating margins. As you may remember, our guidance from January included a more than 200 basis point increase in our 2016 pretax operating margin, on an adjusted basis. We have attained that level year-to-date while continuing to invest on our business, and we remain comfortable with that forecast for the full year as we continue to execute on the restructuring activities in our Medical Device businesses while also investing in growth. 
As you know, in September, we announced a definitive agreement to acquire Abbott Medical Optics . We expect this transaction to close in Q1 of 2017. So for 2016, the transaction is expected to have no impact to our adjusted earnings and is not expected to impact our guidance. For 2017, again assuming a Q1 close, the transaction is expected to be positive to sales growth and immediately accretive to adjusted EPS. We are excited about Abbott Medical Optics' strong and differentiated surgical ophthalmic portfolio, particularly in cataract surgery. That, coupled with our world-leading ACUVUE contact lens business, will help us become a broad-based leader in Vision Care. 
Now I'll take the next few minutes to highlight some key points regarding our results for the quarter, and then I'll provide some updates to our guidance for you to consider in refining your models for the remainder of 2016. I will now turn to our consolidated statement of earnings for the third quarter of 2016. Our operational sales growth this quarter was 4.3%, and when we exclude the impact of acquisitions and divestitures, the impact of hep C sales and the overall impact that Venezuela had, it was strong at more than 6%. 
If you direct your attention to the boxed section of the schedule, you will see we have provided our earnings adjusted to exclude intangible amortization expense and special items. As referenced in the table of non-GAAP measures, the 2016 third quarter net earnings were adjusted to exclude intangible amortization expense and special items of approximately $400 million on an after-tax basis, which consisted primarily of the intangible amortization expense of about $250 million and the anticipated special charges as we continue to execute on the Medical Devices restructuring plan. 
Our adjusted earnings per share is, therefore, $1.68, which exceeded the mean of the analysts' estimates, as published by First Call. This is an increase in adjusted EPS of 12.8% versus the prior year.  Adjusted EPS on a constant-currency basis was the same as the impact of currency was flat year-over-year. 
Now let's take a few moments and talk about other items of the statement of earnings. Cost of goods sold increased by 30 basis points mostly due to unfavorable transaction currency impacts, partly offset by favorable mix and manufacturing efficiencies. Selling, marketing and administrative expenses were 26.8% of sales or 290 basis points lower as compared to the third quarter of 2015 due to overall good cost management. Our investment in research and development as a percent of sales was 12.2%, lower by 40 basis points due primarily to lower milestone payments, partly offset by increased project spending as we advance our promising product pipeline. 
Our pretax operating margin, when excluding special items and intangible amortization expense, was 32% or 310 basis points higher than the third quarter of the prior year. As a reminder, pretax operating margin is defined as gross profit less selling, marketing and administrative expenses and less R&D expenses. As we anticipated, we are seeing improvement as we progressed throughout the year, and through 9 months, we have achieved a 220 basis point improvement in this measure of profitability, consistent with the expectations we communicated to you throughout the year. 
Interest expense net of interest income was similar to last year. Other income and expense was a net gain of approximately $50 million in the quarter compared to a net expense of approximately $400 million in the same period last year. Excluding the special items that are reflected in this line, other income and expense was a net gain of approximately $200 million compared to a net gain of approximately $400 million in the prior year period, which included a higher level of gains from divestitures. 
Excluding special items, the effective tax rate in the quarter was 19.7% compared to 20% in the same period last year. This year's effective rate reflects the R&D tax credit, which was passed by Congress late last year, and it reflects the current mix of our businesses and the impact from a new accounting standard relating to the tax benefit on share-based compensation, which we discussed in our call in July. 
Turning to the next slide. I will now review adjusted income before tax by segment. In the third quarter of 2016, our adjusted income before tax margin for the enterprise improved by 220 basis points versus the third quarter of 2015. You will notice significant improvements in margins for the Medical Devices and Pharmaceutical businesses.
Last year, our Consumer business benefited from a gain in the sale of SPLENDA, and you're seeing that reflected in their lower margin this quarter, although still had very healthy rates.
As you can see on the next slide, on a year-to-date basis, we are pleased to see solid improvement in our consumer margin, and we remain confident it will show an improved adjusted income before tax margin for full year 2016 as compared to 2015.
Overall, we expect adjusted income before tax margins for the enterprise to show an improvement over the prior year for all of 2016 as our increase in pretax operating profit margin, which I noted earlier, more than offsets the lower level of divestiture gains in 2016 as compared to 2015. 
Now I'd like to provide some guidance for you to consider as you refine your models for 2016. I'd like to start with some of the items that we know you are -- you find difficult to forecast. 
Let's start with cash and interest income and expense. At the end of the quarter, we had approximately $13 billion of net cash, which consist of approximately $40 billion of cash and marketable securities and approximately $27 billion of debt. 
Through the end of the third quarter, we completed nearly 60% of our $10 billion share repurchase program, and we expect to complete approximately 75% of the program by the end of this year.
For purposes of your models and assuming no major acquisitions or other major uses of cash, I suggest you consider modeling net interest expense of between $400 million and $450 million. There's a slight tightening of the range. 
Regarding other income and expense as a reminder, this is the account where we record royalty income as well as gains and losses arising from such items as litigation, investments by our development corp, divestitures, asset sales and write-offs. We will be comfortable with your models for 2016 reflecting net other income and expense, excluding special items as a gain, ranging from approximately $750 million to $850 million, a lower range than our previous guidance related to the underlying activity. This impact will be offset by a lower tax rate.
And now for taxes, we're very comfortable with your models reflecting an effective tax rate for 2016, excluding special items, of approximately 18% to 18.5%, which is lower than our previous guidance, primarily due to a higher level of income and lower tax jurisdictions. 
Now turning to sales and earnings. Our sales and earnings guidance for 2016 takes into account several assumptions and key factors that I would like to highlight. Our sales range for 2016 continues to remain the same whether or not a biosimilar REMICADE launches this year in the U.S.
Additionally, we do not anticipate biosimilar or generic competition this year for PROCRIT, ZYTIGA, RISPERDAL CONSTA and INVEGA SUSTENNA, but as expected, there are generic entrants for INVEGA and ORTHO TRI-CYCLEN LO. 
As we've done for several years, our guidance will be first based on a constant currency basis, reflecting our results from operations. This is the way we manage our business, and we believe this provides a good understanding of the underlying performance of our business. 
We've also provided an estimate of our sales and adjusted EPS results for 2016 with the impact that current exchange rates could have on the translation of those results. 
We continue to be comfortable with the sales guidance we provided last quarter, reflecting an operational sales increase on a constant currency basis of between 3% and 4% for the year. This was a result in sales for 2016 on a constant currency basis of between approximately $72.2 billion to $72.9 billion. 
Additionally, by way of comparison to how we described our sales results in 2015, our operational sales growth for 2016, excluding the impact of all acquisition, divestitures and hepatitis C, would be approximately 6%, a higher level of growth than we saw last year even after adjusting for the shipping days in 2015, which we mentioned earlier. 
Although we're not predicting the impact of currency movements, using the euro as of last week at $1.11, the negative impact of foreign currency translation would be approximately 1% on sales growth. This is consistent with our previous guidance as major currencies had not significantly fluctuated since our last update. 
So after impacts of currency, we would expect reported sales to reflect the change in the range of positive 2% to 3% for a total expected level of reported sales of approximately $71.5 billion to $72.2 billion, consistent with our previous guidance. 
And now turning to earnings. As a reminder, we expect transaction currency impacts to be negative to our gross margin by approximately 60 to 80 basis points in 2016 as compared to 2015. We would be comfortable with adjusted operational EPS guidance in the range between $6.71 and $6.76 per share on a constant currency basis, reflecting an operational or constant currency growth rate of 8% to 9%. And this is a narrowing of the range. 
If currency exchange rates for all of 2016 are to remain where they were as of last week, the negative impact to EPS would be approximately $0.03, consistent with our previous guidance. Therefore, we would be comfortable with our reported adjusted EPS range ranging from $6.68 to $6.73 per share, which again is a narrowing of our previous guidance with a midpoint that is $0.03 higher than our previous guidance range. 
Finally, just a reminder of some dynamics you will see in our fourth quarter results this year in comparison to the fourth quarter of 2015. In 2015, we had additional shipping days based on when our year-end closed, and that contributed approximately 4 points of sales growth in the fourth quarter last year. 
Additionally, in the fourth quarter last year, we closed on the Cordis divestiture. And based on our latest guidance for 2016, we will have significantly lower level of other income from divestitures as compared to the prior year. 
In closing, we are very pleased with our performance so far this year, and we remain confident and optimistic about our future full year growth for 2016. Specifically, we're expecting operational sales growth of 3% to 4% and underlying operational sales growth of 6%, a higher level that we experienced last year on a comparable basis. 
Our adjusted pretax operating margin improvements are on track to meet the expectations we laid out on our guidance of more than a 200-basis point improvement over the prior year. We narrowed our guidance and increased the midpoint for adjusted operational EPS growth, which remains strong in the range of $6.71 to $6.76 per share, with the growth rate of 8% to 9%. And we are very well positioned to seize the opportunities in our strong pipelines to continue fueling our future growth. 
Now I'd like to turn things back to Joe for the Q&A portion of the call. Joe?"
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Dominic. Michelle, can you please provide instructions for those on the line wishing to participate in the Q&A?",20,"Thank you, Dominic. Michelle, can you please provide instructions for those on the line wishing to participate in the Q&A?"
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","[Operator Instructions] Your first question comes from Larry Biegelsen with Wells Fargo.",12,"[Operator Instructions] Your first question comes from Larry Biegelsen with Wells Fargo."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Welcome, Joe. So Dominic, I wanted to focus on the 2017, the puts and takes. Dominic, at our health care conference in September, you said the only real delta from 2016 to 2017 is the rate at which a biosimilar REMICADE could penetrate the market, assumin",153,"Welcome, Joe. So Dominic, I wanted to focus on the 2017, the puts and takes. Dominic, at our health care conference in September, you said the only real delta from 2016 to 2017 is the rate at which a biosimilar REMICADE could penetrate the market, assuming Pfizer launches at risk, and you don't think the penetration will be dramatic. I took that to mean that you feel that you can grow sales in 2017 at a similar rate to 2016 minus the impact from biosimilar REMICADE. So my questions are, is that the right interpretation? What gives you the confidence that this level of growth will continue? And second, the biosimilar for Neupogen captured about 7% in the market in year 1. Would you expect inflector penetration to be less than that? Any color that you can give on the expected penetration would be helpful. And I do have one follow-up on pharma."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Sure, Larry. Thanks for the question. I think the way you characterized it is accurate, that excluding the impact of any biosimilar launch, we would expect the business to grow at a rate similar to what we saw this year in the pharma business, overall, as",176,"Sure, Larry. Thanks for the question. I think the way you characterized it is accurate, that excluding the impact of any biosimilar launch, we would expect the business to grow at a rate similar to what we saw this year in the pharma business, overall, as well as I think we will see improved performance in the Medical Device business, and we're see continued share gains in the consumer business. So I think that is a good way to characterize it. We'll provide more color on that when we talk about the 2017 guidance in our discussion in January. We do think that the rate of penetration for a biosimilar will be modest, and there are several reasons for that. As we talked about before, 70% of the patients are treated well with REMICADE. There is no interchangeability available, that's another factor, and we're already in a highly competitive environment with respect to biologics, anti-TNF therapies, as you know. Before any comment on Neupogen, Joaquin, anything else you want to add to overall penetration of biosimilars?"
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","We are confident that we have our readiness plan for our biosimilar launch in the U.S. What we have seen internationally, markets like Australia, Brazil, where we market REMICADE, is that our volume share has been in excess of 90%, so that is consistent w",178,"We are confident that we have our readiness plan for our biosimilar launch in the U.S. What we have seen internationally, markets like Australia, Brazil, where we market REMICADE, is that our volume share has been in excess of 90%, so that is consistent with what you described. We are confident that we have a strong plan based on what Dominic described before. There's been 2.6 million patients treated with REMICADE worldwide. There's no interchangeability and there's a clear patient and physician preference, so it's highly unlikely that you're going to be seeing patients that are stable in the REMICADE switched. So that is 70% of the patients. At the same time, we have a strong patient assistance program, which will prove to be a market differentiator, and we are ready to compete in every channel, trying to bring patients the most affordable option in every situation. So we feel well prepared to face the biosimilar. And as Dominic said, we are convinced that we will continue to grow our business in the face of biosimilar competition."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Well, I am not sure whether Neupogen is a good analog or not. I mean, what we -- who knows, right? Obviously, we have Europe, we have a biosimilar in Europe that Merck is responsible for marketing, and I think there, over about a 2-year period, Merck has",66,"Well, I am not sure whether Neupogen is a good analog or not. I mean, what we -- who knows, right? Obviously, we have Europe, we have a biosimilar in Europe that Merck is responsible for marketing, and I think there, over about a 2-year period, Merck has retained about 75% share. So that's one analog. And you had a follow-up question, you said, on pharma?"
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Yes, maybe for Joaquin. So on INVOKANA, I saw in the presentation that you expect to present the CANVAS and CANVAS-R data in mid-2017. So my questions are, are you going to present CANVAS and CANVAS-R separately before mid-2017? And do you have any plan t",84,"Yes, maybe for Joaquin. So on INVOKANA, I saw in the presentation that you expect to present the CANVAS and CANVAS-R data in mid-2017. So my questions are, are you going to present CANVAS and CANVAS-R separately before mid-2017? And do you have any plan to issue a press release for top line results before the presentation? And lastly, what's your confidence that we'll see similar cardiovascular benefit as we did with the EMPA-REG outcome as well as the lack of significant amputation risk?"
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Larry. INVOKANA remains the leading SGLT2, as I have described in the conference call. And to talk about CANVAS and CANVAS-R and the cardiovascular benefit, I'm going to pass the question to Bill.",35,"Thank you, Larry. INVOKANA remains the leading SGLT2, as I have described in the conference call. And to talk about CANVAS and CANVAS-R and the cardiovascular benefit, I'm going to pass the question to Bill."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Larry, this is Bill. So we plan to evaluate CANVAS and CANVAS-R together as one meta analysis. We're in discussions right now on the degrees of statistical confidence with the FDA. We have very strong reason to suspect based on CANVAS that the combination",55,"Larry, this is Bill. So we plan to evaluate CANVAS and CANVAS-R together as one meta analysis. We're in discussions right now on the degrees of statistical confidence with the FDA. We have very strong reason to suspect based on CANVAS that the combination will give data very similar to what was reported with EMPA"
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Your next question comes from Kristen Stewart with Deutsche Bank.",10,"Your next question comes from Kristen Stewart with Deutsche Bank."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Just going back to, I guess, REMICADE, and just thinking through the pipeline, I guess, what are some of the things that you feel confident on to the extent that the biosimilar could take, I guess, greater share than what you expecting that could start to",57,"Just going back to, I guess, REMICADE, and just thinking through the pipeline, I guess, what are some of the things that you feel confident on to the extent that the biosimilar could take, I guess, greater share than what you expecting that could start to fill in, I guess, some of the gaps from that perspective?"
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Kristen, for the question. I described part of the reasons for optimists during my conversation before, we not only feel that we are going to be able to grow in the face of biosimilar of the pharmaceutical business, overall, but we also are con",347,"Thank you, Kristen, for the question. I described part of the reasons for optimists during my conversation before, we not only feel that we are going to be able to grow in the face of biosimilar of the pharmaceutical business, overall, but we also are confident that we're going to be able to grow our immunology franchise in the phase of biosimilars. Let me give you some examples of why going into the 3 segments: Rheumatology, Psoriasis and Gastroenterology. In Rheumatology, SIMPONI and SIMPONI ARIA are doing very well. As a matter of fact, SIMPONI ARIA, it's already leading in new brand -- in new to brand share in Rheumatology in the U.S. And SIMPONI, it's gaining share in all international markets. We plan to file 2 line extensions of SIMPONI ARIA in ankylosing spondylitis and in psoriatic arthritis by 2017. And also we just filed sirukumab with EMEA, and we're planning to file it here in the U.S. before the end of the year. So that gives us a strong confidence that we're going to be continuing to grow in Rheumatology. Then moving into psoriasis, STELARA continues to be the leading in new to brand share in the U.S. and it's leading in most markets internationally. Together with that, we plan to file guselkumab, that we have presented very impressive data at the last EADV, we plan to file guselkumab before the end of the year. So that's another reason why we feel real confident that we will continue to grow in psoriasis. Finally, gastroenterology, which by the way is, for us, is the largest and fastest-growing segment, we just had the approval of STELARA in Crohn's disease and we are now launching it in the U.S. and we anticipate to be launching it in Europe pretty soon. So that is another reason why, which we believe that we're going to be able to continue to grow in immunology. So overall, we have line extensions, with our continuous penetration and also we have the filing of sirukumab and guselkumab in the second half of the year."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","The next question comes from Mike Weinstein with JPMorgan.",9,"The next question comes from Mike Weinstein with JPMorgan."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","So Dominic, I wanted to follow up on all the discussions in the pharmaceutical business. You made some comments in the investor conference in September that caught my attention. You talked about the 5 major therapeutic categories the company is in today,",90,"So Dominic, I wanted to follow up on all the discussions in the pharmaceutical business. You made some comments in the investor conference in September that caught my attention. You talked about the 5 major therapeutic categories the company is in today, and you opened up, I think for the first time, the potential of the company would consider adding a new therapeutic category. I just want to get a sense of your interest in doing that, and maybe the rest of the team wants to chime in as well."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Yes, sure, Mike. Well, I remember that discussion pretty well. I just want to put it into context for everyone. So this was a discussion about the success of our Pharmaceutical business, which has largely been driven by collaboration, licensing, co-develo",211,"Yes, sure, Mike. Well, I remember that discussion pretty well. I just want to put it into context for everyone. So this was a discussion about the success of our Pharmaceutical business, which has largely been driven by collaboration, licensing, co-development, et cetera, and not at all by any major acquisition, right? And the question that I got posed to me was well, that's been very successful, why would you ever change that, or is there  any reason no to consider a change in that strategy. And my comment was, well, to the extent we have 5 major therapeutic areas today, if we decided that another major therapeutic area was of importance to us and we wanted to get into that therapeutic area and we felt we could add a lot to it, but based on our overall scientific knowledge more broadly, that I would see that perhaps being done not by necessary a licensing strategy, but more of an acquisition type strategy. So it would enhance the overall portfolio of Johnson & Johnson's Pharmaceutical business beyond the current therapeutic areas that we currently are in. And by doing that, that might require a more significant acquisition than we've been doing in the pharma business. So that's the context for that."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","What is important to remember is that our focus is seeing medical innovation. And therefore, our areas in which we'll operate will depend on where science is growing and our own internal capabilities on the development and the commercial side. So from tha",77,"What is important to remember is that our focus is seeing medical innovation. And therefore, our areas in which we'll operate will depend on where science is growing and our own internal capabilities on the development and the commercial side. So from that perspective, we're constantly evaluating in which therapeutic areas we are in, and it's a fluid situation. The focus is in transformational medical innovation and this -- the actual therapeutic areas can change, over time."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","And so is that -- I mean, Dominic, that comment, is that just an indicator of -- that there's an openness or an interest in new therapeutic areas more so today than maybe in the last 5 years?",38,"And so is that -- I mean, Dominic, that comment, is that just an indicator of -- that there's an openness or an interest in new therapeutic areas more so today than maybe in the last 5 years?"
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Well, I think there's always an interest in new therapeutic areas where there's medical innovation where we think we can make a difference to patients in the health  care system. So I'm not sure that, that's changed dramatically, although over the last se",73,"Well, I think there's always an interest in new therapeutic areas where there's medical innovation where we think we can make a difference to patients in the health  care system. So I'm not sure that, that's changed dramatically, although over the last several years, we've built these very prominent disease stronghold within the therapeutic area that we have today, and obviously, they take some time to build. Bill, any other comments on that?"
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","In fact, to get to where we are today, we have to focus down from approximately 33 different diseases we were investing broadly but thinly to 11 diseases where we've developed extremely deep expertise internally from basic discovery right through launchin",136,"In fact, to get to where we are today, we have to focus down from approximately 33 different diseases we were investing broadly but thinly to 11 diseases where we've developed extremely deep expertise internally from basic discovery right through launching commercialization and market understanding to where we are always considering. First, are there -- is there room for further massive innovation because of the development of transformational science or new knowledge that we can go after. And number two is, we've become very familiar with adjacencies to the areas we're in. And if they look attractive, they're often the ones we gave the hardest to look at. So we're always looking to see if there's still massive innovation left to go in our disease areas, in therapeutic areas, and we're always looking closely at adjacencies."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","The next question comes from David Lewis with Morgan Stanley.",10,"The next question comes from David Lewis with Morgan Stanley."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Two questions. First, for Joaquin, and then Dominic, some commentary on medical device utilization. So Joaquin, I found your commentary on the strategy to defend REMICADE pretty compelling. So should we take, from your comments, that your existing strateg",55,"Two questions. First, for Joaquin, and then Dominic, some commentary on medical device utilization. So Joaquin, I found your commentary on the strategy to defend REMICADE pretty compelling. So should we take, from your comments, that your existing strategy is sufficient? Or should we expect more proactive pricing strategies to emerge in '17 and beyond?"
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Our strategy is three-pronged, as I described. The first one is the fact that we believe, based on the track record of REMICADE and the lack of interchangeability, it's unlikely that patients are going to switch if they are stable. So that's a very import",206,"Our strategy is three-pronged, as I described. The first one is the fact that we believe, based on the track record of REMICADE and the lack of interchangeability, it's unlikely that patients are going to switch if they are stable. So that's a very important component for us. The second element is that we plan to compete in all channels. And in planning to compete with -- in all channels, we're going to be utilizing innovative contracting and utilizing the full breadth of our portfolio. And then finally, we plan to utilize market differentiators such as patient assistance programs that are going to enable affordability. So with these 3 components, we feel confident that we are going to be able to have a very strong plan to face the biosimilar. The second element of that, overall, is what I just described before, what are the elements that lead us to believe that we'll continue to grow in immunology, too, and I described the different line extensions and NMEs that we have in the 3 areas: Rheumatology, Gastroenterology and Psoriasis. So combined, we feel strongly that we'll be able to grow in immunology, and overall, the Pharmaceutical business will grow in the face of the biosimilar."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Okay. So if you had to use price next year more aggressively, Joaquin, that would be incremental surprise to you?",20,"Okay. So if you had to use price next year more aggressively, Joaquin, that would be incremental surprise to you?"
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","This is already a very competitive market as it is today. As you can imagine, after -- there's already significant competition in the market today, both in the sub-q area and in the IV area. So we believe that the level of discount, and that is today, mak",57,"This is already a very competitive market as it is today. As you can imagine, after -- there's already significant competition in the market today, both in the sub-q area and in the IV area. So we believe that the level of discount, and that is today, makes it already a high bar for any new entrant."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Okay, very clear. And then, Dominic, you made a series a comments on utilization, I just want to clarify both the near-term and kind of longer-term environment. So if I heard you correctly, it seems like there was some softening potentially in the Medical",141,"Okay, very clear. And then, Dominic, you made a series a comments on utilization, I just want to clarify both the near-term and kind of longer-term environment. So if I heard you correctly, it seems like there was some softening potentially in the Medical Device business in the summer, but that got better in September. I wonder if you could just help us out in terms of how you would characterize the environment here in September and entering into October. Is it stable with what you saw in the first half of the year or different? And then the second part of the question is you also  said in '17, you actually expect some improvement in the Medical Device business. And maybe you could share with us your confidence level in the areas that you would expect to improve in '17."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Sure. So what we saw, David, this is through published sources, many of which are from firms such as yours and many of the sell side that published. We saw -- actually, utilization rates, as depicted in hospital admissions and hospital surgical procedures",305,"Sure. So what we saw, David, this is through published sources, many of which are from firms such as yours and many of the sell side that published. We saw -- actually, utilization rates, as depicted in hospital admissions and hospital surgical procedures, with the first quarter of this year being the highest, by far, and then a slowdown in the second quarter, a slowdown even below the level at which most estimates we're depicting, we're forecasting. And then in the third quarter was even slower than the second quarter, overall. But there's a very marked difference in September. So once September hit, the data showed quite a rebound from the summer months. And the rate of growth in September was actually faster than we saw in the first quarter, which was the highest growth quarter year-over-year in terms of penetration. Now whether that remains at that level or whether it's a rebound effect from the summer, we'll have to see. But I think this is all well chronicled in the multiple reports that many of you, I'm sure, have seen. So overall, I'd say we're now in a stable environment in hospital procedures. Going into '17, I express confidence in our Medical Device business growing faster, and quite frankly, we have a plan for that business to return to growth at above market for the medical device sector, and it's continuing to improve. What gives me confidence there is that the areas that we focus the most on, the growth  platforms and priority platforms just this quarter, they grew at 9%, and within those, 3 of those, in particular, electrophysiology, energy and endocutters, each grew at double-digit growth. So we obviously have a very robust growth coming in the priority platforms, which we expect to continue and drive us to above-market growth in 2017."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Your next question comes from Glenn Novarro with RBC Capital Markets.",11,"Your next question comes from Glenn Novarro with RBC Capital Markets."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Just a follow-up on REMICADE because Dominic, you said REMICADE -- or the biosimilars, sorry, would be in that launch risk. So can you remind us what's next in the legal process? And then, you also did a good job of discussing the impact you thought for t",79,"Just a follow-up on REMICADE because Dominic, you said REMICADE -- or the biosimilars, sorry, would be in that launch risk. So can you remind us what's next in the legal process? And then, you also did a good job of discussing the impact you thought for the top line. Can you talk about the profitability of REMICADE today? Is this a drug that is still heavily marketed? I can't imagine there's a lot of R&D behind REMICADE."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Right. Well, a couple of things. Where we stand on the legal front, as you know, we have an upcoming trial on the media related to the production of the biosimilar, and that trial is scheduled for mid-February of 2017, and we're also appealing the ruling",105,"Right. Well, a couple of things. Where we stand on the legal front, as you know, we have an upcoming trial on the media related to the production of the biosimilar, and that trial is scheduled for mid-February of 2017, and we're also appealing the ruling recently in the Massachusetts Court regarding the patent being invalid, and that will proceed. But we're also separately -- and we had been involved in this process for quite some time, we're continuing the appeals process within the U.S. patent office, and that process has several more steps to go. Joe, anything else you want to add to that?"
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Yes, just with some specific dates, Glenn. So the oral arguments in front of the PTO was heard on September 28. We'd expect that decision to be rendered anywhere from 1 to 3 months in the courts on the 471 patent. The final judgment just came from the ben",70,"Yes, just with some specific dates, Glenn. So the oral arguments in front of the PTO was heard on September 28. We'd expect that decision to be rendered anywhere from 1 to 3 months in the courts on the 471 patent. The final judgment just came from the bench on September 27, so that triggers the time in which we have to appeal and we're going through that process now."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Okay. And with regards to profitability, obviously, a product like REMICADE is an important product that has -- obviously delivers significant profitability to the company. But of course, we have a number of new launches, we have some that are already lau",155,"Okay. And with regards to profitability, obviously, a product like REMICADE is an important product that has -- obviously delivers significant profitability to the company. But of course, we have a number of new launches, we have some that are already launched and are progressing and rapidly growing, and their relative cost does not grow at the rate of their sales growth. And overall, we have to manage through this period of time when eventually, when biosimilar launches and a patent expires, we'd have to prepare ourselves for that in any event. So we're very well prepared to adjust accordingly. And as you know, our major focus always is to grow our sales at a rate faster than the rate in which we can -- our markets grow, so gain share and then grow our earnings at a rate faster than sales, so that's the level at which we plan for each and every year."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","So is there some restructuring that may come out over the next -- announcements that may come out that could service an offset to REMICADE and any potential loss profitability?",30,"So is there some restructuring that may come out over the next -- announcements that may come out that could service an offset to REMICADE and any potential loss profitability?"
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","We don't see any major restructuring related to the REMICADE situation on the horizon, Glenn, not at all.",19,"We don't see any major restructuring related to the REMICADE situation on the horizon, Glenn, not at all."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Your next question comes from Jami Rubin with Goldman Sachs.",10,"Your next question comes from Jami Rubin with Goldman Sachs."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Dominic, just a couple of questions for you. With the upcoming election, obviously, it's been a major area focus for health care investors. I'm just curious of your thoughts on Proposition 61. And as you know, I think that polls are showing that, that act",185,"Dominic, just a couple of questions for you. With the upcoming election, obviously, it's been a major area focus for health care investors. I'm just curious of your thoughts on Proposition 61. And as you know, I think that polls are showing that, that actually might pass in the State of California. Just curious to know what you think the industry's response will be to that. And then secondly, I'm interested in your thoughts on the potential for an international tax reform as part of an infrastructure build. Obviously, you would be huge beneficiaries of such a bill because of repatriation. Can you give us your thoughts on the likelihood of that happening? We've had multiple discussions over the years about tax reform, which never happens. Maybe it will happen this time. Just curious to know what your Washington folks are saying. And are we correct in assuming that if you were to do a large mega-transaction adding that 6 tool to your pharmaceutical division, are you more likely to wait until we get visibility on that? Or is your decision irrespective of potential legislation?"
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Okay, well, let me -- Jami, let me take them in reverse order. So whether or not we do a major transaction would not be dependent on waiting for international tax reform. Obviously, we have plenty of borrowing capacity and, obviously, any transaction that",287,"Okay, well, let me -- Jami, let me take them in reverse order. So whether or not we do a major transaction would not be dependent on waiting for international tax reform. Obviously, we have plenty of borrowing capacity and, obviously, any transaction that's done outside the U.S. will be an effective use of that OUS cash. And as you know, we've had the benefit of being able to structure transactions and effectively use our OUS cash in a tax-efficient manner. And we did that with the Synthes Transaction, we've done that recently with the 2 transaction that we recently announced. With respect to international tax reform and what we're hearing, I can tell you that I visit in Washington often and speak with members of the House Ways and Means Committee and the Senate Finance Committee, and the tax staffs are busily working and working very collaboratively with U.S. multinationals on an appropriate tax reform package. We think there's more bipartisan support now than there has been in the past. We think that often, we hear, as you mentioned, the benefit of investing in U.S. infrastructure as a result of those repatriated earnings coming back into the U.S., so that would be a positive. And we think that, overall, the climate for international tax reform, post the election quite frankly, is more positive than it's been in the last year or so. And then with respect to Proposition 61, there are several opponents to that proposition, and we would prefer to have pricing that is more related to outcomes, evidence-based medicine is something that we are advocates of and therefore, outcome-based pricing is a logical consequence of that. But Joaquin, any other thoughts on Prop 61?"
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you. I mean, as you were saying, Dominic, despite of the rhetoric about pharmaceutical pricing, right, it's always good to take some perspective on that. Pharmaceutical represents 14% of total expenditures, and we understand that we need to work wit",180,"Thank you. I mean, as you were saying, Dominic, despite of the rhetoric about pharmaceutical pricing, right, it's always good to take some perspective on that. Pharmaceutical represents 14% of total expenditures, and we understand that we need to work with different stakeholders in order to try to manage overall health care cost, and we have advanced different ideas in that area as you were describing, Dominic, such as value-based contracting. And we need to work there in order to try to eliminate the regulatory barriers that do not help in that area. As far as Proposition 61, as an example of that rhetoric, as Dominic said, there are different groups that oppose that measure, that includes even veteran groups and seniors and unions. The reason being, it's unclear what the effects of Proposition 61 would be. It is clear that it will be difficult to operationalize and also would create some access barriers to patients. So overall, we don't see Proposition 61 as the right way to try to work on pharmaceutical pricing. We think it's a misguided action."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Our final question comes from Matt Miksic with UBS.",9,"Our final question comes from Matt Miksic with UBS."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","I have one just quick clarification here on, I apologize, for REMICADE, and then I have one on sort of capital allocation. So Dominic and Joaquin, if I could just make sure I'm understanding your comments on pricing and expected biosimilar competition as",131,"I have one just quick clarification here on, I apologize, for REMICADE, and then I have one on sort of capital allocation. So Dominic and Joaquin, if I could just make sure I'm understanding your comments on pricing and expected biosimilar competition as you've gone through a number of times here on the call. The perception is that REMICADE pricing will face some kind of new downward pressure, abrupt pressure here as a result of this launch. It sounds like what you're saying is the net price for the drug is already quite competitive. There will be, obviously, penetration, but it doesn't sound like you're expecting to see any kind of significant or abrupt changes in pricing because of the competitive launch. Is that a fair characterization of what you're saying?"
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Yes, I think you already did right. All drugs -- all medicines face price pressures. This is a particularly competitive market as it is today, and we think the price level, it's already quite competitive, so I think you characterized the situation quite r",70,"Yes, I think you already did right. All drugs -- all medicines face price pressures. This is a particularly competitive market as it is today, and we think the price level, it's already quite competitive, so I think you characterized the situation quite right. I think the competition is going to move into other discussions such as other market differentiators, but the market is already quite competitive as it is."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Got it. And then on capital allocation, just broadly speaking, Dominic, because we get this question quite often. You've made a number of comments throughout September about the kinds of things that you would be interested in strategically, and of course,",106,"Got it. And then on capital allocation, just broadly speaking, Dominic, because we get this question quite often. You've made a number of comments throughout September about the kinds of things that you would be interested in strategically, and of course, you've said previously, you would be interested in ophthalmology and you're now pursuing that. If you wouldn't mind, just for the record, kind of taking through your major divisions, and just -- I think you've touched on pharma already, your preference there, but maybe Consumer and Devices, just remind us of the kinds of things that you're still interested in there, size and maybe area?"
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Well, Matt, we're -- as a broadly based company in human health care, we have an equal amount of interest across each of the businesses. And the way we compensate for that is basically looking at an appropriate risk-adjusted return for the particular asse",319,"Well, Matt, we're -- as a broadly based company in human health care, we have an equal amount of interest across each of the businesses. And the way we compensate for that is basically looking at an appropriate risk-adjusted return for the particular assets that we're interested in. And that is the same even regardless of size. I mean, obviously, size matters for a couple of reasons. One is that the asset may be well understood, the business may be well penetrated, the premium required for the asset may be excessive and therefore, to generate value for our shareholders would be a challenge. But it doesn't mean we wouldn't try to do that or we wouldn't look for areas where that may, in fact, be available for us. So that would be across any of the businesses. Within Consumer and Medical Devices, in particular, Consumer, just like we have in Pharma, we have specific areas of focus. We have 11 need states. The primary focus for us is growing internationally in emerging markets, so strong brands and emerging markets, a focus on over-the-counter medications and beauty space, particularly in Asia, are of interest to us. We just did a recent transaction with Dr.Ci:Labo in Japan, where we have an interest in that Asian marketplace and utilizing that brand throughout broader, throughout Asia, beyond Japan where it's currently marketed just as an example of one. And in Medical Devices, as you know, we have a very strong presence in orthopedics and in general surgery. We keep looking for additional bolt-on acquisitions there. And we have a very strong electrophysiology business in cardiovascular, but there are other areas within cardiovascular that seem attractive, in structural heart, and other areas, but the valuation would be something that we'll always consider. So we'd also be very disciplined about doing a transaction where the valuation seem pretty high, which is what they are today."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","That concludes the Q&A. I will now turn the discussion back over to Dominic for some closing remarks.",19,"That concludes the Q&A. I will now turn the discussion back over to Dominic for some closing remarks."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Okay. Thanks, Joe. Well, as I noted earlier, we're very pleased with our overall performance this quarter, and we're tracking well through the second half of the year. I would like to thank Joaquin and Bill for their outstanding leadership and for the gre",110,"Okay. Thanks, Joe. Well, as I noted earlier, we're very pleased with our overall performance this quarter, and we're tracking well through the second half of the year. I would like to thank Joaquin and Bill for their outstanding leadership and for the great presentation they gave this morning about the continued progress we are making in our Pharmaceutical business. I would also like to thank all of our colleagues around the world for their extraordinary achievements and dedication to the success of Johnson & Johnson. 
Thank you for your time today, and I look forward to updating you on our full year results in January. Have a great day."
139677,381738381,1056317,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Thank you. This concludes today's Johnson & Johnson's Third Quarter 2016 Earnings Conference Call. You may now disconnect.",18,"Thank you. This concludes today's Johnson & Johnson's Third Quarter 2016 Earnings Conference Call. You may now disconnect."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Good morning, and welcome to the Johnson & Johnson Third Quarter 2016 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] I would now like",52,"Good morning, and welcome to the Johnson & Johnson Third Quarter 2016 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] 
I would now like to turn the conference call over to Johnson & Johnson. You may begin."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Good morning. I'm Joe Wolk, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure to welcome you to the review of our business results for the third quarter of 2016.  Joining me on the call today are Dominic Caruso, Chief Finan",1967,"Good morning. I'm Joe Wolk, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure to welcome you to the review of our business results for the third quarter of 2016.  Joining me on the call today are Dominic Caruso, Chief Financial Officer; Joaquin Duato, Worldwide Chairman, Pharmaceuticals; and Dr. Bill Hait, Global Head of Pharmaceutical Research and Development. 
A few logistics before we discuss the results. This review is being made available via webcast, accessible through the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. 
I will begin today's presentation by briefly reviewing the third quarter sales and earnings results for the corporation and sales results for each of our 3 business segments. Next, Joaquin and Bill will provide an update on our Pharmaceutical business, specifically highlighting how our focus on innovation to address unmet medical needs translates to current and future strong performance. Dominic will then provide some additional commentary on the results, review the income statement and discuss guidance for 2016. Lastly, we will open the call to your questions. We expect today's call to last approximately 90 minutes. 
Included with the press release issued earlier this morning is the schedule of sales for key products and businesses to facilitate updating your models. These schedules are available on the Johnson & Johnson website, as is the press release. Please note, we will be using a presentation to complement today's commentary. The presentation is also available on our website. 
I'd like to remind you that some of the statements made during this review are or may be considered forward-looking statements. The 10-K for fiscal year 2015 and the company's subsequent filings identify certain factors that could cause the company's actual results to differ materially from those projected in any forward-looking statements made here today. The company does not undertake to update any forward-looking statements as a result of new information or future events or developments. 
During the review, non-GAAP financial measures are used to provide information pertinent to ongoing business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with GAAP results. Tables reconciling these measures to the most comparable GAAP measures are available in the schedules accompanying the press release and on the Investor Relations section of the Johnson & Johnson website. 
During the course of today's presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. This slide is an acknowledgment of those relationships. 
I would now like to review our results. Worldwide sales to customers were $17.8 billion for the third quarter of 2016, up 4.2% versus the third quarter of 2015. On an operational basis, sales were up 4.3% and currency had a negative impact of 0.1%. 
In the U.S., sales were up 6.7% while regions outside the U.S. were up 1.5%, comprised of 1.7% operational growth, partially offset by negative impact of currency exchange rates of 0.2%. On an operational basis, the Western Hemisphere, excluding the U.S., declined 1.3%. You may recall that we highlighted growth in the second quarter of 2016 being favorably impacted by an inventory build, which did reverse in the third quarter. Europe grew by 3.2% while the Asia-Pacific, Africa region grew 1.4%. 
Excluding the net impact of acquisitions and divestitures and hepatitis C, underlying operational sales growth was 5.9% worldwide, 7.3% in the U.S. and 4.2% outside the U.S. Additionally, operations in Venezuela reduced reported sales growth. Worldwide, this impact was a reduction of 30 basis points; and outside the U.S., 70 basis points. 
Turning now to earnings. Net earnings were $4.3 billion, and earnings per share were $1.53 versus $1.20 a year ago. As referenced in the table reconciling non-GAAP measures, 2016 third quarter net earnings were adjusted to exclude after-tax amortization expense of $236 million and a charge of $175 million for after-tax special items. Dominic will discuss special items in his remarks. 
Excluding amortization expense and special items for both periods, adjusted net earnings for the current quarter were $4.7 billion, and adjusted diluted earnings per share were $1.68, representing increases of 12.2% and 12.8%, respectively, as compared to the same period in 2015. On an operational basis, adjusted diluted earnings per share also grew 12.8%. 
Beginning with Consumer, let's now turn to segment highlights for the quarter. Please note that the percentages quoted for all segments represent operational sales change in comparison to the third quarter of 2015 unless otherwise stated and, therefore, exclude the impact of currency translation. 
Worldwide Consumer segment sales totaled $3.3 billion, increasing 0.1% from the third quarter of 2015. U.S. sales were up 1.1% while sales outside the U.S. declined 0.6%. Excluding the net impact of acquisitions and divestitures, underlying sales fell 0.4% worldwide, with a decline of 1.5% in the U.S. and growth of 0.3% outside the U.S.  
In addition, operations in Venezuela negatively impacted growth worldwide and outside the U.S. by 110 basis points and 180 basis points, respectively, with the most pronounced impact occurring in Women's Health. Growth was driven by worldwide Skin Care and OTC sales outside the U.S. Baby Care experienced declines over the third quarter of 2015. 
Performance in the Consumer segment was negatively impacted by slower market growth and reductions of customer inventory levels. Overall, the impact of inventory reduction was approximately 3 points on Worldwide Consumer sales growth for the quarter, with the most pronounced effect on OTC and Skin Care results. Dominic will discuss these factors in further detail later in the call. 
OTC sales grew 1.8% worldwide. Results were driven by strong consumption in smoking cessation products across Europe and new product launches in Europe and Asia. U.S. sales growth due to share gains was partially offset by trade inventory levels impacting growth in the U.S. by approximately 10 points, where, as highlighted, for the third quarter of 2015, the business experienced launch build in pain, allergy and digestive health. Also, a weak allergy season in the U.S. during 2016 negatively impacted inventory levels in the third quarter of 2016. In the U.S., adult analgesic market share was approximately 14%, up from 13% a year ago, while U.S. pediatric share was approximately 49%, up from 44% a year ago. 
Skin Care grew 12.2% worldwide and 18.9% in the U.S. These results include the sales from the recent Vogue, NeoStrata acquisitions, which are captured in the U.S. O-U.S. results were driven by stocking of Dabao products in China and share gains in Latin America. Inventory levels negatively impacted worldwide sales growth by 3 points. Successful marketing campaigns and new products continue to drive the results for LISTERINE in Oral Care. Divestitures impacted sales growth in Wound Care/Other and Women's Health categories. 
Moving now to our Pharmaceutical segment. Worldwide sales of $8.4 billion increased 9.0%, with U.S. sales up 11.8% and sales outside the U.S. up 5.0%, driven by strong performance of new products as well as growth from our core products. Excluding sales of hepatitis C products, OLYSIO and INCIVO, as well as the impact of acquisitions and divestitures, underlying worldwide sales growth was 10.7% as sales in the U.S. were up 13.0%; and outside the U.S., up 7.0%. Contributors to growth included Immunology products, REMICADE, SIMPONI and STELARA; Oncology products, IMBRUVICA and DARZALEX; as well as INVEGA SUSTENNA/XEPLION/TRINZA and XARELTO. 
In Immunology, REMICADE, STELARA and SIMPONI/SIMPONI ARIA achieved strong growth in the U.S. due to market growth and increasing share for STELARA. The results reported for REMICADE export sales was driven entirely by a change in inventory levels accounting for approximately 90 points of growth. Specifically, there was an inventory build of approximately $55 million in the current period and $110 million impact from lower level inventories that we noted in the third quarter of 2015 results. 
Biosimilar competition continues to negatively impact performance of export sales. 
In Neuroscience, INVEGA SUSTENNA/XEPLION/TRINZA achieved strong results, with worldwide sales growth of 21% due primarily to increased market share. As expected, during the quarter, we saw the impact from generic entries for INVEGA tablets in the U.S. 
In Oncology, strong patient uptake with new indications, approvals and demonstrated efficacy drove results for IMBRUVICA in the U.S. Sales increased 92% worldwide, and IMBRUVICA remains the leader in both new and total patient regimen share in second-line CLL and MCL. 
Outside the U.S., IMBRUVICA continues to experience strong adoption in Canada, in the G5 and has recently launched in Japan, Hong Kong and Korea. 
ZYTIGA sales grew 5.3% worldwide. In the U.S., market growth was essentially flat while market share was up almost 2 points sequentially. Sales outside the U.S. were tied to share gains in Japan and adoption in China since the launch in January of this year. 
DARZALEX continues to gain strong acceptance as a treatment for multiple myeloma and contributed approximately 2 points of Worldwide Pharmaceutical sales growth. 
Turning to Cardiovascular and metabolics. XARELTO continued strong share performance, with TRx market share up 1.7 points versus Q3 of 2015 to 17.5%. Warfarin represents approximately 55% of the total market, down from 62% in the third quarter of 2015. XARELTO continues to be broadly reimbursed, with over 95% of commercial and Medicare Part D patients covered at the lowest branded product copay. 
INVOKANA/INVOKAMET sales declined 3%, with the U.S. down 8.7% due to an increase in price discounts. Some of the increase in discounts is attributable to higher copay program cost in the quarter. While the defined market of type 2 diabetes, excluding insulin and metformin, was up approximately 5%, TRx share was essentially flat to the third quarter of 2015. TRx share with endocrinologists was approximately 11% and approximately 6% with primary care. 
I'll now review the results of the Medical Device segment. Worldwide Medical Device segment sales of $6.2 billion increased 0.7% with U.S. sales increasing 1.4% and sales outside the U.S. decreasing 0.2%. 
As a reminder, Cordis was divested in the fourth quarter of 2015. Excluding the net impact of acquisitions and divestitures, underlying growth was 3.1% worldwide, with the U.S. up 2.3% and growth of 3.9% outside the U.S. Additionally, the devaluation of Venezuela impacted growth worldwide by 10 basis points and outside the U.S. by 30 basis points. 
Growth was driven by electrophysiology, Advanced Surgery, Vision Care and Orthopaedics, slightly offset by general surgery and Diabetes Care. Electrophysiology within Cardiovascular grew 16% worldwide, driven by continued share gains in the U.S. and Europe as the atrial fibrillation procedure market increases. Orthopaedics sales growth was driven by joint reconstruction and U.S. trauma. Pricing pressure continued across all major categories but was partially offset by positive mix in trauma and spine, continued success of the TFNA nailing system in trauma, the ATTUNE platform in knees and the  CORAIL primary stem in hips contributed to the sales results. 
Within Advanced Surgery, endocutters grew 14%, energy was up 10% and biosurgicals up 7%. The acquisition of NeuWave Medical, closed in the second quarter of this year, also contributed modestly to growth. 
Vision Care sales were higher by 5.5% worldwide as new products launched late last year continued on an upward trajectory across all regions. Worldwide general surgery declined by approximately 2% due to discontinuing certain products in Women's Health and hernia, partially offset by both market growth and share gains in sutures. Competitive pressures and price erosion continue to impact Diabetes Care. 
That concludes the segment highlights for Johnson & Johnson's third quarter of 2016. To assist with your models, this slide provides you with a summary of important developments that occurred during the quarter. 
It is now my pleasure to turn the discussion over to Joaquin Duato, Worldwide Chairman, Pharmaceuticals, to inform you about the state of the Pharmaceutical business and the progress made since our May 2015 Business Review Day. Joaquin?"
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thanks, Joe, and good morning, everyone. I'm very pleased to share an update on our Pharmaceutical sector. Since May 2015, when we last met, our Pharmaceuticals business has continued to flourish and remains the primary growth engine of Johnson & Johnson.",1844,"Thanks, Joe, and good morning, everyone. I'm very pleased to share an update on our Pharmaceutical sector. Since May 2015, when we last met, our Pharmaceuticals business has continued to flourish and remains the primary growth engine of Johnson & Johnson. Our market-leading innovative medicines are the foundation of our strong performance, with the vast majority of their growth coming from volume gains. We continue to pursue significant growth opportunities in terms of both penetration within existing indications and planned line extensions. 
Additionally, we have launched DARZALEX, the first of our 10 potential billion-dollars-plus NMEs. As a result, we remain confident that we'll continue to deliver strong growth through 2019 despite biosimilar competition and market dynamics. Our success is a result of our strong track record of execution. Our industry-leading pipeline has delivered 12 NMEs since 2011 and 8 Breakthrough Therapy designations since 2013. And for the fourth year, we are proud to have been named the #1 company in R&D and commercial productive innovation. 
Our focused execution has delivered 11 in-market, billion-dollars-plus brands. 10 of these brands are growing, and 6 of them are growing double digit. Cumulatively, sales from our medicines launched since 2011 are the second highest of any pharmaceutical company. Our R&D and commercial capabilities are a proven strong foundation for future growth. 
First, we will continue to focus on driving volume growth across our current market-leading brands through clinical differentiation. Second, we will accelerate the growth of these in-market brands through approximately 40 potential line extensions. Critically, 10 of these line extensions have more than $0.5 billion potential. Third, as we shared last year, we have a [indiscernible] pipeline investing in 10 potential billion-dollar-plus NMEs planned to be filed through 2019. Of these, we anticipate 5 to deliver significant growth opportunities in the near term. 
Since 2015, our expectations around these near-term opportunities have crystallized. Our latest information provides higher certainty that these products will succeed delivering higher value than originally anticipated. DARZALEX, launched last year, is significantly outperforming expectations. According to your own models, it is well on its way to becoming a multibillion-dollar brand. Sirukumab has just been filed in the U.S. and Europe. Guselkumab has just had very positive data versus Humira presented at the EADV, and we anticipate filing for psoriasis before year-end. 
Apalutamide has a broad clinical development program in both pre-metastatic and metastatic prostate cancer. We also are investigating it in combination with ZYTIGA and with our newly licensed PARP inhibitor, niraparib. Finally, esketamine is already in Phase III and recently received a second Breakthrough Therapy designation. Bill will provide additional clinical details on these near-term opportunities shortly. 
Finally, it is important to note that these 3 strategies will prepare us to deliver robust growth beyond 2019, paving the way for more than 25 potential next-generation NMEs in the 2020 to 2024 time frame. 
The strength of our in-market portfolio, complemented by our near-term line extensions and NME launches, will more than offset upcoming headwinds, including those anticipated for REMICADE. 
We are fully prepared to execute a focused biosimilar readiness plan. Yesterday, the launch of a U.S. biosimilar to REMICADE was announced for later this year. However, the appeals process is still ongoing, and we believe any commercial launch of a biosimilar remains at risk. 
Biosimilars are very different from generics. For example, in Canada, Australia and Brazil, where there is already biosimilar competition to REMICADE, we have maintained more than 90% volume share. Our U.S. commercial team is ready for a potential biosimilar launch. 
I'm confident in our strategy for 3 reasons. First, with no biosimilar approved for interchangeability, REMICADE's significant long-term safety data, a strong advocacy from patients and clear physician preference means that the 70% of patients who are stable on REMICADE are highly unlikely to switch. Second, our patient assistance programs provide a leading market differentiator. Third, we are confident that we can continue to provide a cost-effective option in all channels. The current market is extremely competitive, and REMICADE ASP is already significantly lower than the list price 
Additionally, in developing innovative contracts, we can utilize the full breadth of our portfolio. 
Our Immunology franchise remains poised to grow through 2019. We have a strong market position and a deep near-term pipeline. Let me give you some examples. Already in rheumatoid arthritis, SIMPONI ARIA is the fastest-growing IV product in the U.S. and has higher new-to-brand share than REMICADE. Outside of the U.S., we continue to gain share with SIMPONI, too. Additionally, we plan to file 2 line extensions for SIMPONI ARIA in psoriatic arthritis and ankylosing spondylitis. Together with the recent submissions of sirukumab for the approval in the U.S. and Europe, we will further strengthen our leading position in Rheumatology. 
Turning to psoriasis. STELARA continues to be the #1 biologic in new-to-brand share in the U.S. and maintains clear share leadership in key markets internationally. One of our 10 potential billion-dollars-plus brands, Guselkumab, is expected to provide a significant boost to our leadership in psoriasis, and Bill will share more on this important upcoming filing. 
Finally, moving to Gastroenterology. The most exciting news is the recent launch of STELARA for Crohn's disease in the U.S. and its anticipated launch in Europe. There is tremendous unmet need in this debilitating disease. For example, 70% to 80% of Crohn's patients on anti-TNFs are not in remission at 1 year, and the patient population is expected to grow 50% over the next decade. This is the first in a series of line extensions, including UC, which will drive more than 35% of STELARA performance by 2019. 
Moving now to Cardiovascular and metabolics. INVOKANA continues to be a standout performer. Globally, it is the leading  SGLT2 inhibitor and the third largest known insulin diabetes medicine. Put into perspective, in the U.S., there have been more prescriptions filled for INVOKANA and INVOKAMET than all other SGLT2 inhibitors combined. A total of more than 1.3 million patients are treated in the U.S. alone. 
As Joe mentioned earlier, INVOKANA's performance dipped this quarter due to temporary increased costs to administer copay patient access programs. However, I want to emphasize that this was a transitory event. Our return to growth will be driven by INVOKANA's strong access position across U.S. commercial plans and Medicare Part D and the recent approval of INVOKAMET XR. We are expecting our cardiovascular outcomes data to read out in mid-2017. 
XARELTO is another market leader in our Cardiovascular and metabolics portfolio, delivering double-digit growth every year since its launch in 2011. To date, XARELTO has already treated more than 3.8 million patients in the U.S. and is supported by an extremely robust published real-world dataset, including evidence from more than 91,000 patients demonstrating consistency with our clinical trials. As a result, it is broadly reimbursed, with more than 95% Medicare and commercial patients on formulary at the lowest branded copay. 
These considerable achievements are just a start. Approximately, 54% of potential patients are still utilizing Warfarin, presenting significant growth opportunities in current indications.  Additionally, there are 8 new indications seeking clinical studies underway as part of EXPLORER, the largest clinical development program within the anticoagulant space. If successful, the potential patient pull could increase more than fivefold. 
Turning to Neuroscience. INVEGA TRINZA is a growth catalyst for the entire long-acting therapy franchise. Notably, INVEGA TRINZA is the fastest-growing LAT in the U.S. It has also contributed to growing INVEGA SUSTENNA scripts 26% in the 13 months since launch. 
Significant opportunities for growth remain as only 11% of patients are treated with LATs in the U.S. 
Celebrating 10 years of innovation this year, our HIV portfolio has achieved approximately 20% growth annually and cumulative sales of more than $15 billion. Today, 25% of patients in developed markets are treated with a J&J HIV medicine. Our class-leading portfolio has benefited more than 1 million patients, and this legacy will continue with upcoming line extensions. When Prezista first launched, it was part of a 6-tablet regimen. The first upcoming line extension, darunavir single-tablet regimen, will reduce this number to 1, improving adherence and safety. Also, we expect 2 rilpivirine fixed-dose combinations, one with Gilead's TAF and another one with ViiV's dolutegravir, that will drive additional growth for 2019. 
Finally, let's move to our fastest-growing therapeutic area, Oncology. IMBRUVICA has led the recent growth of our oncology franchise, accelerating from a record-breaking global launch to clear market share leadership in total patients in the first-line chronic lymphocytic leukemia. Today, IMBRUVICA is reimbursed in 41 countries with world-class market access. Since launch, an additional 6 indications have been approved, and we anticipate an additional 7 new registrations ahead, 4 of which have $500 million-plus potential.  Together with a number of promising combination therapies in development, these new indications will usher in a very exciting future for IMBRUVICA. 
IMBRUVICA's leadership in Oncology is mirrored by our recently launched asset, DARZALEX. Only 3 months after its launch, DARZALEX became the #1 prescribed therapy in fourth-line and later multiple myeloma. From a launch-aligned sales perspective, DARZALEX has continued to far outpace its competitors. This first-in-class medicine has since been improved in the EU and Canada and is driving positive share trends in earlier therapy lines in the U.S. We are confident DARZALEX can become the standard of care in multiple myeloma and help even more than the 10,000 patients who have benefited already worldwide. 
Growth will continue to accelerate with the anticipated approval in second-line patient populations and the impressive data from the recently published CASTOR and POLLUX studies. An additional 5 Phase III trials are currently underway as well as development of a subcutaneous formulation. As Bill will detail, we have also seen some positive data that DARZALEX may be effective outside of multiple myeloma. What should be clear today is that all of our current market-leading medicines have significant potential for continued volume growth. 
Additionally, we have a multitude of promising potential line extensions across every therapeutic area, approximately 40 in total, by 2019. Of these, 10 have more than $0.5 billion potential. The remaining 30 potential line extensions are not insignificant.  Cumulatively, the line extensions for XARELTO and INVOKANA have the potential to drive $3 billion to $5 billion in incremental sales for the Cardiovascular franchise. We believe these new indications will be a key driver of our growth through 2019 even in the context of biosimilars and market dynamics. 
In my 6 years leading our Pharmaceutical sector, I have never been more excited and more positive about our future as I am today. We have significant growth potential throughout our portfolio with market-leading brands; 40 anticipated line extensions, 10 of which have more than $0.5 billion potential; and 10 NMEs with more than $1 billion potential to be filed by 2019. Combined, these factors will ensure that we continue to outpace the industry growth through 2019. 
It is now my privilege to turn the call over to Dr. William Hait, who heads up our R&D organization. Bill will provide additional detail about our pipeline that is set to deliver these groundbreaking treatments. Bill?"
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Joaquin. Good morning, everyone. My name is Bill Hait, and I'm the Global Head of Research and Development for the Janssen Pharmaceutical Companies of Johnson & Johnson. As Joaquin indicated, at Janssen, we believe that by continuing to execu",2083,"Thank you, Joaquin. Good morning, everyone. My name is Bill Hait, and I'm the Global Head of Research and Development for the Janssen Pharmaceutical Companies of Johnson & Johnson. 
As Joaquin indicated, at Janssen, we believe that by continuing to execute our current strategy, we will consistently deliver valuable products to patients with serious unmet medical needs and that this will sustain our leadership in the pharmaceutical industry. Our strength is built on a blend of deep internal scientific expertise with industry-leading collaborations through the work of Johnson & Johnson innovation. We continue to find efficiencies that produce savings that we invest in our pipeline, and our strategic focus creates an enviable track record. We are delivering against our anticipated 2015 to 2019 NME and LE results that will produce a cadence of significant clinical data, regulatory filings and approvals. For these reasons and the results I will describe today, Janssen has become one of the most productive and most respected pharmaceutical companies. 
Before I share with you the details of our pipeline progress, let me explain how and why we have been able to sustain industry-leading results. Our 5 end-to-end therapeutic areas span basic drug discovery through launch and life cycle management. This structure produces a focused, seamless R&D organization, promotes efficient phase transitions and ensures dedication to major unmet medical needs where there is compelling, translatable science. These 5 therapeutic areas concentrate on 11 high-priority disease areas through our disease area strongholds, nimble and efficient biotech-like teams embedded in the broader context of the therapeutic areas. Each disease area stronghold undergoes rigorous triennial review by our external scientific advisory board, receives a priority score and proportional funding of discovery and early development. 
Our therapeutic areas are supported by substantial research capabilities through our centers of excellence, including biotechnology; medicinal chemistry; diagnostics; clinical operations; and, most recently, oligonucleotide and nucleic acid chemistry, expertise garnered through the acquisition of Alios. Assets that transition into late development are prioritized into 3 categories to ensure that our investment of resources align with our most promising targets. Currently, our top 2 categories, which represent 40% of our assets and 80% of our overall late-development value, receives 60% of our investment. It is through this approach that we remain at the top of the industry in successful phase transitions and speed to market. 
Janssen has achieved considerable success, and we are poised to continuously deliver near- and long-term growth. Our balanced investment across all aspects of our pipeline allows us to enjoy a constant flow of important new data. We launched 12 new products since 2011. We received the most FDA approvals from 2011 to 2016 as well as 8 Breakthrough Therapy designations. 
For 4 consecutive years, we have been named the innovation leader by IDEA Pharma and became the partner of choice through the work of J&J innovation. And for the third consecutive year, Fortune Magazine ranked Janssen Pharmaceutical Companies of Johnson & Johnson #1 in the pharmaceutical category on its annual World's Most Admired Companies list. Our unwavering commitment to global public health is demonstrated by SIRTURO, the first new drug for the treatment of tuberculosis in over 40 years; as well as our work on new, convenient HIV combinations; the first prime-boost Ebola vaccine using Crucell's adenoviral vector and Bavarian Nordic's MVA vector; as well as new chewable forms of mebendazole for children with worm infestations. 
As Joaquin mentioned and as we highlighted at our 2015 Pharmaceutical Business Review Day, between 2015 and 2019, we plan on filing approximately 10 new drugs, each with a potential for greater than $1 billion in peak year sales and 40 line extensions. This slide highlights 10 of these[ph], anticipated to be filed in the 2015 to 2019 time period, with peak year sales potential greater than $0.5 billion 
In addition, our early pipeline is rich in important assets that have the potential to file between 2020 and 2024. We are on track to deliver our anticipated NME and LE results through a cadence of significant clinical data, regulatory filings and approvals. Since May 2015, we garnered 3 new product approvals and filings, with the fourth, Guselkumab, anticipated this year, and we achieved 16 significant line extensions. 
Now let me use our time together to describe in greater detail some of the progress we have made since our May 2015 Pharmaceutical Business Review. Oncology is the newest of our 5 therapeutic areas and achieved industry-leading growth based on our development of several first-in-class drugs, including ZYTIGA, IMBRUVICA and DARZALEX. Our heme malignancies disease area is anchored by IMBRUVICA and DARZALEX. 
IMBRUVICA, the first BTK inhibitor for the treatment of certain B-cell malignancies, received 4 FDA Breakthrough Therapy designations. IMBRUVICA was recently approved for frontline use, based on the unprecedented results in previously untreated CLL patients reported in the RESONATE-2 study published in the December 15 issue of the New England Journal. As shown on this slide, treatment with ibrutinib decreased progression or death from CLL by 84% compared to chlorambucil and demonstrated a similar improvement in overall survival. 
DARZALEX, the first monoclonal antibody for the treatment of multiple myeloma, received 2 FDA Breakthrough Therapy designations and was approved almost 4 months ahead of its PDUFA date in double-refractory myeloma. As shown on this slide, combination therapy with DARZALEX delivered impressive results in treatment of relapsed or refractory multiple myeloma patients. The CASTOR and POLLUX studies demonstrated that the addition of DARZALEX to Velcade and dexamethasone or REVLIMID and dexamethasone, respectively, produced a greater than 60% decrease in risk of progression or death as compared to that of Vel/dex or REV/dex alone, both of these studies were published in the New England Journal. This month, the FDA granted priority review for daratumumab in combination with lenalidomide and dexamethasone or bortezomib and  dexamethasone for relapsed multiple myeloma with a PDUFA date in February 2017. 
Our prostate cancer disease area is anchored by ZYTIGA, the first CYP17 inhibitor for the treatment of men with metastatic castrate-resistant prostate cancer and is approved for both pre- and post-chemotherapy indications. Furthermore, we are developing ARN-509, now known as apalutamide, a more potent next-generation androgen receptor antagonist that shows a high degree of safety and efficacy in castrate-resistant prostate cancer. As seen in these figures, apalutamide decreased PSA by a median of 85% in patients with non-metastatic castrate-resistant prostate cancer after 12 weeks of treatment. The maximum PSA response, shown on the right-hand figure, was achieved in 94% of patients. 
Earlier this year, we licensed niraparib from TESARO to obtain a highly potent and selective PARP inhibitor for the treatment of prostate cancer patients with DNA repair defects for use in combination with ZYTIGA or apalutamide. Niraparib is in Phase II clinical trials and currently planned to be filed by 2019. This portfolio of assets gives us confidence that we will continue to bring great results to patients with prostate cancer for many years to come. 
While we did not explicitly address immuno-oncology during our 2015 Pharmaceutical Business Review, we continue to make significant progress in this area. Over the last 5 years, we invested in 4 critical areas, including vaccines, T-cell checkpoint inhibitors, T-cell redirection and myeloid mechanisms of actions. We currently have 15 immuno-oncology assets in development, including 8 that are in the clinic. 
Recently, we uncovered an important additional mechanism of action of DARZALEX to be immune-mediated through the depletion of immunosuppressive myeloid in lymphoid populations, including a previously unrecognized super-suppressor, CD38+ T-reg population; as well as activation of CD8 and CD4+ effector T-cells. These results provide the impetus for exploring DARZALEX in indications beyond heme malignancies in solid tumors. 
Our Immunology therapeutic area continues to deliver extraordinary products for patients with psoriasis, inflammatory bowel disease and rheumatoid arthritis. STELARA was the first IL-12, IL-23 monoclonal antibody introduced for moderate to severe plaque psoriasis and active psoriatic arthritis. It was recently approved in moderately to severely active Crohn's disease in the U.S, received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency and offers new options for adult patients with IBD. 
Guselkumab is a first-in-class selective anti-IL-23 monoclonal antibody that demonstrated significant efficacy versus placebo in superiority compared with the antitumor necrosis factor, adalimumab, in moderate to severe plaque psoriasis. The VOYAGE study, whose results are shown in this slide, randomly assigned 750 patients to receive guselkumab, adalimumab or a placebo followed by guselkumab in a 2:2:1 ratio. Patients treated with guselkumab achieved a significantly greater chance of obtaining a PASI 90 score compared to that of patients treated with adalimumab or a placebo at week 16, and the advantage over adalimumab was sustained through week 48. The high degree of efficacy of guselkumab, the less intensive dosing regimen and the potential for a STELARA-like safety profile makes guselkumab highly competitive with newly launched anti-IL-17 antibodies. We plan to file for psoriasis this year and advance guselkumab into Phase III for patients with psoriatic arthritis. 
Neuroscience is a historically strong area for Janssen since Dr. Paul Janssen and colleagues developed haloperidol, the first medication for schizophrenia. We have built on Dr. Paul's legacy with the development of next-generation antipsychotics and pioneered the development of long-acting injectables that help improve compliance for this difficult-to-treat patient population, most recently with the approval of INVEGA TRINZA, an every-3-month injectable formulation. 
Today, we focus our neuroscience investment in drugs that treat serious mood disorders, including depression, suicidality and Alzheimer's disease. Esketamine, an intranasally-delivered enantiomer of ketamine, produced groundbreaking results in major depressive disorder, with onset of action measured in hours to days rather than weeks to months. There's an alarming increase in suicides, both in the U.S. and globally, more than 41,000 each year in the U.S. alone. It's a tragic issue that's emerging as a major health priority. As shown in this slide, esketamine ameliorated suicidal ideation within 4 hours and sustained this effect for over 3 weeks, leading to its second FDA Breakthrough Therapy designation. 
Infectious Diseases is one of our most exciting and important areas in investment for future growth, where we focus on respiratory infections and hepatitis. We are pursuing an aggressive strategy for the cure of hepatitis C. We recently reported a 100% SVR12 in patients with genotype 1, with both an 8- and 6-week duration of treatment using a 3DAA combination of OLYSIO, AL-335 and  odalasvir.
Based on this exceptional data, we are moving the 3DAA regimen into late-development studies. 
Our Cardiovascular and Metabolism therapeutic area developed both INVOKANA and XARELTO in partnership with Mitsubishi Tanabe and Bayer, respectively. New line extensions are designed to continue to bring value to these 2 first-in-class drugs. With XARELTO, we are pursuing studies in congestive heart failure, embolic stroke of undetermined source, VTE prevention in medically ill patients, infrainguinal peripheral artery disease, VTE prevention in cancer patients and an acute coronary syndrome. We anticipate readouts from 2 INVOKANA cardiovascular outcomes studies by mid-2017, which we believe will further strengthen the importance of the SGLT2 inhibitor class in the treatment of patients with diabetes. We are also studying the role of INVOKANA in diabetic kidney disease and plan to address obesity and prediabetes. 
In summary, at the Janssen Pharmaceutical Companies of Johnson & Johnson, we are executing a clearly defined innovation strategy that drives value to patients around the world. We are on track to meeting our anticipated results described in 2015. We are producing the cadence of transformational innovations that are leading to exceptional results. We are a leader in productivity, approvals and FDA Breakthrough Therapy designations, and we are one of the fastest-growing top 10 pharmaceutical companies. 
We have had the most U.S. FDA approvals in the last 5 years, 2011 to 2016, and 8 Breakthrough Therapy designations. We anticipate filing approximately 10 NMEs between 2015 and 2019, each with greater than $1 billion peak year sales potential.  We have approximately 40 planned line extension filings anticipated between 2015 and 2019, several with greater than $500 million in peak year sales potential, supported by a steady flow of clinical data that drive better patient results. Finally, we take pride in delivering years of lives saved and better quality of life for our first credo responsibility to the doctors, nurses and patients who use our products. 
Now before I turn it over to Dominic, for your reference, let me leave you with a current overview of our pipeline across our 5 therapeutic areas. Dominic will now continue with an update of the company's financial results."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Bill and Joaquin, and good morning, everyone. As you just heard, our Pharmaceutical business is well positioned for continued above-industry growth as we make good progress against the pipeline expectations we communicated at our 2015 Pharmaceu",2501,"Thank you, Bill and Joaquin, and good morning, everyone. As you just heard, our Pharmaceutical business is well positioned for continued above-industry growth as we make good progress against the pipeline expectations we communicated at our 2015 Pharmaceutical Business Review. With great leaders like Joaquin and Bill, our strong in-market performance driven by excellent commercial capabilities and our robust R&D pipeline, you can see why we remain confident that our Pharmaceuticals business will continue to be a major driver of growth moving forward. 
I will now turn our discussion back to the quarter. We're pleased with our overall results. As you know, we had a strong start to the year, and as a result, last quarter, we increased our sales and earnings guidance. I'm happy to say we're tracking with those higher expectations while continuing to invest in our business. As you've heard, our Pharmaceutical business delivered strong results this quarter, with underlying operational growth of 10.7%. 
Let me now provide some comments on our other businesses. In our Consumer business, we continued to gain share this quarter. However, as reported by Nielsen, the industry saw a slowdown in many markets, with category growth rates in 2016 about half of the category growth rate we saw in Q3 of 2015. As Joe noted, our sales growth for the quarter was also impacted by lower trade inventory levels. These lower levels are the result of inventory builds in Q3 2015, as we discussed at that time, due to relaunches of certain products as well as inventory reduction programs being implemented at some of the larger retailers this past quarter. When excluding the impact of acquisitions and divestitures and the impact of the devaluation that occurred in Venezuela last year and this overall impact from trade inventory reductions, overall consumer growth was nearly 4%. Based on increasing share trend of our brands, we expect trade levels to align with consumption going forward. 
In Medical Devices, consistent with some recent analyst reports about the market, we believe the industry experienced lower hospital admissions and procedure rates during the mid-summer months. 
Late in the quarter, several reports showed higher levels of activity, and in fact, the data that we recently saw published for September looked encouraging. Additionally, we are very pleased to see our priority platforms continue to deliver robust growth of nearly 9%, with some at double digits, as Joe mentioned earlier. 
Overall, Hospital Medical Devices' operational growth, excluding acquisition and divestitures, was approximately 4% this quarter. 
In the Consumer Medical Device businesses, we saw continued price erosion in our Diabetes business. However, in our Vision Care business, we saw good operational growth of 5.5%. 
So in summary, as we previously discussed, in 2015, our underlying operational growth, which excludes the impact of acquisitions, divestiture as well as hepatitis C sales and the few extra shipping days that we saw in 2015, was about 5.5%. On this same basis, we continued to accelerate our growth, and we delivered strong underlying operational sales growth of approximately 5.9% for the third quarter of 2016. 
Our sales were above analyst estimates, as were earnings, due to significantly higher pretax operating margins. As you may remember, our guidance from January included a more than 200 basis point increase in our 2016 pretax operating margin, on an adjusted basis. We have attained that level year-to-date while continuing to invest in our business, and we remain comfortable with that forecast for the full year as we continue to execute on the restructuring activities in our Medical Device businesses while also investing in growth. 
As you know, in September, we announced a definitive agreement to acquire Abbott Medical Optics . We expect this transaction to close in Q1 of 2017. So for 2016, the transaction is expected to have no impact to our adjusted earnings and is not expected to impact our guidance. For 2017, again assuming a Q1 close, the transaction is expected to be positive to sales growth and immediately accretive to adjusted EPS. We are excited about Abbott Medical Optics' strong and differentiated surgical ophthalmic portfolio, particularly in cataract surgery. That, coupled with our world-leading ACUVUE contact lens business, will help us become a broad-based leader in Vision Care. 
Now I'll take the next few minutes to highlight some key points regarding our results for the quarter, and then I'll provide some updates to our guidance for you to consider in refining your models for the remainder of 2016. I will now turn to our consolidated statement of earnings for the third quarter of 2016. Our operational sales growth this quarter was 4.3%, and when we exclude the impact of acquisitions and divestitures, the impact of hep C sales and the overall impact that Venezuela had, it was strong at more than 6%. 
If you direct your attention to the boxed section of the schedule, you will see we have provided our earnings adjusted to exclude intangible amortization expense and special items. As referenced in the table of non-GAAP measures, the 2016 third quarter net earnings were adjusted to exclude intangible amortization expense and special items of approximately $400 million on an after-tax basis, which consisted primarily of the intangible amortization expense of about $250 million and the anticipated special charges as we continue to execute on the Medical Devices restructuring plan. 
Our adjusted earnings per share is, therefore, $1.68, which exceeded the mean of the analysts' estimates, as published by First Call. This is an increase in adjusted EPS of 12.8% versus the prior year.  Adjusted EPS on a constant-currency basis was the same as the impact of currency was flat year-over-year. 
Now let's take a few moments and talk about other items on the statement of earnings. Cost of goods sold increased by 30 basis points mostly due to unfavorable transaction currency impacts, partly offset by favorable mix and manufacturing efficiencies. Selling, marketing and administrative expenses were 26.8% of sales or 290 basis points lower as compared to the third quarter of 2015 due to overall good cost management. Our investment in research and development as a percent of sales was 12.2%, lower by 40 basis points due primarily to lower milestone payments, partly offset by increased project spending as we advance our promising product pipeline. 
Our pretax operating margin, when excluding special items and intangible amortization expense, was 32% or 310 basis points higher than the third quarter of the prior year. As a reminder, pretax operating margin is defined as gross profit less selling, marketing and administrative expenses and less R&D expenses. As we anticipated, we are seeing improvement as we progressed throughout the year, and through 9 months, we have achieved a 220 basis point improvement in this measure of profitability, consistent with the expectations we communicated to you throughout the year. 
Interest expense net of interest income was similar to last year. Other income and expense was a net gain of approximately $50 million in the quarter compared to a net expense of approximately $400 million in the same period last year. Excluding the special items that are reflected in this line, other income and expense was a net gain of approximately $200 million compared to a net gain of approximately $400 million in the prior year period, which included a higher level of gains from divestitures. 
Excluding special items, the effective tax rate in the quarter was 19.7% compared to 20% in the same period last year. This year's effective rate reflects the R&D tax credit, which was passed by Congress late last year, and it reflects the current mix of our businesses and the impact from a new accounting standard relating to the tax benefit on share-based compensation, which we discussed in our call in July. 
Turning to the next slide. I will now review adjusted income before tax by segment. In the third quarter of 2016, our adjusted income before tax margin for the enterprise improved by 220 basis points versus the third quarter of 2015. You will notice significant improvements in margins for the Medical Devices and Pharmaceutical businesses.
Last year, our Consumer business benefited from a gain in the sale of SPLENDA, and you're seeing that reflected in their lower margin this quarter, although still at very healthy rates.
As you can see on the next slide, on a year-to-date basis, we are pleased to see solid improvement in our consumer margin, and we remain confident it will show an improved adjusted income before tax margin for full year 2016 as compared to 2015.
Overall, we expect adjusted income before tax margins for the enterprise to show an improvement over the prior year for all of 2016 as our increase in pretax operating profit margin, which I noted earlier, more than offsets the lower level of divestiture gains in 2016 as compared to 2015. 
Now I'd like to provide some guidance for you to consider as you refine your models for 2016. I'd like to start with some of the items that we know you are -- you find difficult to forecast. 
Let's start with cash and interest income and expense. At the end of the quarter, we had approximately $13 billion of net cash, which consist of approximately $40 billion of cash and marketable securities and approximately $27 billion of debt. 
Through the end of the third quarter, we completed nearly 60% of our $10 billion share repurchase program, and we expect to complete approximately 75% of the program by the end of this year.
For purposes of your models and assuming no major acquisitions or other major uses of cash, I suggest you consider modeling net interest expense of between $400 million and $450 million. There's a slight tightening of the range. 
Regarding other income and expense as a reminder, this is the account where we record royalty income as well as gains and losses arising from such items as litigation, investments by our development corp, divestitures, asset sales and write-offs. We will be comfortable with your models for 2016 reflecting net other income and expense, excluding special items as a gain, ranging from approximately $750 million to $850 million, a lower range than our previous guidance related to the underlying activity. This impact will be offset by a lower tax rate.
And now for taxes, we're very comfortable with your models reflecting an effective tax rate for 2016, excluding special items, of approximately 18% to 18.5%, which is lower than our previous guidance, primarily due to a higher level of income and lower tax jurisdictions. 
Now turning to sales and earnings. Our sales and earnings guidance for 2016 takes into account several assumptions and key factors that I would like to highlight. Our sales range for 2016 continues to remain the same whether or not a biosimilar REMICADE launches this year in the U.S.
Additionally, we do not anticipate biosimilar or generic competition this year for PROCRIT, ZYTIGA, RISPERDAL CONSTA and INVEGA SUSTENNA, but as expected, there are generic entrants for INVEGA and ORTHO TRI-CYCLEN LO. 
As we've done for several years, our guidance will be first based on a constant currency basis, reflecting our results from operations. This is the way we manage our business, and we believe this provides a good understanding of the underlying performance of our business. 
We've also provided an estimate of our sales and adjusted EPS results for 2016 with the impact that current exchange rates could have on the translation of those results. 
We continue to be comfortable with the sales guidance we provided last quarter, reflecting an operational sales increase on a constant currency basis of between 3% and 4% for the year. This was a result in sales for 2016 on a constant currency basis of between approximately $72.2 billion to $72.9 billion. 
Additionally, by way of comparison to how we described our sales results in 2015, our operational sales growth for 2016, excluding the impact of all acquisition, divestitures and hepatitis C, would be approximately 6%, a higher level of growth than we saw last year even after adjusting for the shipping days in 2015, which we mentioned earlier. 
Although we're not predicting the impact of currency movements, using the euro as of last week at $1.11, the negative impact of foreign currency translation would be approximately 1% on sales growth. This is consistent with our previous guidance as major currencies had not significantly fluctuated since our last update. 
So after impacts of currency, we would expect reported sales to reflect the change in the range of positive 2% to 3% for a total expected level of reported sales of approximately $71.5 billion to $72.2 billion, consistent with our previous guidance. 
And now turning to earnings. As a reminder, we expect transaction currency impacts to be negative to our gross margin by approximately 60 to 80 basis points in 2016 as compared to 2015. We would be comfortable with adjusted operational EPS guidance in the range between $6.71 and $6.76 per share on a constant currency basis, reflecting an operational or constant currency growth rate of 8% to 9%. And this is a narrowing of the range. 
If currency exchange rates for all of 2016 were to remain where they were as of last week, the negative impact to EPS would be approximately $0.03, consistent with our previous guidance. Therefore, we would be comfortable with our reported adjusted EPS ranging from $6.68 to $6.73 per share, which again, is a narrowing of our previous guidance with a midpoint that is $0.03 higher than our previous guidance range. 
Finally, just a reminder of some dynamics you will see in our fourth quarter results this year in comparison to the fourth quarter of 2015. In 2015, we had additional shipping days based on when our year-end closed, and that contributed approximately 4 points of sales growth in the fourth quarter last year. 
Additionally, in the fourth quarter last year, we closed on the Cordis divestiture. And based on our latest guidance for 2016, we will have significantly lower level of other income from divestitures as compared to the prior year. 
In closing, we are very pleased with our performance so far this year, and we remain confident and optimistic about our future full year growth for 2016. Specifically, we're expecting operational sales growth of 3% to 4% and underlying operational sales growth of 6%, a higher level than we experienced last year on a comparable basis. 
Our adjusted pretax operating margin improvements are on track to meet the expectations we laid out on our guidance of more than a 200-basis point improvement over the prior year. We narrowed our guidance and increased the midpoint for adjusted operational EPS growth, which remains strong in the range of $6.71 to $6.76 per share, with the growth rate of 8% to 9%. And we are very well positioned to seize the opportunities in our strong pipelines to continue fueling our future growth. 
Now I'd like to turn things back to Joe for the Q&A portion of the call. Joe?"
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Dominic.",3,"Thank you, Dominic."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","[Operator Instructions] Your first question comes from Larry Biegelsen with Wells Fargo.",12,"[Operator Instructions] Your first question comes from Larry Biegelsen with Wells Fargo."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Welcome, Joe. So Dominic, I wanted to focus on the 2017, the puts and takes. Dominic, at our health care conference in September, you said the only real delta from 2016 to 2017 is the rate at which a biosimilar REMICADE could penetrate the market, assumin",153,"Welcome, Joe. So Dominic, I wanted to focus on the 2017, the puts and takes. Dominic, at our health care conference in September, you said the only real delta from 2016 to 2017 is the rate at which a biosimilar REMICADE could penetrate the market, assuming Pfizer launches at risk, and you don't think the penetration will be dramatic. I took that to mean that you feel that you can grow sales in 2017 at a similar rate to 2016 minus the impact from biosimilar REMICADE. So my questions are, is that the right interpretation? What gives you the confidence that this level of growth will continue? And second, the biosimilar for Neupogen captured about 7% of the market in year 1. Would you expect inflector penetration to be less than that? Any color that you can give on the expected penetration would be helpful. And I did have one follow-up on pharma."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Sure, Larry. Thanks for the question. I think the way you characterized it is accurate, that excluding the impact of any biosimilar launch, we would expect the business to grow at a rate similar to what we saw this year in the pharma business, overall, as",176,"Sure, Larry. Thanks for the question. I think the way you characterized it is accurate, that excluding the impact of any biosimilar launch, we would expect the business to grow at a rate similar to what we saw this year in the pharma business, overall, as well as I think we will see improved performance in the Medical Device business, and we're see continued share gains in the consumer business. So I think that is a good way to characterize it. We'll provide more color on that when we talk about the 2017 guidance in our discussion in January. We do think that the rate of penetration for a biosimilar will be modest, and there are several reasons for that. As we talked about before, 70% of the patients are treated well with REMICADE. There is no interchangeability available, that's another factor, and we're already in a highly competitive environment with respect to biologics, anti-TNF therapies, as you know. Before any comments on Neupogen, Joaquin, anything else you want to add to overall penetration of biosimilars?"
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","We are confident that we have our readiness plan for our biosimilar launch in the U.S. What we have seen internationally, markets like Australia, Brazil, where we market REMICADE, is that our volume share has been in excess of 90%, so that is consistent w",178,"We are confident that we have our readiness plan for our biosimilar launch in the U.S. What we have seen internationally, markets like Australia, Brazil, where we market REMICADE, is that our volume share has been in excess of 90%, so that is consistent with what you described. We are confident that we have a strong plan based on what Dominic described before. There's been 2.6 million patients treated with REMICADE worldwide. There's no interchangeability and there's a clear patient and physician preference, so it's highly unlikely that you're going to be seeing patients that are stable in the REMICADE switched. So that is 70% of the patients. At the same time, we have a strong patient assistance program, which will prove to be a market differentiator, and we are ready to compete in every channel, trying to bring patients the most affordable option in every situation. So we feel well prepared to face the biosimilar. And as Dominic said, we are convinced that we will continue to grow our business in the face of biosimilar competition."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Well, I am not sure whether Neupogen is a good analog or not. I mean, what we -- who knows, right? Obviously, we have Europe, we have a biosimilar in Europe that Merck is responsible for marketing, and I think there, over about a 2-year period, Merck has",66,"Well, I am not sure whether Neupogen is a good analog or not. I mean, what we -- who knows, right? Obviously, we have Europe, we have a biosimilar in Europe that Merck is responsible for marketing, and I think there, over about a 2-year period, Merck has retained about 75% share. So that's one analog. And you had a follow-up question, you said, on pharma?"
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Yes, maybe for Joaquin. So on INVOKANA, I saw in the presentation that you expect to present the CANVAS and CANVAS-R data in mid-2017. So my questions are, are you going to present CANVAS and CANVAS-R separately before mid-2017? And do you have any plan t",84,"Yes, maybe for Joaquin. So on INVOKANA, I saw in the presentation that you expect to present the CANVAS and CANVAS-R data in mid-2017. So my questions are, are you going to present CANVAS and CANVAS-R separately before mid-2017? And do you have any plan to issue a press release for top line results before the presentation? And lastly, what's your confidence that we'll see similar cardiovascular benefit as we did with the EMPA-REG outcomes as well as the lack of significant amputation risk?"
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Larry. INVOKANA remains the leading SGLT2, as I have described in the conference call. And to talk about CANVAS and CANVAS-R and the cardiovascular benefit, I'm going to pass the question to Bill.",35,"Thank you, Larry. INVOKANA remains the leading SGLT2, as I have described in the conference call. And to talk about CANVAS and CANVAS-R and the cardiovascular benefit, I'm going to pass the question to Bill."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Larry, this is Bill. So we plan to evaluate CANVAS and CANVAS-R together as one meta analysis. We're in discussions right now on the degrees of statistical confidence with the FDA. We have very strong reason to suspect, based on CANVAS, that the combinati",55,"Larry, this is Bill. So we plan to evaluate CANVAS and CANVAS-R together as one meta analysis. We're in discussions right now on the degrees of statistical confidence with the FDA. We have very strong reason to suspect, based on CANVAS, that the combination will give data very similar to what was reported with EMPA."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Your next question comes from Kristen Stewart with Deutsche Bank.",10,"Your next question comes from Kristen Stewart with Deutsche Bank."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Just going back to, I guess, REMICADE, and just thinking through the pipeline, I guess, what are some of the things that you feel confident on to the extent that the biosimilar could take, I guess, greater share than what you expecting that could start to",57,"Just going back to, I guess, REMICADE, and just thinking through the pipeline, I guess, what are some of the things that you feel confident on to the extent that the biosimilar could take, I guess, greater share than what you expecting that could start to fill in, I guess, some of the gaps from that perspective?"
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Kristen, for the question. I described part of the reasons for optimists during my conversation before, we not only feel that we are going to be able to grow in the face of biosimilar of the pharmaceutical business, overall, but we also are con",347,"Thank you, Kristen, for the question. I described part of the reasons for optimists during my conversation before, we not only feel that we are going to be able to grow in the face of biosimilar of the pharmaceutical business, overall, but we also are confident that we're going to be able to grow our immunology franchise in the phase of biosimilars. Let me give you some examples of why going into the 3 segments: Rheumatology, Psoriasis and Gastroenterology. In Rheumatology, SIMPONI and SIMPONI ARIA are doing very well. As a matter of fact, SIMPONI ARIA, it's already leading in new brand -- in new to brand share in Rheumatology in the U.S. And SIMPONI, it's gaining share in all international markets. We plan to file 2 line extensions of SIMPONI ARIA in ankylosing spondylitis and in psoriatic arthritis by 2017. And also we just filed sirukumab with EMEA, and we're planning to file it here in the U.S. before the end of the year. So that gives us a strong confidence that we're going to be continuing to grow in Rheumatology. Then moving into psoriasis, STELARA continues to be the leading in new to brand share in the U.S. and it's leading in most markets internationally. Together with that, we plan to file guselkumab, that we have presented very impressive data at the last EADV, we plan to file guselkumab before the end of the year. So that's another reason why we feel real confident that we will continue to grow in psoriasis. Finally, gastroenterology, which by the way is, for us, is the largest and fastest-growing segment, we just had the approval of STELARA in Crohn's disease and we are now launching it in the U.S. and we anticipate to be launching it in Europe pretty soon. So that is another reason why, which we believe that we're going to be able to continue to grow in immunology. So overall, we have line extensions, with our continuous penetration and also we have the filing of sirukumab and guselkumab in the second half of the year."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Your next question comes from Mike Weinstein with JPMorgan.",9,"Your next question comes from Mike Weinstein with JPMorgan."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","So Dominic, I wanted to follow up on all the discussions in the pharmaceutical business. You made some comments in the investor conference in September that caught my attention. You talked about the 5 major therapeutic categories the company is in today,",90,"So Dominic, I wanted to follow up on all the discussions in the pharmaceutical business. You made some comments in the investor conference in September that caught my attention. You talked about the 5 major therapeutic categories the company is in today, and you opened up, I think for the first time, the potential of the company would consider adding a new therapeutic category. I just want to get a sense of your interest in doing that, and maybe the rest of the team wants to chime in as well."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Yes, sure, Mike. Well, I remember that discussion pretty well. I just want to put it into context for everyone. So this was a discussion about the success of our Pharmaceutical business, which has largely been driven by collaboration, licensing, co-develo",211,"Yes, sure, Mike. Well, I remember that discussion pretty well. I just want to put it into context for everyone. So this was a discussion about the success of our Pharmaceutical business, which has largely been driven by collaboration, licensing, co-development, et cetera, and not at all by any major acquisition, right? And the question that I got posed to me was well, that's been very successful, why would you ever change that, or is there any reason no to consider a change in that strategy. And my comment was, well, to the extent we have 5 major therapeutic areas today, if we decided that another major therapeutic area was of importance to us and we wanted to get into that therapeutic area and we felt we could add a lot to it, but based on our overall scientific knowledge more broadly, that I would see that perhaps being done not by necessary a licensing strategy, but more of an acquisition type strategy. So it would enhance the overall portfolio of Johnson & Johnson's Pharmaceutical business beyond the current therapeutic areas that we currently are in. And by doing that, that might require a more significant acquisition than we've been doing in the pharma business. So that's the context for that."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","What is important to remember is that our focus is seeing medical innovation. And therefore, our areas in which we'll operate will depend on where science is growing and our own internal capabilities on the development and the commercial side. So from tha",77,"What is important to remember is that our focus is seeing medical innovation. And therefore, our areas in which we'll operate will depend on where science is growing and our own internal capabilities on the development and the commercial side. So from that perspective, we're constantly evaluating in which therapeutic areas we are in, and it's a fluid situation. The focus is in transformational medical innovation and this -- the actual therapeutic areas can change, over time."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","And so is that -- I mean, Dominic, that comment, is that just an indicator of -- that there's an openness or an interest in new therapeutic areas more so today than maybe in the last 5 years?",38,"And so is that -- I mean, Dominic, that comment, is that just an indicator of -- that there's an openness or an interest in new therapeutic areas more so today than maybe in the last 5 years?"
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Well, I think there's always an interest in new therapeutic areas where there's medical innovation where we think we can make a difference to patients in the health care system. So I'm not sure that, that's changed dramatically, although over the last sev",73,"Well, I think there's always an interest in new therapeutic areas where there's medical innovation where we think we can make a difference to patients in the health care system. So I'm not sure that, that's changed dramatically, although over the last several years, we've built these very prominent disease strongholds within the therapeutic area that we have today, and obviously, they take some time to build. Bill, any other comments on that?"
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","In fact, to get to where we are today, we had to focus down from approximately 33 different diseases we were investing broadly but thinly to 11 diseases where we've developed extremely deep expertise internally from basic discovery right through launching",135,"In fact, to get to where we are today, we had to focus down from approximately 33 different diseases we were investing broadly but thinly to 11 diseases where we've developed extremely deep expertise internally from basic discovery right through launching commercialization and market understanding to where we are always considering, first, are there -- is there room for further massive innovation because of the development of transformational science or new knowledge that we can go after. And number two is, we've become very familiar with adjacencies to the areas we're in. And if they look attractive, they're often the ones we take the hardest look at. So we're always looking to see if there's still massive innovation left to go in our disease areas, in therapeutic areas, and we're always looking closely at adjacencies."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","The next question comes from David Lewis with Morgan Stanley.",10,"The next question comes from David Lewis with Morgan Stanley."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Two questions. First, for Joaquin, and then Dominic, some commentary on medical device utilization. So Joaquin, I found your commentary on the strategy to defend REMICADE pretty compelling. So should we take, from your comments, that your existing strateg",55,"Two questions. First, for Joaquin, and then Dominic, some commentary on medical device utilization. So Joaquin, I found your commentary on the strategy to defend REMICADE pretty compelling. So should we take, from your comments, that your existing strategy is sufficient? Or should we expect more proactive pricing strategies to emerge in '17 and beyond?"
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Our strategy is three-pronged, as I described. The first one is the fact that we believe, based on the track record of REMICADE and the lack of interchangeability, it's unlikely that patients are going to switch if they are stable. So that's a very import",206,"Our strategy is three-pronged, as I described. The first one is the fact that we believe, based on the track record of REMICADE and the lack of interchangeability, it's unlikely that patients are going to switch if they are stable. So that's a very important component for us. The second element is that we plan to compete in all channels. And in planning to compete with -- in all channels, we're going to be utilizing innovative contracting and utilizing the full breadth of our portfolio. And then finally, we plan to utilize market differentiators such as patient assistance programs that are going to enable affordability. So with these 3 components, we feel confident that we are going to be able to have a very strong plan to face the biosimilar. The second element of that, overall, is what I just described before, what are the elements that lead us to believe that we'll continue to grow in immunology, too, and I described the different line extensions and NMEs that we have in the 3 areas: Rheumatology, Gastroenterology and Psoriasis. So combined, we feel strongly that we'll be able to grow in immunology, and overall, the Pharmaceutical business will grow in the face of the biosimilar."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Okay. So if you had to use price next year more aggressively, Joaquin, that would be incremental surprise to you?",20,"Okay. So if you had to use price next year more aggressively, Joaquin, that would be incremental surprise to you?"
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","This is already a very competitive market as it is today. As you can imagine, after -- there's already significant competition in the market today, both in the sub-q area and in the IV area. So we believe that the level of discount, and that is today, mak",57,"This is already a very competitive market as it is today. As you can imagine, after -- there's already significant competition in the market today, both in the sub-q area and in the IV area. So we believe that the level of discount, and that is today, makes it already a high bar for any new entrant."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Okay, very clear. And then, Dominic, you made a series a comments on utilization, I just want to clarify both the near-term and kind of longer-term environment. So if I heard you correctly, it seems like there was some softening potentially in the Medical",141,"Okay, very clear. And then, Dominic, you made a series a comments on utilization, I just want to clarify both the near-term and kind of longer-term environment. So if I heard you correctly, it seems like there was some softening potentially in the Medical Device business in the summer, but that got better in September. I wonder if you could just help us out in terms of how you would characterize the environment here in September and entering into October. Is it stable with what you saw in the first half of the year or different? And then the second part of the question is you also said in '17, you actually expect some improvement in the Medical Device business. And maybe you could share with us your confidence level in the areas that you would expect to improve in '17."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Sure. So what we saw, David, this is through published sources, many of which are from firms such as yours and many of the sell side that publish. We saw -- actually, utilization rates, as depicted in hospital admissions and hospital surgical procedures,",304,"Sure. So what we saw, David, this is through published sources, many of which are from firms such as yours and many of the sell side that publish. We saw -- actually, utilization rates, as depicted in hospital admissions and hospital surgical procedures, with the first quarter of this year being the highest, by far, and then a slowdown in the second quarter, a slowdown even below the level at which most estimates we're depicting, we're forecasting. And then the third quarter was even slower than the second quarter, overall. But there's a very marked difference in September. So once September hit, the data showed quite a rebound from the summer months. And the rate of growth in September was actually faster than what we saw in the first quarter, which was the highest growth quarter year-over-year in terms of penetration. Now whether that remains at that level or whether it's a rebound effect from the summer, we'll have to see. But I think this is all well chronicled in the multiple reports that many of you, I'm sure, have seen. So overall, I'd say we're now in a stable environment in hospital procedures. Going into '17, I express confidence in our Medical Device business growing faster, and quite frankly, we have a plan for that business to return to growth at above market for the medical device sector, and it's continuing to improve. What gives me confidence there is that the areas that we focus the most on, the growth  platforms and priority platforms just this quarter, they grew at 9%, and within those, 3 of those, in particular, electrophysiology, energy and endocutters, each grew at double-digit growth. So we obviously have very robust growth coming in the priority platforms, which we expect to continue and drive us to above-market growth in 2017."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Your next question comes from Glenn Novarro with RBC Capital Markets.",11,"Your next question comes from Glenn Novarro with RBC Capital Markets."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Just a follow-up on REMICADE because, Dominic, you said REMICADE -- or the biosimilars, sorry, would be in that launch risk. So can you remind us what's next in the legal process? And then, you also did a good job of discussing the impact you thought for",79,"Just a follow-up on REMICADE because, Dominic, you said REMICADE -- or the biosimilars, sorry, would be in that launch risk. So can you remind us what's next in the legal process? And then, you also did a good job of discussing the impact you thought for the top line. Can you talk about the profitability of REMICADE today? Is this a drug that is still heavily marketed? I can't imagine there's a lot of R&D behind REMICADE."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Right. Well, a couple of things. Where we stand on the legal front, as you know, we have an upcoming trial on the media related to the production of the biosimilar, and that trial is scheduled for mid-February of 2017, and we're also appealing the ruling",105,"Right. Well, a couple of things. Where we stand on the legal front, as you know, we have an upcoming trial on the media related to the production of the biosimilar, and that trial is scheduled for mid-February of 2017, and we're also appealing the ruling recently in the Massachusetts Court regarding the patent being invalid, and that will proceed. But we're also separately -- and we had been involved in this process for quite some time, we're continuing the appeals process within the U.S. patent office, and that process has several more steps to go. Joe, anything else you want to add to that?"
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Yes, just with some specific dates, Glenn. So the oral arguments in front of the PTO was heard on September 28. We'd expect that decision to be rendered anywhere from 1 to 3 months in the courts on the 471 patent. The final judgment just came from the ben",70,"Yes, just with some specific dates, Glenn. So the oral arguments in front of the PTO was heard on September 28. We'd expect that decision to be rendered anywhere from 1 to 3 months in the courts on the 471 patent. The final judgment just came from the bench on September 27, so that triggers the time in which we have to appeal and we're going through that process now."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Okay. And with regards to profitability, obviously, a product like REMICADE is an important product that has -- obviously delivers significant profitability to the company. But of course, we have a number of new launches, we have some that are already lau",156,"Okay. And with regards to profitability, obviously, a product like REMICADE is an important product that has -- obviously delivers significant profitability to the company. But of course, we have a number of new launches, we have some that are already launched and are progressing and rapidly growing, and their relative cost does not grow at the rate of their sales growth. And overall, we have to manage through this period of time when eventually, when a biosimilar launches and a patent expires, we'd have to prepare ourselves for that in any event. So we're very well prepared to adjust accordingly. And as you know, our major focus always is to grow our sales at a rate faster than the rate in which we can -- our markets grow, so gain share and then grow our earnings at a rate faster than sales, so that's the level at which we plan for each and every year."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","So is there some restructuring that may come out over the next -- announcements that may come out that could serve as an offset to REMICADE and any potential loss profitability?",31,"So is there some restructuring that may come out over the next -- announcements that may come out that could serve as an offset to REMICADE and any potential loss profitability?"
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","We don't see any major restructuring related to the REMICADE situation on the horizon, Glenn, not at all.",19,"We don't see any major restructuring related to the REMICADE situation on the horizon, Glenn, not at all."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Your next question comes from Jami Rubin with Goldman Sachs.",10,"Your next question comes from Jami Rubin with Goldman Sachs."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Dominic, just a couple of questions for you. With the upcoming election, obviously, it's been a major area of focus for health care investors. I'm just curious of your thoughts on Proposition 61. And as you know, I think that polls are showing that, that",186,"Dominic, just a couple of questions for you. With the upcoming election, obviously, it's been a major area of focus for health care investors. I'm just curious of your thoughts on Proposition 61. And as you know, I think that polls are showing that, that actually might pass in the State of California. Just curious to know what you think the industry's response will be to that. And then secondly, I'm interested in your thoughts on the potential for an international tax reform as part of an infrastructure build. Obviously, you would be huge beneficiaries of such a bill because of repatriation. Can you give us your thoughts on the likelihood of that happening? We've had multiple discussions over the years about tax reform, which never happens. Maybe it will happen this time. Just curious to know what your Washington folks are saying. And are we correct in assuming that if you were to do a large mega-transaction adding that 6 stool to your pharmaceutical division, are you more likely to wait until we get visibility on that? Or is your decision irrespective of potential legislation?"
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Okay, well, let me -- Jami, let me take them in reverse order. So whether or not we do a major transaction would not be dependent on waiting for international tax reform. Obviously, we have plenty of borrowing capacity and, obviously, any transaction that",287,"Okay, well, let me -- Jami, let me take them in reverse order. So whether or not we do a major transaction would not be dependent on waiting for international tax reform. Obviously, we have plenty of borrowing capacity and, obviously, any transaction that's done outside the U.S. will be an effective use of that OUS cash. And as you know, we've had the benefit of being able to structure transactions and effectively use our OUS cash in a tax-efficient manner. And we did that with the Synthes Transaction, we've done that recently with the 2 transaction that we recently announced. With respect to international tax reform and what we're hearing, I can tell you that I visit in Washington often and speak with members of the House Ways and Means Committee and the Senate Finance Committee, and the tax staffs are busily working and working very collaboratively with U.S. multinationals on an appropriate tax reform package. We think there's more bipartisan support now than there has been in the past. We think that often, we hear, as you mentioned, the benefit of investing in U.S. infrastructure as a result of those repatriated earnings coming back into the U.S., so that would be a positive. And we think that, overall, the climate for international tax reform, post the election quite frankly, is more positive than it's been in the last year or so. And then with respect to Proposition 61, there are several opponents to that proposition, and we would prefer to have pricing that is more related to outcomes, evidence-based medicine is something that we are advocates of and therefore, outcome-based pricing is a logical consequence of that. But Joaquin, any other thoughts on Prop 61?"
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you. I mean, as you were saying, Dominic, despite of the rhetoric about pharmaceutical pricing, right, it's always good to take some perspective on that. Pharmaceutical represents 14% of total expenditures, and we understand that we need to work wit",180,"Thank you. I mean, as you were saying, Dominic, despite of the rhetoric about pharmaceutical pricing, right, it's always good to take some perspective on that. Pharmaceutical represents 14% of total expenditures, and we understand that we need to work with different stakeholders in order to try to manage overall health care cost, and we have advanced different ideas in that area as you were describing, Dominic, such as value-based contracting. And we need to work there in order to try to eliminate the regulatory barriers that do not help in that area. As far as Proposition 61, as an example of that rhetoric, as Dominic said, there are different groups that oppose that measure, that includes even veteran groups and seniors and unions. The reason being, it's unclear what the effects of Proposition 61 would be. It is clear that it will be difficult to operationalize and also would create some access barriers to patients. So overall, we don't see Proposition 61 as the right way to try to work on pharmaceutical pricing. We think it's a misguided action."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Our final question comes from Matt Miksic with UBS.",9,"Our final question comes from Matt Miksic with UBS."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","I have one just quick clarification here on, I apologize, for REMICADE, and then I have one on sort of capital allocation. So Dominic and Joaquin, if I could just make sure I'm understanding your comments on pricing and expected biosimilar competition as",131,"I have one just quick clarification here on, I apologize, for REMICADE, and then I have one on sort of capital allocation. So Dominic and Joaquin, if I could just make sure I'm understanding your comments on pricing and expected biosimilar competition as you've gone through a number of times here on the call. The perception is that REMICADE pricing will face some kind of new downward pressure, abrupt pressure here as a result of this launch. It sounds like what you're saying is the net price for the drug is already quite competitive. There will be, obviously, penetration, but it doesn't sound like you're expecting to see any kind of significant or abrupt changes in pricing because of the competitive launch. Is that a fair characterization of what you're saying?"
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Yes, I think you already did right. All drugs -- all medicines face price pressures. This is a particularly competitive market as it is today, and we think the price level, it's already quite competitive, so I think you characterized the situation quite r",70,"Yes, I think you already did right. All drugs -- all medicines face price pressures. This is a particularly competitive market as it is today, and we think the price level, it's already quite competitive, so I think you characterized the situation quite right. I think the competition is going to move into other discussions such as other market differentiators, but the market is already quite competitive as it is."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Got it. And then on capital allocation, just broadly speaking, Dominic, because we get this question quite often. You've made a number of comments throughout September about the kinds of things that you would be interested in strategically, and of course,",107,"Got it. And then on capital allocation, just broadly speaking, Dominic, because we get this question quite often. You've made a number of comments throughout September about the kinds of things that you would be interested in strategically, and of course, you've said previously, you would be interested in ophthalmology and you're now pursuing that. If you wouldn't mind, just for the record, kind of ticking through your major divisions, and just -- I think you've touched on pharma already, your preference there, but maybe on Consumer and Devices, just remind us of the kinds of things that you're still interested in there, size and maybe area?"
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Well, Matt, we're -- as a broadly based company in human health care, we have an equal amount of interest across each of the businesses. And the way we compensate for that is basically looking at an appropriate risk-adjusted return for the particular asse",319,"Well, Matt, we're -- as a broadly based company in human health care, we have an equal amount of interest across each of the businesses. And the way we compensate for that is basically looking at an appropriate risk-adjusted return for the particular assets that we're interested in. And that is the same even regardless of size. I mean, obviously, size matters for a couple of reasons. One is that the asset may be well understood, the business may be well penetrated, the premium required for the asset may be excessive and therefore, to generate value for our shareholders would be a challenge. But it doesn't mean we wouldn't try to do that or we wouldn't look for areas where that may, in fact, be available for us. So that would be across any of the businesses. Within Consumer and Medical Devices, in particular, Consumer, just like we have in Pharma, we have specific areas of focus. We have 11 need states. The primary focus for us is growing internationally in emerging markets, so strong brands and emerging markets, a focus on over-the-counter medications and beauty space, particularly in Asia, are of interest to us. We just did a recent transaction with Dr.Ci:Labo in Japan, where we have an interest in that Asian marketplace and utilizing that brand throughout broader, throughout Asia, beyond Japan where it's currently marketed just as an example of one. And in Medical Devices, as you know, we have a very strong presence in orthopedics and in general surgery. We keep looking for additional bolt-on acquisitions there. And we have a very strong electrophysiology business in cardiovascular, but there are other areas within cardiovascular that seem attractive, in structural heart, and other areas, but the valuation would be something that we'd always consider. So we'd also be very disciplined about doing a transaction where the valuation seem pretty high, which is what they are today."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","That concludes the Q&A. I will now turn the discussion back over to Dominic for some closing remarks.",19,"That concludes the Q&A. I will now turn the discussion back over to Dominic for some closing remarks."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Okay. Thanks, Joe. Well, as I noted earlier, we're very pleased with our overall performance this quarter, and we're tracking well through the second half of the year. I would like to thank Joaquin and Bill for their outstanding leadership and for the gre",110,"Okay. Thanks, Joe. Well, as I noted earlier, we're very pleased with our overall performance this quarter, and we're tracking well through the second half of the year. I would like to thank Joaquin and Bill for their outstanding leadership and for the great presentation they gave this morning about the continued progress we are making in our Pharmaceutical business. I would also like to thank all of our colleagues around the world for their extraordinary achievements and dedication to the success of Johnson & Johnson. 
Thank you for your time today, and I look forward to updating you on our full year results in January. Have a great day."
139677,381738381,1056424,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Thank you. This concludes today's Johnson & Johnson's Third Quarter 2016 Earnings Conference Call. You may now disconnect.",18,"Thank you. This concludes today's Johnson & Johnson's Third Quarter 2016 Earnings Conference Call. You may now disconnect."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Good morning, and welcome to the Johnson & Johnson Third Quarter 2016 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] I would now like",52,"Good morning, and welcome to the Johnson & Johnson Third Quarter 2016 Earnings Conference Call. [Operator Instructions] This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions] 
I would now like to turn the conference call over to Johnson & Johnson. You may begin."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Good morning. I'm Joe Wolk, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure to welcome you to the review of our business results for the third quarter of 2016.  Joining me on the call today are Dominic Caruso, Chief Finan",1967,"Good morning. I'm Joe Wolk, Vice President of Investor Relations for Johnson & Johnson, and it is my pleasure to welcome you to the review of our business results for the third quarter of 2016.  Joining me on the call today are Dominic Caruso, Chief Financial Officer; Joaquin Duato, Worldwide Chairman, Pharmaceuticals; and Dr. Bill Hait, Global Head of Pharmaceutical Research and Development. 
A few logistics before we discuss the results. This review is being made available via webcast, accessible through the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. 
I will begin today's presentation by briefly reviewing the third quarter sales and earnings results for the corporation and sales results for each of our 3 business segments. Next, Joaquin and Bill will provide an update on our Pharmaceutical business, specifically highlighting how our focus on innovation to address unmet medical needs translates to current and future strong performance. Dominic will then provide some additional commentary on the results, review the income statement and discuss guidance for 2016. Lastly, we will open the call to your questions. We expect today's call to last approximately 90 minutes. 
Included with the press release issued earlier this morning is the schedule of sales for key products and businesses to facilitate updating your models. These schedules are available on the Johnson & Johnson website, as is the press release. Please note, we will be using a presentation to complement today's commentary. The presentation is also available on our website. 
I'd like to remind you that some of the statements made during this review are or may be considered forward-looking statements. The 10-K for fiscal year 2015 and the company's subsequent filings identify certain factors that could cause the company's actual results to differ materially from those projected in any forward-looking statements made here today. The company does not undertake to update any forward-looking statements as a result of new information or future events or developments. 
During the review, non-GAAP financial measures are used to provide information pertinent to ongoing business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with GAAP results. Tables reconciling these measures to the most comparable GAAP measures are available in the schedules accompanying the press release and on the Investor Relations section of the Johnson & Johnson website. 
During the course of today's presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. This slide is an acknowledgment of those relationships. 
I would now like to review our results. Worldwide sales to customers were $17.8 billion for the third quarter of 2016, up 4.2% versus the third quarter of 2015. On an operational basis, sales were up 4.3% and currency had a negative impact of 0.1%. 
In the U.S., sales were up 6.7% while regions outside the U.S. were up 1.5%, comprised of 1.7% operational growth, partially offset by negative impact of currency exchange rates of 0.2%. On an operational basis, the Western Hemisphere, excluding the U.S., declined 1.3%. You may recall that we highlighted growth in the second quarter of 2016 being favorably impacted by an inventory build, which did reverse in the third quarter. Europe grew by 3.2% while the Asia-Pacific, Africa region grew 1.4%. 
Excluding the net impact of acquisitions and divestitures and hepatitis C, underlying operational sales growth was 5.9% worldwide, 7.3% in the U.S. and 4.2% outside the U.S. Additionally, operations in Venezuela reduced reported sales growth. Worldwide, this impact was a reduction of 30 basis points; and outside the U.S., 70 basis points. 
Turning now to earnings. Net earnings were $4.3 billion, and earnings per share were $1.53 versus $1.20 a year ago. As referenced in the table reconciling non-GAAP measures, 2016 third quarter net earnings were adjusted to exclude after-tax amortization expense of $236 million and a charge of $175 million for after-tax special items. Dominic will discuss special items in his remarks. 
Excluding amortization expense and special items for both periods, adjusted net earnings for the current quarter were $4.7 billion, and adjusted diluted earnings per share were $1.68, representing increases of 12.2% and 12.8%, respectively, as compared to the same period in 2015. On an operational basis, adjusted diluted earnings per share also grew 12.8%. 
Beginning with Consumer, let's now turn to segment highlights for the quarter. Please note that the percentages quoted for all segments represent operational sales change in comparison to the third quarter of 2015 unless otherwise stated and, therefore, exclude the impact of currency translation. 
Worldwide Consumer segment sales totaled $3.3 billion, increasing 0.1% from the third quarter of 2015. U.S. sales were up 1.1% while sales outside the U.S. declined 0.6%. Excluding the net impact of acquisitions and divestitures, underlying sales fell 0.4% worldwide, with a decline of 1.5% in the U.S. and growth of 0.3% outside the U.S.  
In addition, operations in Venezuela negatively impacted growth worldwide and outside the U.S. by 110 basis points and 180 basis points, respectively, with the most pronounced impact occurring in Women's Health. Growth was driven by worldwide Skin Care and OTC sales outside the U.S. Baby Care experienced declines over the third quarter of 2015. 
Performance in the Consumer segment was negatively impacted by slower market growth and reductions of customer inventory levels. Overall, the impact of inventory reduction was approximately 3 points on Worldwide Consumer sales growth for the quarter, with the most pronounced effect on OTC and Skin Care results. Dominic will discuss these factors in further detail later in the call. 
OTC sales grew 1.8% worldwide. Results were driven by strong consumption in smoking cessation products across Europe and new product launches in Europe and Asia. U.S. sales growth due to share gains was partially offset by trade inventory levels impacting growth in the U.S. by approximately 10 points, where, as highlighted, for the third quarter of 2015, the business experienced launch build in pain, allergy and digestive health. Also, a weak allergy season in the U.S. during 2016 negatively impacted inventory levels in the third quarter of 2016. In the U.S., adult analgesic market share was approximately 14%, up from 13% a year ago, while U.S. pediatric share was approximately 49%, up from 44% a year ago. 
Skin Care grew 12.2% worldwide and 18.9% in the U.S. These results include the sales from the recent Vogue, NeoStrata acquisitions, which are captured in the U.S. O-U.S. results were driven by stocking of Dabao products in China and share gains in Latin America. Inventory levels negatively impacted worldwide sales growth by 3 points. Successful marketing campaigns and new products continue to drive the results for LISTERINE in Oral Care. Divestitures impacted sales growth in Wound Care/Other and Women's Health categories. 
Moving now to our Pharmaceutical segment. Worldwide sales of $8.4 billion increased 9.0%, with U.S. sales up 11.8% and sales outside the U.S. up 5.0%, driven by strong performance of new products as well as growth from our core products. Excluding sales of hepatitis C products, OLYSIO and INCIVO, as well as the impact of acquisitions and divestitures, underlying worldwide sales growth was 10.7% as sales in the U.S. were up 13.0%; and outside the U.S., up 7.0%. Contributors to growth included Immunology products, REMICADE, SIMPONI and STELARA; Oncology products, IMBRUVICA and DARZALEX; as well as INVEGA SUSTENNA/XEPLION/TRINZA and XARELTO. 
In Immunology, REMICADE, STELARA and SIMPONI/SIMPONI ARIA achieved strong growth in the U.S. due to market growth and increasing share for STELARA. The results reported for REMICADE export sales was driven entirely by a change in inventory levels accounting for approximately 90 points of growth. Specifically, there was an inventory build of approximately $55 million in the current period and $110 million impact from lower level inventories that we noted in the third quarter of 2015 results. 
Biosimilar competition continues to negatively impact performance of export sales. 
In Neuroscience, INVEGA SUSTENNA/XEPLION/TRINZA achieved strong results, with worldwide sales growth of 21% due primarily to increased market share. As expected, during the quarter, we saw the impact from generic entries for INVEGA tablets in the U.S. 
In Oncology, strong patient uptake with new indications, approvals and demonstrated efficacy drove results for IMBRUVICA in the U.S. Sales increased 92% worldwide, and IMBRUVICA remains the leader in both new and total patient regimen share in second-line CLL and MCL. 
Outside the U.S., IMBRUVICA continues to experience strong adoption in Canada, in the G5 and has recently launched in Japan, Hong Kong and Korea. 
ZYTIGA sales grew 5.3% worldwide. In the U.S., market growth was essentially flat while market share was up almost 2 points sequentially. Sales outside the U.S. were tied to share gains in Japan and adoption in China since the launch in January of this year. 
DARZALEX continues to gain strong acceptance as a treatment for multiple myeloma and contributed approximately 2 points of Worldwide Pharmaceutical sales growth. 
Turning to Cardiovascular and metabolics. XARELTO continued strong share performance, with TRx market share up 1.7 points versus Q3 of 2015 to 17.5%. Warfarin represents approximately 55% of the total market, down from 62% in the third quarter of 2015. XARELTO continues to be broadly reimbursed, with over 95% of commercial and Medicare Part D patients covered at the lowest branded product copay. 
INVOKANA/INVOKAMET sales declined 3%, with the U.S. down 8.7% due to an increase in price discounts. Some of the increase in discounts is attributable to higher copay program cost in the quarter. While the defined market of type 2 diabetes, excluding insulin and metformin, was up approximately 5%, TRx share was essentially flat to the third quarter of 2015. TRx share with endocrinologists was approximately 11% and approximately 6% with primary care. 
I'll now review the results of the Medical Device segment. Worldwide Medical Device segment sales of $6.2 billion increased 0.7% with U.S. sales increasing 1.4% and sales outside the U.S. decreasing 0.2%. 
As a reminder, Cordis was divested in the fourth quarter of 2015. Excluding the net impact of acquisitions and divestitures, underlying growth was 3.1% worldwide, with the U.S. up 2.3% and growth of 3.9% outside the U.S. Additionally, the devaluation of Venezuela impacted growth worldwide by 10 basis points and outside the U.S. by 30 basis points. 
Growth was driven by electrophysiology, Advanced Surgery, Vision Care and Orthopaedics, slightly offset by general surgery and Diabetes Care. Electrophysiology within Cardiovascular grew 16% worldwide, driven by continued share gains in the U.S. and Europe as the atrial fibrillation procedure market increases. Orthopaedics sales growth was driven by joint reconstruction and U.S. trauma. Pricing pressure continued across all major categories but was partially offset by positive mix in trauma and spine, continued success of the TFNA nailing system in trauma, the ATTUNE platform in knees and the  CORAIL primary stem in hips contributed to the sales results. 
Within Advanced Surgery, endocutters grew 14%, energy was up 10% and biosurgicals up 7%. The acquisition of NeuWave Medical, closed in the second quarter of this year, also contributed modestly to growth. 
Vision Care sales were higher by 5.5% worldwide as new products launched late last year continued on an upward trajectory across all regions. Worldwide general surgery declined by approximately 2% due to discontinuing certain products in Women's Health and hernia, partially offset by both market growth and share gains in sutures. Competitive pressures and price erosion continue to impact Diabetes Care. 
That concludes the segment highlights for Johnson & Johnson's third quarter of 2016. To assist with your models, this slide provides you with a summary of important developments that occurred during the quarter. 
It is now my pleasure to turn the discussion over to Joaquin Duato, Worldwide Chairman, Pharmaceuticals, to inform you about the state of the Pharmaceutical business and the progress made since our May 2015 Business Review Day. Joaquin?"
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thanks, Joe, and good morning, everyone. I'm very pleased to share an update on our Pharmaceutical sector. Since May 2015, when we last met, our Pharmaceuticals business has continued to flourish and remains the primary growth engine of Johnson & Johnson.",1844,"Thanks, Joe, and good morning, everyone. I'm very pleased to share an update on our Pharmaceutical sector. Since May 2015, when we last met, our Pharmaceuticals business has continued to flourish and remains the primary growth engine of Johnson & Johnson. Our market-leading innovative medicines are the foundation of our strong performance, with the vast majority of their growth coming from volume gains. We continue to pursue significant growth opportunities in terms of both penetration within existing indications and planned line extensions. 
Additionally, we have launched DARZALEX, the first of our 10 potential billion-dollars-plus NMEs. As a result, we remain confident that we'll continue to deliver strong growth through 2019 despite biosimilar competition and market dynamics. Our success is a result of our strong track record of execution. Our industry-leading pipeline has delivered 12 NMEs since 2011 and 8 Breakthrough Therapy designations since 2013. And for the fourth year, we are proud to have been named the #1 company in R&D and commercial productive innovation. 
Our focused execution has delivered 11 in-market, billion-dollars-plus brands. 10 of these brands are growing, and 6 of them are growing double digit. Cumulatively, sales from our medicines launched since 2011 are the second highest of any pharmaceutical company. Our R&D and commercial capabilities are a proven strong foundation for future growth. 
First, we will continue to focus on driving volume growth across our current market-leading brands through clinical differentiation. Second, we will accelerate the growth of these in-market brands through approximately 40 potential line extensions. Critically, 10 of these line extensions have more than $0.5 billion potential. Third, as we shared last year, we have a [indiscernible] pipeline investing in 10 potential billion-dollar-plus NMEs planned to be filed through 2019. Of these, we anticipate 5 to deliver significant growth opportunities in the near term. 
Since 2015, our expectations around these near-term opportunities have crystallized. Our latest information provides higher certainty that these products will succeed delivering higher value than originally anticipated. DARZALEX, launched last year, is significantly outperforming expectations. According to your own models, it is well on its way to becoming a multibillion-dollar brand. Sirukumab has just been filed in the U.S. and Europe. Guselkumab has just had very positive data versus Humira presented at the EADV, and we anticipate filing for psoriasis before year-end. 
Apalutamide has a broad clinical development program in both pre-metastatic and metastatic prostate cancer. We also are investigating it in combination with ZYTIGA and with our newly licensed PARP inhibitor, niraparib. Finally, esketamine is already in Phase III and recently received a second Breakthrough Therapy designation. Bill will provide additional clinical details on these near-term opportunities shortly. 
Finally, it is important to note that these 3 strategies will prepare us to deliver robust growth beyond 2019, paving the way for more than 25 potential next-generation NMEs in the 2020 to 2024 time frame. 
The strength of our in-market portfolio, complemented by our near-term line extensions and NME launches, will more than offset upcoming headwinds, including those anticipated for REMICADE. 
We are fully prepared to execute a focused biosimilar readiness plan. Yesterday, the launch of a U.S. biosimilar to REMICADE was announced for later this year. However, the appeals process is still ongoing, and we believe any commercial launch of a biosimilar remains at risk. 
Biosimilars are very different from generics. For example, in Canada, Australia and Brazil, where there is already biosimilar competition to REMICADE, we have maintained more than 90% volume share. Our U.S. commercial team is ready for a potential biosimilar launch. 
I'm confident in our strategy for 3 reasons. First, with no biosimilar approved for interchangeability, REMICADE's significant long-term safety data, a strong advocacy from patients and clear physician preference means that the 70% of patients who are stable on REMICADE are highly unlikely to switch. Second, our patient assistance programs provide a leading market differentiator. Third, we are confident that we can continue to provide a cost-effective option in all channels. The current market is extremely competitive, and REMICADE ASP is already significantly lower than the list price 
Additionally, in developing innovative contracts, we can utilize the full breadth of our portfolio. 
Our Immunology franchise remains poised to grow through 2019. We have a strong market position and a deep near-term pipeline. Let me give you some examples. Already in rheumatoid arthritis, SIMPONI ARIA is the fastest-growing IV product in the U.S. and has higher new-to-brand share than REMICADE. Outside of the U.S., we continue to gain share with SIMPONI, too. Additionally, we plan to file 2 line extensions for SIMPONI ARIA in psoriatic arthritis and ankylosing spondylitis. Together with the recent submissions of sirukumab for the approval in the U.S. and Europe, we will further strengthen our leading position in Rheumatology. 
Turning to psoriasis. STELARA continues to be the #1 biologic in new-to-brand share in the U.S. and maintains clear share leadership in key markets internationally. One of our 10 potential billion-dollars-plus brands, Guselkumab, is expected to provide a significant boost to our leadership in psoriasis, and Bill will share more on this important upcoming filing. 
Finally, moving to Gastroenterology. The most exciting news is the recent launch of STELARA for Crohn's disease in the U.S. and its anticipated launch in Europe. There is tremendous unmet need in this debilitating disease. For example, 70% to 80% of Crohn's patients on anti-TNFs are not in remission at 1 year, and the patient population is expected to grow 50% over the next decade. This is the first in a series of line extensions, including UC, which will drive more than 35% of STELARA performance by 2019. 
Moving now to Cardiovascular and metabolics. INVOKANA continues to be a standout performer. Globally, it is the leading  SGLT2 inhibitor and the third largest known insulin diabetes medicine. Put into perspective, in the U.S., there have been more prescriptions filled for INVOKANA and INVOKAMET than all other SGLT2 inhibitors combined. A total of more than 1.3 million patients are treated in the U.S. alone. 
As Joe mentioned earlier, INVOKANA's performance dipped this quarter due to temporary increased costs to administer copay patient access programs. However, I want to emphasize that this was a transitory event. Our return to growth will be driven by INVOKANA's strong access position across U.S. commercial plans and Medicare Part D and the recent approval of INVOKAMET XR. We are expecting our cardiovascular outcomes data to read out in mid-2017. 
XARELTO is another market leader in our Cardiovascular and metabolics portfolio, delivering double-digit growth every year since its launch in 2011. To date, XARELTO has already treated more than 3.8 million patients in the U.S. and is supported by an extremely robust published real-world dataset, including evidence from more than 91,000 patients demonstrating consistency with our clinical trials. As a result, it is broadly reimbursed, with more than 95% Medicare and commercial patients on formulary at the lowest branded copay. 
These considerable achievements are just a start. Approximately, 54% of potential patients are still utilizing Warfarin, presenting significant growth opportunities in current indications.  Additionally, there are 8 new indications seeking clinical studies underway as part of EXPLORER, the largest clinical development program within the anticoagulant space. If successful, the potential patient pull could increase more than fivefold. 
Turning to Neuroscience. INVEGA TRINZA is a growth catalyst for the entire long-acting therapy franchise. Notably, INVEGA TRINZA is the fastest-growing LAT in the U.S. It has also contributed to growing INVEGA SUSTENNA scripts 26% in the 13 months since launch. 
Significant opportunities for growth remain as only 11% of patients are treated with LATs in the U.S. 
Celebrating 10 years of innovation this year, our HIV portfolio has achieved approximately 20% growth annually and cumulative sales of more than $15 billion. Today, 25% of patients in developed markets are treated with a J&J HIV medicine. Our class-leading portfolio has benefited more than 1 million patients, and this legacy will continue with upcoming line extensions. When Prezista first launched, it was part of a 6-tablet regimen. The first upcoming line extension, darunavir single-tablet regimen, will reduce this number to 1, improving adherence and safety. Also, we expect 2 rilpivirine fixed-dose combinations, one with Gilead's TAF and another one with ViiV's dolutegravir, that will drive additional growth for 2019. 
Finally, let's move to our fastest-growing therapeutic area, Oncology. IMBRUVICA has led the recent growth of our oncology franchise, accelerating from a record-breaking global launch to clear market share leadership in total patients in the first-line chronic lymphocytic leukemia. Today, IMBRUVICA is reimbursed in 41 countries with world-class market access. Since launch, an additional 6 indications have been approved, and we anticipate an additional 7 new registrations ahead, 4 of which have $500 million-plus potential.  Together with a number of promising combination therapies in development, these new indications will usher in a very exciting future for IMBRUVICA. 
IMBRUVICA's leadership in Oncology is mirrored by our recently launched asset, DARZALEX. Only 3 months after its launch, DARZALEX became the #1 prescribed therapy in fourth-line and later multiple myeloma. From a launch-aligned sales perspective, DARZALEX has continued to far outpace its competitors. This first-in-class medicine has since been improved in the EU and Canada and is driving positive share trends in earlier therapy lines in the U.S. We are confident DARZALEX can become the standard of care in multiple myeloma and help even more than the 10,000 patients who have benefited already worldwide. 
Growth will continue to accelerate with the anticipated approval in second-line patient populations and the impressive data from the recently published CASTOR and POLLUX studies. An additional 5 Phase III trials are currently underway as well as development of a subcutaneous formulation. As Bill will detail, we have also seen some positive data that DARZALEX may be effective outside of multiple myeloma. What should be clear today is that all of our current market-leading medicines have significant potential for continued volume growth. 
Additionally, we have a multitude of promising potential line extensions across every therapeutic area, approximately 40 in total, by 2019. Of these, 10 have more than $0.5 billion potential. The remaining 30 potential line extensions are not insignificant.  Cumulatively, the line extensions for XARELTO and INVOKANA have the potential to drive $3 billion to $5 billion in incremental sales for the Cardiovascular franchise. We believe these new indications will be a key driver of our growth through 2019 even in the context of biosimilars and market dynamics. 
In my 6 years leading our Pharmaceutical sector, I have never been more excited and more positive about our future as I am today. We have significant growth potential throughout our portfolio with market-leading brands; 40 anticipated line extensions, 10 of which have more than $0.5 billion potential; and 10 NMEs with more than $1 billion potential to be filed by 2019. Combined, these factors will ensure that we continue to outpace the industry growth through 2019. 
It is now my privilege to turn the call over to Dr. William Hait, who heads up our R&D organization. Bill will provide additional detail about our pipeline that is set to deliver these groundbreaking treatments. Bill?"
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Joaquin. Good morning, everyone. My name is Bill Hait, and I'm the Global Head of Research and Development for the Janssen Pharmaceutical Companies of Johnson & Johnson. As Joaquin indicated, at Janssen, we believe that by continuing to execu",2083,"Thank you, Joaquin. Good morning, everyone. My name is Bill Hait, and I'm the Global Head of Research and Development for the Janssen Pharmaceutical Companies of Johnson & Johnson. 
As Joaquin indicated, at Janssen, we believe that by continuing to execute our current strategy, we will consistently deliver valuable products to patients with serious unmet medical needs and that this will sustain our leadership in the pharmaceutical industry. Our strength is built on a blend of deep internal scientific expertise with industry-leading collaborations through the work of Johnson & Johnson innovation. We continue to find efficiencies that produce savings that we invest in our pipeline, and our strategic focus creates an enviable track record. We are delivering against our anticipated 2015 to 2019 NME and LE results that will produce a cadence of significant clinical data, regulatory filings and approvals. For these reasons and the results I will describe today, Janssen has become one of the most productive and most respected pharmaceutical companies. 
Before I share with you the details of our pipeline progress, let me explain how and why we have been able to sustain industry-leading results. Our 5 end-to-end therapeutic areas span basic drug discovery through launch and life cycle management. This structure produces a focused, seamless R&D organization, promotes efficient phase transitions and ensures dedication to major unmet medical needs where there is compelling, translatable science. These 5 therapeutic areas concentrate on 11 high-priority disease areas through our disease area strongholds, nimble and efficient biotech-like teams embedded in the broader context of the therapeutic areas. Each disease area stronghold undergoes rigorous triennial review by our external scientific advisory board, receives a priority score and proportional funding of discovery and early development. 
Our therapeutic areas are supported by substantial research capabilities through our centers of excellence, including biotechnology; medicinal chemistry; diagnostics; clinical operations; and, most recently, oligonucleotide and nucleic acid chemistry, expertise garnered through the acquisition of Alios. Assets that transition into late development are prioritized into 3 categories to ensure that our investment of resources align with our most promising targets. Currently, our top 2 categories, which represent 40% of our assets and 80% of our overall late-development value, receives 60% of our investment. It is through this approach that we remain at the top of the industry in successful phase transitions and speed to market. 
Janssen has achieved considerable success, and we are poised to continuously deliver near- and long-term growth. Our balanced investment across all aspects of our pipeline allows us to enjoy a constant flow of important new data. We launched 12 new products since 2011. We received the most FDA approvals from 2011 to 2016 as well as 8 Breakthrough Therapy designations. 
For 4 consecutive years, we have been named the innovation leader by IDEA Pharma and became the partner of choice through the work of J&J innovation. And for the third consecutive year, Fortune Magazine ranked Janssen Pharmaceutical Companies of Johnson & Johnson #1 in the pharmaceutical category on its annual World's Most Admired Companies list. Our unwavering commitment to global public health is demonstrated by SIRTURO, the first new drug for the treatment of tuberculosis in over 40 years; as well as our work on new, convenient HIV combinations; the first prime-boost Ebola vaccine using Crucell's adenoviral vector and Bavarian Nordic's MVA vector; as well as new chewable forms of mebendazole for children with worm infestations. 
As Joaquin mentioned and as we highlighted at our 2015 Pharmaceutical Business Review Day, between 2015 and 2019, we plan on filing approximately 10 new drugs, each with a potential for greater than $1 billion in peak year sales and 40 line extensions. This slide highlights 10 of these[ph], anticipated to be filed in the 2015 to 2019 time period, with peak year sales potential greater than $0.5 billion 
In addition, our early pipeline is rich in important assets that have the potential to file between 2020 and 2024. We are on track to deliver our anticipated NME and LE results through a cadence of significant clinical data, regulatory filings and approvals. Since May 2015, we garnered 3 new product approvals and filings, with the fourth, Guselkumab, anticipated this year, and we achieved 16 significant line extensions. 
Now let me use our time together to describe in greater detail some of the progress we have made since our May 2015 Pharmaceutical Business Review. Oncology is the newest of our 5 therapeutic areas and achieved industry-leading growth based on our development of several first-in-class drugs, including ZYTIGA, IMBRUVICA and DARZALEX. Our heme malignancies disease area is anchored by IMBRUVICA and DARZALEX. 
IMBRUVICA, the first BTK inhibitor for the treatment of certain B-cell malignancies, received 4 FDA Breakthrough Therapy designations. IMBRUVICA was recently approved for frontline use, based on the unprecedented results in previously untreated CLL patients reported in the RESONATE-2 study published in the December 15 issue of the New England Journal. As shown on this slide, treatment with ibrutinib decreased progression or death from CLL by 84% compared to chlorambucil and demonstrated a similar improvement in overall survival. 
DARZALEX, the first monoclonal antibody for the treatment of multiple myeloma, received 2 FDA Breakthrough Therapy designations and was approved almost 4 months ahead of its PDUFA date in double-refractory myeloma. As shown on this slide, combination therapy with DARZALEX delivered impressive results in treatment of relapsed or refractory multiple myeloma patients. The CASTOR and POLLUX studies demonstrated that the addition of DARZALEX to Velcade and dexamethasone or REVLIMID and dexamethasone, respectively, produced a greater than 60% decrease in risk of progression or death as compared to that of Vel/dex or REV/dex alone, both of these studies were published in the New England Journal. This month, the FDA granted priority review for daratumumab in combination with lenalidomide and dexamethasone or bortezomib and  dexamethasone for relapsed multiple myeloma with a PDUFA date in February 2017. 
Our prostate cancer disease area is anchored by ZYTIGA, the first CYP17 inhibitor for the treatment of men with metastatic castrate-resistant prostate cancer and is approved for both pre- and post-chemotherapy indications. Furthermore, we are developing ARN-509, now known as apalutamide, a more potent next-generation androgen receptor antagonist that shows a high degree of safety and efficacy in castrate-resistant prostate cancer. As seen in these figures, apalutamide decreased PSA by a median of 85% in patients with non-metastatic castrate-resistant prostate cancer after 12 weeks of treatment. The maximum PSA response, shown on the right-hand figure, was achieved in 94% of patients. 
Earlier this year, we licensed niraparib from TESARO to obtain a highly potent and selective PARP inhibitor for the treatment of prostate cancer patients with DNA repair defects for use in combination with ZYTIGA or apalutamide. Niraparib is in Phase II clinical trials and currently planned to be filed by 2019. This portfolio of assets gives us confidence that we will continue to bring great results to patients with prostate cancer for many years to come. 
While we did not explicitly address immuno-oncology during our 2015 Pharmaceutical Business Review, we continue to make significant progress in this area. Over the last 5 years, we invested in 4 critical areas, including vaccines, T-cell checkpoint inhibitors, T-cell redirection and myeloid mechanisms of actions. We currently have 15 immuno-oncology assets in development, including 8 that are in the clinic. 
Recently, we uncovered an important additional mechanism of action of DARZALEX to be immune-mediated through the depletion of immunosuppressive myeloid in lymphoid populations, including a previously unrecognized super-suppressor, CD38+ T-reg population; as well as activation of CD8 and CD4+ effector T-cells. These results provide the impetus for exploring DARZALEX in indications beyond heme malignancies in solid tumors. 
Our Immunology therapeutic area continues to deliver extraordinary products for patients with psoriasis, inflammatory bowel disease and rheumatoid arthritis. STELARA was the first IL-12, IL-23 monoclonal antibody introduced for moderate to severe plaque psoriasis and active psoriatic arthritis. It was recently approved in moderately to severely active Crohn's disease in the U.S, received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency and offers new options for adult patients with IBD. 
Guselkumab is a first-in-class selective anti-IL-23 monoclonal antibody that demonstrated significant efficacy versus placebo in superiority compared with the antitumor necrosis factor, adalimumab, in moderate to severe plaque psoriasis. The VOYAGE study, whose results are shown in this slide, randomly assigned 750 patients to receive guselkumab, adalimumab or a placebo followed by guselkumab in a 2:2:1 ratio. Patients treated with guselkumab achieved a significantly greater chance of obtaining a PASI 90 score compared to that of patients treated with adalimumab or a placebo at week 16, and the advantage over adalimumab was sustained through week 48. The high degree of efficacy of guselkumab, the less intensive dosing regimen and the potential for a STELARA-like safety profile makes guselkumab highly competitive with newly launched anti-IL-17 antibodies. We plan to file for psoriasis this year and advance guselkumab into Phase III for patients with psoriatic arthritis. 
Neuroscience is a historically strong area for Janssen since Dr. Paul Janssen and colleagues developed haloperidol, the first medication for schizophrenia. We have built on Dr. Paul's legacy with the development of next-generation antipsychotics and pioneered the development of long-acting injectables that help improve compliance for this difficult-to-treat patient population, most recently with the approval of INVEGA TRINZA, an every-3-month injectable formulation. 
Today, we focus our neuroscience investment in drugs that treat serious mood disorders, including depression, suicidality and Alzheimer's disease. Esketamine, an intranasally-delivered enantiomer of ketamine, produced groundbreaking results in major depressive disorder, with onset of action measured in hours to days rather than weeks to months. There's an alarming increase in suicides, both in the U.S. and globally, more than 41,000 each year in the U.S. alone. It's a tragic issue that's emerging as a major health priority. As shown in this slide, esketamine ameliorated suicidal ideation within 4 hours and sustained this effect for over 3 weeks, leading to its second FDA Breakthrough Therapy designation. 
Infectious Diseases is one of our most exciting and important areas in investment for future growth, where we focus on respiratory infections and hepatitis. We are pursuing an aggressive strategy for the cure of hepatitis C. We recently reported a 100% SVR12 in patients with genotype 1, with both an 8- and 6-week duration of treatment using a 3DAA combination of OLYSIO, AL-335 and  odalasvir.
Based on this exceptional data, we are moving the 3DAA regimen into late-development studies. 
Our Cardiovascular and Metabolism therapeutic area developed both INVOKANA and XARELTO in partnership with Mitsubishi Tanabe and Bayer, respectively. New line extensions are designed to continue to bring value to these 2 first-in-class drugs. With XARELTO, we are pursuing studies in congestive heart failure, embolic stroke of undetermined source, VTE prevention in medically ill patients, infrainguinal peripheral artery disease, VTE prevention in cancer patients and an acute coronary syndrome. We anticipate readouts from 2 INVOKANA cardiovascular outcomes studies by mid-2017, which we believe will further strengthen the importance of the SGLT2 inhibitor class in the treatment of patients with diabetes. We are also studying the role of INVOKANA in diabetic kidney disease and plan to address obesity and prediabetes. 
In summary, at the Janssen Pharmaceutical Companies of Johnson & Johnson, we are executing a clearly defined innovation strategy that drives value to patients around the world. We are on track to meeting our anticipated results described in 2015. We are producing the cadence of transformational innovations that are leading to exceptional results. We are a leader in productivity, approvals and FDA Breakthrough Therapy designations, and we are one of the fastest-growing top 10 pharmaceutical companies. 
We have had the most U.S. FDA approvals in the last 5 years, 2011 to 2016, and 8 Breakthrough Therapy designations. We anticipate filing approximately 10 NMEs between 2015 and 2019, each with greater than $1 billion peak year sales potential.  We have approximately 40 planned line extension filings anticipated between 2015 and 2019, several with greater than $500 million in peak year sales potential, supported by a steady flow of clinical data that drive better patient results. Finally, we take pride in delivering years of lives saved and better quality of life for our first credo responsibility to the doctors, nurses and patients who use our products. 
Now before I turn it over to Dominic, for your reference, let me leave you with a current overview of our pipeline across our 5 therapeutic areas. Dominic will now continue with an update of the company's financial results."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Bill and Joaquin, and good morning, everyone. As you just heard, our Pharmaceutical business is well positioned for continued above-industry growth as we make good progress against the pipeline expectations we communicated at our 2015 Pharmaceu",2501,"Thank you, Bill and Joaquin, and good morning, everyone. As you just heard, our Pharmaceutical business is well positioned for continued above-industry growth as we make good progress against the pipeline expectations we communicated at our 2015 Pharmaceutical Business Review. With great leaders like Joaquin and Bill, our strong in-market performance driven by excellent commercial capabilities and our robust R&D pipeline, you can see why we remain confident that our Pharmaceuticals business will continue to be a major driver of growth moving forward. 
I will now turn our discussion back to the quarter. We're pleased with our overall results. As you know, we had a strong start to the year, and as a result, last quarter, we increased our sales and earnings guidance. I'm happy to say we're tracking with those higher expectations while continuing to invest in our business. As you've heard, our Pharmaceutical business delivered strong results this quarter, with underlying operational growth of 10.7%. 
Let me now provide some comments on our other businesses. In our Consumer business, we continued to gain share this quarter. However, as reported by Nielsen, the industry saw a slowdown in many markets, with category growth rates in 2016 about half of the category growth rate we saw in Q3 of 2015. As Joe noted, our sales growth for the quarter was also impacted by lower trade inventory levels. These lower levels are the result of inventory builds in Q3 2015, as we discussed at that time, due to relaunches of certain products as well as inventory reduction programs being implemented at some of the larger retailers this past quarter. When excluding the impact of acquisitions and divestitures and the impact of the devaluation that occurred in Venezuela last year and this overall impact from trade inventory reductions, overall consumer growth was nearly 4%. Based on increasing share trend of our brands, we expect trade levels to align with consumption going forward. 
In Medical Devices, consistent with some recent analyst reports about the market, we believe the industry experienced lower hospital admissions and procedure rates during the mid-summer months. 
Late in the quarter, several reports showed higher levels of activity, and in fact, the data that we recently saw published for September looked encouraging. Additionally, we are very pleased to see our priority platforms continue to deliver robust growth of nearly 9%, with some at double digits, as Joe mentioned earlier. 
Overall, Hospital Medical Devices' operational growth, excluding acquisition and divestitures, was approximately 4% this quarter. 
In the Consumer Medical Device businesses, we saw continued price erosion in our Diabetes business. However, in our Vision Care business, we saw good operational growth of 5.5%. 
So in summary, as we previously discussed, in 2015, our underlying operational growth, which excludes the impact of acquisitions, divestiture as well as hepatitis C sales and the few extra shipping days that we saw in 2015, was about 5.5%. On this same basis, we continued to accelerate our growth, and we delivered strong underlying operational sales growth of approximately 5.9% for the third quarter of 2016. 
Our sales were above analyst estimates, as were earnings, due to significantly higher pretax operating margins. As you may remember, our guidance from January included a more than 200 basis point increase in our 2016 pretax operating margin, on an adjusted basis. We have attained that level year-to-date while continuing to invest in our business, and we remain comfortable with that forecast for the full year as we continue to execute on the restructuring activities in our Medical Device businesses while also investing in growth. 
As you know, in September, we announced a definitive agreement to acquire Abbott Medical Optics . We expect this transaction to close in Q1 of 2017. So for 2016, the transaction is expected to have no impact to our adjusted earnings and is not expected to impact our guidance. For 2017, again assuming a Q1 close, the transaction is expected to be positive to sales growth and immediately accretive to adjusted EPS. We are excited about Abbott Medical Optics' strong and differentiated surgical ophthalmic portfolio, particularly in cataract surgery. That, coupled with our world-leading ACUVUE contact lens business, will help us become a broad-based leader in Vision Care. 
Now I'll take the next few minutes to highlight some key points regarding our results for the quarter, and then I'll provide some updates to our guidance for you to consider in refining your models for the remainder of 2016. I will now turn to our consolidated statement of earnings for the third quarter of 2016. Our operational sales growth this quarter was 4.3%, and when we exclude the impact of acquisitions and divestitures, the impact of hep C sales and the overall impact that Venezuela had, it was strong at more than 6%. 
If you direct your attention to the boxed section of the schedule, you will see we have provided our earnings adjusted to exclude intangible amortization expense and special items. As referenced in the table of non-GAAP measures, the 2016 third quarter net earnings were adjusted to exclude intangible amortization expense and special items of approximately $400 million on an after-tax basis, which consisted primarily of the intangible amortization expense of about $250 million and the anticipated special charges as we continue to execute on the Medical Devices restructuring plan. 
Our adjusted earnings per share is, therefore, $1.68, which exceeded the mean of the analysts' estimates, as published by First Call. This is an increase in adjusted EPS of 12.8% versus the prior year.  Adjusted EPS on a constant-currency basis was the same as the impact of currency was flat year-over-year. 
Now let's take a few moments and talk about other items on the statement of earnings. Cost of goods sold increased by 30 basis points mostly due to unfavorable transaction currency impacts, partly offset by favorable mix and manufacturing efficiencies. Selling, marketing and administrative expenses were 26.8% of sales or 290 basis points lower as compared to the third quarter of 2015 due to overall good cost management. Our investment in research and development as a percent of sales was 12.2%, lower by 40 basis points due primarily to lower milestone payments, partly offset by increased project spending as we advance our promising product pipeline. 
Our pretax operating margin, when excluding special items and intangible amortization expense, was 32% or 310 basis points higher than the third quarter of the prior year. As a reminder, pretax operating margin is defined as gross profit less selling, marketing and administrative expenses and less R&D expenses. As we anticipated, we are seeing improvement as we progressed throughout the year, and through 9 months, we have achieved a 220 basis point improvement in this measure of profitability, consistent with the expectations we communicated to you throughout the year. 
Interest expense net of interest income was similar to last year. Other income and expense was a net gain of approximately $50 million in the quarter compared to a net expense of approximately $400 million in the same period last year. Excluding the special items that are reflected in this line, other income and expense was a net gain of approximately $200 million compared to a net gain of approximately $400 million in the prior year period, which included a higher level of gains from divestitures. 
Excluding special items, the effective tax rate in the quarter was 19.7% compared to 20% in the same period last year. This year's effective rate reflects the R&D tax credit, which was passed by Congress late last year, and it reflects the current mix of our businesses and the impact from a new accounting standard relating to the tax benefit on share-based compensation, which we discussed in our call in July. 
Turning to the next slide. I will now review adjusted income before tax by segment. In the third quarter of 2016, our adjusted income before tax margin for the enterprise improved by 220 basis points versus the third quarter of 2015. You will notice significant improvements in margins for the Medical Devices and Pharmaceutical businesses.
Last year, our Consumer business benefited from a gain in the sale of SPLENDA, and you're seeing that reflected in their lower margin this quarter, although still at very healthy rates.
As you can see on the next slide, on a year-to-date basis, we are pleased to see solid improvement in our consumer margin, and we remain confident it will show an improved adjusted income before tax margin for full year 2016 as compared to 2015.
Overall, we expect adjusted income before tax margins for the enterprise to show an improvement over the prior year for all of 2016 as our increase in pretax operating profit margin, which I noted earlier, more than offsets the lower level of divestiture gains in 2016 as compared to 2015. 
Now I'd like to provide some guidance for you to consider as you refine your models for 2016. I'd like to start with some of the items that we know you are -- you find difficult to forecast. 
Let's start with cash and interest income and expense. At the end of the quarter, we had approximately $13 billion of net cash, which consist of approximately $40 billion of cash and marketable securities and approximately $27 billion of debt. 
Through the end of the third quarter, we completed nearly 60% of our $10 billion share repurchase program, and we expect to complete approximately 75% of the program by the end of this year.
For purposes of your models and assuming no major acquisitions or other major uses of cash, I suggest you consider modeling net interest expense of between $400 million and $450 million. There's a slight tightening of the range. 
Regarding other income and expense as a reminder, this is the account where we record royalty income as well as gains and losses arising from such items as litigation, investments by our development corp, divestitures, asset sales and write-offs. We will be comfortable with your models for 2016 reflecting net other income and expense, excluding special items as a gain, ranging from approximately $750 million to $850 million, a lower range than our previous guidance related to the underlying activity. This impact will be offset by a lower tax rate.
And now for taxes, we're very comfortable with your models reflecting an effective tax rate for 2016, excluding special items, of approximately 18% to 18.5%, which is lower than our previous guidance, primarily due to a higher level of income and lower tax jurisdictions. 
Now turning to sales and earnings. Our sales and earnings guidance for 2016 takes into account several assumptions and key factors that I would like to highlight. Our sales range for 2016 continues to remain the same whether or not a biosimilar REMICADE launches this year in the U.S.
Additionally, we do not anticipate biosimilar or generic competition this year for PROCRIT, ZYTIGA, RISPERDAL CONSTA and INVEGA SUSTENNA, but as expected, there are generic entrants for INVEGA and ORTHO TRI-CYCLEN LO. 
As we've done for several years, our guidance will be first based on a constant currency basis, reflecting our results from operations. This is the way we manage our business, and we believe this provides a good understanding of the underlying performance of our business. 
We've also provided an estimate of our sales and adjusted EPS results for 2016 with the impact that current exchange rates could have on the translation of those results. 
We continue to be comfortable with the sales guidance we provided last quarter, reflecting an operational sales increase on a constant currency basis of between 3% and 4% for the year. This was a result in sales for 2016 on a constant currency basis of between approximately $72.2 billion to $72.9 billion. 
Additionally, by way of comparison to how we described our sales results in 2015, our operational sales growth for 2016, excluding the impact of all acquisition, divestitures and hepatitis C, would be approximately 6%, a higher level of growth than we saw last year even after adjusting for the shipping days in 2015, which we mentioned earlier. 
Although we're not predicting the impact of currency movements, using the euro as of last week at $1.11, the negative impact of foreign currency translation would be approximately 1% on sales growth. This is consistent with our previous guidance as major currencies had not significantly fluctuated since our last update. 
So after impacts of currency, we would expect reported sales to reflect the change in the range of positive 2% to 3% for a total expected level of reported sales of approximately $71.5 billion to $72.2 billion, consistent with our previous guidance. 
And now turning to earnings. As a reminder, we expect transaction currency impacts to be negative to our gross margin by approximately 60 to 80 basis points in 2016 as compared to 2015. We would be comfortable with adjusted operational EPS guidance in the range between $6.71 and $6.76 per share on a constant currency basis, reflecting an operational or constant currency growth rate of 8% to 9%. And this is a narrowing of the range. 
If currency exchange rates for all of 2016 were to remain where they were as of last week, the negative impact to EPS would be approximately $0.03, consistent with our previous guidance. Therefore, we would be comfortable with our reported adjusted EPS ranging from $6.68 to $6.73 per share, which again, is a narrowing of our previous guidance with a midpoint that is $0.03 higher than our previous guidance range. 
Finally, just a reminder of some dynamics you will see in our fourth quarter results this year in comparison to the fourth quarter of 2015. In 2015, we had additional shipping days based on when our year-end closed, and that contributed approximately 4 points of sales growth in the fourth quarter last year. 
Additionally, in the fourth quarter last year, we closed on the Cordis divestiture. And based on our latest guidance for 2016, we will have significantly lower level of other income from divestitures as compared to the prior year. 
In closing, we are very pleased with our performance so far this year, and we remain confident and optimistic about our future full year growth for 2016. Specifically, we're expecting operational sales growth of 3% to 4% and underlying operational sales growth of 6%, a higher level than we experienced last year on a comparable basis. 
Our adjusted pretax operating margin improvements are on track to meet the expectations we laid out on our guidance of more than a 200-basis point improvement over the prior year. We narrowed our guidance and increased the midpoint for adjusted operational EPS growth, which remains strong in the range of $6.71 to $6.76 per share, with the growth rate of 8% to 9%. And we are very well positioned to seize the opportunities in our strong pipelines to continue fueling our future growth. 
Now I'd like to turn things back to Joe for the Q&A portion of the call. Joe?"
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Dominic. Michelle, can you please provide instructions for those on the line wishing to participate in the Q&A?",20,"Thank you, Dominic. Michelle, can you please provide instructions for those on the line wishing to participate in the Q&A?"
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","[Operator Instructions] Your first question comes from Larry Biegelsen with Wells Fargo.",12,"[Operator Instructions] Your first question comes from Larry Biegelsen with Wells Fargo."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Welcome, Joe. So Dominic, I wanted to focus on the 2017, the puts and takes. Dominic, at our health care conference in September, you said the only real delta from 2016 to 2017 is the rate at which a biosimilar REMICADE could penetrate the market, assumin",153,"Welcome, Joe. So Dominic, I wanted to focus on the 2017, the puts and takes. Dominic, at our health care conference in September, you said the only real delta from 2016 to 2017 is the rate at which a biosimilar REMICADE could penetrate the market, assuming Pfizer launches at risk, and you don't think the penetration will be dramatic. I took that to mean that you feel that you can grow sales in 2017 at a similar rate to 2016 minus the impact from biosimilar REMICADE. So my questions are, is that the right interpretation? What gives you the confidence that this level of growth will continue? And second, the biosimilar for Neupogen captured about 7% of the market in year 1. Would you expect inflector penetration to be less than that? Any color that you can give on the expected penetration would be helpful. And I did have one follow-up on pharma."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Sure, Larry. Thanks for the question. I think the way you characterized it is accurate, that excluding the impact of any biosimilar launch, we would expect the business to grow at a rate similar to what we saw this year in the pharma business, overall, as",176,"Sure, Larry. Thanks for the question. I think the way you characterized it is accurate, that excluding the impact of any biosimilar launch, we would expect the business to grow at a rate similar to what we saw this year in the pharma business, overall, as well as I think we will see improved performance in the Medical Device business, and we're see continued share gains in the consumer business. So I think that is a good way to characterize it. We'll provide more color on that when we talk about the 2017 guidance in our discussion in January. We do think that the rate of penetration for a biosimilar will be modest, and there are several reasons for that. As we talked about before, 70% of the patients are treated well with REMICADE. There is no interchangeability available, that's another factor, and we're already in a highly competitive environment with respect to biologics, anti-TNF therapies, as you know. Before any comments on Neupogen, Joaquin, anything else you want to add to overall penetration of biosimilars?"
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","We are confident that we have our readiness plan for our biosimilar launch in the U.S. What we have seen internationally, markets like Australia, Brazil, where we market REMICADE, is that our volume share has been in excess of 90%, so that is consistent w",178,"We are confident that we have our readiness plan for our biosimilar launch in the U.S. What we have seen internationally, markets like Australia, Brazil, where we market REMICADE, is that our volume share has been in excess of 90%, so that is consistent with what you described. We are confident that we have a strong plan based on what Dominic described before. There's been 2.6 million patients treated with REMICADE worldwide. There's no interchangeability and there's a clear patient and physician preference, so it's highly unlikely that you're going to be seeing patients that are stable in the REMICADE switched. So that is 70% of the patients. At the same time, we have a strong patient assistance program, which will prove to be a market differentiator, and we are ready to compete in every channel, trying to bring patients the most affordable option in every situation. So we feel well prepared to face the biosimilar. And as Dominic said, we are convinced that we will continue to grow our business in the face of biosimilar competition."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Well, I am not sure whether Neupogen is a good analog or not. I mean, what we -- who knows, right? Obviously, we have Europe, we have a biosimilar in Europe that Merck is responsible for marketing, and I think there, over about a 2-year period, Merck has",66,"Well, I am not sure whether Neupogen is a good analog or not. I mean, what we -- who knows, right? Obviously, we have Europe, we have a biosimilar in Europe that Merck is responsible for marketing, and I think there, over about a 2-year period, Merck has retained about 75% share. So that's one analog. And you had a follow-up question, you said, on pharma?"
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Yes, maybe for Joaquin. So on INVOKANA, I saw in the presentation that you expect to present the CANVAS and CANVAS-R data in mid-2017. So my questions are, are you going to present CANVAS and CANVAS-R separately before mid-2017? And do you have any plan t",84,"Yes, maybe for Joaquin. So on INVOKANA, I saw in the presentation that you expect to present the CANVAS and CANVAS-R data in mid-2017. So my questions are, are you going to present CANVAS and CANVAS-R separately before mid-2017? And do you have any plan to issue a press release for top line results before the presentation? And lastly, what's your confidence that we'll see similar cardiovascular benefit as we did with the EMPA-REG outcomes as well as the lack of significant amputation risk?"
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Larry. INVOKANA remains the leading SGLT2, as I have described in the conference call. And to talk about CANVAS and CANVAS-R and the cardiovascular benefit, I'm going to pass the question to Bill.",35,"Thank you, Larry. INVOKANA remains the leading SGLT2, as I have described in the conference call. And to talk about CANVAS and CANVAS-R and the cardiovascular benefit, I'm going to pass the question to Bill."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Larry, this is Bill. So we plan to evaluate CANVAS and CANVAS-R together as one meta analysis. We're in discussions right now on the degrees of statistical confidence with the FDA. We have very strong reason to suspect, based on CANVAS, that the combinati",55,"Larry, this is Bill. So we plan to evaluate CANVAS and CANVAS-R together as one meta analysis. We're in discussions right now on the degrees of statistical confidence with the FDA. We have very strong reason to suspect, based on CANVAS, that the combination will give data very similar to what was reported with EMPA."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Your next question comes from Kristen Stewart with Deutsche Bank.",10,"Your next question comes from Kristen Stewart with Deutsche Bank."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Just going back to, I guess, REMICADE, and just thinking through the pipeline, I guess, what are some of the things that you feel confident on to the extent that the biosimilar could take, I guess, greater share than what you expecting that could start to",57,"Just going back to, I guess, REMICADE, and just thinking through the pipeline, I guess, what are some of the things that you feel confident on to the extent that the biosimilar could take, I guess, greater share than what you expecting that could start to fill in, I guess, some of the gaps from that perspective?"
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you, Kristen, for the question. I described part of the reasons for optimists during my conversation before, we not only feel that we are going to be able to grow in the face of biosimilar of the pharmaceutical business, overall, but we also are con",347,"Thank you, Kristen, for the question. I described part of the reasons for optimists during my conversation before, we not only feel that we are going to be able to grow in the face of biosimilar of the pharmaceutical business, overall, but we also are confident that we're going to be able to grow our immunology franchise in the phase of biosimilars. Let me give you some examples of why going into the 3 segments: Rheumatology, Psoriasis and Gastroenterology. In Rheumatology, SIMPONI and SIMPONI ARIA are doing very well. As a matter of fact, SIMPONI ARIA, it's already leading in new brand -- in new to brand share in Rheumatology in the U.S. And SIMPONI, it's gaining share in all international markets. We plan to file 2 line extensions of SIMPONI ARIA in ankylosing spondylitis and in psoriatic arthritis by 2017. And also we just filed sirukumab with EMEA, and we're planning to file it here in the U.S. before the end of the year. So that gives us a strong confidence that we're going to be continuing to grow in Rheumatology. Then moving into psoriasis, STELARA continues to be the leading in new to brand share in the U.S. and it's leading in most markets internationally. Together with that, we plan to file guselkumab, that we have presented very impressive data at the last EADV, we plan to file guselkumab before the end of the year. So that's another reason why we feel real confident that we will continue to grow in psoriasis. Finally, gastroenterology, which by the way is, for us, is the largest and fastest-growing segment, we just had the approval of STELARA in Crohn's disease and we are now launching it in the U.S. and we anticipate to be launching it in Europe pretty soon. So that is another reason why, which we believe that we're going to be able to continue to grow in immunology. So overall, we have line extensions, with our continuous penetration and also we have the filing of sirukumab and guselkumab in the second half of the year."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Your next question comes from Mike Weinstein with JPMorgan.",9,"Your next question comes from Mike Weinstein with JPMorgan."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","So Dominic, I wanted to follow up on all the discussions in the pharmaceutical business. You made some comments in the investor conference in September that caught my attention. You talked about the 5 major therapeutic categories the company is in today,",90,"So Dominic, I wanted to follow up on all the discussions in the pharmaceutical business. You made some comments in the investor conference in September that caught my attention. You talked about the 5 major therapeutic categories the company is in today, and you opened up, I think for the first time, the potential of the company would consider adding a new therapeutic category. I just want to get a sense of your interest in doing that, and maybe the rest of the team wants to chime in as well."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Yes, sure, Mike. Well, I remember that discussion pretty well. I just want to put it into context for everyone. So this was a discussion about the success of our Pharmaceutical business, which has largely been driven by collaboration, licensing, co-develo",211,"Yes, sure, Mike. Well, I remember that discussion pretty well. I just want to put it into context for everyone. So this was a discussion about the success of our Pharmaceutical business, which has largely been driven by collaboration, licensing, co-development, et cetera, and not at all by any major acquisition, right? And the question that I got posed to me was well, that's been very successful, why would you ever change that, or is there any reason no to consider a change in that strategy. And my comment was, well, to the extent we have 5 major therapeutic areas today, if we decided that another major therapeutic area was of importance to us and we wanted to get into that therapeutic area and we felt we could add a lot to it, but based on our overall scientific knowledge more broadly, that I would see that perhaps being done not by necessary a licensing strategy, but more of an acquisition type strategy. So it would enhance the overall portfolio of Johnson & Johnson's Pharmaceutical business beyond the current therapeutic areas that we currently are in. And by doing that, that might require a more significant acquisition than we've been doing in the pharma business. So that's the context for that."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","What is important to remember is that our focus is seeing medical innovation. And therefore, our areas in which we'll operate will depend on where science is growing and our own internal capabilities on the development and the commercial side. So from tha",77,"What is important to remember is that our focus is seeing medical innovation. And therefore, our areas in which we'll operate will depend on where science is growing and our own internal capabilities on the development and the commercial side. So from that perspective, we're constantly evaluating in which therapeutic areas we are in, and it's a fluid situation. The focus is in transformational medical innovation and this -- the actual therapeutic areas can change, over time."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","And so is that -- I mean, Dominic, that comment, is that just an indicator of -- that there's an openness or an interest in new therapeutic areas more so today than maybe in the last 5 years?",38,"And so is that -- I mean, Dominic, that comment, is that just an indicator of -- that there's an openness or an interest in new therapeutic areas more so today than maybe in the last 5 years?"
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Well, I think there's always an interest in new therapeutic areas where there's medical innovation where we think we can make a difference to patients in the health care system. So I'm not sure that, that's changed dramatically, although over the last sev",73,"Well, I think there's always an interest in new therapeutic areas where there's medical innovation where we think we can make a difference to patients in the health care system. So I'm not sure that, that's changed dramatically, although over the last several years, we've built these very prominent disease strongholds within the therapeutic area that we have today, and obviously, they take some time to build. Bill, any other comments on that?"
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","In fact, to get to where we are today, we had to focus down from approximately 33 different diseases we were investing broadly but thinly to 11 diseases where we've developed extremely deep expertise internally from basic discovery right through launching",135,"In fact, to get to where we are today, we had to focus down from approximately 33 different diseases we were investing broadly but thinly to 11 diseases where we've developed extremely deep expertise internally from basic discovery right through launching commercialization and market understanding to where we are always considering, first, are there -- is there room for further massive innovation because of the development of transformational science or new knowledge that we can go after. And number two is, we've become very familiar with adjacencies to the areas we're in. And if they look attractive, they're often the ones we take the hardest look at. So we're always looking to see if there's still massive innovation left to go in our disease areas, in therapeutic areas, and we're always looking closely at adjacencies."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","The next question comes from David Lewis with Morgan Stanley.",10,"The next question comes from David Lewis with Morgan Stanley."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Two questions. First, for Joaquin, and then Dominic, some commentary on medical device utilization. So Joaquin, I found your commentary on the strategy to defend REMICADE pretty compelling. So should we take, from your comments, that your existing strateg",55,"Two questions. First, for Joaquin, and then Dominic, some commentary on medical device utilization. So Joaquin, I found your commentary on the strategy to defend REMICADE pretty compelling. So should we take, from your comments, that your existing strategy is sufficient? Or should we expect more proactive pricing strategies to emerge in '17 and beyond?"
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Our strategy is three-pronged, as I described. The first one is the fact that we believe, based on the track record of REMICADE and the lack of interchangeability, it's unlikely that patients are going to switch if they are stable. So that's a very import",206,"Our strategy is three-pronged, as I described. The first one is the fact that we believe, based on the track record of REMICADE and the lack of interchangeability, it's unlikely that patients are going to switch if they are stable. So that's a very important component for us. The second element is that we plan to compete in all channels. And in planning to compete with -- in all channels, we're going to be utilizing innovative contracting and utilizing the full breadth of our portfolio. And then finally, we plan to utilize market differentiators such as patient assistance programs that are going to enable affordability. So with these 3 components, we feel confident that we are going to be able to have a very strong plan to face the biosimilar. The second element of that, overall, is what I just described before, what are the elements that lead us to believe that we'll continue to grow in immunology, too, and I described the different line extensions and NMEs that we have in the 3 areas: Rheumatology, Gastroenterology and Psoriasis. So combined, we feel strongly that we'll be able to grow in immunology, and overall, the Pharmaceutical business will grow in the face of the biosimilar."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Okay. So if you had to use price next year more aggressively, Joaquin, that would be incremental surprise to you?",20,"Okay. So if you had to use price next year more aggressively, Joaquin, that would be incremental surprise to you?"
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","This is already a very competitive market as it is today. As you can imagine, after -- there's already significant competition in the market today, both in the sub-q area and in the IV area. So we believe that the level of discount, and that is today, mak",57,"This is already a very competitive market as it is today. As you can imagine, after -- there's already significant competition in the market today, both in the sub-q area and in the IV area. So we believe that the level of discount, and that is today, makes it already a high bar for any new entrant."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Okay, very clear. And then, Dominic, you made a series a comments on utilization, I just want to clarify both the near-term and kind of longer-term environment. So if I heard you correctly, it seems like there was some softening potentially in the Medical",141,"Okay, very clear. And then, Dominic, you made a series a comments on utilization, I just want to clarify both the near-term and kind of longer-term environment. So if I heard you correctly, it seems like there was some softening potentially in the Medical Device business in the summer, but that got better in September. I wonder if you could just help us out in terms of how you would characterize the environment here in September and entering into October. Is it stable with what you saw in the first half of the year or different? And then the second part of the question is you also said in '17, you actually expect some improvement in the Medical Device business. And maybe you could share with us your confidence level in the areas that you would expect to improve in '17."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Sure. So what we saw, David, this is through published sources, many of which are from firms such as yours and many of the sell side that publish. We saw -- actually, utilization rates, as depicted in hospital admissions and hospital surgical procedures,",304,"Sure. So what we saw, David, this is through published sources, many of which are from firms such as yours and many of the sell side that publish. We saw -- actually, utilization rates, as depicted in hospital admissions and hospital surgical procedures, with the first quarter of this year being the highest, by far, and then a slowdown in the second quarter, a slowdown even below the level at which most estimates we're depicting, we're forecasting. And then the third quarter was even slower than the second quarter, overall. But there's a very marked difference in September. So once September hit, the data showed quite a rebound from the summer months. And the rate of growth in September was actually faster than what we saw in the first quarter, which was the highest growth quarter year-over-year in terms of penetration. Now whether that remains at that level or whether it's a rebound effect from the summer, we'll have to see. But I think this is all well chronicled in the multiple reports that many of you, I'm sure, have seen. So overall, I'd say we're now in a stable environment in hospital procedures. Going into '17, I express confidence in our Medical Device business growing faster, and quite frankly, we have a plan for that business to return to growth at above market for the medical device sector, and it's continuing to improve. What gives me confidence there is that the areas that we focus the most on, the growth  platforms and priority platforms just this quarter, they grew at 9%, and within those, 3 of those, in particular, electrophysiology, energy and endocutters, each grew at double-digit growth. So we obviously have very robust growth coming in the priority platforms, which we expect to continue and drive us to above-market growth in 2017."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Your next question comes from Glenn Novarro with RBC Capital Markets.",11,"Your next question comes from Glenn Novarro with RBC Capital Markets."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Just a follow-up on REMICADE because, Dominic, you said REMICADE -- or the biosimilars, sorry, would be in that launch risk. So can you remind us what's next in the legal process? And then, you also did a good job of discussing the impact you thought for",79,"Just a follow-up on REMICADE because, Dominic, you said REMICADE -- or the biosimilars, sorry, would be in that launch risk. So can you remind us what's next in the legal process? And then, you also did a good job of discussing the impact you thought for the top line. Can you talk about the profitability of REMICADE today? Is this a drug that is still heavily marketed? I can't imagine there's a lot of R&D behind REMICADE."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Right. Well, a couple of things. Where we stand on the legal front, as you know, we have an upcoming trial on the media related to the production of the biosimilar, and that trial is scheduled for mid-February of 2017, and we're also appealing the ruling",105,"Right. Well, a couple of things. Where we stand on the legal front, as you know, we have an upcoming trial on the media related to the production of the biosimilar, and that trial is scheduled for mid-February of 2017, and we're also appealing the ruling recently in the Massachusetts Court regarding the patent being invalid, and that will proceed. But we're also separately -- and we had been involved in this process for quite some time, we're continuing the appeals process within the U.S. patent office, and that process has several more steps to go. Joe, anything else you want to add to that?"
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Yes, just with some specific dates, Glenn. So the oral arguments in front of the PTO was heard on September 28. We'd expect that decision to be rendered anywhere from 1 to 3 months in the courts on the 471 patent. The final judgment just came from the ben",70,"Yes, just with some specific dates, Glenn. So the oral arguments in front of the PTO was heard on September 28. We'd expect that decision to be rendered anywhere from 1 to 3 months in the courts on the 471 patent. The final judgment just came from the bench on September 27, so that triggers the time in which we have to appeal and we're going through that process now."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Okay. And with regards to profitability, obviously, a product like REMICADE is an important product that has -- obviously delivers significant profitability to the company. But of course, we have a number of new launches, we have some that are already lau",156,"Okay. And with regards to profitability, obviously, a product like REMICADE is an important product that has -- obviously delivers significant profitability to the company. But of course, we have a number of new launches, we have some that are already launched and are progressing and rapidly growing, and their relative cost does not grow at the rate of their sales growth. And overall, we have to manage through this period of time when eventually, when a biosimilar launches and a patent expires, we'd have to prepare ourselves for that in any event. So we're very well prepared to adjust accordingly. And as you know, our major focus always is to grow our sales at a rate faster than the rate in which we can -- our markets grow, so gain share and then grow our earnings at a rate faster than sales, so that's the level at which we plan for each and every year."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","So is there some restructuring that may come out over the next -- announcements that may come out that could serve as an offset to REMICADE and any potential loss profitability?",31,"So is there some restructuring that may come out over the next -- announcements that may come out that could serve as an offset to REMICADE and any potential loss profitability?"
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","We don't see any major restructuring related to the REMICADE situation on the horizon, Glenn, not at all.",19,"We don't see any major restructuring related to the REMICADE situation on the horizon, Glenn, not at all."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Your next question comes from Jami Rubin with Goldman Sachs.",10,"Your next question comes from Jami Rubin with Goldman Sachs."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Dominic, just a couple of questions for you. With the upcoming election, obviously, it's been a major area of focus for health care investors. I'm just curious of your thoughts on Proposition 61. And as you know, I think that polls are showing that, that",186,"Dominic, just a couple of questions for you. With the upcoming election, obviously, it's been a major area of focus for health care investors. I'm just curious of your thoughts on Proposition 61. And as you know, I think that polls are showing that, that actually might pass in the State of California. Just curious to know what you think the industry's response will be to that. And then secondly, I'm interested in your thoughts on the potential for an international tax reform as part of an infrastructure build. Obviously, you would be huge beneficiaries of such a bill because of repatriation. Can you give us your thoughts on the likelihood of that happening? We've had multiple discussions over the years about tax reform, which never happens. Maybe it will happen this time. Just curious to know what your Washington folks are saying. And are we correct in assuming that if you were to do a large mega-transaction adding that 6th tool to your pharmaceutical division, are you more likely to wait until we get visibility on that? Or is your decision irrespective of potential legislation?"
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Okay, well, let me -- Jami, let me take them in reverse order. So whether or not we do a major transaction would not be dependent on waiting for international tax reform. Obviously, we have plenty of borrowing capacity and, obviously, any transaction that",287,"Okay, well, let me -- Jami, let me take them in reverse order. So whether or not we do a major transaction would not be dependent on waiting for international tax reform. Obviously, we have plenty of borrowing capacity and, obviously, any transaction that's done outside the U.S. will be an effective use of that OUS cash. And as you know, we've had the benefit of being able to structure transactions and effectively use our OUS cash in a tax-efficient manner. And we did that with the Synthes Transaction, we've done that recently with the 2 transaction that we recently announced. With respect to international tax reform and what we're hearing, I can tell you that I visit in Washington often and speak with members of the House Ways and Means Committee and the Senate Finance Committee, and the tax staffs are busily working and working very collaboratively with U.S. multinationals on an appropriate tax reform package. We think there's more bipartisan support now than there has been in the past. We think that often, we hear, as you mentioned, the benefit of investing in U.S. infrastructure as a result of those repatriated earnings coming back into the U.S., so that would be a positive. And we think that, overall, the climate for international tax reform, post the election quite frankly, is more positive than it's been in the last year or so. And then with respect to Proposition 61, there are several opponents to that proposition, and we would prefer to have pricing that is more related to outcomes, evidence-based medicine is something that we are advocates of and therefore, outcome-based pricing is a logical consequence of that. But Joaquin, any other thoughts on Prop 61?"
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Thank you. I mean, as you were saying, Dominic, despite of the rhetoric about pharmaceutical pricing, right, it's always good to take some perspective on that. Pharmaceutical represents 14% of total expenditures, and we understand that we need to work wit",180,"Thank you. I mean, as you were saying, Dominic, despite of the rhetoric about pharmaceutical pricing, right, it's always good to take some perspective on that. Pharmaceutical represents 14% of total expenditures, and we understand that we need to work with different stakeholders in order to try to manage overall health care cost, and we have advanced different ideas in that area as you were describing, Dominic, such as value-based contracting. And we need to work there in order to try to eliminate the regulatory barriers that do not help in that area. As far as Proposition 61, as an example of that rhetoric, as Dominic said, there are different groups that oppose that measure, that includes even veteran groups and seniors and unions. The reason being, it's unclear what the effects of Proposition 61 would be. It is clear that it will be difficult to operationalize and also would create some access barriers to patients. So overall, we don't see Proposition 61 as the right way to try to work on pharmaceutical pricing. We think it's a misguided action."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Our final question comes from Matt Miksic with UBS.",9,"Our final question comes from Matt Miksic with UBS."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","I have one just quick clarification here on, I apologize, for REMICADE, and then I have one on sort of capital allocation. So Dominic and Joaquin, if I could just make sure I'm understanding your comments on pricing and expected biosimilar competition as",131,"I have one just quick clarification here on, I apologize, for REMICADE, and then I have one on sort of capital allocation. So Dominic and Joaquin, if I could just make sure I'm understanding your comments on pricing and expected biosimilar competition as you've gone through a number of times here on the call. The perception is that REMICADE pricing will face some kind of new downward pressure, abrupt pressure here as a result of this launch. It sounds like what you're saying is the net price for the drug is already quite competitive. There will be, obviously, penetration, but it doesn't sound like you're expecting to see any kind of significant or abrupt changes in pricing because of the competitive launch. Is that a fair characterization of what you're saying?"
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Yes, I think you already did right. All drugs -- all medicines face price pressures. This is a particularly competitive market as it is today, and we think the price level, it's already quite competitive, so I think you characterized the situation quite r",70,"Yes, I think you already did right. All drugs -- all medicines face price pressures. This is a particularly competitive market as it is today, and we think the price level, it's already quite competitive, so I think you characterized the situation quite right. I think the competition is going to move into other discussions such as other market differentiators, but the market is already quite competitive as it is."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Analysts","Got it. And then on capital allocation, just broadly speaking, Dominic, because we get this question quite often. You've made a number of comments throughout September about the kinds of things that you would be interested in strategically, and of course,",107,"Got it. And then on capital allocation, just broadly speaking, Dominic, because we get this question quite often. You've made a number of comments throughout September about the kinds of things that you would be interested in strategically, and of course, you've said previously, you would be interested in ophthalmology and you're now pursuing that. If you wouldn't mind, just for the record, kind of ticking through your major divisions, and just -- I think you've touched on pharma already, your preference there, but maybe on Consumer and Devices, just remind us of the kinds of things that you're still interested in there, size and maybe area?"
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Well, Matt, we're -- as a broadly based company in human health care, we have an equal amount of interest across each of the businesses. And the way we compensate for that is basically looking at an appropriate risk-adjusted return for the particular asse",319,"Well, Matt, we're -- as a broadly based company in human health care, we have an equal amount of interest across each of the businesses. And the way we compensate for that is basically looking at an appropriate risk-adjusted return for the particular assets that we're interested in. And that is the same even regardless of size. I mean, obviously, size matters for a couple of reasons. One is that the asset may be well understood, the business may be well penetrated, the premium required for the asset may be excessive and therefore, to generate value for our shareholders would be a challenge. But it doesn't mean we wouldn't try to do that or we wouldn't look for areas where that may, in fact, be available for us. So that would be across any of the businesses. Within Consumer and Medical Devices, in particular, Consumer, just like we have in Pharma, we have specific areas of focus. We have 11 need states. The primary focus for us is growing internationally in emerging markets, so strong brands and emerging markets, a focus on over-the-counter medications and beauty space, particularly in Asia, are of interest to us. We just did a recent transaction with Dr.Ci:Labo in Japan, where we have an interest in that Asian marketplace and utilizing that brand throughout broader, throughout Asia, beyond Japan where it's currently marketed just as an example of one. And in Medical Devices, as you know, we have a very strong presence in orthopedics and in general surgery. We keep looking for additional bolt-on acquisitions there. And we have a very strong electrophysiology business in cardiovascular, but there are other areas within cardiovascular that seem attractive, in structural heart, and other areas, but the valuation would be something that we'd always consider. So we'd also be very disciplined about doing a transaction where the valuation seem pretty high, which is what they are today."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","That concludes the Q&A. I will now turn the discussion back over to Dominic for some closing remarks.",19,"That concludes the Q&A. I will now turn the discussion back over to Dominic for some closing remarks."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Executives","Okay. Thanks, Joe. Well, as I noted earlier, we're very pleased with our overall performance this quarter, and we're tracking well through the second half of the year. I would like to thank Joaquin and Bill for their outstanding leadership and for the gre",110,"Okay. Thanks, Joe. Well, as I noted earlier, we're very pleased with our overall performance this quarter, and we're tracking well through the second half of the year. I would like to thank Joaquin and Bill for their outstanding leadership and for the great presentation they gave this morning about the continued progress we are making in our Pharmaceutical business. I would also like to thank all of our colleagues around the world for their extraordinary achievements and dedication to the success of Johnson & Johnson. 
Thank you for your time today, and I look forward to updating you on our full year results in January. Have a great day."
139677,381738381,1056642,"Johnson & Johnson, Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Johnson & Johnson","Operator","Thank you. This concludes today's Johnson & Johnson's Third Quarter 2016 Earnings Conference Call. You may now disconnect.",18,"Thank you. This concludes today's Johnson & Johnson's Third Quarter 2016 Earnings Conference Call. You may now disconnect."
